<SEC-DOCUMENT>0001013762-25-004072.txt : 20250328
<SEC-HEADER>0001013762-25-004072.hdr.sgml : 20250328
<ACCEPTANCE-DATETIME>20250328160524
ACCESSION NUMBER:		0001013762-25-004072
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		104
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250328
DATE AS OF CHANGE:		20250328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		25785916

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ea0235481-10k_immucell.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iccc="http://immucell.com/20241231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 2pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED
STATES<br/>
SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-13804">10-K</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font: 1pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-13805"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-13806">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-13807">2024</ix:nonNumeric></ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-76"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid"><b>001-12934</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Commission
file number)</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-decoration: underline solid"><b><span style="-sec-ix-hidden: hidden-fact-0">ImmuCell
Corporation</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its charter)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-105"><span style="font-family: Times New Roman, Times, Serif"><b>Delaware</b></span></ix:nonNumeric></p></td> <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityTaxIdentificationNumber" id="ixv-113"><span style="font-family: Times New Roman, Times, Serif"><b>01-0382980</b></span></ix:nonNumeric></p></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(State of incorporation)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(I.R.S. Employer <br/> Identification No.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-13808">56 Evergreen Drive</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-13809">Portland</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="ixv-13810">Maine</ix:nonNumeric></b></span></p></td> <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-141"><span style="font-family: Times New Roman, Times, Serif"><b>04103</b></span></ix:nonNumeric></p></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Address of principal executive offices)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Zip Code)</b></span></td></tr> </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline"><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode" id="ixv-13811">(207)</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber" id="ixv-13812">878-2770</ix:nonNumeric></span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Registrant&#8217;s
telephone number)</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-family: Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Title
of each class</b></span></p></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading symbol(s)</b></span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle" id="ixv-195"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.10 par value per share</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol" id="ixv-200"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ICCC</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-13813">Nasdaq</ix:nonNumeric> Capital Market</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(g) of the Act: None </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160; </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-size: 10pt; font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-13814">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-13815">No</ix:nonNumeric>
&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-13816">Yes</ix:nonNumeric> &#9746; &#8239;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-13817">Yes</ix:nonNumeric> &#9746; &#8239;No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company or an emerging growth company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Large accelerated filer &#9744;&#160;Accelerated filer
&#9744;&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-13818">Non-accelerated filer</ix:nonNumeric>&#160;&#9746;&#160;Smaller reporting
company&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-13819">&#9746;</ix:nonNumeric>&#160;Emerging growth company&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-13820">&#9744;</ix:nonNumeric></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="ixv-13821">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-13822">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that require a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-13823">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2024 was approximately $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityPublicFloat" scale="0" unitRef="usd" id="ixv-13824">30,634,000</ix:nonFraction>
based on the closing sales price on June 28, 2024 of $4.85 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">The
number of shares of the registrant&#8217;s common stock outstanding as of March 21, 2025 was <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13825">8,982,623</ix:nonFraction>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">Documents
incorporated by reference: <ix:nonNumeric contextRef="c0" escape="true" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="ixv-13826">Portions of the registrant&#8217;s definitive Proxy Statement to be filed in connection with the 2025 Annual
Meeting of Stockholders are incorporated by reference into Part III hereof.</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; width: 100%"><div style="border-top: Black 1pt solid; font: 1pt Times New Roman, Times, Serif; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December
31, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 8%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 83%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#a_001">PART I</a></b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom; width: 9%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1A</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1B</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved
    Staff Comments</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    1C</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cybersecurity</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    2</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    3</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    Proceedings</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    4</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
    Safety Disclosures</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><a href="#a_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    II</b></span></a></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    5</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market
    for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    6</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s
    Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    7A</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative
    and Qualitative Disclosures about Market Risk</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    8</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements and Supplementary Data</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    In and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9A</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls
    and Procedures</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9B</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Information</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    9C</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure
    Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    III</b></span></a></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    10</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors,
    Executive Officers and Corporate Governance</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    11</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Compensation</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    12</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    13</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    14</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Accountant Fees and Services</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><a href="#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    IV</b></span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    15</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    and Financial Statement Schedules</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM
    16</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    10-K Summary</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audited
    Financial Statements</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1
    to F-26</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="#a_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
I</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 1
&#8211; BUSINESS</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cautionary
Note Regarding Forward-Looking Statements (Safe Harbor Statement):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K (Annual Report) contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly
to historical or current facts and will often include words such as &#8220;expects&#8221;, &#8220;may&#8221;, &#8220;anticipates&#8221;,
&#8220;aims&#8221;, &#8220;intends&#8221;, &#8220;would&#8221;, &#8220;could&#8221;, &#8220;should&#8221;, &#8220;will&#8221;, &#8220;plans&#8221;,
&#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;targets&#8221;, &#8220;projects&#8221;, &#8220;forecasts&#8221;, &#8220;seeks&#8221;
and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans,
goals and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending
or anticipated applications for regulatory approvals and pending or anticipated regulatory inspections of our facilities and those of
our contract manufacturers; future demand for our products; future adoption of <b>Re-Tain<sup>&#174;</sup></b> by dairy producers; growth
in acceptance of our <b>First Defense<sup>&#174;</sup></b> product line by dairy and beef producers; the impact of international disputes
(including Russia&#8217;s  invasion of Ukraine and unrest in the Middle East) on the world economy including inflation and
the price and availability of grain and oil; the impact of the global supply-chain disruptions on our ability to obtain, in a timely
and cost-effective fashion, all the supplies and components we need to produce our products; the impact of inflation and rising interest
rates on our operating expenses and financial results; the scope and timing of ongoing and future product development work and commercialization
of our products; future costs of product development efforts; future incidence rates of subclinical mastitis and producers&#8217; level
of interest in treating subclinical mastitis; the expected efficacy of new products; estimates about the market size for our products;
future market share of and revenue generated by current products and products still in development; our ability to increase production
output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties with which
we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships;
the efficacy of our contamination remediation efforts; whether or not we will experience future contamination events; the anticipated
costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects;
the robustness of our manufacturing processes to meet future demand and related technical issues; estimates about our future production
capacity, efficiency and yield; the salability of products currently held in inventory pending regulatory approval; future regulatory
requirements relating to our products; future expense ratios and margins; the future consequences and effectiveness of our investments
in our business; future compliance with, or waivers of, bank debt covenants; anticipated changes in our manufacturing capabilities and
efficiencies; our future effectiveness in competing against competitors within both our existing and our anticipated product markets;
projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not
historical facts. These statements are intended to provide management&#8217;s current expectation of future events as of the date of
this earnings release, are based on management&#8217;s estimates, projections, beliefs and assumptions as of the date hereof; and are
not guarantees of future performance. Such statements involve known and unknown risks and uncertainties that may cause the Company&#8217;s
actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these
forward-looking statements, including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development,
testing, regulatory approval, production and marketing of our products (including the <b>First Defense<sup>&#174;</sup></b> product line
and <b>Re-Tain<sup>&#174;</sup></b>), competition within our anticipated product markets, customer acceptance of our new and existing
products, product performance, alignment between our manufacturing resources and product demand (including the consequences of backlogs),
uncertainty associated with the timing and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply
chain disruptions on our operations and customer and supplier relationships, commercial and operational risks relating to our current
and planned expansion of production capacity, and other risks and uncertainties detailed from time to time in filings we make with the
Securities and Exchange Commission (SEC), including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K and our Current
Reports on Form 8-K. Such statements involve risks and uncertainties and are based on our current expectations, but actual results may
differ materially due to various factors, including the risk factors summarized under <b>PART II: OTHER INFORMATION, ITEM 1A-RISK FACTORS
</b>and uncertainties otherwise referred to in this Annual Report. In addition, there can be no assurance that future risks, uncertainties
or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking statement, whether
written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>OUTLINE
TO ITEM 1 &#8211; BUSINESS:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Summary</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Production
                                            Capacity Increase and Product Contamination</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Animal
                                            Health Products</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Sales
                                            and Markets</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Product
                                            Development</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
                                            Property</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Government
                                            Regulation</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Employees</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Public
                                            Information</b></span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Summary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">ImmuCell
Corporation was founded in 1982 and completed an initial public offering of common stock in 1987. After achieving approval from the Center
for Veterinary Biologics, U.S. Department of Agriculture (USDA) to sell <b>First Defense</b><sup>&#174;</sup> in 1991, we focused most
of our efforts during the 1990&#8217;s on attempting to develop human product applications of the underlying milk protein purification
technology. Beginning in 1999, we re-focused our business strategy on the <b>First Defense</b><sup>&#174;</sup> product line. We support
the dairy and beef industries&#8217; purpose to produce nutritious, protein-rich food efficiently while ensuring food quality and safety.
Our products help address the growing human health concerns through reduced use of antibiotics in food-producing animals. We have experienced
significant growth in sales of our <b>First Defense</b><sup>&#174;</sup> product line, a product that provides significant <b>Immediate
Immunity&#8482;</b> to newborn dairy and beef livestock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that our purified Nisin treatment for subclinical mastitis in lactating dairy cows (<b>Re-Tain</b><sup>&#174;</sup>) could revolutionize
the way that farmers treat mastitis, the single most significant cause of economic loss to the dairy industry. Full commercial sales
of this product cannot be made without prior approval of our New Animal Drug Application (NADA) by the Center for Veterinary Medicine,
U.S. Food and Drug Administration (FDA). We have achieved FDA approval for four out of five of the significant Technical Sections required
for product approval. We are now awaiting FDA action on our fourth submission of the fifth and final Technical Section, which we submitted
in January of 2025. At the same time, we are initiating Investigational Product use of this product, as discussed in more detail later
in this Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are making ongoing efforts to maintain compliance with current Good Manufacturing Practice (cGMP) regulations in all of our manufacturing
operations, which requires a sustained investment but further enhances the quality of all of our products and our operating efficiency.
We continue to invest in personnel, equipment and facility modifications to increase the efficiency and quality of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Over
the past nine years, we funded our operations, constructed an FDA-regulated Drug Substance (DS) manufacturing facility for <b>Re-Tain</b><sup>&#174;
</sup>and invested capital to increase our production capacity for the <b>First Defense<sup>&#174; </sup></b>product line. From the first
quarter of 2016 through the second quarter of 2021, we issued an aggregate of 4,553,017 shares of common stock, raising gross proceeds
of approximately $26.7 million in six separate transactions. During 2024, we issued an aggregate of 1,228,227 shares of common stock,
raising gross proceeds of approximately $4.6 million, through our At-The-Market (ATM) Offering. In order to minimize the dilutive effects
of these transactions on our existing stockholders, we chose not to issue any form of convertible or preferred securities and issued
these common shares without any warrants. Net of debt issuance and debt discount costs, we had approximately $10.5 million in outstanding
debt as of December 31, 2024 compared to approximately $3.2 million as of December 31, 2015. This increase in equity and debt capital
has been, and is being, used to increase the production capacity for the <b>First Defense<sup>&#174;</sup></b> product line and to complete
the development of <b>Re-Tain</b><sup>&#174;</sup> without relying on funding from a partner or licensee, thereby keeping control over
all product rights and future revenues. During this time, our total assets have increased to $45.1 million as of December 31, 2024 from
$14.6 million as of December 31, 2015, and our stockholders&#8217; equity has increased to $27.5 million as of December 31, 2024 from
$10.6 million as of December 31, 2015. This represents a 209%, or $30.5 million, increase in total assets and a 159%, or $16.9 million,
increase in stockholders&#8217; equity over this nine-year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Production
Capacity Increase and Product Contamination</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2019, we began a series of investments to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line
to $30 million or more per year. The facility expansions and new equipment needed to increase production capacity were in place by the
end of 2022. Around the end of the third quarter of 2022, as this increased production capacity was coming online, we detected a product
contamination event that required us to scrap significant inventory. We took immediate steps to address the contamination, and production
ran without issue during the balance of the fourth quarter of 2022. Then during the first quarter of 2023, we detected a second contamination
event. We slowed down our production output to take the necessary steps to assess and remediate the issues and perform a deep sanitization
of our facilities and process equipment. After several months of processing without further contamination, we experienced a third contamination
event during the third quarter of 2023. Scrapped product from contamination events and other production process losses resulted in a
total charge to costs of goods sold of approximately $407,000 and $527,000 during 2024 and 2023, respectively. We have been operating
without any new contamination events since April of 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">It
was relatively simple to run at lower production capacities for the 30 years between 1991 (the original USDA approval of <b>First Defense</b><sup>&#174;</sup>)
and 2021. We believe that the contamination events we suffered between 2022 and 2024 stemmed from us processing more milk (colostrum)
from more farms than ever before in order to increase production output and meet increasing customer demand. We believe that we now have
significantly improved processes and controls in place to better support large-scale production from our raw material source farms through
liquid processing. Our most important customer-focused objectives going forward are to fulfill the backlog of orders and then resume
being a reliable supplier of a very effective product to the dairy and beef calf markets. Once achieved, our goal is to continue to expand
our penetration of the beef market and less price sensitive dairies with <b>Tri-Shield<sup>&#174;</sup></b>, while simultaneously launching
a lower-cost spray-dried product without USDA claims, targeting more price sensitive large calf ranches and dairies. Overall, our goal
is to continue to grow sales and differentiate our brands in both the beef and dairy markets.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Animal
Health Products</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
<b>First Defense</b><sup>&#174; </sup>product line is manufactured from hyperimmunized cows&#8217; colostrum (the antibody rich milk that
a cow produces immediately after giving birth) utilizing our proprietary vaccine and milk protein purification technologies. The <b>First
Defense</b><sup>&#174;</sup> product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately
after birth. The target disease, calf scours (bovine enteritis), causes diarrhea and dehydration in newborn calves and often leads to
serious sickness and even death. The <b>First Defense</b><sup>&#174;</sup> product line is the only USDA-licensed, orally
delivered scours preventive product on the market for calves with claims against three leading causes of scours. A single dose of our
product provides a measured level of protection proven to reduce mortality and morbidity. Our pre-formed antibody products provide <b>Immediate
Immunity&#8482; </b>during the first few critical weeks of life when calves need this protection most. Studies have shown that calves
with scours are more susceptible to other diseases later in life and under-perform calves that do not contract scours. The direct, two-part
mode-of-action of the <b>First Defense</b><sup>&#174;</sup> product line delivers specific immunoglobulins at the gut level to immediately
protect against disease, while also providing additional antibodies that are absorbed into the bloodstream. These circulating antibodies
function like a natural timed-release mechanism, as they are re-secreted into the gut later to provide extended protection. The <b>First
Defense</b><sup>&#174; </sup>product line is convenient to use. A calf needs to receive only one dose of <b>First Defense</b><sup>&#174;</sup>
within the first twelve hours after birth. Our capsule format of this product, which requires no mixing, is stored at room temperature,
while the gel tube formats of this product require refrigeration in accordance with product label indications. We are the market leader
(in terms of both unit volume and dollar sales) when compared to other calf-level scours preventatives and have greater market potential
as we gain market share from the dam-level (pre-calving scour vaccines) competitors. The third quarter of 2024 marked the 33<sup>rd</sup>
anniversary of the original USDA approval of this product in 1991. During the fourth quarter of 2024, our cumulative sales of <b>First
Defense<sup>&#174; </sup></b>since inception passed 36 million doses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
product line extension, <b>Tri-Shield First Defense<sup>&#174;</sup></b></span>, is the first calf-level, passive antibody product on
the market with USDA-approved disease claims providing <b>Immediate Immunity&#8482;</b> against each of the three leading causes of calf
scours (<i>E. coli</i>, coronavirus and rotavirus). This product achieved USDA approval during the fourth quarter of 2017 and was listed
with the Organic Materials Research Institute (OMRI) during the first quarter of 2019, which means it can be used on organic farms. <b>Tri-Shield<span style="font-size: 10pt"><sup>&#174;</sup></span></b>
combines the <i>E. coli</i> and coronavirus antibodies contained in our bivalent product with rotavirus antibodies in a single-dose gel
tube delivery format. This unique breadth of claims further differentiates our product from calf-level competitive products on the market
that contain only one or two of these label claims. The unique virus-like particle (VLP) technology that is used in our production process
increases rotavirus titers in colostrum to a level much greater than traditional vaccine technology can. Because it is possible that
some farms may not have (or do not perceive to have) a rotavirus problem, we are continuing to sell the bivalent formats of the <b>First
Defense<sup>&#174; </sup></b>product line as options for customers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
<b>First Defense<sup>&#174;</sup></b> product line continues to benefit from wide acceptance by dairy and beef producers as an effective
tool to prevent scours in newborn calves, which is the leading cause of death in preweaned calves. Our <b>Beyond Vaccination<sup>&#174;
</sup></b>marketing campaign focuses on providing antibodies without vaccination. A 100% vaccine protection rate is biologically impossible.
The <b>First Defense<sup>&#174;</sup></b> product line removes the variability associated with a scour vaccine response and instead provides
a measured level of pre-formed antibodies, protecting each calf with an equal level of scours protection. There is a strong link between
how we sell our product and the challenges we face in producing it. We know better than most how variable a cow&#8217;s response is to
any vaccine. We see this in every batch of <b>First Defense<sup>&#174;</sup></b> that we produce. The value in <b>First Defense<sup>&#174;
</sup></b>is that we adjust for this variability by standardizing the antibody content, as needed, so the newborn is given a steady,
equal level of protection with each dose. This technology removes a producer&#8217;s reliance on variable vaccine responses to generate
passive antibody protection and instead protects every calf equally with a measured dose of <b>Immediate Immunity&#8482;</b>. Preventing
newborn calves from becoming sick helps them to reach their genetic potential and reduces the need to use treatment antibiotics later
in life. Plus, an effectively treated calf is much less likely to require expensive antibiotic treatments or build antibiotic resistance.
We are the only manufacturer within the scour prevention space offering polyclonal multi-pathogen antibodies. The market is learning
that the best preventative for scours may not be a vaccine, and we are continuing to educate the market about the health benefits of
a measured dose of pre-formed antibodies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Historically,
the most common tool to help combat scours has been to vaccinate the mother cow (dam) with a scours vaccine and deliver the antibodies
that she produces in her milk to the newborn. It is generally believed that only 80% of animals respond to a vaccine, which could leave
about 20% of calves unprotected. We believe that the variability in a cow&#8217;s immune response to vaccines creates a sales opportunity
for our product. Additionally, our research suggests that treatment protocols for dam-level scours vaccine programs are not always followed,
leaving even more calves compromised. We are competing effectively against these dam-level vaccine products. Our marketing campaign,
<b>Beyond Vaccination<span style="font-size: 10pt"><sup>&#174;</sup></span></b>, emphasizes that by delivering <b>Immediate Immunity&#8482;</b>
directly to the calf via the <b>First Defense<span style="font-size: 10pt"><sup>&#174;</sup></span></b> product line, producers can reduce
stress-causing injections to the cow. Reliance on a dam-level scours vaccine requires that money be spent before it is known whether
the cow is carrying a viable, valued calf. With the <b>First Defense<span style="font-size: 10pt"><sup>&#174;</sup></span></b> product
line, that investment can be targeted to the calves that are most critical to the operation. This, in turn, can free up space in the
cow&#8217;s vaccination schedule to improve her immune response to vaccines that are critical to her health.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>First
Defense Technology<sup>&#174;</sup></b> is a unique colostrum concentrate that is processed utilizing our proprietary colostrum (first
milk) protein purification methods, for the nutritional and feed supplement markets without the claims of our USDA-licensed product.
We are working to expand this product category to include a spray-dried, bulk powder format. During 2012, we initiated a limited launch
of a gel tube delivery format of our <b>First Defense Technology<sup>&#174;</sup></b> in a gel solution. We achieved USDA claims for this
product format during the fourth quarter of 2018 and Canadian approval during the first quarter of 2019, and it is now being sold as
<b>Dual-Force First Defense<sup>&#174;</sup></b>. We are selling the same concentrated whey proteins in a bulk powder format (no capsule),
which is delivered with a scoop and mixed with colostrum for feeding to calves. We are working to achieve USDA claims for this product
format. During 2011, Milk Products, LLC of Chilton, Wisconsin launched commercial sales of their product, Ultra Start<sup>&#174;</sup>
150 Plus and certain similar private label products, which are colostrum replacers with <b>First Defense Technology<sup>&#174;</sup> Inside</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2001, we began to offer our own, internally developed <b>California Mastitis Test (CMT)</b>. <b>CMT </b>is most often used as a quick
on-farm diagnostic to determine which quarter of the udder is mastitic. This test can be performed at cow-side for early detection of
mastitis. <b>CMT </b>products are also made by other manufacturers and are readily available to the dairy producer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Sales
and Markets</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that the long-term growth in sales of the <b>First Defense<sup>&#174;</sup></b> product line may reflect, at least in part, the
success of our strategic decision to invest in additional sales and marketing efforts to help us introduce the expanding <b>First Defense<sup>&#174;
</sup></b>product line to new customers. Our communications campaign continues to emphasize how the unique ability of the <b>First Defense<sup>&#174;
</sup></b>product line to provide <b>Immediate Immunity&#8482; </b>generates a dependable and competitive return on investment for dairy
and beef producers. Our sales and marketing team consists of one vice president, one commercial leader of stakeholder engagement, one
director of marketing and six regional sales managers. The <b>First Defense<sup>&#174;</sup></b> product line and <b>CMT </b>are sold
primarily through major animal health distributors who, in turn, sell to veterinary clinics, fleet stores and direct to farms. Our sales
and marketing team has proven to be a worthy investment, validating that our message resonates well with customers. Now that our increased
production capacity is in place, we are more actively marketing to the beef market and pursuing new international territories. We anticipate
being able to escalate our growth curve after we recover from the brand damage that can come with an extended duration of short supply.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Sales
of the <b>First Defense</b><sup>&#174;</sup> product line are normally seasonal, with higher sales expected during the first quarter,
largely driven by the beef calving season, which runs primarily from January to April, unlike the dairy industry in which operations
generally calve year round. Warm and dry weather reduces the producer&#8217;s perception of the need for a disease preventative product
like the <b>First Defense<sup>&#174;</sup></b><sup> </sup>product line. However, heat stress on calves caused by extremely hot summer
weather and cold stress during the winter months can increase the incidence of scours. Other competition for resources that dairy producers
allocate to their calf enterprises has been increased by the many new products (principally feed supplements) that have been introduced
to the calf market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
estimate that the total U.S. market for scours preventative products (including sales of our product) that are given to newborn calves
(the calf-level market) is approximately $31.1 million per year. With the additional claim for our new product (<b>Tri-Shield First Defense<sup>&#174;</sup></b>)
against rotavirus, we are now also competing against the dam-level vaccine products that are given to the mother cow to increase the
antibody level against specific scours-causing pathogens in the colostrum that she produces for her newborn. We estimate that the dam-level
product category covers approximately twice as many calves as the calf-level product segment reaches. We estimate that the total domestic
addressable market (both calf and dam levels) is approximately $81.8 million per year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Based
on market share information that we purchase from the leading source of this data for the animal health sector, we believe that we are
gaining market share in the United States year after year, but we also believe that these gains have been limited by our short supply
of product to the market in recent years. We aim to continue these market share gains in both the dairy and beef segments. Our share
of the dairy and beef market (calculated on the basis of calves treated) of the scour preventative products administered at the calf-level
was approximately:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">36%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">41%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">43%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">44%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">48%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">48%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
share of the dairy and beef market (calculated on the basis of calves treated) of both products administered at the calf-level and vaccines
administered to the dam prior to calving (adjusting for two doses of dam-level scour vaccines required for primary vaccination of first-calf
heifers) was approximately:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2019</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2020</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">11%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">13%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">13%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">14%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">14%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">15%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"/></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
continue our efforts to grow sales of the <b>First Defense</b><sup>&#174;</sup> product line in North America, where there are approximately
37.3 million dairy and beef cows in the United States and approximately 4.4 million dairy and beef cows in Canada. We believe that significant
market opportunities exist in other international territories. The majority of our international sales are to Canada. We price our products
in U.S. dollars. To the extent that the value of the dollar declines with respect to any other currency, our competitive position may
be enhanced. Conversely, an increase in the value of the dollar in any country in which we sell products may have the effect of increasing
the local price of our products, thereby leading to a potential reduction in demand. Generally, our international sales have been generated
through relationships with in-country distributors that have knowledge of the local regulatory and marketing requirements. We are implementing
our plan to expand the number of countries to which our <b>First Defense</b><sup>&#174;</sup> product line is approved for export. Generally,
it is our intent to be the holder of these product registrations for each country rather than rely on distribution partners to gain and
hold these registrations. This is a long regulatory process but allows us to maximize the use of our product label claims. Industry practices,
economic conditions, cause of disease, distribution channels and regulatory requirements may differ in these international markets from
what we experience in North America, potentially making it more difficult or costly for us to generate and sustain sales volumes at profitable
margins in these markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
introduced <b>First Defense</b><sup>&#174;</sup> into South Korea in 2005 through Medexx Co., Ltd of Gyeonggi-do, Korea and its equivalent
into Japan in 2007 through NYS Co., Ltd of Iwate, Japan. We are working with Medexx to expand our business in South Korea to include
the registration of <b>Tri-Shield First Defense<sup>&#174;</sup>.</b> The business in Japan is currently not active, but we are working
to resume sales in this territory. We entered into distribution contracts covering certain Middle Eastern countries with Triplest for
Drugs and Trade of Madaba, Jordan during the first quarter of 2017 and covering Iran with Senikco, LLC of Laguna Niguel, California during
the fourth quarter of 2016. We are investigating the requirements to sell the <b>First Defense</b><sup>&#174;</sup> product line in Mexico,
Pakistan and India.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">With
<b>Re-Tain</b><sup>&#174;</sup>, we are working to expand our product portfolio to include this intramammary infusion for the treatment
of subclinical mastitis in lactating dairy cows. Mastitis is inflammation of the mammary gland typically associated with a bacterial
infection. It is estimated to cost the U.S. dairy industry approximately $2 billion in economic harm per year. It is the most costly
and common disease affecting the dairy industry. This illness is categorized as either clinical mastitis or subclinical mastitis. Clinical
mastitis infections cause visibly abnormal milk which cannot be sold. On the other hand,&#160;subclinical mastitis infections do not
cause any visible changes in milk or udder appearance, making it difficult to detect. Most mastitis cases treated today are those that
reach the clinical stage even though it is understood that clinical cases are only the tip of the mastitis iceberg. Milk from cows with
subclinical mastitis can still be sold if not treated with traditional antibiotics. Milk from cows treated with traditional antibiotics
must be discarded for the duration of the treatment and for 1.5 to 4 days after the last treatment, depending on the antibiotic that
was used. The cost of that milk discard along with the stress and risk in moving the cow to the hospital pen is thought to be a primary
reason more subclinical mastitis cases are not treated today. However, the cascade of negative events triggered by subclinical mastitis
for both the dairy producer and the milk processor are significant. These include lower milk production (some have estimated approximately
1,500 pounds of lost milk, or about $270 at $18.00 per hundredweight per infected cow per lactation), higher rates of clinical mastitis,
lower conception rates, increased abortions, increased cull rates, reduced or foregone milk quality premiums, shorter shelf life for
fluid milk, and both lower yields and less flavor for cheese. Cows with subclinical mastitis maintain a reservoir of infection within
the herd and increase exposure of healthy cows to contagious pathogens. Subclinical mastitis also increases the risk of various quality
defects on a variety of final dairy products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
active ingredient in <b>Re-Tain</b><sup>&#174; </sup>is pharmaceutical-grade Nisin A. FDA approval for this drug would establish an entirely
new class of anti-infective that is different from those currently available to treat mastitis. This new class, called bacteriocins,
are anti-microbial polypeptides with no resistance risk for human health. Bacteriocins selectively target Gram+ bacteria, the same bacteria
that commonly cause mastitis. We expect <b>Re-Tain</b><sup>&#174; </sup>will be the first FDA-approved intramammary treatment for subclinical
mastitis without an FDA-required milk discard or pre-slaughter withdrawal period. This gives us the opportunity to revolutionize the
way mastitis is treated, since <b>Re-Tain</b><sup>&#174; </sup>is specifically designed to treat ahead of clinical signs without an FDA-required
milk discard or pre-slaughter withdrawal period. As a result, we believe that our product can help cows reach their peak milk production
and not be sent to the hospital pen. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Referencing
the big picture, we are introducing an entirely new class of socially-responsible antimicrobials as an animal drug, a bacteriocin, that
does not promote resistance against antibiotics used in human medicine. As the great NHL hockey player, Wayne Gretzky, is known to have
said, &#8220;I skate to where the puck is going to be, not where it has been.&#8221; This is motivational to us. We believe our product
fits very well with where the industry is going to be in the coming years. Sustainability objectives of the industry require that less
antibiotics be used in food producing animals, yet a new product to treat mastitis has not been developed in years (other than new formulations
of the same old stuff). The over-use of antibiotics that are medically important to human healthcare is a growing concern of our society
and an active issue with the FDA, largely because of the growing evidence that this over-use contributes to antibiotic resistance. The
industry could keep treating this very significant disease with traditional antibiotics, but it takes innovation to bring a bacteriocin
like Nisin to market. We believe that societal animal welfare objectives will place increased pressure on the industry to treat cows
with subclinical infections rather than ignore them and leave them sick.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
Nisin is a naturally occurring bacteriocin that is not used in human medicines, it could alleviate some of the social and public health
concerns that the widespread use of antibiotics encourages the growth of antibiotic-resistant bacteria. For example, there is a fear
that the possible overuse of antibiotics in livestock undermines the effectiveness of these drugs to combat human illnesses and contributes
to a rising number of life-threatening human infections from antibiotic-resistant bacteria, commonly known as &#8220;superbugs&#8221;.
The FDA has expressed a commitment to addressing this public health risk. Citing concerns about untreatable, life-threatening infections
in humans, new FDA and European regulations are aimed at restricting the use of antibiotics (such as penicillin and cephalosporins) in
food animals and at improving milk quality. By reducing the risk of antibiotic residues and slowing the development of antibiotic-resistant
organisms, we believe that we can improve food quality and preserve medically important antibiotics for human disease treatment. This
current environment is favorable to the introduction of our new product as an alternative to traditional antibiotics. We believe that
this changing environment of new regulations and public opinion supports the value of our ongoing development and commercialization efforts
for <b>Re-Tain</b><sup>&#174;</sup>. Additionally, we believe that the use of our <b>First Defense</b><sup>&#174;</sup> product line is
consistent with this trend of reducing the use of antibiotics because the prevention of calf scours early in life with our purified colostrum
antibodies can reduce the need to use treatment antibiotics later in a calf&#8217;s life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
estimate that the approximate cost to the U.S. dairy industry of discarded milk associated with the use of traditional antibiotic products
currently on the market may be around $300 million per year. These high milk discard costs associated with traditional antibiotic treatments
lead producers to only treat mastitis after clinical signs develop. The <b>Re-Tain</b><sup>&#174;</sup> label will be for subclinical
mastitis (not clinical). Without an FDA-required milk discard or pre-slaughter withdrawal cost, we expect producers to be more motivated
to identify and treat cows at the subclinical stage. To validate our confidence in the value proposition of our product, we initiated
a stochastic model led by researchers at Michigan State University. This model simulated the dynamics of subclinical mastitis detected
during the first week of lactation. The study involved assessing probabilities of events, both production and health related, and their
associated costs using a model grounded in pathogen-specific assumptions drawn from peer-reviewed literature. The study indicated that
treatment with our product generated a positive economic benefit and was the optimal economic strategy for treating subclinical mastitis
in most herds. The extent of the economic benefit varies depending on factors such as bacteriological cure rates, parity of the animal
and the cost of <b>Re-Tain</b><sup>&#174;</sup>. These findings, which were subsequently published in the Journal of Dairy Science in
January of 2024, will guide our pricing strategies. In addition, we expect that <b>Re-Tain</b><sup>&#174;</sup> will be priced at a premium
to the traditional antibiotic products currently on the market, which are all sold subject to milk discard and pre-slaughter withdrawal
period requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">It
is difficult to accurately estimate the potential size of the subclinical mastitis market because presently this disease is largely left
untreated. We believe that approximately 20% to 40% of the U.S. dairy herd is infected with subclinical mastitis at any given time. This
compares to approximately 2% of the U.S. herd that is thought to be infected with clinical mastitis, where approximately $40 million
per year is spent on drug treatments. We believe more than this amount is spent on dry cow treatments. Rarely is an industry revolutionized
overnight. Getting producers to change protocols to make subclinical mastitis treatment a standard and routine procedure is going to
take initiative, but we believe producers are eager for something new and better since the FDA has not approved an intramammary treatment
within the last 20 years. Similar market opportunities are likely to exist outside the United States. We believe the use of <b>Re-Tain</b><sup>&#174;
</sup>could be expanded, with additional data and regulatory approval, to support treatment late in lactation. We also believe there
may be a market for <b>Re-Tain<sup>&#174;</sup></b> in small ruminants, where the majority of mastitis cases are caused by strep-like
organisms aligned with our effectiveness data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Based
on consultations with industry experts and key opinion leaders, we have opted to carefully control the launch of this novel product upon
FDA approval, as we seek to transform the way that mastitis is treated in the dairy industry over the long term, which we refer to as
our &#8220;Controlled Launch&#8221; strategy. Our goal is to help early adopters select treatment candidates, develop easy to use protocols,
optimize treatment results and realize a positive return on their investment. We intend to limit initial distribution of <b>Re-Tain<sup>&#174;
</sup></b>to a level that enables our sales team to select the optimal dairy farms at which to introduce <b>Re-Tain<sup>&#174; </sup></b>and
to limit the initial numbers of participating farms so that the desired levels of support and guidance relating to effective usage of
<b>Re-Tain<sup>&#174; </sup></b>can be provided with our available resources. Our overarching objective is to minimize the risk of early-stage
unsatisfactory outcomes that could harm the longer-term prospects and market acceptance of <b>Re-Tain<sup>&#174;</sup></b>. This strategy
is also prudent since our saleable inventory is fixed until an FDA-approved alternative contract manufacturer for aseptic filling is
identified or our own aseptic filling capability is developed and approved by the FDA. While we are dedicated to increasing our sales
revenue, we must consider the damage a mass market strategy could cause to the long-term value of the product. We have seen products
sold by much larger companies that were substantially damaged by such failed market launch strategies. We continue to develop detailed
launch plans, focusing on the readiness of dairy operators to successfully introduce <b>Re-Tain<sup>&#174;</sup></b> to their herds. We
believe that these prudent steps, while potentially leading to lower initial <b>Re-Tain<sup>&#174;</sup></b> revenues, may create a smooth
and successful launch and could safeguard the longer-term performance of our investment in <b>Re-Tain<sup>&#174;</sup></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect the DS production facility that we constructed to have initial annual production capacity sufficient to meet approximately $10
million in sales of <b>Re-Tain</b><sup>&#174;</sup> at current production yields without factoring in potential yield improvements, but
our supply of finished Drug Product (DP) will be limited until we find an alternative aseptic formulation and filling capability, as
discussed above. This production capacity estimate does not yet reflect any inventory build strategies or ongoing yield improvement initiatives.
We have available space in our existing DS facilities to double the production capacity by installing a second DS equipment train. A
decision on whether to use this space for a doubling of the DS production capacity or for in-house aseptic formulation and filling DP
equipment will be made post-approval. Our objective is to supply initial market launch with product produced at our DS facility and filled
by our contract DP manufacturer. We are expecting a pause in supply to the market after the Controlled Launch after goods produced by
our contract DP manufacturer are consumed and before we obtain FDA approval of an alternative DP manufacturing option. Although these
projections are subject to many risks and uncertainties (some of which are detailed in this Annual Report), if executed correctly, we
believe this strategy will lend itself to a more gradual adoption curve but higher and more sustainable sales over the long-term. Note
16, &#8220;Segment Information&#8221;, to the accompanying audited financial statements displays a break-out of our financial results
among the following three components of our business: i) Scours, ii) Mastitis and iii) Other, in order to allow investors to see our
progress with both products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Through
our anticipated growth in sales of the <b>First Defense</b><sup>&#174;</sup> product line, and as additional resources are dedicated to
production, sales, marketing and technical services, it is our objective to exceed our total product sales of $26.5 million achieved
during the year ended December 31, 2024 as soon as possible. Our longer-term goal is to exceed $35 million in product sales by approximately
2027.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Product
Development</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Most
of our product development spending has been focused on the development of <b>Re-Tain<sup>&#174;</sup></b>, our purified Nisin treatment
for subclinical mastitis in lactating cows. Between 2000 and 2024, we invested an aggregate of approximately $30.2 million in direct
expenditures for the development of this product (excluding depreciation, the capital cost of our DS production facility and overhead
expenses). Approximately $2.9 million of this investment was offset by related product licensing revenues and grant income, most of which
was earned from 2001 to 2007. More recently, we have initiated a preliminary investigation into potential applications
of Nisin for human healthcare, but we do not see a clear commercial path at this time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2004, we entered into a product development and marketing agreement with Zoetis (formerly Pfizer Animal Health, a division of Pfizer,
Inc.) covering this product. That company elected to terminate the agreement in 2007. We believe that this decision was not based on
any unanticipated efficacy or regulatory issues. Rather, we believe the decision was primarily driven by a marketing concern relating
to their fear that the milk from treated cows could interfere with the manufacture of certain cultured dairy products. Due to the zero-milk
discard feature, there is a risk that Nisin from the milk of treated cows could interfere with the manufacture of certain (but not all)
commercial cultured dairy products, such as some kinds of cheese and yogurt, if a process tank contains a high enough percentage of milk
from treated cows. The impact of this potential interference ranges from a delay in the manufacturing process (which does happen at times
for other reasons) to the less likely stopping of a cheese starter culture. Milk from cows that have been treated with our product that
is sold exclusively for fluid milk products presents no such risk. We worked with scientists and mastitis experts to conduct a formal
risk assessment to quantify the impact that milk from treated cows may have on cultured dairy products. This study concluded that the
dilution of milk from treated cows through comingling with milk from untreated cows during normal milk hauling and storage practices
reduces the risk of interference with commercial dairy cultures when the product is used in accordance with the product label. Further,
we believe that such a premium-priced product will be used selectively, which reduces the risk of cheese interference and is consistent
with modern &#8220;precision dairying&#8221; practices that discourage the indiscriminate use of drug treatments. Among the measures
that we intend to deploy will be detailed guidance on limiting the portion of a herd that is treated with <b>Re-Tain<sup>&#174;</sup></b>
at any one time in order to avoid concentration levels in the milk that could lead to the rejection of the contents in a cheese tank.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2000, we acquired an exclusive license from Nutrition 21, Inc. (formerly Applied Microbiology Inc. or AMBI) to develop and market Nisin-based
products for animal health applications, which allowed us to initiate the development of <b>Re-Tain<sup>&#174;</sup></b>. In 2004, we
paid Nutrition 21 approximately $965,000 to buy out this royalty and milestone-based license to Nisin, thereby acquiring control of the
animal health applications of Nisin. Nisin is a well characterized substance, having been used in food preservation applications for
over 50 years. Food-grade Nisin, however, cannot be used in pharmaceutical applications because of its low purity. Our Nisin technology
includes patented processing and purification methods to achieve pharmaceutical-grade purity. A much less pure preparation of our active
ingredient, Nisin, is commonly used as a food preservative and has been given &#8220;Generally Regarded as Safe&#8221; (GRAS) status
by the FDA. We are also investigating potential applications of Nisin for other animal health applications as well as for humans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our second most important product development
initiative (in terms of dollars invested and, we believe, potential market impact) has been focused on other improvements, extensions
or additions to our <b>First Defense<sup>&#174;</sup></b> product line. We anticipate initiating commercial sales of a new spray-dried
format of our <b>First Defense Technology<sup>&#174;</sup></b> in a bulk powder later this year. During the second quarter of 2009, we
entered into a perpetual, exclusive license with the Baylor College of Medicine covering the underlying rotavirus vaccine technology used
to generate the specific antibodies for use with animals. We achieved product license approval and initiated market launch of this product,
<b>Tri-Shield First Defense<sup>&#174;</sup></b>, during the fourth quarter of 2017. During the third quarter of 2018, we obtained approval
from the Canadian Food Inspection Agency to sell <b>Tri-Shield<sup>&#174;</sup></b> in Canada. We initiated sales in Canada through our
in-country distributor during the fourth quarter of 2019. We achieved USDA approval of our bivalent gel tube formulation (formerly marketed
as <b>First Defense Technology<sup>&#174;</sup></b>) during the fourth quarter of 2018 and have re-branded this product format as <b>Dual-Force
First Defense</b><sup>&#174;</sup>. We are currently working to establish USDA claims for our bivalent bulk powder formulation of <b>First
Defense Technology<sup>&#174;</sup></b>.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are also working to expand our product development pipeline of antimicrobials that can be used as alternatives to traditional antibiotics
through expansions of our Nisin technology and yield improvements. We intend to begin new development projects that are aligned with
our core competencies and market focus. We also remain interested in acquiring, on suitable terms, other new products and technologies
that fit with our sales focus on the dairy and beef industries when we have adequate cash reserves.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
competition in the animal health market includes other biotechnology companies and major animal health companies. Most, if not all, of
these competitors have substantially greater financial, marketing, manufacturing and human resources and more extensive product development
capabilities than we do.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
are several other products on the market (some with claims and some without) that are delivered to newborn calves to prevent scours.
We believe that the <b>First Defense<sup>&#174;</sup></b> product line offers two significant competitive advantages. First, the <b>First
Defense<sup>&#174;</sup></b> product line is the only calf-level product that provides protection against <i>E. coli, </i>coronavirus
and rotavirus, three of the leading causes of calf scours. Second, being derived from colostrum, our product offers <b>Immediate Immunity<sup>TM
</sup></b>through antibodies that both function at the gut level and are absorbed into the blood stream for future protection. All formats
of our product can be administered immediately after birth and are not negatively affected by maternal colostrum.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Zoetis
sells a product (Calf-Guard<sup>&#174;</sup>) that competes directly with the <b>First Defense<sup>&#174;</sup></b> product line in preventing
scours via oral delivery to newborn calves. Their product is a modified-live virus vaccine. Newborn calves respond poorly to vaccines,
and the immune system must be given time to develop a response to vaccines. Both our product and Calf-Guard<sup>&#174;</sup> carry claims
against coronavirus and rotavirus infections, but this competing product does not carry a claim against <i>E. coli </i>infections like
our product does. It is common practice to delay colostrum feeding when dosing a calf with Calf-Guard<sup>&#174;</sup> so that the antibodies
in the colostrum do not inactivate this vaccine product. There is no nutritional or health benefit to withholding milk from newborn calves.
In contrast, we encourage the feeding of four quarts of high quality colostrum immediately after birth when dosing a calf with our product,
which is standard practice for good calf health. Because the antibodies in our product would likely work to inactivate a modified-live
virus vaccine, rendering it useless or less useful, our product label historically included a precaution that <b>First Defense<sup>&#174;
</sup></b>should not be used within five days of such a vaccine. During the first quarter of 2015, the USDA granted us permission to
remove this precaution from our label, and we have done so. We believe that this precaution should be required on the Calf-Guard<sup>&#174;
</sup>label to prevent inactivation of that product by <b>First Defense<sup>&#174;</sup></b> antibodies or by colostrum. Our product is
priced at a premium to Calf-Guard<sup>&#174;</sup>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
the fourth quarter of 2016, Merck launched a new competing product into this market space. This product (BOVILIS<sup>&#174;</sup> Coronavirus)
is a modified-live virus intranasal vaccine that carries a claim against coronavirus only. Around the end of 2019, Elanco Animal Health
gave notice to the market that it had discontinued the manufacture of its competing products, Bovine Ecolizer<sup>&#174;</sup> and Bovine
Ecolizer + C20, and subsequently exited the market during the first quarter of 2021. This product was the smallest of our three significant
calf-level competitors. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">When
compared to the other USDA-approved calf-level scours preventatives, we lead in both sales dollars and calves treated within the U.S.
market. This product category is comprised of the three primary brands discussed above that are given either orally or intranasally to
newborn dairy and beef calves immediately after birth. With the rotavirus claim for our product (<b>Tri-Shield First Defense<sup>&#174;</sup></b>),
we are now also competing against dam-level vaccine products that are given to the mother cow to increase the antibody level against
scours-causing pathogens in the colostrum that she produces for her newborn. Those products are sold by Elanco (Scour Bos&#8482;), Merck
(Guardian<sup>&#174;</sup>) and Zoetis (ScourGuard<sup>&#174;</sup>). Despite the best-managed dam vaccine program, colostrum quality is
naturally variable and newborn calves do not always get the antibodies they need from maternal colostrum. We believe that the measured
dose of antibodies in our product provides more consistent protection than such vaccine products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
would consider any company that sells an antibiotic to treat mastitis, such as Boehringer Ingelheim, Merck Animal Health and Zoetis,
to be among the potential competitors with respect to <b>Re-Tain<sup>&#174;</sup></b>. We expect the FDA to grant a period of five years
of market exclusivity for our product (meaning the FDA would not grant approval to a second NADA with the same active drug for a period
of five years after the first NADA approval is granted) under Section 512(c)(2)F of the Federal Food, Drug, and Cosmetic Act. Our Nisin
A is produced from our high-yielding, proprietary <i>L. lactis</i> strain and purified to a high level, providing us with a level of
protection over a competitor that might try to develop a similar product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may not be aware of competition that we face, or may face in the future, from other companies. Our competitive position will be highly
influenced by our ability to attract and retain key scientific, manufacturing, managerial and sales and marketing personnel, to develop
and effectively produce and market proprietary technologies and products. We need to obtain USDA, FDA or foreign approvals for new products
to effectively promote and market our products. We must have available properly-licensed, efficient and effective raw material and finished
product manufacturing resources to continue to profitably sell our current products. We currently compete on the basis of product performance,
price, distribution capability and customer support. We continue to monitor our network of independent distributors to maintain our competitive
position.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own a collection of registered and unregistered intellectual property rights relating to our research, products and processes. These
rights include patents, copyrights, trademarks, trade dress, trade secrets, know-how and other intellectual property rights in the United
States and other countries. We believe the ownership of our intellectual property rights is an important factor in our business and that
our success depends in part on such ownership. We also rely heavily on the innovative skills, technical competence and marketing abilities
of our personnel. The Nisin A that is produced from our proprietary strain of <i>L. lactis</i> is an essential component of our <b>Re-Tain</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>&#174;
</sup></span></b><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">product and related intellectual
property. We enter into and rely on confidentiality and proprietary rights agreements with our employees, contractors and business partners
to protect our trade secrets, proprietary developments and confidential information. </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
own U.S. Patent No. 10,023,617 entitled &#8220;Methods and Systems of Producing Pharmaceutical Grade Lantibiotics&#8221;, which covers
key, novel and proprietary aspects of our manufacturing process for preparing pharmaceutical-grade Nisin and was issued during the third
quarter of 2018. In the future, we may file additional patent applications for certain products under development. There can be no assurance
that patents will be issued with respect to any pending or future applications. In some cases, we have chosen (and may choose in the
future) not to seek patent protection for certain products or processes. In those instances, we have sought (and may seek in the future)
to maintain the confidentiality of any relevant intellectual property and other proprietary rights through operational measures and contractual
agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
own numerous trademarks and trade dress that are very important to our business and have several trademark and trade dress registrations
in the United States, Canada and Iran. We own the following U.S. trademark registrations: <b>IMMUCELL</b>, <b>FIRST DEFENSE</b>, <b>FD
FIRST DEFENSE (&amp; Design), FIRST DEFENSE TECHNOLOGY</b>, <b>TRI-SHIELD FIRST DEFENSE, TRI-SHIELD FIRST DEFENSE (&amp; Design), YOUR
CALF CREW, BEYOND VACCINATION, BEYOND VACCINATION (&amp; Design), CALF HERO, DUAL-FORCE, TRI-SHIELD and RE-TAIN. </b><span style="font-style: normal; font-weight: normal">We
also own U.S. registrations claiming rights in the color blue for our blue gel and blue bolus </span><b>FIRST DEFENSE</b> <span style="font-style: normal; font-weight: normal">products.
We also own common law rights in the </span><b>IMMEDIATE IMMUNITY</b> <span style="font-style: normal"><span style="font-weight: normal">trademark
and other trademarks.</span></span></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that we are in compliance with current regulatory requirements relating to our business and products. The manufacture and sale
of animal health biologicals within the United States is generally regulated by the USDA. We have received USDA and Canadian Food Inspection
Agency approval for the bolus format of <b>First Defense<sup>&#174; </sup></b>and for the gel tube formats of <b>Tri-Shield First Defense<sup>&#174;
</sup></b>and <b>Dual-Force First Defense<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174;</sup></b> is regulated by the FDA, which regulates
veterinary drugs. Regulations in the European Union will likely require that <b>Re-Tain<sup>&#174;</sup></b> be sold subject to a milk
discard requirement in that territory, although the duration of the milk discard requirement may be shorter than the discard requirement
applicable to competing antibiotic products in that market. Comparable agencies exist in foreign countries, and foreign sales of our
products will be subject to regulation by such agencies. Many countries have laws regulating the production, sale, distribution or use
of biological products, and we may have to obtain approvals from regulatory authorities in countries in which we propose to sell our
products. Depending upon the product and its applications, obtaining regulatory approvals may be a relatively brief and inexpensive procedure
or it may involve extensive clinical tests, incurring significant expenses and an approval process of several years&#8217; duration.
We generally rely on in-country experts to assist us with or to perform international regulatory applications.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
currently employ 75 employees (including 6 part-time employees) in comparison to 79 employees (including 5 part-time employees) approximately
a year ago. Approximately 57 full-time equivalent employees are engaged in quality and manufacturing operations, 8.5 full-time equivalent
employees in sales and marketing, 2.5 full-time equivalent employees in product development activities (primarily supporting facility
maintenance and operation, regulatory filings and commercial scale-up for <b>Re-Tain<sup>&#174;</sup></b>) and 4 full-time equivalent
employees in finance and administration. As needed, we augment our staff with contracted temporary employees. All of our employees are
required to execute non-disclosure and invention assignment agreements (and some are required to execute non-compete agreements) intended
to protect our rights in our proprietary products. We are not a party to any collective bargaining agreement and consider our employee
relations to be excellent.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Public
Information</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
a reporting company, we file quarterly and annual reports with the Securities and Exchange Commission (SEC) on Form 10-Q and Form 10-K,
respectively. We also file current reports on Form 8-K, whenever events warrant or require such a filing. The public may read and copy
any materials that we file with the SEC at the SEC&#8217;s Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The
public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an
internet site that contains reports, proxy and information statements and other information about us that we file electronically with
the SEC at <i>http://www.sec.gov</i>. Our internet address is http://www.immucell.com. References to our website in this Annual Report
are inactive textual references only, and the content of our website should not be deemed incorporated by reference for any purpose.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 1A&#8212;
RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>OUTLINE
TO ITEM 1A &#8211; RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Financial
                                            Risks</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Product
                                            Risks</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Regulatory
                                            Risks</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Economic
                                            Risks Pertaining to the Dairy and Beef Industries</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Small
                                            Size of the Company</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Global
                                            Risks</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Risk
                                            Pertaining to Common Stock</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Other
                                            Risks</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Financial
Risks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Gross
margin on product sales:</i> One of our goals is to achieve a gross margin as a percentage of total sales of 40% or more (including depreciation
expense) after the initial launch of new products. Depreciation expense will be a larger component of costs of goods sold for <b>Re-Tain<sup>&#174;
</sup></b>than it is for the <b>First Defense<sup>&#174;</sup></b> product line. Gross margins generally improve over time, but this anticipated
improvement may not be realized for <b>Re-Tain<sup>&#174;</sup></b>. Many factors discussed in this Annual Report (including contaminations,
process yields, inflation, cost increases, supply-chain disruptions and the rising price of oil and other commodities and supplies) impact
our costs of goods sold. There is a risk that we are not able to achieve our gross margin goal, which would adversely affect our operating
results and could impact our future operating plans. We missed our gross margin goal during the years ended December 31, 2024 and 2023
with realized gross margins of 30% and 22%, respectively. There is a risk that our plans to maintain or improve our gross margin may
not be realized due to cost increases, production yield losses, additional manufacturing contamination events, production equipment failures,
price inelasticity or any combination of these factors. In addition, such negative events, depending on their severity, could deplete
our cash resulting in an inability to fund our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Exposure
to interest rates and debt service obligations:</i> Rising interest rates could negatively affect the operating costs of dairy and beef
producers and thus put further financial pressure on an already stressed business sector, which could indirectly, but materially and
adversely, affect our business. Increases in interest rates since 2020 have had only limited effect on our direct cost of borrowing.
During the first quarter of 2020, we refinanced our bank debt (with the exception of our line of credit) with fixed rate notes. Our mortgage
debt outstanding as of December 31, 2024 was $5.6 million bearing interest at the fixed rate of 3.53% per annum. Our equipment loans
outstanding as of December 31, 2024 were $1.9 million bearing interest at the fixed rate of 3.50% per annum. The outstanding balance
on the two State of Maine loans as of December 31, 2024 was approximately $592,000 bearing interest at the fixed rate of 5% per annum.
The $3 million in debt that we borrowed during the third quarter of 2023 (which had an outstanding balance of approximately $2.5 million
as of December 31, 2024) bears interest at the blended fixed rate of 7.33% per annum illustrating the effect of rising interest rates.
Our outstanding debt as of December 31, 2024 aggregating $10.6 million (gross of debt issuance and debt discount costs) bears interest
at the blended fixed rate of 4.51% per annum. Increasing interest rates would negatively impact the cost of any future borrowings. This
was experienced on the new debt facilities aggregating $3 million that we closed during the third quarter of 2023. The additional debt
we incurred to fund our growth objectives has significantly increased our total debt service costs. We are obligated to make principal
and interest payments aggregating approximately $2 million and $3.7 million during the years ending December 31, 2025 and 2026, respectively.
See Note 9 to the accompanying audited financial statements for more details about our debt. A decline in sales or gross margin, coupled
with this debt service burden, could impair our ability to fund our capital and operating needs and objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Debt
covenants:</i> Our debt with Maine Community Bank (formerly Gorham Savings Bank) and the Finance Authority of Maine is subject to certain
financial covenants. We are required to meet a minimum debt service coverage (DSC) ratio of 1.35. Our actual DSC ratios were 0.73, (1.10),
0.44, 2.68 and 2.03 for the years ended December 31, 2024, 2023, 2022, 2021 and 2020, respectively. During the first quarter of 2023,
the DSC ratio covenant for the year ended December 31, 2023 was preemptively waived by our lender. Instead, we were required to meet
a minimum DSC ratio requirement of 1.35 for the twelve-month periods ended June 30, 2024, September 30, 2024 and December 31, 2024, and
then again annually after that. During the first quarter of 2024, the DSC ratio covenant for the twelve-month period ended June 30, 2024
was preemptively waived by our lenders. During the third quarter of 2024, the DSC ratio covenant for the twelve-month period ended September
30, 2024 was preemptively waived by our lenders. During the fourth quarter of 2024, the DSC ratio covenant for the twelve-month period
ended December 31, 2024 was preemptively waived by our lenders. Our next compliance obligation is for the year ending December 31, 2025.
There is no assurance that we will be able to achieve the required DSC ratio going forward. If we are unable to do so or reach a favorable
agreement with our lenders regarding that requirement (including an amendment to or waiver of such requirement), we would be in violation
of that covenant, which could result in unfavorable amendments to the terms of our bank debt (including a possible bank requirement to
prepay our debt) or have other adverse impacts on our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Currency
exchange fluctuation: </i>We do not believe that currency exchange rates have had a significant effect on our revenues and expenses.
However, future increases in the value of the U.S. dollar could affect our customers and the demand for our products. We hope to increase
the level of our future sales of products outside the United States. The cost of our products to international customers could be affected
by currency fluctuations. The decline of the U.S. dollar against other currencies could make our products less expensive to international
customers. Conversely, a stronger U.S. dollar could make our products more costly for international customers. A weaker U.S. dollar makes
international purchases more expensive for us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Inflation,
supply disruptions, tax rates and economic downturns:</i> Inflation is having a material and adverse impact on almost all supplies we
purchase and labor we hire and retain. Continuing or increasing inflationary trends could materially reduce our gross margin on product
sales if we are unable or unwilling to impose offsetting price increases on our customers. The extent and duration of the negative impact
on the economics of our customers and on the demand for our products going forward are very difficult to assess. The dairy market, similar
to many others, has been unstable as a result of the pandemic. The price paid to producers for milk has been very volatile. The Class
III milk price has been extremely volatile since the onset of the pandemic. Market conditions have improved somewhat, but this volatility
remains a concern. Additionally, like most input costs, the cost of grain and other feed is rising, which puts a strain on the profitability
of our customers. There is also economic uncertainty for beef producers, as the supply chain is interrupted or otherwise adversely affected
due to closures of processing plants and reduced throughput. This is a very unusual situation for farmers who work so hard to improve
production quality and efficiency in order to help feed a growing population with high-quality and cost-effective proteins. The pandemic
created risk and continues to create uncertainty and challenges for us and has created or contributed to global supply-chain disruptions
and has affected international trade, while creating a worldwide health and economic crisis. Stock market valuations have declined and
recovered somewhat but remain very volatile. Inflation has increased significantly, and tax rates may increase. There is a risk of a
period of economic downturn, the severity and duration of which are difficult to know. Prior to the pandemic and the responsive federal
economic stimulus programs, many feared the United States had taken on too much national debt. Now the debt load is significantly higher.
A combination of the conditions, trends and concerns summarized above could have a corresponding negative effect on our business and
operations, including the supply of the colostrum we purchase to produce our <b>First Defense<sup>&#174;</sup></b> product line, the demand
for our products in the U.S. market and our ability to penetrate or maintain a profitable presence in international markets. Our exposure
to this risk is mitigated to some extent by the fact that our supply chain is not heavily dependent on foreign manufacturers, by our
on-going cross-training of our employees, by qualifying alternate suppliers and components and by our early and continued compliance
with recommended hygiene.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Projection
of net (loss) income:</i> Generally speaking, our financial performance can differ significantly from management projections, due to
numerous factors that are difficult to predict or that are beyond our control. Weaker than expected sales of the <b>First Defense<sup>&#174;
</sup></b>product line could lead to deeper operating losses or less profits. The timing of FDA approval of <b>Re-Tain<sup>&#174;</sup></b>
will continue to have a material impact on our net (loss) income until sufficient commercial sales are generated and sustained, unless
we adequately reduce product development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Risks
associated with our funding strategy for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>:</i> The inability to maintain adequate cash and
liquidity to support the commercialization of <b>Re-Tain<sup>&#174;</sup></b> is a risk to our business. Achieving FDA approval of our
pharmaceutical-grade Nisin produced at commercial-scale is the most critical action remaining in front of us on our path to U.S. regulatory
approval of <b>Re-Tain<sup>&#174;</sup></b>. Having completed the construction and equipping of the DS production facility (as described
in more detail in <b>PART I: ITEM 2</b> of this Annual Report) at a cost of approximately $20.8 million, we will continue to incur product
development expenses to operate and maintain this facility until commercialization, although we are reducing these expenses now that
production of inventory for our Controlled Launch is complete.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Uncertainty
of market size and product sales estimates:</i> Estimating the size of the total addressable market and future sales growth potential
for our <b>First Defense<sup>&#174;</sup></b> product line is based on our experience and understanding of market dynamics but is inherently
subjective. Estimating the size of the market for any new product, such as <b>Re-Tain<sup>&#174;</sup></b>, involves more uncertainties
than do projections for established products. We do not know whether, or to what extent, our products will achieve, maintain or increase
market acceptance and profitability. Some of the uncertainties surrounding <b>Re-Tain<sup>&#174;</sup></b> include the product&#8217;s
effectiveness against currently prevalent pathogens, market acceptance, the effect of a premium selling price on market penetration,
cost of manufacture, competition from new and existing products sold by substantially larger competitors with greater market reach and
promotional resources and other risks described under &#8220;Product Risks&#8221; &#8211; &#8220;Sales risks pertaining to <b>Re-Tain<sup>&#174;</sup></b>&#8221;
below. Since <b>Re-Tain<sup>&#174;</sup></b> is a novel approach to treating mastitis, there are many uncertainties with regards to how
quickly and to what extent we can develop the subclinical mastitis treatment market. We believe that polypeptide antimicrobial technology
may be viewed positively (relative to traditional antibiotics). If realized, this may offset some of these risks and result in better
overall market acceptance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Net
deferred tax assets:</i> The realizability of our net deferred tax assets is a subjective estimate that is contingent upon many variables.
During the second quarter of 2018, we recorded a full valuation allowance against our net deferred tax assets that significantly increased
our net loss in comparison to other periods. This non-cash expense could be reversed, and this valuation allowance could be reduced or
eliminated, if warranted by our actual and projected profitability in the future. We will continue to assess the need for the valuation
allowance each quarter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Product
Risks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Product
risks generally:</i> We set objectives for our products that we believe we can achieve, but the achievement of such goals is not a certainty.
The sale of our products is subject to production, financial, efficacy, regulatory, competitive and other market risks. Elevated standards
to achieve and maintain regulatory compliance required to sell our products continue to evolve. Failure to achieve acceptable biological
yields from our production processes can materially increase our costs of goods sold and reduce our production output, leading to lower
margins and/or an order backlog that could adversely affect our customer relationships and operating results. <b>First Defense<sup>&#174;
</sup></b>is sold, and we expect <b>Re-Tain<sup>&#174;</sup></b> to be sold, at significant price premiums relative to competitive products.
There is no assurance that we will continue to achieve market acceptance of the <b>First Defense<sup>&#174;</sup></b> product line, or
achieve and sustain market acceptance of <b>Re-Tain<sup>&#174;</sup></b>, at a profitable price level or that we can continue to manufacture
our products at a low enough cost to result in a sufficient gross margin to justify their continued manufacture and sale. As we bring
<b>Re-Tain<sup>&#174;</sup></b> to market, these risks could be heightened by the additional uncertainties associated with introducing
a new product requiring a shift in customer behavior.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Contamination
events, equipment failures and gross margin from our production process:</i> During the first three and a half months of 2024 as well
as during 2023 and late 2022, we experienced certain contamination events and equipment failures in our production process that resulted
in scrapped inventory and a slowdown of our production process, which had a significant negative impact on our operating results. The
realization of this risk following the contamination events discussed above did result in a slowdown of our production output during
2023 to remediate this problem, which led to less sales and gross margin during the year. We are at risk of further such production contaminations
or equipment failures resulting in more scrapped inventory. Additional contamination events or equipment failures causing significantly
less production output, depending on their severity, could deplete our cash resulting in an inability to fund our business operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
risks pertaining to <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>: </i>Actual or prospective <b>Re-Tain<sup>&#174; </sup></b>customers
may decide to discontinue, reduce or avoid usage of <b>Re-Tain<sup>&#174; </sup></b>due to the following risks:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1)
A rejection of a tank of milk by a positive milk inhibitor test because too much of the milk in a bulk tank is comprised of milk from
cows being treated with <b>Re-Tain<sup>&#174;</sup></b>, when tested randomly for inhibitors by a milk hauler, which could create legal
liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2)
A failed or stalled cheese tank occurs when a Nisin susceptible cheese starter culture is impacted by residues in milk that exceed our
on-farm treatment recommendations, which aims to limit concentrations of bulk tanks or tankers to 1% of milk from cows treated with <b>Re-Tain<sup>&#174;
</sup></b>or is not effectively diluted through the milk collection and transportation system. After we study this potential impact during
our Controlled Launch of <b>Re-Tain<sup>&#174;</sup></b>, we may decide to seek a post-approval label change requiring a short discard
of milk, which may be limited to just the treated quarter of the cow.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3)
Producers&#8217; current practice generally is to treat only clinical mastitis, which has the visual indicator of abnormal milk. In order
to gain market penetration for <b>Re-Tain<sup>&#174;</sup></b>, we will need to change that practice and increase awareness of the importance
of treating subclinical disease. This will require the producers&#8217; ability and willingness to diagnose without visual indicators.
Users of <b>Re-Tain<sup>&#174;</sup></b> could have unsatisfactory treatment outcomes if they lack the equipment needed to measure and
monitor somatic cell counts (SCC) of the herd or individual cows (for which data is needed). This risk limits our access to treatment
cows because about 40% of farms do not presently have access to this kind of testing at the cow level, and thus are not good candidates
for the use of <b>Re-Tain<sup>&#174;</sup></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4)
Lower than anticipated treatment cure rates could be experienced because the product is administered to cows that we would not identify
as the best treatment candidates based on SCC data or because the product is administered to cows that are infected with pathogens outside
of our label claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5)
Off-label use of our product in cows infected with clinical mastitis before we have run the required studies and achieved a label claim
extension for this disease state, resulting in negative treatment outcomes and potential legal liability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6)
Producers either do not choose to use it or might use it improperly, rather than follow our label instructions to administer one dose
after each of three consecutive milkings, or they may limit use within the herd in an abundance of caution to avoid the negative outcomes
described above.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7)
Our agreement to have DP filled by our current contract manufacturer expired in November of 2024. However, this agreement does provide
for ongoing product labeling and packaging through the first quarter of 2026. Based on the anticipated best-case product expiration dating
for <b>Re-Tain<sup>&#174;</sup></b>, we could have inventory available for sale into the first quarter of 2026. We would need to secure
a new DP manufacturing agreement, or bring the process in-house, to fill more inventory after that.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Reliance
on sales of the <b>First Defense<sup>&#174;</sup></b> product line:</i> We presently are reliant on the market acceptance of the <b>First
Defense<sup>&#174;</sup></b> product line to generate product sales and fund our operations. Our business would not have been profitable
during the years ended December 31, 2012, 2013, 2015 and 2016, during the nine-month periods ended September 30, 2017 or during the three-month
periods ended March 31, 2019, December 31, 2020, June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and December 31,
2024 without the gross margin that we earned on sales of the <b>First Defense<sup>&#174;</sup></b> product line. Our anticipated return
to profitability is contingent upon the gross margin we earn from <b>First Defense<sup>&#174;</sup></b> and prudent management of product
development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Concentration
of sales:</i> Sales of the <b>First Defense<sup>&#174;</sup></b> product line aggregated 99% of our total product sales during both of
the years ended December 31, 2024 and 2023. Our primary customers for the majority of our product sales (86% and 91% during the years
ended December 31, 2024 and 2023, respectively), are in the U.S. dairy and beef industries. The concentration of our sales from one product
into just two markets (the dairy and beef markets) is a risk to our business. The animal health distribution segment has been aggressively
consolidating over the last few years, with larger distributors acquiring smaller distributors. A large portion of our product sales
(77% and 79% during the years ended December 31, 2024 and 2023, respectively), was made to two large distributors. A large portion of
our trade accounts receivable (78% and 79% as of December 31, 2024 and 2023, respectively) was due from these two distributors. We have
a good history with these distributors, but the concentration of sales and accounts receivable with a small number of customers does
present a risk to us, including risks related to such customers experiencing financial difficulties or altering the basis on which they
do business with us in a manner unfavorable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Production
capacity constraints:</i> We invested $9.9 million from 2019 to December 31, 2024 to increase our annual production capacity (in terms
of annual sales dollars) for the <b>First Defense<sup>&#174;</sup></b> product line from approximately $16.5 million to approximately
$30 million or more based on current selling prices and estimated production yields. We are making initial plans to further increase
our production capacity. While previous capacity expansion investments have proceeded very close to budget, there is a risk of cost overruns
in our ongoing projects and any future production expansions that we may undertake, and a risk that we will not be able to achieve our
production capacity growth objectives on a timely basis, resulting in a continuing or increasing shortfall in supply to the market. The
inability to meet market demand for our products is a risk to our business. The historically large backlog of orders, as well as any
ongoing order backlog, presents a risk that we could lose customers during this period that are not easily regained thereafter, when
our production capacity is expected to meet or exceed sales demand. Our long-term capital plan to continue to expand the <b>First Defense<sup>&#174;
</sup></b>product line requires ongoing review of equipment capacity and utilization across the manufacturing value stream at <b>Building
56</b> and our leased facilities at <b>Building 175A</b> and <b>175B</b>, as well as assessment of costs, functional obsolescence and
reliability of equipment. This review and assessment could identify a need to fund unexpected equipment maintenance or replacement costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Product
liability:</i> The manufacture and sale of our products entails a risk of product liability. Our exposure to product liability is mitigated
to some extent by the fact that our products are directed towards the animal health market. We have maintained product liability insurance
in an amount which we believe is reasonable in relation to our potential exposure in this area. We have no history of claims of this
nature being made.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Regulatory
Risks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Regulatory
requirements for the <b>First Defense<sup>&#174;</sup></b> product line:</i> <b>First Defense<sup>&#174;</sup></b> is sold in the United
States subject to a product license from the Center for Veterinary Biologics, USDA, which was first obtained in 1991, with subsequent
approvals of line extensions in 2017 and 2018. As a result, our operations are subject to periodic inspection by the USDA, and we are
at risk of an unfavorable outcome from such inspections. The potency of serial lots is directly traceable to the original serial used
to obtain the product performance claims (the Reference Standard). Due to the unique nature of the label claims, host animal re-testing
is not required as long as periodic laboratory analyses continue to support the stability of the stored Reference Standard. To date,
these analyses have demonstrated strong stability. However, if the USDA were not to approve requalification of the Reference Standard,
additional clinical studies could be required to meet regulatory requirements and allow for continued sales of the product, which could
interrupt sales and adversely affect our operating results. Territories outside of the United States may require additional regulatory
oversight that we may not be able to meet with our current facilities, processes and resources. There is a risk that we will become subject
to regulatory actions in the future, including actions that result in our inability to ship product. In these cases, the resulting interruption
in sales could have a material and adverse effect on our operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Regulatory
requirements for <b>Re-Tain</b></i><b><sup>&#174;</sup></b><i>: </i>Commercial introduction of this product in the United States requires
us to obtain FDA approval. Completing the process of obtaining FDA approval of the pending NADA involves risk. The regulatory development
process timeline has been extensive (approximately 17 years from when the product rights were returned to us by a former partner in 2007)
and has involved multiple commercial production strategies and multiple submissions of the Chemistry, Manufacturing and Controls (CMC)
Technical Section. We received an Incomplete Letter from the FDA regarding this CMC Technical Section during the third quarter of 2022
that clarified the required path to product approval. During May of 2024, we received an Incomplete Letter from the FDA in response to
our November of 2023 re-submission. To reduce the risk associated with this process, we are working with a qualified contract manufacturer
(Norbrook) for alignment of the required validations and DP manufacture and have met with the FDA to clarify filing strategy and requirements.
Early during the first quarter of 2024, the FDA conducted another pre-approval inspection of our DS facility. This resulted in the issuance
of one deficiency as identified on the FDA&#8217;s Form 483. Since then, we have cleared the inspectional observation with the FDA. However,
our efforts continue to be subject to inspection and approval by the FDA and other factors outside of our control, and there remains
a risk that the required FDA approvals of our product and facilities could be further delayed or not obtained. The facility of our contract
manufacturer is subject to similar inspectional obligations and is currently working to resolve certain inspectional observations at
their facility and is subject to re-inspection by the FDA. International regulatory approvals would be required for sales of <b>Re-Tain<sup>&#174;
</sup></b>outside of the United States, and there is a risk that these approvals would be or become too costly to pursue or be delayed
or not obtained.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>Regulatory requirements limiting access to
suppliers and customer base:</i> Maine, where our principal executive office and manufacturing facilities are located, has adopted product
reporting and phase-out requirements for per- and polyfluoroalkyl substances (&#8220;PFAS&#8221;). Maine&#8217;s statute establishes a
phased ban for products that contain intentionally added PFAS, with all products (subject to certain exceptions) other than cooling, heating,
ventilation, air conditioning or refrigeration equipment being banned by 2032 unless the Maine Department of Environmental Protection
(&#8220;DEP&#8221;) has determined that the use of PFAS within the product is a &#8220;currently unavoidable use.&#8221; Beginning January
1, 2032, the sale of products containing intentionally added but &#8220;currently unavoidable&#8221; PFAS also is banned if the manufacturer
of such products has failed to report to the DEP information concerning the presence of PFAS in those products. The phased bans may limit
our ability to access supplies and may limit those customers to whom we may sell our products. The U.S. Environmental Protection Agency
also has adopted a PFAS reporting law, which requires that importers of articles that contain PFAS report the presence of such substances
to the extent such information is known or reasonably ascertainable. This reporting requirement may limit our ability to import supplies.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Economic
Risks Pertaining to the Dairy and Beef Industries</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Immigration:
</i>The U.S. government is stepping up deportation efforts, resulting in a rising rate of deportations of criminals that are in our country
illegally. Many farms employ hard-working, non-criminal employees who have not yet achieved legal citizenship. Significant deportations
of these individuals could have a negative impact on the operations of our customers and of our source farms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
industry data referred to below is compiled from USDA databases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Cattle
count:</i> The January count of all cattle and calves in the United States had steadily declined from 97,000,000 as of January 1, 2007
to 88,500,000 as of January 1, 2014. Then this figure increased each year, reaching 94,800,000 as of January 1, 2019 before declining
to 93,800,000 as of both January 1, 2020 and January 1, 2021. This count continued to decline to 92,100,000 as of January 1, 2022 and
to 88,800,000 as of January 1, 2023 and to 87,200,000 as of January 1, 2024. This count dropped to 86,700,000 as of January 1, 2025.
The cattle count has not been this low since it was 82,100,000 in 1951. Reflecting seasonal trends, this figure was equal to 102,000,000,
101,000,000, 98,600,000 and 95,900,000 as of July 1, 2020, 2021, 2022 and 2023, respectively. The USDA did not make this data point available
as of July 1, 2024. A significant decline in the cattle count could negatively affect the size of our addressable market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Herd
size:</i> Prior to 1957, there were over 20,000,000 cows in the U.S. dairy herd. Prior to 1986, there were over 10,000,000 cows in the
U.S. dairy herd. From 1998 through 2021, the size (annual average) of the U.S. dairy herd ranged from the low of 9,011,000 in 2004 to
the high of 9,448,000 in 2021. This average declined to 9,402,000 during the year ended December 31, 2022 and then declined to 9,386,000
during the year ended December 31, 2023. This average declined slightly to 9,342,000 during the year ended December 31, 2024. A significant
decline in the herd size could negatively affect the size of our addressable market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: normal bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">ImmuCell
Corporation</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Milk
cow price:</i> The all-time high value (annual average) for a milk cow was $1,993 during 2015. Since then, this annual average value
steadily declined to $1,205 during 2019 before increasing to $1,300 during 2020 and to $1,363 during 2021. This price for 2022 increased
significantly to an average of $1,598, which is a 17% increase over 2021. The 2023 average price of $1,763 represents a 10% increase
over prior year. This price for 2024 increased to an average of $2,243, which is a 27% increase over 2023. A significant decline in the
milk cow price could negatively affect the size of our addressable market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Milk
price:</i> The dairy market, similar to many others, has been unstable for several reasons including as a result of the pandemic. The
price paid to producers for milk has been very volatile. This market volatility, and the resulting impact on our primary end users, could
negatively impact our ability to maintain and grow sales at a profitable level. The Class III milk price (an industry benchmark that
reflects the value of product used to make cheese) is an important indicator because it defines our customers&#8217; revenue level. This
annual average milk price level (measured in dollars per hundred pounds of milk) reached its highest point (since these prices were first
reported in 1980) during 2014 at $22.34 (peaking at $24.60 in September of 2014), which price level has never been repeated. During the
year ended December 31, 2020, this average milk price was equal to $18.16, but it was extremely volatile during the year due largely
to disruption in demand related to the COVID-19 pandemic. The one-month fluctuation of 73% from a low of $12.14 in May of 2020 to $21.04
in June of 2020 set an all-time record for variability. The average price for 2021 decreased by 6% to $17.08. This price average increased
by 29% to $21.96 during the year ended December 31, 2022. The average price decreased by 22% to $17.02 during the year ended December
31, 2023. This average price increased by 11% to $18.89 during the year ended December 31, 2024. The annual fluctuations in this milk
price level are demonstrated in the following table:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Average Class III Milk Price During the Years
    Ended December 31,</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22.34</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2015</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15.80</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(29)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2016</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(6)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2017</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.17</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">9%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2018</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14.61</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(10)%</td><td style="text-align: left">&#160;&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2019</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">16%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.08</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(6)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21.96</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">29%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(22)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18.89</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">11%</td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Feed
Costs:</i> The actual level of milk prices may be less important than its level relative to feed costs. One measure of this relationship
is known as the milk-to-feed price ratio, which represents the amount of feed that one pound of milk can buy. An increase in feed costs
also has a negative impact on the beef industry and therefore could have a resulting negative impact on our business and results of operations.
This ratio varies farm-to-farm based on individual operating parameters. Since this ratio reached 3.24 in 2005, it has not exceeded 3.00.
This ratio averaged 1.74 for 2021, amounting to a significant decline of 25% from the 2020 average of 2.32. This average has not been
lower since 2012. During 2022, this ratio improved by 10% to 1.91. This ratio dropped by 12% to 1.67 during the year ended December 31,
2023. This ratio increased to 2.49 during the year ended December 31, 2024, representing an increase of 49%. The following table demonstrates
the annual volatility and the low values of this ratio recently:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Average Milk-To-Feed Price Ratio During the Years Ended December 31,</td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">(Decrease) Increase</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2014</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.54</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2015</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(16)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2016</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.26</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">6%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2017</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">7%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.05</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(15)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.32</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">3%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.74</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(25)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">10%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.67</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">(12)%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.49</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">49%</td><td style="text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Volatility
of the dairy market</i>: While the number of cows in the U.S. herd and the production of milk per cow directly influence the supply of
milk, the price for milk is also influenced by very volatile international demand for milk products. Given our focus on the dairy and
beef industries, the volatile market conditions and the resulting financial insecurities of our primary end users are risks to our ability
to maintain and grow sales at a profitable level. These factors also heighten the challenge of selling premium-priced animal health products
(such as <b>Tri-Shield<sup>&#174;</sup></b> and <b>Re-Tain<sup>&#174;</sup></b>) into the dairy market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Small
Size of the Company</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Dependence
on key personnel: </i>We are a small company with approximately 75 employees (including 6 part-time employees). As such, we rely on certain
key employees to support multiple operational functions, with limited redundancy in capacity. The loss of any of these key employees
could adversely affect our operations until a qualified replacement is hired and trained, which could be even more challenging in the
present difficult labor market. Our competitive position will be highly influenced by our ability to attract, retain and motivate key
scientific, manufacturing, managerial and sales and marketing personnel. The cost of attracting and retaining the needed additional personnel
in this current job market and inflationary environment could adversely affect our margins and profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Reliance
on outside party to provide certain services under contract for us: </i>We are exposed to additional regulatory compliance risks through
the subcontractors that we choose to work with to produce <b>Re-Tain<sup>&#174;</sup></b>, who also need to satisfy certain regulatory
requirements in order to provide us with the products and services we need. One example of this outside reliance is Norbrook, our DP
contract manufacturer. Because Norbrook notified us of its intent to terminate its supply agreement with us, we initiated an investment
of approximately $4 million during 2022 to construct and equip our own DP formulation and aseptic filling capability for <b>Re-Tain<sup>&#174;
</sup></b>in our existing DS facility. Due to the loss in gross margin during 2023 caused by the slowdown in production output necessary
to remediate product contamination events, we have decided to defer spending of approximately $2 million of these funds for the near
term. The objective of this investment is to end our reliance on an outside party to perform these services for us. Actual project costs
could exceed our current estimates. Completion of this project could be delayed due to a number of factors outside our control, including
delays in equipment fabrication, equipment delivery or facility construction. In addition, there is a risk that we fail to achieve regulatory
approval of the new facility or that such approval is delayed or requires significant additional expenditures to obtain. We are evaluating
alternatives for DP supply going forward, which include the resumption of the investment in our own in-house DP services (when prudent
based on our cash reserves) or another contract manufacturing agreement or a further extension with Norbrook. We anticipate a supply
interruption under our Controlled Launch of <b>Re-Tain<sup>&#174;</sup></b> after the DP supply provided from our contract manufacturer
is consumed and until new supply from a new contract manufacturing agreement or our own formulation and aseptic filling facility is implemented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Competition
from others:</i> Many of our competitors are significantly larger and more diversified in the relevant markets than we are and have substantially
greater financial, marketing, manufacturing and human resources and more extensive product development and sales/distribution capabilities
than we do, including greater ability to withstand adverse economic or market conditions and declining revenues and/or profitability.
Merck and Zoetis, among other companies, sell products that compete directly with the <b>First Defense<sup>&#174;</sup></b> product line
in preventing scours in newborn calves. The scours product sold by Zoetis sells for approximately half the price of our product, although
it does not have an <i>E. coli</i> claim (which ours does). With <b>Tri-Shield<sup>&#174;</sup></b>, we can compete more effectively against
vaccines that are given to the mother cow (dam) to improve the quality of the colostrum that she produces for the newborn calf. Elanco,
Merck and Zoetis provide these dam vaccine products to the market. There are many companies competing in the mastitis treatment market,
most notably Boehringer Ingelheim, Merck and Zoetis. The mastitis products sold by these large companies are well established in the
market and are priced lower than what we expect for <b>Re-Tain<sup>&#174;</sup></b>, but all of them involve traditional antibiotics and
are sold subject to a requirement to discard milk during and for a period of time after treatment (unlike our product which does not
carry an FDA-required milk discard or pre-slaughter withdrawal period). There is no assurance that our products will compete successfully
in these markets. We may not be aware of other companies that compete with us or intend to compete with us in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Global
Risks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Tariffs
and Trade Policies: </i>Changes in tariffs or cross-border trade policies could affect our ability to expand sales of our products into
foreign markets. The businesses of some of our U.S. dairy and beef customers could be significantly affected by changes in tariffs or
trade policies, thus negatively affecting demand for our products. Additionally, tariffs on products and materials that we import could
increase our costs of goods sold.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>International
Conflicts: </i>International conflicts, including ongoing wars in Ukraine and the Middle East, give rise to uncertainties and stress
on the global economy, which in turn can affect the demand for our products and our costs of operation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Climate
change:</i> Our business, and our activities and the activities of our customers and suppliers, could be disrupted by climate change.
Potential physical risks from climate change may include altered distribution and intensity of rainfall, prolonged droughts or flooding,
increased frequency of wildfires and other natural disasters, rising sea levels, and a rising heat index, any of which could cause negative
impacts to our and our customers&#8217; and suppliers&#8217; businesses. Increased temperatures and rising water levels may negatively
impact our dairy and beef livestock customers by increasing the prevalence of parasites and diseases that affect food animals. The physical
changes caused by climate change may also prompt changes in regulations or consumer preferences which in turn could have negative consequences
for our and our customers&#8217; businesses. Climate change may negatively impact our customers&#8217; operations. In addition, concerns
regarding greenhouse gas emissions and other potential environmental impacts of livestock production have led to some consumers opting
to limit or avoid consuming animal products. If such events affect our customers&#8217; businesses, they may purchase fewer of our products,
and our revenues may be negatively impacted. Climate driven changes could have a material adverse impact on the financial performance
of our business and on our customers. In addition, increased frequency of natural disasters and adverse weather conditions may disrupt
our manufacturing processes or our supply chain. These disruptions may have a material adverse effect on our business, financial condition,
results of operations and/or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Bovine
diseases: </i>The potential for epidemics of bovine diseases such as Highly Pathogenic Avian Influenza (HPAI), Foot and Mouth Disease,
Bovine Tuberculosis, Brucellosis and Bovine Spongiform Encephalopathy (BSE) presents a risk to us and our customers. We have seen a severe
negative impact of bird flu on the U.S. poultry flock causing a significant increase in the price of eggs. We have seen a cross-over
to cows in the dairy industry. Documented cases of BSE in the United States have led to an overall tightening of regulations pertaining
to ingredients of animal origin, especially bovine. The <b>First Defense<sup>&#174;</sup></b> product line is manufactured from concentrated
bovine colostrum, which is not considered a BSE risk material. Future regulatory action to increase protection of the human food supply
could affect the <b>First Defense<sup>&#174;</sup></b> product line, although presently we do not anticipate that this will be the case.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Pertaining to Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Stock
market valuation and liquidity:</i> Our common stock trades on The Nasdaq Capital Market (Nasdaq: ICCC). Our average daily trading volume
(which was 7,100 shares per day during the 20-day period ended March 21, 2025) is lower, our bid/ask stock price spread can be larger
and our share price can be more volatile than what other companies experience. Those factors could result in investors facing difficulty
selling their stock for proceeds that they may expect or desire. Our share price as of March 21, 2025 was $4.91. Most companies in the
animal health sector have market capitalization values that greatly exceed our market capitalization of approximately $44.1 million as
of March 21, 2025. Our product sales during the year ended December 31, 2024 were $26.5 million. This means that our market capitalization
as of March 21, 2025 was equal to approximately 1.66 times our sales during the year ended December 31, 2024. Before adequate gross margin
from the sale of new products is achieved, our market capitalization may be heavily dependent on the perceived potential for growth from
our product under development and may therefore be negatively affected by the related uncertainties and risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Certain
provisions might discourage, delay or prevent a change in control of our Company or changes in our management:</i> Provisions of our
certificate of incorporation, our bylaws or Delaware law may discourage, delay or prevent a merger, acquisition or other change in control
that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares
of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.
These provisions include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">limitations
                                            on the removal of directors;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">advance
                                            notice requirements for stockholder proposals and nominations;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">the
                                            ability of our Board of Directors to alter or repeal our bylaws;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.85in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Section
                                            203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware corporation
                                            from engaging in a business combination with an interested stockholder (generally defined
                                            as a person which together with its affiliates owns, or within the last three years has owned,
                                            15% of our voting stock, for a period of three years after the date of the transaction in
                                            which the person became an interested stockholder) unless the business combination is approved
                                            in a prescribed manner.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
existence of the foregoing provisions and anti-takeover measures could depress the trading price of our common stock or limit the price
that investors might be willing to pay in the future for shares of our common stock. They could also deter potential acquirers of our
Company, thereby reducing the likelihood of obtaining a premium for our common stock in an acquisition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>No
expectation to pay any dividends or repurchase stock for the foreseeable future:</i> We do not anticipate paying any dividends to, or
repurchasing stock from, our stockholders for the foreseeable future. Instead, we expect to use cash to fund product development costs
and investments in our facilities and production equipment, and to increase our working capital. Stockholders must be prepared to rely
on market sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination
to pay dividends or repurchase stock in the future will be made at the discretion of our Board of Directors and will depend on our financial
condition, results of operations, contractual restrictions, restrictions imposed by applicable laws, current and anticipated needs for
liquidity and other factors our Board of Directors deems relevant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Possible
dilution:</i> We are accessing the capital markets and issuing additional common stock, from time to time, under an ATM Offering in order
to fund our operations, as described elsewhere in this Annual Report. Such issuances have a dilutive effect on our existing stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Risks</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Access
to raw materials and contract manufacturing services: </i>Our objective is to maintain more than one source of supply for the components
used to manufacture and test our products that we obtain from third parties. However, we may experience difficulty in efficiently acquiring
essential supplies. We have significantly increased the number of farms from which we purchase colostrum for the <b>First Defense<sup>&#174;
</sup></b>product line. A significant reduction in farm capacity could make it difficult for us to produce enough inventory to meet customer
demand. The specific antibodies that we purify from colostrum for the <b>First Defense<sup>&#174;</sup></b> product line are not readily
available from other sources. We are and will be dependent on our manufacturing facilities and operations in Portland, Maine for the
production of the <b>First Defense<sup>&#174;</sup></b> product line and <b>Re-Tain<sup>&#174;</sup></b>. We will be dependent on one manufacturer
for the supply of syringes for <b>Re-Tain<sup>&#174;</sup></b>. We were dependent on a contract with Norbrook for the DP formulation and
aseptic filling for supply of our Nisin DP through 2024. Any facility used to perform these services will be subject to FDA inspection
and approval, the outcome and timing of which are not within our control. We anticipate that this FDA approval process would take at
least two years. The potential alternative options for these services are narrowed considerably because our product cannot be formulated
or filled in a facility that also processes traditional antibiotics (i.e., beta lactams). Any significant damage to or other disruption
in the services at any of these third-party facilities or our own facilities (including due to lack of financing, regulatory issues or
non-compliance) would adversely affect the production of inventory and result in significant added expenses and potential loss of future
sales. We anticipate a supply interruption and adverse effects on our Controlled Launch of <b>Re-Tain<sup>&#174; </sup></b>beginning during
the first quarter of 2026 (subject to confirmation of final product shelf-life disposition by the FDA). These goods represent the initial
DP production from our contract manufacturer. The extent of the interruption will be subject to the supply timeline from a new contract
manufacturing agreement or from our own formulation and aseptic filling facility for DP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Failure
to protect intellectual property: </i>The protection and enforcement of our intellectual property rights may require the expenditure
of significant financial, managerial and operational resources. We rely on trademark, copyright and patent law, trade secret protection,
agreements and other methods with our employees and others to protect our proprietary rights. However, we may be unable to adequately
protect our intellectual property rights or prevent third parties from infringing or misappropriating our intellectual property rights.
We may not be able to obtain registration for all intellectual property we seek to register, and effective intellectual property protection
may not be available in every country in which our products are sold. In some cases, we have chosen (and may choose in the future) not
to seek patent protection for certain products or processes. Instead, we have sought (and may seek in the future) to maintain the confidentiality
of any relevant proprietary technology through trade secrets, operational safeguards and contractual agreements. Reliance upon trade
secrets, rather than patent protection may cause us to be vulnerable to competitors who successfully replicate (knock off) our manufacturing
techniques and processes. Further, our confidentiality agreements may not effectively prevent disclosure of our proprietary information,
technologies and processes and may not provide an adequate remedy in the event of unauthorized disclosure of such information. Others
may independently develop similar trade secrets or technology or obtain access to our unpatented trade secrets or proprietary technology.
Others may have filed patent applications and may have been issued patents involving products or technologies potentially useful to us
or necessary for us to commercialize our products or achieve our business goals. If that were to be the case, there can be no assurance
that we will be able to obtain licenses to such patents on terms that are acceptable to us. Any of our intellectual property rights may
be challenged by others or invalidated through administrative process or litigation. Third parties may claim in the future, that we have
infringed their intellectual property rights, which could result in significant costs and potential damages and license requirements.
We may initiate claims or litigation against others for infringement, misappropriation or violation of our intellectual property rights
or other proprietary rights or to establish the validity of such rights. However, we may be unable to discover or determine the extent
of any infringement, misappropriation or other violation of our intellectual property rights and other proprietary rights. In addition,
we may be unable to prevent third parties from infringing upon, misappropriating or otherwise violating our intellectual property rights
and other proprietary rights.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Increasing
dependence on the continuous and reliable operation of our information technology systems: </i>We rely on information systems throughout
our company. Any disruption of these systems or significant security breaches could adversely affect our business. Although we maintain
information security policies and employ system backup measures and engage in information system redundancy planning and processes, such
policies, measures, planning and processes, as well as our current disaster recovery plan may be ineffective or inadequate to address
all eventualities. As information systems and the use of software and related applications by us, our business partners, suppliers, and
customers become more cloud-based, we become inherently more susceptible to cyberattacks. There has been an increase in global cybersecurity
vulnerabilities and threats, including more sophisticated and targeted cyber-related attacks that pose a risk to the security of our
information systems and networks and the confidentiality, availability and integrity of data and information. There are reports of increased
activity by hackers and scammers since the COVID-19 pandemic. Any such attack or breach could compromise our networks and the information
stored thereon could be accessed, publicly disclosed, lost, or stolen. While we have invested in our data and information technology
infrastructure (including working with an information security technology consultant to assess and enhance our security systems and procedures,
and periodically training our employees in such systems and procedures), there can be no assurance that these efforts will prevent a
system disruption, attack, or security breach and, as such, the risk of system disruptions and security breaches from a cyberattack remains.
We have not experienced any material adverse effect on our business or operations as a consequence of any such attack or breach but may
incur increasing costs in performing the tasks described above. Given the unpredictability of the timing, nature and scope of such disruptions
and the evolving nature of cybersecurity threats, which vary in technique and sources, if we or our business partners or suppliers were
to experience a system disruption, attack or security breach that impacts any of our critical functions, or our customers were to experience
a system disruption, attack or security breach via any of our connected products and services, we could potentially be subject to production
downtimes, operational delays or other detrimental impacts on our operations. Furthermore, any access to, public disclosure of, or other
loss of data or information, including any of our (or our customers&#8217; or suppliers&#8217;) confidential or proprietary information
or personal data or information, as a result of an attack or security breach could result in governmental actions or private claims or
proceedings, which could damage our reputation, cause a loss of confidence in our products and services, damage our ability to develop
(and protect our rights to) our proprietary technologies and have a material adverse effect on our business, financial condition, results
of operations or prospects. While this exposure is common to all companies, larger companies with greater resources may be better able
to mitigate this risk than we can. See also <b>PART I, ITEM 1C &#8211; CYBERSECURITY</b> below.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 1B
&#8212; UNRESOLVED STAFF COMMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
1C &#8211; CYBERSECURITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-3054"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Risk
Management and Strategy</b></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities and test those systems
pursuant to our process. Our cybersecurity risk assessment is part of our overall risk management program. We also regularly engage outside
consultants to assess, identify and manage material risks from cybersecurity threats, including those threats associated with our use
of <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="ixv-13827">third-party</ix:nonNumeric> service providers. These consultants recommend, implement and monitor systems to protect against cybersecurity threats.
<ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-13828">Based on the information available to us through the time of this filing on March 28, 2025, we are <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-13829">not</ix:nonNumeric> aware of any risks from cybersecurity
threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial
condition.</ix:nonNumeric> However, despite our cybersecurity risk management processes, there can be no assurance that we, or the third parties with
which we interact, will not experience a cybersecurity incident in the future that may materially affect us. Refer to the risk factor
captioned <i>&#8220;Increasing dependence on the continuous and reliable operation of our information technology systems&#8221;</i> under
<b>PART I, ITEM 1A &#8211; RISK FACTORS</b> above for additional description of cybersecurity risks and potential related impacts on
the Company.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Governance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-3079"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="ixv-13830">Our
<ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-13831">Board of Directors</ix:nonNumeric> has overall oversight responsibility with respect to our approach to risk management, including risks relating to
cybersecurity. Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our
President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity
risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-13832">While our management
team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks. Our Board of Directors
reviews cybersecurity threats and risk controls at quarterly meetings based on information provided by management and outside consultants.</ix:nonNumeric></span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 2
&#8212; PROPERTIES</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Building
56:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
1993, we purchased a 15,000 square foot facility (that included 5,000 square feet of unfinished office space on the second floor) at
56 Evergreen Drive in Portland, Maine. We currently use this space for substantially all of our: i) office and laboratory needs, ii)
vaccine manufacturing operations, iii) liquid processing operations and iv) freeze-drying operations for our USDA-regulated product line.
All of our powder milling and filling operations, gel formulation operations and assembly services have been relocated out of this building.
During 2001, we completed a construction project that added approximately 5,200 square feet of new manufacturing space on the first floor
and approximately 4,100 square feet of storage space on the second floor. During 2007, we built out the 5,000 square feet of unfinished
space on the second floor into usable office space. After moving offices from the first floor into this new space on the second floor,
we modified and expanded the laboratory space on the first floor and added approximately 2,500 additional square feet of storage space
on the second floor. During 2009, we added 350 square feet of cold storage space connected to our first floor production area and added
an additional 600 square feet to the second floor storage area. During 2015, we completed construction of a two-story addition connected
to our facility to provide us with approximately 7,100 additional square feet for cold storage, production and warehouse space for our
operations. These additions increased the size of the facility to approximately 34,850 square feet.</span></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Building
33:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2015, we exercised an option to acquire land at 33 Caddie Lane in Portland, Maine which is near our facility at 56 Evergreen Drive, on
which we initiated construction of our DS production facility for <b>Re-Tain<sup>&#174;</sup></b> during the third quarter of 2016. During
the fourth quarter of 2017, we obtained a Certificate of Occupancy from the City of Portland for our 16,202 square foot (9,803 on the
first floor and 6,399 on the second floor) DS production facility. Our FDA-regulated operations are conducted in this building.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Building
14:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2017, we purchased a 4,080 square foot facility adjacent to the DS production facility for <b>Re-Tain<sup>&#174;</sup></b> at 14 Wedge
Way in Portland, Maine. We are using this warehouse space primarily for storage of inventory, materials and equipment. During the middle
of 2023, we completed modifications to this facility for packing, shipping and cold storage for <b>Re-Tain<sup>&#174; </sup></b>and other
warehousing needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Building
175A:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space at 175 Industrial Way in Portland,
Maine to expand our USDA-regulated manufacturing operations. We have renovated this space (a Certificate of Occupancy was issued during
the second quarter of 2020) to help us expand our production capacity and improve quality for the <b>First Defense<sup>&#174;</sup></b>
product line. This space is being used for all of our powder milling and filling, gel formulation and assembly services. The original
lease term was ten years with a right to renew for a second ten-year term and a right of first offer to purchase. During the third quarter
of 2022, we entered into a new 20-year lease covering a facility that has been constructed for us by our landlord (<b>Building 175B</b>,
described below), which is adjacent to (and has been connected to) <b>Building 175A</b>. In connection with this new lease, the lease
to <b>Building 175A</b> was extended by approximately 13 years to match the expiration of the other lease to <b>Building 175B</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Building
175B:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2022, we committed to lease an additional 15,400 square feet of space at 175 Industrial Way in Portland, Maine, which has been constructed
and connected to <b>Building 175A</b>, over a 20-year term. The lease commencement date was April 1, 2023. Lease payments began four
months after this date. In connection with the lease commitment for space in <b>Building 175B</b>, the term of the original lease for
<b>Building 175A</b> was extended by approximately 13 years. We are using this space for the following three purposes: 1) much needed
additional warehouse space, 2) the relocation of all shipping and receiving services from <b>Building 56</b> and 3) space for additional
freeze-drying equipment in the future to increase our production capacity to approximately $40 million per year. Due to the loss in gross
margin on product sales during 2023 caused by the slowdown in production output necessary to remediate product contamination events,
we reduced the scope of the investment to build out <b>Building 175B </b>at least for the time being. The objective of moving our powder
milling operations out of <b>Building 56</b> has been achieved by moving powder milling to <b>Building 175A</b> for the time being. We
have completed Phase I of this build out plan, which included pouring a concrete floor and bringing utilities and heat to the space.
Upon issuance of a Certificate of Occupancy by the city, we relocated all shipping and receiving operations from <b>Building 56</b> to
<b>Building 175B</b> and began to benefit from the new warehouse space. When we have adequate cash, we will initiate Phase II of the
build out plan, which includes construction of process rooms and installation of production equipment necessary to further increase our
production capacity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Other:</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
March of 2021, we entered into a renewable, two-year lease for approximately 1,300 square feet of office, storage and parking space in
New York. Subsequently, we entered into a new two-year lease for the same property through March of 2025 that includes an option to renew
for an additional two-year term. During February of 2025, we exercised this option and extended the lease through March 1, 2027. In addition,
we are renting approximately 960 square feet in Winona, Minnesota for a sales office. This lease automatically renews with 4% increases
for one-year terms unless we or the landlord give 60-days&#8217; notice of a change. The current term expires in June of 2025. We do
not expect to provide notice of cancellation at this time. We also maintain access to cows (as a source of colostrum used in the production
of the <b>First Defense<sup>&#174;</sup></b> product line) through contractual relationships with commercial dairy farms. We maintain
property insurance in amounts that approximate replacement cost and a modest amount of business interruption insurance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 3
&#8212; LEGAL PROCEEDINGS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of business, we may become subject to periodic lawsuits, investigations and claims. Although we cannot predict with
certainty the ultimate resolution of any such lawsuits, investigations and claims against us, we do not believe that any pending or threatened
legal proceedings to which we are or could become a party will have a material adverse effect on our business, results of operations,
or financial condition.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 4
&#8212; MINE SAFETY DISCLOSURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None</span></p><div>


</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_029"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
5 &#8212; MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
common stock trades on The Nasdaq Capital Market tier of The Nasdaq Stock Market under the symbol ICCC. As of March 21, 2025, we had
15,000,000 common shares authorized and 8,982,623 common shares outstanding, and there were approximately 572 stockholders of record.
We have not paid dividends on our common stock and do not have any present plan or expectation to pay dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM 6
&#8212; [RESERVED]</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -48.95pt"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
7 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
focus on the two most critical stages of dairy productivity, those being the first 30 days of life and the first 30 days of lactation.
Our concentrated colostrum and purified Nisin technologies offer unique animal health solutions during these periods when immunity is
at its most vulnerable. Both of our product lines present growth opportunities and, in the future, may potentially be applied to other
species or potentially the human health sector, alongside the animal health sector that we currently serve. The <b>First Defense<sup>&#174;
</sup></b>production capacity expansion that we initially thought might have been completed in a year to a year and a half ended up taking
about three years to complete, but our fourth quarter sales results do demonstrate that we have increased our production capacity to,
or above, $30 million per year. The increased capacity is enabling us to address our order backlog that was equal to approximately $4.4
million and $4.7 million, as of December 31, 2024 and March 21, 2025, respectively. The following discussion and analysis of our financial
condition and results of operations should be read together with our audited financial statements and the related notes and other financial
information included in <b>Part II: ITEM 8</b> &#8212; <b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b> of this Annual Report. Some
of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with
respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. One should
review the Cautionary Note under <b>Part I: ITEM 1 </b>&#8212; <b>BUSINESS and Part I: ITEM 1A </b>&#8212; <b>RISK FACTORS</b> of this
Annual Report for a discussion of some of the important factors that could cause actual results to differ materially from the results,
objectives or expectations described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>OUTLINE
TO ITEM 7 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTES OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
                                            and Capital Resources</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Capital
                                            Expenditure Investments</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Production
                                            Contamination Events</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Results
                                            of Operations (Subsections a through i)</b></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.75pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
                                            Accounting Policies and Estimates</b></span></td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">We
are fortunate to be experiencing strong customer demand for the </span><span style="font-family: Times New Roman, Times, Serif">First
Defense<sup>&#174;</sup> <span style="font-weight: normal">product line, but the significant investments in facilities, equipment and staffing
necessary to double our production capacity have been challenging. Despite delays in the installation of certain equipment, we completed
these capacity-expanding investments around the end of 2022. In late 2022, we began experiencing production contamination events that
became more frequent during 2023 and continued through April of 2024. With newly implemented controls in place, we now believe that we
have successfully remediated the issues underlying these contamination events. Our next challenge is to resume our past production yields
and achieve our gross margin goals in excess of 40%. By both remediating the contamination events and optimizing the operation of the
new equipment installed to increase production output, we began to improve process yields beginning during the fourth quarter of 2024,
as demonstrated by the 37% gross margin we achieved during the fourth quarter of 2024. We did not find one &#8220;smoking gun&#8221;
as the root cause to the contamination and yield losses. We think the solution is more about optimizing and controlling critical process
parameters and multiple production inputs and process steps. </span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">Concurrently,
we are reducing product development expenses as we await approval of </span><span style="font-family: Times New Roman, Times, Serif">Re-Tain<sup>&#174;
</sup><span style="font-weight: normal">by the FDA. After an investment of about 25 years and approximately $50 million in the development
of this technology, we are committed to seeing this product through to regulatory approval and our previously disclosed limited distribution,
controlled launch strategy (Controlled Launch). At the same time, we are also in the very early stages of exploring potential strategic
options that could offset some of our product development expenses and enhance a mass-market launch of </span>Re-Tain<sup>&#174;</sup><span style="font-weight: normal">.
In order to help fund these gross margin losses and production capacity expansions, we raised some new debt during 2023 and equity during
2024.</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by operating activities was
$358,000 during the year ended December 31, 2024 in contrast to net cash (used for) operating activities of ($4.7 million) during the
year ended December 31, 2023. This $5 million improvement in net cash provided by operating activities between the years was largely due
to a $3.6 million decrease in the net loss and a $2.5 million swing from cash used for inventory during 2023 to cash generated by reductions
in inventory during 2024, which sources of cash were net against $1.2 million more cash being used for accounts receivable during 2024
than during 2023. Our inventory balance decreased by $699,000 to $7.1 million as of December 31, 2024 from $7.8 million as of December
31, 2023. Interest expense (excluding amortization of debt issuance and debt discount costs) was $526,000 and $453,000 during the years
ended December 31, 2024 and 2023, respectively. Our debt bears interest at fixed rates, which on a blended basis amounts to 4.51% per
annum. We anticipate that interest expense (excluding amortization of debt issuance and debt discount costs) will be $452,000 and $322,000
during the years ending December 31, 2025 and 2026, respectively. Our total non-cash depreciation, amortization and stock-based compensation
expense was approximately $3.1 million during both of the years ended December 31, 2024 and 2023. We anticipate that depreciation expense
(largely pertaining to Re-Tain<sup>&#174;</sup>), while not affecting our cash flows from operations, will be a significant factor in creating
annual net operating losses until and unless product sales increase sufficiently to offset these non-cash expenses. Further, as we fill
the order backlog for <b>First Defense<sup>&#174;</sup></b>, we will require additional capital to fund an anticipated increase in inventory
levels.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
cash used for investing activities was ($461,000) during the year ended December 31, 2024 versus ($1.9 million) during the prior year
consisting primarily of cash spent to fund the purchase of property, plant and equipment. To conserve cash at this time, we have deferred
all large dollar capital expenditure projects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
cash provided by financing activities was $2.9 million during the year ended December 31, 2024 versus of $1.8 million during the prior
year. During the third quarter of 2023, we received $3 million in new debt proceeds. We had aggregate debt outstanding (net of debt issuance
and debt discount costs) of approximately $10.5 million and $12 million as of December 31, 2024 and 2023, respectively. Debt principal
repayments (excluding the line of credit) aggregated $1.5 million and $1.2 million during the years ended December 31, 2024 and 2023,
respectively. We anticipate that debt principal repayments will aggregate approximately $1.5 million and $3.3 million during the years
ending December 31, 2025 and 2026, respectively. During the first quarter of 2024, the availability of our $1 million line of credit,
which bears interest at the National Prime Rate per annum, was extended until September 11, 2025. No draw on our line of credit was outstanding
as of December 31, 2024 or December 31, 2023. See Note 9 to the accompanying audited financial statements for more information about
our bank debt. During the second quarter of 2024, we entered into an At-The-Market (ATM) Agreement with Craig-Hallum Capital Group LLC,
under which we may offer and sell up to $11 million of shares of our common stock. As of December 31, 2024, we had sold 1,228,227 shares
under this ATM Offering conducted pursuant to the ATM Agreement. Net proceeds through December 31, 2024 (net of approximately $152,000
in upfront legal, accounting and other fees and approximately $140,000 in sales commissions) were approximately $4.4 million. The ATM
Agreement gives our board the flexibility to evaluate the potential uses of the proceeds while considering the cost of dilution in real
time. This funding has provided a very productive financial bridge for us to fund our operations, while we work to improve our gross
margin and reduce product development expenses. While the capital raised is not enough to fund larger capital expenditure investments,
such as further increasing <b>First Defense<sup>&#174;</sup></b> production capacity or building our own facility for the aseptic filling
services for <b>Re-Tain<sup>&#174;</sup></b>, it has allowed us to release funding for certain smaller and necessary capital expenditures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>


</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
project (based on our best estimates) that our existing cash and cash equivalents, together with gross margin anticipated to be earned
from ongoing product sales will be sufficient to meet our currently planned working capital and capital expenditure requirements and
to finance our ongoing business operations for at least the next 12 months (the period of time required to be addressed for such purposes
by accounting disclosure standards). The table below summarizes the changes in selected key accounts (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of</b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of </b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increase</b></span></td>
    <td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b>December&#160;31,&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></b></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><b>December&#160;31,&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></b></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td>
    <td style="vertical-align: bottom; font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,758</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">979</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,779</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net working capital</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,631</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,272</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,358</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">46</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total assets</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,100</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">43,808</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,292</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stockholders&#8217; equity</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">27,518</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,993</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,525</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common shares outstanding<sup>(1)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,979</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,228</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
                                            </span><span style="font-family: Times New Roman, Times, Serif">were 664,000 and 618,500
                                            shares of common stock reserved for issuance for stock options that were outstanding as of
                                            December 31, 2024 and 2023, <span style="font-size: 10pt">respectively.</span></span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Capital
Expenditure Investments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
the three-year period ended December 31, 2016, we invested the aggregate of $4.2 million to construct a 7,100 square foot facility addition
at 56 Evergreen Drive (<b>Building 56</b>) and related equipment (primarily Freeze-Dryer #2) and cold storage capacity increasing our
freeze-drying capacity by 100% and making other improvements to our liquid processing capacity, which increased our annual production
capacity (in terms of annual sales dollars) to approximately $16.5 million. When we describe the production capacity for the <b>First
Defense<sup>&#174;</sup></b> product line in this Annual Report, it should be noted that the actual value of this capacity varies based
on biological and process yields, product format mix, selling price and other factors. During the first quarter of 2016, we completed
this investment, which also included the construction and equipping of a pilot plant for small-scale DS production for <b>Re-Tain<sup>&#174;
</sup></b>within <b>Building 56</b>. After construction of the DS production facility for <b>Re-Tain<sup>&#174;</sup></b> at 33 Caddie
Lane (<b>Building 33)</b> was completed, this space was converted for use in the production of the gel tube formats of the <b>First Defense<sup>&#174;
</sup></b>product line. After renovations of our leased facility at 175 Industrial Way (<b>Building 175A)</b> were completed during the
second quarter of 2020, this space was converted to double our liquid processing capacity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
the four-year period ended December 31, 2018, we invested the aggregate of $21.6 million to construct a DS production facility for <b>Re-Tain<sup>&#174;
</sup></b>at <b>Building 33</b>. During the fourth quarter of 2017, we completed construction of the DS production facility. We began
equipment installation during the third quarter of 2017, and we completed this installation during the third quarter of 2018. The total
cost of this investment for the DS production facility and related processing equipment was $20.8 million plus $331,000 for the land
and $472,000 for the acquisition of an adjacent 4,080 square foot warehouse facility at 14 Wedge Way (<b>Building 14)</b>, which will
be used for packing, shipping and cold storage of <b>Re-Tain<sup>&#174;</sup></b> and other warehousing needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During
2018, it became clear that demand for <b>Tri-Shield First Defense<sup>&#174;</sup></b> was outpacing production. In response to this increasing
demand, we began a series of investments during 2019 to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b>
product line from approximately $16.5 million to approximately $30 million or more per year (with an option to increase further to approximately
$40 million in the future). The additional investment in <b>First Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">should
allow us</span> to fulfill the current backlog of <b>First Defense<sup>&#174;</sup> </b><span style="font-style: normal; font-weight: normal">orders</span>
and materially reduce the risk of another order backlog. Operating at very close to 100% of available capacity is not efficient or sustainable.
Our objective is to be in position to operate without significant contaminations at the capacity level we choose to cover sales with
adequate buffer stock, which would allow more time for necessary preventative maintenance. We also need to meet or exceed our production
yield assumptions to succeed. Our production process is complex and difficult to scale-up quickly. We remain deeply committed to meeting
demand for <b>First Defense<sup>&#174;</sup></b> and overcoming the current short supply that we have been experiencing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
primary purpose of the additional investments in <b>Re-Tain<sup>&#174; </sup></b>is to bring the formulation and aseptic filling capabilities
for <b>Re-Tain<sup>&#174;</sup></b> DP into available space in our DS facility in order to lessen or eliminate our reliance on third-party
DP manufacturing services as well as the build out of warehouse space at <b>Building 14</b> for packing and shipping facilities for <b>Re-Tain<sup>&#174;</sup></b>.
We began initial installation of the filling equipment during the first quarter of 2022 and then paused this installation work due to
the lack of adequate cash.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">The
amount and timing of these additional investments in </span><span style="font-family: Times New Roman, Times, Serif">First Defense<sup>&#174;
</sup><span style="font-weight: normal">and </span>Re-Tain<sup>&#174;</sup> <span style="font-weight: normal">that were initiated beginning
in 2019 are detailed in the following table (in thousands):</span></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: left; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif"><b>Paid
During the</b></span></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>First Defense<sup>&#174;</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif"><b>Re-Tain<sup>&#174;</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Year Ended December 31, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">279</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">574</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,391</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Year Ended December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,938</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">581</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,073</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year Ended December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,633</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">976</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,609</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Year Ended December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,975</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Year Ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">410</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">466</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Total Paid through December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,855</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,375</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,177</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,407</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Estimate to Complete<sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,246</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Total Project Cost</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">14,101</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,375</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,177</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,653</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            investments of approximately $3 million of these funds to increase <b>First Defense<sup>&#174;
                                            </sup></b><span style="font-style: normal; font-weight: normal">production capacity from</span>
                                            <span style="font-style: normal; font-weight: normal">approximately $30 million to
                                            $40 million per year</span> and approximately $2 million to build an in-house aseptic filling
                                            facility for <b>Re-Tain<sup>&#174; </sup></b>have been deferred for the time being, due to
                                            cash constraints caused by production slowdowns implemented during 2023 to remediate certain
                                            contamination events. These estimated costs to complete are based on historic quotations
                                            and have not been updated or adjusted to account for inflation, project scope change and
                                            other factors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
first phase of the additional investments in <b>First Defense<sup>&#174;</sup> </b><span style="font-style: normal; font-weight: normal">beginning
in 2019</span> included significant renovations to a 14,300 square foot leased facility at <b>Building 175A</b>, some facility
modifications at <b>Building 56</b> and the necessary production equipment (including Freeze-Dryer #3) to increase our liquid processing
capacity by 100% and our freeze-drying capacity by 50%. This resulted in increasing the annual production capacity of the <b>First Defense<sup>&#174;</sup></b>
product line (in terms of annual sales dollars) from approximately $16.5 million to approximately $23 million. Renovations of <b>Building
175A</b> to enable this expansion were completed during the second quarter of 2020. By moving our powder and gel filling and assembly
operations from <b>Building 56</b> into this new space, we created space at <b>Building 56</b> for the installation of the expanded freeze-drying
capacity. The new facilities are built to contemporary cGMP standards with efficient material and people flows. A site license approval
for this new facility was issued by the USDA during the third quarter of 2020. During the second quarter of 2021, we completed the relocation
of our gel formulation equipment from <b>Building 56</b> to <b>Building 175A</b>, which created the space necessary to double our liquid
processing capacity at <b>Building 56</b>. We obtained site license approval of the expanded freeze-drying capacity (Freeze-Dryer #3)
at <b>Building 56</b> from the USDA during the third quarter of 2021, and we obtained site license approval of the expanded liquid processing
capacity at <b>Building 56</b> from the USDA during the third quarter of 2022. This investment also included equipment and vehicle purchases
necessary to expand and improve our colostrum collection capabilities and logistics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
second phase of the additional investments in <b>First Defense</b><sup>&#174; </sup>included the installation of Freeze-Dryer #4 to further
increase the estimated annual production capacity of the <b>First Defense</b><sup>&#174;</sup> product line (in terms of annual sales
dollars) by an additional 33% from approximately $23 million to approximately $30 million or more. As of July of 2022, we had completed
almost all of the facility expansion work and new equipment installations needed to increase our production capacity to approximately
$30 million or more per year. However, the most critical piece of new equipment (being Freeze-Dryer #4) was delivered six months late
by the fabricator. Regardless, by the end of 2022, we had Freeze-Dryer #4 installed and approved for use by the USDA. At the same time,
Freeze-Dryer #2 stopped operating requiring a six-month repair and netting us back to three operating freeze dryers during the first
half of 2023. As of July of 2023, we were back to four operating freeze dryers. This investment also included equipment and facility
modifications to scale-up and upgrade our vaccine manufacturing capacity and improve our quality laboratories at <b>Building 56</b> as
well as the installation of new equipment to increase the throughput of our gel filling operations at <b>Building 175A</b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
third phase of the additional investments in <b>First Defense<sup>&#174;</sup></b> involved the construction of an additional 15,400 square
feet of space adjacent to and connected to <b>Building 175A</b> at 175 Industrial Way (<b>Building 175B</b>) and new equipment to further
increase our estimated annual <b>First Defense<sup>&#174;</sup></b> production capacity from approximately $30 million to approximately
$40 million with options for further expansion. Given the long lead time required for investments like this, we initiated this project
by entering into a lease amendment during the third quarter of 2022 covering a to-be-constructed building shell for approximately $250,000
per year. Construction of the building shell by our landlord was substantially complete as of April 1, 2023, and rent payments commenced
as of August 1, 2023. We made this lease commitment because of the unique proximity of the land adjacent to our currently leased space
and the high level of demand for properties of this type in the Portland market. We did not want to risk losing this opportunity to others.
The anticipated benefits to us from this new lease include: i) space for the potential to install Freeze-Dryers #5, #6, #7 and #8 if
justified by market demand in the future, ii) improved space and quality for our powder milling operations by separating our upstream
processes (liquid processing) at <b>Building 56</b> from our clean downstream processes (milling, formulation, filling and packaging)
at <b>Building 175A</b> and iii) much needed additional warehouse space. We have been running our equipment and staff close to 100% of
capacity in order to fill the backlog of orders. One of our objectives is to create a more sustainable production schedule. Freeze-Dryer
#5 is the key piece of equipment required to allow us to increase our estimated annual production capacity to above $30 million. Based
on past experience, we are planning for approximately 18 months of lead time for fabrication, installation, qualification and implementation
of Freeze-Dryer #5. However, due to the loss in gross margin during 2023 caused by the slowdown in production output necessary to remediate
the product contamination events discussed below, we have decided to defer most of this investment, for the time being. Instead, we initiated
the initial steps on a portion of this project with a reduced budget of approximately $700,000 at <b>Building 175B</b> during the third
quarter of 2023. This work was completed during the first quarter of 2024, which provided additional warehousing space and allowed us
to move all shipping and receiving functions out of <b>Building 56</b> to create more space for liquid processing at <b>Building 56</b>.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Production
Contamination Events</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
our increased production capacity was coming online around the end of the third quarter of 2022, our standard in-process quality control
testing detected a product contamination event likely related to our incoming raw material (which is sourced from many different cows
at many different farms). We took immediate steps to address the contamination, and production ran without issue during the balance of
the fourth quarter of 2022. Subsequently, as we began to operate at a higher level of capacity at the beginning of 2023, we were forced
to slow down production again to remediate a second contamination event also likely related to our incoming raw material. We then ran
for approximately six months without contamination and then experienced a smaller third contamination event in September of 2023 impacting
two lots of Work-in-Progress inventory, likely related to process changes implemented to run our increased level of liquid processing.
Although all of the incoming material utilized in this production phase had passed quality control testing, the product failed the quality
control tests later in the production process. We experienced a fourth contamination event impacting three lots of Work-in-Process inventory
during the first three and a half months of 2024. New remediation steps implemented in response to this fourth event during the second
half of April of 2024 appear to have been successful so far because we have run without contamination since then. Throughout these contamination
events, all product that was sold to market met all in-process and final release testing to meet USDA-required quality standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
we look back at these production contamination events, we believe that the root cause of the initial contaminations was associated with
rapid growth in our purchases from the farms where we acquire our raw material. Having largely remediated that problem, we then experienced
additional contaminations that we believe were largely caused by rapidly increasing our production capacity. Our proprietary production
process does allow us to create an effective product out of a non-aseptic starting raw material. This requires a careful monitoring,
however, of the tradeoff between the benefit of adding more heat for longer periods of time to reduce bacterial load against the alternative
benefit of less heat for shorter periods of time to preserve more antibody content. Although using more heat could potentially reduce
bacterial load, our yield is higher when we use less heat. We know that putting our Work-in-Process inventory through freeze/thaw cycles
is not beneficial to yield and increases the risk of contamination. One effective improvement we have implemented, where appropriate,
is to lengthen the time of a heat treatment step instead of running two shorter heat treatment steps separated by a freeze/thaw. As we
continue to optimize these critical process parameters, we believe we can significantly reduce the risk of further contaminations and
improve our gross margin.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Although
these types of losses are expected to happen from time to time in the production of a biological product such as ours, we believe that
the sudden and large contamination events were related in several different ways to our efforts to increase production output. We also
believe we have mitigated the risk of large-scale reoccurrence of such losses by implementing various new quality control steps and manufacturing
process and facility improvements. To meet our goals, we must run without significant equipment failures or contamination losses, and
we must continue to improve our production yields.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">The
production contamination events and other production process losses experienced resulted in scrapped inventory valued as shown in the
following table (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Approximate
    Cost of <br/> Work-in-Process Scrap</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate
    Retail Value of<br/> Finished Goods<sup>(1)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">589</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,193</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">527</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,487</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year
    Ended December 31, 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">407</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,766</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
                                            estimate approximates the retail value of this work-in-process inventory in the event that
                                            additional costs had been incurred to complete the production process to prepare it for sale
                                            utilizing the approximate product format mix and selling prices effective during the period.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
still have more work to do to catch up to product demand for <b>First Defense<sup>&#174;</sup></b>. We continue to optimize our investments
to increase production capacity and to implement the corrective actions being taken in response to these contamination events. Although
we produced far less than we needed during 2023 and 2024, we believe that our remediation efforts are allowing us to steadily ramp back
up to full production capacity. Our current goal is to exceed $30 million in annual production output, while also allowing for essential preventative maintenance. We believe that the $7.8 million in sales recorded during the fourth quarter
of 2024 suggests that during the quarter we achieved, even exceeded, this goal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
lessons from the remediation of the contamination events have improved our production processes going forward. We have implemented several
important improvements at the source farm level including more product and environmental testing, more training of farm staff and better
enforcement of our protocols. While we never release product to the market that does not pass our in-process and final quality control
release tests, we had allowed product to advance in the production process at risk, while the in-process quality control tests were being
performed. We no longer advance product to the next stage before complete in-process quality control test results for the current stage
are reviewed. Although this adds time to the overall production cycle, we believe that it has helped us reduce the chance of further
contaminations. Notwithstanding the challenges that contamination events have posed for us, we are excited to have reached both our estimated
full capacity of at least $30 million per year for <b>First Defense<sup>&#174;</sup></b> (with an option to increase our estimated full
capacity to approximately $40 million per year in the future with the additional capital investments, as discussed above) while, at the
same time, advancing to the final stages of a very significant FDA product development initiative with <b>Re-Tain<sup>&#174;</sup></b>.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
pursued an insurance claim under our business interruption policy to offset at least some portion of the losses that we incurred from
the contamination events discussed above. Although not a total recovery of our financial losses, we did settle our insurance claim during the first quarter
of 2025 and received an insurance payout of approximately $427,000, which is in addition to the $250,000 that we previously received
during the third quarter of 2023 under this claim.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">a)
Product Sales</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
near-term goal is to increase and stabilize supply of <b>First Defense<sup>&#174;</sup></b>, regain lost business and continue our growth
curve. This goal not only aims to meet end-user demand but also to replenish our distributors with the necessary buffer stock.
The significant increase in sales recognized during the fourth quarter of 2024 results from our higher production output, but also from
the comparison to 2023 when our sales were limited due to a production slowdown necessary to remediate certain contamination events.
We do not anticipate being able to repeat this high level of year-over-year sales growth when we compare 2025 to 2024. We do not solely
benchmark our sales expectations off trailing twelve-month sales results. Instead, we look at the sales of competitive products to assess
the size of the addressable market and plan for growth when projecting our future production capacity needs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Sales
during the three-month period ended December 31, 2024 were $7.8 million, representing a 52%, or $2.7 million, increase over sales of
$5.1 million during the fourth quarter of 2023. Sales during the year ended December 31, 2024 were $26.5 million, representing a 52%,
or $9 million, increase over sales of $17.5 million during the year ended December 31, 2023. By increasing production capacity and mitigating
contamination events, we were able to significantly increase sales during the most recent periods compared to the year prior. Quarter
to quarter sales since the beginning of 2022 are displayed in the following table:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><img alt="" src="image_001.jpg" style="height: 402px; width: 650px"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">We
captured a 52% increase in sales revenue during the fourth quarter of 2024 compared to the fourth quarter of 2023. Domestic sales during
the three-month period ended December 31, 2024 increased by 35%, and international sales increased by 308%, in comparison to the three-month
period ended December 31, 2023. International sales aggregated 17% and 6% of total sales during the three-month periods ended December
31, 2024 and 2023, respectively. The quarterly sales results are summarized in the following table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During
                                            the Three-Month<br/>
                                            Periods Ended December 31,</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Increase</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,096</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,655</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">52%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">We
captured a 52% increase in sales revenue during the year ended December 31, 2024 compared to the year ended December 31, 2023. Domestic
sales during the year ended December 31, 2024 increased by 44%, and international sales increased by 136%, in comparison to the year
ended December 31, 2023. International sales aggregated 14% and 9% of total sales during the years ended December 31, 2024 and 2023,
respectively. The sales results for the years are summarized in the following table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Years<br/> Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Increase</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    Product Sales</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,493</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,472</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">52%</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Sales
of the <b>First Defense<sup>&#174;</sup></b> product line made up 99% of our total sales during both of the three-month periods ended
December 31, 2024 and 2023 and during both of the years ended December 31, 2024 and 2023. Our sales are generally seasonal with highest
demand expected during the first quarter of each year. The compound annual growth rate (CAGR) of our total product sales was 52%, 14%
and 16% during the year, five-year and six-year periods ended December 31, 2024, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
obtained USDA approval of <b>Tri-Shield First Defense<sup>&#174;</sup></b> (the trivalent format of our product delivered via a gel tube,
which provides broader protection to calves) near the end of 2017. Around the time of this new product format launch, total product sales
during the years ended December 31, 2017 and 2018 were $10.4 million and $11 million, respectively. <b>Tri-Shield<sup>&#174; </sup></b>requires
two separate liquid production processes for each dose manufactured and sold (in contrast to the bivalent product formats that require
just one) making it more expensive to produce. This new product format has become the highest revenue contributor, as demonstrated in
the table below (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During the Three-Month Periods Ended December&#160;31,</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>During the Years Ended December 31,</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>% of<br/> Total</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2023</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>% of <br/> Total</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>% of<br/> Total</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2023</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>% of<br/> Total</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 20%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tri-Shield<sup>&#174;</sup></b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,227</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">55%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,768</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">74%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,762</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">59%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,316</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">59%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,524</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">45</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">26</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,731</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">41</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,156</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">41</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total Product Sales</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">100%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,096</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">100%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,493</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">100%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,472</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">100%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
likely lost some business beginning in late 2022 and through the first half of 2024 as a result of the backlog. During the first half
of 2023, the impact of tight supplies hit even harder, leaving our customers without product during their busiest calving season. The
2023 production shortage caused largely by the contamination events discussed above may prove to be more detrimental to our growth curve
than any prior production shortage because it depleted distributor inventories and impacted more customers for a longer period of time.
Our inability to timely meet the needs of our customers could result in the loss of some customers who seek alternative scours management
products during this period of short supply, and some of these customers may not resume purchasing our product when we have eliminated
the backlog. While we worked to allocate product directly to certain large customers during this period of short supply, we likely lost
some customers that could not procure product. While backlog is a better problem to have than seeing product expiring on our shelves,
it is nonetheless a significant challenge when we do not get our customers everything that they want. Our sales team has resumed more
normal sales growth initiatives now, in anticipation of increasing product supply. We will work to regain end-user customers that we
may have lost while we were short on product and will aggressively compete for new business. As we emerge from an extended period of
time on backlog, we anticipate higher than normal sales fluctuations quarter to quarter. What is most important to us at this time is
that we achieve sales growth over the longer periods of time, even if we experience some quarter-to-quarter fluctuations. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
production slowdown during the first ten months of 2023 helped cause an increase in the amount of our order backlog. Valuation of the
backlog is a non-GAAP estimate that is based on purchase orders on hand at the time that could not be met because of a lack of available
inventory. We are reporting this figure because it reflects the orders on our books presently that we cannot ship. Quantification of
the backlog during the current periods has become far less comparable to prior periods. At times, customers have placed orders for more
than a month&#8217;s worth of their demand, perhaps in reaction to our ongoing backlog situation, whereas in the past they ordered more
closely in line with their current demand. We are concerned that this backlog amount may not be highly relevant at this time as it includes
very old orders, redundancy in demand and orders that may be cancelled given the time that has passed since they were originally placed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
backlog was reduced from approximately $2.4 million as of December 31, 2021 to approximately $205,000 as of September 30, 2022. In part
because of a first contamination event experienced around the end of the third quarter of 2022, our backlog increased to approximately
$2.5 million as of December 31, 2022. In part because of a second contamination event experienced during the first quarter of 2023, the
backlog continued to increase to approximately $7.5 million as of March 31, 2023, to approximately $8 million as of June 30, 2023, to
approximately $8.9 million as of September 30, 2023 and to approximately $9.4 million as of December 31, 2023. We were able to reduce
this backlog modestly to approximately $9.1 million as of March 31, 2024 and then reduce it further to approximately $8.9 million as
of June 30, 2024. We were able to reduce this backlog further to approximately $7.3 million as of September 30, 2024 and then further
to $4.4 million as of December 31, 2024. The backlog of orders was worth approximately $4.7 million as of March 21, 2025. As sales demand
increased while our production output was reduced, the value of our order backlog has fluctuated as demonstrated in the following table:</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><img alt="" src="image_002.jpg" style="height: 373px; width: 600px"/></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
also sell our own <b>CMT</b>, which is used to detect somatic cell counts in milk. Sales of <b>CMT</b> aggregated approximately 1% of
our total product sales during the periods reported. Sales of <b>CMT</b> decreased by 30%, or $17,000, to $39,000 during the three-month
period ended December 31, 2024, in comparison to the three-month period ended December 31, 2023. Sales of <b>CMT</b> increased by 1%,
or $1,000, to $179,000 during the year ended December 31, 2024 in comparison to the year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Effective
January 1, 2022, we increased our selling price of the <b>First Defense<sup>&#174; </sup></b>product line by approximately 5% and <b>CMT
</b>by approximately 7%. Effective January 1, 2023, we increased our selling price of the <b>First Defense<sup>&#174; </sup></b>product
line by approximately 4% (a range of 2% to 8%) and <b>CMT</b> by approximately 5%. Effective November 15, 2023, we increased our selling
price of the <b>First Defense<sup>&#174; </sup></b>product line by approximately 8%. Also, effective November 15, 2023, we increased our
selling price for <b>CMT</b> by approximately 12%. Effective January 1, 2025, we increased our selling price of the <b>First Defense<sup>&#174;
</sup></b>product line by approximately 6% (a range of 5% to 7.5%). At the same time, we also increased our selling price for <b>CMT
</b>by approximately 7%.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">b)
Gross Margin</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
change in our gross margin (product sales less costs of goods sold) and our gross margin as a percentage of product sales during the
three-month periods and years ended December 31, 2024 and 2023 are summarized in the following tables (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Three-Month <br/> Periods Ended December&#160;31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Increase</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,832</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,258</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,574</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">125</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Percent
    of product sales</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">48</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">During
    the Years <br/> Ended December 31,</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Increase</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Gross
    margin</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,072</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Percent
    of product sales</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
gross margin during recent periods was significantly less than what we anticipate going forward. The 2023 reduction in production output
was largely the result of our decision to slow down our production rate while remediating the production contamination events discussed
above. During 2023, we did not benefit from spreading our fixed costs over higher volumes as we normally do. Further, we did not furlough
any labor during this production slowdown. As we build back sales, we are increasing the amount of gross margin earned compared to prior
periods and improving the gross margin as a percentage of sales compared to 2023. The gross margin as a percentage of product sales was
30%, 22%, 41%, 45%, 45%, 49%, 47% and 50% during the years ended December 31, 2024, 2023, 2022, 2021, 2020, 2019, 2018 and 2017, respectively.
The 22% gross margin percentage during the year ended December 31, 2023 (including even lower gross margin percentages during the three-month
period ended March 31, 2023 and the six-month period ended June 30, 2023) was our lowest ever. Achieving process yield improvements (in
addition to running without significant equipment failures or product contaminations) will be essential to increasing our gross margin
in future periods. Some of the critical process parameters that we are investigating include optimizing: 1) the time and temperature
for pasteurization steps, 2) a critical filtration step and 3) the antibody content of incoming Work-in-Process inventory. As we fully
integrate and utilize our increased capacity and evaluate our product costs and selling price, we believe we could increase our gross
margin by approximately 3 to 8 percentage points over the 37% gross margin reported for the three-month period ended December 31, 2024.
Our immediate goal is to resume a 40% gross margin. This goal has been reduced from prior projections given the lower rates experienced
during 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
our biological and process yields continue to be variable, we have seen a favorable improvement to our finished goods yield recently.
The <b>Tri-Shield<sup>&#174;</sup></b> product format is more complex (i.e., three antibodies versus two antibodies for <b>Dual-Force<sup>&#174;</sup></b>)
making it more costly to produce, and both the bivalent and trivalent gel product formats are more expensive to produce than the bolus
format. These new formats are creating sales growth for us, and we are focused on increasing total gross margin dollars, even if that
is accomplished with a lower gross margin as a percentage of sales. A number of other factors contribute to the variability in our costs,
resulting in some fluctuations in gross margin percentages from quarter to quarter and from year to year. We also invest to sustain compliance
with cGMP in our production processes. Increasing production can be more expensive in the initial stages. To achieve our inventory production
growth objectives, we continue to acquire more raw material (colostrum) from many more cows at several new farms. Additionally, the biological
yields from our raw material are always variable, which affects our costs of goods sold in a similar way. Just as our customers&#8217;
cows respond differently to commercial dam-level vaccines, depending on the time of year and immune competency, our source cows have
similar biological variances in response to our proprietary vaccines. As is the case with any vaccine program, animals respond less effectively
to their first exposure to a new vaccine, and thereafter the effectiveness of their immune response improves in response to subsequent
immunizations. While this variability impacts our costs of producing inventory, one of the key commercial benefits of our <b>First Defense<sup>&#174;
</sup></b>product line is that we compensate for the variability in a cow&#8217;s immune response by standardizing each dose of finished
product. This ensures that every calf is equally protected, which is something that dam-level commercial scours vaccines cannot offer.
We continue to work on processing and yield improvements and other opportunities to reduce costs, while enhancing process knowledge and
robustness.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
the significant global supply-chain disruptions that almost all industries are experiencing presently are a challenge to us. The costs
of our critical supplies, components, raw materials, utilities and services increased significantly during 2021 and that trend has continued
since then. We have little choice but to pay the higher prices and try to take on more months of supply than we would have held previously
if we could get our orders fulfilled timely. We believe that gross margin trends going forward should be viewed over longer periods of
time than just one quarter.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following table displays the relationship between sales and gross margin during recent periods (in thousands except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Product <br/> Sales</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Gross<br/> Margin <br/> Dollars</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Gross <br/> Margin<br/> Percentage</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2021</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,243</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,656</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">45%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,472</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">22%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2022</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,568</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,649</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">41%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease during 2023 under 2022</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">1,096</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right">(<span style="font-family: Times New Roman, Times, Serif">3,780</span></td>
    <td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)<sup>(1)</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(19%)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended March 31, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,447</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">301</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">9%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended June 30, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,533</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,044</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">30%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended September 30, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,396</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,267</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">23%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended December 31, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,096</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,257</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">25%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,472</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,869</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">22%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended March 31, 2024</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,258</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,295</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">32%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended June 30, 2024</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,473</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,230</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">22%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended September 30, 2024</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,011</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,584</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">26%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Three-Month Period Ended December 31, 2024</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,751</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,832</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">37%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2024</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,493</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">30%</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
                                            $3.8 million decrease in gross margin earned resulted in a very sudden, material and unexpected
                                            decrease in our available cash.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
demonstrated in the table below, Work-in-Process inventory as a percentage of total inventory has ranged from 57% to 81%, and the dollar
value of Work-in-Process inventory has increased significantly since December 31, 2021. The hyper-immunized colostrum we purchase for
use in the production of <b>First Defense<sup>&#174;</sup></b> is the largest component of Work-in-Process inventory. As we began to increase
our production capacity, we also increased the supplier base that we work with in order to increase the availability of this critical
ingredient. As certain contamination events discussed above slowed the implementation of our increased capacity, we accumulated more
colostrum than originally planned. While this is a good safety measure to have in place to ensure that we do not run short of colostrum,
we do expect to reduce this use of cash as we move forward with our increased production rate. Also, we are developing what could potentially
be a spray-dried alternative format of <b>First Defense Technology<sup>&#174;</sup></b> that would not require the liquid processing and
freeze-drying production steps used to produce <b>First Defense<sup>&#174;</sup></b> in a capsule or gel tube. If successful, this effort
could expand our product portfolio with a bulk product designed to meet the needs of large dairy and calf-ranch customers at a lower
cost. This would help us turn some of this inventory to cash sooner. In a frozen state, this colostrum has a 30-month useable shelf life.
The increase in Work-in-Process inventory is demonstrated in the following table (in thousands, except for percentages):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As
    of</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Frozen
                                            Colostrum</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Other</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Work-in-Process
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Inventory</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>%
                                            of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Inventory</b></span></p></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2021</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,032</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">870</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,902</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2022</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,418</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,051</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,469</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2023</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,811</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,004</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,815</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">December
    31, 2024</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,591</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,156</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,747</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-style: normal">c)
Product Development Expenses and Strategy</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Overview:
<span style="font-style: normal">The majority of our product development expenses pertain to the development of <b>Re-Tain<sup>&#174;</sup></b>.
During the three-month period ended December 31, 2024, product development expenses decreased by 23%, or $247,000, to $819,000 in comparison
to $1.1 million during the three-month period ended December 31, 2023. Product development expenses aggregated 11% and 21% of product
sales during the three-month periods ended December 31, 2024 and 2023, respectively. Product development expenses included non-cash depreciation
and stock-based compensation expenses of $371,000 and $369,000 during the three-month periods ended December 31, 2024 and 2023, respectively.
Approximately $341,000 of these non-cash expenses were comprised of depreciation expenses pertaining largely to our DS facility and equipment
for <b>Re-Tain<sup>&#174; </sup></b>during both of the three-month periods ended December 31, 2024 and 2023. During the year ended December
31, 2024, product development expenses decreased by 11%, or $496,000, to $3.9 million in comparison to $4.4 million during the year ended
December 31, 2023. Product development expenses aggregated 15% and 25% of product sales during the years ended December 31, 2024 and
2023, respectively. Product development expenses included non-cash depreciation and stock-based compensation expenses of approximately
$1.5 million during both of the years ended December 31, 2024 and 2023. Approximately $1.4 million of these non-cash expenses consisted
of depreciation expenses pertaining largely to our DS facility and equipment for <b>Re-Tain<sup>&#174; </sup></b>during both of the years
ended December 31, 2024 and 2023. We began depreciating this asset when the Certificate of Occupancy for the new construction was issued
during the fourth quarter of 2017, but sales of our new product cannot be realized until we achieve FDA approval. Product development
expenses (excluding depreciation expense of $1.4 million) were $3 million during the year ended December 31, 2023, when we were in production
mode. Beginning during the second half of 2024, we implemented an aggressive idle of product development expenses pertaining to <b>Re-Tain</b></span><b><sup>&#174;
</sup></b><span style="font-style: normal">after the production of inventory intended for our Controlled Launch was completed. It was
our goal to reduce product development expenses (excluding depreciation) to approximately $2.5 million during the year ended December
31, 2024. The actual  expense incurred was $2,532,000, representing a 16%, or $477,000, reduction from the 2023 expense (excluding
depreciation). Product development expenses (excluding depreciation) were $1.6 million during the six-month period ended June 30, 2024.
This means that we reduced product development expenses (excluding depreciation) by approximately 43%, or approximately $689,000, during
the second half of 2024 in comparison to the first half of 2024. It is our further objective to reduce product development expenses (excluding
depreciation) to approximately $2.1 million during the year ending December 31, 2025, which would be an 18%, or approximately $462,000,
decrease from the 2024 level. This aggressive idle strategy (as opposed to a complete shut down) allows us to continue our pursuit of
FDA approval while reducing our cash spend and ensuring no adverse impact to critical equipment. We have a plan to bring the DS plant
back to full production mode in approximately two to three months, subject to available funding.</span></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i style="font-style: normal; font-weight: normal">During
the third quarter of 2016, the City of Portland approved a Tax Increment Financing (TIF) credit enhancement package that reduces the
real estate taxes on <b>Building 33</b> (our DS production facility for <b>Re-Tain<sup>&#174;</sup></b>) by 65% over the eleven-year period
beginning on July 1, 2017 and ending June 30, 2028 and by 30% during the year ending June 30, 2029, at which time the rebate expires.
During the second quarter of 2017, the TIF was approved by the Maine Department of Economic and Community Development. The value of the
tax savings will increase (decrease) in proportion to any increases (decreases) in the assessment of the building for city real estate
tax purposes or the City&#8217;s tax rate. The following table discloses how much of the new taxes we have generated is being relieved
by the TIF and how much we are paying:</i></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Assessed Value</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Twelve-Month<br/>
 Period Ended</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total New Taxes<br/>
 Generated by <br/>
the Project</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Less:<br/>
 TIF Credit</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Net Amount<br/>
 Paid by<br/>
 ImmuCell</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">$1.7 million @ April 1, 2017</td><td style="width: 1%">&#160;</td>
    <td style="text-align: center; width: 15%; padding-left: 5.4pt">June 30, 2018</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$4.0 million @ April 1, 2018</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$4.0 million @ April 1, 2019</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$4.0 million @ April 1, 2020</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">60,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$4.3 million @ April 1, 2021</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>$4.3 million @ April 1, 2022</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$4.3 million @ April 1, 2023</td><td>&#160;</td>
    <td style="text-align: center; padding-left: 5.4pt">June 30, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">39,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">$4.3 million @ April 1, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 5.4pt">June 30, 2025</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">552,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">353,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">199,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal"><b>Re-Tain<sup>&#174;</sup></b></span>
Development objective: <span style="font-style: normal">Our product, <b>Re-Tain</b><sup>&#174;</sup>, could be the first mastitis product
to be marketed without FDA-required milk discard or pre-slaughter withdrawal period label restrictions. As we work to change the way that
mastitis is managed in the dairy industry, we aim to demonstrate that our bacteriocin, Nisin A, which is designed specifically for subclinical
mastitis, can provide producers the freedom to change when and how mastitis is treated. <b>Re-Tain<sup>&#174; </sup></b>is not a broad-spectrum
antibiotic used in human health. Rather, it consists of a highly targeted active ingredient without an FDA-required milk discard or pre-slaughter
withdrawal period. While milk prices vary, the cost of the milk discard associated with traditional antibiotics ranges from approximately
$53.00 (for 4 days of milk at 70 pounds per day at the Class III milk price average of $18.89 per hundredweight during 2024) to approximately
$145.00 (for 11 days of milk at 70 pounds per day at the Class III milk price average of $18.89 per hundredweight during 2024) per treated
animal. These high milk discard costs associated with traditional antibiotic treatments lead producers to only treat mastitis after clinical
signs develop. We expect that <b>Re-Tain<sup>&#174; </sup></b>will be a first-of-its-kind product that can be used to economically treat
at the earliest stage of infection, giving producers the ability to get ahead of mastitis before clinical signs develop so the best cows
stay at their best performance level and in the herd longer.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">The active
ingredient, Nisin A, is an antibacterial peptide that was designated as Generally Regarded as Safe (GRAS) over 40 years ago for use in
many foods to prevent the growth of pathogens. Nisin degrades in the gastrointestinal tract to amino acids, which further supports its
safety. The Nisin we produce is more than 96% pure, which is purer than any nisin used in food preservation applications. Our product
has been subject to the FDA&#8217;s phased review process since 2004. We received our first major Technical Section Complete Letter from
the FDA during the third quarter of 2008, and we received our fourth major Technical Section Complete Letter from the FDA during the third
quarter of 2018. The remaining fifth major Technical Section (CMC) is related to commercial manufacturing. We made our first submission
of the CMC Technical Section during the first quarter of 2019, and our most recent fourth submission of this Technical Section was made
as part of our Non-Administrative NADA submission during January of 2025. As part of this process, we have produced over 50,000 treatments
(150,000 doses) worth of product that are now quickly approaching their expiration dating. More specifically, approximately 16,000 treatments
would expire between April to May of 2025 if the FDA approves only 18-months of shelf life (or between October to November of 2025 if
24-months of shelf life is approved), and approximately 34,000 treatments would expire between July to August of 2025 if the FDA approves
only 18-months of shelf life (or between January to February of 2026 if 24-months of shelf life is approved). We may not be able to utilize
all available inventory prior to its expiration dating. The following chart displays the approximate timeline associated with the issuance
of the five major Technical Section Complete Letters:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_003.jpg" style="height: 140px; width: 620px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="margin-left: 20pt; text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-style: normal"><b>*</b> TS=Technical Section</span></p><div>



</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>Re-Tain<sup>&#174;</sup></i></b><i> Development
status</i>: Approval by the FDA of our NADA for <b>Re-Tain<sup>&#174;</sup></b> is required before any sales of the product can be initiated.
The NADA is comprised of five principal Technical Sections plus a sixty-day administrative review at the end. Each Technical Section can
be reviewed and approved separately. By statute, each Technical Section submission is generally subject to one or more six-month review
cycles by the FDA. Upon review and assessment by the FDA that all requirements for a Technical Section have been met, the FDA may issue
a Technical Section Complete Letter. The current status of our work on these submissions to the FDA is as follows:</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">1) Environmental
Impact: During the third quarter of 2008, we received the Environmental Impact Technical Section Complete Letter from the FDA. During
the second quarter of 2021, we received further clarification through a new Environmental Impact Technical Section Complete Letter covering
the current dosage regimen and labeling.</span></p><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">2) Target
Animal Safety: During the second quarter of 2012, we received the Target Animal Safety Technical Section Complete Letter from the FDA.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">3) Effectiveness:
During the first quarter of 2013, we received the Effectiveness Technical Section Complete Letter from the FDA. The anticipated product
label (which remains subject to FDA approval) carries claims for the treatment of subclinical mastitis associated with </span>Streptococcus
agalactiae<span style="font-style: normal">, </span>Streptococcus dysgalactiae<span style="font-style: normal">, </span>Streptococcus
uberis<span style="font-style: normal">, and coagulase-negative staphylococci in lactating dairy cattle. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">Subclinical
mastitis, and the study required to achieve an effectiveness claim for it, is defined under the FDA/Center for Veterinary Medicine Guidance
#49: Target Animal Safety and Drug Effectiveness Studies for Anti-Microbial Bovine Mastitis Products (Lactating and Non-Lactating Cow
Products).&#160;Trial eligibility requires both pretreatment samples to be positive for the mastitis pathogen (except for </span>Staphylococcus
aureus <span style="font-style: normal">and </span>Streptococcus agalactiae<span style="font-style: normal">, where a single pretreatment
sample qualifies a cow for enrollment).&#160;For all pathogens, both samples taken between 14 and 28 days post treatment (and at least
5 days apart) must be negative to be judged a cure.&#160;These conservative criteria generally result in enrolling cows with chronic subclinical
disease, which rarely self-resolves</span>.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">4) Human
Food Safety: During the third quarter of 2018, we received the Human Food Safety Technical Section Complete Letter from the FDA confirming,
among other things, a zero milk discard period and a zero pre-slaughter withdrawal period during and after treatment with our product.
Achieving this critical differentiating feature for our product encouraged us to continue the significant product development investment
necessary to bring <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">to market. It would have been hard to
justify an ongoing investment of this nature in a product without this significant competitive advantage. During the second quarter of
2021, we updated this Technical Section Complete Letter with FDA approval of the official analytical method to measure Nisin in milk.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">At this
point (almost 6.5 years ago), the remaining hurdle to market launch was focused on the commercial manufacture of the Drug Substance. Details
of this effort are described in the next eight paragraphs.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">5) Chemistry, Manufacturing and Controls (CMC):
The CMC Technical Section is complex and comprehensive. Having previously achieved the four different Technical Section Complete Letters
from the FDA discussed above, approval of the CMC Technical Section is the fifth and final significant step required before <b>Re-Tain<sup>&#174;</sup></b>
product sales can be initiated in the United States. Implementing DS production, which is a required component of the CMC Technical Section,
has been the lengthiest part of this project. We previously entered into an agreement with a multi-national pharmaceutical ingredient
manufacturer for our commercial-scale supplies of DS. However, we determined during 2014 that the agreement did not offer us the most
advantageous supply arrangement in terms of either cost or long-term dependability. As a result, we presented this product development
opportunity to a variety of large and small animal health companies. While such a corporate partnership could have provided access to
a much larger sales and marketing team and allowed us to avoid the large investment in a commercial-scale production facility, we concluded
that a partner would have taken an unduly large share of the gross margin from all future product sales of <b>Re-Tain<i><sup>&#174;</sup></i></b>.
However, the regulatory and marketing feedback that we received from prospective partners, following their due diligence, was positive.
During the third quarter of 2014, we completed an investment in facility modifications and processing equipment necessary to produce our
DS at pilot-scale at <b>Building 56</b>. This small-scale facility was used to: i) expand our process knowledge and controls, ii) establish
operating ranges for critical process parameters, iii) conduct product stability studies, iv) optimize process yields and v) determine
the cost of production. We believe these efforts have reduced the risks associated with our investment in the commercial-scale DS production
facility. Having raised equity during 2016 and 2017, we were able to move away from these earlier partnering strategies and assume control
over the commercial-scale manufacturing process in our own facility. During the fourth quarter of 2015, we acquired land near our existing
Portland facility for the construction of a new commercial-scale DS production facility. We commenced construction of this facility during
the third quarter of 2016 and completed construction during the fourth quarter of 2017. Equipment installation and qualification was initiated
during the third quarter of 2017 and completed during the third quarter of 2018. Total construction and equipment costs aggregated approximately
$20.8 million. With construction of the facility complete, we continue to work with outside parties to investigate improvements to our
DS production yields as well as potential efficacy enhancements.</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">Under
the FDA&#8217;s phased submission process, we made a first-phased DS submission (without the DP submission) during the first quarter of
2019 that included data from the DS Registration Batches produced at commercial scale in our new DS manufacturing facility. This first-phased
submission was followed by a second-phased submission covering both DS and DP, during the first quarter of 2021. The second-phased DS
and DP submission responded to comments raised by the FDA regarding the first-phased DS submission and included detailed information about
the manufacturing process and controls for DP. One of the key components of the second-phased DS and DP submission was also demonstrating
stability of the product through expiry. During the third quarter of 2021, the FDA issued a Technical Section Incomplete Letter (Incomplete
Letter) with regard to this second-phased DS and DP submission. This response was not unexpected as it is common for the FDA to issue
queries and comments, especially related to an aseptic DP submission. We made a second DS and DP submission of the CMC Technical Section
during the first quarter of 2022. During the third quarter of 2022, we received an Incomplete Letter from the FDA with regards to this
second DS and DP submission of the CMC Technical Section. The Incomplete Letter required that internal and external laboratories re-develop
and qualify several analytical tests and associated controls. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">We made
a third DS and DP submission of the CMC Technical Section during the third quarter of 2023. During the fourth quarter of 2023, the FDA
notified us that it was refusing to review our third submission because Norbrook was identified as the DP manufacturer in our submission,
but the FDA had been expecting that we would identify our own in-house services as the DP manufacturer (instead of Norbrook). This miscommunication
arose from our April of 2022 response to an FDA 483 inspectional observation in which we noted that Norbrook was expected to exit the
DP manufacturing agreement with us at the end of 2022. Termination of the Norbrook arrangement at that time would have required us to
procure and install some long lead time equipment (filler and labeler) in our DS suite in late 2022. Instead, we were able to extend the
agreement with Norbrook to complete the manufacture of DP inventory for the initial commercial sales under our Controlled Launch strategy.
As a result, we continued to identify Norbrook as our DP manufacturer. As a result of this miscommunication, we were required to re-submit
our third submission the CMC Technical Section in November of 2023. In May of 2024, the FDA issued another Incomplete Letter to us. In
that letter, the FDA raised some minor questions about our third submission that required a fourth submission of the CMC Technical Section.
The FDA also advised that all inspectional observations at our DS facility and at the DP facility of our contract manufacturer must be
cleared before this fourth submission could be made. Subsequently, the FDA notified us during the second quarter of 2024 that the inspectional
observation at our DS facility had been cleared. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">In early
January of 2025, we made a Non-Administrative NADA submission that included our fourth submission of the CMC Technical Section, together
with the minor technical sections covering All Other Information and Product Labeling. We implemented this filing strategy to eliminate
the need for an Administrative NADA submission covering All Other Information and Product Labeling at the end of the application process,
which would then be subject to an additional 60-day review at that time. By statute, this CMC Technical Section submission would be subject
to a review period of up to 180 days, but because these latest responses to the CMC Incomplete Letter are not complex, we are hopeful
for a shorter review period. We expect the FDA to complete its review only after it clears the inspectional observations at the DP facility
of our contract manufacturer. This now appears to be the critical path constraint.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although the FDA could have refused our Non-Administrative
NADA submission because of the open inspection, it did not do so and has used this filing to schedule the on-site re-inspection at Norbrook
to be completed by early April. If the inspectional observations are cleared and our contract manufacturer resumes &#8220;No Action Indicated&#8221;
or &#8220;Voluntary Action Indicated&#8221; status, we anticipate that the path to NADA approval could be expedited. Reflecting the innovative
nature of our product and considering the short expiry dating of the inventory on hand, we may now be able to move forward with Investigational
Product use with inventory on hand that has a relatively short shelf life. This would allow us to begin to test market acceptance of this
novel product.</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">While
mindful of being prudent with how much cash we invested in inventory that would have short expiry dating if market launch were delayed,
we did build DS inventory during 2022 and 2023 to support potential initial commercial sales of <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
Upon FDA approval, we intend to implement our Controlled Launch with relatively short product expiration dating, subject to confirmation
of final product shelf-life disposition by the FDA. We presently have no agreement in place to aseptically fill additional DP inventory.
We do not anticipate the Controlled Launch to be a significant source of new sales, nor do we anticipate the initial sales to generate
gross margin in excess of the associated product development expenses. During the second half of 2024, we began to reduce operating costs
at our DS production facility until initial market acceptance (and perhaps the interest of a marketing partner) justifies a new agreement
for aseptic filling and the production of additional inventory. We do anticipate a pause in the supply of product to market after the
initial goods are sold and before the product is re-launched with DP produced by our in-house aseptic filling operations if that investment
is re-funded (or, if not, then by an alternative contractor that has not been identified yet). While we do not expect <b>Re-Tain</b></span><b><sup>&#174;</sup></b>
<span style="font-style: normal">to make a significant contribution to our sales growth in the early years after market launch, we do
see value in achieving regulatory approval and testing market acceptance of the product. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">Our DS
manufacturing facility and our potential future DP manufacturing facility (or that of a DP contract manufacturer for us) would be subject
to ongoing FDA inspections. During the third quarter of 2019, the FDA conducted a pre-approval inspection of our DS facility. This resulted
in the issuance of certain deficiencies as identified on the FDA&#8217;s Form 483. We submitted responses and data summaries in a phased
manner over the fourth quarter of 2019 and first quarter of 2020. During the first quarter of 2022, the FDA conducted another pre-approval
inspection of our DS facility. This also resulted in the issuance of certain deficiencies as identified on the FDA&#8217;s Form 483. We
have responded to all of the queries. Early during the first quarter of 2024, the FDA conducted another pre-approval inspection of our
DS facility. This resulted in the issuance of one deficiency as identified on the FDA&#8217;s Form 483. During the first quarter of 2024,
we successfully responded to this inspectional observation and achieved &#8220;Voluntary Action Indicated&#8221; status. The remaining
critical path milestone is for Norbrook to successfully complete closure of deficiencies at their DP facility, which is currently underway.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">We had
concluded that the fastest route to FDA approval and market launch is with the services of Norbrook, reducing our risk by benefiting from
their demonstrated expertise in aseptic filling. From 2010 to the present, we have worked with Norbrook under several amended contract
manufacturing agreements covering the DP formulation, aseptic filling and final packaging services. Norbrook filled DP for our Controlled
Launch before the filling contract expired during the fourth quarter of 2024. This contract continues through March of 2026 with regards
to labeling and packaging services. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">Our potential
alternative third-party options for the formulation and aseptic filling services that are presently being performed by Norbrook are narrowed
considerably because our product cannot be formulated or filled in a facility that also processes traditional antibiotics (i.e., beta
lactams). During the first quarter of 2022, we initiated an investment in the installation of equipment to produce DP at our own facility
at <b>Building 33</b>. Given the loss in gross margin during the first ten months of 2023 caused by the slowdown in production output
that was necessary to remediate the production contamination events discussed above and after weighing feedback from the FDA during their
2022 inspection, we decided to defer the completion of our potential DP manufacturing facility for the time being. If we decide to resume
our in-house strategy, we would anticipate FDA approval of this facility (which is a requirement for commercial manufacturing) would take
at least two years after we resume spending on this project, allowing for two six-month review cycles, subject to the timing of our installation
and validation work. This would be a post-approval submission. </span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-style: normal">If we
decide to complete our potential future DP manufacturing facility, we anticipate it would have enough formulation and aseptic filling
capacity to exceed the expected production capacity of our DS facility, which is approximately $10 million in annual sales. This production
capacity estimate is based on our assumptions as to product pricing and does not yet reflect inventory build strategies in advance of
product approval or ongoing yield improvement initiatives. Establishing our own DP formulation and aseptic filling capability would provide
us with the longer-term advantage of controlling the manufacturing process for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">in
one facility, thereby potentially reducing our manufacturing costs and eliminating international cold chain shipping logistics and costs.
The DP formulation and aseptic filling operation, if completed, will be located in existing facility space that we had intended to utilize
to double our DS production capacity if warranted by sales volumes following market launch. As a result, if we decide to complete this
DP facility (rather than utilizing a third party for these services), we would need to explore alternative strategies (in parallel with
ongoing DS yield improvement initiatives) to expand our DS production capacity. This integrated manufacturing capability for <b>Re-Tain</b></span><b><sup>&#174;</sup></b>
<span style="font-style: normal">would substantially reduce our dependence on third parties. Upon completion of our formulation and aseptic
filling facility, the only significant third-party input for <b>Re-Tain</b></span><b><sup>&#174;</sup></b> <span style="font-style: normal">would
be the DP syringes. It is anticipated that Hubert De Backer of Belgium (HDB) will supply these syringes in accordance with purchase orders
that we submit. HDB is a syringe supplier for many of the largest participants in the human and veterinary medical industries, and with
whom Norbrook presently works. Based on HDB&#8217;s performance history and reputation in the industry, we are confident that HDB will
be a dependable supplier of syringes in the quantity and of the quality needed for <b>Re-Tain</b></span><b><sup>&#174;</sup></b><span style="font-style: normal">.
</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Other product development initiatives: Our next
most important product development initiative has been focused on other improvements, line extensions or additions to our <b>First Defense<sup>&#174;</sup></b>
product line. The bolus format of <b>First Defense<sup>&#174;</sup></b> and <b>Tri-Shield First Defense<sup>&#174;</sup></b> have been listed
with the Organic Materials Research Institute (OMRI) since 2013 and 2019, respectively. This means they can be used on organic farms.
During the third quarter of 2024, the gel tube format of <b>First Defense<sup>&#174;</sup></b> also became OMRI listed. As discussed above,
we are developing a potential spray-dried, bulk powder format of our <b>First Defense Technology<sup>&#174;</sup></b>. During the third
quarter of 2024, we entered into a research agreement with the Mayo Clinic, a non-profit, educational, research and healthcare institution,
to explore potential applications of Nisin in certain human surgical situations. This data may be published in the future, but we do not
see a clear commercial path forward at this time. Subject to the availability of resources, we intend to begin new development projects
that are aligned with our core competencies and market focus. We also remain interested in acquiring, on suitable terms, other new products
and technologies that fit with our sales focus on the dairy and beef industries, subject to the availability of the needed funding.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">d) Sales and Marketing Expenses
and Selling Strategy</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
see ourselves as the &#8220;non-Pharma&#8221; pharma company. Rather than offering variations of &#8220;copy-cat&#8221; technology like
vaccines and antibiotics, we have taken the path less traveled by developing first-of-their kind products fueled by novel active ingredients
such as polyclonal antibodies (for <b>First Defense</b><sup>&#174;</sup>) and bacteriocins (for </span><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">).
While we expect that </span><b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b><span style="font-family: Times New Roman, Times, Serif">
could be a significant market disrupter, we project the <b>First Defense</b><sup>&#174;</sup> market could be larger, especially during
the next five years. We anticipate that these category developing innovations will drive greater value for the livestock industry and,
in turn, for our stockholders. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month period ended December
31, 2024, sales and marketing expenses increased by 25%, or $165,000, to $836,000 in comparison to $672,000 during the three-month period
ended December 31, 2023, amounting to 11% and 13% of product sales during the three-month periods ended December 31, 2024 and 2023, respectively.
Sales and marketing expenses included non-cash depreciation and stock-based compensation expenses of $27,000 and $61,000 during the three-month
periods ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, sales and marketing expenses increased
by 12%, or $378,000, to $3.5 million in comparison to $3.1 million during the year ended December 31, 2023, amounting to 13% and 18% of
product sales during the years ended December 31, 2024 and 2023, respectively. Sales and marketing expenses included non-cash depreciation
and stock-based compensation expenses of $158,000 and $182,000 during the years ended December 31, 2024 and 2023, respectively. Our current
budgetary guideline is to keep sales and marketing expenses under 20% of total sales. We continue to leverage the efforts of our small
sales force by using animal health distributors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The <b>First Defense</b><sup>&#174;</sup> product
line serves dairy and beef producers by protecting their calf crop from scours, the leading cause of pre-weaning mortality and morbidity.
When calves are healthy during this crucial development period, they mature into more productive milking cows and more efficient beef
generators. Our primary competition in this category is vaccines that are also regulated for effectiveness and safety by the USDA. However,
animal responses to vaccines are inherently variable. COVID breakthrough infections in humans have reminded us that a vaccine does not
guarantee immunity. That is true for our competitors as well. In the most controlled research settings, only 80% of animals respond to
a vaccine. This leaves 20% of the calf crop unprotected when the scour prevention program relies on scour vaccines. Those unprotected
calves can be disease carriers. Not only are they more susceptible to death or likely to require life-saving treatment (sometimes with
antibiotics), but they also shed pathogens into the environment creating a greater disease pressure for their herd mates. The <b>First
Defense</b><sup>&#174;</sup> product line removes the inconsistency inherent with vaccine protection. We sell the only USDA-licensed products
in the scour prevention category that are therapeutic multi-valent polyclonal antibodies. This technology eliminates a producer&#8217;s
reliance on a variable vaccine response to generate antibodies and, instead, can protect every calf equally with a measured dose of antibody-driven
immunity against both bacterial and viral scour pathogens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the years ended December 31, 2024 and
2023, we treated more calves than our next largest calf-level competitive product, which is a vaccine administered to the newborn at birth.
Compared to the dam-level competitive products (which are vaccines given to the cow pre-calving), we are second in sales dollars to the
market leader. Despite these successes, there remains significant opportunity to displace more competition within North America. There
is also opportunity to grow our sales by expanding into international markets. We are being strategic in how we invest in international
market development in order not to divert our limited resources away from achieving domestic growth, which is often more efficient to
obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We believe that <b>Re-Tain</b><sup>&#174;</sup> could
revolutionize the way that mastitis is managed by making earlier treatment of subclinical infections (while these cows are still producing
saleable milk) economically feasible without an FDA-required milk discard or pre-slaughter withdrawal period during, or for a period of
time after, treatment. No other FDA-approved mastitis treatment product on the market can offer this value proposition. We believe we
can demonstrate a return on investment to the dairy producer and the milk processor that will justify a premium over other mastitis treatments
on the market today, which are all sold subject to milk discard and pre-slaughter withdrawal period requirements. By creating this value
for our customers, we believe we can, in turn, create value for our stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Re-Tain<sup>&#174;</sup></b> could increase the
lifetime profitability of a cow and reduce disease transfer to herd mates. It is common practice to move sick cows from their regular
herd group to a sick cow group for treatment and the related milk discard. This movement causes stress on the cow and a reduction in milk
production. While practices may vary farm-to-farm, there would be no requirement to move cows treated with our product, allowing this
costly drop in production to be avoided. It is generally current practice to treat mastitis only when the disease has progressed to the
clinical stage where the milk from an infected cow cannot be sold, leaving most subclinically infected cows untreated. Without a milk
discard cost, we expect producers to be more motivated to identify and treat cows at the subclinical stage. This creates a substantial
animal welfare benefit. By treating mastitis early at the subclinical level, producers could preserve optimal milk yields. We also know
that animals infected with subclinical mastitis have higher abortion rates and often progress to the clinical disease state requiring
antibiotic treatment and milk discard. We believe that societal animal welfare objectives will put more and more pressure on the industry
to treat cows with subclinical infections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The over-use of antibiotics that are medically
important to human healthcare is a growing public health concern of our society and an active issue with the FDA, largely because of the
growing evidence that this over-use contributes to antibiotic resistance and the rise of &#8220;superbugs&#8221;. Sustainability objectives
require that less antibiotics be used in food producing animals, yet a new FDA-approved drug to treat mastitis has not been developed
in years. Our product improves sustainability by utilizing a bacteriocin as an alternative to traditional antibiotics that are used in
human medicine. In the big picture, we are introducing an entirely new class of antimicrobial as an animal drug, a bacteriocin, that does
not promote resistance against antibiotics used in human medicine making it more socially responsible. The industry could keep treating
this very significant disease with traditional antibiotics, but it takes innovation to bring a bacteriocin like Nisin to market. <b>Re-Tain<sup>&#174;</sup></b>
would, when introduced, offer a needed alternative to these traditional antibiotics, while at the same time improving milk quality and
the quantity of milk produced by treated cows. We believe our product fits very well with where the industry is going to be in the coming
years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
with all new products, the market determines value. Our objective is to gain market acceptance of this new product concept as we develop
a new product category. Despite our product&#8217;s exciting benefits, it will take time to change this longstanding treatment</span>
paradigm and develop this new market. It will take time for the market to understand, evaluate, implement and adapt to the use and benefits
of <b>Re-Tain<span style="font-family: Times New Roman, Times, Serif"><sup>&#174;</sup></span></b>. <span style="font-family: Times New Roman, Times, Serif">Based
on consultations with industry experts and key opinion leaders, we have opted to carefully control the launch of this novel product into
the first quarter of 2026 or so, as we seek to transform the way that mastitis is treated in the dairy industry over the long term. Our
goal is to help early adopters select treatment candidates, develop easy to use protocols, optimize treatment results and realize a positive
return on their investment. We intend to limit initial distribution of <b>Re-Tain<sup>&#174; </sup></b>to a level that enables our sales
team to select the optimal dairy farms at which to introduce <b>Re-Tain<sup>&#174; </sup></b>and to limit the initial number of participating
farms so that the desired levels of support and guidance relating to effective usage of <b>Re-Tain<sup>&#174; </sup></b>can be provided
with our available resources.&#160;We recognize that it will be important to manage expectations from the producer to the milk processor
because it is possible that processors may express reservations with regards to the zero milk discard claim. Our Controlled Launch strategy
reduces the amount of inventory that we would need to build at risk before regulatory approval is achieved. This strategic choice means
that we have elected not to pursue an alternative strategy that might have maximized short-term, initial sales quickly through a mass
market approach where we provide product to distribution and let them sell it to as many farms as possible. While we are dedicated to
increasing our sales revenue, we considered available product supply and the damage a mass market strategy could cause to the long-term
value of the product. We have seen products sold by much larger companies that were substantially damaged by such failed market launch
strategies. We believe that these prudent steps, while potentially leading to lower initial <b>Re-Tain<sup>&#174;</sup></b> revenues, may
create a smooth and successful launch and could safeguard the longer term performance of our investment in <b>Re-Tain<sup>&#174;</sup></b>.
We also believe that the operational adjustments and accommodations that dairy farmers will need to make to effectively use <b>Re-Tain<sup>&#174;</sup></b>
and avoid potential problems that would deter its adoption and usage. Our overarching objective is to minimize the risk of early-stage
unsatisfactory outcomes that could harm the longer-term prospects and market acceptance of <b>Re-Tain<sup>&#174;</sup></b>. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in">e) Administrative Expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month period ended December
31, 2024, administrative expenses increased by 6%, or $31,000, to $555,000 in comparison to $523,000 during the three-month period ended
December 31, 2023. Administrative expenses amounted to 7% and 10% of product sales during the three-month periods ended December 31, 2024
and 2023, respectively. Administrative expenses included non-cash depreciation and stock-based compensation expenses of $51,000 and $50,000
during the three-month periods ended December 31, 2024 and 2023, respectively. During the year ended December 31, 2024, administrative
expenses increased by 4%, or $82,000, to $2.2 million in comparison to $2.1 million during the year ended December 31, 2023. Administrative
expenses amounted to 8% and 12% of product sales during the years ended December 31, 2024 and 2023, respectively. Administrative expenses
included non-cash depreciation and stock-based compensation expenses of $198,000 and $210,000 during the years ended December 31, 2024
and 2023, respectively. We strive to be efficient with these expenses while funding all the legal, audit and other costs associated with
being a publicly-held company with a team of four employees. Prior to 2014, we had limited our investment in investor relations spending.
Beginning in the second quarter of 2014, we initiated an investment in a more active investor relations program. Recently, this initiative
has pivoted to a virtual meeting format, which is less expensive. Having experienced this efficiency, it is our intent to continue with
the same strategy, for the most part, even though travel restrictions have been eliminated. At the same time, we continue to provide full
disclosure of the status of our business and financial condition in three quarterly reports and one annual report each year, as well as
in Current Reports on Form 8-K when legally required or deemed appropriate by management. We believe these efforts have helped us access
the capital markets to fund our growth objectives. Considering our objective to hire a Chief Financial Officer during the first half of
2025 as well as inflation and all the necessary support services that fit into this category, we believe that approximately $2.7 million
per year is an efficient budget goal to fund the administrative expenses of a publicly-held company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in">f) Net Operating
Income (Loss)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month period ended December
31, 2024, our net operating income was $621,000 in contrast to a net operating loss of $1 million during the three-month period ended
December 31, 2023. The $1.6 million swing from net operating loss to net operating income was largely caused by a $1.6 million increase
in gross margin. During the year ended December 31, 2024, our net operating loss of $1.6 million was significantly less than our net operating
loss of $5.7 million during the year ended December 31, 2023. The $4.1 million decrease in our net operating loss during the year ended
December 31, 2024 compared to the year ended December 31, 2023 was largely caused by the $4.1 million increase in gross margin.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">g) Other Expenses, net </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month period ended December
31, 2024, other expenses, net, aggregated $101,000 in comparison $135,000 during the three-month period ended December 31, 2023. <span style="font-family: Times New Roman, Times, Serif">Interest
expense decreased to $136,000 during the three-month period ended December 31, 2024 from $152,000 during the three-month period ended
December 31, 2023. Non-cash amortization of debt issuance and debt discount costs (which is included as a component of interest expense)
was $11,000 and $10,000 during the three-month periods ended December 31, 2024 and 2023, respectively. Interest income was $36,000 and
$17,000 during the three-month periods ended December 31, 2024 and 2023, respectively. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the year ended December 31, 2024, other
expenses, net, aggregated $506,000 in comparison to $22,000 during the year ended December 31, 2023. <span style="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2023, we benefited from $365,000 of insurance recoveries, compared to no such benefit during the year ended
December 31, 2024. Interest expense increased to $569,000 during the year ended December 31, 2024 from $476,000 during the year ended
December 31, 2023 due to the additional debt taken out during the third quarter of 2023. Non-cash amortization of debt issuance and debt
discount costs (which is included as a component of interest expense) was $43,000 and $23,000 during the years ended December 31, 2024
and 2023, respectively. </span>We anticipate that our interest expense (excluding non-cash amortization of debt issuance and debt discount
costs) will be approximately $452,000 and $322,000 during the years ending December 31, 2025 and 2026, respectively. Interest income was
$78,000 and $97,000 during the years ended December 31, 2024 and 2023, respectively. We incurred a $15,000 loss on disposal of property,
plant and equipment during the year ended December 31, 2024 compared to an $8,000 loss during the year ended December 31, 2023.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>ImmuCell
Corporation</b></span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-style: normal">h) Income (Loss) Before Income
Taxes </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month period ended December
31, 2024, our income before income taxes was $521,000 in contrast to a loss before income taxes of $1.1 million during the three-month
period ended December 31, 2023. The $1.7 million reduction in our loss before income taxes during the three-month period ended December
31, 2024 compared to the three-month period ended December 31, 2023 was largely the result of a $1.6 million improvement in gross margin
and a $247,000 decrease in product development expenses that were offset, in part, by a $165,000 increase in sales and marketing expenses.
During the year ended December 31, 2024, our loss before income taxes was $2.1 million in comparison to a loss before income taxes of
$5.8 million during the year ended December 31, 2023. The $3.6 million decrease in our net loss during the year ended December 31, 2024
compared to the year ended December 31, 2023 was largely the result of the $4.1 million increase in gross margin that was reduced by an
increase of $485,000 in other expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in">i) Income Taxes and Net Income (Loss)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">During the three-month periods ended December
31, 2024 and 2023, we recorded income tax expense of $6,000 and $1,000, respectively, which is comprised of minimum state tax liabilities.
Our net income of $515,000, or $0.06 per diluted share, during the three-month period ended December 31, 2024 was in contrast to net (loss)
of ($1.1 million), or ($0.15) per basic share, during the three-month period ended December 31, 2023. During the years ended December
31, 2024 and 2023, we recorded income tax expense of $10,000 and $5,000, respectively, which is comprised of minimum state tax liabilities.
Our net (loss) of ($2.2 million), or ($0.26) per basic share, during the year ended December 31, 2024 was in comparison to net (loss)
of ($5.8 million), or ($0.75) per basic share, during the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have substantial net operating loss carryforwards
that will largely offset future income tax liabilities. As of December 31, 2024, our federal net operating loss carryforward was $17.6
million. As of December 31, 2024, our state net operating loss carryforward was $5.2 million. On December 22, 2017, the Tax Cuts and Jobs
Act was signed into law. This legislation made significant changes in the U.S. tax laws, including a reduction in the corporate tax rates,
changes to net operating loss carryforwards and carrybacks, and a repeal of the corporate alternative minimum tax. The legislation reduced
the U.S. corporate tax rate from 34% to 21%. Our income tax rate differs from this statutory tax rate primarily because we are currently
providing for a full valuation allowance against our deferred tax assets. While we are recording this full valuation allowance, we are
not recognizing the benefit of our tax losses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In addition to the results discussed above from
our Statements of Operations, we believe it is important to consider our Statements of Cash Flows in the accompanying audited financial
statements and the discussion under <b>Liquidity and Capital Resources</b> above to assess the cash generating ability of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0in"><b>Critical Accounting Policies and Estimates	</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The audited financial statements are presented
on the basis of accounting principles that are generally accepted in the United States. All professional accounting standards that were
effective and applicable to us as of December 31, 2024 have been taken into consideration in preparing the financial statements. The preparation
of financial statements requires that we make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates. Significant
estimates include our valuation of inventory, deferred tax assets and costs of goods sold. We base our estimates on historical experience
and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions. We have chosen to highlight certain policies that we consider critical
to the operations of our business and understanding of our financial statements. These critical accounting estimates have been consistently
applied.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We sell products that provide <b>Immediate Immunity&#8482;</b>
to newborn dairy and beef cattle. We recognize revenue in accordance with the five step model in ASC 606. These include the following:
i) identification of the contract with the customer, ii) identification of the performance obligations in the contract, iii) determination
of the transaction price, iv) allocation of the transaction price to the separate performance obligations in the contract and v) recognition
of revenue associated with performance obligations as they are satisfied. We recognize revenue at the time of shipment (including to distributors)
for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that
collectability is reasonably assured. We do not bill for or collect sales tax because our sales are generally made to distributors and
thus our sales to them are not subject to sales tax. We generally have experienced an immaterial amount of product returns.	</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. Inventory valuations is a critical
accounting policy because of the estimates and assumptions used by management to determine its cost accounting and because of the variability
of the cost per dose due to fluctuations in the biological yield.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 7A &#8212; QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-weight: normal">Not Applicable</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 8 &#8212; FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our financial statements, together with the notes
thereto and the report of the independent registered public accounting firm thereon, are set forth on Pages F-1 through F-26 at the end
of this report. The index to these financial statements is as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 90%"> <p><a href="#a_027">Report of Wipfli LLP, Independent Registered Public Accounting Firm (PCAOB ID#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-13833">344</ix:nonNumeric>)</a></p></td> <td style="width: 10%; text-align: center">F-1 to F-2</td></tr> <tr style="vertical-align: bottom"> <td><a href="#f_002">Balance Sheets as of December 31, 2024 and 2023</a></td> <td style="text-align: center">F-3</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#f_003">Statements of Operations during the years ended December 31, 2024 and 2023</a></td> <td style="text-align: center">F-4</td></tr> <tr style="vertical-align: bottom; "> <td><a href="#f_004">Statements of Stockholders&#8217; Equity during the years ended December 31, 2023 and 2024</a></td> <td style="text-align: center">F-5</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><a href="#f_005">Statements of Cash Flows during the years ended December 31, 2024 and 2023</a></td> <td style="text-align: center">F-6 to F-7</td></tr> <tr style="vertical-align: bottom; "> <td><a href="#notes_001">Notes to Audited Financial Statements</a></td> <td style="text-align: center">F-8 to F-26</td></tr> </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 9 &#8212; CHANGES IN
AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">None</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 9A &#8212; CONTROLS
AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>Disclosure Controls and Procedures: </i>Disclosure
controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under
the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms
and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer, as appropriate
to allow timely decisions regarding required disclosures. Because of its inherent limitations, internal control over financial reporting
may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance
with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the
policies or procedures may deteriorate. Our management, with the participation of the individual who serves as our principal executive
and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules
13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of December 31, 2024. Based on this
evaluation, that officer concluded that our disclosure controls and procedures were effective as of that date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>Management&#8217;s Annual Report on Internal
Control over Financial Reporting:</i> The management of the Company is responsible for establishing and maintaining adequate internal
control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. We conducted an evaluation of the effectiveness of the internal controls over financial reporting based
on the framework in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission. This evaluation included a review of the documentation of controls, evaluation of the design effectiveness of controls, testing
the operating effectiveness of the controls and a conclusion on this evaluation. Also, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. This Annual Report does not include an attestation report from our independent
registered public accounting firm regarding internal control over financial reporting. Management&#8217;s internal control report was
not subject to annual or quarterly attestation by our independent registered public accounting firm pursuant to rules of the Securities
and Exchange Commission that permit the Company to provide only management&#8217;s report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><i>Changes in Internal Controls over Financial
Reporting: </i>Our principal executive and principal financial officer and our Director of Finance and Administration periodically evaluate
any change in internal control over financial reporting which has occurred during the prior fiscal quarter. We have concluded that there
was no change in our internal control over financial reporting that occurred during the quarter ended December 31, 2024 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">ITEM 9B &#8212; OTHER
INFORMATION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="ixv-13834"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="ixv-13835"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="ixv-13836"><ix:nonNumeric contextRef="c27" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="ixv-13837">None</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 9C &#8212; DISCLOSURE
REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Not Applicable</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell
Corporation</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>PART
III</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 10 &#8212; DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Executive Officers of the
Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our executive officers as of March 21, 2025 were
as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>MICHAEL F. BRIGHAM </b>(Age: 64, Officer since
1991, Director since 1999) was appointed to serve as President and Chief Executive Officer in February 2000, while maintaining the titles
of Treasurer and Secretary, and was appointed to serve as a Director of the Company in March 1999. He previously had been elected Vice
President of the Company in December 1998 and had served as Chief Financial Officer since October 1991. He has served as Secretary since
December 1995 and as Treasurer since October 1991. Prior to that, he served as Director of Finance and Administration since originally
joining the Company in September 1989. Mr. Brigham served as a member of the Board of Directors of the United Way of York County from
2012 to 2019, serving as its Treasurer until June 2016 and as Chair of the Board of Directors for one year and as a member of its Executive
Committee. Mr. Brigham served as the Treasurer of the Board of Trustees of the Kennebunk Free Library from 2005 to 2011. He re-joined
the Finance Committee of the library in 2012. Prior to joining the Company, he was employed as an audit manager for the public accounting
firm of Ernst &amp; Young. Mr. Brigham earned his Masters in Business Administration from New York University in 1989 and a Bachelor of
Arts degree (with a double major in Economics and Spanish) from Trinity College in Hartford, Connecticut in 1983.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>BOBBI JO BROCKMANN </b>(Age: 48, Officer since
February 2015, Director since January 2018) served as a Director of the Company from March 2017 to September 2017 and from January 2018
to the present. She was promoted to Vice President of Sales and Marketing in February 2015. She joined the Company as Director of Sales
and Marketing in January 2010. Prior to that, she had been employed as Director of Sales since May 2008 and Sales Manager from February
2004 to April 2008 at APC, Inc. of Ankeny, Iowa, a developer and marketer of functional protein products for animal health and nutrition.
Prior to that, she held other sales and marketing positions at APC,&#160;W &amp; G Marketing Company, Inc. of Ames, Iowa, The Council
for Agricultural Science and Technology of Ames, Iowa and Meyocks Group Advertising of West Des Moines, Iowa after graduating from Iowa
State University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Information with respect to our directors is incorporated
herein by reference to the section of our 2025 Proxy Statement titled &#8220;Election of the Board of Directors&#8221;, which we intend
to file with the Securities and Exchange Commission within 120 days after December 31, 2024. There is no family relationship between any
director, executive officer, or person nominated or chosen by the Company to become a director or executive officer.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 11 &#8212; EXECUTIVE
COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Information regarding compensation paid to our executive
officers is incorporated herein by reference to the section of our 2025 Proxy Statement titled &#8220;Executive Officer Compensation&#8221;,
which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2024.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 12 &#8212; SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Information regarding ownership of our common stock
by certain owners and management is incorporated herein by reference to the section of our 2025 Proxy Statement titled &#8220;Security
Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221;, which we intend to file with the Securities
and Exchange Commission within 120 days after December 31, 2024.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 13 &#8212; CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Information regarding certain relationships and
related transactions and director independence is incorporated herein by reference to the section of our 2025 Proxy Statement titled &#8220;Certain
Relationships and Related Transactions and Director Independence&#8221;, which we intend to file with the Securities and Exchange Commission
within 120 days after December 31, 2024.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 14 &#8212; PRINCIPAL
ACCOUNTANT FEES AND SERVICES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Information regarding our principal accounting fees
and services is incorporated by reference to the section of our 2025 Proxy Statement titled &#8220;Principal Accounting Fees and Services&#8221;,
which we intend to file with the Securities and Exchange Commission within 120 days after December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell
Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>PART IV</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>ITEM 15 &#8212; EXHIBITS
AND FINANCIAL STATEMENT SCHEDULES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>1.1</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390024031647/ea020357301ex1-1_immucell.htm">At the Market Agreement between the Company and Craig-Hallum Capital Group LLC dated as of April 8, 2024 (incorporated by reference to Exhibit 1.1 of the Company&#8217;s Current Report on Form 8-K Filed on April 9, 2024).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 9%">3.1</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%">Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company&#8217;s 1987 Registration Statement No. 33-12722 on Form S-1 as filed with the Commission).</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>3.2</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex32.htm">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective July 23, 1990 (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>3.3</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000119312509065667/dex33.htm">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective August 24, 1992 (incorporated by reference to Exhibit 3.3 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2008).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>3.4</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390016014285/f8k061616a1ex3i_immucellcorp.htm">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 16, 2016 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Amended Current Report on Form 8-K/A filed on June 16, 2016).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>3.5</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390018007801/f8k061418ex3-1_immucellcorp.htm">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 18, 2018 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 18, 2018).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>3.6</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020014682/ea122959ex3-1_immucell.htm">Certificate of Amendment to the Company&#8217;s Certificate of Incorporation effective June 11, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 11, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>3.7</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024081304/ea021549201ex3-2_immucell.htm">Bylaws of the Company as amended and restated September 20, 2024 (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on September 24, 2024).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.1</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390021018473/f10k2020ex4-2_immucell.htm">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.1+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000119312507067375/dex103a.htm">Form of Indemnification Agreement (updated) entered into with each of the Company&#8217;s Directors and Officers (incorporated by reference to Exhibit 10.3A of the Company&#8217;s Annual Report on Form&#160;10-KSB for the year ended December 31, 2006).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.2+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000119312511079611/dex106.htm">2010 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.3+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000119312511079611/dex107.htm">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.4+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390017008652/f10q0617ex10i_immucell.htm">2017 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q for the three-month period ended June 30, 2017).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.5+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020007650/f10k2019ex10-9_immucell.htm">Form of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.6+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023024080/f10k2022ex10-7_immucellcorp.htm">Amendment to the 2017 Stock Option and Incentive Plan of the Company (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022).</a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>ImmuCell Corporation</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%">10.7+</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390022016147/f10k2021ex10-9_immucellcorp.htm">Amended and Restated Separation and Deferred Compensation Agreement between the Company and Michael F. Brigham dated as of March 28, 2022 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Annual Report on Form 10-K filed on March 30, 2022).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.8+</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024028718/ea020227701ex10-11_immucell.htm">Fourth Amended and Restated Incentive Compensation Agreement between the Company and Bobbi Jo Brockmann dated as of March 27, 2024 (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.9+</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024106933/ea022411901ex10-1_immucell.htm">Employment and Separation Agreement between the Company and Elizabeth L. Williams dated as of December 6, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed December 9, 2024).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.10+*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex10-10_immucell.htm">Incentive Compensation Agreement between the Company and Michael F. Brigham dated as of March 27, 2025.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.11+*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex10-11_immucell.htm">Amended and Restated Incentive Compensation and Severance Agreement between the Company and Bobbi Jo Brockmann dated as of March 27, 2025.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.12</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390019017687/f8k090519ex99-2_immucellcorp.htm">Development Services and Commercial Supply Agreement between the Company and Norbrook Laboratories Limited dated as of September 5, 2019 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on September 11, 2019).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.13</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/ea0201306ex10-1_immucell.htm">Amending Agreement between the Company and Norbrook Laboratories dated as of March 4, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed March 6, 2024).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.14</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024104543/ea022331501ex10-1_immu.htm">Amending Agreement between the Company and Norbrook Laboratories dated as of November 29, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed December 2, 2024).</a> </td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.15</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390019018253/f8k091219ex99-2_immucell.htm">Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on September 17, 2019).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.16</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390022049025/ea164617ex99-1_immucell.htm">Second Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of August 15, 2022 (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K filed on August 17, 2022).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.17</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023087893/ea188617ex10-1_immucell.htm">Third Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of November 14, 2023 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on November 16, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.18</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-2_immucell.htm">Term Note for $5,100,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.19</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-4_immucell.htm">Loan Agreement for $5,100,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.4 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.20</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390022014793/ea157362ex99-1_immucell.htm">Allonge to and Amendment of Term Note, dated March 23, 2022, between the Company and Gorham Savings Bank (incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on March 24, 2022).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.21</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390022014793/ea157362ex99-2_immucell.htm">Mortgage Modification Agreement, dated March 23, 2022, between the Company and Gorham Savings Bank (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 24, 2022).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.22</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-3_immucell.htm">Term Note for $3,500,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.3 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.23</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-5_immucell.htm">Loan Agreement for $3,500,000 between the Company and Gorham Savings Bank dated March 11, 2020 (incorporated by reference to Exhibit 99.5 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.24</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020006089/ea119564ex99-6_immucell.htm"><span style="font-family: Times New Roman, Times, Serif">Line of Credit Agreement for up to $1,000,000 executed by ImmuCell Corporation in favor of Gorham Savings Bank dated March 11, 2020 (</span>incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on March 12, 2020<span style="font-family: Times New Roman, Times, Serif">).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.25</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024017522/ea0200796ex10-1_immucell.htm">Allonge to and Amendment of Line of Credit Loan for up to $1,000,000 between the Company and Gorham Savings Bank dated March 23, 2022 (incorporated by reference to Exhibit 10.23 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022).</a></p></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.26</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024017522/ea0200796ex10-1_immucell.htm">Allonge to and Amendment of Line of Credit between the Company and Gorham Savings Bank, dated February 22, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on February 27, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.27</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020015079/ea123091ex99-2_immucell.htm">Note Purchase Agreement executed by the Company in favor of the Maine Technology Institute dated June 12, 2020 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on June 16, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.28</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020015079/ea123091ex99-3_immucell.htm">Subordinated Promissory Note for $500,000 executed by the Company in favor of the Maine Technology Institute dated June 12, 2020 (incorporated by reference to Exhibit 99.3 of the Company&#8217;s Current Report on Form 8-K filed on June 16, 2020).</a></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>ImmuCell Corporation</b></p><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%">10.29</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390021035662/ea143716ex99-1_immucell.htm">Note Purchase Agreement executed by the Company in favor of the Maine Technology Institute dated June 30, 2021 (incorporated by reference to Exhibit 99.1 of the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.30</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390021035662/ea143716ex99-2_immucell.htm">Subordinated Promissory Note for $400,000 executed by the Company in favor of the Maine Technology Institute dated June 30, 2022 (incorporated by reference to Exhibit 99.2 of the Company&#8217;s Current Report on Form 8-K filed on July 6, 2021).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.31</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020043105/ea131766ex10-1_immucell.htm">Term Note for $1,500,000 executed by the Company in favor of Gorham Savings Bank dated December 15, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.32</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390020043105/ea131766ex10-2_immucell.htm">Loan Agreement for $1,500,000 executed by the Company in favor of Gorham Savings Bank dated December 15, 2020 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on December 17, 2020).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.33</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-1_immucell.htm"><span style="font-family: Times New Roman, Times, Serif">Term Note for $2,000,000 executed by ImmuCell Corporation in favor of Gorham Savings Bank dated July 17, 2023 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.34</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-2_immucell.htm">Loan Agreement, by and between ImmuCell Corporation and Gorham Savings Bank dated July 17, 2023 (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.35</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-3_immucell.htm"><span style="font-family: Times New Roman, Times, Serif">Economic Recovery/SSBCI Program Loan Promissory Note for $1,000,000 executed by ImmuCell Corporation in favor of the Finance Authority of Maine dated July 17, 2023 (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</span></a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.36</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390023058672/ea182107ex10-4_immucell.htm">Economic Recovery Loan Program Loan Agreement, by and between ImmuCell Corporation and the Finance Authority of Maine dated July 17, 2023 (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Current Report on Form 8-K filed on July 21, 2023).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.37</td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/811641/000121390024031647/ea020357301ex10-1_immucell.htm">Consent and First Amendment to Economic Recovery Loan Program Loan Agreement, by and between ImmuCell Corporation and the Finance Authority of Maine dated as of April 8, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on April 9, 2024).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>10.38</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024052776/ea020791901ex10-1_immucell.htm">Fourth Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of June 11, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on June 14, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>10.39</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024081304/ea021549201ex10-1_immucell.htm">Fifth Amendment of Indenture of Lease for Premises Located in Portland, Maine between the Company and TVP, LLC dated as of September 20, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on September 24, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td>14</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000110262414000412/exh14.htm">Code of Business Conduct and Ethics (incorporated by reference to Exhibit 14 of the Company&#8217;s Current Report on Form 8-K filed on March 20, 2014).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>19*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex19_immucell.htm">Insider Trading Policy of the Company adopted as of December 11, 2024.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>23.1*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex23-1_immucell.htm">Consent of Independent Registered Public Accounting Firm.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>24.1</td>
    <td>&#160;</td>
    <td><a href="#poa_001">Power of Attorney (incorporated by reference to the signature page of this Form 10-K).</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>31*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex31_immucell.htm">Certification Pursuant to Rule 13a-14(a).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>32*</td>
    <td>&#160;</td>
    <td><a href="ea023548101ex32_immucell.htm">Certification Pursuant to Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>97.1</td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/811641/000121390024028718/ea020227701ex97-1_immucell.htm">ImmuCell Corporation Clawback Policy (incorporated by reference to Exhibit 97.1 of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023).</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.INS</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">XBRL Instance Document-the instance document does not appear in
the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr>
  <tr style="vertical-align: top; ">
    <td>101.SCH</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.CAL</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>101.DEF</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.LAB</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>101.PRE</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cover Page Interactive Data File-the cover page interactive data file
    does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr>
</table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Management contract or compensatory plan or arrangement.</td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>


</div><table cellpadding="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed herewith.</td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><div><a id="a_026"></a></div><p style="margin-top: 0; margin-right: 0; margin-bottom: 0"><b>ITEM 16 &#8211; FORM 10-K SUMMARY</b> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To the Stockholders and the Board of Directors of ImmuCell
Corporation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_027"></a></div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-7375"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Opinion on the Financial Statements</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">We have audited the accompanying balance
sheets of ImmuCell Corporation (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related statements of operations,
stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States
of America.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an
understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Critical Audit Matter</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">The critical audit matter communicated
below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way
our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing
a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;<i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 0.5in"><span style="font-style: normal"><b>Valuation
of Inventory</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 30%"><i>Description of the Matter</i></td>
    <td style="width: 70%">At December 31, 2024, the Company&#8217;s inventory was $7,112,623. As discussed in Note 2 of the financial statements, inventory is recorded at the lower of cost or net realizable value.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Auditing management&#8217;s valuation of inventory is complex and highly judgmental because of the estimates and assumptions used by management to determine the cost accounting and because of the variability of the cost per dose due to fluctuations in the biological yield achieved.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><i>How We Addressed the Matter In Our Audit</i>

</td><td>The primary procedures we performed to address this critical audit matter included the following:</td></tr>
  <tr style="vertical-align: top">
    <td/>
    <td>We obtained an understanding of the cost accounting developed by management and the related assumptions and estimates used. We tested the cost accounting by examining the underlying data used by the Company to prepare the cost accounting. We evaluated the effect of the variability of the cost per dose on the inventory value by comparing the biological yield to historical results and by performing a sensitivity analysis of the potential range in inventory value within a corridor of historical results based on minimum and maximum outcomes for the biological yield.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-13838">WIPFLI LLP</ix:nonNumeric></span></span></td> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&#8217;s auditor since 2019.</span></td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-7483"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Radnor, Pennsylvania</span></ix:nonNumeric></td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td> <td>&#160;</td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>As
of December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 20pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-13839">3,758,232</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-13840">978,741</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 20pt">Trade accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-13841">3,771,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-13842">2,185,383</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-13843">7,112,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-13844">7,811,841</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 20pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-13845">400,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-13846">493,885</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-13847">15,042,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd" id="ixv-13848">11,469,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10.1pt">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-13849">25,349,019</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-13850">27,575,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-13851">4,560,679</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-13852">4,571,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">Goodwill</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-13853">95,557</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="0" unitRef="usd" id="ixv-13854">95,557</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-13855">19,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-13856">38,208</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-13857">33,368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd" id="ixv-13858">57,655</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-13859">45,100,477</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-13860">43,808,102</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center; text-indent: -10.1pt; padding-left: 10.1pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 10.1pt">Current portion of debt obligations</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-13861">1,497,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="0" unitRef="usd" id="ixv-13862">1,428,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-13863">432,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd" id="ixv-13864">644,276</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13865">2,482,522</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13866">2,124,337</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20.15pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13867">4,412,213</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-13868">4,197,420</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 30.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LONG-TERM LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10.1pt">Debt obligations, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-13869">9,040,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="0" unitRef="usd" id="ixv-13870">10,540,496</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-13871">4,129,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd" id="ixv-13872">4,077,109</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 30.25pt">Total long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-13873">13,170,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="0" unitRef="usd" id="ixv-13874">14,617,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 30.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">TOTAL LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-13875">17,582,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd" id="ixv-13876">18,815,025</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">CONTINGENT LIABILITIES AND COMMITMENTS (See Note 10)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 10.1pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">STOCKHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Common stock, $<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-13877"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-13878">0.10</ix:nonFraction></ix:nonFraction> par value per share, with <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-13879"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-13880">15,000,000</ix:nonFraction></ix:nonFraction> shares authorized &#160;and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-13881">9,042,392</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-13882">7,814,165</ix:nonFraction> shares issued and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13883">8,979,091</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13884">7,750,864</ix:nonFraction> shares outstanding as of December 31, 2024 and 2023, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-13885">904,240</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-13886">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 10.1pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-13887">40,916,155</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd" id="ixv-13888">36,357,239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-13889">14,163,726</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd" id="ixv-13890">12,007,097</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Treasury stock, at cost, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-13891"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-13892">63,301</ix:nonFraction></ix:nonFraction> shares as of both December 31, 2024 and 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-13893">138,482</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd" id="ixv-13894">138,482</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13895">27,518,187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13896">24,993,077</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-13897">45,100,477</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd" id="ixv-13898">43,808,102</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Years Ended<br/>
 December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13899">26,493,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-13900">17,471,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13901">18,552,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-13902">13,602,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13903">7,941,044</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-13904">3,869,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13905">3,898,582</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-13906">4,394,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13907">3,466,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-13908">3,088,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13909">2,216,549</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-13910">2,134,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">&#160;&#160;&#160;Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13911">9,581,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-13912">9,617,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">NET OPERATING LOSS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13913">1,640,159</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13914">5,748,078</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-13915">506,414</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-13916">21,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13917">2,146,573</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd" id="ixv-13918">5,769,971</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13919">10,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-13920">4,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">NET LOSS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13921">2,156,629</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13922">5,774,598</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">Basic weighted average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13923">8,167,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-13924">7,747,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;&#160;&#160;Basic net loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13925">0.26</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-13926">0.75</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Diluted weighted average common shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13927">8,167,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-13928">7,747,686</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10pt; padding-left: 10pt">&#160;&#160;&#160;Diluted net loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13929">0.26</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-13930">0.75</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Common Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Treasury Stock</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Additional<br/>
paid-in&#160;capital</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Accumulated Deficit</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Amount</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid; font-weight: bold">Total Stockholders&#8217; Equity</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 26.5%">December 31, 2022</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13931">7,814,165</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13932">781,417</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13933">35,978,364</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13934">6,232,499</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13935">67,301</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13936">147,233</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13937">30,380,049</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13938">5,774,598</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13939">5,774,598</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-13940">10,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" sign="-" unitRef="shares" id="ixv-13941">4,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-13942">8,751</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-13943">18,760</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13944">368,866</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13945">368,866</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in">December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13946">7,814,165</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13947">781,417</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13948">36,357,239</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c17" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13949">12,007,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13950">63,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13951">138,482</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13952">24,993,077</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13953">2,156,629</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13954">2,156,629</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">At-the-Market Offering of common stock, net of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:OfferingCostsAtthemarketOfferingOfCommonStock" scale="0" unitRef="usd" id="ixv-13955">291,834</ix:nonFraction> of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-13956">1,228,227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13957">122,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13958">4,233,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-13959">4,356,188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13960">325,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd" id="ixv-13961">325,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">BALANCE,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; padding-bottom: 4pt">December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13962">9,042,392</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13963">904,240</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13964">40,916,155</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13965">14,163,726</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-13966">63,301</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" sign="-" unitRef="usd" id="ixv-13967">138,482</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd" id="ixv-13968">27,518,187</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Years Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13969">2,156,629</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-13970">5,774,598</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 30.25pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-13971">2,668,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-13972">2,697,897</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-13973">19,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-13974">19,104</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt">Amortization of debt issuance costs and debt discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-13975">42,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" unitRef="usd" id="ixv-13976">22,619</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-13977">325,551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd" id="ixv-13978">368,866</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Loss on disposal of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-13979">15,391</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" sign="-" unitRef="usd" id="ixv-13980">8,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Non-cash rent (benefit) expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" unitRef="usd" id="ixv-13981">149,741</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-13982">95,724</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Changes in:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 30.25pt">Trade accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-13983">1,585,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd" id="ixv-13984">426,783</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 30.25pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd" id="ixv-13985">699,218</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd" id="ixv-13986">1,773,302</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" sign="-" unitRef="usd" id="ixv-13987">93,123</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" unitRef="usd" id="ixv-13988">87,830</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 30pt">Other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-13989">24,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="0" sign="-" unitRef="usd" id="ixv-13990">18,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 30pt">Accounts payable and accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-13991">362,606</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd" id="ixv-13992">156,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Net cash provided by (used for) operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" unitRef="usd" id="ixv-13993">357,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd" id="ixv-13994">4,674,236</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-13995">465,725</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-13996">1,892,513</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Proceeds from sale of property, plant and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-13997">4,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-13998">2,474</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Net cash used for investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-13999">461,225</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd" id="ixv-14000">1,890,039</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Proceeds from debt issuance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14001">3,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Proceeds from line of credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" unitRef="usd" id="ixv-14002">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Proceeds from At-The-Market Offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14003">4,648,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Debt principal repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-14004">1,468,338</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="0" unitRef="usd" id="ixv-14005">1,185,774</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Line of credit repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="0" unitRef="usd" id="ixv-14006">2,000,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Payments of debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-14007">5,037</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="0" unitRef="usd" id="ixv-14008">35,425</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Payments of debt discounts</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:PaymentsOfDebtDiscounts" scale="0" unitRef="usd" id="ixv-14009">46,107</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Payments of equity issuance fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd" id="ixv-14010">291,834</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" unitRef="usd" id="ixv-14011">18,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-14012">2,882,813</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd" id="ixv-14013">1,751,454</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" unitRef="usd" id="ixv-14014">2,779,491</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" sign="-" unitRef="usd" id="ixv-14015">4,812,821</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">BEGINNING CASH AND CASH EQUIVALENTS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14016">978,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14017">5,791,562</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">ENDING CASH AND CASH EQUIVALENTS</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14018">3,758,232</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd" id="ixv-14019">978,741</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>The
accompanying notes are an integral part of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>STATEMENT OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Years Ended <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">CASH PAID FOR:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Income taxes</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-14020">7,293</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="0" unitRef="usd" id="ixv-14021">6,466</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-14022">528,907</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd" id="ixv-14023">444,954</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">NON-CASH ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in capital expenditures included in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-14024">4,421</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-14025">50,086</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Change in payments of debt discounts included in accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" scale="0" unitRef="usd" id="ixv-14026">16,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Operating lease right-of-use asset and operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14027">103,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14028">2,472,203</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><i>The accompanying notes are an integral part
of these financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&#160;</i></p><div>


</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div><a id="notes_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:NatureOfOperations" id="ixv-9281"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>1. BUSINESS OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">ImmuCell Corporation (the &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 16, &#8220;Segment Information&#8221;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate Immunity&#8482;</b> to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>,
coronavirus and rotavirus pathogens. We are also developing <b>Re-Tain<sup>&#174;</sup></b>, a treatment for lactating dairy cows with
subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need
to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and
third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products
and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends
and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions in the United States and/or
internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases in key
components, supportive services, transportation and other supplies that are causing our costs of goods sold to increase. We have experienced
contamination events from time to time in our production process, beginning in the third quarter of 2022, as disclosed previously. We
implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower sales and gross margin.
The last identified contamination event occurred during the first half of April of 2024, and we have been operating without further contamination
events since then and through the time of this filing on March 28, 2025.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-9296"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-9301"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(a) Basis of Presentation</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have prepared the accompanying audited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-9310"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(b) Cash and Cash Equivalents </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" unitRef="usd" id="ixv-14029">250,000</ix:nonFraction> per financial institution per depositor.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesPolicyTextBlock" id="ixv-9318"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(c) Trade Accounts Receivable</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ReceivablesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts receivable are carried at the original
invoice amount less an estimate made for credit losses, when applicable. Management determines the allowance for credit losses on a monthly
basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors.
Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due
accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the years ended
December 31, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of December
31, 2024 or 2023. As of December 31, 2024 and 2023, we determined that no allowance for credit losses was necessary. Accounts receivable
are written off when deemed uncollectible. No accounts receivable were written off during the years ended December 31, 2024 or 2023. Recoveries
of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the years
ended December 31, 2024 or 2023. See Note 3.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-9349"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(d) Inventory</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 4.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-9357"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(e) Property, Plant and Equipment, net</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately <ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage" scale="-2" unitRef="pure" id="ixv-14030">86</ix:nonFraction>% of these assets are being depreciated over
<ix:nonNumeric contextRef="c28" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14031">10</ix:nonNumeric> years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the <ix:nonNumeric contextRef="c29" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14032">10</ix:nonNumeric>-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 6 for additional disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-9372"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(f) Operating Leases</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account for our real estate leases using a
right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the
lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related
to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received
and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs
are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease.
When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of
determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets
or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined
lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent
payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes.
These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use
an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease
payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset
may not be recoverable. See Notes 2(h) and 11 for additional disclosures.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="ixv-9380"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(g) Intangible Assets and Goodwill</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> goodwill impairments were recorded during the years ended
December 31, 2024 or 2023. See Notes 2(h) and 7 for additional disclosures.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-9417"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(h) Valuation of Long-Lived Assets</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39">No</span></span> impairment was recognized during the years ended December 31, 2024 or
2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-9427"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(i) Fair Value Measurements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In <span style="font-style: normal; font-weight: normal">determining</span>
fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification
Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements.
The topic provides a consistent definition of fair value which focuses on an exit price, which is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The topic
also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes
a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of
the measurement date. As of December 31, 2024 and 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory,
prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their
short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.
Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.5in">Level 1</td>
    <td style="width: 0.25in">&#8212;</td>
    <td>Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 2</td>
    <td>&#8212;</td>
    <td>Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 3</td>
    <td>&#8212;</td>
    <td>Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the years ended December 31, 2024 and 2023, there were no transfers between levels. As of December 31, 2024 and 2023, our Level 1 assets
measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities
measured at fair value on a nonrecurring basis as of December 31, 2024 or 2023. The carrying values of our cash and money market accounts
as of December 31, 2024 and 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the
carrying values of our fixed rate bank debt as of December 31, 2024 and 2023 differed from their fair market values. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" id="ixv-14033">These values are
reflected in the following tables</ix:nonNumeric>:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock-c0_cont_1"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14034">3,758,232</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14035">3,758,232</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14036">9,465,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14037">9,465,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>As of December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14038">978,741</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd" id="ixv-14039">978,741</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14040">10,431,817</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd" id="ixv-14041">10,431,817</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-9726"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(j) Concentration of Risk</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. <ix:nonNumeric contextRef="c0" continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_1" escape="true" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="ixv-14042">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_2" id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_1"><ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years Ended<br/> December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14043">47</ix:nonFraction>%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14044">47</ix:nonFraction>%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14045">30</ix:nonFraction>%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14046">32</ix:nonFraction>%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#8239;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10.1pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14047">77</ix:nonFraction>%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14048">79</ix:nonFraction>%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_4" id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-c0_cont_2"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14049">57</ix:nonFraction>%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14050">43</ix:nonFraction>%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14051">21</ix:nonFraction>%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14052">36</ix:nonFraction>%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14053">78</ix:nonFraction>%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c49" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" unitRef="pure" id="ixv-14054">79</ix:nonFraction>%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-9857"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(k) Revenue Recognition</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 13 for additional disclosures.</p></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="iccc:ExpenseRecognitionPolicyTextBlock" id="ixv-9865"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(l) Expense Recognition </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="iccc_ExpenseRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-9873"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(m) Income Taxes</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account
for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability
or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary
differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning strategies
in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine that it is
more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over a reasonably
short period of time, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise,
if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in the future, an
increase to the valuation allowance would be charged to income in the period such determination was made.&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2024 or 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 15.<b>&#160;</b></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-9886"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(n) Stock-Based Compensation </b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1">We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14055">325,551</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" unitRef="usd" id="ixv-14056">368,866</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively.</ix:continuation> See Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-9895"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(o) Net Loss Per Common Share</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-14057">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14058">664,000</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-14059">618,500</ix:nonFraction> during
the years ended December 31, 2024 and 2023, respectively.</ix:nonNumeric></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/> Ended December 31, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14060">2,156,629</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14061">5,774,598</ix:nonFraction></td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14062">8,167,244</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-14063">7,747,686</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14064">8,167,244</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-14065">7,747,686</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14066">0.26</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-14067">0.75</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14068">0.26</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-14069">0.75</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table></ix:continuation></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-10036"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(p) Use of Estimates</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in
the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation
of inventory, deferred tax assets and costs of goods sold.</p></ix:continuation>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-10043"><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(q) New Accounting
Pronouncement Adopted</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments require disclosure of significant
segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and loss. The adoption
of ASU 2023-07 did not have a material impact on our financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c0" continuedAt="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1" escape="true" name="iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="ixv-10054"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(r) New Accounting Pronouncements Not Yet Adopted</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_2" id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November
of 2024, the FASB issued ASU 2024-03, <i>Disaggregation of Income Statement Expenses</i>, to provide disaggregated disclosures of specific
expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements
will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal
years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is
permitted. We are evaluating ASU 2024-03 to determine its impact on our financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In December
of 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to assess the
impact on our financial statement disclosures and to determine the transition method in which the new guidance will be adopted.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="ixv-10069"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>3. TRADE ACCOUNTS RECEIVABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Trade accounts receivable amounted to $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14070">3,771,133</ix:nonFraction>
and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14071">2,185,383</ix:nonFraction> as of December 31, 2024 and 2023, respectively. No allowance for credit losses or product returns was recorded as of December
31, 2024 or 2023. We consider a broad range of information to estimate credit losses. Historically, we have experienced a very low level
of credit loss expense, and most of our trade receivables are collected by the due date or within a few days of the due date. We anticipate
no future events or conditions that would impact our ability to collect our accounts receivable. Because of the generally short duration
from the balance sheet date to the date of collection, our collection rate is not expected to be significantly impacted by events occurring
after the balance sheet date. The trade accounts receivable balances included $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14072">52,097</ix:nonFraction> and $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd" id="ixv-14073">42,507</ix:nonFraction> due from a related party as of December
31, 2024 and 2023, respectively. See Note 17.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-10097"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>4. INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-10101"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-14074">1,356,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd" id="ixv-14075">1,594,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-14076">5,746,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd" id="ixv-14077">5,815,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-14078">9,530</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd" id="ixv-14079">402,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-14080">7,112,623</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd" id="ixv-14081">7,811,841</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">These inventory figures are net of write-offs of
scrapped inventory in the amounts of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-14082">406,565</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWriteDown" scale="0" unitRef="usd" id="ixv-14083">527,133</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively, that resulted
principally from contamination events and other production process losses.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-10161"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="ixv-10165"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Prepaid expenses and other current assets consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-14084">360,207</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" unitRef="usd" id="ixv-14085">454,152</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-14086">40,555</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="0" unitRef="usd" id="ixv-14087">39,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14088">400,762</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd" id="ixv-14089">493,885</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-10213"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>6. PROPERTY, PLANT AND EQUIPMENT, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-10217"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Property, plant and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%; text-align: left">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><ix:nonNumeric contextRef="c52" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14090">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c53" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14091">10</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14092">21,234,259</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14093">20,953,601</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c56" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14094">10</ix:nonNumeric>-<ix:nonNumeric contextRef="c57" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14095">39</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14096">20,889,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14097">20,784,565</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c60" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14098">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c61" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-14099">10</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14100">1,056,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14101">1,036,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-40">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14102">2,693,904</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14103">2,768,224</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-41">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14104">516,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14105">516,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14106">46,390,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd" id="ixv-14107">46,059,631</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14108">21,041,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14109">18,483,948</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14110">25,349,019</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd" id="ixv-14111">27,575,683</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">As of December 31, 2024 and 2023, construction
in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b> production capacity expansion project and
equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b> in-house. The costs associated with property,
plant and equipment disposals were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14112">130,365</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentDisposals" scale="0" unitRef="usd" id="ixv-14113">100,142</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively. Depreciation
expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14114">2,668,077</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd" id="ixv-14115">2,697,897</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="ixv-10363"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>7. INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14116">191,040</ix:nonFraction> were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be <ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="ixv-14117">10</ix:nonNumeric> years.
Intangible amortization expense was $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14118"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14119">19,104</ix:nonFraction></ix:nonFraction> during both of the years ended December 31, 2024 and 2023. The net value of these intangibles
was $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14120">19,104</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14121">38,208</ix:nonFraction> as of December 31, 2024 and 2023, respectively. Intangible asset amortization expense is estimated to be $<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" unitRef="usd" id="ixv-14122">19,104</ix:nonFraction>
during the year ending December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="ixv-10369"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2024 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/>
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14123">184,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14124">165,690</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14125">18,410</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14126">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14127">1,170</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14128">130</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14129">5,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14130">5,076</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14131">564</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14132">191,040</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14133">171,936</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14134">19,104</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2023 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated <br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14135">184,100</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14136">147,280</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14137">36,820</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14138">1,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14139">1,040</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14140">260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14141">5,640</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14142">4,512</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14143">1,128</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" unitRef="usd" id="ixv-14144">191,040</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" unitRef="usd" id="ixv-14145">152,832</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" unitRef="usd" id="ixv-14146">38,208</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-10523"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="ixv-10527"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts payable and accrued expenses consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-14147">934,883</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="0" unitRef="usd" id="ixv-14148">874,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-14149">8,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="0" unitRef="usd" id="ixv-14150">13,175</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-14151">1,195,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedPayrollTaxesCurrent" scale="0" unitRef="usd" id="ixv-14152">942,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-14153">102,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" unitRef="usd" id="ixv-14154">97,800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14155">234,552</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14156">192,754</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-14157">5,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" unitRef="usd" id="ixv-14158">3,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14159">2,482,522</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="0" unitRef="usd" id="ixv-14160">2,124,337</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-10615"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>9. BANK DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loans #1 and #2</b>: During the first quarter
of 2020, we closed on a debt financing with Maine Community Bank (formerly known as Gorham Savings Bank) (MCB) aggregating $<ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14161">8,600,000</ix:nonFraction>,
which was comprised of a $<ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EscrowDeposit" scale="0" unitRef="usd" id="ixv-14162">5,100,000</ix:nonFraction> mortgage note (Loan #1) that bears interest at a fixed rate of <ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14163">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c77" format="ixt-sec:duryear" name="iccc:InterestPaymentsTerm" id="ixv-14164">10</ix:nonNumeric>-year term
and <ix:nonNumeric contextRef="c77" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14165">25</ix:nonNumeric>-year amortization schedule and a balloon principal payment of $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14166">3,145,888</ix:nonFraction> due during the first quarter of 2030) and a $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14167">3,500,000</ix:nonFraction>
note (Loan #2) that bears interest at a fixed rate of <ix:nonFraction contextRef="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14168">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="iccc:InterestPaymentsTerm" id="ixv-14169">7</ix:nonNumeric>-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working capital.
During the first quarter of 2022, we closed on an additional $<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" scale="0" unitRef="usd" id="ixv-14170">2,000,000</ix:nonFraction> in mortgage debt, which bears interest at the fixed rate of <ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14171">3.58</ix:nonFraction>%
per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal
balance from $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-14172">4,233,957</ix:nonFraction> to $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized" scale="0" unitRef="usd" id="ixv-14173">6,233,957</ix:nonFraction> bearing interest at the blended fixed rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14174">3.53</ix:nonFraction>% per annum. This increased the balloon payment
from $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14175">3,145,888</ix:nonFraction> to $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14176">3,687,608</ix:nonFraction> and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter of
2032.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Line of Credit (LOC)</b>: Also during the first
quarter of 2020, MCB extended a $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14177">1,000,000</ix:nonFraction> LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of December 31, 2024
or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #3</b>: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $<ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-14178">500,000</ix:nonFraction>. The first <ix:nonNumeric contextRef="c86" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14179">2.25</ix:nonNumeric> years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of <ix:nonFraction contextRef="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14180">5</ix:nonFraction>% per annum over the final <ix:nonNumeric contextRef="c88" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="ixv-14181">five years</ix:nonNumeric> of the loan, through
the third quarter of 2027 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #4</b>: During the fourth quarter of 2020,
we closed on a $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14182">1,500,000</ix:nonFraction> note with MCB that bears interest at a fixed rate of <ix:nonFraction contextRef="c89" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14183">3.50</ix:nonFraction>% per annum (with a <ix:nonNumeric contextRef="c90" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14184">7</ix:nonNumeric>-year term and amortization schedule).
Proceeds of $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" unitRef="usd" id="ixv-14185">624,167</ix:nonFraction> were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to <ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="iccc:LoanToValueRatio" scale="-2" unitRef="pure" id="ixv-14186">80</ix:nonFraction>% of the most recent appraised value of the property securing the debt, which allowed MCB to release the $<ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14187">1,400,000</ix:nonFraction> that
had been held in escrow. The remaining proceeds were available for general working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #5</b>: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd" id="ixv-14188">400,000</ix:nonFraction>, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of <ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14189">5</ix:nonFraction>% per annum are due quarterly over the final <ix:nonNumeric contextRef="c94" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14190">5.5</ix:nonNumeric> years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #6: </b>During the third quarter of 2023,
we closed on a $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14191">2,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14192">7</ix:nonFraction>% per annum from MCB. The Finance Authority of Maine (FAME) provided
$<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FinancingReceivableLoanInProcess" scale="0" unitRef="usd" id="ixv-14193">1,000,000</ix:nonFraction> of loan insurance to MCB. This loan is repayable under a <ix:nonNumeric contextRef="c96" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14194">7</ix:nonNumeric>-year amortization schedule with a balloon payment of $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14195">1,285,047</ix:nonFraction>
due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #7:</b> Also during the third quarter of
2023, we closed on a $<ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="0" unitRef="usd" id="ixv-14196">1,000,000</ix:nonFraction> term loan bearing interest at a fixed rate of <ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-14197">8</ix:nonFraction>% per annum from FAME. The loan is repayable under a <ix:nonNumeric contextRef="c99" format="ixt-sec:duryear" name="us-gaap:DebtInstrumentTerm" id="ixv-14198">7</ix:nonNumeric>-year
amortization schedule with a balloon payment of $<ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" scale="0" unitRef="usd" id="ixv-14199">649,259</ix:nonFraction> due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of <ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="iccc:DebtServiceCoverageRatio" scale="0" unitRef="pure" id="ixv-14200">1.35</ix:nonFraction> for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsCurrentGross" scale="0" unitRef="usd" id="ixv-14201">173,305</ix:nonFraction>. The amortization
of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net,
and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated
to our indebtedness to MCB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms
of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These
loans may be prepaid without penalty at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock" id="ixv-10674"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Debt proceeds received and principal repayments
made (excluding our $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14202">1,000,000</ix:nonFraction> line of credit) are reflected by loan during the periods as described in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds
from<br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds&#160;from</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt&#160;Principal</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Repayments</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14203">230,763</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14204">223,222</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14205">512,139</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14206">494,455</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14207">96,104</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c107" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14208">91,446</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14209">213,227</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14210">205,884</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14211">66,470</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14212">32,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14213">235,393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14214">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c113" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14215">93,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14216">114,242</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14217">1,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14218">45,696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14219">1,468,338</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" unitRef="usd" id="ixv-14220">3,000,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="0" unitRef="usd" id="ixv-14221">1,185,774</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="ixv-10898"><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Principal payments (net of debt issuance and debt
discount costs) due under bank loans outstanding as of December 31, 2024 (excluding our $<ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LineOfCredit" scale="0" unitRef="usd" id="ixv-14222">1,000,000</ix:nonFraction> line of credit) are reflected in the
following table by the year that payments are due:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2029</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14223">239,864</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14224">248,604</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14225">257,649</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14226">266,537</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" unitRef="usd" id="ixv-14227">276,720</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-14228">4,321,768</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14229">5,611,142</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14230">530,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14231">549,881</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14232">140,423</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14233">1,221,042</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14234">101,001</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14235">106,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14236">83,143</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14237">290,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14238">220,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14239">228,965</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14240">240,438</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14241">690,401</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14242">69,856</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14243">73,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14244">77,156</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14245">81,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14246">301,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14247">253,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14248">1,418,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14249">1,671,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14250">124,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14251">715,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14252">840,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14253">1,539,824</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" unitRef="usd" id="ixv-14254">3,341,259</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" unitRef="usd" id="ixv-14255">798,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" unitRef="usd" id="ixv-14256">347,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="0" unitRef="usd" id="ixv-14257">276,720</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="0" unitRef="usd" id="ixv-14258">4,321,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="0" unitRef="usd" id="ixv-14259">10,626,003</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2025" scale="0" unitRef="usd" id="ixv-14260">21,314</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2026" scale="0" unitRef="usd" id="ixv-14261">13,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2027" scale="0" unitRef="usd" id="ixv-14262">5,420</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2028" scale="0" unitRef="usd" id="ixv-14263">3,513</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCosts2029" scale="0" unitRef="usd" id="ixv-14264">3,513</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtIssuanceCostshereafter" scale="0" unitRef="usd" id="ixv-14265">7,834</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" unitRef="usd" id="ixv-14266">55,174</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2025" scale="0" unitRef="usd" id="ixv-14267">20,891</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCost2026" scale="0" unitRef="usd" id="ixv-14268">11,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:DebtDiscountCostTotal" scale="0" unitRef="usd" id="ixv-14269">32,235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2025" scale="0" unitRef="usd" id="ixv-14270">1,497,619</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2026" scale="0" unitRef="usd" id="ixv-14271">3,316,335</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2027" scale="0" unitRef="usd" id="ixv-14272">793,389</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebtTotal2028" scale="0" unitRef="usd" id="ixv-14273">344,110</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebt2029" scale="0" unitRef="usd" id="ixv-14274">273,207</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:LongTermDebtThereafter" scale="0" unitRef="usd" id="ixv-14275">4,313,934</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" unitRef="usd" id="ixv-14276">10,538,594</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-11293"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>10. CONTINGENT LIABILITIES AND COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability
for such obligations as of December 31, 2024 or 2023. Since our incorporation, we have had no occasion to make any indemnification payment
to any of our officers or directors for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the time of this filing on March 28, 2025. We believe that we have reasonable levels of
liability insurance to support our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of December 31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;</sup></b> Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP terminated on November 30, 2024. This contract was extended through March of 2026 for the purpose of
final packaging of existing DP inventory, but this contract extension does not anticipate the production of new DP inventory. During 2019,
we initiated an investment in the necessary equipment to perform the DP formulation and aseptic filling services in-house, but this investment
has been paused at the present time.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off. Accordingly, an expense of $<ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="0" unitRef="usd" id="ixv-14277">222,379</ix:nonFraction> for earned and unpaid sick time was accrued during
the first quarter of 2022 and a related accrual of $<ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14278"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14279">230,162</ix:nonFraction></ix:nonFraction> was included in accounts payable and accrued expenses as of December 31, 2024
and 2023. Additionally, Mr. Brigham was paid $<ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14280">300,000</ix:nonFraction> in deferred compensation during the first quarter of 2025 (which was accrued over
the three-year period ending in December 2024). This deferred compensation payment vested as to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14281">300,000</ix:nonFraction>, $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14282">200,000</ix:nonFraction> and $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent" scale="0" unitRef="usd" id="ixv-14283">100,000</ix:nonFraction> on January
1, 2025, 2024 and 2023, respectively. Deferred compensation of $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14284">300,000</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd" id="ixv-14285">200,000</ix:nonFraction> was included in accounts payable and accrued expenses
on the accompanying balance sheets as of December 31, 2024 and 2023, respectively. In addition, upon termination of Mr. Brigham&#8217;s
employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case
as described and defined in the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham <ix:nonFraction contextRef="c131" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" unitRef="pure" id="ixv-14286">100</ix:nonFraction>% of his then current annual
base salary and a lump sum payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered
dependents for a twelve-month period following termination, and certain equity incentive awards granted to Mr. Brigham would continue
to vest following such termination in accordance with the terms of the Deferred Compensation Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(formerly our Vice President of Manufacturing Operations), which, at times, allow these executives to earn incentive compensation if certain
regulatory and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts
related to these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will
be earned) based on our best estimate of the amounts expected to be </span>earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In addition to the commitments discussed above,
we had committed $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="iccc:CapitalExpendituresCommitted" scale="0" unitRef="usd" id="ixv-14287">67,000</ix:nonFraction> to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line, $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="iccc:PurchaseofInventory" scale="0" unitRef="usd" id="ixv-14288">1,629,000</ix:nonFraction> to
the purchase of inventory and $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="iccc:CommitmentsRelatedToCommercialManufacture" scale="0" unitRef="usd" id="ixv-14289">686,000</ix:nonFraction> to information technology services and other obligations as of December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-11366"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>11. OPERATING LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">On September
12, 2019, we entered into a lease covering approximately <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-14290">14,300</ix:nonFraction> square feet of office and warehouse space with a possession date of November
15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building 175A</b>),
which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our
needs in expanding our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease term was <ix:nonNumeric contextRef="c134" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-14291">ten
years</ix:nonNumeric> with a right to renew for a second <ix:nonNumeric contextRef="c134" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-14292">10</ix:nonNumeric>-year term and a right of first offer to purchase. At the time we entered into this lease,
we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that reason, a 10-year
period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed
to lease an additional <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfLand" scale="0" unitRef="sqft" id="ixv-14293">15,400</ix:nonFraction> square feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected to the original space,
over a <ix:nonNumeric contextRef="c135" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-14294">20</ix:nonNumeric>-year term. The ROU asset and lease liability for the committed space at <b>Building 175B</b> was recorded as of April 1, 2023
after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of
August 1, 2023. In connection with the lease commitment for space at <b>Building 175B</b><span style="font-style: normal; font-weight: normal">,</span>
the term of the original lease for <b>Building 175A</b> was extended by approximately <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="iccc:TermOfExtensionOfLease" id="ixv-14295">13</ix:nonNumeric> years. On November 14, 2023, June 11,
2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements on the leased premises to be paid
for by our landlord. These improvements will provide heat to an unfinished space, provide additional warehouse space, and create a new
primary shipping and receiving facility. As a result of these three amendments and in consideration for the landlord agreeing to pay
for the cost of those certain tenant improvements, we agreed to make additional rent payments of $<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-14296">20,000</ix:nonFraction> per month from November of 2023
through June of 2025 and a one-time additional rent payment of $<ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="0" unitRef="usd" id="ixv-14297">248,743</ix:nonFraction> in July of 2025. Because of these modifications to the lease
payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured as of the modification
dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges. As of December
31, 2024, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-14298">4,560,679</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14299">4,561,174</ix:nonFraction>. As of December
31, 2023, the balance of the operating lease ROU asset was $<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd" id="ixv-14300">4,571,149</ix:nonFraction> and the operating lease liability was $<ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14301">4,721,385</ix:nonFraction>. The calculated
amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for the present value
of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying assets, and instead
to account for them as a single lease component. Variable lease cost primarily represents variable payments such as real estate taxes
and common area maintenance. <ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-14302">The following tables describe our lease costs and other lease information:</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<ix:continuation id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/>
Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Lease Cost</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14303">427,519</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-14304">348,929</ix:nonFraction></td> <td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14305">66,523</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:VariableLeaseCost" scale="0" unitRef="usd" id="ixv-14306">36,774</ix:nonFraction></td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14307">494,042</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="0" unitRef="usd" id="ixv-14308">385,703</ix:nonFraction></td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating Lease</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Cash paid for operating lease liabilities</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14309">577,260</ix:nonFraction></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-14310">248,595</ix:nonFraction></td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14311">18.1</ix:nonNumeric></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-14312">19.1</ix:nonNumeric></td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14313">6.6</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-14314">7.11</ix:nonFraction></td> <td style="text-align: left">%</td></tr> </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-11508"><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Future lease payments required under non-cancelable
operating leases in effect as of December 31, 2024 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">During the years ending December 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" unitRef="usd" id="ixv-14315">711,623</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" unitRef="usd" id="ixv-14316">349,744</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" unitRef="usd" id="ixv-14317">356,732</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" unitRef="usd" id="ixv-14318">363,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" unitRef="usd" id="ixv-14319">371,144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" unitRef="usd" id="ixv-14320">5,578,344</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" unitRef="usd" id="ixv-14321">7,731,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" unitRef="usd" id="ixv-14322">3,170,283</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-14323">4,561,174</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-11576"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>12. STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Common Stock Issuances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">From February of 2016 to April of 2021, we sold
the aggregate of <ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14324">4,553,017</ix:nonFraction> shares of common stock in six different transactions raising gross proceeds of $<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14325">26,714,403</ix:nonFraction> at the weighted
average price of $<ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares" id="ixv-14326">5.87</ix:nonFraction> per share. These funds have been essential to funding our business growth plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">On April 9, 2024, our shelf registration on Form
S-3 relating to the offer, issuance and sale by the Company of up to $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="0" unitRef="usd" id="ixv-14327">20,000,000</ix:nonFraction> of securities was declared effective by the Securities
and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market (ATM) Agreement with Craig-Hallum Capital Group LLC,
pursuant to which we may offer and sell up to $<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-14328">11,000,000</ix:nonFraction> of shares of our common stock. Legal, accounting and other fees in the amount
of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="iccc:FeesInitiallyCapitalizedAndLaterOffset" scale="0" unitRef="usd" id="ixv-14329">152,272</ix:nonFraction> associated with the completion of the shelf registration and the ATM Agreement were initially capitalized and then were offset
against the initial proceeds received during the second quarter of 2024. As of December 31, 2024, we have sold <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-14330">1,228,227</ix:nonFraction> shares under
the ATM Offering conducted pursuant to the ATM Agreement. Net proceeds through December 31, 2024 from shares sold pursuant to the ATM
Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesCommissionsAndFees" scale="0" unitRef="usd" id="ixv-14331">139,562</ix:nonFraction>, were $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd" id="ixv-14332">4,356,188</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Stock Option Plans</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14333">300,000</ix:nonFraction> shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-14334">10</ix:nonNumeric> years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14335">183,500</ix:nonFraction> and
<ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14336">188,500</ix:nonFraction> options outstanding under the 2010 Plan as of December 31, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In June of 2017, our stockholders approved the
2017 Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under
which employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less
than fair market value on the date of grant. At that time, <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14337">300,000</ix:nonFraction> shares of common stock were reserved for issuance under the 2017 Plan.
An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14338">300,000</ix:nonFraction> shares to <ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14339">650,000</ix:nonFraction>
shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined
by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan
expire no later than <ix:nonNumeric contextRef="c151" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="ixv-14340">10</ix:nonNumeric> years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can
be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their
terms. As of December 31, 2024 and 2023, there were <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14341">480,500</ix:nonFraction> and <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14342">430,000</ix:nonFraction> options outstanding under the 2017 Plan, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-11616"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Activity under the stock option plans described
above was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate <br/>
Intrinsic <br/>
Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14343">202,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c162" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14344">402,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14345">7.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">661,310</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-14347">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14348">5.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c164" decimals="INF" format="ixt:num-dot-decimal" id="ix_6_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">94,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_7_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">7.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c163" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-14352">4,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14353">4.69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c165" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14354">188,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c166" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14355">430,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14356">6.82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">1,071,121</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-14358">86,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14359">3.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c167" decimals="INF" format="ixt:num-dot-decimal" id="ix_8_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">5,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c168" decimals="INF" format="ixt:num-dot-decimal" id="ix_9_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">35,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_10_fact" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14363">183,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-14364">480,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14365">6.46</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" sign="-" unitRef="usd">870,558</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-14367">183,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" scale="0" unitRef="shares" id="ixv-14368">136,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" scale="0" unitRef="usdPershares" id="ixv-14369">6.97</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">582,340</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c169" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-14371">183,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-14372">480,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14373">6.46</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" sign="-" unitRef="usd">870,558</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c170" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-14375">151,500</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Terminations and forfeitures are recognized when they occur.</ix:footnote></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-11885"><p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">The following table displays additional information about the stock
option plans described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average <br/>
Exercise <br/>
Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-14378">337,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14379">3.66</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14380">7.14</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-14381">344,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14382">3.12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14383">6.25</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options granted during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-14384">86,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14385">1.84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14386">3.91</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-14387">54,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14388">4.31</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14389">9.73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-14390">40,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14391">3.33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c173" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-14392">6.55</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-85">No</span> stock options were exercised during the year
ended December 31, 2024. During the year ended December 31, 2023, <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-14393">4,000</ix:nonFraction> stock options were exercised by one employee with $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" unitRef="usd" id="ixv-14394">18,760</ix:nonFraction> in cash.
The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitRef="usd" id="ixv-14395">1,040</ix:nonFraction>. The weighted average remaining
life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2024 was approximately <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-14396">4</ix:nonNumeric> years and <ix:nonNumeric contextRef="c151" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-14397">10</ix:nonNumeric> months.
The weighted average remaining life of the options exercisable under these plans as of December 31, 2024 was approximately <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-14398">2</ix:nonNumeric> years and
<ix:nonNumeric contextRef="c151" format="ixt-sec:durmonth" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-14399">8</ix:nonNumeric> months. The exercise price of the options outstanding under these plans as of December 31, 2024, ranged from $<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14400">3.60</ix:nonFraction> to $<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14401">10.04</ix:nonFraction> per share.
The <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-14402">86,000</ix:nonFraction> stock options granted during the year ended December 31, 2024 had an average exercise price of $<ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14403">3.91</ix:nonFraction> per share. The <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-14404">122,000</ix:nonFraction>
stock options granted during the year ended December 31, 2023 had an average exercise price of $<ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-14405">5.16</ix:nonFraction> per share. The weighted-average grant
date fair values of options granted during the years ended December 31, 2024 and 2023 were $<ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-14406">1.84</ix:nonFraction> and $<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-14407">2.80</ix:nonFraction> per share, respectively. As
of December 31, 2024, total unrecognized stock-based compensation related to non-vested stock options aggregated $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-14408">365,124</ix:nonFraction> which will be
recognized over a weighted average remaining period of approximately <ix:nonNumeric contextRef="c146" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-14409">1</ix:nonNumeric> year and <ix:nonNumeric contextRef="c151" format="ixt-sec:durmonth" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-14410">3</ix:nonNumeric> months. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-14411">The fair value of each stock option grant has
been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following
weighted-average assumptions:</ix:nonNumeric></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/> Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" id="ix_11_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.77</ix:nonFraction></td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" id="ix_12_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">3.59</ix:nonFraction></td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_13_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_14_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" id="ix_15_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">52</ix:nonFraction></td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" id="ix_16_fact" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">54</ix:nonFraction></td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" id="ix_17_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.6</ix:nonNumeric> years</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" id="ix_18_fact" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.2</ix:nonNumeric> years</span></td> <td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify"><ix:footnote id="ix_2_footnote" xml:lang="en-US">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify"><ix:footnote id="ix_3_footnote" xml:lang="en-US">The dividend yield and expected volatility are derived from
averages of our historical data.</ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: justify"><ix:footnote id="ix_4_footnote" xml:lang="en-US">The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.</ix:footnote></td>
</tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Common Stock Rights Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In September of 1995, our Board of Directors
adopted a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of <ix:nonFraction contextRef="c160" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsShares" scale="0" unitRef="shares" id="ixv-14423">one</ix:nonFraction> common share purchase right (a &#8220;Right&#8221;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitled the registered holder to purchase from
the Company <ix:nonFraction contextRef="c160" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-14424">one</ix:nonFraction> share of common stock at an initial purchase price of $<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" unitRef="usdPershares" id="ixv-14425">70.00</ix:nonFraction> per share, subject to adjustment. The description and terms
of the Rights were set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent. At various times
over the years, our Board of Directors, which has the authority to amend the Rights Plan, voted to authorize amendments to the Rights
Plan to extend the expiration date of the Rights Plan. During 2024, our Board of Directors determined not to further extend the Rights
Plan because these plans are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as
of September 19, 2024. No shares were issued under Rights Plan while it was in effect.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="ixv-12096"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>13. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the years ended December 31, 2024 or 2023. We do not have any contract assets for which we have satisfied
the performance obligations, but do not yet have the right to bill for, or contract liabilities such as customer advances. All trade receivables
on our balance sheets are from contracts with customers. We incur no material costs to obtain contracts.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="ixv-12108"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales
disaggregated by geographic area:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14426">22,893,721</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c175" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14427">86</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14428">15,949,382</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c177" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14429">91</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14430">3,599,448</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c179" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14431">14</ix:nonFraction>%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14432">1,522,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14433">9</ix:nonFraction>%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14434">26,493,169</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14435">100</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14436">17,471,669</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14437">100</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="ixv-12186"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales disaggregated
by major product category:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14438">26,314,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c183" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14439">99</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14440">17,293,933</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c185" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14441">99</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14442">178,919</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c187" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14443">1</ix:nonFraction>%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14444">177,736</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14445">1</ix:nonFraction>%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14446">26,493,169</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14447">100</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" unitRef="usd" id="ixv-14448">17,471,669</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitRef="pure" id="ixv-14449">100</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-12294"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>14. OTHER EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-12298"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Other expenses net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/>
 Ended December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" id="ix_19_fact" name="us-gaap:InterestRevenueExpenseNet" scale="0" sign="-" unitRef="usd">568,725</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_20_fact" name="us-gaap:InterestRevenueExpenseNet" scale="0" sign="-" unitRef="usd">475,598</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-14452">15,391</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="0" unitRef="usd" id="ixv-14453">8,099</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14454">77,702</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeOther" scale="0" unitRef="usd" id="ixv-14455">96,570</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" id="ix_21_fact" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd">365,127</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd" id="ixv-14457">107</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14458">506,414</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd" id="ixv-14459">21,893</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify"><ix:footnote id="ix_5_footnote" xml:lang="en-US">Interest expense includes amortization of debt issuance and
debt discount costs of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14461">42,666</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="0" unitRef="usd" id="ixv-14462">22,619</ix:nonFraction> during the years ended December 31, 2024 and 2023, respectively.</ix:footnote></td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify"><ix:footnote id="ix_6_footnote" xml:lang="en-US">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd" id="ixv-14464">250,000</ix:nonFraction>) and a
recovery from a vendor&#8217;s policy related to an equipment malfunction (in the amount of $<ix:nonFraction contextRef="c191" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InsuranceRecoveries" scale="0" unitRef="usd" id="ixv-14465">115,127</ix:nonFraction>).</ix:footnote></td>
</tr></table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-12401"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>15. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our income tax expense aggregated $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14466">10,056</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14467">4,627</ix:nonFraction>
(amounting to less than <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" scale="-2" unitRef="pure" id="ixv-14468">1</ix:nonFraction>% of our loss before income taxes) during the years ended December 31, 2024 and 2023, respectively. As of December
31, 2024, we had federal net operating loss carryforwards of $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-14469">17,647,250</ix:nonFraction> of which $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14470">15,935,343</ix:nonFraction> do not expire and of which $<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14471">1,711,907</ix:nonFraction> <ix:nonNumeric contextRef="c193" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14472">expire
in 2034 through 2037</ix:nonNumeric> (if not utilized before then) and state net operating loss carryforwards of $<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14473">5,194,515</ix:nonFraction> that <ix:nonNumeric contextRef="c195" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14474">expire in 2037 through
2038</ix:nonNumeric> (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $<ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14475">842,565</ix:nonFraction> that <ix:nonNumeric contextRef="c197" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14476">expire in
2027 through 2042</ix:nonNumeric> (if not utilized before then) and state tax credit carryforwards of $<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="0" unitRef="usd" id="ixv-14477">777,459</ix:nonFraction> that <ix:nonNumeric contextRef="c199" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-14478">expire in 2025 through 2042</ix:nonNumeric> (if not
utilized before then).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeTaxExpense" scale="0" unitRef="usd" id="ixv-14479">563,252</ix:nonFraction> in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to <ix:nonFraction contextRef="c3" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" unitRef="usd" id="ixv-14480">zero</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying audited
financial statements.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="ixv-12434"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The income tax provision consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years<br/>
 Ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14481">10,056</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14482">4,627</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14483">10,056</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14484">4,627</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14485">500,927</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14486">1,179,474</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14487">59,032</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14488">145,802</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Deferred subtotal, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14489">559,959</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14490">1,325,276</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14491">559,959</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredOtherTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14492">1,325,276</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred subtotal, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14493">10,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14494">4,627</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-12565"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The actual income tax expense differs from the
expected tax computed by applying the U.S. federal corporate tax rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-14495"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-14496">21</ix:nonFraction></ix:nonFraction>% to the loss before income taxes during the years ended December
31, 2024 and 2023 respectively, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
                                            the Years Ended December 31,</b></p></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Computed expected income tax expense rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-14497">450,780</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-14498">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" sign="-" unitRef="usd" id="ixv-14499">1,211,694</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" unitRef="pure" id="ixv-14500">21.00</ix:nonFraction></td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes, net of federal expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-14501">36,681</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-14502">1.71</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" sign="-" unitRef="usd" id="ixv-14503">117,149</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" sign="-" unitRef="pure" id="ixv-14504">2.03</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd" id="ixv-14505">49,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-14506">2.28</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="0" unitRef="usd" id="ixv-14507">56,214</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-14508">0.97</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd" id="ixv-14509">116,091</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-14510">5.41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="0" unitRef="usd" id="ixv-14511">53,241</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitRef="pure" id="ixv-14512">0.92</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-14513">559,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-14514">26.09</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-14515">1,325,276</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" unitRef="pure" id="ixv-14516">0.09</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-14517">4,619</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-14518">0.22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="0" unitRef="usd" id="ixv-14519">5,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-14520">22.97</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income tax expense/rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14521">10,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-14522">0.47</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-14523">4,627</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-14524">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-12748"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The significant components of our deferred tax
assets, net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;As
of <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Property, plant and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14525">1,833,727</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" unitRef="usd" id="ixv-14526">2,121,940</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal general business tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-14527">842,565</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="0" unitRef="usd" id="ixv-14528">726,474</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-14529">3,705,923</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" unitRef="usd" id="ixv-14530">3,729,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State tax credits and net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd" id="ixv-14531">900,569</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="0" unitRef="usd" id="ixv-14532">886,428</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#167;174 R &amp; D expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="0" unitRef="usd" id="ixv-14533">727,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" scale="0" unitRef="usd" id="ixv-14534">592,915</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-14535">82,370</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="0" unitRef="usd" id="ixv-14536">50,722</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-14537">24,718</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="0" unitRef="usd" id="ixv-14538">37,124</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">UNICAP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-14539">22,443</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" unitRef="usd" id="ixv-14540">32,607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Incentive compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-14541">121,718</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="0" unitRef="usd" id="ixv-14542">100,200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-14543">4,593,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" unitRef="usd" id="ixv-14544">4,034,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SegmentReportingDisclosureTextBlock" id="ixv-12907"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>16. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, <i>Segment Reporting</i>, we operate in the following <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" unitRef="pure" id="ixv-14545">two</ix:nonFraction> reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b> product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174;
</sup></b>is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#8220;Other&#8221; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for <b>First Defense<sup>&#174;</sup></b> or Center for Veterinary Medicine, U.S. Food and Drug Administration for <b>Re-Tain<sup>&#174;</sup></b>)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. <ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="ixv-14546">Our chief operating decision-maker is our
President and CEO.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_ScheduleOfSegmentReportingInformationBySegmentTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14547">26,314,251</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14548">178,918</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14549">26,493,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14550">18,382,949</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14551">169,176</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14552">18,552,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14553">7,931,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14554">9,742</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14555">7,941,044</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14556">243,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14557">3,493,298</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14558">161,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14559">3,898,582</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14560">2,909,799</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14561">556,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14562">3,466,072</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14563">2,216,549</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14564">2,216,549</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14565">3,153,377</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14566">4,049,571</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14567">2,378,255</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14568">9,581,203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14569">4,777,925</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14570">4,039,829</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14571">2,378,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14572">1,640,159</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
the Year Ended December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14573">17,293,933</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14574">177,736</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-14575">17,471,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14576">13,453,514</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14577">148,871</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd" id="ixv-14578">13,602,385</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14579">3,840,419</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14580">28,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd" id="ixv-14581">3,869,284</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14582">11,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14583">4,242,329</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14584">141,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd" id="ixv-14585">4,394,852</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14586">2,447,137</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14587">641,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="0" unitRef="usd" id="ixv-14588">3,088,215</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14589">2,134,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" unitRef="usd" id="ixv-14590">2,134,295</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14591">2,458,240</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14592">4,883,407</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14593">2,275,715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd" id="ixv-14594">9,617,362</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" unitRef="usd" id="ixv-14595">1,382,179</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14596">4,854,542</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14597">2,275,715</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd" id="ixv-14598">5,748,078</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14599">24,644,294</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14600">16,523,048</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14601">3,933,135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14602">45,100,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14603">24,735,413</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14604">17,827,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14605">1,244,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd" id="ixv-14606">43,808,102</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14607">1,373,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14608">1,277,218</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14609">78,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14610">2,729,847</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14611">1,365,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14612">1,287,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14613">86,032</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostDepreciationAmortizationAndDepletion" scale="0" unitRef="usd" id="ixv-14614">2,739,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c201" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14615">409,696</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c202" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14616">53,721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c203" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14617">2,308</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14618">465,725</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14619">1,096,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14620">795,694</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" unitRef="usd" id="ixv-14621">1,892,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>ImmuCell Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Notes to Audited Financial Statements (continued)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-13493"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>17. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line and <b>CMT</b>). His affiliated company purchased $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-14622">567,114</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" unitRef="usd" id="ixv-14623">231,405</ix:nonFraction> of products from us during the years ended December 31, 2024
and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts receivable (subject
to standard and customary payment terms) due from this affiliated company aggregated $<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-14624">52,097</ix:nonFraction> and $<ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="0" unitRef="usd" id="ixv-14625">42,507</ix:nonFraction> as of December 31, 2024 and 2023,
respectively.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-13509"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>18. EMPLOYEE BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-14626">100</ix:nonFraction>% of the first <ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryPercentage" scale="-2" unitRef="pure" id="ixv-14627">3</ix:nonFraction>% of each employee&#8217;s salary that is contributed
to the Plan and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-14628">50</ix:nonFraction>% of the next <ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="iccc:EmployeesSalaryContributionPercentage" scale="-2" unitRef="pure" id="ixv-14629">2</ix:nonFraction>% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid
$<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14630">203,756</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="0" unitRef="usd" id="ixv-14631">178,150</ix:nonFraction> into the Plan for the years ended December 31, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-13518"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>19. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have evaluated subsequent events through the
time of this filing on March 28, 2025. First, in January of 2025, we settled a long outstanding insurance claim related to previously
disclosed contamination events in our production process incurred from late 2022 through April of 2024. As a result of the settlement,
we received $<ix:nonFraction contextRef="c215" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InsuranceSettlementsReceivable" scale="0" unitRef="usd" id="ixv-14632">426,587</ix:nonFraction> during January of 2025, which is in addition to the $<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="0" unitRef="usd" id="ixv-14633">250,000</ix:nonFraction> that was previously received on this claim and recognized
for financial statement purposes during the third quarter of 2023. Second, net proceeds from January 1, 2025 through March 21, 2025 from
<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-14634">3,532</ix:nonFraction> shares sold pursuant to our ATM Agreement (less sales commissions of $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SalesCommissionsAndFees" scale="0" unitRef="usd" id="ixv-14635">584</ix:nonFraction>) were $<ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" unitRef="usd" id="ixv-14636">18,849</ix:nonFraction>. As of the time of this filing on March
28, 2025, there were no additional material, reportable subsequent events.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Signatures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 60%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p></td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ImmuCell Corporation</span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 28, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="poa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">POWER OF ATTORNEY</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We, the undersigned directors and employees of ImmuCell
Corporation, hereby severally constitute and appoint Michael F. Brigham our true and lawful attorney-in-fact and agent with full power
of substitution and re-substitution, for us and in our stead, in any and all capacities, to sign any and all amendments to this report
and all documents relating thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with
the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each
and every act and thing necessary or advisable to be done in and about the premises, as fully to all intents and purposes as he might
or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may
lawfully do or to be done by virtue hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Pursuant to the requirements of the Securities Exchange
Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Signature</b></p></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gloria J. Basse</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gloria J. Basse</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Michael F. Brigham</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer,</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bobbi Jo Brockmann</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President of Sales and Marketing and Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bobbi Jo Brockmann</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bryan K. Gathagan</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bryan K. Gathagan</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven T. Rosgen</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven T. Rosgen</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David S. Tomsche</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S. Tomsche, DVM</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Elizabeth S. Toothaker</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controller</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elizabeth S. Toothaker</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul R. Wainman</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul R. Wainman</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityRegistrantName">IMMUCELL CORP /DE/</ix:nonNumeric>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-3" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-4" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-5" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-10" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-11" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-12" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-13" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-17" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-18" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-19" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-20" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-21" name="us-gaap:RepaymentsOfLinesOfCredit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-22" name="iccc:PaymentsOfDebtDiscounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-23" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-24" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-25" name="iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-26" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-27" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-28" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-29" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-31" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-32" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:ShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-34" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-35" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-36" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c64" id="hidden-fact-40" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c66" id="hidden-fact-41" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c102" id="hidden-fact-42" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-43" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-44" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-45" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-46" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-47" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-48" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-49" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c110" id="hidden-fact-50" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-51" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-52" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-53" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-54" name="us-gaap:ProceedsFromIssuanceOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-55" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-56" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-57" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-58" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-59" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-60" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-61" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-62" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-63" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-64" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c120" id="hidden-fact-65" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-66" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-67" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-68" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c121" id="hidden-fact-69" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c122" id="hidden-fact-70" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c122" id="hidden-fact-71" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c122" id="hidden-fact-72" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c122" id="hidden-fact-73" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-74" name="iccc:DebtDiscountCost2027" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-75" name="iccc:DebtDiscountCost2028" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-76" name="iccc:DebtDiscountCost2029" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-77" name="iccc:DebtDiscountCostThereafter" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c163" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-83" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-84" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-85" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-86" name="us-gaap:InsuranceRecoveries" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-87" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-88" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-89" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-90" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-91" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-92" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-93" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-94" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-95" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-96" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c203" id="hidden-fact-97" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c201" id="hidden-fact-98" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c202" id="hidden-fact-99" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-100" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-101" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-102" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-103" name="us-gaap:SellingAndMarketingExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c204" id="hidden-fact-104" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c205" id="hidden-fact-105" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c206" id="hidden-fact-106" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-14746">0000811641</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-14747">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentAnnualReport" id="ixv-14748">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-14749">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentTransitionReport" id="ixv-14750">false</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iccc-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_11_fact ix_12_fact" toRefs="ix_2_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_13_fact ix_14_fact ix_15_fact ix_16_fact" toRefs="ix_3_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_17_fact ix_18_fact" toRefs="ix_4_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_19_fact ix_20_fact" toRefs="ix_5_footnote"/>
<ix:relationship xmlns="" fromRefs="hidden-fact-86 ix_21_fact" toRefs="ix_6_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2027-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2027-09-30</xbrli:startDate>
    <xbrli:endDate>2027-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-30</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2026-01-01</xbrli:startDate>
    <xbrli:endDate>2026-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2026-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:BankLoansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL4H4g3wquC8W9YnZAJaDiEV] CSR-->
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-01-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:ReTainMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-31</xbrli:startDate>
    <xbrli:endDate>2025-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2021-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-09</xbrli:startDate>
    <xbrli:endDate>2024-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-09</xbrli:startDate>
    <xbrli:endDate>2024-04-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iccc:CommonStockRightsPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:BusinessInterruptionPolicyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:VendorsPolicyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>2
<FILENAME>ea023548101ex10-10_immucell.htm
<DESCRIPTION>INCENTIVE COMPENSATION AGREEMENT BETWEEN THE COMPANY AND MICHAEL F. BRIGHAM DATED AS OF MARCH 27, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCENTIVE COMPENSATION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Incentive Compensation Agreement, dated
as of March 27, 2025, is by and between&nbsp;IMMUCELL CORPORATION, a Delaware corporation (the &ldquo;Company&rdquo;) and&nbsp;MICHAEL
F. BRIGHAM&nbsp;(the &ldquo;Executive&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> WHEREAS,
the Executive serves as the Company&rsquo;s President, Chief Executive Officer, Treasurer and Secretary; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> WHEREAS,
the Company wishes to provide the Executive with certain incentive compensation opportunities, as more fully set forth herein, in order
to induce the Executive to continue his employment with the Company and to contribute to the Company&rsquo;s attainment of certain specific
objectives and outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> NOW
THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by the parties, the Company and the Executive hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. <U>At-Will Nature of Executive&rsquo;s Employment</U>.
The parties agree and acknowledge that the Executive&rsquo;s employment with the Company is &ldquo;at will,&rdquo; and that nothing contained
in this Agreement shall be deemed to modify the &ldquo;at will&rdquo; nature of such employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. <U>Retention Incentive</U>. The Company agrees
to pay to the Executive, subject to all required tax withholdings, the amount of $50,000 if the Executive is employed by the Company continuously
to January 1, 2026, to be paid in cash not later than January 31, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3. <U>Incentive
Compensation</U>. The Company will pay to the Executive not later than March 31, 2026, the amount of $50,000 if the Company&rsquo;s EBITDA
objective for 2025 as set forth in <U>Exhibit A</U> is achieved or exceeded; provided, however, that such payment shall be due and payable
only if the Executive is employed by the Company at the payment date. Such payment shall be subject to all required tax withholdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4. <U>Successors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) This Agreement is personal to the
Executive and without the prior written consent of the Company shall not be assignable by the Executive otherwise than by will or
the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive&rsquo;s legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) This Agreement shall inure to the
benefit of and be binding upon the Company and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) The Company will require any
successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business
and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that
the Company would be required to perform it if no such succession had taken place. As used in this Agreement,
&ldquo;<U>Company</U>&rdquo; shall mean the Company as hereinbefore defined and any successor to its business and/or assets as
aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.&nbsp;  <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) This Agreement shall be governed
by and construed in accordance with the laws of the State of Maine, without reference to principles of conflict of laws. The
captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement may not be
amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) All notices and other
communications hereunder shall be in writing and shall be given by hand delivery to the other party, by registered or certified
mail, return receipt requested, postage prepaid, or by e-mail, read receipt requested, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> <U>If
to the Executive</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">at the address and e-mail address on
file in the Company&rsquo;s records</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><U>If to the Company</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">ImmuCell Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">56 Evergreen Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Portland, Maine 04103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: Chair of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;or to such other address as either party shall have furnished
to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) The invalidity or unenforceability
of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) The Company may withhold from any amounts
payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any
applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(e) The Executive&rsquo;s or the
Company&rsquo;s failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the
Executive or the Company may have hereunder, shall not be deemed to be a waiver of such provision or right or any other provision of
or right under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(f) From and after the Effective Date this
Agreement shall supersede any other communications, agreement and understandings, written or oral, between the parties with respect
to the subject matter. Agreements between the parties with respect to other matters, including the Amended and Restated Separation
and Deferred Compensation Agreement by and between the Company and the Executive, dated as of March 28, 2022, remain in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) The Executive agrees that
jurisdiction and venue for any action arising from or relating to this Agreement or the relationship between the parties, including
but not limited to matters concerning validity, construction, performance, or enforcement, shall be exclusively in the federal and
Maine state courts located in Cumberland County (collectively, the &ldquo;<U>Selected Courts</U>&rdquo;) (provided, that a final
judgment in any such action shall be conclusive and enforceable in other jurisdictions) and further agree that service of process
may be made in any manner permitted by law. The Executive irrevocably waives and agrees not to assert (i) any objection which he may
ever have to the laying of venue of any action or proceeding arising out of this Agreement or the transactions contemplated hereby
in the Selected Courts, and (ii) any claim that any such action brought in any such court has been brought in an inconvenient forum.
This Section 4(g) is intended to fix the location of potential litigation between the parties and does not create any causes of
action or waive any defenses or immunities to suit or obviate the rights of the parties to agree to arbitration with respect to any
conflicts related to this Agreement or the Executive&rsquo;s employment hereunder. EACH PARTY WAIVES ANY RIGHT TO A TRIAL BY JURY,
TO THE EXTENT LAWFUL, AND AGREES THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE
KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY LITIGATION
WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT OR THE CONTEMPLATED TRANSACTIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(h) This Agreement may be executed by .pdf or
facsimile signatures in any number of counterparts, each of which shall be deemed an original, but all such counterparts shall
together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Remainder of page intentionally left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Executive has executed
this Agreement, and, pursuant to the authorization from its Board of Directors, the Company has caused this Agreement to be executed in
its name on its behalf, all as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXECUTIVE:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Michael F. Brigham</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <td>&nbsp;</td>
    <td>Michael F. Brigham</td></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">IMMUCELL CORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"> /s/ Steven T. Rosgen</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> Steven T. Rosgen</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> Chair of Compensation and Stock Option&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <td><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</p></td>
    <td><p style="margin-top: 0; margin-bottom: 0">Committee of Board of Directors</P>
                    <P STYLE="margin-top: 0; margin-bottom: 0"></P></td></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>ea023548101ex10-11_immucell.htm
<DESCRIPTION>AMENDED AND RESTATED INCENTIVE COMPENSATION AND SEVERANCE AGREEMENT BETWEEN THE COMPANY AND BOBBI JO BROCKMANN DATED AS OF MARCH 27, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCENTIVE COMPENSATION AND SEVERANCE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Amended and Restated Incentive Compensation
and Severance Agreement, dated as of March 27, 2025, is by and between IMMUCELL CORPORATION, a Delaware corporation (the &#8220;Company&#8221;)
and BOBBI JO BROCKMANN (the &#8220;Executive&#8221;), and replaces and supersedes in its entirety the Fourth Amended and Restated Incentive
Compensation Agreement, dated as of March 27, 2024, by between the Company and the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> WHEREAS,
the Company wishes to provide the Executive with certain benefits and assurances in connection with a termination of the Executive&#8217;s
employment under certain circumstances, as more fully set forth herein, in order to induce the Executive to continue her employment with
the Company, and to provide Executive with incentive compensation opportunities to remain in the Company&#8217;s employ and to further
incentivize her to continue her leadership efforts relating to certain products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> NOW
THEREFORE, in consideration of the mutual covenants and promises contained in this Agreement and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged by the parties, the Company and the Executive hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. <U>At-Will Nature of
Executive&#8217;s Employment</U>. The parties agree and acknowledge that the Executive&#8217;s employment with the Company is
&#8220;at will,&#8221; and that nothing contained in this Agreement shall be deemed to modify the &#8220;at will&#8221; nature of
such employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. <U>Incentive Compensation</U>. The Company
agrees to pay the Executive the following amounts, in each case subject to the conditions set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) The
Company shall pay the Executive as follows in connection with sales of a new spray-dried product in 2025 and 2026:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i) The
Company shall pay the Executive $30,000 in February, 2026, if the Company makes any sales of a new spray-dried product in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii) If
the amount that may be earned in 2025 under Section 2(a)(i) is earned, the Company shall pay the Executive an additional $30,000 in February,
2027, if the Company&#8217;s sales of such new spray-dried product in 2026 exceed sales of the product in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) In
addition to the payment, if any, provided under Section 2(a) above, the Company shall pay the Executive as follows in connection with
sales of Re-Tain<SUP>&reg;</SUP> in 2025 and 2026:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i) The
Company shall pay the Executive $30,000 in February, 2026, for market entry of Re-Tain<SUP>&reg;</SUP> in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii) If the amount that may be
earned in 2025 under Section 2(b)(i) is not earned because the Company decides not to enter the market ahead of approval with
investigational status or if Re-Tain doesn&#8217;t get approved in 2025, such amount shall nevertheless be paid to the Executive as
provided in Section 2(b)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iii) If
the amount that may be earned in 2025 under Section 2(b)(i) is earned, the Company shall pay the Executive an additional $30,000 in February,
2027, if the Company&#8217;s sales of Re-Tain<SUP>&reg;</SUP> in 2026 exceed sales of Re-Tain<SUP>&reg;</SUP> in 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv) If
the amount that may be earned in 2026 under Section 2(b)(iii) above is not earned because the Company does not have sufficient supply
of Re-Tain<SUP>&reg;</SUP> in 2026 to exceed 2025 sales, such amount shall nevertheless be paid to the Executive as provided in Section
2(b)(iii) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) In
addition to the payments, if any, provided under Sections 2(a) and 2(b) above, the Company shall pay to the Executive not later than March
31, 2026, an amount up to $30,000, determined based on the Company&#8217;s achievement of its 2025 sales revenue targets, as set forth
in <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<U> Termination
following a Change in Control</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)<U> Severance
Benefits</U>. If, within twelve (12) months following a Change in Control, the Executive&#8217;s employment with the Company is terminated
by the Company other than for Cause, or by the Executive with Good Reason:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(i) The
Company shall pay to the Executive in a lump sum in cash the following amounts: the sum of (1) the Executive&#8217;s base salary as then
in effect through the date of termination to the extent not theretofore paid, (2) any unused paid time off, paid out at the per-business-day
base salary rate then in effect with respect to the Executive, (3) any additional vested benefits in accordance with the applicable terms
of applicable Company arrangements, and (4) any unreimbursed expenses; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii) The
Company shall provide the Executive with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">A. A
lump sum payment equal to 100% of the Executive&#8217;s annual base salary then in effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">B. Subject
to the Executive&#8217;s timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended, the employer portion of the costs of continued health benefits for the Executive and her covered dependents in effect at the
date of termination for the twelve (12) month period following the date of termination, or, if such benefit would violate the nondiscrimination
rules applicable to health plans or self-insured plans under Section 105(h) of the Code or otherwise result in adverse tax consequences,
a single lump sum payment of an equivalent amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Amounts payable under this Section 3(a) following
the Executive&#8217;s termination of employment, other than those expressly payable on a deferred basis, will be paid in the payroll period
next following the payroll period in which termination of employment occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(b) <U>Change
in Control</U>. For purposes of this Agreement, a &#8220;Change of Control&#8221; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (i) The acquisition by an individual, entity
or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the
&#8220;<U>Exchange Act</U>&#8221;)) (a &#8220;<U>Person</U>&#8221;) of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act) of 35% or more of either (x) the then-outstanding shares of common stock of the Company (the
&#8220;<U>Outstanding Company Common Stock</U>&#8221;) or (y) the combined voting power of the then-outstanding voting securities of
the Company entitled to vote generally in the election of directors (the &#8220;<U>Outstanding Company Voting
Securities</U>&#8221;); provided, however, that for purposes of this subsection (i), the following acquisitions shall not constitute
a Change of Control: (a) any acquisition directly from the Company, (b) any acquisition by the Company, (c) any acquisition by any
employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company, or (d)
any acquisition by any corporation pursuant to a transaction which satisfies the criteria set forth in clauses (x), (y) and (z) of
subsection (iii) of this Section 6(b); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (ii)
A change in the composition of the Board of Directors of the Company (the &#8220;Board&#8221;),
as a result of which fewer than one-half of the incumbent directors are directors who either (x) had been directors of the Company 24
months prior to such change or (y) were elected, or nominated for election, to the Board with the affirmative votes of at least a majority
of the directors who had been directors of the Company 24 months prior to such change and who were still in office at the time of the
election or nomination; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (iii)
Consummation of a reorganization, merger or consolidation or sale or other disposition of all
or substantially all of the assets of the Company (a &#8220;<U>Business Combination</U>&#8221;), in each case, unless, immediately following
such Business Combination, (x) all or substantially all of the individuals and entities who were the beneficial owners, respectively,
of the Outstanding Company Common Stock or the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially
own, directly or indirectly, more than a majority of, respectively, the then-outstanding shares of common stock and the combined voting
power of the then-outstanding voting securities entitled to vote generally in the election of directors, of the corporation resulting
from such Business Combination (which as used in this Section 3(b)(iii) shall include, without limitation, a corporation which as a result
of such transaction owns the Company or all or substantially all of the Company&#8217;s assets either directly or through one or more
subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding
Company Common Stock or the Outstanding Company Voting Securities, (y) no Person (excluding any corporation resulting from such Business
Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination)
beneficially owns, directly or indirectly, 20% or more of, respectively, the then outstanding shares of common stock of the corporation
resulting from such Business Combination, or the combined voting power of the then-outstanding voting securities of such corporation and
(z) at least half of the members of the board of directors of the corporation resulting from such Business Combination were members of
the Company&#8217;s Board at the time of the execution of the initial agreement, or of the action of the Board, providing for such Business
Combination; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (iv)
Approval by the shareholders of the Company of a complete liquidation or dissolution of the
Company or the consummation of a sale of all or substantially all of the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(c) <U>Cause</U>. For purposes of this
Agreement, &#8220;<U>Cause</U>&#8221; shall mean any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (i)
The Executive&#8217;s having engaged in willful misconduct or gross negligence in the performance
of any of her duties to the Company, which, if capable of being cured, is not cured to the reasonable satisfaction of the Board within
thirty (30) days after the Executive receives from the Board written notice of such willful misconduct or gross negligence;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (ii)
The Executive&#8217;s willful failure or refusal to perform reasonably assigned directives of
the Board or to cooperate with an internal investigation being conducted by or at the direction of the Board which, if capable of being
cured, is not cured to the reasonable satisfaction of the Board within thirty (30) days after the Executive receives from the Board written
notice of such failure or refusal;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (iii)
Any conviction of the Executive of, or plea of guilty or nolo contendere by the Executive to,
(x) any felony or (y) any crime (whether or not a felony) involving fraud, theft, breach of trust or similar acts, in any case, whether
under the laws of the United States or any state thereof or any foreign law to which the Executive may be subject;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (iv)
The Executive&#8217;s willful or continued failure to comply with any written rules, regulations,
policies or procedures of the Company which, if not complied with, would reasonably be expected to have a material adverse effect on the
business, financial condition or reputation of the Company, as determined by the Company in its reasonable discretion, which, in the case
of a failure that is capable of being cured, is not cured to the reasonable satisfaction of the Board within thirty (30) days after the
Executive receives from the Company written notice of such failure; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (v)
The Executive&#8217;s abuse of alcohol or another controlled substance that would reasonably
be expected to result in a material adverse effect on the business, financial condition or reputation of the Company, as determined by
the Board in its reasonable discretion, which, if capable of being cured, is not cured to the reasonable satisfaction of the Board within
thirty (30) days after the Executive receives from the Company written notice of such circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Good Reason</U>. For purposes of this
Agreement, &#8220;<U>Good Reason</U>&#8221; shall mean one or more of the following conditions arising without the consent of the Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (i)
A material diminution in the Executive&#8217;s annual base salary;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (ii)
A material diminution in the Executive&#8217;s authority, duties, or responsibilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> (iii)
A material diminution in the budget over which the Executive retains authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(iv) A
material change in the geographic location at which the Executive must perform services; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(v)A
material breach of this Agreement or any successor incentive compensation agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0">Any notice of termination for Good Reason must be
given to the Company within sixty (60) days of the initial existence of one or more conditions described in this Section 3(d) which the
Executive believes constitute Good Reason. The Company shall be entitled to a period of thirty (30) days during which it may remedy the
conditions alleged to give rise to Good Reason. Failing such remedy, a termination of employment by the Executive for Good Reason shall
be effective on the day following the expiration of such thirty (30) day period. It is intended that a termination by the Executive due
to one or more of the conditions described in this Section 3(d), pursuant to notice given in accordance with the foregoing procedures,
shall be treated as an involuntary separation from service within the meaning of the good reason safe harbor set forth in Treasury Regulations
section 1.409A-1(n)(2)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp; 4.&nbsp; <U>Successors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (a)
This Agreement is personal to the Executive and without the prior written consent of the Company
shall not be assignable by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to
the benefit of and be enforceable by the Executive&#8217;s legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (b)
This Agreement shall inure to the benefit of and be binding upon the Company and its successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (c)
The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation
or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used
in this Agreement, &#8220;<U>Company</U>&#8221; shall mean the Company as hereinbefore defined and any successor to its business and/or
assets as aforesaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5. <U>Release</U>. As a condition of receipt
of the separation payments and benefits set forth in Section 3, the Executive shall be required to sign a release of claims reasonably
acceptable to the Company (the &#8220;Release&#8221;) and to abide by the provisions thereof. The Release shall contain a release and
waiver of any claims the Executive or her representatives may have against the Company, any of its affiliated companies, and any of their
respective officers, directors, affiliates and/or representatives, and shall release those entities and persons from any liability for
such claims including but not limited to all employment discrimination claims. Payments and benefits under this Agreement will be paid
when and as provided herein following the Executive&#8217;s termination of employment provided the Executive has executed and submitted
the Release and the statutory period during which the Executive is entitled to revoke the Release has expired on or before that payment
date. If the Executive fails to so execute or revokes the Release, the Executive will not be entitled to receive any of the separation
payments or benefits, the receipt of which is made contingent upon such execution and non-revocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.&nbsp; <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (a)
This Agreement shall be governed by and construed in accordance with the laws of the State of
Maine, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall
have no force or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto
or their respective successors and legal representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (b)
All notices and other communications hereunder shall be in writing and shall be given by hand
delivery to the other party, by registered or certified mail, return receipt requested, postage prepaid, or by e-mail, read receipt requested,
addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> If
to the Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> at
the address and e-mail address on file in the Company&#8217;s records</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"> If
to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">ImmuCell Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">56 Evergreen Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Portland, Maine 04103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">or to such other address as either party shall have furnished
to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (c)
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity
or enforceability of any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (d)
The Company may withhold from any amounts payable under this Agreement such Federal, state,
local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (e)
The Executive&#8217;s or the Company&#8217;s failure to insist upon strict compliance with any
provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation,
the right of the Executive to terminate employment for Good Reason pursuant to Section 3(d) of this Agreement, shall not be deemed to
be a waiver of such provision or right or any other provision of or right under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (f)
From and after the Effective Date this Agreement shall supersede any other communications, agreements
and understandings, written or oral, between the parties with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(g) The
Executive agrees that jurisdiction and venue for any action arising from or relating to this Agreement or the relationship between the
parties, including but not limited to matters concerning validity, construction, performance, or enforcement, shall be exclusively in
the federal and Maine state courts located in Cumberland County (collectively, the &#8220;<U>Selected Courts</U>&#8221;) (provided, that
a final judgment in any such action shall be conclusive and enforceable in other jurisdictions) and further agree that service of process
may be made in any manner permitted by law. The Executive irrevocably waives and agrees not to assert (i) any objection which she may
ever have to the laying of venue of any action or proceeding arising out of this Agreement or the transactions contemplated hereby in
the Selected Courts, and (ii) any claim that any such action brought in any such court has been brought in an inconvenient forum. This
Section 11(g) is intended to fix the location of potential litigation between the parties and does not create any causes of action or
waive any defenses or immunities to suit, or obviate the rights of the parties to agree to arbitration with respect to any conflicts related
to this Agreement or the Executive&#8217;s employment. EACH PARTY WAIVES ANY RIGHT TO A TRIAL BY JURY, TO THE EXTENT LAWFUL, AND AGREES
THAT ANY OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT
AMONG THE PARTIES IRREVOCABLY TO WAIVE ITS RIGHT TO TRIAL BY JURY IN ANY LITIGATION WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT
OR THE CONTEMPLATED TRANSACTIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> (h)
This Agreement may be executed by .pdf or facsimile signatures in any number of counterparts,
each of which shall be deemed an original, but all such counterparts shall together constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of this page intentionally left blank.</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Executive has executed
this Agreement, and the Company has caused this Agreement to be executed in its name on its behalf, all as of the day and year first above
written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXECUTIVE:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">/s/ Bobbi Jo Brockmann</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <td style="padding-left: 0.375in">&nbsp;</td>
    <td style="padding-left: 0pt">Bobbi Jo Brockmann</td></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">IMMUCELL CORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> /s/ Steven T. Rosgen</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> Steven T. Rosgen</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> Chair of Compensation and Stock Option&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <td>&nbsp;</td>
    <td>Committee of Board of Directors</td></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>ea023548101ex19_immucell.htm
<DESCRIPTION>INSIDER TRADING POLICY OF THE COMPANY ADOPTED AS OF DECEMBER 11, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 19</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSIDER TRADING POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Purpose </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Insider Trading Policy
(the &ldquo;Policy&rdquo;) provides guidelines with respect to transactions in the common stock of ImmuCell Corporation (the &ldquo;Company&rdquo;)
and the handling of confidential information about the Company and the companies with which the Company does business. The Company&rsquo;s
Board of Directors has adopted this Policy to promote compliance with federal and state securities laws that prohibit certain persons
who are aware of material nonpublic information (&ldquo;MNPI&rdquo;) about a company from: (i) trading in securities of that company;
or (ii) providing MNPI to other persons who may trade in securities on the basis of that information. This Policy supersedes and replaces
all existing policies and procedures of the Company prohibiting insider trading and related procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Persons Subject to the Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy applies to all
officers, directors and employees of the Company. The Company may also determine that other persons should be subject to this Policy,
such as contractors or consultants who have access to MNPI. This Policy also applies to family members, other members of a person&rsquo;s
household and entities controlled by a person covered by this Policy, as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transactions Subject to the Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy applies to transactions
in the Company&rsquo;s common stock, options to purchase the Company&rsquo;s common stock or any other type of securities that the Company
may issue, as well as transactions in securities issued by other entities where the person engaging in the transaction uses information
obtained while working for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Individual Responsibility</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Persons subject to this Policy
have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage in transactions
in Company stock while in possession of MNPI about the Company. Persons subject to this Policy must not engage in illegal trading and
must also avoid the appearance of improper trading. Each individual is responsible for making sure that they comply with this Policy,
and that any family member, household member or entity whose transactions are subject to this Policy, as discussed below, also comply
with this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In all cases, the responsibility
for determining whether an individual is in possession of MNPI rests with that individual, and any action on the part of the Company,
the Compliance Officer (as defined below) or any other employee or director pursuant to this Policy (or otherwise) does not in any way
constitute legal advice or insulate an individual from liability under applicable securities laws. You could be subject to severe legal
penalties and disciplinary action by the Company for any conduct prohibited by this Policy or applicable securities laws, as described
below in more detail under the heading &ldquo;Consequences of Violations&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition to the policies
and procedures set out in this Policy, directors and certain officers must also comply with Section 16 of the Securities Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which imposes additional disclosure requirements and trading restrictions on directors,
officers, and certain shareholders. Individuals subject to Section 16 of the Exchange Act are responsible for the content and timeliness
of all filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Administration of the Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The President or their designee
(the &ldquo;Compliance Officer&rdquo;) shall be responsible for administration of this Policy. All determinations and interpretations
by the Compliance Officer shall be final and not subject to further review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Statement of Policy</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">It is the policy of the Company
that no director, officer, other employee of the Company, or any other person designated by this Policy or by the Compliance Officer as
subject to this Policy who is aware of MNPI relating to the Company may, directly, or indirectly through family members or other persons
or entities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify">Engage in transactions in Company stock, except as otherwise specified in this Policy under the headings
&ldquo;Transactions Under Company Plans&rdquo; or &ldquo;Transactions Not Involving a Purchase or Sale&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify">Recommend the purchase or sale of Company stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify">Disclose MNPI to persons within the Company whose jobs do not require them to have that information, or
outside of the Company to other persons, including but not limited to family, friends, business associates, investors and expert consulting
firms, unless any such disclosure is made in accordance with the Company&rsquo;s policies regarding the protection or authorized external
disclosure of information regarding the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify">Assist anyone engaged in the above activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, it is the policy
of the Company that no director, officer, other employee of the Company, or any other person designated as subject to this Policy who,
in the course of working for the Company learns of MNPI about a company with which the Company does business, including a customer or
vendor of the Company, may trade in that company&rsquo;s securities until the information becomes public or is no longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">There are no exceptions to
this Policy, except as specifically noted herein. Transactions that may be necessary or justifiable for independent reasons (such as the
need to raise money for an emergency expenditure), or small transactions, are not excepted from this Policy. The securities laws do not
recognize any mitigating circumstances, and, in any event, even the appearance of an improper transaction must be avoided to preserve
the Company&rsquo;s reputation for adhering to the highest standards of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Definition of MNPI</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Material Information</U>.
Information is considered &ldquo;material&rdquo; if a reasonable investor would consider that information important in making a decision
to buy, hold or sell securities. Any information that could be expected to affect the Company&rsquo;s stock price when publicly disclosed
or known, whether it is positive or negative, should be considered material. There is no bright-line standard for assessing materiality;
rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities
with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information
that ordinarily would be regarded as material are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Projections of or expectations for future earnings or losses, or other earnings guidance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Changes to previously announced earnings guidance, or the decision to suspend the announcement of earnings
guidance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Changes in the Company&rsquo;s prospects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Significant write-downs in assets or increase in reserves;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures,
recapitalizations, strategic alliances, licensing arrangements, or purchases or sales of substantial assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A pending or proposed acquisition or disposition of a significant asset;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A restructuring;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A change in dividend policy, the declaration of a stock split, or an offering of additional securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Borrowings or other financing transactions out of the ordinary course;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">The establishment of a repurchase program for Company stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A change in the Company&rsquo;s revenues or cost structure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Major marketing changes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A change in management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A change in auditors or notification that the auditor&rsquo;s reports may no longer be relied upon;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Pending or threatened significant litigation or regulatory investigation or proceedings, or the resolution
of such litigation or proceedings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">Impending bankruptcy or the existence of severe liquidity problems, or pending default under a material
agreement or other obligation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">The gain or loss of a significant customer or vendor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">A significant cybersecurity incident, such as a data breach; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: left; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol; font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify">The imposition of an event-specific restriction on trading in Company stock or the securities of another
company or the extension or termination of such restriction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Material information is not limited to historical
facts but may also include projections and forecasts. With respect to a future event, such as a merger, acquisition or introduction of
a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability
that the event will occur against the magnitude of the effect the event would have on a company&rsquo;s operations or stock price should it
occur. Thus, information concerning an event that would have a large effect on stock price, such as a merger, may be material even if
the probability that the event will occur is relatively small or highly uncertain. When in doubt about whether particular non-public information
is material, you should presume it is material. If you are unsure whether information is material, you should consult the Compliance Officer
before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities
to which that information relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>When Information is considered
Nonpublic</U>. Information that has not been disclosed to the public is generally considered to be nonpublic information. In order to
establish that the information has been disclosed to the public, it may be necessary to demonstrate that the information has been widely
disseminated. Information generally would be considered widely disseminated if it has been disclosed through newswire services, a broadcast
on widely-available radio or television programs, publication in a widely-available newspaper, magazine or news website, or public disclosure
documents filed with the SEC that are available on the SEC&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">By contrast, information would
likely not be considered widely disseminated if it is available only to the Company&rsquo;s employees, or if it is only available to a
select group of analysts, brokers and institutional investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Once information is widely
disseminated, it is still necessary to provide the investing public with sufficient time to absorb the information. As a general rule,
information should not be considered fully absorbed by the marketplace until the second trading day after the day the information is released.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">If, for example, the Company
were to make an announcement on a Monday, you should not trade in Company stock until Wednesday. Depending on the particular circumstances,
the Company may determine that a longer or shorter period should apply to the release of specific MNPI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transactions by Family Members &amp; Others</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy applies to your
family members who reside with you (including spouse, child, child away at college, stepchildren, grandchildren, parents, stepparents,
grandparents, siblings, and in-laws), anyone else who lives in your household, and any family members who do not live in your household
but whose transactions in Company stock are directed by you or are subject to your influence or control, such as parents or children who
consult with you before they trade in Company stock (collectively referred to as &ldquo;Family Members&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">You are responsible for the
transactions of these other persons and therefore should make them aware of the need to confer with you before they trade in Company stock;
and you should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were
for your own account. This Policy does not, however, apply to personal securities transactions of Family Members where the purchase or
sale decision is made by a third party not controlled by, influenced by or related to you or your Family Member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transactions by Entities that You or Family
Members Influence or Control</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy applies to any
entities that you or your Family Members influence or control, including any corporations, limited liability companies, partnerships or
trusts (collectively referred to as &ldquo;Controlled Entities&rdquo;), and transactions by these Controlled Entities should be treated
for the purpose of this Policy and applicable securities laws as if they were for your own account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Transactions Under Company Plans</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy does not apply
in the case of the following transactions, except as specifically noted:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Stock Option Exercises</U></I>.
This Policy does not apply to the exercise of an employee stock option for cash consideration pursuant to the Company plans. This Policy
does apply, however, to any sale of stock as part of a cashless exercise of an option, or any other market sale for the purpose of generating
the cash needed to pay the exercise price of an option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Restricted Stock Awards</U></I>.
This Policy does not apply to the vesting of restricted stock nor the automatic deduction of shares by the Company from stock awards to
satisfy the minimum statutory tax withholding liability upon the vesting of restricted stock award. The policy does apply, however, to
any open market sale of vested shares, including to satisfy tax liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>10b5-1 Plan</U></I>.
This policy does not apply to transactions under a pre-existing written plan, contract, instruction, or arrangement under Rule 10b5-1
under the Securities Exchange Act of 1934 (an &ldquo;Approved 10b5-1 Plan&rdquo;) that has been approved by the Compliance Officer. If you
are considering entering into, modifying, or terminating an Approved 10b5-1 Plan, please contact the Compliance Officer. You should consult
your own legal and tax advisors before entering into, or modifying or terminating, an Approved 10b5-1 Plan. A trading plan, contract,
instruction or arrangement will not qualify as an Approved 10b5-1 Plan without the prior review and approval of the Compliance Officer
as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Transaction Not Involving a Purchase or
Sale</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>Bona fide</I> gifts of
Company stock are not transactions subject to this Policy, unless the person making the gift has reason to believe that the recipient
intends to sell the Company stock while the officer, employee or director is aware of MNPI, or the person making the gift is subject to
the trading restrictions specified below under the heading &ldquo;Additional Procedures&rdquo; and the sale by the recipient of the Company
stock occurs during a blackout period. For Section 16 purposes, bona fide gifts require a Form 4 filing within two business days. Further,
transactions in mutual funds that are invested in Company stock are not transactions subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Prohibited Transactions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has determined
that there is a heightened legal risk and/or the appearance of improper or inappropriate conduct if the persons subject to this Policy
engage in certain types of transactions. It therefore is the Company&rsquo;s policy that any persons covered by this Policy may not engage
in any of the following transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I><U>Short-Term Trading</U>. </I>Short-term trading
of Company stock may be distracting to the person and may unduly focus the person on the Company&rsquo;s short-term stock market performance
instead of the Company&rsquo;s long-term business objectives. For these reasons, any director, officer or other employee of the Company
who purchases Company stock in the open market may not sell any Company stock of the same class during the six months following the purchase
(or vice versa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Short Sales</U>. </I>Short
sales of Company stock <I>(i.e., </I>the sale of a security that the seller does not own) may evidence an expectation on the part of the
seller that the stock will decline in value, and therefore have the potential to signal to the market that the seller lacks confidence
in the Company&rsquo;s prospects. In addition, short sales may reduce a seller&rsquo;s incentive to seek to improve the Company&rsquo;s
performance. For these reasons, short sales of Company stock are prohibited. In addition, Section 16(c) of the Exchange Act prohibits
directors and officers from engaging in short sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Options Trading</U></I>.
Options trading may be distracting to the person and may unduly focus the person on the Company&rsquo;s short-term stock market performance
instead of the Company&rsquo;s long-term business objectives. For these reasons, any director, officer or other employee of the Company
are prohibited from buying or selling puts or calls or other derivative securities on the Company stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Hedging</U></I>. Hedging
and other monetization transactions may evidence an expectation on the part of the holder of the Company stock that the stock will decline
in value, and therefore have the potential to signal to the market that the seller lacks confidence in the Company&rsquo;s prospects.
In addition, hedging transactions may reduce a seller&rsquo;s incentive to seek to improve the Company&rsquo;s performance. For these
reasons, any director, officer or other employee of the Company may not enter hedging or monetization transactions or similar arrangements
with respect to Company stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Margin Accounts and
Pledged Securities</U>. </I>Securities held in margin accounts as collateral for a margin loan may be sold by the broker without the customer&rsquo;s
consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold
in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledger is
aware of MNPI or otherwise is not permitted to trade in Company stock, directors, officers and other employees of the Company are prohibited
from holding Company stock in a margin account or otherwise pledging Company stock as collateral for a loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Standing and&nbsp;Limit
Orders</U></I>. Standing and&nbsp;limit orders&nbsp;create heightened risks for insider trading violations similar to the use of margin
accounts. There is no control over the timing of purchases or sales that result from standing instructions to a broker, and as a result
the broker could execute a transaction when a director, officer or other employee is in possession of MNPI. The Company therefore discourages
placing standing or&nbsp;limit orders&nbsp;on Company Securities. If a person subject to this Policy determines that they must use a standing
order or limit order, the order should be limited to short duration and should otherwise comply with the restrictions and procedures outlined
below under the heading &ldquo;Additional Procedures.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Additional Procedures</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company has established
additional procedures to assist the Company in the administration of this Policy, to facilitate compliance with laws prohibiting insider
trading while in possession of MNPI, and to avoid the appearance of any impropriety. The Additional Procedures are applicable only to
those individuals described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Pre-Clearance Procedures</U>.
</I>Any director, officer or any other person designated by the Compliance Officer from time to time, as well as the Family Members and
Controlled Entities of such persons is subject to these procedures and may not engage in any transaction in Company stock without first
obtaining pre-clearance of the transaction from the Compliance Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">A request for
pre-clearance should be submitted to the Compliance Officer at least two business days in advance of the proposed transaction. The
Compliance Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the
transaction. If a person seeks pre-clearance and permission to engage in the transaction is not granted, then they should refrain
from initiating any transaction in Company stock and should not inform any other person of the restriction. Unless revoked or
otherwise limited by a blackout period, a grant of permission will be effective for three trading days after permission is granted.
If the transaction does not occur within those three days, pre-clearance of the transaction must be re-requested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">When a request for pre-clearance
is made, the requestor should carefully consider whether they may be aware of any MNPI about the Company, and should describe fully those
circumstances to the Compliance Officer. The requestor should also indicate whether they have effected any non-exempt &ldquo;opposite-way&rdquo;
transactions within the past six months, and should be prepared to report the proposed transaction to the SEC on an appropriate Form 4
or Form 5. The requestor should also be prepared to comply with SEC Rule 144 and file Form 144, if necessary, at the time of any sale.
Under no circumstance may a person trade while aware of MNPI about the Company. Thus, if a person becomes aware of MNPI after receiving
pre-clearance but before the trade has been executed, they must not effect the pre-cleared transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Quarterly Trading Restriction</U>s.
</I>All officers, directors and employees of the Company may not conduct any transactions involving the Company&rsquo;s stock (other than
as specified by this Policy) during a &ldquo;Blackout Period&rdquo; beginning ten calendar days before the end of each fiscal quarter
and ending at the end of the first trading day following the date of the public release of the Company&rsquo;s earnings results for that
quarter. In other words, these persons may only conduct transactions in Company stock during the &ldquo;Window Period&rdquo; beginning
on the second trading day following the public release of the Company&rsquo;s quarterly earnings and ending ten days prior to the close of the
next fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Event-Specific Trading
Restriction Periods</U>. </I>From time to time, an event may occur that is material to the Company and is known by only a few directors,
officers and/or employees. So long as the event remains material and nonpublic, the persons designated by the Compliance Officer may not
trade Company stock. In addition, the Company&rsquo;s financial results may be sufficiently material in a particular fiscal quarter that, in
the judgment of the Compliance Officer, designated persons should refrain from trading in Company stock even sooner than the typical Blackout
Period described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In that situation, the Compliance
Officer may notify these persons that they should not trade in the Company&rsquo;s stock, without disclosing the reason for the restriction.
The existence of an event-specific trading restriction period or extension of a Blackout Period may not be announced to the Company as
a whole and should not be communicated to any other person. Even if the Compliance Officer has not designated you as a person who should
not trade due to an event-specific restriction, you should not trade while aware of MNPI. Exceptions will not be granted during an event-specific
trading restriction period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><I><U>Exceptions. </U></I>The
quarterly trading restrictions and event-specific trading restrictions do not apply to those transactions to which this Policy does not
apply, as described above under the headings &ldquo;Transactions Under Company Plans&rdquo; and &ldquo;Transactions Not Involving a Purchase
or Sale.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Post-Termination Transactions</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Policy continues to apply
to transactions in Company stock even after termination of service to the Company. If an individual is in possession of MNPI about the
Company when their service terminates, that individual may not trade in Company stock until that information has become public or is no
longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Consequences of Violations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The purchase or sale of securities
while aware of MNPI about the Company or other entities having business dealings with the Company, or the disclosure of MNPI to others
who then trade in the Company&rsquo;s stock (or the securities of such other entity), is prohibited by the federal and state laws. Insider trading
violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities. Punishment for insider trading violations
is severe, and could include significant fines and imprisonment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">While the regulatory authorities
concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws
also impose potential liability on companies and other &ldquo;controlling persons&rdquo; if they fail to take reasonable steps to prevent
insider trading by company personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, an individual&rsquo;s
failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not
the employee&rsquo;s failure to comply results in a violation of law. Needless to say, a violation of law, or even an SEC investigation that
does not result in prosecution, can tarnish a person&rsquo;s reputation and irreparably damage a career.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Company Assistance</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This policy is general in
nature, and you should consult with the Compliance Officer in advance of any contemplated transaction in Company Stock (or other securities
to the extent addressed in this policy) where you have any questions as to your obligations or possible liability under the securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Certification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">All persons subject to this
Policy must certify their understanding of, and intent to comply with, this Policy. Employees and directors who become subject to this
Policy after its effective date will certify their understanding of, and intent to comply with, this Policy within thirty days of becoming
subject to this Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Approved by the Board of Directors on December 11, 2024.<BR STYLE="clear: both">
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Certification</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>I certify that:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></font></TD><TD STYLE="text-align: justify"><B>I have read and understand the Company&rsquo;s Insider Trading Policy (the &ldquo;Policy&rdquo;). I understand
that the Compliance Officer is available to answer any questions I have regarding the Policy.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD><TD STYLE="text-align: justify"><B>Since the date the Policy became effective, or such shorter period of time that I have been an employee
of the Company, I have complied with the Policy.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD><TD STYLE="text-align: justify"><B>I will continue to comply with the Policy for as long as I am subject to the Policy.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Print name: <U>          &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Signature:</B>  <U>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date: <U> <U>          &nbsp;<U>          &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></U></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in"><B></B></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.65pt; text-align: left; text-indent: -0.25in"><B></B>&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ea023548101ex23-1_immucell.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.15pt; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.15pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consent of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 111.15pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We consent to the incorporation by reference in
the Registration Statements (Nos. 333-228479  and 333-278438) on Form S-3 and the Registration Statements (Nos. 333-02631, 333-167721, 333-237428 and 333-273227) on Form S-8 of ImmuCell Corporation of our report dated March 28, 2025, relating to
the financial statements of ImmuCell Corporation, appearing in this Annual Report on Form 10-K of ImmuCell Corporation for the years ended
December 31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt"><U>/s/ WIPFLI LLP</U></FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Radnor, Pennsylvania</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">March 28, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>ea023548101ex31_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: right"><B>Exhibit 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO REQUIRED
BY RULE 13a-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">I, Michael F. Brigham, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">1.</td><td style="text-align: left">I have reviewed this Annual Report on Form 10-K of ImmuCell
Corporation (the Company);</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">2. </td><td style="text-align: left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
                                                                                   to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,
                                                                                   not misleading with respect to the period covered by this report;</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">3.</td><td style="text-align: left">Based on my knowledge, the financial statements, and other financial information included in this
                                                                                  report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of,
                                                                                  and for, the periods presented in this report;</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">4.</td><td style="text-align: left">I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: left">designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Company
is made known to me by others within the Company, particularly during the period in which this report is being prepared;</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: left">designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">c)</td><td style="text-align: left">evaluated the effectiveness of the Company&rsquo;s disclosure
controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">d)</td><td style="text-align: left">disclosed in this report any change in the Company&rsquo;s
internal control over financial reporting that occurred during the Company&rsquo;s most recent fiscal quarter (the Company&rsquo;s fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s
internal control over financial reporting; and</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">5.</td><td style="text-align: left">I have disclosed, based on my most recent evaluation of internal
control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s Board of Directors (or
persons performing the equivalent function):</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: left">all significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s
ability to record, process, summarize and report financial information; and</td>
</tr></table>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: left">any fraud, whether or not material, that involves management
or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</td>
</tr></table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Date: March 28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Michael F. Brigham</U></FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and<br>
 Principal Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>7
<FILENAME>ea023548101ex32_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906<br>
 OF THE SARBANES- OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Annual Report on Form 10-K of ImmuCell Corporation
(the &ldquo;Company&rdquo;) for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof
(the &ldquo;Report&rdquo;), I, Michael F. Brigham, President, Chief Executive Officer and Principal Financial Officer of the Company,
certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">the Report fully complies with the requirements of Section
13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;); and</td>
</tr></table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: left">the information contained in the Report fairly presents,
in all material respects, the financial condition, results of operations and cash flows of the Company.</td>
</tr></table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification is provided pursuant to 18 U.S.C. Section 1350 and
Item 601(b)(32) of Regulation S-K (&ldquo;Item 601(b)(32)&rdquo;) promulgated under the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32), this certification (A) shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, and (B) shall not be deemed
to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Company specifically
incorporates it by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Michael F. Brigham </U></FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael F. Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer and <br>
Principal Financial Officer </FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 28, 2025</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section 906
has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and Exchange Commission
or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &[ M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^[+PEX2\*
MW?A7PS=77AGP_<W5SX?T:XN;FXT739I[B>;3;:2:>>:2V:26:61FDDDD9GD=
MF9F+$FN@_P"$*\&_]"EX9_\ !#I7_P B4>"O^1-\)?\ 8LZ#_P"FJTKIJ .9
M_P"$*\&_]"EX9_\ !#I7_P B4?\ "%>#?^A2\,_^"'2O_D2NFHH YG_A"O!O
M_0I>&?\ P0Z5_P#(E'_"%>#?^A2\,_\ @ATK_P"1*Z:B@#F?^$*\&_\ 0I>&
M?_!#I7_R)1_PA7@W_H4O#/\ X(=*_P#D2OA/]JOXQ>.C\:/ ?[-OA;XP_#+]
MFBY\5^'O"GQ+\(?$SXI:?XAU)?B]XW\._%G0(K7X#> X='^)?PDMS=Z@UAI5
MG\1-+'B/Q)K_ (I\&>/H?#^A>$"ESJ.L6O0>-/C3^T7JOQ0\3?!OX;7OP'\$
M>-OA5^SYX,^,GCN?XA>'O&WC_1_'GB/QK>^+]*C\+?#Y-&\>?"C4O#'@[PYJ
M7@+4X=;^(NNP>+;O/BCP["? UE+8W/\ :H!]F?\ "%>#?^A2\,_^"'2O_D2C
M_A"O!O\ T*7AG_P0Z5_\B5\]']JOPW#^QG#^V/>:!>0^'G^!-K\:Y/":7\$E
M\K7/A.+Q"OA6+5C!':S7+:A*NB0ZHMJ()Y"EY';-&ZPGP+QA^U=\:OV9%N-0
M_:@@^%/B[2=<_9Y^)?QI\-#X.^&/%O@:70/%_P ([3P]J7B?X4ZK?>,O'WQ!
MM_&BZ]8^+],_X1;QO96O@64R:!KDMYX'>.^MDTP _0+_ (0KP;_T*7AG_P $
M.E?_ ")1_P (5X-_Z%+PS_X(=*_^1*_/WQA^U=\:OV9%N-0_:@@^%/B[2=<_
M9Y^)?QI\-#X.^&/%O@:70/%_PCM/#VI>)_A3JM]XR\??$&W\:+KUCXOTS_A%
MO&]E:^!93)H&N2WG@=X[ZV33/5OAW\5OV@/#7QC^''PK_:#F^$6N#XT?##Q3
MXW\(ZG\)_"/C'P?'X*\7?#Z?PO-XN^'VNR^+?B!X^3QW;7>C^,[*^\.>,=/@
M\ 3S?\(QKQO/!BQ:A;G2@#ZL_P"$*\&_]"EX9_\ !#I7_P B4?\ "%>#?^A2
M\,_^"'2O_D2OEKXB_%?XY>*?C5XT^"/[/&H?"3PYJWPJ^%'AOXC^-O$/Q:\'
M^+?'UIK.M_$74_%FG_#WP-H6B^$/B-\,Y] BE@\">(M3\3^+]1U77VT^&]T&
MVT[PCJ!FN[F'R+P1^U=\:OVG6T?3_P!F^#X4_#S5M*_9Y\"?&GX@'XP>&/%O
MQ+BA\7_$^[\5Z;X5^%.CV/A#Q]\*+C2UTJ^^'_B[_A*O&^IW6J2VT;Z%%8^!
MYY+B]>V /T"_X0KP;_T*7AG_ ,$.E?\ R)1_PA7@W_H4O#/_ ((=*_\ D2OB
M#1OVK?B!\;K;]F3PW\$+7P+X!\=?'CX1>)OCCXJU+XH:%K_Q&T3X;^$_!,OA
M7PYKWARW\*>&?&'PLU7Q3XFN_B!XTTSP_9W=QXK\,6-AI>CZ_JUS9WEY';:.
MWT)^S3\6?$/Q>^&]UJGC72]'T?X@^"O'7C_X4_$.S\.B^3PY-XR^&?BO4O">
MJZUX<M]4GNM4L/#WB=-/MO%&AZ9J=[J5]I>EZS::?<ZMK$EL=5O0#UO_ (0K
MP;_T*7AG_P $.E?_ ")1_P (5X-_Z%+PS_X(=*_^1*Z:B@#F?^$*\&_]"EX9
M_P#!#I7_ ,B4?\(5X-_Z%+PS_P""'2O_ )$KIJ* .9_X0KP;_P!"EX9_\$.E
M?_(E'_"%>#?^A2\,_P#@ATK_ .1*Z:B@#F?^$*\&_P#0I>&?_!#I7_R)1_PA
M7@W_ *%+PS_X(=*_^1*Z:B@#F?\ A"O!O_0I>&?_  0Z5_\ (E'_  A7@W_H
M4O#/_@ATK_Y$KIJ* .9_X0KP;_T*7AG_ ,$.E?\ R)1_PA7@W_H4O#/_ ((=
M*_\ D2NFHH YG_A"O!O_ $*7AG_P0Z5_\B4?\(5X-_Z%+PS_ ."'2O\ Y$KI
MJ* .9_X0KP;_ -"EX9_\$.E?_(E'_"%>#?\ H4O#/_@ATK_Y$KIJ* .9_P"$
M*\&_]"EX9_\ !#I7_P B4?\ "%>#?^A2\,_^"'2O_D2NFHH YG_A"O!O_0I>
M&?\ P0Z5_P#(E'_"%>#?^A2\,_\ @ATK_P"1*Z:B@#F?^$*\&_\ 0I>&?_!#
MI7_R)1_PA7@W_H4O#/\ X(=*_P#D2NFHH YG_A"O!O\ T*7AG_P0Z5_\B4?\
M(5X-_P"A2\,_^"'2O_D2NFHH YG_ (0KP;_T*7AG_P $.E?_ ")1_P (5X-_
MZ%+PS_X(=*_^1*Z:B@#F?^$*\&_]"EX9_P#!#I7_ ,B4?\(5X-_Z%+PS_P""
M'2O_ )$KIJ* .9_X0KP;_P!"EX9_\$.E?_(E'_"%>#?^A2\,_P#@ATK_ .1*
MZ:B@#F?^$*\&_P#0I>&?_!#I7_R)1_PA7@W_ *%+PS_X(=*_^1*Z:B@#F?\
MA"O!O_0I>&?_  0Z5_\ (E'_  A7@W_H4O#/_@ATK_Y$KIJ* .9_X0KP;_T*
M7AG_ ,$.E?\ R)1_PA7@W_H4O#/_ ((=*_\ D2NFHH YG_A"O!O_ $*7AG_P
M0Z5_\B4?\(5X-_Z%+PS_ ."'2O\ Y$KIJ* .9_X0KP;_ -"EX9_\$.E?_(E'
M_"%>#?\ H4O#/_@ATK_Y$KIJ* .9_P"$*\&_]"EX9_\ !#I7_P B4?\ "%>#
M?^A2\,_^"'2O_D2NFHH YG_A"O!O_0I>&?\ P0Z5_P#(E'_"%>#?^A2\,_\
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M ((=*_\ D2NFHH YG_A"O!O_ $*7AG_P0Z5_\B4?\(5X-_Z%+PS_ ."'2O\
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MQ3J7BO6-*\/27\-OJ-QX=\-C4+?PSH-[J5O:W]_I.CV=[=6.FR7!TVT]YHH
M*Y^X\)^%;N>6ZN_#/A^ZN9Y&EGN+C1M.FGFE<Y>2662V:221B26=V9F/))-=
M!10!S/\ PA7@W_H4O#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")7344
M<S_PA7@W_H4O#/\ X(=*_P#D2C_A"O!O_0I>&?\ P0Z5_P#(E=-10!S/_"%>
M#?\ H4O#/_@ATK_Y$H_X0KP;_P!"EX9_\$.E?_(E=-10!S/_  A7@W_H4O#/
M_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\ PA7@W_H4O#/_ ((=*_\
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MO#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")7344 <S_PA7@W_H4O#/\
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M-EXR\1Z?JNGZY;^(;YH_#G@KP_;V^B7MYXN:+Q+8K$ ?;M%>&O\ M ^![/\
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MM5\2_P!@>(=:/B*Q,'@HFPN6M^ZU7Q!\5KSQ1X6_:8^+7P2\1_!CP_\ LL_
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M(EI7_/WXF_\ "U\9?_+ZNFHH YG_ (1+2O\ G[\3?^%KXR_^7U'_  B6E?\
M/WXF_P#"U\9?_+ZNFHH YG_A$M*_Y^_$W_A:^,O_ )?4?\(EI7_/WXF_\+7Q
ME_\ +ZNFHH YG_A$M*_Y^_$W_A:^,O\ Y?4?\(EI7_/WXF_\+7QE_P#+ZNFH
MH YG_A$M*_Y^_$W_ (6OC+_Y?4?\(EI7_/WXF_\ "U\9?_+ZNFHH YG_ (1+
M2O\ G[\3?^%KXR_^7U'_  B6E?\ /WXF_P#"U\9?_+ZNFHH YG_A$M*_Y^_$
MW_A:^,O_ )?4?\(EI7_/WXF_\+7QE_\ +ZNFHH YG_A$M*_Y^_$W_A:^,O\
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M?L[0^"M>/Q4^#/PRL]:NKGXB?$'_ (6=X6@\/IX!^+)N=,2+P#)-J_MOQY^
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M 5-5_:TU2<^)?B)X!^$=WXR_9H^'OB_X<>#/B'\3;K]HOQ_X?^)UE>>.])\
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MOBK.Y1=; <)9/-V;K8OEC6SC&TU*&4Y0L17J3AB*^%@_YD;"U<%KRY^:XFY
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M7_H=?$W_ (">#?\ YDJZ:B@#F?[!U7_H=?$W_@)X-_\ F2H_L'5?^AU\3?\
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M!3IU[/IFH#QCHVB:9?:CX8-AJ-K<Z?>C6[:Q^RWMO/:3^7/#)&N;X3^/_P
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M=_ZICX=U^>=?Z7\%?\D=PI_V3F2_^J[#G^9'%/\ R4_$7_8\S7_U.K'[)?\
M!#[_ ).O^(/_ &;SXL_]63\)J_>']M3]D3P7^V+\'M0\!:[]FTCQCI'VC6?A
MIXW,&^[\)^*!!MC\YXT:XG\.ZR(XK'Q)ID>X75H(;VW1=6TS2KJU_![_ ((?
M?\G7_$'_ +-Y\6?^K)^$U?U/5_)OCWAJ&,XXQ^%Q-.-6A7R/):=6G):2C+"X
MSKO&2=I0E&TH3C&46I11_37@9G&9\/Y%E.=Y/BZN S/+,]S'%X+%47:=*M2Q
M.&:NG[M2E4BYT:]"HI4J]"K6H5H3IU9)?DK_ ,$[OVN_&FM:KKW[&?[4(N="
M_:9^#0GTFQNM<GS=_$OPMI$*20WT=]*0NL^(=,TIK:^DU"%Y7\6^%I;+Q?;R
M7[KKU['^M5?F)_P41_8PUKXV:3H7Q]^ \\WA?]J?X+>1KG@K6]'>.RU#QEIN
MC3MJ2>%+FY(\M]6LYO/N_"4]X);1KN>\T#44&F:W+=:?Z=^P5^V?HG[7GPOD
MFU:"'PW\:? #6^@_%SP,\<EG<:?K,?F6R>(=-L+D+=0Z%KT]I=-':S!KC0]3
M@O\ 0KQYFLK>^O\ \&RW$U\#B?[$S"I*I4C"4\JQM3?,,'3WHU);/'X./+"M
M&_-7HJ&(BG^\M_27&63Y9Q-D[\2^$L)2P>%JXBEAN.>&L*O=X3XAQ5W''X.B
MKSCPKQ%6]KB,MJ\OL\LS"IB<HK2II8/F^[:\GNCO^.FB <?9_A-XI+9_B^V>
M,/!^S;_N_89-^<??3&?FQZQ7DK?-\=80?^6'PEN=F._VKQC:>9NZYV_8XMF,
M8W2;MV5V_0GY*>M5^5'P@TGXF2?M3>-- ^$7PQ^,?P*^'6@^.OBS%^T]I_C'
MXK_#SXA?L\^+]?\ %VCZEXR\">*O@'X8@\>>-/B3\/?B#XPU?Q[X;^*OB+3?
M#OA'X&>!9]%USQ7'\1M'UWXAKX:E/ZKT4 ?B]^S9\//B[^R1IWACQ)XT\%?M
M%^#?AW^SK^SGXS\,?&P^*?VBE^-/P^_:(\9>'H/!UA\/KO\ 9;^"5[\:/B4/
MA\;^;PQXANO#.B)X7_9TN[=?&F@?#NW\'ZZMVT/A3T7QG\,/VA=1MOVB/@GI
M?P,U_7?#W[3?QT\)_%O2/C=J/C'X4P> /AEX/U?3OA-#XKT3XA^&;_X@P_%<
M?$#P(GPZUJW\.:7X \!>._"6O7MWX.D_X370+6?7V\+_ *N44 ?#]EJGQ;_X
M;6UKQ)+^S1\7X/AE<?"+3_A7;?%F3Q/^SDWA&?5-!\6^*?&7]OIH,'Q[F^**
M>&]6M]2LM&TMY_AW%KZZS-_Q-?#^EZ/'+K">6_"_XF?%G0/$GQO_ &F/VH_V
M8_C=\+-8T;X9ZG;^'K)?$7[.?C/P9X?^'G@S5Y]5T7X6> (OAQ^T)XS\=>/O
MC#\4]9U(ZW>:UK?@'P5HFKZG;>'? .F+I<F@Z;?>,_T3\4WNMZ;X?U34?#NG
M1:QK%A;B]M=(E=HSJJ6LL<]WIMM*KHL6H7]E'<6NF33-]FBU&6UDNE>V65&_
M/O\ ;H_;PTC]G_X7^&=-^$QC\:_'OXWV=I9?!GPI86C:I?6ZZY)'86WC#5-&
M1)+AH[2\N5L="T6YMS/X@\3JNE+:RVFGZ\]ARXW&8? 8:KB\3/DHT8WDTKRE
M)M1A3IP7O5*M6;C3I4XIRG.225KN/M\.</9KQ5G6 R')<,\3F&85O9TXN2IT
M*%*$75Q.,QE>7[O"X'!8:%;%XW%5I0I8?#4*DY2;=.%3\N_VR_BC\<-;\<?'
M?_@G-\!_ <OBWXI?M<_'/P[\6=1\>CQ!X?GTWX3_  Z\0^#/AC<ZIX3\9646
MJ7.K^&?'_@^;X>WE[K%UIUMK^@Z7X*?0=6TC6/[4UPP>%?H?X!?L-?%KX4_!
M[P'^QYI_P2E\-R^$_CEXE^*GQ$_;!N?$_P -;WP+\1--LY/'6H>"-2\'>'M+
M\>W?QOM_'$EKXF\+>$KCPUXG^'7A/PKX4MM-\;7MAXU\0.^F7OC+[$_X)[_L
M52_LU>$]7^)'Q3NF\5_M-?%XR:[\4/%VHW*ZM?Z,-5NAJTO@ZPU9VE:XV7S+
M?^*M2@F=->\0H'\^ZTW2M%:+]'*X<MI8FO\ \*.8THTL563^KX767U#"R=Z=
M.4I77UNI!J6*E348J4G2C=1F?3<98[)<L_XP_A#'UL?DF7S@LVSMJ%"/%.=T
MDHXK&TJ=%0D\BPF(C4I9%1QDJ]:5"E''U.6=>A;\TO@!X"^/.H>)?V2]!^(?
MP*U7X3:/^R-\)M?\$^)/'/B+QG\+O%.E_%'Q5-X%\.?##2S\'8/ /C7Q/XK7
MP3J%KH^K^+]3U7XJ>&/A;XAAM_\ A$]-7P?<:E<ZTGAW]+:**]@_/C_//HHH
MK_3 _@\_J>_X(??\FH?$'_LX;Q9_ZK;X35^R5?C;_P $/O\ DU#X@_\ 9PWB
MS_U6WPFK]DJ_@CQ,_P"3@<6_]CFM_P"HV6G]A\!_\D;PW_V*Z?\ Z?QP5S/C
M7_D3?%O_ &+.O?\ IJNZZ:N9\:_\B;XM_P"Q9U[_ --5W7PQ]:'@K_D3?"7_
M &+.@_\ IJM*Z:N9\%?\B;X2_P"Q9T'_ --5I734 %?%?[=_[.?CC]HWX.^'
MK+X4:]HGAWXQ_"#XK> /CO\ "&\\4I-+X2NO'WPXU"XNM.TKQ1';P7,YTC5+
M&_U*T,D<,@@OI+*>96MHIE/VFR[E9<LNY2NY3AER",J>S#J#V/-?AKXZ_P""
M4G@_P)H6O>//'W_!2?\ ;(\"^$-(5]1UOQ'XG^.6G>'O#>B6UQ=)%&]]JVJI
M:6%E US<06EN;B>/S9Y8+>/=++&C 'Q7X(_8\_X*P?&"+XL_L[_&/X4_"KX)
M_ +]I/\ :7U#]H3X_>/]/\3>%-=U7S]1UGPSK^M>%_ UEHOQ1\:ZRNAW4OAC
M2[CPU8W.@+J*:G$MOXA\:VMB;R)/ZFX8D@AB@CR(X8TB0$Y.R-0BY/<[0,GN
M:_F%B^!/[!HEC*_\%M?CL["1"J']IK1"'(884C9R&/'XU_3S %$$(25IT$48
M2=W$K3*$ 65I!Q(T@PY<<.26'!H _.3]L:X^"T'Q!\.77B&V_:J^'7Q^MO"<
M-I\%?C%^S9X&^+FOZIXLF36+_P ;W?PF,GP^\.>-_AQXUBAN/A^-5\2?#OX_
M^%;OP>GAO6+O6].2*UE\1:UH_P \:QX)^)UG\2/!'Q6_:Z\-?M)#5O&_[%WP
MR\)>);W]DF[_ &@7UG1_C_X \1>,-7\4>&_$$?[(]\^J6<>L6OCY=3T1]9NV
M^#TNNVFM0)>3OIND7=?LI>Z)HVHWVCZIJ&D:9?ZGX>N;J]T#4;VPM;J^T.\O
MM/NM)O;O1[N>*2XTRYO-*OKW3+J>RD@EN-/O+JRE=[:XEC?3H _+'Q8/BW\5
M_P!D/6_V*O'>G^*]5_:Q\4_L-2^*_%VLR7'AN?P_#XIOXI?".D^%_&'B[3]8
M_L^U\9>+O$&GZC:O+':-X:UN+1_%NH6/B":WTZX>O//VC/"'CC]NG1#9_##X
M=_%7P2_@_P#9+^/_ (<U.3XL_#3QW\%]0O/BC\8-#\#:;X4^%6DR?$SP_P"%
ME\46R2>$M;F\8Z]X<.J^!K*2#P\Q\4.;RV63]?[;1='LM2U/6;/2=,M-8UM+
M"/6=5MK"U@U+5TTN*6#3$U.^BB2ZOTTZ&>>&P6[EE%G%-+';B-)'!TJ /QN_
M:,\(>./VZ=$-G\,/AW\5?!+^#_V2_C_X<U.3XL_#3QW\%]0O/BC\8-#\#:;X
M4^%6DR?$SP_X67Q1;))X2UN;QCKWAPZKX&LI(/#S'Q0YO+99/99?B?%X_P#B
MI\,OVAG^'_Q9\!?#?]E[]G?XV^*OBG?_ !2^%?CCX1ZS'K_C'1O!$T/P^\.P
M_%#1?!T7C"32-,\$^)]6\2:SX=N-0\#6M_I_A@GQ66O;42?I96;K&BZ/XATV
MZT;7])TS7-'OD2.]TK6+"UU/3;Q(Y4GC2ZL;V*>UN$2:*.9%FB<++&DB@.BD
M 'YR6OQ#O/AQ^T!XX_:(UCX5?'W5? _[2W[,7P-O/!.G>&/@YX]^(GB7P[XQ
M^'5W\1M2U'X9>._#WPWT7QA/\.]?U'3OBAX>N+.^\5RZ9X.?4K;Q1;R>*%ET
MJYV^-_LY>$/''[$6MP7GQ3^'?Q5\5)\0?V2_@CX<M(_A!\-/'?QDT_P_\4?A
M1KGQ3U+Q-\*KN/X9^'_%+>$;9X_BGHD/A+7O$HTGP->QZ;KJQ^* --F8?LC1
M0!^1_P -?AKXW_95U3]BCQY\1?"/CS7=&\'?LP_$SX&?$FS^%'@;QG\8+GX<
M^.O&_B+X;_$[1XSX-^%VA>+O%]WX5CD\&>(O!3:_H.A:KH^F7EGX:M[^]MK&
M^L[V;[#_ &//"/B?PY\,_%FO>*]"O_"E_P#%?XU_&7XRZ?X2U:UDT[6?#7AK
MXC^/-6USPKI^O:3+^^T7Q%=>'7TW6O$FBW.+W2]?U74K+48K;48;NT@^K:*
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M=<:G"T/_  L;X4AHU@MM4TETE+F-EF-RZ*B.A@8R+)'_ %#?9/&7_0>\,_\
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M;?QP_;0_X7+_ ,)SIOPI\*?\*V_X5Y_9?_")^$_%Y^W_ /"8_P#"<_;?M_\
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M)XFFTCQ9"UCH?_$WFM;2;5],U&=M/5KFW^QI<H8O)-Q#^HE?DW\/_P!N?6-
MT7_@I/\ &;XS>--!7P/^R[\8_%'PW^'GPO\ L.B:%JVEV7@;0X8-%ENM0B#Z
M]J]]\9O%FJ6FE>'YM5>:U%Y82)HR10R75M; 'X"?'+X7_L_?!/XB_M%?LK6'
M[+OB74/VM-8_:V\,>,_V.=<MO"K:UX"N_A%K^O\ A+5/#_@_5-(UK6KBW\4>
M#(=#M?$>E:E87?AGQ+8:I-J;1:C=6LVD:C_9W]K-LKK;P+(D<4BPQ*\<(VPQ
MN$4,D2Y.(T8%4&3A0!FOY7?!GQG_ ."H7ACX):'_ ,%3_B)\=-*O_A/?>/\
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MEJO_ ,VM'V3QE_T'O#/_ (26J_\ S:U\:_MH?"'XW?$;5/A7XF^&-R=5\'>
M-/\ B9=?$7X?#]L3]H?]C ^*I]7T[PVWA+51\1/V>/"WB;6=6/A=]'U\C1O$
MPTS0E_MG[4]]&4E:/Y"^/'C^]^)7[/?P[_:H^$OB[X@>%? W@;]FWX6?&OQ5
M!'^V;\5?"GQ0^"/@5X_^$[C\3W?P$\/(O@3]J?QCXO\ "FEZSI#2_M+_ !H@
M\*>,)_"2Q^'TU@ZIXK/B8 _8?[)XR_Z#WAG_ ,)+5?\ YM:/LGC+_H/>&?\
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M ,*1^T?VCI-UJGFY_P"%N^5Y/V;6M'\C9B7S-_VCS=Z;?)\MO-_H%^R>,O\
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M#5?B\WQ*C^-<OP,M_&$7ARR\+^']?T*\TN/X#7/B./Q]96FAKI;>'-07QE
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MXD>#U/RI]EUN_P!GCG2K<'&]M*\7W(U^YV*$AA\<Z= "=AQZS0!Y#XT_9]^
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M]I/Y8?\ @N#_ ,G7_#[_ +-Y\)_^K)^+-?C;7[)?\%P?^3K_ (??]F\^$_\
MU9/Q9K\;:_O?PS_Y-_PE_P!B:C_ZDYD?QYQY_P EEQ)_V-*G_IC GZ&?\$I_
M^3^/@-_W5'_U3'Q$K^R2OXV_^"4__)_'P&_[JC_ZICXB5_9)7\]>/_\ R6.6
M_P#9.83_ -6.:'[3X-_\DQCO^QYB?_4'+PHHHK\-/UH_C;_X*L?\G\?'G_NE
MW_JF/AW7YYU^AG_!5C_D_CX\_P#=+O\ U3'P[K\\Z_T*X*_Y([A3_LG,E_\
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M+_H ^&?_  K=5_\ F*K_ #]:_P!#"O\ //K^F/H[?\U=_P!T+_WJGX/XV?\
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MGB-7FV4UW3SK)J].5.=+'8"%*-6"Q=1G]#OQ<_X*@>%OAOXU\7:5\(O!]O\
M'WXY?$?4-+\,>!/"?@K4M;UG3-*T/P]8SV_AE]5FLO#4-WKB:SX@U7Q/XITK
M1/#SKJFI:-JUJ]T^@P7%EJM[SOPV_P"">?Q^_:2\<:7\?_\ @H9X@M?&VH*H
MO/"_P!M?%=YH/AGPE:RNDL6E:VGA[1]6TVRLE"1-<^'_  S?"ZU"6&WN?%'B
M?5KJ34=/?^=3PE\1?B%X!\1WOC#P+X[\8>"?%FHQ7$%[XD\&^(M5\)ZS<6MT
MZ27%D;[PY<Z9-'82-%%FPA,=F!#"H@"Q1A?[%?\ @FEXO\6>//V)O@MXK\<>
M)_$7C/Q1JO\ PL?^U/$GBO6M2\1:_J7V'XM>/--LOM^L:O<WFHWGV/3K.TL+
M7[1<R?9[*UMK6'9!!%&O+Q;X,<0<-Y1@>(>,,URS&+$9A1PE+AK+%BYX/ UJ
ME'$XBG5QF,FJ5#-JT(X7WFJ<,+"I42HTJD:<JE3Z+A_Q]X6IXG&<+>$&29KE
M.*_LRK4S7Q)SU8/_ %IS>DYT*&)PF0X6"JRX.RNI+$NG%8:<L[QE&DYXW'X5
MUXX:A]5^'M'U+PCH>E^&?"O@;P'X;\.Z)9Q:?H^A:%KMUI6D:78P#$-II^G6
M/@6"TM+>,$[88(D0$D[<DD[/VOQE_P! 'PS_ .%;JO\ \Q5=-17R:2BE&*48
MQ248Q2C&*2222222222222222222\.I4G5G.K5G.K5J3E4J5*DYU*E2I.4IS
MJ5*E24ZE2<YRE.<YSG.<I2E.<I2E)_FO_P %2[CQ*_["'QT74-)T*ULS_P *
MQ\Z>S\17]]<ICXQ_#TQ^7:S^%].BEW2A$?=>0[(V:1?,9!$_\>]?V2?\%6/^
M3!_CS_W2[_U<_P .Z_C;K^O_   _Y([,O^RCQ?\ ZKLK/YF\9/\ DI\#_P!B
M/#?^IV8!7]Q/[)ESXL7]E;]F=;;1?#TMNO[/WP9$$L_B?4K>:2$?#GPV(I)H
M(_"-RD$KIM:2%+FX2-R46>4*)&_AVK^ZK]D7_DU#]F'_ +-Y^"W_ *K;PU7F
M?2&_Y$O#'_8YS#_U4TSO\%?^1KGW_8KP7_JRF>P?:_&7_0!\,_\ A6ZK_P#,
M51]K\9?] 'PS_P"%;JO_ ,Q5=-17\J']#GY0?M/?\$S/"_QFU\?%;X/1:1^S
MA\?=/O?[9T[X@?#WQ3K6G:7J6LJYE^VZ]H&E>%=*,&J3NTWF>)/#EYH^L//=
M2WNK?V_L6S;PWPG^WK^U9^R#XGT/X,?MZ_"J;Q-::IJ%OH?@G]H+P>S+HWB7
M>3#:#5)-,T>?3=>N7PKW#65EX?\ %MA:".?6?"E]<W#WK_8O_!5C_DP?X\_]
MTN_]7/\ #NOXV71)%*.JNIZJP#*?J#D5^@\%>"$N-LKQO$>2\1QX:S"CF5;!
M3PG]FRQF6YC.CA\+B5/'T:>+H*'M?K+I/$87#QQ5*WM4Z[_=O3/?I%2X;E@N
M">/N%UXA<.++(U<OQV(S-8+BOA>-:IBL/!\.9[/#5\3*CAIT*==Y-FV)QN3X
MJ,'A^3 \T:]+^WS]F7XN^&/B)\.-#/PY\7_"7X@:B]M>>(?%4?ASXEB_U.Q\
M1>)=3NM?\1_VQH]IX8NM1T>7^WM6O0(=0C20(T)$DJ21RR7_ -HW3OVIM:\%
MZ8GP!;X/Z;XF7Q-I5AXC\/\ Q,T.^^)W@7Q?X%\1NWAKQ/9ZYHB:M\(M4MD\
M-V6K_P#":BXTKQO'/J5MX;O/#9\/^(9-=M[2/^&*72;9SNB,EN_4&-CM!]=K
M9/X*RU_1S\#?"/\ P5C^"?P3^#_C;X,>-?AS^T=\*==^%7@+Q/H'PH\9"U@\
M1>%M!UCPGI&KV/AZUN]5D\*ZI+!H6EW,.DZ5;:7\0[V!TLU2T\/0Y@M9/F>,
M>$.,O#Z.&GQ/DU+%87%XFKA\+FO#6-I9I@ZWL:"KS]IE^)C@<[PU50:FX3P^
M(I<E^2M.HE!_2\,?\0N\276CX?>(U/+LPH8>E6K<->)V55N$\PIRJU?8QIX?
MB3+I9WP=C8.HG3A5J8G*YN7*ZE.G!RFOO/PM^R_^TU\)?@I\./@U\#_BY\#_
M  YH_AKPUX\T'QMI'Q&^#.H_$'X<^(9O'OB&3Q/++X"\">&/%OPKU'X::!X0
MNM1U_P ->!? ]WXV\>>$](\ 7^G>&=7TWQ#?Z':^(IMS2_V9-=U3X<Z%^RIX
MX\(VVN_LT_"7X=? C1? 'B*7XT_$3P=\9?$GQ$^%FKMK5EXN?Q_\)#X,U?P]
M:^%9/#'@"_TL:1I?A*]D\6QZQ+8QQ>'+#2;>;Y=\._\ !7[3O FKVWA#]L+]
MFSXO?L[>)7*PG5!H]]KWAN[9 /-U%+75+'PYK\6G2<O -$M?& 9"I2\F1O-'
MZ1_"#]J/]GCX^01R_"'XP>"/&MS)&)CHECJ\=EXI@B*EQ)>^$-773O%-@A4-
MAKW1[<$I(H.Z.0+\CA,YRS'2]GA\92==.TL-5<L-BHR_EEAL3&A74EV4)^5U
MJ=G$'AUQMPQ16+S?AW'PRV4>>EG. 5+.,CK4[Z5:.=9+6S7+)4I=)U,3AUK9
M\LDXKY8\'_\ !//P'H7A[4O#WB67XE^+@OQS\8?'3P?K_P#PV/\ M>:!XS\$
M:_XHTO7O#<<.D^/-/^(,WC@WD/A3Q/KN@Z]JT?B.S_X30:G=ZGXCTZYU&3SU
MU/"7[%FM^%/@1\%?V>4\52:SX#^&_P 3O#7Q'\=?\)'\0/B=XKU;XGQ>#=;N
M_&OAWPBFK>,=1\2ZGX0\+I\0;+P;KVK:)'>^(=!U+1O#FI>%XM%L(/%%YJ-G
M^AU>;:7JFHV/Q2\4>&=0O)[C3M=\-Z+XQ\+Q3N66V?3I6\,^,-.LU/,=I92#
MPCJC(C%#>^);N0I&[L\_IGQ1\[?'#X9_'OXYWNM>%((/A_\ #CPWX&O/A#\2
MO@WX]GOM2\6ZO_PO/P-XQU'Q?)J6O^&XH],M==^%UC::=X6T#5?"UPO@[Q1K
MS:IXL.C>+=!:VT#7X?()_P!C_P#:(NO$</QON?C%\+)/VJ+/XC6WC;3O'8^'
MGBL? ZRT"V^&VI?"0_#M/@9)XXE\8-X=G\):UK&LS:HOQ\C\4_\ "P;TZ_'K
M<?A:/_A!'_3&B@#\R](_8\_:*\"ZWI/Q5^&?QF^%^G?M":DOQ5B^*OC;X@?#
MOQ/XY^&?CFU^+?B?0/&.IV_AWX6:'XT^'WB#P$O@S6/"?AS3?AZ?^%L>*%L?
M"MK?:5XTC\=ZS>P>);#Z\^"GPW\1?!3X5^"?A=IL=AXEA\(:0+*Y\2:]XNNS
MK7B35[NZN-4U[Q#J:67@2VL8+S7-;OM0U6>UL;>"QLWNS:V4,5K#%&OO%% '
MA/Q0?QCIMAI/Q!@T#0OMGPWOI_$%VMEXDU2ZNK_PI/9RV/C+2A!_PB$#W"/H
MTC:U;6T;L\FM:#H\B0W$D"02>EPZCXLN88KBWT;PK/;W$4<T$T7C#4Y(IH94
M#Q2Q2)X+*O'(C*Z.I*LI#*2"#74NB2(\<B+)'(K(Z.H9'1@59'5@5964D,I!
M!!(((->2_#.[B\-:=XC\ :I<QVZ_#&[^S:?=7DRQQGX=WT,VI>"[^6>9@JVV
MDZ1'=>%+J[GD#3W_ (1U.]D$<<J@ TFVDDVVTDDFVVVDDDDVVVTDDFVVDDVT
MGF?%[XR0? SX;^+/BK\1H/"VB^$/!VER:EJ=T?%FIR7-PY=(+'2]-MCX-C-[
MJ^KW\UMIFDV*.K7=_=6\&] Y=?R+_9 ^%?Q3_;;^.\O_  4(^/GAC3SX.TF]
MFT[]FGX7Z_JU_9Z7HNGZ->.-,\40Q?V#JD>HV6B71N[BROY+>U.N^.)-0\3P
MPV-GI.C6TN%XGU#7?^"MO[4$?@;P_=:EI_[#'[.VO1WWB?7;5KBSC^+'BZ'S
M(5CLIHWC+MK4/VBQT%U(N/#O@R;5?$<LEIK'B73=*K][M'T?2O#VD:7H&A:;
M9:/HFB:=9:1H^DZ;;16>G:7I>G6T=G8:?86D")!:V=E:PQ6]M;PHD4,,:1QJ
MJJ /F:7_  OXV.)EKDN75V\)%KW,TS"C)Q>,DGI/!8*:<<*FG"OB5*O[T*=-
MG[1C6O"GANKD])J'B3Q?EL5G]:+7UC@GA3,*4*M/A^E--RPW$?$>'G3KY[*$
MH8C+,GG0RIRI8C&XN*R_M?C+_H ^&?\ PK=5_P#F*H^U^,O^@#X9_P#"MU7_
M .8JNFHKZ8_%C^=3_@NK+K,O_#+7]KV&F6.W_A=WV?\ L[5KK5/-S_PJ+S?.
M^TZ+H_D;,1>7L^T>;O?=Y/EKYO\ /U7]#'_!>;_FU3_NN7_O'J_GGK^Y/![_
M )-UP]_W5/\ U<8\_DOQ-_Y+;.O^Z?\ ^JS!GT#^R89E_:I_9G:VCBEN%_:!
M^#)@BGF>WADF'Q&\-F*.:>."Y>")WVK),EM</&A+K!*5$;?W$_:_&7_0!\,_
M^%;JO_S%5_#W^R+_ ,G7_LP_]G#?!;_U9/AJO[JJ_(/I#?\ (ZX8_P"Q-F'_
M *MJ9^E^"O\ R*L^_P"QI@O_ %6S.9^U^,O^@#X9_P#"MU7_ .8JC[7XR_Z
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M;PR_Y(G)?^ZA_P"K/&',_:_&7_0!\,_^%;JO_P Q5'VOQE_T ?#/_A6ZK_\
M,57345^9GWA_"A^UF9F_:I_:8:YCBBN&_:!^,QGB@F>XACF/Q&\2&6.&>2"V
M>>)'W+',]M;O(@#M!$6,:_/U?0W[77_)U_[3W_9PWQI_]63XEKYYK_1W)/\
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MZFL["28%-K%GM(2&+*%8*';!\:_\B;XM_P"Q9U[_ --5W735S/C7_D3?%O\
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M^R3_ ()3_P#)@_P&_P"ZH_\ JY_B)7I^/_\ R1V6_P#91X3_ -5V:'!X-_\
M)3X[_L1XG_U.R\_0RBBBOY!/Z6/SS_X*L?\ )@_QY_[I=_ZN?X=U_&W7]DG_
M  58_P"3!_CS_P!TN_\ 5S_#NOXVZ_K[P _Y([,O^RCQ?_JNRL_FGQD_Y*?
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MVM]-MT\#>,-9^''C7PEJ7CWPL1I5M,= \:W&O:0MU+J%S%91S:KJ3W>SX_\
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M_P FH?#[_LX;PG_ZK;XLU_+#7]H^!O\ R;_#?]CG//\ U)P9_+7BU_R65?\
M[%>4_P#IC$A7^@5_;VJ_]"5XF_\  OP;_P#-;7^?K7^AA7PWTB?^:1_[KO\
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M^_[-Y\)_^K)^+-?C;7][^&?_ ";_ (2_[$U'_P!2<R/X\X\_Y++B3_L:5/\
MTQ@3] _^"6EQ+:_MW_ N>"RNM1E3_A9VVSLWLTN9MWP<^(2-Y;:A=V-H/+5C
M*_G7468T81[Y2D;_ -@_]O:K_P!"5XF_\"_!O_S6U_(#_P $I_\ D_CX#?\
M=4?_ %3'Q$K^R2OYZ\?_ /DL<M_[)S"?^K'-#]I\&_\ DF,=_P!CS$_^H.7G
M,_V]JO\ T)7B;_P+\&__ #6T?V]JO_0E>)O_  +\&_\ S6UTU%?AI^M'\:7_
M  5+N);K]N_XZ3SV5UITK_\ "L=UG>/9O<P[?@Y\/47S&T^[OK0^8JB5/)NI
M<1NHDV2AXT_/ROT,_P""K'_)_'QY_P"Z7?\ JF/AW7YYU_H5P5_R1W"G_9.9
M+_ZKL.?Q;Q3_ ,E/Q%_V/,U_]3JQ^PG_  1.N[BR_:I\?RVVEWVK.W[/WBJ,
MVVGR:9',B'XC?"EC.S:KJ.F6YB4HL;!)WFWR(5A9!(\?]0W]O:K_ -"5XF_\
M"_!O_P UM?S#_P#!#[_DZ_X@_P#9O/BS_P!63\)J_J>K^5/'+_DX&)_[$V1_
M^HV,/Z'\)?\ DC:'_8TS;_T_ACF?[>U7_H2O$W_@7X-_^:VC^WM5_P"A*\3?
M^!?@W_YK:Z:BOR _2S^-+_@J7<2W7[=_QTGGLKK3I7_X5CNL[Q[-[F';\'/A
MZB^8VGW=]:'S%42IY-U+B-U$FR4/&GY^5^AG_!5C_D_CX\_]TN_]4Q\.Z_/.
MO]"N"O\ DCN%/^R<R7_U78<_BWBG_DI^(O\ L>9K_P"IU8_H%_X(57]U8_\
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M?_5E *_LD_X)3_\ )@_P&_[JC_ZN?XB5_&W7]DG_  2G_P"3!_@-_P!U1_\
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M\+O%7AKQ5XCU?QE>_"7XV?&?X-:9XPU^_DU?7_$?A?X<^/M7T3PE>:_KD_\
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M^'/Q60A;G5=,LK=Y<R*5@25IF0/(L92.1D_EYK^I[_@N#_R:A\/O^SAO"?\
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MG6"":YF9(_B-X;=A#;6T<MQ<2D*1'!!%)-*^(XHW=E4_W$_\);I7_/IXF_\
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M<,?]B;,/_5M3/TOP5_Y%6??]C3!?^JV9S/\ PENE?\^GB;_PBO&7_P H:/\
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MZ&*_B[QA_P"3B\0_]TO_ -4^ /ZE\,O^2)R7_NH?^K/&',_\);I7_/IXF_\
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M]5_1Y_Y$O$__ &.<O_\ 534/YX\:O^1KD/\ V*\;_P"K* 5_9)_P2G_Y,'^
MW_=4?_5S_$2OXVZ_LD_X)3_\F#_ ;_NJ/_JY_B)7I^/_ /R1V6_]E'A/_5=F
MAP>#?_)3X[_L1XG_ -3LO/T,HHHK^03^EC\\_P#@JQ_R8/\ 'G_NEW_JY_AW
M7\;=?V2?\%6/^3!_CS_W2[_U<_P[K^-NOZ^\ /\ DCLR_P"RCQ?_ *KLK/YI
M\9/^2GP/_8CPW_J=F 5_=5^R+_R:A^S#_P!F\_!;_P!5MX:K^%6O[JOV1?\
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M?0W[77_)U_[3W_9PWQI_]63XEKYYK_1W)/\ D2Y+_P!B;)__ %4Y4?P]FO\
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MX&_\$&?^;J_^Z&_^]AK^ABOXN\8?^3B\0_\ =+_]4^ /ZE\,O^2)R7_NH?\
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M^JV\2U_"K7]5_1Y_Y$O$_P#V.<O_ /534/YX\:O^1KD/_8KQO_JR@%?V2?\
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M^R+_ ,G7_LP_]G#?!;_U9/AJO[JJ_(/I#?\ (ZX8_P"Q-F'_ *MJ9^E^"O\
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MN_\ 5,?#NOSSK]#/^"K'_)_'QY_[I=_ZICX=U^>=?Z%<%?\ )'<*?]DYDO\
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M *:KNOACZT/!7_(F^$O^Q9T'_P!-5I735S/@K_D3?"7_ &+.@_\ IJM*Z:@
MHHHH **** "BBB@ HHHH **** "OSM_:K^,7CH_&CP'^S;X6^,/PR_9HN?%?
MA[PI\2_"'Q,^*6G^(=27XO>-_#OQ9T"*U^ W@.'1_B7\)+<W>H-8:59_$32Q
MXC\2:_XI\&>/H?#^A>$"ESJ.L6OZ)5\6_M1V_P ;?%-W:_"/0/@)\"?CO\)?
MB]I+>&[U/BSKGC'2]+\!>*-'T[Q3XIF\2?$+1]/^$GQ4\->)?!9ET7PHGA5&
MO/!6M0>.EM=.AO)FU6RUKP\ 4/%'Q9_:.\6?$[6_@G\'[KX'^%/'?PM^"?@K
MXD_%?6O'GA?QS\2?#&I^-_B-/XFL/"?@'P38:!X\^$VK:5HGVCP)XIU#5O&^
MO7.IWUMIMYX;CM_!%Q<7-]);_0GP"^+%M\=/@O\ #/XO6VD2^'Q\0/"&D>(K
MKP_-<_;9O#^J75N%UC0I;S[/:&ZDT;58[W3'N&M+1YFM3(]K;.S01_''@?\
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M\&_]"EX9_P#!#I7_ ,B5^F>'7B+_ *@_VO\ \)']J_VK]1_YCOJ7L/J7UO\
MZA,5[3VGUK^YR<GVN;W?@^-N"?\ 7'^S?^%+^SO[.^M_\PGUKVWUKZO_ -1&
M'Y.3ZO\ W^;G^SRZ_P"?K7]3W_!#[_DU#X@_]G#>+/\ U6WPFK];/^$*\&_]
M"EX9_P#!#I7_ ,B4?\(5X-_Z%+PS_P""'2O_ )$KW>.?%[_7/A^KD7^K_P#9
MWM,;@<7]:_M3ZW;ZE5K5/9^Q^H8>_M/:VYO:+DY;\LKV7D<)>&O^JV<T\W_M
MGZ]R87%X;ZO_ &?]6O\ 6J=*'/[7ZY6MR>SOR^S?->UXVN^FHKF?^$*\&_\
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M[K^-NO\ 0*_X0KP;_P!"EX9_\$.E?_(E'_"%>#?^A2\,_P#@ATK_ .1*_7^
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M-0_9A_[-Y^"W_JMO#5>P?\(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\
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M%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\ !#I7_P B5\AXA\>?Z^XW+,9_9?\
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M?_(E'_"%>#?^A2\,_P#@ATK_ .1*_IC_ (F)_P"J1_\ ,[_^"C\'_P"()_\
M52_^8C_\(GY)_P#!#[_DU#X@_P#9PWBS_P!5M\)J_9*N9_X0KP;_ -"EX9_\
M$.E?_(E'_"%>#?\ H4O#/_@ATK_Y$K\$XFSK_6+B#-\]^K?4_P"U<;/%_5?:
M^W]ASTL-3]G[;V=+VEOJ]^;V<+\]N7W;O]AR'*_[$R;+<H]O]9_L_"QPWUCV
M?L?;<M2O/G]ESU.2_MK<OM)_#>^METU<SXU_Y$WQ;_V+.O?^FJ[K>M+.TL+>
M*TL;6WLK2$%8;6T@BM[>%69G98H852.,%V9B$4 LS,>236#XU_Y$WQ;_ -BS
MKW_IJNZ\(]</!7_(F^$O^Q9T'_TU6E=-7,^"O^1-\)?]BSH/_IJM*Z:@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\EW:Q7%O:2W-O%=78F:
MTMI)HTN+I;94:X:WA9A),+=9$:8QJPB5T+[0P)\;^-7Q]\"_ K3_  _-XIM/
M&/B/Q!XOU&ZTOP;X ^&O@OQ#\1/B)XNNM.M?[1UJ30/"'A>ROM4N=/\ #^EA
MM3U[5IX[;2M*M3 EW>I=W^G6MY^=?QO^$'P8^-/[.G[0/[=O@OQ9>>./BDG@
M;Q1\;/V>?B]/:ZMX?\3_  /?X*^#S?\ ASX;^&+*XN$N?"UGIOC;P;XBA^)&
ME2:5I>J:YJGB'Q1I/B_3[RXM(DC /V HKP[X0?'WP;\;-0\76?@:VUK5=,\#
M'1-+UWQM%96__"!7GC*_MKFYU_P1X9U_[:TOB+7_  (8K6V\;/I]C)HNAZGJ
MEKH)UBY\0V/B#2=%]QH **** "H3<6XN%M#/"+IH6N%MC*GVAK='2-YUAW>8
M84DD2-I0NQ7=$+!F /S_ /'']IWX8_ &;1].\6P^-_$GB76],UCQ#9^#/AAX
M"\4_$OQA#X2\."#_ (2/QKJ>@>$=-U*\T?P?H375K!?:_J@M+*2]N8--L'O=
M2E6T/PA\7?@K\*]&^%5K^W1X&\6M\0/C/-\8?AW\<?!W[05M/?6FJZK\*/'/
MQ@\.VUA\(;+=?W)B^%,'P1\42?#=/"FZTT[4)(G\4ZAIUCXAOKXQ@'ZZT5Y)
M\)_C1X/^-<'BS5OA_'K.J>$?#'BB\\)6/CN6QBM_!WCO4=)CCCUZ^^'NI_:Y
M)_%'AW0]7-SX<N_$L-E;Z'?:[INJ6VA7VKVUC-=CUN@ HHHH **^9OC%^UW^
MS]\#_$]EX%^(WQ'MO"_BG4K'3K^8_P#",>+?$NC>#--U^_GT7P[XD^).L^&]
M(OM"^'OAO6-=A?3=+U7QSK7AC3]5N8+M;.^\BQU&ZLOD74?@C9_LE>,?V6_C
M'_PL;Q-JWQ#\:?$R/X9_M5>/_$?C'Q$_AGXQ:=XV^&OQ UN_\3^(/#^LZU>>
M'/"]MX/^(FA:%K'@-=)MM-L_!?A<77A6&4:'+)&H!^J=%>=?"KXH^%/C+X*T
M[XA^!VU:X\(ZW<ZHGA[5M6T;4-#7Q%I>G:E=:=:^)M$M]3AM[F^\+^(8[8:M
MX7UM85M==T*[L=7LB]I>0NWHM !1110 45\C?&3]KSX,?#OQ5J7P?U/QYJ_A
MCQW=6VCZ%>^-+#X=>+?&?@+X/^)OB+"UA\,[CXJ^*],TJ7P5X-N?$.I7-E=Z
M'H_B_P 0:,VJ6C6UU>/8:1?VVHR_,E[\'?A9^P[\8OV8_B%H/B.X\,P?$:3X
MF_#/]ISXB>+?%&I21?%6+P]\"/B+\;HOBK\4+S7]6N;&7Q7H_B+X5:G>1>*'
M9+S3=*\3ZOX?AD70I+:TL@#]5**X3X9?$#2_BIX%\/?$+0])\3:+H?BFVN=1
MT2T\8:'<^&M?N-&%_=VVE:S<:%?-_:&FV?B*PM[?Q!HUOJ<5GJO]BZGI\FJ:
M=IFH/<Z=:]W0 4444 %5X+NUNC<+;7-O<M:7#6EVL$T<QMKI$CE>VN!&S&&X
M2*:*1H9-LBI+&Y4*ZD_%WQH_:I^%#:WXO_9WM?&_Q"\">+O$K+\&_P#A>'AS
MX<>)]9^'/PE^+?Q)\/\ D^!M#U;XCBPC\$Z=\0S+K>@ZAHVA7FKA8=4U7P]8
MZO/I]QJEO"_R%X[^#_Q&_8@\0_'OX^?LO^#_ ()?![X,> _@UX6B\2:!\3=8
M\6:X/VCO$WA7^UO%>I^(+&V\,>+--;PK\1-2&L6_PUT7Q_XT'B;Q3XK\62ZD
MM_X-U;2[O0=9O #]EJ*R]#U&;5]%T?5KC3KO2)]4TO3]1GTG4%5;_2YKVTAN
M9-.O57*K=V3RM;7*J2HFB<#C%:E !1110 5#!<6]U&9;:>&XB$L\)D@E2:,3
M6T\EM<PEXV91+;W,,MO/'G?%/%)%(%D1E'PE\4OVC?@M\8M7U;]ES3OB%\1O
M M_X^\53_"=/BUH?@?QGIO@#6O%GAS5X;SXE_!3P;\9%M=-\,0_$W4_"FC^*
M_"?FZ-KWV_P_JKZFNCW%YXO\.S:$GS/J'@_XK_L):Y\8_BK\$/AY\&OAW^SA
MK7Q&^"_A?3OV>M1O?$=]XN^)%^VJVG@35_%WPD/AOQ,/!_P\\=?$:Y\3Z?;Z
M7X?U'0_&&H^-#X0T6Z\1Z=X4U>\OY) #]BZ*** "BBD) !)(  )))P !R22>
M  .IH 6BO@C6?C%\ OVU-3M_@)\/?C?J<=I9ZROB[XBZ'H>D>/\ P>WQI^$/
MA[^U=%US1/AU\1I;3PO9>)? ]]X[N_#%AXT\5_#/7O$5G=:!9ZIX6N+BVL_%
MEOJ(\4^"&M?'?]D_5_ _@+Q!\-M TK]G+XR?M+^*O 7PA\':Y\5=<\5?'KX6
MZ!XMM=;UKPE =(ELM=\,7_@JSE\+ZSXBU#PWI_C_ %K6?!7AKQ#)>37TMOX?
MOM+MP#]8J*** "BBJ>H:A8:387VJZI>VNFZ9IEG<ZAJ.HWUQ%:6-A864+W-Y
M>WEU.\<%M:VMO')/<7$SI%##&\DCJBD@ N45^>MS\2OV??V]=5TGX1Z?XL\8
MR>$= 8?%#Q?\+O%7P^\>_#W3OVD?A5+I>J^'_#FK:%J/BJT\*/XV^#4?C;5-
M&UJ_OM"75=#U_4M'T'3=:5-#U:W_ +5\M_9QU#]H#]EK6OV?_@7XW\'?#[2_
MA-\;/B/\9-&^&OPRL?''B'QC\:/@3X833_'?Q=\*:+K&L2RZAX0\2^!/A[X9
MTFP\ :_'X?U&\L?".K:WX:M-$\5>(='ETZWD /U<HHHH ***PO%'B?P]X)\-
M>(/&/BW6+#P]X6\*Z-J?B+Q'KVJ7"6NFZ-H>C6<VH:IJ=_<R$)!:6-E;S7-Q
M(W"1QL<$\$ NZKJVEZ'I]UJVMZEI^CZ58QB6]U/5;RVT_3[.(LJ"6ZO;N2&V
MMXR[H@>61%W,JYRP!T*_+?\ :#^,7PG_ &ROV7_VE_AGX;\+>,I?&/@;X>:-
M\9+?X4_&'X;>+/AUK7CS0?!>L6?Q*\$ZMI&@>,-,TV\U_P "^.M9\#GPK)J5
MI$\<4UU/I>MV]A)=107'*?L8?&OXI_\ "R="^%O@6#QC\9OV&+X>*]*^"W[2
MVO\ A;6M9\06NHZ+H&F:W:?"K6O%:Z\DNJ^ O!0A\2^&/#_QPU_P]>:9XLUK
M2[/X<KK%[K^GIKVL 'ZYT444 %%%<7\1/B'X-^%'@KQ#\0_B#KMMX;\'^%[)
M;[6=7NH[B<0I+<0V5G:VMG90W-_J6IZGJ%U::7H^D:;:W>J:QJMY9:7IEI=7
M]W;V\@!TNHZKIFD0PW&K:E8:7!<WUAIEO/J-Y;V4,^I:K=PZ?I>GPRW,D22W
MVI7]Q;V5A:(S3WEW/#;6\<DTJ(U^OR6_:R^(7P/_ &N_V8?'UY=Z'XR@B_9L
M^*7PI^(OQ<^&?Q*\'^+OA;\0/#'@^QUJUG\5:M?Z'KEMH_B+1(M5^"^M>.?$
MG@7QCI;[+;4]/M]3T^^AU30KR&R[3]BCXU?'C7O&5Y\,/&MAXH^)'[/UIX<\
M07?[.W[5VK^#=3AU7XX^&_#VM:/807?CS5+/4?[,T+4--T_4&LO#/BW5_#FD
M6_[06EVY^(OAA[*V@G3Q" ?IK1110 445YO\5OB[\//@EX1F\<?$SQ"GA[P_
M'?Z?H]JT6G:MKFL:UKFKS_9M)\/>&O#7AZPU7Q'XH\1:K/NCT[0?#VE:EJUY
MY<SP6;QP3/& >BM(B&-7=%:5S'$K,%,CA'E*1@D%W$4<DA5<D)&[XVJQ#Z_(
M;]K[7?@O^T/X1_9:_:5\-?&C6OA_X$\"?%KQSX6D^,VE7FJ^"]3^!OB7Q%X.
M\1:;I_BWQ7X<\50Z.=/U/PM\5?!7@WP-XL\'_$'2+.*[\+^,_$^B:C!!::R7
MG^B/V'_VE?C!\>M'\5Z7\;/AA/\ #[Q-X1L?"5]X>U^'P[XYT30OC!X+\06V
MJ1Z3\7M!MO%7A[2XO#6D^-+C2+N[T[P#>:E?>,?"T4<T'B>VLVELO- /O&BB
MB@ HHKR3XQ?&[P#\"_#VG>(/'5SKDLFOZU!X9\)>%_"'A?Q#XY\=>-O$US9W
MNHP^'?!O@KPGIVK^)/$>K'3=-U'4YX--T^9+'2]/OM3U"6TT^SN;F( ]2EO;
M.&YM;*:[MHKR]$[6=I+/%'<W:VJH]TUK SB6X%LDD;SF)'$*NC2;0RDV:_%W
M]LK6_@;\:K;]E/\ :]T7XQ:]\-/"FBW'QF\!>$OCGH-IKMEX@^$'Q*OM"/BS
MPY?ZQX$U&T@U&_U&'Q5\%O$'P;\5?#'7=#-UXNE^(%UX#N]/;5=3T2>Q^T?V
M*?CA\>/C+X)\21_M(_"#4/@W\3_"=]X9ADT5_#GB'2]&\0^&]>\'Z/J>E^,-
M+U?5);S2KFZUW55\03ZMX.T_4)]<^&<B6GA#QA"-:MO[0U, ^T:*** "N9\:
M_P#(F^+?^Q9U[_TU7==-7,^-?^1-\6_]BSKW_IJNZ #P5_R)OA+_ +%G0?\
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M:** "O"/VF/C%<? 3X*^+OBA9Z78:M?Z-=>$-$TVWUF]ETSP]::IX[\;^&_
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M;U+Q,-5N[6O\&O@I\4QX_P##WQI^._Q:\/?%7Q5X4^'/B+X=?#6X\+?"6_\
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M:HNC:QXS\>:QJ7B/7M>\5ZGJ>N:G=:^FFV\<6GZ=H.C:5!#?2ZE]0T %%%%
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M\'?A-\8/V>O WQE\16]Y\"=)M?%5O^TOH[?L\_%F\TV+QW8:O?\ B-_ FO\
MQ \/^+? 47CS3/@_)X5\/WES91:;I=CXVU+6I+>"_P#>/C?^S7\1OC?XN\5Z
MS=_';XD_#;0M"\'Z/:_ G2?A%XY\0>!6\/?$F-=<N]<^(/Q&M],BBM/'K/>S
M>&]*T?POX@DUOPC!X?T[6([G03?Z[>7#?*WP9?7_ (DWGPN^+/[-?QT\'_"?
M]H#]H;]G+X9_'S]HOX,^)?AGK_Q.^#VOWGB7PIX;TV/XIWF@>'?%'@5_AC\2
M)M5OY=,TN[A\::8/BKI?AV:XO?#/B1/"&L:W8 &_XV^('BOQE^T;I7B?]F/P
M'9?$VP_:K_9#\!Z=I/Q-\0:+?3_ _0O#FB^/_'&J#QA\3W9;&36O[#\,_$*]
MAL/AQ%+#XK\3ZGK%EX9N1X?TEM;US1?U-L+=[2QLK65K9Y+:TMK>1K.U%C:,
M\,*1NUK8B:X%G;%E)@M1/.+>(K#YTNS>WF7P-^$NE? SX4^#OA9H^IWFMVWA
M:RO!=:W?P6MG<ZWK>M:MJ'B+Q)K+V%BD=AI<>K>(=7U34+?2+!$L-(M[F+3;
M%1:6L(KUB@ HHHH R/$.M6GAK0-<\17\=U-8Z!I&I:U>PV-NUU?2VFE64]]<
M1V=JI5KFZ>&!UM[=65IIBD8(+ U^7UU^T9XX>P^ '[3_ .TA\%OAQ<_LUZO<
MZ'\3OAW\2/AOXN\5>)O%'[,=Y\1?!^J>'/#GBCXT:->:=IV@>)?#][X/\=W>
MC>(_'7A02Z3\.]5U34#/I%_IEM9>,CT'[4/A;]HOP)X5^._[69^.7C/0K_X&
MW5[\0OAK\&O".I:>?@WKGP2^'&E6&L>+/#OQ*\-7>A#4/%7B[XA:1;^-;G4-
M>GU6WN/!]]<>&X/"]Q!:>'Y;C6,R#X!^,]$U'XV?LV?LN?''X12_!+Q+H]Q:
M?$/X*_$?PYJ_C35?V9[?XS6>N3WW_"J)_#VL:?IUSX<\5:5/K.N:+\'O'/D:
M5X;N9[+6M.U2#POK4>@ZB 9VF:GK=]^U1^U3^SUX'^$/A_Q[I'COXT_ WXT>
M.M5^)'AJ74O@GX"\'M\)/A'_ &]XKFMY5CLO%/Q(\6Z_X$4?#OPYHL@N(_&>
MEW_C[Q)?6&F^')!JOZN5SO@_PS8>"O"7A?P;I4MW/I?A+P[HGAG39K^9;B^F
ML-!TRUTJSEO;A8XEGNY+>TC>YF6*-99B[B- VT=%0 4444 <3\2_&]E\,OAS
MX_\ B1J5A?ZIIWP^\$^*O&]_IFE(LNIZC9>%-"O]>NK#3HW*I)?WD%A);V:.
MRJ]Q)&K$ DU^>H^./Q3\#ZK\%OC_ /M5?#[X,ZW\(/$UG:?\(9\:/@M=>+[B
M3]FV;XPV6CV]C:?$V#Q-J5_9^*_ _B.&71_#]Y\;/#,/AZPTV^DA.J^!]!T+
M56U0'[0'P[^-'PRTKQA^U=K7QW^(,_BKPC\8=&U*S^$FB>+=4;]GV[_9RN/B
M5I7@R3X=:[\,[RPCT35O%6N_"K4KKQ+XA\;7.F77B72?B5>R6_A[6IO#FC:8
MMQB6O[-6L:_I_P =/V6_V?\ ]H7P3)^RYJM[K/P\^*_PK\4>!M8\<>+/V?X_
M&^BQZAXM^'/P1\=0^)-,\-V5KJ&B:U*^F>$_%>F>)S\'KO5K.\L(I8$LO#0
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M>./$&F^(]>LI-;\8)'K&IW_A>/5-7MM+TJ;PU'XBN]2\8Z5/<:7]C4 %%%%
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MM_++J]_%/J=Q8VE[)H.CZU?6J72O#IUW.8;:7R3]J_X]>//@CX1TZ_\ @]X
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M32Y]>U+Q-9^ =(UMK"SUO4?!G@^YU3^RM%DU,07.KKI\?B#5+.'6+^["^OT
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M[XV>+O&'B[QMX_\ C?X$NPWC?XA_$GP4_C2]T+P%KWAFR\1V]SX$M;71;5/
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M >1?!KX^>(M;_:D\4?&[3_"7B'Q#XMUK1M(^$_QQ^!-CXEN/B1J'@WP1X?\
M'5]X5T#]HG]C_P 5S:5H4/Q9_9ZN_&,.HV'Q;\.^'-*L=1\/^)H=1\0QV)U"
MR;3-<_4#PU^S/\"/!WQ:\2?'3PO\-/#^B?%3Q;'?KKWBFR^WH;JXU<6 US5+
M;16O6\.Z5K_B)=*TU/$WB/2=(L=>\21V%I'KNHZA'!&J^=?LZ_LC>'O@/-IF
MJZQXUUWXP>*O"?@3PQ\(_ASXJ\;^'? NF:I\.?A#X+BU&#PYX'\,KX/\-:!!
M#+-%JDY\7>)I4?6_&<MMI*ZQ,;/1=*LK/ZYH ***I:GJ>FZ+IU_K&L:A8Z3I
M.E6=SJ.J:IJ=W!8:=INGV4+W-Y?7]]=216UG9VEO')/<W5Q+'!!#&\LKHBLP
M +M> ?'+XYR_"4^&O#_AGP)JWQ1^)7C2S\4ZOX9\#:7KOASPG;#PSX$M=,O/
M&_C+Q/XP\6WVG^'_  MX3\-#7/#VG7FIW<EU/-KOB?PYI5K8RG49;FS\YC_;
M<^#'CCPUX\N_V<_$.@_M'_$#P'H]GXFF^$G@/Q)I^F^-_$WA@:A8)J^K^#+7
M7X[2+Q/':Z//>WNC3:69]'\0ZS:V?AF'6;*_U2&:+XN^*/BBV^,2:?IOP8^*
M'B7XM_ O]O\ 7Q-\-]9\*6]W:>(/B1^SEXUM_#*'Q-X[\/Z#XQU&RNK?X5Z.
M-%T[1/V@/@5XDFTT>&M0FADT".T;7-1\.W0!M? ?XEV_Q"^)^L?M1? BT\3?
M&WX0?M(R^ /A5^TA\'/%]_:ZM\5_V:_$.GR:Y)X6UG1M/U75[S3M4^"]XGQ"
MU;5?%?A*RO[_ $FVT'Q##\2OAKJ.L^#)[W1K;[Z^"'[,'P<_9WN?$UQ\*]#U
MG1H_$J6%D-/U3QAXL\3:1X7\.Z5>:OJ6E^#/ 6D>(]9U33O G@K3=5\0:]JE
MGX6\+6VEZ1#>:M<L+<Q164-I4^ _[/Z?"B_\<^//&.O:)\1/C?\ %._TFZ^(
MOQ1TSP+IW@!-5TWPSH6F>&?"'A/0_#EIJGB&?0?"'AC1M)A.G:/<^(];E?6+
M_7-:N+Z2ZU:58_HV@ HHK!\4^*O#7@?P[K7B_P 9:_H_A;PKX<T^YU;7O$7B
M#4;32=%T;3+1#)<WVI:E?2P6EG:PH"7FGE1!P,Y(! -ZOEO]HG]H[4_@NUKH
MW@WX;O\ %#QA_P (AXI^)>O6%]XX\.?#'PAX-^&/@=]/B\2^+_%WQ \5I/H^
MC[KC4[6Q\/:6UK-+K-U'J5Q=7.CZ)HVL:S8^:ZC_ ,%&_P!F)=)N/$'A?Q/K
M/C?1O#6KZ,GQ1.B^&M;TGQ!\*/ FMI?0P_&#Q3X(\86/AKQMJ/PKT_5HM-L-
M<\7>$_#_ (AL=(M=536[D_V59W=PGAFL6WC_ ,7^)->_8A\7_$GQ9\1O!?Q@
M\.Z;\>/V>/VGO"^BZ=XYUCP-I'A;QUIOQ!T/PG\<HH;"7P=KWAB/Q!X;L['P
M;XPOQ;^'/B=X3F?P!KYMM>NK.[UH L?LWZM;^(O''BGXK?![2/$7QA_9\_:O
M\3RZ;^T#\,OB3=&;XM_LO_%N/0YK/6])\5:!X[U)I[SX7:A8S+I'B?X<74MS
M=>#WO=*UKX>P>(?A[KT6F6'W-\$?V;O@W^SI8Z[I_P (?"D_AJV\136#:B+S
MQ+XJ\42QZ?HPOE\/^'=)N/%FMZW/H/A'PS%J>HQ>&O".B2:?X;T%-0OSIFEV
MTE]>23L^!OP+TKX.67BG5KW5(/&OQ4^)6M#Q-\6OBK/X;T7PUK7C[7(?M$.D
MK<Z?HD0M]/T#PMI<_P#87A+0_M-]_8^DQD37VH:E=ZEJ5][M0 445QWC[X@^
M!_A9X3U?QU\1O%6A^"_"&A0I-JOB#Q#J$&FZ;:B65+>VA\Z=E,]Y>W4L-GI]
MA;+-?:C?3P65C;W%W/#"X!V-?''[2'[6LOP(O];T_P /_"G7?BE)X"\$:3\4
M/BO=6/BCPSX,T[P5X#U_6];\.>&8M.OO%,\,'C#XC>--9\-^(;+P3\.]*:WN
MM;FT:X@N]8T>ZU'PY;Z[F:Y^W5\*;OP/JWQ&^#\=U\</#GP[\4Z78?'?1O"
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M^$C\;>*+F"WCUOQQXSO].LM/AUKQ?XDGMTO-;U8VD GFV06T%K86UG9V_J%
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M'U+!!!:P0VMK#%;6UM%'!;V\$:0P000H(XH88HU6.***-52.-%5$10JJ% %
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MGZ]HMY=:1J5E<2_0444<,<<,,:10Q(D4442+''%'&H5(XT4!41% 5$4!54
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MJTO$OH].UC3KN!HTU#39VBNHHX+ZQNI;6:"0^J4 %%%% !37#,K*K%&*L%<
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MR:7I6FZ;)J5U)?:C)86-K9O?WLK,\MY>M;Q1M=74KN[R7$YDE=G9F<EB3HT
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MH **** "BBB@ KF?&O\ R)OBW_L6=>_]-5W735S/C7_D3?%O_8LZ]_Z:KN@
M\%?\B;X2_P"Q9T'_ --5I735S/@K_D3?"7_8LZ#_ .FJTKIJ "BBB@ HHHH
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MLV:=^T!H6E7G[;7P7^''C+XK_#2^U'P3HWQ2\.78M=%^,?@ QZ=J=AXH;2]
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MSO;/P=K/PZT^RO=;^.6F:CI/B/XG^*?%$WAQ/"":UX/U'P]:^&OUHKQ_XW?
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M 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\
M"X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y
M2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN
M'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C
M0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)
M17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B
M-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_
M^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?
M]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\
MY64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW
M_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,
M7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'
M_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_
MY2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64
M?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +
MA^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(
MT+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?
MB-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"
M_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%
M?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W
M_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y
M64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T
M,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E
M90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_
M  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E(T+_ .5E 'W)17PW_P +A^(W_0Q?
M^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]R45\-_\ "X?B-_T,7_E(T+_Y64?\
M+A^(W_0Q?^4C0O\ Y64 ?<E%?#?_  N'XC?]#%_Y2-"_^5E'_"X?B-_T,7_E
M(T+_ .5E 'W)17PW_P +A^(W_0Q?^4C0O_E91_PN'XC?]#%_Y2-"_P#E90!]
MR5S/C7_D3?%O_8LZ]_Z:KNOD'_A</Q&_Z&+_ ,I&A?\ RLJO=_%7Q[J5I=:=
J>Z]YUG?V\UE=P_V7HT?FVUU&T$\7F1:='+'YD4CKOB=)%SN1U8 @ __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ P4# 2(  A$! Q$!_\0
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M\9?_ "AH Z:BN9_X2W2O^?3Q-_X17C+_ .4-'_"6Z5_SZ>)O_"*\9?\ RAH
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M>)O_  BO&7_RAH Z:BN9_P"$MTK_ )]/$W_A%>,O_E#1_P );I7_ #Z>)O\
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MQS\/K+XL:;XB\(_#OXJ>/=#\/?#'4-4_L.V\?_$W5O W@CQ%8?!WPB=:BO\
M1Y]>^+5QX)TVSU30O$^GW=Q!=^%/$D.E=7J?[97[.6D?%6T^#5[X]OCXSN_%
MOAGX?F^LO 'Q*U/X;Z?\0?&FAVWB3PA\/M<^,^F>#[SX.>'?'WBC1;[2[[P_
MX)U[QYIOBC6%UOP_!8:3<7/B'1(;\ ^GZ*** /F+]KO0?&WBSX-R>%/AU\1=
M%^'/C'Q%X^^%MEILFM_$OQ'\&T\?:=:?$+P[K/BOX1:9\5?!-EJGC[X>ZW\5
M?!NE^(?!.F>+_A_I.J^-= GU?^T] L)KNV!3\R_"VC^)KOX1?#CP7\)?A_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _.S]O@6-G=? [6)?@W\
M?/&_B0^(_$?A?X8?%+]F3XM>"/AG\7/A3\6?%H\,V?@_2UT_XB>// '@?QCX
M"\?V]GK<_B_3_'DWCKX<P7?@GPW9^._A7XQT/69+K0/A'X^?LO\ [;?Q2/A[
MQ#\1?AYXY\=?&Z/]E+X'>"M'\7? ;XF_!'P=\"_$WQU\,>(_$'C/Q?IW[<GP
M\^(GB3P3)\8?@WHGC633'T_P=X+^'_Q$\'W'@GQU\9_^$4\$^$_&.O:%/9?T
M T4 ?FO\;-<_X7\UKKWPX\ ?M3ZM\3OV4/CSJO@C1_B;^S-??LK:1=1>-=1^
M#1TSXK7/A"/]K/QM;_#/QQ\.-)A\?ZA\*?%R>(?"U_X@T;XI:%J5EH&FQ:CX
M*O\ Q#I_Q-\2_P#@G)^U]K'[%,GA#2_B5X#\5?%"T^!'[7-O<?![QI\/[#Q7
MJFJ_%W]K3XC?$?XF>--0\+_%GP]\5/@+\,_#'Q&DT3QS#\);;QQJOPQU7P1H
M5NWC#4_#/AW1O#GC;6=$F_H!HH _++]HWX7_ +1'Q(\:?#:QL/A5XYUSXK^
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M_D7_ &P/V.=?^%O[3WQ'\(?'GXV^,OVC?B'HI\'W7B/X@^(;G5K.?Q!>>(?
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M.L9F2WU?[&ECX=;R?F[XC_MZ_$GX,?LW_LZ^-;_]HO\ 9J\?Z=XOOOB]X?\
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MZ1<Z7-\2O%7CJ\\0:KKFB:%I<P!\WZ)^VS\8=-L?A5\8O&VC_#/5/@?\=/\
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M>&O$GPN\5K=:K#XXN[#6])U;0S#H^D7-A>OJ'U97AGPA^!6G?"G6_'_C"_\
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M7_RAKIJ* .9_X2W2O^?3Q-_X17C+_P"4-'_"6Z5_SZ>)O_"*\9?_ "AKIJ*
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MIX&OO$TVK+I^@?&CP*OP6^&\'PNU:>#1=3:SMY?$?B*:^N]-U6T@A":;<70
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M'6;_ .&7PKGT#Q_X1U>+1_[6TC2=,\6^%;VQUZTNM#\;:D]K?6\'V90!S/\
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MZ;^5M[\*_P!JWXQ_"7X9ZIJ_@O\ :<\3?!73_P!H/_A8WPEL=+^-OP2\+?\
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MH5NT:2W4P07>J:I>SO/J.M:U?M&DFHZWJ]W?:KJ$BK)>7<S*I'R1_P %6/\
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MDE?QM_\ !5C_ )/X^//_ '2[_P!4Q\.Z_<O #_DL<R_[)S%_^K'*S\E\9/\
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M#7C"Z^&_@O4+K3/#-G9WWB?X@W_C'[\HKW3\I/SR?]@W2-<_:EL/VG?%MO\
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M3X'_ !T_X:4B\*^#_"N@>*]%^)'P_P#^%*>"OB?\4/"5_P")/'NL>--<\/\
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M\-_]BNG_ .G\<=-17,_\);I7_/IXF_\ "*\9?_*&C_A+=*_Y]/$W_A%>,O\
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M?^K:F?6^"O\ R*L^_P"QI@O_ %6S.FHKF?\ A+=*_P"?3Q-_X17C+_Y0T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0P. >IX'/ YZ^_UI,#I@8],5Y-I_Q-ETC4+3P[\3])C\$:W>2"VTS6UNFOO
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M\PRK%ULTSK-,?CL]S[-,12Q]/#+$8W.,WK8O&.<Z5U.EA7@,([VCA(QC"$?
MQ/TL?'GZ1.58[!>)7&TI\)Y'F6&I<->&_!^491P!X7<+866%JXFEA,A\/>#,
M)DG#5".'J-.CC,QPN?YMS)U:N;U,14K8BJ4445\(?-A7\;?_  58_P"3^/CS
M_P!TN_\ 5,?#NO[)*_C;_P""K'_)_'QY_P"Z7?\ JF/AW7[EX ?\ECF7_9.8
MO_U8Y6?DOC)_R3&!_P"QYAO_ %!S _/.OZGO^"'W_)J'Q!_[.&\6?^JV^$U?
MRPU_4]_P0^_Y-0^(/_9PWBS_ -5M\)J_7_'+_DW^)_['.1_^I.,/S3PE_P"2
MRH?]BO-O_3&&/V2HHHK^+C^I0K\\_P#@JQ_R8/\ 'G_NEW_JY_AW7Z&5^>?_
M  58_P"3!_CS_P!TN_\ 5S_#NOIN"O\ DL>%/^RCR7_U8X<\'BG_ ))CB+_L
M1YK_ .H-8_C;KZ&_9%_Y.O\ V8?^SAO@M_ZLGPU7SS7T-^R+_P G7_LP_P#9
MPWP6_P#5D^&J_O?._P#D2YU_V)LX_P#53FI_'F5?\C7*_P#L:99_ZLLO/[JJ
M***_SB/[A"BBB@#^-O\ X*L?\G\?'G_NEW_JF/AW7YYU^AG_  58_P"3^/CS
M_P!TN_\ 5,?#NOSSK_0K@K_DCN%/^R<R7_U78<_BWBG_ )*?B+_L>9K_ .IU
M8_J>_P""'W_)J'Q!_P"SAO%G_JMOA-7[)5^-O_!#[_DU#X@_]G#>+/\ U6WP
MFK]DJ_B[Q,_Y.!Q;_P!CFM_ZC9:?U+P'_P D;PW_ -BNG_Z?QP4445\,?6GY
MY_\ !5C_ ),'^//_ '2[_P!7/\.Z_C;K^R3_ (*L?\F#_'G_ +I=_P"KG^'=
M?QMU_7W@!_R1V9?]E'B__5=E9_-/C)_R4^!_[$>&_P#4[,#Z&_9%_P"3K_V8
M?^SAO@M_ZLGPU7]U5?PJ_LB_\G7_ +,/_9PWP6_]63X:K^ZJOAOI#?\ (ZX8
M_P"Q-F'_ *MJ9];X*_\ (JS[_L:8+_U6S"BBBOYZ/VD*_C;_ ."K'_)_'QY_
M[I=_ZICX=U_9)7\;?_!5C_D_CX\_]TN_]4Q\.Z_<O #_ )+',O\ LG,7_P"K
M'*S\E\9/^28P/_8\PW_J#F!^>=?T,?\ !!G_ )NK_P"Z&_\ O8:_GGK^AC_@
M@S_S=7_W0W_WL-?N7C#_ ,FZXA_[I?\ ZN, ?DOAE_R6V2_]U#_U68P_H8HH
MHK^&S^M KY"_;>_8U^&'[<GP'\2?!CXC6L=K>RI+K'P^\:PV\<VL?#[QS;6L
M\6C^)-,9MKRVVZ5K'7])\V*+6]"N;[3WEMYY+:]M/KVOEC]M?XX>+/V;_P!F
M3XE_&CP/I_AW5?%'@S_A#?[+L/%=IJ5]H$__  D7Q \*>%+W[?:Z1JVA:C+Y
M6G:[=S6OV?5;79>QVTDWGP)+;3-9%3XHE#ANKA</C:>?5*>4O"XIQCAZ[Q\X
MX:%.K4E&2I1<ZD)*LES4)PA6@XSI0E'V.'N.,^\-,[ROQ"X8SK,.'>(."\;1
MXERC.\JG.&89;C,HE]<IXC#J$DJWNTZM&OA*JJ8;'87$8S 8NAB,)C<30J_E
M'_P3!_;&^)7@/Q/XK_X)A?MNW-QHG[2/PAL]0T;X1^*==NFFM?B[\/K'3)KC
M2M+T_6KE86UW4M,\/QQZIX3U1A]J\4^"5"WD4.O>&]5.H?MO\%I/-^#GPFEZ
M^;\,_ <GK]_PMI3=>_6OXE/V\?VNOBQ^UY-\/OBKJOA/X;> /C1\";H:[X ^
M)/PITOQCX>\9BSTZ[_MJ+0+J_P!7\=>(K>ZLM/U:,Z]H0%DE]I>L_:?[/NX+
M?6-7M[[[&^"O_!<_]IBY^&/@^PT3X>_ 1+#PUHFG>$HH=0\._$*]U&%/#=E;
MZ5;#4+NV^)NGVUS>3V-O:7<T\%A8PRFX$D=G;*P@3HX6\+O$'(.*Y>$^>2R_
M$YE2R*KQ)P9F>*SBBWGW">#QM++L;A*V+>%=.OGG"V)Q&"PF84[1K8C*\3EN
M9N,H.O.'[EX^\5^%WBMX:Y?],7PTRJMP]EF><8T> /I"\"91E$J.5^'/C=FN
M5U^(,LS_ (>P$,0JV#\//&7+<%G?$>04>3ZIP]Q=@.+>$U62EE5&K_7C1117
M,?SJ%%%% !1110 4444 %%%% !7\<?[6VB_L=_"K]J?_ (*,:9^VG\*/B=K?
MQ6^)E^?%/[+>O>%6U,:*EOXE\*WM]I&KZ;<:?XAT73I-1'B2?0[?4IM;L?$.
MF6IT[4-'DLDGM]4LK_\ L<K^??\ :[_;O_:G^(_[86M_LE_L'_L[?#7XP>.?
M@-#!XA\2>._'^D:/J]QH&OQ66F76L/X;U'Q9XA\'>%_!,&B76J:;X?N-5U#5
M9=4UKQ#!+9:-Y2PVS7H!^(WP'_:'_9N\2_M8_L_^-?VT)I/B+\(_A[^S/H'P
M?\93>,O!6N^+[#3/%VB>"O$&D:-IVJZ%'IEYJVK-HMS=/;VNJ1:??W$>LVZZ
MU:2LUBNIP?TK_P#!$]]1E_81\-W'DZQ;>#;GXI_&*?X6VNL/(\EI\.W\<:C_
M &;;6AE>1A:Q:V/$"N/,=3?_ &YU=E8,?F_]BC]HF/\ :-^,GQF_8=_;]_8_
M^"/@KX\/I*^/_$=O!\/O#K:3\4+FR6SNY;[Q)ITQ\2V6H>+;72?$%MXET/QA
MIGB._M;^R;4[S2WTNXM(S=?O!X<\-^'?!^A:3X6\):#HOA;PSH-C!IFA^'?#
MNEV.B:%HVFVJ".VT_2M(TR"VT_3K&WC 2"TL[>&") %CC4#% &U7YU?!;X[?
M'3QQ\=_'/@[QYX\^%/P_U.XTSXBZ1X>_9L\8?"[QUX.^(O@Z/P9X\\7Z5\/_
M (Q>"O&.N>);;3?VI_!OCCPY;VM[\2+OX?+X7\'^'(H?"-GH.N>'M<@\5)XM
M_16OCKX;?LN:_P"'_BY/\2/B7\9_B5\6=-^'GB7QC+^SAX7\8ZOX6O[7X=>&
MOB#X0\+67B:ZU[6-)^'_ (8\;>+_ !=::U)\0?"OARZ\:^-?'&GZ;\,]1T&.
M1)O%RW^LH 5?@M\1?V@]8_:+^*GPF^('B[X-_$'P5\*O '@Z\\3>)OAW\'/'
M?PHU'2?BIX]NYM8T+P/N\4_';XP6.N1Z=\.K&/Q9XC-K;:8]DGC7P,L%[,\V
MIVL/S]\6?VV?C#\,[/XD?'!='^&>J?L^_"G]IVV_9O\ $'P^&@>*X_BWK%O-
M+H'@RZ^(MA\36\:1^$M):Q^)?B:U9? C?"/7C>^#=*GE7QM:ZOJZ+HOU?%\#
M/%WP[\'2>&/@?XYNM'U_QW\?H?BQ\7OB;XX.CZ[XPU/1->\;6_BSXC6^B:8O
M@Z?PA<:SKGA?2M/^#WA2TET/0M*\&>"[BUURRN+G7O"MC!K/'>)_V%_A7XQ\
M3^([SQ#XL^)FH_#+QA\3Y?C1XK_9_DU?PH/A+KOQ1FT"WT63Q7<72^#!\6;-
M'O;.Q\7/X6TKXI:?X(D\96BZ[)X9>2YOX;L ^;-7_;4_:&^%?AO^U/B=HGP:
M\8ZI\1/V3;/]HOX50>"-#\;>!M)\(>+9?'?PL^'UW\-_'M[K?C3XAZAXYT2'
M5_CIX!O+?Q]H&E?#R[N-/T#Q1YG@BWN-6TY-&^N?@9\3_BSJ?Q<^.?P+^,EQ
M\/\ Q%XD^%6B?"'QUH?CSX;>$_$/P^T+Q%X0^+]MX[L+/2=0\#^)OB!\4]1T
MOQ!X:\2?"[Q6MUJL/CB[L-;TG5M#,.CZ1<V%Z^H<%8_L!?#"7POXB\*>.?B+
M\:/BI9ZE\&=,^ 7A+4O&WB/PC8Z_\+?AGHVJ:=KVG:;X$UCX?^!? UU<:]#X
M@\/^#M=F\;>/3XX\9WVI^"?#4VH:]=1Q:G#JG4VO[.GC_P #-KNN?#KXR^*?
M$'Q3^*?Q&^$5U\7/C3\5K?X?77B^/X/_  SO4N+GP+X*\)^!_A3X9^%T4VH:
M+_PD7A72FF\%Z1<Z7-\2O%7CJ\\0:KKFB:%I<P!\WZ)^VS\8=-L?A5\8O&VC
M_#/5/@?\=/\ AI2+PKX/\*Z!XKT7XD?#_P#X4IX*^)_Q0\)7_B3Q[K'C37/#
M_CU?&/@CX/>);37M+TKX8> F\,^)?$&D+9:KX@T[1;F37<K5_P!M3]H;X5^&
M_P"U/B=HGP:\8ZI\1/V3;/\ :+^%4'@C0_&W@;2?"'BV7QW\+/A]=_#?Q[>Z
MWXT^(>H>.=$AU?XZ> ;RW\?:!I7P\N[C3] \4>9X(M[C5M.31OI/PO\ L+_"
MOP[JNF)J/BSXF>-/AYX5MOBY:_#GX->+=7\*3?#SX:Q_&Y=8M/'O_"-7F@^#
M- ^)&K+-H/B7Q1X4T"#Q]\0O&EKX6\,>(]2TOP]!IPBTR73LBQ_8"^&$OA?Q
M%X4\<_$7XT?%2SU+X,Z9\ O"6I>-O$?A&QU_X6_#/1M4T[7M.TWP)K'P_P#
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MY^)__"+\8?\ RBH_X2[2_P#GS\3_ /A%^,/_ )15T]% ',?\)=I?_/GXG_\
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M/10!S'_"7:7_ ,^?B?\ \(OQA_\ **C_ (2[2_\ GS\3_P#A%^,/_E%73T4
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MK\E/^"'W_)J'Q!_[.&\6?^JV^$U?LE7\7>)G_)P.+?\ L<UO_4;+3^I> _\
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M_21XDQ&?Y.L9!*,GBLO\*."N"<-3]JG.CALU4(*BJE6E4^AOV1?^3K_V8?\
MLX;X+?\ JR?#5?W55_"K^R+_ ,G7_LP_]G#?!;_U9/AJO[JJ]7Z0W_(ZX8_[
M$V8?^K:F?R]X*_\ (JS[_L:8+_U6S"BBBOYZ/VD*_C;_ ."K'_)_'QY_[I=_
MZICX=U_9)7\;?_!5C_D_CX\_]TN_]4Q\.Z_<O #_ )+',O\ LG,7_P"K'*S\
ME\9/^28P/_8\PW_J#F!^>=?U/?\ !#[_ )-0^(/_ &<-XL_]5M\)J_EAK^I[
M_@A]_P FH?$'_LX;Q9_ZK;X35^O^.7_)O\3_ -CG(_\ U)QA^:>$O_)94/\
ML5YM_P"F,,?LE1117\7']2A7YY_\%6/^3!_CS_W2[_U<_P .Z_0ROSS_ ."K
M'_)@_P >?^Z7?^KG^'=?3<%?\ECPI_V4>2_^K'#G@\4_\DQQ%_V(\U_]0:Q_
M&W7T-^R+_P G7_LP_P#9PWP6_P#5D^&J^>:^AOV1?^3K_P!F'_LX;X+?^K)\
M-5_>^=_\B7.O^Q-G'_JIS4_CS*O^1KE?_8TRS_U99>?W54445_G$?W"%%%%
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M#\E\,O\ DMLE_P"ZA_ZK,8?T,4445_#9_6@5^>?_  58_P"3!_CS_P!TN_\
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MX1QB.5-3O]5L5$9,;06<+G$IEKLJ\E\/#[)\:/B;9YPNH>"OA9XA0=GFEO\
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MU_X/=,_^2J/^$V\&_P#0V>&O_![IG_R50!T]%<Q_PFW@W_H;/#7_ (/=,_\
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M&SPU_P"#W3/_ )*H_P"$V\&_]#9X:_\ ![IG_P E5_/1^TG3U_&W_P %6/\
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M.9X6^'/PIC698KB:-VB9XI$60*5+QNH.58#]@_\ A-O!O_0V>&O_  >Z9_\
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M -#9X:_\'NF?_)5?PV?UH=/7YY_\%6/^3!_CS_W2[_U<_P .Z^Y?^$V\&_\
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M2=4T_4XX7$<TFGWMM>I$[#<J2-;R2*C,OS!6()'(&*T: "BBB@ K\+?VK?\
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M\'Z!<^-/&WC>PT[X8:IH43K+XO6_UJ/[4HH ^!] _8S\0_"B?P7J/PA^-7Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\XC^X0HHHH _C;_X*L?\G\?'G_NEW_JF/AW7YYU^AG_!5C_D_CX\_P#=+O\
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M#_'G_NEW_JY_AW7Z&5^>?_!5C_DP?X\_]TN_]7/\.Z^FX*_Y+'A3_LH\E_\
M5CASP>*?^28XB_[$>:_^H-8_C;HHHK_0H_BT_P!#"OE/]M[]FC1_VO?V6OC%
M\ M36TCO_&GA6Y?P=JEY&KIH/C_0WCUOP/K7F'$L,%IXDL-/35/LTL$UWHL^
MIZ<9E@O9@WU917^8N.P6&S+!8S+L;25;"8_"XC!XJE+:IA\51J4*L;V=FX5&
MXR6L)QISC:4(M?Z'\*\3YWP5Q/PYQCPUCJF6\1<*9[E'$F1YA2^/!YMD>8X/
M-,OKI<T5.$<3@J<:U&3]GB,-6Q6&JITL55B_Q>_X(=_M-:S\8_V4;GX&_$9[
MFT^-'[(7B!O@KXUT?5),ZU!X8TU[VV\ 7-_$9IGB.FV6DZMX"8,0S77@6YE8
M'SE9_P!H:_FT^.+G_@F[_P %DOAU\?+=?['_ &<_^"@&FR> _B?(H>+1="^)
M\U]I-AJ&LW1*36]F\?BE_!?CJ[U2XDCGDLO%'Q$BMA#9P7)/])=?&^'^-Q*R
MK%\-YE5E5S?@W'3X?Q=2>E3%X&C3C6R#,VF[N.89)/!MS5XO$8/$PYFX-'])
M_2^X8R1\>9!XU<$X"E@/#KZ2G"^'\7^'L%A;2PG#O%698NMEOBWP,I12C3K<
M(>)^%XDIT\/)0JK*.(LEQ#I1IXB,GY+\3/\ 1M>^#.J]!I_Q4C@D;UAU_P
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M^X^B?^"^$UQ%_P $_=92&25([CXM?#2&Z6-F"S6ZW6JW"QS <-$+J"VE"O\
M*)HHF'S*M?SP>*_VO/V+6_:2_82^+'P]^!7B/PIX%_9U\&_#O1_C;H5OX!^'
MNEZKX_\ $G@BY-X=?TS3=.\9W&D^+=0DNV,YU_QAJ>CZYJDB0'5I)/(A$8!^
MXO\ P1S\9?\ !.SQG\0OB]-^S/\  OQ=\#/CS9:'<7'B+PU\0?$VL^,M03X;
MW.OZ<EU%X+UC4=5OX[31--U]] M-?L;RST_6X[JYT-)[O6;8">V_H K^5;]C
MS]IWX;?M;_\ !;4_'+X/>'_%WA3PGXN^">O:9J.G^+]+T/0_$&H:GX>\"6.F
M7MYK%IX9\0>)=,N8IIM-TW[+/+JUQ-(EE9M-%#)!$J_U4T %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!P7Q5^(6B_"3X8?$7XJ>(V">'_A
MKX%\6>/=;)D6'.E>$=!O]?OU$K!E1WMK"5$)5OG9<*QPI_$W_@WT^'VM?\,P
M?%S]ICQB/M'C7]JCX[^,?&-_JWE-'_:NB^%;R[T=)]SL\DFWQ[??$E\F1U3S
M]F3(LK-ZY_P7@^-+_"7_ ()X_$+0-/N3!X@^.'BGP?\ !S1DB8M=26VKWTOB
MCQ0D4"'S)8KOPCX3US2)V"F-#JL*-^\EA1_OO]C3X+)^SM^RE^S[\%C;"UO_
M (?_  J\(Z1XAC"A _B^?2X=3\:76P ;/MOBV_UJ\V'<R>?L>21@TC?GE;_A
M6\3L'2^+#\'<+8C'3ZQCFW%>*6!PU^BJ4\FRK%U(WM)0Q+:TE)/^Q<M_XU_]
M!KB7,'^XSCZ1_CSD_"V%E\-6MX>_1_R"?%.>..TY8/&^)7'O#^%J\O-2J8C)
M80J)U*%&<?@7_@N#_P FH?#[_LX;PG_ZK;XLU_+#7]3W_!<'_DU#X??]G#>$
M_P#U6WQ9K^6&O]%/ W_DW^&_['.>?^I.#/\ )7Q:_P"2RK_]BO*?_3&)/H;]
MD7_DZ_\ 9A_[.&^"W_JR?#5?W55_"K^R+_R=?^S#_P!G#?!;_P!63X:K^ZJO
MS/Z0W_(ZX8_[$V8?^K:F?>>"O_(JS[_L:8+_ -5LPHHHK^>C]I"OXV_^"K'_
M "?Q\>?^Z7?^J8^'=?V25_&W_P %6/\ D_CX\_\ =+O_ %3'P[K]R\ /^2QS
M+_LG,7_ZL<K/R7QD_P"28P/_ &/,-_Z@Y@?GG7]3W_!#[_DU#X@_]G#>+/\
MU6WPFK^6&OZGO^"'W_)J'Q!_[.&\6?\ JMOA-7Z_XY?\F_Q/_8YR/_U)QA^:
M>$O_ "65#_L5YM_Z8PQ^R5%%%?Q<?U*%?GG_ ,%6/^3!_CS_ -TN_P#5S_#N
MOT,K\\_^"K'_ "8/\>?^Z7?^KG^'=?3<%?\ )8\*?]E'DO\ ZL<.>#Q3_P D
MQQ%_V(\U_P#4&L?QMU]#?LB_\G7_ +,/_9PWP6_]63X:KYYKZ&_9%_Y.O_9A
M_P"SAO@M_P"K)\-5_>^=_P#(ESK_ +$V<?\ JIS4_CS*O^1KE?\ V-,L_P#5
MEEY_=51117^<1_<(4444 ?QM_P#!5C_D_CX\_P#=+O\ U3'P[K\\Z_0S_@JQ
M_P G\?'G_NEW_JF/AW7YYU_H5P5_R1W"G_9.9+_ZKL.?Q;Q3_P E/Q%_V/,U
M_P#4ZL?U/?\ !#[_ )-0^(/_ &<-XL_]5M\)J_9*OQM_X(??\FH?$'_LX;Q9
M_P"JV^$U?LE7\7>)G_)P.+?^QS6_]1LM/ZEX#_Y(WAO_ +%=/_T_C@HHHKX8
M^M/SS_X*L?\ )@_QY_[I=_ZN?X=U_&W7]DG_  58_P"3!_CS_P!TN_\ 5S_#
MNOXVZ_K[P _Y([,O^RCQ?_JNRL_FGQD_Y*? _P#8CPW_ *G9@?0W[(O_ "=?
M^S#_ -G#?!;_ -63X:K^ZJOX5?V1?^3K_P!F'_LX;X+?^K)\-5_=57PWTAO^
M1UPQ_P!B;,/_ %;4SZWP5_Y%6??]C3!?^JV84445_/1^TA7\;?\ P58_Y/X^
M//\ W2[_ -4Q\.Z_LDK^-O\ X*L?\G\?'G_NEW_JF/AW7[EX ?\ )8YE_P!D
MYB__ %8Y6?DOC)_R3&!_['F&_P#4',#\\Z_H8_X(,_\ -U?_ '0W_P![#7\\
M]?T,?\$&?^;J_P#NAO\ [V&OW+QA_P"3=<0_]TO_ -7& /R7PR_Y+;)?^ZA_
MZK,8?T,4445_#9_6@5^>?_!5C_DP?X\_]TN_]7/\.Z_0ROSS_P""K'_)@_QY
M_P"Z7?\ JY_AW7TW!7_)8\*?]E'DO_JQPYX/%/\ R3'$7_8CS7_U!K'\;=%%
M%?Z%'\6G^AA1117^9Y_>!^:__!63]DE?VPOV*_B=X)T?3!J'Q)\"VK?%;X4>
M7$LE[-XQ\&V=[<3:!9XC:1IO&/AR?7?"=O#YD,!U+5].N[APEDI5_P#P2?\
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M73T4 <Q_PFW@W_H;/#7_ (/=,_\ DJC_ (3;P;_T-GAK_P 'NF?_ "573T4
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M'QY_[I=_ZICX=U^Y> '_ "6.9?\ 9.8O_P!6.5GY+XR?\DQ@?^QYAO\ U!S
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M7!#.\K[(D>1]JG;&C.V%4D?Q\5_9)_P58_Y,'^//_=+O_5S_  [K^-NOZ^\
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M_P#N10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXL_]5M\)J_EAK^I[_@A]_P FH?$'_LX;Q9_ZK;X35^O^.7_)O\3_ -CG(_\
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MJQ_R8/\ 'G_NEW_JY_AW7\;=?V2?\%6/^3!_CS_W2[_U<_P[K^-NOZ^\ /\
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M@O\ 4;.SF>%OAS\*8UE6*XFC=HF>.1%D"E2\;J#E6 _83_A-?!W_ $-?AO\
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M8'_L>8;_ -0<P/S\K^AC_@@S_P W5_\ =#?_ 'L-?SSU_0+_ ,$*M:T;1_\
MAJ7^UM6TW2_M'_"D?L_]H7UM9>?Y/_"W?-\G[3+'YGE>;'YFS=L\Q-V-ZY_<
MO&'_ )-UQ#_W2_\ U<8 _)?#+_DMLE_[J'_JLQA_1717,_\ ":^#O^AK\-_^
M#S3/_DFC_A-?!W_0U^&__!YIG_R37\-G]:'35^>?_!5C_DP?X\_]TN_]7/\
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MJ7P?X7NHI=:$']E-/+96US;S2::9YQ'Y-M<_O/7\[_[ OPO_ &X/C1_P4/\
M'G[=?[1GP8E_9S\-W_POE\!S^%KFSO\ P_<>*I4TO0-$T328="U>]N/$FH06
M,>B1>(=6U_7(H+(W]EIEEI49C6.WTS^B"@ K\\-'_91^)?Q(^-.K>./VEO%G
M@OQ=X=^'6G_%'X6?#34_!WPVA^&_Q,^*GPM^+?@;08K]OBG\0_#?Q%U:?^QO
M"D_BGQYX,TWPEX3\*?#1[GQ;X:L?BS!+9&^TW2D_0^B@#\[=%_9#U?\ 9T^)
MVL?$[]FV[\5>(=0^(%C^SQ\'H_"_Q1^*_P 8_'?@WX4?##P%XN\7ZG\2_&.J
MIX[^-]W?>.V_X0/7Y/#_ ,)_"=K8O)\._&26LNA):^%?&WQ&FC;X\_8+O?B'
M=^// ^N?%^)?V<?B5\=)?VA?%7PVM?A\T7Q,/C:6QTV].AZ3\7_^$W.@V?@1
M?B!HVF^/%TN^^$&J^)XYDN=!A\91::]DVG_HI10!^:T_[ GBGQCX1U'PY\7/
MCW;^)]2T3]G;2_V<_A)XD\#_  I@\!7/@S1M+\4>#?&I\<^,-,UKQ[\0],\>
M^-]3\4?##X8WNJKI$/P^\'S6?AS4].M?"=E%KJ2:3Z?IGPH_:"^&^O\ C3XH
M6'B'P%\6_CC\;_&WP(\%>*M=M? M]\-OA/\ #3X&?#?4M4FUB\M? VJ_%[Q?
MXSUG7++1/%'Q/NM-DM/B'JLVK^/_ !CX0CF\/Z3X1T;7[L_;5% 'YU^&OV"[
MVVA\'>!?&_Q?B\5_ WX5VWQX@^%7@O2/A\WA3Q_IK?'71?&?@Z[?QW\29?&_
MB+1/&0\$^ /B-XV\+>%GT'X9> ;N=]0T[6?$-WK5[I]VNJY4_P"P)XI\8^$=
M1\.?%SX]V_B?4M$_9VTO]G/X2>)/ _PI@\!7/@S1M+\4>#?&I\<^,-,UKQ[\
M0],\>^-]3\4?##X8WNJKI$/P^\'S6?AS4].M?"=E%KJ2:3^E-% 'SG\&/@MX
MO\#^./BM\6/B?\0- ^(7Q-^*]MX T'4;SP9X!U#X:>"M"\%_#&Q\0)X2T'1?
M"NM>/_BCKOVX:QXT\:ZYK6LZAXXO8]0GURWMK'2M(@TT_;/HRBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /CG_@H-\;!^SO^Q3^TK\7(KL6.J>'/A7XAT[PQ=&3RC!XT\8QQ^"?
M!$H/#,8_%OB+1I#&A6255:.-XV8.OR__ ,$1_@I_PI;_ ()S_!+[5:_9=<^+
M/]N_&O7/W?E_:/\ A/+U?^$4NN?F?SOAYI7@W]XWWMOR?NA'7R__ ,' 'BS6
MO%?PL_9=_8\\&W(3QG^U7^T1X;T:"U0-.]SH_ANYT[28+>:UC=7:&3QMXZ\%
MWR,Q D;294C.Y7>+]X?!GA/1? 7@_P *>!O#=O\ 8_#W@OPUH7A/0;3Y3]ET
M7PYI=KH^EV^55%/D6-G!%\JJOR\*!P/SS"?\*WB9FV)^+#\(\,X')Z+WC'->
M)L1+-\PL]E4IY5@,MI2VDH5TG>,DE_8O$'_&O_H/>'^1K]QG'TB?&_BKQ'S&
M/PU:W 7@?DU'PZX14UI*6#Q?'O%O&>84+\U&IB,KG4CRUJ$G/I:***_0S^.C
M\;?^"X/_ ":A\/O^SAO"?_JMOBS7\L-?U/?\%P?^34/A]_V<-X3_ /5;?%FO
MY8:_M'P-_P"3?X;_ +'.>?\ J3@S^6O%K_DLJ_\ V*\I_P#3&)/H;]D7_DZ_
M]F'_ +.&^"W_ *LGPU7]U5?PJ_LB_P#)U_[,/_9PWP6_]63X:K^ZJOS/Z0W_
M ".N&/\ L39A_P"K:F?>>"O_ "*L^_[&F"_]5LPHHHK^>C]I"OXV_P#@JQ_R
M?Q\>?^Z7?^J8^'=?V25_&W_P58_Y/X^//_=+O_5,?#NOW+P _P"2QS+_ +)S
M%_\ JQRL_)?&3_DF,#_V/,-_Z@Y@?GG7]3W_  0^_P"34/B#_P!G#>+/_5;?
M":OY8:_J>_X(??\ )J'Q!_[.&\6?^JV^$U?K_CE_R;_$_P#8YR/_ -2<8?FG
MA+_R65#_ +%>;?\ IC#'[)4445_%Q_4H5^>?_!5C_DP?X\_]TN_]7/\ #NOT
M,K\\_P#@JQ_R8/\ 'G_NEW_JY_AW7TW!7_)8\*?]E'DO_JQPYX/%/_),<1?]
MB/-?_4&L?QMU]#?LB_\ )U_[,/\ V<-\%O\ U9/AJOGFOH;]D7_DZ_\ 9A_[
M.&^"W_JR?#5?WOG?_(ESK_L39Q_ZJ<U/X\RK_D:Y7_V-,L_]667G]U5%%%?Y
MQ']PA1110!_&W_P58_Y/X^//_=+O_5,?#NOSSK]#/^"K'_)_'QY_[I=_ZICX
M=U^>=?Z%<%?\D=PI_P!DYDO_ *KL.?Q;Q3_R4_$7_8\S7_U.K']3W_!#[_DU
M#X@_]G#>+/\ U6WPFK]DJ_&W_@A]_P FH?$'_LX;Q9_ZK;X35^R5?Q=XF?\
M)P.+?^QS6_\ 4;+3^I> _P#DC>&_^Q73_P#3^."BBBOACZT_//\ X*L?\F#_
M !Y_[I=_ZN?X=U_&W7]DG_!5C_DP?X\_]TN_]7/\.Z_C;K^OO #_ )([,O\
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MXVU_>_AG_P F_P"$O^Q-1_\ 4G,C^/.//^2RXD_[&E3_ -,8$_H8_P""#/\
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M -5F,/Z&****_AL_K0*_//\ X*L?\F#_ !Y_[I=_ZN?X=U^AE?GG_P %6/\
MDP?X\_\ =+O_ %<_P[KZ;@K_ )+'A3_LH\E_]6.'/!XI_P"28XB_[$>:_P#J
M#6/XVZ***_T*/XM/]#"BBBO\SS^\ HHHH _EA_X+@_\ )U_P^_[-Y\)_^K)^
M+-?C;7[)?\%P?^3K_A]_V;SX3_\ 5D_%FOQMK^]_#/\ Y-_PE_V)J/\ ZDYD
M?QYQY_R67$G_ &-*G_IC G]#'_!!G_FZO_NAO_O8:_H8K^>?_@@S_P W5_\
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M?66LZO#K#1Z=])5\Y_!CX+>+_ _CCXK?%CXG_$#0/B%\3?BO;> -!U&\\&>
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M7]I:WD#1W%O%(FU_PFO@[_H:_#?_ (/-,_\ DFNFHH YG_A-?!W_ $-?AO\
M\'FF?_)-'_":^#O^AK\-_P#@\TS_ .2:Z:B@#F?^$U\'?]#7X;_\'FF?_)-'
M_":^#O\ H:_#?_@\TS_Y)KIJ* .9_P"$U\'?]#7X;_\ !YIG_P DT?\ ":^#
MO^AK\-_^#S3/_DFNFHH YG_A-?!W_0U^&_\ P>:9_P#)-'_":^#O^AK\-_\
M@\TS_P"2:Z:B@#F?^$U\'?\ 0U^&_P#P>:9_\DT?\)KX._Z&OPW_ .#S3/\
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MS^D-_P CKAC_ +$V8?\ JVIGWG@K_P BK/O^QI@O_5;,YG_A-?!W_0U^&_\
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M_5Q@#\E\,O\ DMLE_P"ZA_ZK,8?OE_PFO@[_ *&OPW_X/-,_^2:/^$U\'?\
M0U^&_P#P>:9_\DUTU%?PV?UH<S_PFO@[_H:_#?\ X/-,_P#DFOS]_P""I?B?
MPUJ/["'QTL]/\0:)?7<W_"L?)M;/5;&YN)?+^,?P]ED\N&&=Y'V1(\C[5.U$
M9SA5)'Z45^>?_!5C_DP?X\_]TN_]7/\ #NOIN"O^2QX4_P"RCR7_ -6.'/!X
MI_Y)CB+_ +$>:_\ J#6/XVZ***_T*/XM/] K_A-?!W_0U^&__!YIG_R31_PF
MO@[_ *&OPW_X/-,_^2:Z:BO\SS^\#F?^$U\'?]#7X;_\'FF?_)-'_":^#O\
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M>+O#WPQO/B-\8="^,_CQ?AA\/HOAU:^"/BSXQ\+1:[J'CR:QT#7?#/Q \5>
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M)&_.3PC^R9^U3\*_BA:?M0^"[?\ 9_\ %GQN\9Z_^U _Q2^%7BGXD?$7PO\
M"_1?#'Q_UGX)ZSX9A\"_%C2/@WXH\4Z]KWP\'[.WP_TS5[G7?@_X;T_QU;:_
MXJNK:T\%75EIGVS[I_99^#-[^SW^SU\)_@WJNN6OB;6_ WA2VL/$7B"PLYM/
MTW6/$U]<W.L^)K_2["XFN+BRTFXU[4M1DTJTN)YKBWT\VT,\CRH[$ ]^HHHH
M **** "BBB@ HHHH **** "BBB@#RO4_A7IT6H77B#P'JM[\.?$EY*;F^N=
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M_JMOA-7\L-?U/?\ !#[_ )-0^(/_ &<-XL_]5M\)J_7_ !R_Y-_B?^QSD?\
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MS2IC?'/Q=Q"IR<<5'.>+\/5X+X1JU95Y8/@+@+*<-AZL:.85E7_J>_X(??\
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M_P#D_?X\?]TO_P#5,_#NOW+P _Y+',O^R<Q?_JQRL_)?&3_DF,#_ -CS#?\
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M4+QHQ&54C^7BOZGO^"X/_)J'P^_[.&\)_P#JMOBS7\L-?VCX&_\ )O\ #?\
M8YSS_P!2<&?RUXM?\EE7_P"Q7E/_ *8Q)] _LF0PW/[5/[,]O<0Q7%O<?M _
M!F&>":-)89H9?B-X;CEAFBD#))%(C,DD;JR.C%6!!(K^XK_A#/!__0I^&O\
MP1:7_P#(M?P]?LB_\G7_ +,/_9PWP6_]63X:K^ZJOS/Z0W_(ZX8_[$V8?^K:
MF?>>"O\ R*L^_P"QI@O_ %6S.:_X0SP?_P!"GX:_\$6E_P#R+1_PAG@__H4_
M#7_@BTO_ .1:Z6BOYZ/VDYK_ (0SP?\ ]"GX:_\ !%I?_P BU_'O_P %3+*S
MT[]N_P".EGI]I;6-I#_PK'RK6S@BMK:+S/@Y\/99/+@A1(DWRN\C[5&Z1V=L
MLQ)_LMK^-O\ X*L?\G\?'G_NEW_JF/AW7[EX ?\ )8YE_P!DYB__ %8Y6?DO
MC)_R3&!_['F&_P#4',#\\Z_J'_X(G>']!U;]E;Q_<:IHFD:E<)^T#XJA2?4-
M-LKR9(5^'/PID6%9;B&1UB5Y)'6,,$#R.P&68G^7BOZGO^"'W_)J'Q!_[.&\
M6?\ JMOA-7Z_XY?\F_Q/_8YR/_U)QA^:>$O_ "65#_L5YM_Z8PQ^MO\ PAG@
M_P#Z%/PU_P""+2__ )%H_P"$,\'_ /0I^&O_  1:7_\ (M=+17\7']2G-?\
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M\DQ@?^QYAO\ U!S _/.OZ&/^"#/_ #=7_P!T-_\ >PU_//7]#'_!!G_FZO\
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M%7@O2/A\WA3Q_IK?'71?&?@Z[?QW\29?&_B+1/&0\$^ /B-XV\+>%GT'X9>
M;N=]0T[6?$-WK5[I]VNJY4_[ GBGQCX1U'PY\7/CW;^)]2T3]G;2_P!G/X2>
M)/ _PI@\!7/@S1M+\4>#?&I\<^,-,UKQ[\0],\>^-]3\4?##X8WNJKI$/P^\
M'S6?AS4].M?"=E%KJ2:2 ?2_P5^-WC'QUX_^+GPB^*'PZT/X=?$OX26GP[\1
M7UOX,\?:C\3? WB+P3\4['Q&WA/7=%\6:W\/OA7K:ZI'K?@;QQH>OZ%?>"+6
M+36T;3[ZRUG5X=8:/3OI*OG/X,?!;Q?X'\<?%;XL?$_X@:!\0OB;\5[;P!H.
MHWG@SP#J'PT\%:%X+^&-CX@3PEH.B^%=:\?_ !1UW[<-8\:>-=<UK6=0\<7L
M>H3ZY;VUCI6D0::?MGT90!_GGT445_I@?P>?V1_\$J"/^&"/@/R/^:H]_P#J
MLWQ$K]#,CU'YBOS8_P""6?ACPWJ/["'P+O-0\/:'?7<W_"SO-NKS2;"YN9?+
M^,?Q"BC\R>:W>5]D2)&FYCMC147"J /T#_X0SP?_ -"GX:_\$6E__(M?YZ\:
M_P#)8\5_]E'G7_JQQ!_:7"W_ "3'#O\ V(\J_P#4&B=)D>H_,49'J/S%<W_P
MAG@__H4_#7_@BTO_ .1:/^$,\'_]"GX:_P#!%I?_ ,BU\R>\?DC_ ,%P"#^R
MA\/L$'_C(;PGW_ZIO\6:_EBK^H?_ (+8^']!TG]E;P!<:7HFD:;</^T#X5A>
M?3]-LK.9X6^'/Q6D:%I;>&-VB9XXW:,L4+QHQ&54C^7BO[1\#?\ DW^&_P"Q
MSGG_ *DX,_EKQ:_Y+*O_ -BO*?\ TQB3]#/^"5'_ "?O\!_^ZH_^J9^(E?V1
MY'J/S%?QI_\ !+.RL]1_;O\ @79ZA:6U]:3?\+.\VUO((KFVE\OX.?$*6/S(
M)D>)]DJ)(FY3MD177#*"/["/^$,\'_\ 0I^&O_!%I?\ \BU^0>/_ /R6.6_]
MDYA/_5CFA^E^#?\ R3&._P"QYB?_ %!R\Z3(]1^8KCOB#\/_  1\5_!7B;X<
M?$?PSH_C+P-XQTJYT3Q+X9UVU2\TO5M-N@/,@GA?#))'(L=S:7<#Q7EA>0V]
M]93V]Y;P3QW?^$,\'_\ 0I^&O_!%I?\ \BT?\(9X/_Z%/PU_X(M+_P#D6OPJ
MI3IUJ=2E5IPJTJL)TZM*K"-2G4IU(RA4IU*<XSA.$X2E"<)QE&492C*+3:?[
M'@\9C,NQF$S#+\7BL!C\!B</C<#CL%B*^#QN"QN$KTL3A,7@\7A:V'Q.%Q6%
MQ-"AB,/B</7HUZ%>C2JTJM.I3A-?S*:SIOQ__P""#/Q8N/$?A6+Q5\<_^"8_
MQ2\5Q/KGAUYCJ7BCX$^(-9N$@CF@GE9+?3]5P8K;3]6E:R\.?$>V@M="\1/I
M'C"+0]7/] ^F_$WX:?M0?LVZWX[^#_BW2_&_@7XD_#GQ1#H&NZ1,6!EOM#O[
M*2SN[=Q'>Z3KFE7KM::EI5]#:ZII.I6\EK=V\%U"RKZ3XE^$_P +_&7A_6?"
MGBOX=^"?$/AOQ#IUWI&N:)JWAC1KW3=4TR^A:"[LKVUFLVBF@FB=E967C(92
MK!6'\T/Q9_9[^,7_  12^+NK?M&?L_\ AB\^.?\ P3[\<ZU;/\9?@OJ\::[K
M7PC-Y.EM'JVGWFHQ7<MI#9B1+/PWXZ?,-U"MGX.^(YFD'A[Q'=?ELZ>.\-*T
MJ^&AB<Q\.ZM24\3@H*KBL?P/*K-RJ8K P7M:^,X6=2I*IB,%'VF(R12G6PRJ
M8%3I4_[RPV-X7^FYEU#+,\Q.3<&_3(R_!TL+DO$N*G@,CX2^E)0P.&A1PF1\
M48AK Y7PWX\K"X6EA,FXEJK!9-XGSHX;+<[E@N*JF&QV-_I^\)ZTGB/PMX:\
M0JRE==T#1M94K@*5U33K:^!4#@ B?( X Z5\0?\ !1K0?A7XG^#'@C2/BY\8
M/@[\'O#K?&;PEJFFW_[1OA!/'/[.'C7Q#X=\/>,?$=A\/OCKX>O?%W@#0+GP
M1K5KI.H:EIK^)?&_AK34^(&B>"4L+C5O$TGA_P -ZWW_ .R#XM^"WQH^ 7P[
M\3>!QX.\46<'AG2;&Y(T[1Y==TZ.&V$>CIXFTYXY-1TG4]1T6*QU1(-42*XN
MK2[@OXC/;7,-Q+[GXT^#'PJ^(7AG5/!WB_P'X<U;PYK*VJ:EIZV"::;E+.]M
MM1MT-YI)L;^)5N[.WD=8+J(3(C03"2WEEB?]1HUJ6(I4Z]"K3K4:L(U*=6E.
M-2G4A)*490G"4HR34D[I];-1=XK^$,QR[,,HQV+RS-<#B\MS+ 8BKA<;@,?A
MJ^$QF$Q-"I4I5:.(PV(I4:U*I"I2J1:E"SY'*$ZM-PJU/PG^)_Q7_8>\4_L4
M_"+P5\1?A7^S3\-?%WQ/O_VGOA=^R]X5^(/Q'L;W]F'P1+??$?4](\9_M._"
M[QY\4++P!H&E_!GPY'_9WQ'^#OB#2?"WA#QS9>#]3M/A3^SGIEEIOB&VM+_D
M?VCF^$.J3?M)67BCQ]X5^*'[4"?"K]B@?\$W_BGJVJZ;K/Q>^(SS>%/#]QX3
M^)O[*.N->ZKJ>K2^*_CE_P )+XA^(&O?!J]OY;R&1+KQW>7?AU-%N)/Z+?\
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M_0I^&O\ P1:7_P#(M?PWXF?\G XM_P"QS6_]1LM/ZTX#_P"2-X;_ .Q73_\
M3^..DR/4?F*,CU'YBN;_ .$,\'_]"GX:_P#!%I?_ ,BT?\(9X/\ ^A3\-?\
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M_P#H4_#7_@BTO_Y%H_X0SP?_ -"GX:_\$6E__(M '\@'_!5?_D_?X\?]TO\
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M$6E__(M?ST?M)TF1ZC\Q7\;G_!5?_D_?X\?]TO\ _5,_#NOZ_P#_ (0SP?\
M]"GX:_\ !%I?_P BU_'O_P %3+*ST[]N_P".EGI]I;6-I#_PK'RK6S@BMK:+
MS/@Y\/99/+@A1(DWRN\C[5&Z1V=LLQ)_<O #_DL<R_[)S%_^K'*S\E\9/^28
MP/\ V/,-_P"H.8'Y^5_0Q_P0:('_  U5D@?\D-Z_]UAK^>>OZ!O^"%6BZ/J_
M_#4O]K:3IFJ?9_\ A2/V?^T;"UO?(\[_ (6[YOD_:8I?*\WRH_,V;=_EINSL
M7'[EXP_\FZXA_P"Z7_ZN, ?DOAE_R6V2_P#=0_\ 59C#^BG(]1^8HR/4?F*Y
MO_A#/!__ $*?AK_P1:7_ /(M'_"&>#_^A3\-?^"+2_\ Y%K^&S^M#I,CU'YB
MOSS_ ."JY'_#!'QXY'_-+^__ %6;X=U]T?\ "&>#_P#H4_#7_@BTO_Y%K\_/
M^"IGACPWIW["'QTO-/\ #VAV-W#_ ,*Q\JZL])L+:YB\SXQ_#V*3RYX;=)4W
MQ.\;[6&Z-V1LJQ!^FX*_Y+'A3_LH\E_]6.'/!XI_Y)CB+_L1YK_Z@UC^/>BB
MBO\ 0H_BT_T+\CU'YBC(]1^8KF_^$,\'_P#0I^&O_!%I?_R+1_PAG@__ *%/
MPU_X(M+_ /D6O\SS^\#I,CU'YBC(]1^8KF_^$,\'_P#0I^&O_!%I?_R+1_PA
MG@__ *%/PU_X(M+_ /D6@#^8;_@N 0?VK_A]@Y_XQY\)_P#JR?BS7XVU^PG_
M  6QTS3=)_:I\ 6^EZ?8Z;;O^S]X5F>#3[2WLX7F;XC?%:-IFBMXXT:5DCC1
MI"I<I&BDX50/Q[K^]_#/_DW_  E_V)J/_J3F1_'G'G_)9<2?]C2I_P"F,"?T
M,?\ !!G_ )NK_P"Z&_\ O8:_H8K^>?\ X(,_\W5_]T-_][#7]#%?RIXP_P#)
MQ>(?^Z7_ .J? ']#^&7_ "1.2_\ =0_]6>,"BBBOS,^\"BBB@ HHHH ****
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MEQF1\3Y/F&29G13E*,:JPV88:@Z^&JN$G0QF#JX_ 8F*<\+C\3#WEZ]7RO\
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M!XG$JC"ICJJ11117MGY<?PJ_M=?\G7_M/?\ 9PWQI_\ 5D^):^>:^AOVNO\
MDZ_]I[_LX;XT_P#JR?$M?/-?Z.Y)_P B7)?^Q-D__JIRH_A[-?\ D:YI_P!C
M3,__ %99@?U/?\$/O^34/B#_ -G#>+/_ %6WPFK]DJ_&W_@A]_R:A\0?^SAO
M%G_JMOA-7[)5_#?B9_R<#BW_ +'-;_U&RT_K3@/_ )(WAO\ [%=/_P!/XX**
M**^&/K3\;?\ @N#_ ,FH?#[_ +.&\)_^JV^+-?RPU_4]_P %P?\ DU#X??\
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M#_U;4SZWP5_Y%6??]C3!?^JV84445_/1^TA7\;?_  58_P"3^/CS_P!TN_\
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M ,F#_ ;_ +JC_P"KG^(E?H97YY_\$I_^3!_@-_W5'_U<_P 1*_0RO\]>-?\
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MQ"BBB@#^%7]KK_DZ_P#:>_[.&^-/_JR?$M?/-?0W[77_ "=?^T]_V<-\:?\
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M^$U?LE7XV_\ !#[_ )-0^(/_ &<-XL_]5M\)J_9*OXN\3/\ DX'%O_8YK?\
MJ-EI_4O ?_)&\-_]BNG_ .G\<%%%%?#'UI^>?_!5C_DP?X\_]TN_]7/\.Z_C
M;K^R3_@JQ_R8/\>?^Z7?^KG^'=?QMU_7W@!_R1V9?]E'B_\ U796?S3XR?\
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M_#/_ )-_PE_V)J/_ *DYD?QYQY_R67$G_8TJ?^F,"?T,?\$&?^;J_P#NAO\
M[V&OZ&*_GG_X(,_\W5_]T-_][#7]#%?RIXP_\G%XA_[I?_JGP!_0_AE_R1.2
M_P#=0_\ 5GC HHHK\S/O HHHH **** "BBB@ HHHH **** ,G7EUQ]#UI?"\
MNDP>)6TG45\/3Z];WEWH<.N-9S#29=:M=/N;*_N=)COS;OJ-O8WEI>36:S1V
MUS!,R2I^0_A;]D'XR_$?X?\ QVM[+P7\+_V2]+\6:/I_ASPG\"/ OB?XA>)_
M@YJWQI^"GQM?5U^-4_@S4? WPOT3X9>$_B4_PV\.P:;_ ,*Y\)7VL^,O 'BE
M/B!XFU34O$@L--/['44 ?+7P*^&'Q/T?XG_''XV_%ZT\">'_ !9\7;?X7>&M
M/\$_#KQ7X@\?:!X;\)_"G1_$46FW-UXV\2>!?AEJ&LZWKVO>-O%%[=VT?@72
M[32-/BTFSBO]7F^T7$?U+110!R=OX"\"V=O!:6G@OPG:VMK#%;VUM;^'-'@M
M[>W@18H8((8K-8X888U6.**-52-%5$4* !-_PA7@W_H4O#/_ ((=*_\ D2O,
MOC%^TK\#O@!/X>MOB]\0-.\&3^*1?3:3%<Z?KFJ.--TN:PM]6\0:L-!TO5?^
M$=\)Z//JNF0ZSXO\0_V7X7TB6_LTU+5[5KB(-[=#-#<PQ7%O-%<6]Q%'-!/#
M(DL,T,J"2*:*6,LDD4B,KQR(S(Z,&4D$&FVVVVVVVVVVVVVVVVVVVVVVVVVV
MVVVVVTDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDN>_X0KP;_T*7AG_ ,$.E?\
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MRRO+:6*XM;JWED@N()(YH9'C=6-V@+',_P#"%>#?^A2\,_\ @ATK_P"1*/\
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M=-10!S/_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
MPA7@W_H4O#/_ ((=*_\ D2C_ (0KP;_T*7AG_P $.E?_ ")735Y'\8_CO\*/
M@#X>LO%'Q9\6)X8TK4]1;2=)BM]'\0>)M;UC4([&[U2YMM&\,>$M)UWQ-K#6
M&E6%_J^J/IFD746E:18WFJ:D]KI]K/<Q@';?\(5X-_Z%+PS_ ."'2O\ Y$H_
MX0KP;_T*7AG_ ,$.E?\ R)5WP[XAT/Q=X?T+Q7X9U2RUSPWXGT;3/$/A[6M.
MF6YT_6-#UJR@U+2=4L+A,I/9:A87-O=VLR?++!,CKPPK9H"R[(YG_A"O!O\
MT*7AG_P0Z5_\B4?\(5X-_P"A2\,_^"'2O_D2NFHH YG_ (0KP;_T*7AG_P $
M.E?_ ")1_P (5X-_Z%+PS_X(=*_^1*Z:B@#F?^$*\&_]"EX9_P#!#I7_ ,B4
M?\(5X-_Z%+PS_P""'2O_ )$KS'P[^TO\#?%GQ:UOX&>'OB#IVI?%#P]#J\FH
M^'4T_78+:2;P[<6MKXETS2?$MUI4'A3Q!KWA>>]M4\4^'- US4]>\-">.37=
M-T^,[Q[I0*R[+[E_D<S_ ,(5X-_Z%+PS_P""'2O_ )$H_P"$*\&_]"EX9_\
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M\2 "QWO_  A7@W_H4O#/_@ATK_Y$H_X0KP;_ -"EX9_\$.E?_(E=-10!S/\
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M1S0R+'<6UQ'+;7,4-Q#+$G3T!9=E]R.9_P"$*\&_]"EX9_\ !#I7_P B4?\
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M_ 6O^*]2M;?0++7-#TR[TL L_L!^"?VE_!/PJ\+>&?CA8Z5X#\)_#OP)X?\
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M\(V=K#XD\?\ PTL;;QYX);XD^+O#>NZ5<:!I7B/48=&LM>U+0M9M;( ]\_:
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MS2KW1M7^.(\:Z;HD?PXU&'0KRVMO%7PY\<W.MZ?\2GU>6^^%/BVPU.37$@0
M[WQ[X ^'O[4OP%^%7Q&^%7@WQD/'_B?X3:_XR^%'P8\!_%K2/@U_PISQQ\>[
M^YUKQK\9_%FKZ7K/@CQ;JEEX5\>2W&G:]=:8OC#1]0O8M2G\/?#?Q!>ZK)<V
M_P"H'@C2M=T+P9X1T/Q1KK>*/$VC>&- TKQ%XF:#[,WB+7=.TJTM-7UUK8%A
M;MJ^H0W&H& ,WE&X\O)VYKP/]F+]DCX9?LL:%JEAX.GU[Q/XBUO[/::OX\\:
M7D&J^++GPYH\EPGA/P;;7<%M:6NE>$?"&GSFST70=*M;.Q^TR7^N7L5UKFKZ
MGJ%U]1T %%%% !65JFM:9HZVPO[VS@N;^;['I-E/?6%E=:QJ+(SPZ9I:ZA=6
MD-UJ%R5V00"9-S$%V2,,Z^=?%CXS>$/A%HNHW>LO=ZQXF3P;XR\9>&/A]H,)
MOO&GCNV\$)HR:QI_A32AM^W7<5]XE\.6-Q-+)!8Z8-9@U+5[JQT>VO\ 4+3\
MG?B3XE@^*W[0'B76OVL/V2+W7?"'PX^%WAWX;?%GX>Z=(?CEJ?P5T+XD:SKG
MC;P%^TA\.[KPEIEGK^IZ%XD'AOQ+X*^)FI> ?#EC\0/ &L?#C2-2T:\\0:1I
M]Q=0@'N?B[Q7\?O'.D^*O@#^U1;?"/P)I'[2O[,_Q>\=^!-<\-'5]%;X ^*/
M =EX8&J>$OB7XAU3Q+XCTCQ)<^$+/QEX?\<#XCZ+%X<T2TUSPQXHLHM+O=+&
MAWC>B?L;?LT>.OA7K_B#XR>(/B)X:_L_XT>'Y/$.J? OX:G6-1^"'P\\2Z]J
MMAX@CUKX/:I/XACTM;/Q!:R:EJ/CJ]@\'P6OC/Q5JR^(_#;>$M'AGT36>%^$
MO[-V@?M.>!/AQK'QYNOB?XV\)_!#XC?$_2O@I=^.O[6\*ZG\<O@7JU]X7OO!
MMS\=_"VO:)I?B#Q39PW7AO1((%UBS\/CX@6O@K1/%_B73=5L/%-_:7_Z>1QI
M$B11(D<4:+'''&H1(T0!41$4!515 554 *    * 'T444 %%%?GS^T)^UU>:
M=X'\9:G\)? 7BOXB?"W2OA%<>._B3\>? GB&UTM?AOX+\17/B[PV?%7PVTNY
MMH[OXJ>,/!"^$_%'BO7?#NAZQX=&@66@117WB&RUK4-.T^8 ]W^,7B#X]ZW<
M:!X<_9DN/A3'?&X\6R>-OB#\1[?4/&'A'PA?^$4T,Z9X O/"_A'Q=X8\22>)
M/&^HZPUM/?QWI@\):!HOB#4;RTGUB7P[IVH_G!K7PBUG]NS6_AE\2]$\5^#?
M@3K/Q?\ @SX-\:^.+G0O$MS/^T1\(/'_ ,%?$?CGP??ZY\&8K";2KEM$\67?
MCV?X;^,O&][=C1KKP=X5LM#NM#N-5U_2;S2\[X.Z+9?"[Q7^SSH'PW^$/B/X
M0_M1^&->^''PS^,&F_#KX?Z])\ _VG/@ ^I6>E>+_C?>?$+1])N/A[KMGIWA
MB>Y^*?ACQGXDUJR^*FD>,X)?AGJ_V]/$J'4OTJ_9W_91^$O[,T'BIOA_;:[J
M>N>,M6N[_6_%WC/54\0>*7TIM2U#4M&\&V&I+9V,6E^"?"KZG>0^'?#NGVMO
M:P/<7FJ:BVI:_J6JZQ? 'N/@W1]4\/>$/"F@:WJT&OZUH?AO0M'U?7;:RO-,
MMM:U33-+M;*_U:WTW4=9\1:AI\&I7<$MY%97WB#7;RTCF6"ZUG4YXWO9^DHH
MH ***\L^*7Q@\&_"31[V_P#$=S=7FLKX3\;^+M \&:):3:IXP\9VGP_T9-<\
M16'A+1+9'N=8U.VLYK4FUA \M;E+B=HK6*XGA /1+_5=+TO[%_:>I6&G?VC?
MV^E:?]OO+>S^WZI>;_LFFV7VB2/[5?W7ER?9[.#S+B?RW\J-MK8_-CQ'XP^/
M7C*6[^!G[4VC_"SPC\/?VMO@C\<E\-Q^'8M2L_$_P#O_  [X8LY;SPK\3?$%
M]XKUOPOXSF3P;KTOB67QIX7'AFQT#Q;X=UO3H([_ $B30M97P3XJ>+KSXI_'
ME[[]J?\ 9&O=>\+?#+X3#P]\2O@OOT_X\ZEX%\!?&;6;B^\)?M+_  JM] M+
M:X\1WMAJ_P /?$7PY^,D'@#P])X\^'R:7H.M^%=>\4:>3&_L'PD_9J\)?M0?
M#KPQ;_%_5/BWXT^%GP2^,?C.#X :CXT;7?!^N?&3X#ZIX6\)MIVB_&'2/$NB
M:=XO\4^%+'7Y=8\'PR:S'HNH?$;P[X$T/7O$4NL:+XIU6TU< [?]C#]FCXB_
M#O7&^.WB7XI^$[BW^+WA*XUOQ%\&OA=)K&M_ W2/$7B=/!^II\0OA?K;>(;#
M1WUOQPNAW'B7XCZ_:^"_[(\9:WK\=YX6M_#5E97]YXN_1JH;:VM[.W@M+2"&
MUM+6&*VMK:VB2"WMK>!%BA@@AB58X888U6.**-52-%5$4* !-0 4444 %?/W
MQA\:_%HQZ%X7_9UTWP!X@\;:KXFNM(\3>)O'5U?:IX$^%NEZ=H&K:S+>^+]$
M\):O8>++_5M:O[+3_#V@:-:W&EP&YU&XU'4]6LX].@L=6\]^*O[:OPS^%?B*
M+3IO#?CSQMX0TG1_ _BCXE_%?P#IV@Z_\-_A)X1^)-]=Z;X*\2^,-4/B.UUC
M4K+6);==6DA\$:%XLNM+\)N?%>JQ6>DO8R7_ .=/@[P+??L_W7PV\$^%_A3X
MN\$?MO\ PP\1>$/!L'CKP+\/_%>H_#7]N#X1WOC2SM/&7BCXF^/--L-4\*M-
MK7A:^OO'OCW4_BAK&F^+/A+\3(I-4\/7=[I$MC#K0!Z3XJ^&/C3]MNZ^"OQ#
M:_\ !WP5\7^*]!\;?#7XO"+7[W_A:GPN^(/[)_QWU;21XW_9SD1+"^OO$GAS
MQG)\5O"=KXCU-H;#POX;^(5M?:S9>(X+^Y\.:U^J'PH\(ZYX ^&?@+P+XE\4
M_P#";ZWX-\)Z%X6O_%[6&HZ9/XE;0=/@TN'6;ZTU;Q%XLU(:G?VUK#<:K<7G
MB+5)KW4GNKUID%P((O(O@M^RC\-_@IXY^)/Q)TNZ\0>*O&WQ%\7_ ! \11ZY
MXOOHM3E\":!\1_B%XA^*>O\ P]^'T"6\%OX9\&W'COQ7K_B6^MK6,ZAKFJWZ
M7.NZAJ(T[28]/^G: "BBB@ K.U/5])T6W2[UG5-.TFUDN(;6.YU.]MK"WDNK
M@E8+9)KJ6*-KB=@5AA5C)(00BL0:Y7Q[\2_!7PTLK*\\8:W!ITNK?V[%X?TJ
M-);S7/$U]X<\*:_XWU72?#>CVJ2W^MZO#X9\,:YJ<6G6$,MS<)8M%"CSR0QR
M?D3\8_B9XC^,_P 6/AC<_'G]C#4M=\*_#_X5^.?'7B3X"ZI=Z'\9-;\3?!?X
MS77A'PW#\9/#/A;3K:SL)_C+\$=9\*)X;\8?#1+37=;TSP?\6==O_ WB+6M7
M^SVUR >Z_$B7XW?$7Q[\-O ?[1GA7P5X3^%GQG^)7C_1O@O?>!I=0TOXV_LY
M_%+X0^'/B#\3_A7\3;[QZWB+Q/X0\0Z[XK\"_#WQ?JT]MHFAZ-HGA_-GX9U.
M7Q=HNJ>(;75NP_9I^#5MX6^.>I_$?X677BJY^#>H?" ^'_%GQ(\3?%9?B0G[
M5/Q1UK6O!OB/P[\9](%AXK\5Z<+7P?H%EXST2\\23+X5EUC4_']YH6B>&8/#
MGA.RN'\Q^$GP \)?M-?#S4OAWXJU?XQ:[^S%\)?C=I/C']FG7M=?QG\.?&'B
M;P+?_"C6_"7B[X1>(I/&.CZ5\1?$OPDT.V^(OCCX<VNLZ@FDZMXD\)WA\+0Z
M[=V7AM]0U']3-+TO3-#TS3M%T73K'2-'TBQM-+TG2=+M+?3],TO3-/MX[2PT
M[3K"TCAM;*QLK6&*VM+2VBBM[:WBCAAC2-%4 %ZBBB@ HHHH **** "BBB@
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M=0\:_$OQSJ4<SZ/X.\(Z67C%SJ-X()KF]OKF2WTG0='M=0U[7;VPT?3KR[B
M+OQ9^,_@SX0>$?&OB;6[DZQJ7@KPD/&$_@7P_=:7=>.=9L;N_?1=!M]'T*\U
M"Q=Y?$WB-4\-:'=WLUEI=UK<GV-[^(Q3M%\L_%WQ_P"'_BY\%_ G[8'P*DF\
M1>(?V=O$FI?$3^PI-.FL?%T_AC3+&]\-_M#?!3Q%H5W$VJ>'_&DG@B?78?\
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M7\56UK19V\1VFD?$/PWK?@GXR>'O$6BS6>M:3)XIDU'PY);:C:0ST >5Z?\
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M?$F73;V/1-5\/>"-&B@31Y=-@_MGQC!JLF@^*M6NO!&C6OA[5OIKPAX/\,^
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M>W^F2:5J,_FGC/XMW_Q:^$NC_M76OPNUCP)\4_V/OBAXWTWXO_"'Q#<66O\
MB:R^&$VFV=M\;?A_>SZ.)M*U:YUWX/:QX.^,VBV%C!?17?B+PYX/TJWN+E?-
MN;GWS7_V=K#XB?M"> ?VB_!WCB?P?X0G\(:'J'C:+X;:WK&CWO[05]HNL:3X
MB^%@\?W>G746B:KX,\&VMJUS875O;R>(_$^FZQ-X-U;5O^%?&^\/:R <)JGP
M&\._M7_$WX7_ +4.C?%?6/\ A1GB_P"#OP]&I?#GP]%)I%S\1QX:\6:[\1_
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FU[#3(94T[2+-H-*TFUL=*L[.RM^NHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #K!!,# 2(  A$! Q$!_\0
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MFF_^2J/L?C#_ *#NA_\ @FF_^2J .@HKG_L?C#_H.Z'_ .":;_Y*H^Q^,/\
MH.Z'_P"":;_Y*H Z"BN?^Q^,/^@[H?\ X)IO_DJC['XP_P"@[H?_ ()IO_DJ
M@#H**Y_['XP_Z#NA_P#@FF_^2J/L?C#_ *#NA_\ @FF_^2J .@HKG_L?C#_H
M.Z'_ .":;_Y*H^Q^,/\ H.Z'_P"":;_Y*H Z"BN?^Q^,/^@[H?\ X)IO_DJC
M['XP_P"@[H?_ ()IO_DJ@#H**Y_['XP_Z#NA_P#@FF_^2J/L?C#_ *#NA_\
M@FF_^2J .@HKC]=N/&&B>'M3U;^U]#F^PVDMSY7]D3+OV(6VY^TG&<8S@UV%
M !1110 4444 %%%% &7JOB#3]&N+>WN_M;3W".\4=K937+%4*AB1$C$ %T&3
MCJ*I_P#"9:7_ ,^NN?\ @BO?_C-%Y_R4/1O^P5?_ /HVTKH* .?_ .$RTO\
MY]=<_P#!%>__ !FC_A,M+_Y]=<_\$5[_ /&:Z"B@#G_^$RTO_GUUS_P17O\
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MU '045S_ /PANE_\_6N?^#V]_P#CU'_"&Z7_ ,_6N?\ @]O?_CU '045S_\
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M^?K7/_![>_\ QZC_ (0W2_\ GZUS_P 'M[_\>H Z"BN?_P"$-TO_ )^M<_\
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M Z"BBB@ HHHH **** "BBB@ KG_'?_)//$O_ &"KK_T4U=!7/^._^2>>)?\
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M:T>\DL_AQ=Z;9:?/IDUSJ=QI]E&QC^4R3N/E",WW 6S_ +AQD<T[76GE^/\
MPZ_$2\_Z_JS_  .RC\:>'Q86]Y>:I::='<[S +ZXCA:558KN4%N5.,CV(Z5N
MQR)-$DL3J\;@,K*<A@>A![BN'U^/1]!EM5@\22:)?6MA]GM( (BMP@/RH%D0
MESE0,(0W/N*ZO0[F]O-!T^ZU&W%O>S6\;SP@8V.5!8?G1T;7]?U^ M>I?HHH
MI#"BBB@ KG[/_DH>L_\ 8*L/_1MW705S]G_R4/6?^P58?^C;N@#H**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#G_!O_ " [G_L*ZE_Z6S5T%<_X
M-_Y =S_V%=2_]+9JZ"@##/C/PL+DVQ\2Z,)P_EF(W\6[=G&W&[.<\8J_!K&F
M76H3:?;ZC9RWL S+;1SJTD?^\H.1^-9K?\E 3_L%M_Z-6N;T"^M+#Q)::3I-
MW::M9333RF/RL76F,VYV,AZA23MPP5N>K41UM_7?_(3>_D=[-=6]NZ)//%$S
MYV!W"EL#)QGK@<FJ%[XH\/Z;Y/V[7=,M?/020^?=QIYB'HRY/(]Q7G?Q1@OI
MM;>2WAW1VNC7$NX:M<6^"S*@.Q%VDC)XS\^<$@*,Z&I+:>'+6%H_$<NDZ[!I
MB0QV/FK<K<["S*B^;'YDOS$CY"#@CIQ0MKO^MRNMOZZ?YG=:GJ]OI=I#<2!Y
M1--'!$L(#%V=@HQD@8YR?8&HH/$N@W6IG3;?6]-EOPS*;6.Z1I05ZC8#G(P<
M\=JPX9IM>\5:3%=Q"-]+LEO;J$9PES*NU%_ >;^8K,T^_BT_Q#8V'A[7Y=3A
MN;Z8WVG2)$QLU??(SDJBO'A^ )"<YP*JVMG_ %_5F3>ZNOZZ_P"1Z'1114C"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_P &_P#(#N?^PKJ7
M_I;-705S_@W_ ) =S_V%=2_]+9J .@HHHH **** "BBB@ HHHH *Y_QW_P D
M\\2_]@JZ_P#135T%<_X[_P"2>>)?^P5=?^BFH Z"BBD9E12S$*H&22< "@"@
M=$TYK"XL3; V]Q*TTB;VY=FW%@<Y!W<C&,'IBDTO0[#1_--G')YDQ!EFGG>:
M5\=-SR,S$#)P">*DT[6-,U>.233-1M+U(VV.UM.L@5O0E2<&F6VO:/>W\EA:
MZM8SWD6?,MXKA&D3'JH.10#\QJ:#ID=XMVEMB=;A[D/O;_6NNQFQG'W>/0=J
MJ#PEI::TVLQF^&HD$>:VHW#+C).W89-NS)SMQCVK3O\ 4K'2K4W6HWMM9VX(
M!EN)5C0$]!EB!4=QK.EVFG+J-SJ5G#8N 5N9)U6(@],,3CF@"GI?ANVL?#2:
M-<,;I&#-/*<H99&8LS\'*DL2>#QZU9TO0M/T<RO9Q2>;-CS9IYY)Y7 S@%Y&
M9B!DX&>,T^XUG2[33EU&YU*SAL7 *W,DZK$0>F&)QS276NZ18V$=_=ZK8V]G
M+CR[B6X1(WSTPQ.#3;U;#<OT4R&:*XA2:"1)8G 9'1@RL#T((ZBGT@"BBB@
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MCD8=FS@D=*Z^CI<.M@HHHH **** "N?\"?\ )//#7_8*M?\ T4M=!7/^!/\
MDGGAK_L%6O\ Z*6@#H*Y_P /?\ASQ9_V%8__ $BM:Z"N?\/?\ASQ9_V%8_\
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M7E=7P\BL'=54;D&T,.N=HK;L/!VC:;-=RV\=XS7BE;@7&H7$ZRY 7++(Y!.
M!G&<<59TSPYIFD7+W-K%,UPR>7YMQ<RW#JG7:K2,Q5>.@P*.M_('L_4U:***
M0!1110 5S_C+_D!VW_85TW_TMAKH*Y_QE_R [;_L*Z;_ .EL- '04444 %%%
M% !1110 4444 %<_>?\ )0]&_P"P5?\ _HVTKH*Y^\_Y*'HW_8*O_P#T;:4
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M9_[!5A_Z-NZ .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?\
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M?\D\\-?]@JU_]%+705S_ ($_Y)YX:_[!5K_Z*6D,Z"N?\/?\ASQ9_P!A6/\
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M[KH*Y^S_ .2AZS_V"K#_ -&W=2!T%%%% !1110 4444 %%%% !1110 4444
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M0ZI_T)FN?]_K+_Y(H_X2'5/^A,US_O\ 67_R10!T%%<__P )#JG_ $)FN?\
M?ZR_^2*/^$AU3_H3-<_[_67_ ,D4 =!17/\ _"0ZI_T)FN?]_K+_ .2*/^$A
MU3_H3-<_[_67_P D4 'CO_DGGB7_ +!5U_Z*:N@KB_$NH:UK/A75]+M_!^LK
M/>V4UO&TD]D%#.A4$XN"<9/H:[2@ HHHH **** "BBB@#G[S_DH>C?\ 8*O_
M /T;:5T%8>L:/J5UK-CJFEZC:6D]K;SV[+=6;3JZRM$V1MD0@@PCN>IJ/['X
MP_Z#NA_^":;_ .2J .@HKG_L?C#_ *#NA_\ @FF_^2J/L?C#_H.Z'_X)IO\
MY*H Z"BN?^Q^,/\ H.Z'_P"":;_Y*H^Q^,/^@[H?_@FF_P#DJ@#;:UMWNH[I
MX(FN(E98Y2@+H&QD ]0#@9^@J6N?^Q^,/^@[H?\ X)IO_DJC['XP_P"@[H?_
M ()IO_DJ@#H**Y_['XP_Z#NA_P#@FF_^2J/L?C#_ *#NA_\ @FF_^2J .@HK
MG_L?C#_H.Z'_ .":;_Y*H^Q^,/\ H.Z'_P"":;_Y*H Z"BN?^Q^,/^@[H?\
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MW83=E<H?\(]JG_0YZY_WYLO_ )'H_P"$>U3_ *'/7/\ OS9?_(]=!14C.?\
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MFA_^"Z'_ .)H Z"BN?\ ^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXF@#H**Y_P#X03P?_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B: .@HKG_
M /A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_ .)H Z"BN?\ ^$$\'_\
M0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\ XF@#H**Y_P#X03P?_P!"IH?_ (+H
M?_B:/^$$\'_]"IH?_@NA_P#B: .@KG_!O_(#N?\ L*ZE_P"ELU'_  @G@_\
MZ%30_P#P70__ !-;%C86>F6<=G86D%I:QYV0P1B-%R23A1P,DD_C0!8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (XIXII)
MDC;+0OLD&#PVT-C\F!_&I*SM-_X_]8_Z_%_]$15HU4E9B3N@HHHJ1A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54TZZ>[MGDD"A
MEGFC&WT21D'XX45;K.T3_CPE_P"ORZ_]'R527NLE[HT:***DH**** "L[6_^
M/"+_ *_+7_T?'6C6=K?_ !X1?]?EK_Z/CJH?$B9?"S1HHHJ2@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"*XN(K2VDN)W"11J6=CV J16#*&!R",BL?Q:2/"FI8./W)K8 "@
M# ' %5;W;DW]ZPM%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I@_Y[1_\
M?0H^TP?\]H_^^A0!+147VF#_ )[1_P#?0H^TP?\ /:/_ +Z% $M%1?:8/^>T
M?_?0H^TP?\]H_P#OH4 4]-_X_P#6/^OQ?_1$5:-96G7$(OM7)FCYNU(^8<_N
M(JT/M,'_ #VC_P"^A53W_KLB8[$M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH5)
M1+147VF#_GM'_P!]"C[3!_SVC_[Z% $M%1?:8/\ GM'_ -]"C[3!_P ]H_\
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M%'VF#_GM'_WT* ):*B^TP?\ /:/_ +Z%'VF#_GM'_P!]"@"6BHOM,'_/:/\
M[Z%'VF#_ )[1_P#?0H EHJ+[3!_SVC_[Z%'VF#_GM'_WT* ):*B^TP?\]H_^
M^A1]I@_Y[1_]]"@#*\4_-HZQGH]U I^GFK6U6#XDGB>SLXQ*A#WUN&PPX'F#
MFMG[3!_SVC_[Z%:/X%\_T(7Q/Y$M%1?:8/\ GM'_ -]"C[3!_P ]H_\ OH5F
M62T5%]I@_P">T?\ WT*/M,'_ #VC_P"^A0!+147VF#_GM'_WT*/M,'_/:/\
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MTO=59T95>Z5D)&-P\F(9'J,@C\#5^BBFW=W$E8****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *AM;5+2%HXRQ5I))#N]7<N?
MPRQJ:BBX!1110 4444 %0W5JEW"L<A8*LD<@V^J.''X945-10G8 HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH RM=ADGCL$CC9\7T+L54G:JMG)]N/UK5HHIMW20K:W"B
MBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "HE_P"/J3_<7^;5+42_\?4G^XO\VH EHHHH *BMO^/6'_<'\JEJ*V_X]8?]
MP?RH EHHIKL5&0C-[#']: '45%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (T 2T5%
MYK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>:_\ S[R?FO\ C0!+
M147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\ S[R?FO\ C1YK_P#/O)^:_P"-
M $M%1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:_P"-'FO_ ,^\GYK_
M (T 2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>:_\ S[R?
MFO\ C0!+147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\ S[R?FO\ C1YK_P#/
MO)^:_P"- $M%1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:_P"-'FO_
M ,^\GYK_ (T 2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>
M:_\ S[R?FO\ C0!+147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\ S[R?FO\
MC1YK_P#/O)^:_P"- $M%1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:
M_P"-'FO_ ,^\GYK_ (T 2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\
MGYK_ (T>:_\ S[R?FO\ C0!+147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\
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M1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:_P"-'FO_ ,^\GYK_ (T
M2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>:_\ S[R?FO\
MC0!+147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\ S[R?FO\ C1YK_P#/O)^:
M_P"- $M%1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:_P"-'FO_ ,^\
MGYK_ (T 2T5%YK_\^\GYK_C1YK_\^\GYK_C0!+147FO_ ,^\GYK_ (T>:_\
MS[R?FO\ C0!+147FO_S[R?FO^-'FO_S[R?FO^- $M%1>:_\ S[R?FO\ C1YK
M_P#/O)^:_P"- $M%1>:__/O)^:_XT>:__/O)^:_XT 2T5%YK_P#/O)^:_P"-
M'FO_ ,^\GYK_ (T 2T5&)') ,$@]R5X_6I* "HE_X^I/]Q?YM4M1+_Q]2?[B
M_P VH EHHHH *BMO^/6'_<'\JEJ*V_X]8?\ <'\J ):*** "BFNZQHSNP55&
M23T JA9Z[IU_=_98)W\_9YBI)"\9=>FY=P&X>XS0!HT5F1>(=+GO%M8[K,CN
M8T8QL(W8=55R-K'V!-#>(=+2\^RM=8D\SR=WEMY8D_N;\;=WMG- &G163>>(
M].T\2M=?;(DB.'D-C.4';.X)C'OG%:JL'0,O0C(XQ0 M%%9^H:W8:6Q6ZE=2
M$\Q@D+R;%_O-M!VC@\G XH T**HW&L6%K;P3R3[DN,>2(D:1I<C/RJH)/'/
MJ/\ M[3/[/6^%T# [^6NU6+%_P"Z$QNW?[.,T :5%9JZ_IC6$E[]J AB?RWW
M(RNK_P!TH1NW>V,U-8ZK9ZD95MI&,D) DCDC:-TSTRK $9^E %RBBF2RQP0O
M-*X2-%+,S'  '4T /HK/LM<T^_N7MH)G$ZIYACEA>)BO]X!@,CW'%,MO$.EW
M=TEM#<[GD+",F-E20CKL<C:V/8F@#3HK,7Q#I;7@M1=?O&D,*MY;>69!_ 'Q
MM+>V<T/X@TN.]^RM<D2"00EO+<QAST0OC:&]LYH TZ*** "BLZ_UW3M,D*7<
MSJ54.Y2%W"*> 6*@A1[G%/N]7L;*.!Y9BWG\Q+$C2M(,9RJJ"2,=P* +U%9S
MZ[I<>D_VH]]$ME_SU)P,^F.N?;K4CZO81Z9%J+W %K*JM&^TY?=]T!<9)/IC
M- %VBJEAJ=IJ22-:REC$VR1'1D=#Z,K $?B*MT %%1SSQ6T#SS.$BC4LS-T
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MC)(5 3CWZ59M+NWOK6.YM95E@D&5=3P: )J**@O+V"P@\ZX<JF0HVJ6+$]
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M\/H+I[5&CG"RJJDA]JX W C)&>Q[UH>&K^ZO8+Y+F;[0+:[>".XVA?-48Y.
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MMFVT?3+-)4M=.M(%E&V010*H<>AP.>M+%I.FP6LEK#I]I';R_P"LB2%0C_4
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M4%KXRUF^EE1+6WL85GD)X5LL<'WQCCW%;D.CZ9;VTMM#IUI'!+_K(D@4*_U
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M* (OLT'_ #QC_P"^11]F@_YXQ_\ ?(J6B@"+[-!_SQC_ .^11]F@_P">,?\
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M_?(J6B@"+[-!_P \8_\ OD4?9H/^>,?_ 'R*EHH B^S0?\\8_P#OD4?9H/\
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M%'V:#_GC'_WR*EHH B^S0?\ /&/_ +Y%'V:#_GC'_P!\BI:* (OLT'_/&/\
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7C_[Y%/2../.Q%7/7:,4ZB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>iccc-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:iccc="http://immucell.com/20241231" targetNamespace="http://immucell.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iccc-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet" id="iccc_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" id="iccc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedIncomeStatement" id="iccc_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ShareholdersEquityType2or3" id="iccc_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" id="iccc_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>995305 - Statement - Statements of Stockholders&#8217; Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ConsolidatedCashFlow" id="iccc_r_ConsolidatedCashFlow">
        <link:definition>995306 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BusinessOperations" id="iccc_r_BusinessOperations">
        <link:definition>995307 - Disclosure - Business Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies" id="iccc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>995308 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivable" id="iccc_r_TradeAccountsReceivable">
        <link:definition>995309 - Disclosure - Trade Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Inventory" id="iccc_r_Inventory">
        <link:definition>995310 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" id="iccc_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>995311 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet" id="iccc_r_PropertyPlantandEquipmentNet">
        <link:definition>995312 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssets" id="iccc_r_IntangibleAssets">
        <link:definition>995313 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses" id="iccc_r_AccountsPayableandAccruedExpenses">
        <link:definition>995314 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebt" id="iccc_r_BankDebt">
        <link:definition>995315 - Disclosure - Bank Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments" id="iccc_r_ContingentLiabilitiesandCommitments">
        <link:definition>995316 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeases" id="iccc_r_OperatingLeases">
        <link:definition>995317 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquity" id="iccc_r_StockholdersEquity">
        <link:definition>995318 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/Revenue" id="iccc_r_Revenue">
        <link:definition>995319 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNet" id="iccc_r_OtherExpensesNet">
        <link:definition>995320 - Disclosure - Other Expenses, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxes" id="iccc_r_IncomeTaxes">
        <link:definition>995321 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformation" id="iccc_r_SegmentInformation">
        <link:definition>995322 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactions" id="iccc_r_RelatedPartyTransactions">
        <link:definition>995323 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefits" id="iccc_r_EmployeeBenefits">
        <link:definition>995324 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SubsequentEvents" id="iccc_r_SubsequentEvents">
        <link:definition>995325 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountingPoliciesByPolicy" id="iccc_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" id="iccc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryTables" id="iccc_r_InventoryTables">
        <link:definition>996002 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="iccc_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables" id="iccc_r_PropertyPlantandEquipmentNetTables">
        <link:definition>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsTables" id="iccc_r_IntangibleAssetsTables">
        <link:definition>996005 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" id="iccc_r_AccountsPayableandAccruedExpensesTables">
        <link:definition>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtTables" id="iccc_r_BankDebtTables">
        <link:definition>996007 - Disclosure - Bank Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeasesTables" id="iccc_r_OperatingLeasesTables">
        <link:definition>996008 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityTables" id="iccc_r_StockholdersEquityTables">
        <link:definition>996009 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RevenueTables" id="iccc_r_RevenueTables">
        <link:definition>996010 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetTables" id="iccc_r_OtherExpensesNetTables">
        <link:definition>996011 - Disclosure - Other Expenses, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxesTables" id="iccc_r_IncomeTaxesTables">
        <link:definition>996012 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformationTables" id="iccc_r_SegmentInformationTables">
        <link:definition>996013 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" id="iccc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" id="iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable">
        <link:definition>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable" id="iccc_r_ScheduleofConcentrationofRiskTable">
        <link:definition>996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" id="iccc_r_ScheduleofNetIncomeLossPerCommonShareTable">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/TradeAccountsReceivableDetails" id="iccc_r_TradeAccountsReceivableDetails">
        <link:definition>996018 - Disclosure - Trade Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/InventoryDetails" id="iccc_r_InventoryDetails">
        <link:definition>996019 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofInventoryTable" id="iccc_r_ScheduleofInventoryTable">
        <link:definition>996020 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" id="iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable">
        <link:definition>996021 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL7fWyfpbHugMhNVFtg+5QLG] CSR-->
      <link:roleType roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" id="iccc_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>996022 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" id="iccc_r_ScheduleofPropertyPlantandEquipmentTable">
        <link:definition>996023 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IntangibleAssetsDetails" id="iccc_r_IntangibleAssetsDetails">
        <link:definition>996024 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable" id="iccc_r_ScheduleofIntangibleAssetsTable">
        <link:definition>996025 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" id="iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable">
        <link:definition>996026 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/BankDebtDetails" id="iccc_r_BankDebtDetails">
        <link:definition>996027 - Disclosure - Bank Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" id="iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable">
        <link:definition>996028 - Disclosure - Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable" id="iccc_r_ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable">
        <link:definition>996029 - Disclosure - Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" id="iccc_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>996030 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OperatingLeasesDetails" id="iccc_r_OperatingLeasesDetails">
        <link:definition>996031 - Disclosure - Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" id="iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable">
        <link:definition>996032 - Disclosure - Operating Leases - Schedule of Lease Costs and Other Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" id="iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable">
        <link:definition>996033 - Disclosure - Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/StockholdersEquityDetails" id="iccc_r_StockholdersEquityDetails">
        <link:definition>996034 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" id="iccc_r_ScheduleofActivityUndertheStockOptionPlansTable">
        <link:definition>996035 - Disclosure - Stockholders&#8217; Equity - Schedule of Activity Under the Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" id="iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable">
        <link:definition>996036 - Disclosure - Stockholders&#8217; Equity - Schedule of Additional Information About the Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" id="iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable">
        <link:definition>996037 - Disclosure - Stockholders&#8217; Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable">
        <link:definition>996038 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" id="iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable">
        <link:definition>996039 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/OtherExpensesNetDetails" id="iccc_r_OtherExpensesNetDetails">
        <link:definition>996040 - Disclosure - Other Expenses, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable" id="iccc_r_ScheduleofOtherExpensesNetTable">
        <link:definition>996041 - Disclosure - Other Expenses, Net - Schedule of Other Expenses Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/IncomeTaxesDetails" id="iccc_r_IncomeTaxesDetails">
        <link:definition>996042 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable" id="iccc_r_ScheduleofIncomeTaxProvisionTable">
        <link:definition>996043 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" id="iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable">
        <link:definition>996044 - Disclosure - Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" id="iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable">
        <link:definition>996045 - Disclosure - Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SegmentInformationDetails" id="iccc_r_SegmentInformationDetails">
        <link:definition>996046 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable" id="iccc_r_ScheduleofSegmentInformationTable">
        <link:definition>996047 - Disclosure - Segment Information - Schedule of Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails" id="iccc_r_RelatedPartyTransactionsDetails">
        <link:definition>996048 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/EmployeeBenefitsDetails" id="iccc_r_EmployeeBenefitsDetails">
        <link:definition>996049 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/SubsequentEventsDetails" id="iccc_r_SubsequentEventsDetails">
        <link:definition>996050 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://immucell.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
  <xs:element name="ScheduleOfConcentrationOfRiskAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfConcentrationOfRiskAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfIntangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfIntangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
  <xs:element name="ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract"/>
  <xs:element name="ScheduleOfActivityUnderTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
  <xs:element name="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
  <xs:element name="ScheduleOfSegmentInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScheduleOfSegmentInformationAbstract"/>
  <xs:element name="BalanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BalanceAbstract"/>
  <xs:element name="BalanceAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BalanceAbstract0"/>
  <xs:element name="OfferingCostsAtthemarketOfferingOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_OfferingCostsAtthemarketOfferingOfCommonStock"/>
  <xs:element name="PaymentsOfDebtDiscounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_PaymentsOfDebtDiscounts"/>
  <xs:element name="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
  <xs:element name="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
  <xs:element name="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
  <xs:element name="ExpenseRecognitionPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ExpenseRecognitionPolicyTextBlock"/>
  <xs:element name="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable"/>
  <xs:element name="BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable"/>
  <xs:element name="BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable"/>
  <xs:element name="DebtIssuanceCosts2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2025"/>
  <xs:element name="DebtIssuanceCosts2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2026"/>
  <xs:element name="DebtIssuanceCosts2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2027"/>
  <xs:element name="DebtIssuanceCosts2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2028"/>
  <xs:element name="DebtIssuanceCosts2029" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCosts2029"/>
  <xs:element name="DebtIssuanceCostshereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtIssuanceCostshereafter"/>
  <xs:element name="DebtDiscountCost2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2025"/>
  <xs:element name="DebtDiscountCost2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2026"/>
  <xs:element name="DebtDiscountCost2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2027"/>
  <xs:element name="DebtDiscountCost2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2028"/>
  <xs:element name="DebtDiscountCost2029" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCost2029"/>
  <xs:element name="DebtDiscountCostThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostThereafter"/>
  <xs:element name="DebtDiscountCostTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtDiscountCostTotal"/>
  <xs:element name="LongTermDebt2025" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2025"/>
  <xs:element name="LongTermDebt2026" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2026"/>
  <xs:element name="LongTermDebt2027" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2027"/>
  <xs:element name="LongTermDebtTotal2028" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebtTotal2028"/>
  <xs:element name="LongTermDebt2029" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebt2029"/>
  <xs:element name="LongTermDebtThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_LongTermDebtThereafter"/>
  <xs:element name="StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
  <xs:element name="StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable"/>
  <xs:element name="RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="TradeAccountsReceivableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_TradeAccountsReceivableDetailsTable"/>
  <xs:element name="IntangibleAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IntangibleAssetsDetailsTable"/>
  <xs:element name="BankDebtDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_BankDebtDetailsTable"/>
  <xs:element name="InterestPaymentsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_InterestPaymentsTerm"/>
  <xs:element name="LoanToValueRatio" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_LoanToValueRatio"/>
  <xs:element name="DebtServiceCoverageRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtServiceCoverageRatio"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="CapitalExpendituresCommitted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CapitalExpendituresCommitted"/>
  <xs:element name="PurchaseofInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_PurchaseofInventory"/>
  <xs:element name="CommitmentsRelatedToCommercialManufacture" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommitmentsRelatedToCommercialManufacture"/>
  <xs:element name="OperatingLeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_OperatingLeasesDetailsTable"/>
  <xs:element name="TermOfExtensionOfLease" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TermOfExtensionOfLease"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_StockholdersEquityDetailsTable"/>
  <xs:element name="FeesInitiallyCapitalizedAndLaterOffset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
  <xs:element name="OtherExpensesNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_OtherExpensesNetDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_IncomeTaxesDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="EmployeeBenefitsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_EmployeeBenefitsDetailsTable"/>
  <xs:element name="EmployeesSalaryPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryPercentage"/>
  <xs:element name="EmployeesSalaryContributionPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeesSalaryContributionPercentage"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iccc_SubsequentEventsDetailsTable"/>
  <xs:element name="ATMAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ATMAgreementMember"/>
  <xs:element name="BankLoansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BankLoansMember"/>
  <xs:element name="BusinessInterruptionPolicyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_BusinessInterruptionPolicyMember"/>
  <xs:element name="CommonStockIssuancesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommonStockIssuancesMember"/>
  <xs:element name="CommonStockRightsPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CommonStockRightsPlanMember"/>
  <xs:element name="CompanyAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyAMember"/>
  <xs:element name="CompanyBMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CompanyBMember"/>
  <xs:element name="CustomerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_CustomerMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSevenMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
  <xs:element name="DebtInstrumentRedemptionPeriodSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DebtInstrumentRedemptionPeriodSixMember"/>
  <xs:element name="EmployeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeMember"/>
  <xs:element name="EmployeeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_EmployeeOneMember"/>
  <xs:element name="FederalGeneralBusinessMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FederalGeneralBusinessMember"/>
  <xs:element name="FirstDefenseProductLineMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_FirstDefenseProductLineMember"/>
  <xs:element name="GorhamSavingsBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_GorhamSavingsBankMember"/>
  <xs:element name="MaineTechnologyInstituteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MaineTechnologyInstituteMember"/>
  <xs:element name="MastitisMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MastitisMember"/>
  <xs:element name="MrBrighamMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_MrBrighamMember"/>
  <xs:element name="NisinDrugSubstanceMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_NisinDrugSubstanceMember"/>
  <xs:element name="OtherAnimalHealthMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherAnimalHealthMember"/>
  <xs:element name="OtherStatesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_OtherStatesMember"/>
  <xs:element name="ReTainMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ReTainMember"/>
  <xs:element name="ScoursMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_ScoursMember"/>
  <xs:element name="StateTaxCreditMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StateTaxCreditMember"/>
  <xs:element name="StockOptionPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_StockOptionPlansMember"/>
  <xs:element name="SubtotalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_SubtotalMember"/>
  <xs:element name="TwoThousandSeventeenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlanMember"/>
  <xs:element name="TwoThousandSeventeenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandSeventeenPlansMember"/>
  <xs:element name="TwoThousandTenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlanMember"/>
  <xs:element name="TwoThousandTenPlansMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_TwoThousandTenPlansMember"/>
  <xs:element name="VendorsPolicyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_VendorsPolicyMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iccc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>iccc-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"/>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfDebt" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="6" weight="-1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL7f/itNk+FOU0vMAbtw+W5T] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20241231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="iccc_PaymentsOfDebtDiscounts" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>iccc-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeases" roleURI="http://immucell.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeasesTables" roleURI="http://immucell.com/role/OperatingLeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxesTables" roleURI="http://immucell.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofConcentrationofRiskTable" roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofOtherExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeasesDetails" roleURI="http://immucell.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformationDetails" roleURI="http://immucell.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SubsequentEventsDetails" roleURI="http://immucell.com/role/SubsequentEventsDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Goodwill" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" xlink:href="iccc-20241231.xsd#iccc_OfferingCostsAtthemarketOfferingOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20241231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iccc_PaymentsOfDebtDiscounts" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20241231.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" order="32" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BusinessOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/TradeAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLeases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/Revenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RevenueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofConcentrationofRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20241231.xsd#iccc_CompanyAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20241231.xsd#iccc_CompanyBMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CompanyBMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CustomerMember" xlink:href="iccc-20241231.xsd#iccc_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="iccc_CustomerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ManufacturingFacilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CustomerRelationshipsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_NoncompeteAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20241231.xsd#iccc_SubtotalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_SubtotalMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2025" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2026" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2027" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2028" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2028" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2029" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2029"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCosts2029" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtIssuanceCostshereafter" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2025" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2026" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2027" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2028" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2028" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2029" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2029"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCost2029" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCostThereafter" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_DebtDiscountCostTotal" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2025"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2025" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2026"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2026" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2027"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2027" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtTotal2028" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtTotal2028"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebtTotal2028" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2029" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2029"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebt2029" order="25" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL7tDM5lNDLzbB7sfYKO+Fo2] CSR-->
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="iccc_LongTermDebtThereafter" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20241231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20241231.xsd#iccc_OtherStatesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="iccc_OtherStatesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20241231.xsd#iccc_FirstDefenseProductLineMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_FirstDefenseProductLineMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20241231.xsd#iccc_OtherAnimalHealthMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_OtherAnimalHealthMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofOtherExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestRevenueExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20241231.xsd#iccc_ScoursMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_ScoursMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20241231.xsd#iccc_MastitisMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="iccc_MastitisMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_AllOtherSegmentsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20241231.xsd#iccc_NisinDrugSubstanceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iccc_NisinDrugSubstanceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20241231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="iccc_TradeAccountsReceivableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="iccc_IntangibleAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/BankDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_BankDebtDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20241231.xsd#iccc_GorhamSavingsBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_GorhamSavingsBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20241231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_MaineTechnologyInstituteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_MortgageBankingMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_BankLoansMember" xlink:href="iccc-20241231.xsd#iccc_BankLoansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_BankLoansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20241231.xsd#iccc_InterestPaymentsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_InterestPaymentsTerm" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20241231.xsd#iccc_LoanToValueRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_LoanToValueRatio" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtServiceCoverageRatio" xlink:href="iccc-20241231.xsd#iccc_DebtServiceCoverageRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="iccc_DebtServiceCoverageRatio" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ReTainMember" xlink:href="iccc-20241231.xsd#iccc_ReTainMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_ReTainMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20241231.xsd#iccc_MrBrighamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_MrBrighamMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20241231.xsd#iccc_CapitalExpendituresCommitted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CapitalExpendituresCommitted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_PurchaseofInventory" xlink:href="iccc-20241231.xsd#iccc_PurchaseofInventory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_PurchaseofInventory" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20241231.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OperatingLeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_OperatingLeasesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OperatingLeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="iccc_OperatingLeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_OperatingLeasesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_OperatingLeasesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TermOfExtensionOfLease" xlink:href="iccc-20241231.xsd#iccc_TermOfExtensionOfLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="iccc_TermOfExtensionOfLease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockIssuancesMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockIssuancesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iccc_CommonStockIssuancesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandTenPlansMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_TwoThousandSeventeenPlansMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionPlansMember" xlink:href="iccc-20241231.xsd#iccc_StockOptionPlansMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iccc_StockOptionPlansMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockRightsPlanMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockRightsPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iccc_CommonStockRightsPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20241231.xsd#iccc_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="iccc_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20241231.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/OtherExpensesNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherExpensesNetDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="iccc_OtherExpensesNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_OtherExpensesNetDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_BusinessInterruptionPolicyMember" xlink:href="iccc-20241231.xsd#iccc_BusinessInterruptionPolicyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_BusinessInterruptionPolicyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_VendorsPolicyMember" xlink:href="iccc-20241231.xsd#iccc_VendorsPolicyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="iccc_VendorsPolicyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="us-gaap_InsuranceRecoveries" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="iccc_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20241231.xsd#iccc_FederalGeneralBusinessMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_FederalGeneralBusinessMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20241231.xsd#iccc_StateTaxCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="iccc_StateTaxCreditMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="iccc_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeeBenefitsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iccc_EmployeeOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryPercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="iccc_EmployeesSalaryContributionPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://immucell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="iccc_SubsequentEventsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iccc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20241231.xsd#iccc_ATMAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="iccc_ATMAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>iccc-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross margin</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">NET OPERATING LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">NET OPERATING INCOME (LOSS)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss attributable to stockholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used for) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used for investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BEGINNING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">ENDING CASH AND CASH EQUIVALENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Business Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Schedule of Net Income (Loss) Per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Diluted weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrentAbstract_lbl" xml:lang="en-US">Trade Accounts Receivable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Schedule of Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Bank Debt [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2025" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebt2025_lbl" xml:lang="en-US">Total 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2026" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebt2026_lbl" xml:lang="en-US">Total 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2027" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebt2027_lbl" xml:lang="en-US">Total 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtTotal2028" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtTotal2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebtTotal2028_lbl" xml:lang="en-US">Total 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebt2029" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2029"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebt2029_lbl" xml:lang="en-US">Total 2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2029" xlink:to="iccc_LongTermDebt2029_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LongTermDebtThereafter" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="iccc_LongTermDebtThereafter_lbl" xml:lang="en-US">Total Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments (undiscounted cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Outstanding, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Non-vested stock options as of beginning balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, Non-vested stock options as of ending balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price, Non-vested stock options as of ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expenses, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Schedule of Other Expenses Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred subtotal, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US">Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax expense/rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Trade accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0" xml:lang="en-US">Net Book Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US">Intangible assets net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current portion of debt obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Debt obligations, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.10 par value per share, with 15,000,000 shares authorized and 9,042,392 and 7,814,165 shares issued and 8,979,091 and 7,750,864 shares outstanding as of December 31, 2024 and 2023, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Costs of goods sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Product development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average common shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average common shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_BalanceAbstract" xlink:href="iccc-20241231.xsd#iccc_BalanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BalanceAbstract_lbl" xml:lang="en-US">BALANCE,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract" xlink:to="iccc_BalanceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Exercise of stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Stock options exercised during period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">At-the-Market Offering of common stock, net of $291,834 of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">At-the-Market Offering of common stock, net of $291,834 of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Shares sold under at-the-market offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" xlink:href="iccc-20241231.xsd#iccc_OfferingCostsAtthemarketOfferingOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl" xml:lang="en-US">Offering costs at-the-market offering of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" xlink:to="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BalanceAbstract0" xlink:href="iccc-20241231.xsd#iccc_BalanceAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BalanceAbstract0_lbl" xml:lang="en-US">BALANCE,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract0" xlink:to="iccc_BalanceAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl0" xml:lang="en-US">Intangible amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Debt Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from At-The-Market Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">CASH PAID FOR:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl" xml:lang="en-US">Change in payments of debt discounts included in accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20241231.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right-of-use asset and operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Treasury stock, at cost, 63,301 shares as of both December 31, 2024 and 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Non-cash rent (benefit) expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Trade accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Debt principal repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Line of credit repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_PaymentsOfDebtDiscounts" xlink:href="iccc-20241231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl" xml:lang="en-US">Payments of debt discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of equity issuance fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">BUSINESS OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and money market accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Bank debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of Concentration of Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Income (Loss) Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Dilutive impact of share-based compensation awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">TRADE ACCOUNTS RECEIVABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, plant and equipment, Estimated Useful Lives (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, plant and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Intangible assets gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts payable &#8211; capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">BANK DEBT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl" xml:lang="en-US">Debt Principal Repayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Principal Payments Due Under Bank Loans Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">During the Years Ending December 31, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">During the Years Ending December 31, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">During the Years Ending December 31, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">During the Years Ending December 31, 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xml:lang="en-US">During the Years Ending December 31, 2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl" xml:lang="en-US">During the Years Ending December 31, Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">During the Years Ending December 31, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2029" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2029"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCost2029_lbl" xml:lang="en-US">Debt discount cost, 2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2029" xlink:to="iccc_DebtDiscountCost2029_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostThereafter" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtDiscountCostThereafter_lbl" xml:lang="en-US">Debt discount cost, Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs and Other Lease Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Grants (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercises (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20241231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl" xml:lang="en-US">Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved for future grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Stock options granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, Stock options that vested (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options that vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Stock options that were terminated or forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value at Grant Date, Stock options hat were terminated or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Stock options hat were terminated or forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0" xml:lang="en-US">Total product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl" xml:lang="en-US">Percentage of product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">OTHER EXPENSES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Expenses Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US">Loss on disposal of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred subtotal, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Expense Differs from the Expected Tax Computed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Computed expected income tax expense rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal expense, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Share-based compensation, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Components of Our Deferred Tax Assets Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Federal general business tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Federal net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State tax credits and net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">&#167;174 R &amp; D expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Prepaid expenses and other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">UNICAP</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Incentive compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Product development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2025" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2025_lbl" xml:lang="en-US">Debt issuance costs, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2026" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2026_lbl" xml:lang="en-US">Debt issuance costs, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2027" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2027_lbl" xml:lang="en-US">Debt issuance costs, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2028" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2028_lbl" xml:lang="en-US">Debt issuance costs, 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCosts2029" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2029"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCosts2029_lbl" xml:lang="en-US">Debt issuance costs, 2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2029" xlink:to="iccc_DebtIssuanceCosts2029_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtIssuanceCostshereafter" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtIssuanceCostshereafter_lbl" xml:lang="en-US">Debt issuance costs, Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2025" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2025"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2025_lbl" xml:lang="en-US">Debt discount cost, 2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2026" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2026"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2026_lbl" xml:lang="en-US">Debt discount cost, 2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2027" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2027"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2027_lbl" xml:lang="en-US">Debt discount cost, 2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCost2028" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2028"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCost2028_lbl" xml:lang="en-US">Debt discount cost, 2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtDiscountCostTotal" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iccc_DebtDiscountCostTotal_lbl" xml:lang="en-US">Debt discount cost, Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest (discount effect of cash flows)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Terminations/forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestRevenueExpenseNet_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRevenueExpenseNet" xlink:to="us-gaap_InterestRevenueExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InsuranceRecoveries_lbl" xml:lang="en-US">Insurance recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InsuranceRecoveries_lbl0" xml:lang="en-US">Income from insurance recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Income - other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl" xml:lang="en-US">Computed expected income tax expense rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl0" xml:lang="en-US">U.S. federal corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyAMember" xlink:href="iccc-20241231.xsd#iccc_CompanyAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyAMember_lbl" xml:lang="en-US">Company A [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CompanyBMember" xlink:href="iccc-20241231.xsd#iccc_CompanyBMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CompanyBMember_lbl" xml:lang="en-US">Company B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CustomerMember" xlink:href="iccc-20241231.xsd#iccc_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CustomerMember" xlink:to="iccc_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US">Laboratory and manufacturing equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed technology [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Non-compete agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US">Loan #1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xml:lang="en-US">Loan #2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xml:lang="en-US">Loan #3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl" xml:lang="en-US">Loan #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0" xml:lang="en-US">Loans #4 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl" xml:lang="en-US">Loan #5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl" xml:lang="en-US">Loan #6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl" xml:lang="en-US">Loan #7 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SubtotalMember" xlink:href="iccc-20241231.xsd#iccc_SubtotalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_SubtotalMember_lbl" xml:lang="en-US">Subtotal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlanMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherStatesMember" xlink:href="iccc-20241231.xsd#iccc_OtherStatesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherStatesMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FirstDefenseProductLineMember" xlink:href="iccc-20241231.xsd#iccc_FirstDefenseProductLineMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FirstDefenseProductLineMember_lbl" xml:lang="en-US">First Defense&#174; product line [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherAnimalHealthMember" xlink:href="iccc-20241231.xsd#iccc_OtherAnimalHealthMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_OtherAnimalHealthMember_lbl" xml:lang="en-US">Other animal health [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScoursMember" xlink:href="iccc-20241231.xsd#iccc_ScoursMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ScoursMember_lbl" xml:lang="en-US">Scours [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MastitisMember" xlink:href="iccc-20241231.xsd#iccc_MastitisMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MastitisMember_lbl" xml:lang="en-US">Mastitis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllOtherSegmentsMember_lbl" xml:lang="en-US">Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal deposit insurance corporation limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Asset depreciated percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Impairment of recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive amounted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory write off</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US">Property, plant and equipment disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset amortized, useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Debt financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Bearing interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_InterestPaymentsTerm" xlink:href="iccc-20241231.xsd#iccc_InterestPaymentsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_InterestPaymentsTerm_lbl" xml:lang="en-US">Interest payments, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Loan amortization, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Balloon principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl" xml:lang="en-US">Mortgage debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl" xml:lang="en-US">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Interest fixed rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from issuance of loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_LoanToValueRatio" xlink:href="iccc-20241231.xsd#iccc_LoanToValueRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_LoanToValueRatio_lbl" xml:lang="en-US">Loan to value ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl" xml:lang="en-US">Finance loan provided</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_DebtServiceCoverageRatio" xlink:href="iccc-20241231.xsd#iccc_DebtServiceCoverageRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_DebtServiceCoverageRatio_lbl" xml:lang="en-US">DSC ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Total accrued amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl" xml:lang="en-US">Deferred compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred compensation agreement annual base salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CapitalExpendituresCommitted" xlink:href="iccc-20241231.xsd#iccc_CapitalExpendituresCommitted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CapitalExpendituresCommitted_lbl" xml:lang="en-US">Capital expenditures committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_PurchaseofInventory" xlink:href="iccc-20241231.xsd#iccc_PurchaseofInventory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_PurchaseofInventory_lbl" xml:lang="en-US">Purchase of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20241231.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl" xml:lang="en-US">Commitments related to commercial manufacture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area for lease (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewal term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TermOfExtensionOfLease" xlink:href="iccc-20241231.xsd#iccc_TermOfExtensionOfLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TermOfExtensionOfLease_lbl" xml:lang="en-US">Term of extension of lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TermOfExtensionOfLease" xlink:to="iccc_TermOfExtensionOfLease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Additional rent payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Common stock shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sold shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Issuance and sale (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20241231.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl" xml:lang="en-US">Legal, accounting and other fees amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl" xml:lang="en-US">Sales commissions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesCommissionsAndFees_lbl0" xml:lang="en-US">Sales commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining life of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining life of the options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Stock options granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Stock-based compensation related to non-vested stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xml:lang="en-US">Dividend shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Share of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xml:lang="en-US">Common stock purchase price (in Dollars per share)</label>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL6MXlgYzZGv/xPA7Z2KS+9G] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xml:lang="en-US">Loss income before income taxes, rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards not expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Expiration term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl" xml:lang="en-US">Non-cash income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Value of our deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Reportable business segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related party products purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeesSalaryContributionPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl" xml:lang="en-US">Employee&#8217;s salary contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl" xml:lang="en-US">Employee benefits paid (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl" xml:lang="en-US">Settlement received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivable" xlink:to="us-gaap_InsuranceSettlementsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Previously received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Sold amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Trade Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Intangible Assets and Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Expense Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_NisinDrugSubstanceMember" xlink:href="iccc-20241231.xsd#iccc_NisinDrugSubstanceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_NisinDrugSubstanceMember_lbl" xml:lang="en-US">Nisin Drug Substance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_GorhamSavingsBankMember" xlink:href="iccc-20241231.xsd#iccc_GorhamSavingsBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_GorhamSavingsBankMember_lbl" xml:lang="en-US">Gorham Savings Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MaineTechnologyInstituteMember" xlink:href="iccc-20241231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MaineTechnologyInstituteMember_lbl" xml:lang="en-US">Maine Technology Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MortgageBankingMember_lbl" xml:lang="en-US">Mortgage Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankLoansMember" xlink:href="iccc-20241231.xsd#iccc_BankLoansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BankLoansMember_lbl" xml:lang="en-US">Bank Loans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankLoansMember" xlink:to="iccc_BankLoansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_MrBrighamMember" xlink:href="iccc-20241231.xsd#iccc_MrBrighamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_MrBrighamMember_lbl" xml:lang="en-US">Mr. Brigham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ReTainMember" xlink:href="iccc-20241231.xsd#iccc_ReTainMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ReTainMember_lbl" xml:lang="en-US">Re-Tain [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockIssuancesMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockIssuancesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommonStockIssuancesMember_lbl" xml:lang="en-US">Common Stock Issuances [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockIssuancesMember" xlink:to="iccc_CommonStockIssuancesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ATMAgreementMember" xlink:href="iccc-20241231.xsd#iccc_ATMAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_ATMAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ATMAgreementMember" xlink:to="iccc_ATMAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandTenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandTenPlansMember_lbl" xml:lang="en-US">2010 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TwoThousandSeventeenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl" xml:lang="en-US">2017 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockOptionPlansMember" xlink:href="iccc-20241231.xsd#iccc_StockOptionPlansMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StockOptionPlansMember_lbl" xml:lang="en-US">Stock Option Plans [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionPlansMember" xlink:to="iccc_StockOptionPlansMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_CommonStockRightsPlanMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockRightsPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_CommonStockRightsPlanMember_lbl" xml:lang="en-US">Common Stock Rights Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockRightsPlanMember" xlink:to="iccc_CommonStockRightsPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BusinessInterruptionPolicyMember" xlink:href="iccc-20241231.xsd#iccc_BusinessInterruptionPolicyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_BusinessInterruptionPolicyMember_lbl" xml:lang="en-US">Business Interruption Policy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BusinessInterruptionPolicyMember" xlink:to="iccc_BusinessInterruptionPolicyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_VendorsPolicyMember" xlink:href="iccc-20241231.xsd#iccc_VendorsPolicyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_VendorsPolicyMember_lbl" xml:lang="en-US">Vendor&#8217;s Policy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_VendorsPolicyMember" xlink:to="iccc_VendorsPolicyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_FederalGeneralBusinessMember" xlink:href="iccc-20241231.xsd#iccc_FederalGeneralBusinessMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_FederalGeneralBusinessMember_lbl" xml:lang="en-US">Federal General Business [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StateTaxCreditMember" xlink:href="iccc-20241231.xsd#iccc_StateTaxCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_StateTaxCreditMember_lbl" xml:lang="en-US">State Tax Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeMember_lbl" xml:lang="en-US">Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeOneMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iccc_EmployeeOneMember_lbl" xml:lang="en-US">Employee One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Schedule of Concentration of Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Schedule of Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable_lbl" xml:lang="en-US">Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:to="iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable_lbl" xml:lang="en-US">Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:to="iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xml:lang="en-US">Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity - Schedule of Activity Under the Stock Option Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:to="iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Activity Under the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity - Schedule of Additional Information About the Stock Option Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:to="iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Additional Information About the Stock Option Plans [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable_lbl" xml:lang="en-US">Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:to="iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Schedule of Segment Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="iccc_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_TradeAccountsReceivableDetailsTable" xlink:href="iccc-20241231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TradeAccountsReceivableDetailsTable_lbl" xml:lang="en-US">Trade Accounts Receivable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TradeAccountsReceivableDetailsTable" xlink:to="iccc_TradeAccountsReceivableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Trade Accounts Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IntangibleAssetsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IntangibleAssetsDetailsTable_lbl" xml:lang="en-US">Intangible Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IntangibleAssetsDetailsTable" xlink:to="iccc_IntangibleAssetsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0" xml:lang="en-US">Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_BankDebtDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankDebtDetailsTable_lbl" xml:lang="en-US">Bank Debt (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankDebtDetailsTable" xlink:to="iccc_BankDebtDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Bank Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="iccc_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OperatingLeasesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OperatingLeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OperatingLeasesDetailsTable_lbl" xml:lang="en-US">Operating Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OperatingLeasesDetailsTable" xlink:to="iccc_OperatingLeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl" xml:lang="en-US">Operating Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_StockholdersEquityDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockholdersEquityDetailsTable" xlink:to="iccc_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_OtherExpensesNetDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherExpensesNetDetailsTable_lbl" xml:lang="en-US">Other Expenses, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherExpensesNetDetailsTable" xlink:to="iccc_OtherExpensesNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_lbl" xml:lang="en-US">Other Expenses, Net [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_IncomeTaxesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_IncomeTaxesDetailsTable" xlink:to="iccc_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_RelatedPartyTransactionsDetailsTable" xlink:to="iccc_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_EmployeeBenefitsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeBenefitsDetailsTable_lbl" xml:lang="en-US">Employee Benefits (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeBenefitsDetailsTable" xlink:to="iccc_EmployeeBenefitsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Employee Benefits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_SubsequentEventsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubsequentEventsDetailsTable" xlink:to="iccc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CapitalExpendituresCommitted_lbl0" xml:lang="en-US">Capital expenditures committed.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl0" xml:lang="en-US">Amount of change in payments of debt discounts included in accounts payable and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl0" xml:lang="en-US">Commitments related to commercial manufacture.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2025_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2026_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2027_lbl0" xml:lang="en-US">Amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2028_lbl0" xml:lang="en-US">Represent the amount of debt discount cost 2028.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCost2029_lbl0" xml:lang="en-US">Represent the amount of debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2029" xlink:to="iccc_DebtDiscountCost2029_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostThereafter_lbl0" xml:lang="en-US">Amount of debt discount cost thereafter.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtDiscountCostTotal_lbl0" xml:lang="en-US">Amount of total debt discount cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2025_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2026_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2027_lbl0" xml:lang="en-US">Amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2028_lbl0" xml:lang="en-US">Represent the amount of debt issuance costs 2028.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCosts2029_lbl0" xml:lang="en-US">Represent the amount of debt issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2029" xlink:to="iccc_DebtIssuanceCosts2029_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtIssuanceCostshereafter_lbl0" xml:lang="en-US">Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DebtServiceCoverageRatio_lbl0" xml:lang="en-US">Ratio applied to the debt service coverage ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl0" xml:lang="en-US">Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary contribution percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_EmployeesSalaryPercentage_lbl0" xml:lang="en-US">Employee&#8217;s salary percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Entire disclosure of accounting policy for expense recognition.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl0" xml:lang="en-US">Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_InterestPaymentsTerm_lbl0" xml:lang="en-US">Amount of interest payments term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LoanToValueRatio_lbl0" xml:lang="en-US">The ratio of loan to value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2025_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2026_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2027_lbl0" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebt2029_lbl0" xml:lang="en-US">Represent the amount of long term debt total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2029" xlink:to="iccc_LongTermDebt2029_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebtThereafter_lbl0" xml:lang="en-US">Long term debt thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_LongTermDebtTotal2028_lbl0" xml:lang="en-US">Represent the amount of long term debt total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity&apos;s financial reporting. Include, but is not limited to, quantification of the expected or actual impact.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl0" xml:lang="en-US">Offering costs at-the-market offering of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" xlink:to="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl0" xml:lang="en-US">Payments of debt discounts.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_PurchaseofInventory_lbl0" xml:lang="en-US">Represent the amount of purchase of inventory.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award options exercisable weighted average vested.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TermOfExtensionOfLease_lbl0" xml:lang="en-US">Term of extension of lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TermOfExtensionOfLease" xlink:to="iccc_TermOfExtensionOfLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_OtherStatesMember_lbl0" xml:lang="en-US">Continent of Other States.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_ReTainMember_lbl0" xml:lang="en-US">Re-Tain [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl0" xml:lang="en-US">Two thousand seventeen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iccc_TwoThousandTenPlanMember_lbl0" xml:lang="en-US">Two thousand ten plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StateTaxCreditMember_lbl0" xml:lang="en-US">State Tax Credit Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StateTaxCreditMember" xlink:to="iccc_StateTaxCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostThereafter_lbl1" xml:lang="en-US">Debt Discount Cost Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostThereafter" xlink:to="iccc_DebtDiscountCostThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl0" xml:lang="en-US">Customer Relationships [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl0" xml:lang="en-US">Variable Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_VendorsPolicyMember_lbl0" xml:lang="en-US">Vendors Policy Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_VendorsPolicyMember" xlink:to="iccc_VendorsPolicyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryContributionPercentage_lbl1" xml:lang="en-US">Employees Salary Contribution Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryContributionPercentage" xlink:to="iccc_EmployeesSalaryContributionPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl0" xml:lang="en-US">Developed Technology Rights [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FederalGeneralBusinessMember_lbl0" xml:lang="en-US">Federal General Business Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FederalGeneralBusinessMember" xlink:to="iccc_FederalGeneralBusinessMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0" xml:lang="en-US">Other Deferred Compensation Arrangements, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl0" xml:lang="en-US">Building [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl0" xml:lang="en-US">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherAnimalHealthMember_lbl0" xml:lang="en-US">Other Animal Health Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherAnimalHealthMember" xlink:to="iccc_OtherAnimalHealthMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CapitalExpendituresCommitted_lbl1" xml:lang="en-US">Capital Expenditures Committed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CapitalExpendituresCommitted" xlink:to="iccc_CapitalExpendituresCommitted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSixMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Current, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl1" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2029_lbl1" xml:lang="en-US">Debt Issuance Costs2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2029" xlink:to="iccc_DebtIssuanceCosts2029_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2028_lbl1" xml:lang="en-US">Debt Issuance Costs2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2028" xlink:to="iccc_DebtIssuanceCosts2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2027_lbl1" xml:lang="en-US">Debt Issuance Costs2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2027" xlink:to="iccc_DebtIssuanceCosts2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2026_lbl1" xml:lang="en-US">Debt Issuance Costs2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2026" xlink:to="iccc_DebtIssuanceCosts2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCosts2025_lbl1" xml:lang="en-US">Debt Issuance Costs2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCosts2025" xlink:to="iccc_DebtIssuanceCosts2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0" xml:lang="en-US">Property, Plant and Equipment, Disposals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl0" xml:lang="en-US">Escrow Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule Of Activity Under The Stock Option Plans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl0" xml:lang="en-US">Leases, Operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlanMember_lbl1" xml:lang="en-US">Two Thousand Seventeen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlanMember" xlink:to="iccc_TwoThousandSeventeenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceSettlementsReceivable_lbl0" xml:lang="en-US">Insurance Settlements Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivable" xlink:to="us-gaap_InsuranceSettlementsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl0" xml:lang="en-US">Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesCommissionsAndFees_lbl1" xml:lang="en-US">Sales Commissions and Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesCommissionsAndFees" xlink:to="us-gaap_SalesCommissionsAndFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1" xml:lang="en-US">Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BalanceAbstract_lbl0" xml:lang="en-US">Balance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract" xlink:to="iccc_BalanceAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_GorhamSavingsBankMember_lbl0" xml:lang="en-US">Gorham Savings Bank Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_GorhamSavingsBankMember" xlink:to="iccc_GorhamSavingsBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommitmentsRelatedToCommercialManufacture_lbl1" xml:lang="en-US">Commitments Related To Commercial Manufacture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommitmentsRelatedToCommercialManufacture" xlink:to="iccc_CommitmentsRelatedToCommercialManufacture_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlanMember_lbl1" xml:lang="en-US">Two Thousand Ten Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlanMember" xlink:to="iccc_TwoThousandTenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BusinessInterruptionPolicyMember_lbl0" xml:lang="en-US">Business Interruption Policy Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BusinessInterruptionPolicyMember" xlink:to="iccc_BusinessInterruptionPolicyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0" xml:lang="en-US">Long-Term Debt and Lease Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NisinDrugSubstanceMember_lbl0" xml:lang="en-US">Nisin Drug Substance Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NisinDrugSubstanceMember" xlink:to="iccc_NisinDrugSubstanceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandSeventeenPlansMember_lbl0" xml:lang="en-US">Two Thousand Seventeen Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandSeventeenPlansMember" xlink:to="iccc_TwoThousandSeventeenPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageBankingMember_lbl0" xml:lang="en-US">Mortgage Banking [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageBankingMember" xlink:to="us-gaap_MortgageBankingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value Measurements, Nonrecurring [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCostTotal_lbl1" xml:lang="en-US">Debt Discount Cost Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCostTotal" xlink:to="iccc_DebtDiscountCostTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2025_lbl1" xml:lang="en-US">Debt Discount Cost2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2025" xlink:to="iccc_DebtDiscountCost2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2026_lbl1" xml:lang="en-US">Debt Discount Cost2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2026" xlink:to="iccc_DebtDiscountCost2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2027_lbl1" xml:lang="en-US">Debt Discount Cost2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2027" xlink:to="iccc_DebtDiscountCost2027_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2028_lbl1" xml:lang="en-US">Debt Discount Cost2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2028" xlink:to="iccc_DebtDiscountCost2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ATMAgreementMember_lbl0" xml:lang="en-US">ATMAgreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ATMAgreementMember" xlink:to="iccc_ATMAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtDiscountCost2029_lbl1" xml:lang="en-US">Debt Discount Cost2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtDiscountCost2029" xlink:to="iccc_DebtDiscountCost2029_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OtherStatesMember_lbl1" xml:lang="en-US">Other States Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OtherStatesMember" xlink:to="iccc_OtherStatesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0" xml:lang="en-US">Participating Mortgage Loans, Unamortized Debt Discount, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl1" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfSegmentInformationAbstract_lbl" xml:lang="en-US">Schedule Of Segment Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfSegmentInformationAbstract" xlink:to="iccc_ScheduleOfSegmentInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingImprovementsMember_lbl0" xml:lang="en-US">Building Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingImprovementsMember" xlink:to="us-gaap_BuildingImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl0" xml:lang="en-US">Inventory Write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FirstDefenseProductLineMember_lbl0" xml:lang="en-US">First Defense Product Line Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FirstDefenseProductLineMember" xlink:to="iccc_FirstDefenseProductLineMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TermOfExtensionOfLease_lbl1" xml:lang="en-US">Term Of Extension Of Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TermOfExtensionOfLease" xlink:to="iccc_TermOfExtensionOfLease_lbl1"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfIntangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Intangible Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfIntangibleAssetsAbstract" xlink:to="iccc_ScheduleOfIntangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule Of Additional Information About The Stock Option Plans Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeesSalaryPercentage_lbl1" xml:lang="en-US">Employees Salary Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeesSalaryPercentage" xlink:to="iccc_EmployeesSalaryPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2026_lbl1" xml:lang="en-US">Long Term Debt2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2026" xlink:to="iccc_LongTermDebt2026_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2025_lbl1" xml:lang="en-US">Long Term Debt2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2025" xlink:to="iccc_LongTermDebt2025_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl" xml:lang="en-US">Schedule Of Debt Proceeds Received And Principal Repayments Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebtThereafter_lbl1" xml:lang="en-US">Long Term Debt Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtThereafter" xlink:to="iccc_LongTermDebtThereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2029_lbl1" xml:lang="en-US">Long Term Debt2029</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2029" xlink:to="iccc_LongTermDebt2029_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebt2027_lbl1" xml:lang="en-US">Long Term Debt2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebt2027" xlink:to="iccc_LongTermDebt2027_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_TwoThousandTenPlansMember_lbl0" xml:lang="en-US">Two Thousand Ten Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_TwoThousandTenPlansMember" xlink:to="iccc_TwoThousandTenPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_StockOptionPlansMember_lbl0" xml:lang="en-US">Stock Option Plans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_StockOptionPlansMember" xlink:to="iccc_StockOptionPlansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl0" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl0" xml:lang="en-US">Lease, Cost [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl0" xml:lang="en-US">Number of Reportable Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl1" xml:lang="en-US">Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:to="iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommonStockRightsPlanMember_lbl0" xml:lang="en-US">Common Stock Rights Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockRightsPlanMember" xlink:to="iccc_CommonStockRightsPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Principal Payments Due Under Bank Loans Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract" xlink:to="iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Five [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtServiceCoverageRatio_lbl1" xml:lang="en-US">Debt Service Coverage Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtServiceCoverageRatio" xlink:to="iccc_DebtServiceCoverageRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BankLoansMember_lbl0" xml:lang="en-US">Bank Loans Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BankLoansMember" xlink:to="iccc_BankLoansMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ExpenseRecognitionPolicyTextBlock_lbl1" xml:lang="en-US">Expense Recognition Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="iccc_ExpenseRecognitionPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US">Amortization of Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ManufacturingFacilityMember_lbl0" xml:lang="en-US">Manufacturing Facility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_PaymentsOfDebtDiscounts_lbl1" xml:lang="en-US">Payments Of Debt Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PaymentsOfDebtDiscounts" xlink:to="iccc_PaymentsOfDebtDiscounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MrBrighamMember_lbl0" xml:lang="en-US">Mr Brigham Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MrBrighamMember" xlink:to="iccc_MrBrighamMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property Plant And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="iccc_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense_lbl0" xml:lang="en-US">Other Noncash Income Tax Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeTaxExpense" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl1" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl1" xml:lang="en-US">Fees Initially Capitalized And Later Offset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_FeesInitiallyCapitalizedAndLaterOffset" xlink:to="iccc_FeesInitiallyCapitalizedAndLaterOffset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestRevenueExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestRevenueExpenseNet" xlink:to="us-gaap_InterestRevenueExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl0" xml:lang="en-US">Proceeds from Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl0" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Major Product Category Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:to="iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl0" xml:lang="en-US">Long-Term Debt, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_InterestPaymentsTerm_lbl1" xml:lang="en-US">Interest Payments Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_InterestPaymentsTerm" xlink:to="iccc_InterestPaymentsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ReTainMember_lbl1" xml:lang="en-US">Re Tain Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ReTainMember" xlink:to="iccc_ReTainMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfConcentrationOfRiskAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfConcentrationOfRiskAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfConcentrationOfRiskAbstract_lbl" xml:lang="en-US">Schedule Of Concentration Of Risk Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfConcentrationOfRiskAbstract" xlink:to="iccc_ScheduleOfConcentrationOfRiskAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeOneMember_lbl0" xml:lang="en-US">Employee One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeOneMember" xlink:to="iccc_EmployeeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SubtotalMember_lbl0" xml:lang="en-US">Subtotal Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SubtotalMember" xlink:to="iccc_SubtotalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyBMember_lbl0" xml:lang="en-US">Company BMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyBMember" xlink:to="iccc_CompanyBMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0" xml:lang="en-US">Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl0" xml:lang="en-US">Area of Land</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CommonStockIssuancesMember_lbl0" xml:lang="en-US">Common Stock Issuances Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CommonStockIssuancesMember" xlink:to="iccc_CommonStockIssuancesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsShares_lbl0" xml:lang="en-US">Common Stock Dividends, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl0" xml:lang="en-US">Fair Value, Nonrecurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl0" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_BalanceAbstract0_lbl0" xml:lang="en-US">Balance Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_BalanceAbstract0" xlink:to="iccc_BalanceAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancingReceivableLoanInProcess_lbl0" xml:lang="en-US">Financing Receivable, Loan in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableLoanInProcess" xlink:to="us-gaap_FinancingReceivableLoanInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MaineTechnologyInstituteMember_lbl0" xml:lang="en-US">Maine Technology Institute Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MaineTechnologyInstituteMember" xlink:to="iccc_MaineTechnologyInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_PurchaseofInventory_lbl1" xml:lang="en-US">Purchaseof Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_PurchaseofInventory" xlink:to="iccc_PurchaseofInventory_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl0" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl" xml:lang="en-US">Schedule Of Product Sales Disaggregated By Geographic Area Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfBankDebt_lbl0" xml:lang="en-US">Repayments of Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfBankDebt" xlink:to="us-gaap_RepaymentsOfBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LongTermDebtTotal2028_lbl1" xml:lang="en-US">Long Term Debt Total2028</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LongTermDebtTotal2028" xlink:to="iccc_LongTermDebtTotal2028_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceRecoveries_lbl1" xml:lang="en-US">Insurance Recoveries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceRecoveries" xlink:to="us-gaap_InsuranceRecoveries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_LoanToValueRatio_lbl1" xml:lang="en-US">Loan To Value Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_LoanToValueRatio" xlink:to="iccc_LoanToValueRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_MastitisMember_lbl0" xml:lang="en-US">Mastitis Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_MastitisMember" xlink:to="iccc_MastitisMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:to="iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl1" xml:lang="en-US">Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0" xml:lang="en-US">Cost, Depreciation, Amortization and Depletion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_EmployeeMember_lbl0" xml:lang="en-US">Employee Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_EmployeeMember" xlink:to="iccc_EmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllOtherSegmentsMember_lbl0" xml:lang="en-US">Other Operating Segment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllOtherSegmentsMember" xlink:to="us-gaap_AllOtherSegmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl1" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl0" xml:lang="en-US">Noncompete Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl0" xml:lang="en-US">Cash, FDIC Insured Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtIssuanceCostshereafter_lbl1" xml:lang="en-US">Debt Issuance Costshereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtIssuanceCostshereafter" xlink:to="iccc_DebtIssuanceCostshereafter_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_lbl0" xml:lang="en-US">Interest Income, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CustomerMember_lbl0" xml:lang="en-US">Customer Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CustomerMember" xlink:to="iccc_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_CompanyAMember_lbl0" xml:lang="en-US">Company AMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_CompanyAMember" xlink:to="iccc_CompanyAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl0" xml:lang="en-US">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_ScoursMember_lbl0" xml:lang="en-US">Scours Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_ScoursMember" xlink:to="iccc_ScoursMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl1" xml:lang="en-US">Offering Costs Atthemarket Offering Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_OfferingCostsAtthemarketOfferingOfCommonStock" xlink:to="iccc_OfferingCostsAtthemarketOfferingOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0" xml:lang="en-US">Property, Plant and Equipment, Salvage Value, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0" xml:lang="en-US">Debt Instrument Redemption Period Seven Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iccc_DebtInstrumentRedemptionPeriodSevenMember" xlink:to="iccc_DebtInstrumentRedemptionPeriodSevenMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross_lbl0" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentGross" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>iccc-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 26 20:06:30 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedBalanceSheet" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedIncomeStatement" roleURI="http://immucell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ShareholdersEquityType2or3" roleURI="http://immucell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ConsolidatedCashFlow" roleURI="http://immucell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BusinessOperations" roleURI="http://immucell.com/role/BusinessOperations"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPolicies" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_TradeAccountsReceivable" roleURI="http://immucell.com/role/TradeAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_Inventory" roleURI="http://immucell.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNet" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssets" roleURI="http://immucell.com/role/IntangibleAssets"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountsPayableandAccruedExpenses" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebt" roleURI="http://immucell.com/role/BankDebt"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ContingentLiabilitiesandCommitments" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeases" roleURI="http://immucell.com/role/OperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquity" roleURI="http://immucell.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_Revenue" roleURI="http://immucell.com/role/Revenue"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNet" roleURI="http://immucell.com/role/OtherExpensesNet"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxes" roleURI="http://immucell.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformation" roleURI="http://immucell.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RelatedPartyTransactions" roleURI="http://immucell.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_EmployeeBenefits" roleURI="http://immucell.com/role/EmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SubsequentEvents" roleURI="http://immucell.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountingPoliciesByPolicy" roleURI="http://immucell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_InventoryTables" roleURI="http://immucell.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNetTables" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssetsTables" roleURI="http://immucell.com/role/IntangibleAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_AccountsPayableandAccruedExpensesTables" roleURI="http://immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebtTables" roleURI="http://immucell.com/role/BankDebtTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeasesTables" roleURI="http://immucell.com/role/OperatingLeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquityTables" roleURI="http://immucell.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RevenueTables" roleURI="http://immucell.com/role/RevenueTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNetTables" roleURI="http://immucell.com/role/OtherExpensesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxesTables" roleURI="http://immucell.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformationTables" roleURI="http://immucell.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" roleURI="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofConcentrationofRiskTable" roleURI="http://immucell.com/role/ScheduleofConcentrationofRiskTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofNetIncomeLossPerCommonShareTable" roleURI="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofInventoryTable" roleURI="http://immucell.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" roleURI="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPropertyPlantandEquipmentTable" roleURI="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIntangibleAssetsTable" roleURI="http://immucell.com/role/ScheduleofIntangibleAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAccountsPayableandAccruedExpensesTable" roleURI="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" roleURI="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable" roleURI="http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofLeaseCostsandOtherLeaseInformationTable" roleURI="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" roleURI="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofActivityUndertheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" roleURI="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" roleURI="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" roleURI="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofOtherExpensesNetTable" roleURI="http://immucell.com/role/ScheduleofOtherExpensesNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxProvisionTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" roleURI="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" roleURI="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ScheduleofSegmentInformationTable" roleURI="http://immucell.com/role/ScheduleofSegmentInformationTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_TradeAccountsReceivableDetails" roleURI="http://immucell.com/role/TradeAccountsReceivableDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_InventoryDetails" roleURI="http://immucell.com/role/InventoryDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_PropertyPlantandEquipmentNetDetails" roleURI="http://immucell.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IntangibleAssetsDetails" roleURI="http://immucell.com/role/IntangibleAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_BankDebtDetails" roleURI="http://immucell.com/role/BankDebtDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OperatingLeasesDetails" roleURI="http://immucell.com/role/OperatingLeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_StockholdersEquityDetails" roleURI="http://immucell.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_OtherExpensesNetDetails" roleURI="http://immucell.com/role/OtherExpensesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_IncomeTaxesDetails" roleURI="http://immucell.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SegmentInformationDetails" roleURI="http://immucell.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_RelatedPartyTransactionsDetails" roleURI="http://immucell.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_EmployeeBenefitsDetails" roleURI="http://immucell.com/role/EmployeeBenefitsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iccc-20241231.xsd#iccc_r_SubsequentEventsDetails" roleURI="http://immucell.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsAtthemarketOfferingOfCommonStock" xlink:href="iccc-20241231.xsd#iccc_OfferingCostsAtthemarketOfferingOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="OfferingCostsAtthemarketOfferingOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentsOfDebtDiscounts" xlink:href="iccc-20241231.xsd#iccc_PaymentsOfDebtDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfDebtDiscounts" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" xlink:href="iccc-20241231.xsd#iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" xlink:href="iccc-20241231.xsd#iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BusinessOperations" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/TradeAccountsReceivable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebt" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitments" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLeases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/Revenue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/EmployeeBenefits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpenseRecognitionPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_ExpenseRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ExpenseRecognitionPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="iccc-20241231.xsd#iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebtTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RevenueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofConcentrationofRiskTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConcentrationOfRiskAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfConcentrationOfRiskAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConcentrationOfRiskAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CompanyAMember" xlink:href="iccc-20241231.xsd#iccc_CompanyAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyAMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompanyBMember" xlink:href="iccc-20241231.xsd#iccc_CompanyBMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CompanyBMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="iccc-20241231.xsd#iccc_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CustomerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ManufacturingFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofIntangibleAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIntangibleAssetsAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfIntangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIntangibleAssetsAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_CustomerRelationshipsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_NoncompeteAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract" xlink:to="BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract" xlink:to="BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubtotalMember" xlink:href="iccc-20241231.xsd#iccc_SubtotalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="SubtotalMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2025" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2025" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2026" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2026" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2027" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2027" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2028" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2028"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2028" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCosts2029" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCosts2029"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCosts2029" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtIssuanceCostshereafter" xlink:href="iccc-20241231.xsd#iccc_DebtIssuanceCostshereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtIssuanceCostshereafter" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2025" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2025" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2026" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2026" order="15.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2027" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2027" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2028" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2028"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2028" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCost2029" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCost2029"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCost2029" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostThereafter" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCostThereafter" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtDiscountCostTotal" xlink:href="iccc-20241231.xsd#iccc_DebtDiscountCostTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="DebtDiscountCostTotal" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2025" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2025"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2025" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2026" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2026"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2026" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2027" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2027"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2027" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebtTotal2028" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtTotal2028"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbY2yHOqde+bt8NhnsjkMwInWzkiaYJmrGBX9ANHbqN6KcdyN7/tlo+8zitcBZOpZd5FWkDhY6SIPR9IaHkpcGPDoLfQ9xdNM4Stk2t4NKYW/O2nkZr7LMHUxjEU7dqdeht3sAjPYT70YN9Z6NONpBCBGpU4glEkjHdMbbapHNSBg6DGU66A4ULjl7Q+MM0JZC/FKhs0ytZCRftSiLzLTCp7gTZK6rBFL7GVmYFJ70P53GC8iVClm4J] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebtTotal2028" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebt2029" xlink:href="iccc-20241231.xsd#iccc_LongTermDebt2029"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebt2029" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermDebtThereafter" xlink:href="iccc-20241231.xsd#iccc_LongTermDebtThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="LongTermDebtThereafter" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_OperatingLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfActivityUnderTheStockOptionPlansAbstract" xlink:to="StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlanMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" xlink:href="iccc-20241231.xsd#iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="iccc-20241231.xsd#iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract" xlink:to="StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract" xlink:to="RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherStatesMember" xlink:href="iccc-20241231.xsd#iccc_OtherStatesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="OtherStatesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstDefenseProductLineMember" xlink:href="iccc-20241231.xsd#iccc_FirstDefenseProductLineMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="FirstDefenseProductLineMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherAnimalHealthMember" xlink:href="iccc-20241231.xsd#iccc_OtherAnimalHealthMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="OtherAnimalHealthMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofOtherExpensesNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestRevenueExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestRevenueExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestRevenueExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InsuranceRecoveries" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherIncome" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ScheduleofSegmentInformationTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentInformationAbstract" xlink:href="iccc-20241231.xsd#iccc_ScheduleOfSegmentInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentInformationAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ScoursMember" xlink:href="iccc-20241231.xsd#iccc_ScoursMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="ScoursMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MastitisMember" xlink:href="iccc-20241231.xsd#iccc_MastitisMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="MastitisMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllOtherSegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_AllOtherSegmentsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_GrossProfit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostDepreciationAmortizationAndDepletion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDepreciationAmortizationAndDepletion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostDepreciationAmortizationAndDepletion" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NisinDrugSubstanceMember" xlink:href="iccc-20241231.xsd#iccc_NisinDrugSubstanceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="NisinDrugSubstanceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/TradeAccountsReceivableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesNetCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="TradeAccountsReceivableDetailsTable" xlink:href="iccc-20241231.xsd#iccc_TradeAccountsReceivableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesNetCurrentAbstract" xlink:to="TradeAccountsReceivableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAccountsReceivableDetailsTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/InventoryDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/PropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_Depreciation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <loc xlink:type="locator" xlink:label="IntangibleAssetsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IntangibleAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="IntangibleAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IntangibleAssetsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/BankDebtDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="BankDebtDetailsTable" xlink:href="iccc-20241231.xsd#iccc_BankDebtDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="BankDebtDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSixMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSixMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFiveMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentRedemptionPeriodSevenMember" xlink:href="iccc-20241231.xsd#iccc_DebtInstrumentRedemptionPeriodSevenMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodSevenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankLoansMember" xlink:href="iccc-20241231.xsd#iccc_BankLoansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="BankLoansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GorhamSavingsBankMember" xlink:href="iccc-20241231.xsd#iccc_GorhamSavingsBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="GorhamSavingsBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MaineTechnologyInstituteMember" xlink:href="iccc-20241231.xsd#iccc_MaineTechnologyInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MaineTechnologyInstituteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageBankingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MortgageBankingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_MortgageBankingMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankDebtDetailsTable" xlink:to="us-gaap_DebtConversionLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EscrowDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_EscrowDeposit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingFixedInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPaymentsTerm" xlink:href="iccc-20241231.xsd#iccc_InterestPaymentsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="InterestPaymentsTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_LineOfCredit" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanToValueRatio" xlink:href="iccc-20241231.xsd#iccc_LoanToValueRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="LoanToValueRatio" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancingReceivableLoanInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancingReceivableLoanInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_FinancingReceivableLoanInProcess" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtServiceCoverageRatio" xlink:href="iccc-20241231.xsd#iccc_DebtServiceCoverageRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="DebtServiceCoverageRatio" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsCurrentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsCurrentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DeferredFinanceCostsCurrentGross" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MrBrighamMember" xlink:href="iccc-20241231.xsd#iccc_MrBrighamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MrBrighamMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReTainMember" xlink:href="iccc-20241231.xsd#iccc_ReTainMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ReTainMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalExpendituresCommitted" xlink:href="iccc-20241231.xsd#iccc_CapitalExpendituresCommitted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CapitalExpendituresCommitted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseofInventory" xlink:href="iccc-20241231.xsd#iccc_PurchaseofInventory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PurchaseofInventory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommitmentsRelatedToCommercialManufacture" xlink:href="iccc-20241231.xsd#iccc_CommitmentsRelatedToCommercialManufacture"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="CommitmentsRelatedToCommercialManufacture" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OperatingLeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OperatingLeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansAndLeasesReceivableDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesDetailsTable" xlink:to="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfLand"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_AreaOfLand" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermOfExtensionOfLease" xlink:href="iccc-20241231.xsd#iccc_TermOfExtensionOfLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="TermOfExtensionOfLease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_PaymentsForRent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LoansAndLeasesReceivableDisclosureLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="iccc-20241231.xsd#iccc_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuancesMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockIssuancesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockIssuancesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandTenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTenPlansMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenPlansMember" xlink:href="iccc-20241231.xsd#iccc_TwoThousandSeventeenPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSeventeenPlansMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionPlansMember" xlink:href="iccc-20241231.xsd#iccc_StockOptionPlansMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="StockOptionPlansMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="iccc-20241231.xsd#iccc_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockRightsPlanMember" xlink:href="iccc-20241231.xsd#iccc_CommonStockRightsPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="CommonStockRightsPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FeesInitiallyCapitalizedAndLaterOffset" xlink:href="iccc-20241231.xsd#iccc_FeesInitiallyCapitalizedAndLaterOffset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="FeesInitiallyCapitalizedAndLaterOffset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/OtherExpensesNetDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherExpensesNetDetailsTable" xlink:href="iccc-20241231.xsd#iccc_OtherExpensesNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="OtherExpensesNetDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesNetDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BusinessInterruptionPolicyMember" xlink:href="iccc-20241231.xsd#iccc_BusinessInterruptionPolicyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="BusinessInterruptionPolicyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VendorsPolicyMember" xlink:href="iccc-20241231.xsd#iccc_VendorsPolicyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="VendorsPolicyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherExpensesNetDetailsTable" xlink:to="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceRecoveries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="us-gaap_InsuranceRecoveries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="iccc-20241231.xsd#iccc_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalGeneralBusinessMember" xlink:href="iccc-20241231.xsd#iccc_FederalGeneralBusinessMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="FederalGeneralBusinessMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StateTaxCreditMember" xlink:href="iccc-20241231.xsd#iccc_StateTaxCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="StateTaxCreditMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeTaxExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeTaxExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OtherNoncashIncomeTaxExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SegmentInformationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_EmployeeBenefitsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeOneMember" xlink:href="iccc-20241231.xsd#iccc_EmployeeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="EmployeeOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitsDetailsTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesSalaryContributionPercentage" xlink:href="iccc-20241231.xsd#iccc_EmployeesSalaryContributionPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="EmployeesSalaryContributionPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://immucell.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="iccc-20241231.xsd#iccc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ATMAgreementMember" xlink:href="iccc-20241231.xsd#iccc_ATMAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ATMAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InsuranceSettlementsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_InsuranceSettlementsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesCommissionsAndFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesCommissionsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SalesCommissionsAndFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended"/>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended"/>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement to be filed in connection with the 2025 Annual
Meeting of Stockholders are incorporated by reference into Part III hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUCELL CORP /DE/<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000811641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">01-0382980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,634,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">56 Evergreen Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Portland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">ME<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">04103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">878-2770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.10 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ICCC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,982,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WIPFLI LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Radnor, Pennsylvania<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Opinion on the Financial Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in">We have audited the accompanying balance
sheets of ImmuCell Corporation (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related statements of operations,
stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States
of America.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,758,232<span></span>
</td>
<td class="nump">$ 978,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable</a></td>
<td class="nump">3,771,133<span></span>
</td>
<td class="nump">2,185,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,112,623<span></span>
</td>
<td class="nump">7,811,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">400,762<span></span>
</td>
<td class="nump">493,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">15,042,750<span></span>
</td>
<td class="nump">11,469,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">25,349,019<span></span>
</td>
<td class="nump">27,575,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">4,560,679<span></span>
</td>
<td class="nump">4,571,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">95,557<span></span>
</td>
<td class="nump">95,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">19,104<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">33,368<span></span>
</td>
<td class="nump">57,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">45,100,477<span></span>
</td>
<td class="nump">43,808,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of debt obligations</a></td>
<td class="nump">1,497,619<span></span>
</td>
<td class="nump">1,428,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">432,072<span></span>
</td>
<td class="nump">644,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">2,482,522<span></span>
</td>
<td class="nump">2,124,337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,412,213<span></span>
</td>
<td class="nump">4,197,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Debt obligations, net of current portion</a></td>
<td class="nump">9,040,975<span></span>
</td>
<td class="nump">10,540,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">4,129,102<span></span>
</td>
<td class="nump">4,077,109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">13,170,077<span></span>
</td>
<td class="nump">14,617,605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">17,582,290<span></span>
</td>
<td class="nump">18,815,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.10 par value per share, with 15,000,000 shares authorized and 9,042,392 and 7,814,165 shares issued and 8,979,091 and 7,750,864 shares outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">904,240<span></span>
</td>
<td class="nump">781,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">40,916,155<span></span>
</td>
<td class="nump">36,357,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(14,163,726)<span></span>
</td>
<td class="num">(12,007,097)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 63,301 shares as of both December 31, 2024 and 2023</a></td>
<td class="num">(138,482)<span></span>
</td>
<td class="num">(138,482)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">27,518,187<span></span>
</td>
<td class="nump">24,993,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 45,100,477<span></span>
</td>
<td class="nump">$ 43,808,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">9,042,392<span></span>
</td>
<td class="nump">7,814,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">8,979,091<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock</a></td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="nump">$ 26,493,169<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">18,552,125<span></span>
</td>
<td class="nump">13,602,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">7,941,044<span></span>
</td>
<td class="nump">3,869,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">3,898,582<span></span>
</td>
<td class="nump">4,394,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">3,466,072<span></span>
</td>
<td class="nump">3,088,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,216,549<span></span>
</td>
<td class="nump">2,134,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">9,581,203<span></span>
</td>
<td class="nump">9,617,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING LOSS</a></td>
<td class="num">(1,640,159)<span></span>
</td>
<td class="num">(5,748,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">506,414<span></span>
</td>
<td class="nump">21,893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(2,146,573)<span></span>
</td>
<td class="num">(5,769,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">10,056<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (2,156,629)<span></span>
</td>
<td class="num">$ (5,774,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">8,167,244<span></span>
</td>
<td class="nump">7,747,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in Shares)</a></td>
<td class="nump">8,167,244<span></span>
</td>
<td class="nump">7,747,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">$ 35,978,364<span></span>
</td>
<td class="num">$ (6,232,499)<span></span>
</td>
<td class="num">$ (147,233)<span></span>
</td>
<td class="nump">$ 30,380,049<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,774,598)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,774,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10,009<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,751<span></span>
</td>
<td class="nump">18,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">368,866<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">368,866<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 781,417<span></span>
</td>
<td class="nump">36,357,239<span></span>
</td>
<td class="num">(12,007,097)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 24,993,077<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">7,814,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">7,750,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,156,629)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (2,156,629)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">At-the-Market Offering of common stock, net of $291,834 of offering costs</a></td>
<td class="nump">$ 122,823<span></span>
</td>
<td class="nump">4,233,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,356,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">At-the-Market Offering of common stock, net of $291,834 of offering costs (in Shares)</a></td>
<td class="nump">1,228,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">325,551<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 325,551<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 904,240<span></span>
</td>
<td class="nump">$ 40,916,155<span></span>
</td>
<td class="num">$ (14,163,726)<span></span>
</td>
<td class="num">$ (138,482)<span></span>
</td>
<td class="nump">$ 27,518,187<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">9,042,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,301<span></span>
</td>
<td class="nump">8,979,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Parentheticals)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_OfferingCostsAtthemarketOfferingOfCommonStock', window );">Offering costs at-the-market offering of common stock</a></td>
<td class="nump">$ 291,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_OfferingCostsAtthemarketOfferingOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs at-the-market offering of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_OfferingCostsAtthemarketOfferingOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,156,629)<span></span>
</td>
<td class="num">$ (5,774,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used for) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2,668,077<span></span>
</td>
<td class="nump">2,697,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">19,104<span></span>
</td>
<td class="nump">19,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs and debt discounts</a></td>
<td class="nump">42,666<span></span>
</td>
<td class="nump">22,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">325,551<span></span>
</td>
<td class="nump">368,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="nump">15,391<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Non-cash rent (benefit) expense</a></td>
<td class="num">(149,741)<span></span>
</td>
<td class="nump">95,724<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(1,585,750)<span></span>
</td>
<td class="num">(426,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">699,218<span></span>
</td>
<td class="num">(1,773,302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">93,123<span></span>
</td>
<td class="num">(87,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">24,287<span></span>
</td>
<td class="nump">18,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">362,606<span></span>
</td>
<td class="nump">156,995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used for) operating activities</a></td>
<td class="nump">357,903<span></span>
</td>
<td class="num">(4,674,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(465,725)<span></span>
</td>
<td class="num">(1,892,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property, plant and equipment</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">2,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(461,225)<span></span>
</td>
<td class="num">(1,890,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from At-The-Market Offering</a></td>
<td class="nump">4,648,022<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt principal repayments</a></td>
<td class="num">(1,468,338)<span></span>
</td>
<td class="num">(1,185,774)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Line of credit repayments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="num">(5,037)<span></span>
</td>
<td class="num">(35,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_PaymentsOfDebtDiscounts', window );">Payments of debt discounts</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(46,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of equity issuance fees</a></td>
<td class="num">(291,834)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,760<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,882,813<span></span>
</td>
<td class="nump">1,751,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">2,779,491<span></span>
</td>
<td class="num">(4,812,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">978,741<span></span>
</td>
<td class="nump">5,791,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">ENDING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">3,758,232<span></span>
</td>
<td class="nump">978,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>CASH PAID FOR:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">7,293<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">528,907<span></span>
</td>
<td class="nump">444,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses', window );">Change in capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="nump">4,421<span></span>
</td>
<td class="nump">50,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses', window );">Change in payments of debt discounts included in accounts payable and accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability', window );">Operating lease right-of-use asset and operating lease liability</a></td>
<td class="nump">$ 103,115<span></span>
</td>
<td class="nump">$ 2,472,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in capital expenditures included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of change in payments of debt discounts included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PaymentsOfDebtDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of debt discounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PaymentsOfDebtDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>1. BUSINESS OPERATIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">ImmuCell Corporation (the &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 16, &#8220;Segment Information&#8221;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the <b>First Defense<sup>&#174;</sup></b> product line, providing <b>Immediate Immunity&#8482;</b> to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting <i>E. coli</i>,
coronavirus and rotavirus pathogens. We are also developing <b>Re-Tain<sup>&#174;</sup></b>, a treatment for lactating dairy cows with
subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need
to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and
third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products
and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends
and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions in the United States and/or
internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases in key
components, supportive services, transportation and other supplies that are causing our costs of goods sold to increase. We have experienced
contamination events from time to time in our production process, beginning in the third quarter of 2022, as disclosed previously. We
implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower sales and gross margin.
The last identified contamination event occurred during the first half of April of 2024, and we have been operating without further contamination
events since then and through the time of this filing on March 28, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(a) Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have prepared the accompanying audited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(b) Cash and Cash Equivalents </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(c) Trade Accounts Receivable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts receivable are carried at the original
invoice amount less an estimate made for credit losses, when applicable. Management determines the allowance for credit losses on a monthly
basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors.
Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due
accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the years ended
December 31, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of December
31, 2024 or 2023. As of December 31, 2024 and 2023, we determined that no allowance for credit losses was necessary. Accounts receivable
are written off when deemed uncollectible. No accounts receivable were written off during the years ended December 31, 2024 or 2023. Recoveries
of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the years
ended December 31, 2024 or 2023. See Note 3.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(d) Inventory</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(e) Property, Plant and Equipment, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 6 for additional disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(f) Operating Leases</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account for our real estate leases using a
right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the
lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related
to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received
and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs
are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease.
When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of
determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets
or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined
lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent
payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes.
These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use
an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease
payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset
may not be recoverable. See Notes 2(h) and 11 for additional disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(g) Intangible Assets and Goodwill</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> goodwill impairments were recorded during the years ended
December 31, 2024 or 2023. See Notes 2(h) and 7 for additional disclosures.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(h) Valuation of Long-Lived Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39">No</span></span> impairment was recognized during the years ended December 31, 2024 or
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(i) Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In <span style="font-style: normal; font-weight: normal">determining</span>
fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification
Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements.
The topic provides a consistent definition of fair value which focuses on an exit price, which is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The topic
also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes
a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of
the measurement date. As of December 31, 2024 and 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory,
prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their
short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.
Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.5in">Level 1</td>
    <td style="width: 0.25in">&#8212;</td>
    <td>Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 2</td>
    <td>&#8212;</td>
    <td>Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 3</td>
    <td>&#8212;</td>
    <td>Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the years ended December 31, 2024 and 2023, there were no transfers between levels. As of December 31, 2024 and 2023, our Level 1 assets
measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities
measured at fair value on a nonrecurring basis as of December 31, 2024 or 2023. The carrying values of our cash and money market accounts
as of December 31, 2024 and 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the
carrying values of our fixed rate bank debt as of December 31, 2024 and 2023 differed from their fair market values. These values are
reflected in the following tables:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>As of December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(j) Concentration of Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years Ended<br/> December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">30%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">32%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#8239;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10.1pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">77%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">57%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">43%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">21%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">36%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">78%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(k) Revenue Recognition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 13 for additional disclosures.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(l) Expense Recognition </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(m) Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account
for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability
or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary
differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning strategies
in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine that it is
more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over a reasonably
short period of time, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise,
if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in the future, an
increase to the valuation allowance would be charged to income in the period such determination was made.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2024 or 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 15.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(n) Stock-Based Compensation </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $325,551 and $368,866 during the years ended December 31, 2024 and 2023, respectively. See Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(o) Net Loss Per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/> Ended December 31, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(2,156,629</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(5,774,598</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,167,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,747,686</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,167,244</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,747,686</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(p) Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in
the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation
of inventory, deferred tax assets and costs of goods sold.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(q) New Accounting
Pronouncement Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments require disclosure of significant
segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and loss. The adoption
of ASU 2023-07 did not have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(r) New Accounting Pronouncements Not Yet Adopted</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November
of 2024, the FASB issued ASU 2024-03, <i>Disaggregation of Income Statement Expenses</i>, to provide disaggregated disclosures of specific
expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements
will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal
years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is
permitted. We are evaluating ASU 2024-03 to determine its impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In December
of 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to assess the
impact on our financial statement disclosures and to determine the transition method in which the new guidance will be adopted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrentAbstract', window );"><strong>Trade Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">TRADE ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>3. TRADE ACCOUNTS RECEIVABLE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Trade accounts receivable amounted to $3,771,133
and $2,185,383 as of December 31, 2024 and 2023, respectively. No allowance for credit losses or product returns was recorded as of December
31, 2024 or 2023. We consider a broad range of information to estimate credit losses. Historically, we have experienced a very low level
of credit loss expense, and most of our trade receivables are collected by the due date or within a few days of the due date. We anticipate
no future events or conditions that would impact our ability to collect our accounts receivable. Because of the generally short duration
from the balance sheet date to the date of collection, our collection rate is not expected to be significantly impacted by events occurring
after the balance sheet date. The trade accounts receivable balances included $52,097 and $42,507 due from a related party as of December
31, 2024 and 2023, respectively. See Note 17.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>4. INVENTORY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,356,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,594,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,746,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,815,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,112,623</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,811,841</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">These inventory figures are net of write-offs of
scrapped inventory in the amounts of $406,565 and $527,133 during the years ended December 31, 2024 and 2023, respectively, that resulted
principally from contamination events and other production process losses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Prepaid expenses and other current assets consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">360,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">454,152</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,555</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">400,762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">493,885</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>6. PROPERTY, PLANT AND EQUIPMENT, net</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Property, plant and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%; text-align: left">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">3-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">21,234,259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,953,601</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center">10-39</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,889,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,784,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">3-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-40">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,768,224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-41">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,390,570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,059,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,041,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,483,948</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,349,019</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,575,683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">As of December 31, 2024 and 2023, construction
in progress consisted principally of payments toward the <b>First Defense<sup>&#174;</sup></b> production capacity expansion project and
equipment needed to bring the formulation and aseptic filling for <b>Re-Tain<sup>&#174;</sup></b> in-house. The costs associated with property,
plant and equipment disposals were $130,365 and $100,142 during the years ended December 31, 2024 and 2023, respectively. Depreciation
expense was $2,668,077 and $2,697,897 during the years ended December 31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>7. INTANGIBLE ASSETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets of $191,040 were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be 10 years.
Intangible amortization expense was $19,104 during both of the years ended December 31, 2024 and 2023. The net value of these intangibles
was $19,104 and $38,208 as of December 31, 2024 and 2023, respectively. Intangible asset amortization expense is estimated to be $19,104
during the year ending December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2024 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/>
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(165,690</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,170</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,076</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">564</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(171,936</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,104</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2023 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated <br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(147,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,040</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(152,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,208</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts payable and accrued expenses consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">934,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,195,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,482,522</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,124,337</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BANK DEBT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>9. BANK DEBT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loans #1 and #2</b>: During the first quarter
of 2020, we closed on a debt financing with Maine Community Bank (formerly known as Gorham Savings Bank) (MCB) aggregating $8,600,000,
which was comprised of a $5,100,000 mortgage note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term
and 25-year amortization schedule and a balloon principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000
note (Loan #2) that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working capital.
During the first quarter of 2022, we closed on an additional $2,000,000 in mortgage debt, which bears interest at the fixed rate of 3.58%
per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal
balance from $4,233,957 to $6,233,957 bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon payment
from $3,145,888 to $3,687,608 and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter of
2032.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Line of Credit (LOC)</b>: Also during the first
quarter of 2020, MCB extended a $1,000,000 LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of December 31, 2024
or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #3</b>: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $500,000. The first 2.25 years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of 5% per annum over the final five years of the loan, through
the third quarter of 2027 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #4</b>: During the fourth quarter of 2020,
we closed on a $1,500,000 note with MCB that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule).
Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to 80% of the most recent appraised value of the property securing the debt, which allowed MCB to release the $1,400,000 that
had been held in escrow. The remaining proceeds were available for general working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #5</b>: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $400,000, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of 5% per annum are due quarterly over the final 5.5 years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #6: </b>During the third quarter of 2023,
we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from MCB. The Finance Authority of Maine (FAME) provided
$1,000,000 of loan insurance to MCB. This loan is repayable under a 7-year amortization schedule with a balloon payment of $1,285,047
due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><b>Loan #7:</b> Also during the third quarter of
2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from FAME. The loan is repayable under a 7-year
amortization schedule with a balloon payment of $649,259 due during the third quarter of 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of 1.35 for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $173,305. The amortization
of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net,
and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated
to our indebtedness to MCB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms
of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These
loans may be prepaid without penalty at any time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds
from<br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds&#160;from</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt&#160;Principal</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Repayments</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">230,763</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">223,222</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,446</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,884</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,017</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,242</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,468,338</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,185,774</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Principal payments (net of debt issuance and debt
discount costs) due under bank loans outstanding as of December 31, 2024 (excluding our $1,000,000 line of credit) are reflected in the
following table by the year that payments are due:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2029</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,604</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">257,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">276,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,321,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,611,142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">690,401</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,671,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">715,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,539,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,341,259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,321,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,626,003</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,174</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,235</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,497,619</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,316,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">793,389</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344,110</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">273,207</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,313,934</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,538,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Contingent Liabilities and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>10. CONTINGENT LIABILITIES AND COMMITMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability
for such obligations as of December 31, 2024 or 2023. Since our incorporation, we have had no occasion to make any indemnification payment
to any of our officers or directors for any reason.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the time of this filing on March 28, 2025. We believe that we have reasonable levels of
liability insurance to support our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of December 31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to <b>Re-Tain<sup>&#174;</sup></b> Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP terminated on November 30, 2024. This contract was extended through March of 2026 for the purpose of
final packaging of existing DP inventory, but this contract extension does not anticipate the production of new DP inventory. During 2019,
we initiated an investment in the necessary equipment to perform the DP formulation and aseptic filling services in-house, but this investment
has been paused at the present time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#8220;Deferred Compensation Agreement&#8221;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#8217;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off. Accordingly, an expense of $222,379 for earned and unpaid sick time was accrued during
the first quarter of 2022 and a related accrual of $230,162 was included in accounts payable and accrued expenses as of December 31, 2024
and 2023. Additionally, Mr. Brigham was paid $300,000 in deferred compensation during the first quarter of 2025 (which was accrued over
the three-year period ending in December 2024). This deferred compensation payment vested as to $300,000, $200,000 and $100,000 on January
1, 2025, 2024 and 2023, respectively. Deferred compensation of $300,000 and $200,000 was included in accounts payable and accrued expenses
on the accompanying balance sheets as of December 31, 2024 and 2023, respectively. In addition, upon termination of Mr. Brigham&#8217;s
employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case
as described and defined in the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual
base salary and a lump sum payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered
dependents for a twelve-month period following termination, and certain equity incentive awards granted to Mr. Brigham would continue
to vest following such termination in accordance with the terms of the Deferred Compensation Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(formerly our Vice President of Manufacturing Operations), which, at times, allow these executives to earn incentive compensation if certain
regulatory and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts
related to these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will
be earned) based on our best estimate of the amounts expected to be </span>earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In addition to the commitments discussed above,
we had committed $67,000 to increase our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line, $1,629,000 to
the purchase of inventory and $686,000 to information technology services and other obligations as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>11. OPERATING LEASES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">On September
12, 2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession date of November
15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (<b>Building 175A</b>),
which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our
needs in expanding our production capacity for the <b>First Defense<sup>&#174;</sup></b> product line. The original lease term was ten
years with a right to renew for a second 10-year term and a right of first offer to purchase. At the time we entered into this lease,
we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that reason, a 10-year
period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed
to lease an additional 15,400 square feet of space at 175 Industrial Way (<b>Building 175B</b>), which is connected to the original space,
over a 20-year term. The ROU asset and lease liability for the committed space at <b>Building 175B</b> was recorded as of April 1, 2023
after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of
August 1, 2023. In connection with the lease commitment for space at <b>Building 175B</b><span style="font-style: normal; font-weight: normal">,</span>
the term of the original lease for <b>Building 175A</b> was extended by approximately 13 years. On November 14, 2023, June 11,
2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements on the leased premises to be paid
for by our landlord. These improvements will provide heat to an unfinished space, provide additional warehouse space, and create a new
primary shipping and receiving facility. As a result of these three amendments and in consideration for the landlord agreeing to pay
for the cost of those certain tenant improvements, we agreed to make additional rent payments of $20,000 per month from November of 2023
through June of 2025 and a one-time additional rent payment of $248,743 in July of 2025. Because of these modifications to the lease
payments, the ROU asset and lease liability associated with the space at <b>Building 175B</b> were remeasured as of the modification
dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges. As of December
31, 2024, the balance of the operating lease ROU asset was $4,560,679 and the operating lease liability was $4,561,174. As of December
31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385. The calculated
amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for the present value
of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying assets, and instead
to account for them as a single lease component. Variable lease cost primarily represents variable payments such as real estate taxes
and common area maintenance. The following tables describe our lease costs and other lease information:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/>
Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Lease Cost</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">427,519</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">348,929</td> <td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">66,523</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">36,774</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">494,042</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">385,703</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating Lease</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Cash paid for operating lease liabilities</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right">577,260</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right">248,595</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">18.1</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">19.1</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">6.6</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">7.11</td> <td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Future lease payments required under non-cancelable
operating leases in effect as of December 31, 2024 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">During the years ending December 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">711,623</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,578,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,731,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,170,283</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,561,174</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>12. STOCKHOLDERS&#8217; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Common Stock Issuances</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">From February of 2016 to April of 2021, we sold
the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds of $26,714,403 at the weighted
average price of $5.87 per share. These funds have been essential to funding our business growth plans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">On April 9, 2024, our shelf registration on Form
S-3 relating to the offer, issuance and sale by the Company of up to $20,000,000 of securities was declared effective by the Securities
and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market (ATM) Agreement with Craig-Hallum Capital Group LLC,
pursuant to which we may offer and sell up to $11,000,000 of shares of our common stock. Legal, accounting and other fees in the amount
of $152,272 associated with the completion of the shelf registration and the ATM Agreement were initially capitalized and then were offset
against the initial proceeds received during the second quarter of 2024. As of December 31, 2024, we have sold 1,228,227 shares under
the ATM Offering conducted pursuant to the ATM Agreement. Net proceeds through December 31, 2024 from shares sold pursuant to the ATM
Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $139,562, were $4,356,188.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Stock Option Plans</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#8220;2010 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than 10 years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were 183,500 and
188,500 options outstanding under the 2010 Plan as of December 31, 2024 and 2023, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In June of 2017, our stockholders approved the
2017 Stock Option and Incentive Plan (the &#8220;2017 Plan&#8221;) pursuant to the provisions of the Internal Revenue Code of 1986, under
which employees and certain service providers may be granted options to purchase shares of the Company&#8217;s common stock at no less
than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan.
An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000
shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined
by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan
expire no later than 10 years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can
be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their
terms. As of December 31, 2024 and 2023, there were 480,500 and 430,000 options outstanding under the 2017 Plan, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Activity under the stock option plans described
above was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate <br/>
Intrinsic <br/>
Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">202,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">402,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(661,310</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,071,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">480,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(870,558</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">136,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(582,340</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">480,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(870,558</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">151,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">Terminations and forfeitures are recognized when they occur.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">The following table displays additional information about the stock
option plans described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average <br/>
Exercise <br/>
Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options granted during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.55</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"><span style="-sec-ix-hidden: hidden-fact-85">No</span> stock options were exercised during the year
ended December 31, 2024. During the year ended December 31, 2023, 4,000 stock options were exercised by one employee with $18,760 in cash.
The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was $1,040. The weighted average remaining
life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2024 was approximately 4 years and 10 months.
The weighted average remaining life of the options exercisable under these plans as of December 31, 2024 was approximately 2 years and
8 months. The exercise price of the options outstanding under these plans as of December 31, 2024, ranged from $3.60 to $10.04 per share.
The 86,000 stock options granted during the year ended December 31, 2024 had an average exercise price of $3.91 per share. The 122,000
stock options granted during the year ended December 31, 2023 had an average exercise price of $5.16 per share. The weighted-average grant
date fair values of options granted during the years ended December 31, 2024 and 2023 were $1.84 and $2.80 per share, respectively. As
of December 31, 2024, total unrecognized stock-based compensation related to non-vested stock options aggregated $365,124 which will be
recognized over a weighted average remaining period of approximately 1 year and 3 months. The fair value of each stock option grant has
been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following
weighted-average assumptions:</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/> Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">3.77</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">3.59</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">52</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">54</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 years</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 years</span></td> <td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: justify">The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Common Stock Rights Plan</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In September of 1995, our Board of Directors
adopted a Common Stock Rights Plan (the &#8220;Rights Plan&#8221;) and declared a dividend of one common share purchase right (a &#8220;Right&#8221;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitled the registered holder to purchase from
the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms
of the Rights were set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent. At various times
over the years, our Board of Directors, which has the authority to amend the Rights Plan, voted to authorize amendments to the Rights
Plan to extend the expiration date of the Rights Plan. During 2024, our Board of Directors determined not to further extend the Rights
Plan because these plans are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as
of September 19, 2024. No shares were issued under Rights Plan while it was in effect.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>13. REVENUE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
primarily offer the <b>First Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the years ended December 31, 2024 or 2023. We do not have any contract assets for which we have satisfied
the performance obligations, but do not yet have the right to bill for, or contract liabilities such as customer advances. All trade receivables
on our balance sheets are from contracts with customers. We incur no material costs to obtain contracts.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales
disaggregated by geographic area:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,893,721</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">86%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,949,382</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">91%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,599,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">14%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,522,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">9%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26,493,169</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,471,669</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales disaggregated
by major product category:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,314,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">99%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">99%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26,493,169</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,471,669</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">OTHER EXPENSES, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>14. OTHER EXPENSES, NET</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Other expenses net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/>
 Ended December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">568,725</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">475,598</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">15,391</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,099</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(77,702</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(96,570</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(107</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">506,414</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">21,893</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#8217;s policy related to an equipment malfunction (in the amount of $115,127).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>15. INCOME TAXES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our income tax expense aggregated $10,056 and $4,627
(amounting to less than 1% of our loss before income taxes) during the years ended December 31, 2024 and 2023, respectively. As of December
31, 2024, we had federal net operating loss carryforwards of $17,647,250 of which $15,935,343 do not expire and of which $1,711,907 expire
in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of $5,194,515 that expire in 2037 through
2038 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $842,565 that expire in
2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $777,459 that expire in 2025 through 2042 (if not
utilized before then).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to zero.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying audited
financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The income tax provision consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years<br/>
 Ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">10,056</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,627</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,627</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(500,927</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,179,474</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,032</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(145,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Deferred subtotal, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(559,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,325,276</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">559,959</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,325,276</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred subtotal, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The actual income tax expense differs from the
expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before income taxes during the years ended December
31, 2024 and 2023 respectively, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
                                            the Years Ended December 31,</b></p></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Computed expected income tax expense rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(450,780</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,211,694</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes, net of federal expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,681</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.71</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.03</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(116,091</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,241</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.92</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">559,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325,276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.09</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income tax expense/rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.47</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The significant components of our deferred tax
assets, net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;As
of <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Property, plant and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,833,727</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,121,940</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal general business tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">842,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">726,474</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,705,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,729,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State tax credits and net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900,569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">886,428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#167;174 R &amp; D expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,915</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,722</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,718</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,124</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">UNICAP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Incentive compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,718</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,593,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,034,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>16. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, <i>Segment Reporting</i>, we operate in the following two reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the <b>First Defense<sup>&#174;</sup></b> product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, <b>CMT </b>and <b>Re-Tain<sup>&#174;</sup></b>. <b>Re-Tain<sup>&#174;
</sup></b>is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#8220;Other&#8221; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for <b>First Defense<sup>&#174;</sup></b> or Center for Veterinary Medicine, U.S. Food and Drug Administration for <b>Re-Tain<sup>&#174;</sup></b>)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our
President and CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,314,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178,918</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,493,169</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,382,949</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,552,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,931,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,941,044</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,578</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,493,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,898,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,909,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,466,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,216,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,216,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,153,377</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,049,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,378,255</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,581,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,777,925</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,039,829</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,378,255</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,640,159</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
the Year Ended December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177,736</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,471,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,453,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,602,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,869,284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,242,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,394,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,447,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,088,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,458,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,883,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,275,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,617,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,854,542</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,275,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,748,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,644,294</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,523,048</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,933,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45,100,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,735,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,827,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,244,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,808,102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,373,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,277,218</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,729,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,365,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,287,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,739,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">409,696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">465,725</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,096,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">795,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,892,513</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>17. RELATED PARTY TRANSACTIONS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the <b>First
Defense</b></span><b><span style="font-family: Symbol"><sup>&#210;</sup></span></b> <span style="font-family: Times New Roman, Times, Serif">product
line and <b>CMT</b>). His affiliated company purchased $567,114 and $231,405 of products from us during the years ended December 31, 2024
and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts receivable (subject
to standard and customary payment terms) due from this affiliated company aggregated $52,097 and $42,507 as of December 31, 2024 and 2023,
respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>18. EMPLOYEE BENEFITS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee&#8217;s salary that is contributed
to the Plan and 50% of the next 2% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid
$203,756 and $178,150 into the Plan for the years ended December 31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>19. SUBSEQUENT EVENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have evaluated subsequent events through the
time of this filing on March 28, 2025. First, in January of 2025, we settled a long outstanding insurance claim related to previously
disclosed contamination events in our production process incurred from late 2022 through April of 2024. As a result of the settlement,
we received $426,587 during January of 2025, which is in addition to the $250,000 that was previously received on this claim and recognized
for financial statement purposes during the third quarter of 2023. Second, net proceeds from January 1, 2025 through March 21, 2025 from
3,532 shares sold pursuant to our ATM Agreement (less sales commissions of $584) were $18,849. As of the time of this filing on March
28, 2025, there were no additional material, reportable subsequent events.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (2,156,629)<span></span>
</td>
<td class="num">$ (5,774,598)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif"><b>Risk
Management and Strategy</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities and test those systems
pursuant to our process. Our cybersecurity risk assessment is part of our overall risk management program. We also regularly engage outside
consultants to assess, identify and manage material risks from cybersecurity threats, including those threats associated with our use
of third-party service providers. These consultants recommend, implement and monitor systems to protect against cybersecurity threats.
Based on the information available to us through the time of this filing on March 28, 2025, we are not aware of any risks from cybersecurity
threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial
condition. However, despite our cybersecurity risk management processes, there can be no assurance that we, or the third parties with
which we interact, will not experience a cybersecurity incident in the future that may materially affect us. Refer to the risk factor
captioned <i>&#8220;Increasing dependence on the continuous and reliable operation of our information technology systems&#8221;</i> under
<b>PART I, ITEM 1A &#8211; RISK FACTORS</b> above for additional description of cybersecurity risks and potential related impacts on
the Company.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">Based on the information available to us through the time of this filing on March 28, 2025, we are not aware of any risks from cybersecurity
threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial
condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to
cybersecurity. Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our
President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity
risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents. While our management
team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks. Our Board of Directors
reviews cybersecurity threats and risk controls at quarterly meetings based on information provided by management and outside consultants.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our
Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to
cybersecurity. Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our
President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity
risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">While our management
team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks. Our Board of Directors
reviews cybersecurity threats and risk controls at quarterly meetings based on information provided by management and outside consultants.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(a) Basis of Presentation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We have prepared the accompanying audited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB <i>Accounting Standards Codification</i>&#8482;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(b) Cash and Cash Equivalents </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(c) Trade Accounts Receivable</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts receivable are carried at the original
invoice amount less an estimate made for credit losses, when applicable. Management determines the allowance for credit losses on a monthly
basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors.
Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due
accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the years ended
December 31, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of December
31, 2024 or 2023. As of December 31, 2024 and 2023, we determined that no allowance for credit losses was necessary. Accounts receivable
are written off when deemed uncollectible. No accounts receivable were written off during the years ended December 31, 2024 or 2023. Recoveries
of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the years
ended December 31, 2024 or 2023. See Note 3.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(d) Inventory</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 4.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(e) Property, Plant and Equipment, net</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for <b>Re-Tain<sup>&#174;</sup></b> (<b>Building 33</b>) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new <b>First Defense<sup>&#174; </sup></b>production facility at 175
Industrial Way (<b>Building 175A</b>) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (<b>Building 175B</b>). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 6 for additional disclosures.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(f) Operating Leases</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account for our real estate leases using a
right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the
lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related
to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received
and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs
are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease.
When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of
determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets
or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined
lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent
payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes.
These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use
an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease
payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset
may not be recoverable. See Notes 2(h) and 11 for additional disclosures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(g) Intangible Assets and Goodwill</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31<sup>st</sup>)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. <span style="-sec-ix-hidden: hidden-fact-36"><span style="-sec-ix-hidden: hidden-fact-37">No</span></span> goodwill impairments were recorded during the years ended
December 31, 2024 or 2023. See Notes 2(h) and 7 for additional disclosures.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(h) Valuation of Long-Lived Assets</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. <span style="-sec-ix-hidden: hidden-fact-38"><span style="-sec-ix-hidden: hidden-fact-39">No</span></span> impairment was recognized during the years ended December 31, 2024 or
2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(i) Fair Value Measurements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In <span style="font-style: normal; font-weight: normal">determining</span>
fair value measurements, we follow the provisions of Codification Topic 820, <i>Fair Value Measurements and Disclosures</i>. Codification
Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements.
The topic provides a consistent definition of fair value which focuses on an exit price, which is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The topic
also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes
a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of
the measurement date. As of December 31, 2024 and 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory,
prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their
short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.
Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.5in">Level 1</td>
    <td style="width: 0.25in">&#8212;</td>
    <td>Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 2</td>
    <td>&#8212;</td>
    <td>Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Level 3</td>
    <td>&#8212;</td>
    <td>Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability.</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the years ended December 31, 2024 and 2023, there were no transfers between levels. As of December 31, 2024 and 2023, our Level 1 assets
measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities
measured at fair value on a nonrecurring basis as of December 31, 2024 or 2023. The carrying values of our cash and money market accounts
as of December 31, 2024 and 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the
carrying values of our fixed rate bank debt as of December 31, 2024 and 2023 differed from their fair market values. These values are
reflected in the following tables:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>As of December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(j) Concentration of Risk</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years Ended<br/> December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">30%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">32%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#8239;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10.1pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">77%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">57%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">43%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">21%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">36%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">78%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(k) Revenue Recognition</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We recognize revenue in accordance with Codification
Topic 606, <i>Revenue from Contracts with Customers (ASC 606)</i>. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 13 for additional disclosures.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ExpenseRecognitionPolicyTextBlock', window );">Expense Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(l) Expense Recognition </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(m) Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">We account
for income taxes in accordance with Codification Topic 740, <i>Income Taxes</i>, which requires that we recognize a current tax liability
or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary
differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning strategies
in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine that it is
more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over a reasonably
short period of time, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise,
if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in the future, an
increase to the valuation allowance would be charged to income in the period such determination was made.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2024 or 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 15.<b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(n) Stock-Based Compensation </b></p>We account for stock-based compensation in accordance
with Codification Topic 718, <i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $325,551 and $368,866 during the years ended December 31, 2024 and 2023, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(o) Net Loss Per Common Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Net loss per common share has been computed in
accordance with Codification Topic 260-10, <i>Earnings Per Share</i>. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/> Ended December 31, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(2,156,629</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(5,774,598</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,167,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,747,686</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,167,244</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,747,686</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(p) Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in
the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation
of inventory, deferred tax assets and costs of goods sold.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(q) New Accounting
Pronouncement Adopted</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November of 2023, the FASB issued ASU 2023-07,
<i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,</i> which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments require disclosure of significant
segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and loss. The adoption
of ASU 2023-07 did not have a material impact on our financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">New Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>(r) New Accounting Pronouncements Not Yet Adopted</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In November
of 2024, the FASB issued ASU 2024-03, <i>Disaggregation of Income Statement Expenses</i>, to provide disaggregated disclosures of specific
expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements
will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal
years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is
permitted. We are evaluating ASU 2024-03 to determine its impact on our financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">In December
of 2023, the FASB issued ASU 2023-09<i>, Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which includes amendments
that enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to assess the
impact on our financial statement disclosures and to determine the transition method in which the new guidance will be adopted.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExpenseRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of accounting policy for expense recognition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExpenseRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Include, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock', window );">Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis</a></td>
<td class="text">These values are
reflected in the following tables<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">3,758,232</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">9,465,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>As of December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Cash and money market accounts</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">978,741</td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Bank debt</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,431,817</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Risk</a></td>
<td class="text">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years Ended<br/> December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">47%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">30%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">32%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#8239;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 10.1pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">77%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2024</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>As of<br/>
 December 31,<br/> 2023</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Company A</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">57%</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">43%</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Company B</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">21%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">36%</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">78%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: center">79%</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Net Income (Loss) Per Common Share</a></td>
<td class="text">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/> Ended December 31, </b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 4pt">Net loss attributable to stockholders</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(2,156,629</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="width: 1%; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; width: 9%; text-align: right">(5,774,598</td>
    <td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average common shares outstanding - Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,167,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">7,747,686</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Dilutive impact of share-based compensation awards</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Weighted average common shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">8,167,244</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">7,747,686</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Basic</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Diluted</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.26</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(0.75</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Inventory consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,356,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,594,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Work-in-process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,746,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,815,194</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">402,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,112,623</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,811,841</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Prepaid expenses and other current assets consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of <br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 66%; text-align: left">Prepaid expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">360,207</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">454,152</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other receivables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,555</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">400,762</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">493,885</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Property, plant and equipment consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br/> Useful Lives <br/> (in years)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 53%; text-align: left">Laboratory and manufacturing equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">3-10</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">21,234,259</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">20,953,601</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Buildings and improvements</td><td>&#160;</td>
    <td style="text-align: center">10-39</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,889,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,784,565</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">3-10</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,056,145</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,036,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Construction in progress</td><td>&#160;</td>
    <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-40">n/a</div></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693,904</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,768,224</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Land</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-41">n/a</div></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">516,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Property, plant and equipment, gross</td><td>&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,390,570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">46,059,631</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,041,551</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,483,948</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in">Property, plant and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,349,019</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,575,683</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2024 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/>
Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated<br/>
 Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(165,690</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18,410</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,170</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,076</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">564</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(171,936</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,104</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Intangible assets as of December 31, 2023 consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Gross<br/>
 Carrying <br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accumulated <br/> Amortization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt">Developed technology</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">184,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(147,280</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,820</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Customer relationships</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,040</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Non-compete agreements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,512</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,128</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">191,040</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(152,832</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">38,208</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Accounts payable and accrued expenses consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of<br/> December&#160;31,&#160;2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accounts payable &#8211; trade</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">934,883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">874,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts payable &#8211; capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,175</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,195,703</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">942,999</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97,800</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234,552</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">192,754</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Income tax payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,815</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.125in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,482,522</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,124,337</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt Proceeds Received and Principal Repayments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2024</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>During
the Year Ended <br/>
December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds
from<br/>
Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Debt&#160;Principal<br/>
 Repayments</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Proceeds&#160;from</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt Issuance</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Debt&#160;Principal</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Repayments</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">230,763</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">223,222</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">512,139</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">494,455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">91,446</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">213,227</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">205,884</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,470</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,017</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">235,393</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">114,242</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,696</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,468,338</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,000,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,185,774</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal Payments Due Under Bank Loans Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Principal payments (net of debt issuance and debt
discount costs) due under bank loans outstanding as of December 31, 2024 (excluding our $1,000,000 line of credit) are reflected in the
following table by the year that payments are due:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2027</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2028</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2029</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Thereafter</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 16%">Loan #1</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">239,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">248,604</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">257,649</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,537</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">276,720</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,321,768</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,611,142</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">530,738</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">549,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">140,423</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,221,042</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">101,001</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,146</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">83,143</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,290</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220,998</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228,965</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240,438</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">690,401</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loan #5</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,856</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73,415</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,156</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81,086</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">301,513</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Loan #6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">253,003</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,418,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,671,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loan #7</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,364</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">715,698</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,539,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,341,259</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">798,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">276,720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,321,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,626,003</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Debt issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(21,314</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,580</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,420</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,513</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,834</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,174</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Debt discount cost</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(20,891</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,344</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(32,235</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,497,619</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,316,335</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">793,389</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">344,110</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">273,207</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,313,934</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,538,594</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs and Other Lease Information</a></td>
<td class="text">The following tables describe our lease costs and other lease information:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years <br/>
Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Lease Cost</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left">Operating lease cost</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">427,519</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">348,929</td> <td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Variable lease cost</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">66,523</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right">36,774</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total lease cost</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">494,042</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td> <td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td> <td style="border-bottom: Black 4pt double; text-align: right">385,703</td> <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating Lease</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">&#160;</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left">Cash paid for operating lease liabilities</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right">577,260</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">$</td> <td style="text-align: right">248,595</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left">Weighted average remaining lease term (in years)</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">18.1</td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">19.1</td> <td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in">Weighted average discount rate</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">6.6</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">7.11</td> <td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Future lease payments required under non-cancelable
operating leases in effect as of December 31, 2024 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">During the years ending December 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Amount</b></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2025</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">711,623</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,744</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">356,732</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">363,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2029</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371,144</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,578,344</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total lease payments (undiscounted cash flows)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,731,457</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest (discount effect of cash flows)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,170,283</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total operating liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,561,174</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity Under the Stock Option Plans</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Activity under the stock option plans described
above was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2010 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2017 Plan</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
Average <br/>
Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate <br/>
Intrinsic <br/>
Value<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of December 31, 2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">202,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">402,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.19</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(661,310</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">430,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.82</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,071,121</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10.1pt">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminations/forfeitures<b><sup>(2)</sup></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10.1pt">Exercises</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">480,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(870,558</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Vested as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">136,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.97</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(582,340</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">183,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">480,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">6.46</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">(870,558</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Reserved for future grants</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">151,500</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">Terminations and forfeitures are recognized when they occur.</td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Additional Information About the Stock Option Plans</a></td>
<td class="text"><p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif">The following table displays additional information about the stock
option plans described above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average <br/> Fair Value at Grant Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Average <br/>
Exercise <br/>
Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3.66</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Non-vested stock options as of December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.12</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options granted during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">86,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.84</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.91</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that vested during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">54,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.31</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.73</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Stock options that were terminated or forfeited during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.33</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6.55</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions</a></td>
<td class="text">The fair value of each stock option grant has
been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following
weighted-average assumptions:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/> Ended December 31,</b></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td> <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td> <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate<sup>(1)</sup></span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">3.77</td> <td style="width: 1%; text-align: left">%</td> <td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td> <td style="width: 9%; text-align: right">3.59</td> <td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend yield<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">0</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility<sup>(2)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">52</td> <td style="text-align: left">%</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right">54</td> <td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected life<sup>(3)</sup></span></td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6 years</span></td> <td style="text-align: left">&#160;</td> <td>&#160;</td> <td style="text-align: left">&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2 years</span></td> <td style="text-align: left">&#160;</td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(3)</sup></td><td style="text-align: justify">The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Product Sales Disaggregated by Geographic Area</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales
disaggregated by geographic area:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">United States</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,893,721</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">86%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">15,949,382</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">91%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,599,448</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">14%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,522,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">9%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26,493,169</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,471,669</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Sales Disaggregated by Major Product Category</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The following table presents our product sales disaggregated
by major product category:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>First
    Defense<sup>&#174;</sup></b> <span style="font-style: normal; font-weight: normal">product line</span></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,314,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">99%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: center">99%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other animal health</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,919</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">177,736</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">1%</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total Product Sales</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">26,493,169</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">17,471,669</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: center">100%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Expenses Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">Other expenses net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>During the Years<br/>
 Ended December 31,</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">568,725</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">475,598</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss on disposal of property, plant and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">15,391</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,099</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(77,702</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(96,570</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance recoveries<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86">&#8212;</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(365,127</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Income - other</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87">&#8212;</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(107</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Other expenses (income), net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">506,414</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">21,893</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><sup>&#160;</sup></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(1)</sup></td><td style="text-align: justify">Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.</td>
</tr></table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"></td><td style="width: 0.25in; text-align: left"><sup>(2)</sup></td><td style="text-align: justify">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#8217;s policy related to an equipment malfunction (in the amount of $115,127).</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The income tax provision consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Years<br/>
 Ended&#160;December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Federal</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt">State</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">10,056</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,627</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Current subtotal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,056</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,627</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Deferred</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 0.3in">Federal</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(500,927</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,179,474</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">State</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(59,032</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(145,802</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Deferred subtotal, gross</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(559,959</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,325,276</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">559,959</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,325,276</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deferred subtotal, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Expense Differs from the Expected Tax Computed</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The actual income tax expense differs from the
expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before income taxes during the years ended December
31, 2024 and 2023 respectively, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
                                            the Years Ended December 31,</b></p></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2024</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>$</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>%</b></td><td style="padding-bottom: 1.5pt"><b>&#160;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Computed expected income tax expense rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(450,780</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,211,694</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(21.00</td><td style="width: 1%; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State income taxes, net of federal expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(36,681</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.71</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117,149</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.03</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.97</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(116,091</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.41</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(53,241</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.92</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">559,959</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26.09</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,325,276</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.09</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,619</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.22</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22.97</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Income tax expense/rate</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.47</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,627</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of Our Deferred Tax Assets Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">The significant components of our deferred tax
assets, net, consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;As
of <br/>
December 31,</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt">Property, plant and equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,833,727</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,121,940</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal general business tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">842,565</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">726,474</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Federal net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,705,923</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,729,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">State tax credits and net operating loss carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">900,569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">886,428</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">&#167;174 R &amp; D expenditures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">727,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,915</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Deferred compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,370</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,722</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Prepaid expenses and other</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,718</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,124</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">UNICAP</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,443</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,607</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Incentive compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,718</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,593,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,034,030</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Deferred tax assets, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#8212;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text">Our chief operating decision-maker is our
President and CEO.<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">During the Year Ended December 31, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,314,251</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">178,918</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">26,493,169</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,382,949</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">169,176</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,552,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,931,302</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,941,044</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">243,578</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,493,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">161,706</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,898,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,909,799</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">556,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,466,072</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,216,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,216,549</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,153,377</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,049,571</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,378,255</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,581,203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,777,925</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,039,829</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,378,255</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,640,159</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>&#160;During
the Year Ended December 31, 2023</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt">Product sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,293,933</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">177,736</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">17,471,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Costs of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,453,514</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,602,385</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt">Gross margin</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,419</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,869,284</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Product development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,242,329</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">141,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,394,852</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,447,137</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">641,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,088,215</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt">Administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,134,295</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt">Operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,458,240</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,883,407</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,275,715</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,617,362</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -10.1pt; padding-left: 20.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt">NET OPERATING INCOME (LOSS)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,179</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,854,542</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(2,275,715</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,748,078</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&#160;</b></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Scours</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Mastitis</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">24,644,294</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,523,048</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,933,135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">45,100,477</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -10pt; padding-left: 10pt">Total Assets as of December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">24,735,413</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">17,827,839</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,244,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,808,102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,373,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,277,218</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">78,814</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,729,847</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Depreciation and amortization expense during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,365,988</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,287,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">86,032</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,739,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">409,696</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">53,721</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,308</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">465,725</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt">Capital Expenditures during the year ended December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,096,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">795,694</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,892,513</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation limits</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Asset depreciated percentage</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of recognized</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 325,551<span></span>
</td>
<td class="nump">$ 368,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive amounted (in Shares)</a></td>
<td class="nump">664,000<span></span>
</td>
<td class="nump">618,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember', window );">Nisin Drug Substance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_NisinDrugSubstanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details) - Fair Value, Nonrecurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">$ 3,758,232<span></span>
</td>
<td class="nump">$ 978,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">9,465,500<span></span>
</td>
<td class="nump">10,431,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="nump">3,758,232<span></span>
</td>
<td class="nump">978,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="nump">9,465,500<span></span>
</td>
<td class="nump">10,431,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and money market accounts</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Bank debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company A [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company A [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company B [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Company B [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Schedule of Concentration of Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CompanyBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CompanyBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=iccc_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=iccc_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Schedule of Net Income (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders (in Dollars)</a></td>
<td class="num">$ (2,156,629)<span></span>
</td>
<td class="num">$ (5,774,598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - Basic</a></td>
<td class="nump">8,167,244<span></span>
</td>
<td class="nump">7,747,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive impact of share-based compensation awards</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - Diluted</a></td>
<td class="nump">8,167,244<span></span>
</td>
<td class="nump">7,747,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 3,771,133<span></span>
</td>
<td class="nump">$ 2,185,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Trade Accounts Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">$ 52,097<span></span>
</td>
<td class="nump">$ 42,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write off</a></td>
<td class="nump">$ 406,565<span></span>
</td>
<td class="nump">$ 527,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,356,228<span></span>
</td>
<td class="nump">$ 1,594,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">5,746,865<span></span>
</td>
<td class="nump">5,815,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">9,530<span></span>
</td>
<td class="nump">402,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 7,112,623<span></span>
</td>
<td class="nump">$ 7,811,841<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Schedule of Prepaid Expenses and Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 360,207<span></span>
</td>
<td class="nump">$ 454,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">40,555<span></span>
</td>
<td class="nump">39,733<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 400,762<span></span>
</td>
<td class="nump">$ 493,885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposals</a></td>
<td class="nump">$ 130,365<span></span>
</td>
<td class="nump">$ 100,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,668,077<span></span>
</td>
<td class="nump">$ 2,697,897<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 46,390,570<span></span>
</td>
<td class="nump">$ 46,059,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(21,041,551)<span></span>
</td>
<td class="num">(18,483,948)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">25,349,019<span></span>
</td>
<td class="nump">27,575,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">21,234,259<span></span>
</td>
<td class="nump">20,953,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">20,889,395<span></span>
</td>
<td class="nump">20,784,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,056,145<span></span>
</td>
<td class="nump">1,036,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 2,693,904<span></span>
</td>
<td class="nump">2,768,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 516,867<span></span>
</td>
<td class="nump">$ 516,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Laboratory and manufacturing equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, Estimated Useful Lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset amortized, useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="nump">19,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="nump">$ 38,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization expense</a></td>
<td class="nump">$ 19,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">$ 191,040<span></span>
</td>
<td class="nump">$ 191,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(171,936)<span></span>
</td>
<td class="num">(152,832)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">19,104<span></span>
</td>
<td class="nump">38,208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">184,100<span></span>
</td>
<td class="nump">184,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(165,690)<span></span>
</td>
<td class="num">(147,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">18,410<span></span>
</td>
<td class="nump">36,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,170)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-compete agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Value</a></td>
<td class="nump">5,640<span></span>
</td>
<td class="nump">5,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,076)<span></span>
</td>
<td class="num">(4,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 1,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable &#8211; trade</a></td>
<td class="nump">$ 934,883<span></span>
</td>
<td class="nump">$ 874,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable &#8211; capital</a></td>
<td class="nump">8,754<span></span>
</td>
<td class="nump">13,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="nump">1,195,703<span></span>
</td>
<td class="nump">942,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">102,815<span></span>
</td>
<td class="nump">97,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">234,552<span></span>
</td>
<td class="nump">192,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">5,815<span></span>
</td>
<td class="nump">3,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,482,522<span></span>
</td>
<td class="nump">$ 2,124,337<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2027</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount', window );">Mortgage debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember', window );">Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_BankLoansMember', window );">Bank Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,687,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,145,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_InterestPaymentsTerm', window );">Interest payments, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_InterestPaymentsTerm', window );">Interest payments, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loans #4 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableLoanInProcess', window );">Finance loan provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 624,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LoanToValueRatio', window );">Loan to value ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member] | Gorham Savings Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Bearing interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 649,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtServiceCoverageRatio', window );">DSC ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Maine Technology Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest fixed rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #6 [Member] | Mortgage Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Bank Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Loan amortization, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the debt service coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LoanToValueRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ratio of loan to value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LoanToValueRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableLoanInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableLoanInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the related debt discount at the end of the accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481212/470-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_GorhamSavingsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_BankLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_BankLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_MaineTechnologyInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_MortgageBankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">1,468,338<span></span>
</td>
<td class="nump">1,185,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">230,763<span></span>
</td>
<td class="nump">223,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">512,139<span></span>
</td>
<td class="nump">494,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">96,104<span></span>
</td>
<td class="nump">91,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">213,227<span></span>
</td>
<td class="nump">205,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">66,470<span></span>
</td>
<td class="nump">32,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">235,393<span></span>
</td>
<td class="nump">93,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Schedule of Debt Proceeds Received and Principal Repayments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Debt Issuance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfBankDebt', window );">Debt Principal Repayments</a></td>
<td class="nump">$ 114,242<span></span>
</td>
<td class="nump">$ 45,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle a bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2025', window );">Debt issuance costs, 2025</a></td>
<td class="num">$ (21,314)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2026', window );">Debt issuance costs, 2026</a></td>
<td class="num">(13,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2027', window );">Debt issuance costs, 2027</a></td>
<td class="num">(5,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2028', window );">Debt issuance costs, 2028</a></td>
<td class="num">(3,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCosts2029', window );">Debt issuance costs, 2029</a></td>
<td class="num">(3,513)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtIssuanceCostshereafter', window );">Debt issuance costs, Thereafter</a></td>
<td class="num">(7,834)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, Total</a></td>
<td class="num">(55,174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2025', window );">Debt discount cost, 2025</a></td>
<td class="num">(20,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2026', window );">Debt discount cost, 2026</a></td>
<td class="num">(11,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2027', window );">Debt discount cost, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2028', window );">Debt discount cost, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCost2029', window );">Debt discount cost, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostThereafter', window );">Debt discount cost, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_DebtDiscountCostTotal', window );">Debt discount cost, Total</a></td>
<td class="num">(32,235)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2025', window );">Total 2025</a></td>
<td class="nump">1,497,619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2026', window );">Total 2026</a></td>
<td class="nump">3,316,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2027', window );">Total 2027</a></td>
<td class="nump">793,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebtTotal2028', window );">Total 2028</a></td>
<td class="nump">344,110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebt2029', window );">Total 2029</a></td>
<td class="nump">273,207<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_LongTermDebtThereafter', window );">Total Thereafter</a></td>
<td class="nump">4,313,934<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">10,538,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember', window );">Loan #1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">239,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">248,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">257,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="nump">266,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="nump">276,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="nump">4,321,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">5,611,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember', window );">Loan #2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">530,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">549,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">140,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">1,221,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember', window );">Loan #3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">101,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">106,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">83,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">290,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember', window );">Loan #4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">220,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">228,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">240,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">690,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember', window );">Loan #5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">69,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">73,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">77,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="nump">81,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">301,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember', window );">Loan #6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">253,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">1,418,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">1,671,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember', window );">Loan #7 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">124,364<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">715,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">840,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember', window );">Subtotal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">During the Years Ending December 31, 2025</a></td>
<td class="nump">1,539,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">During the Years Ending December 31, 2026</a></td>
<td class="nump">3,341,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">During the Years Ending December 31, 2027</a></td>
<td class="nump">798,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">During the Years Ending December 31, 2028</a></td>
<td class="nump">347,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">During the Years Ending December 31, 2029</a></td>
<td class="nump">276,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">During the Years Ending December 31, Thereafter</a></td>
<td class="nump">4,321,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">During the Years Ending December 31, Total</a></td>
<td class="nump">$ 10,626,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt discount cost 2028.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCost2029">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCost2029</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount cost thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtDiscountCostTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total debt discount cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtDiscountCostTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt issuance costs 2028.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCosts2029">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCosts2029</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DebtIssuanceCostshereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DebtIssuanceCostshereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2025">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2025</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2026">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2026</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2027">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2027</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebt2029">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of long term debt total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebt2029</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebtThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long term debt thereafter</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebtThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_LongTermDebtTotal2028">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of long term debt total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_LongTermDebtTotal2028</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_DebtInstrumentRedemptionPeriodSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=iccc_SubtotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Total accrued amount</a></td>
<td class="nump">$ 222,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CapitalExpendituresCommitted', window );">Capital expenditures committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_PurchaseofInventory', window );">Purchase of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_ReTainMember', window );">Re-Tain [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_CommitmentsRelatedToCommercialManufacture', window );">Commitments related to commercial manufacture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember', window );">Mr. Brigham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred compensation agreement annual base salary percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Contingent Liabilities and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CapitalExpendituresCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital expenditures committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CapitalExpendituresCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommitmentsRelatedToCommercialManufacture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments related to commercial manufacture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommitmentsRelatedToCommercialManufacture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PurchaseofInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of purchase of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PurchaseofInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_ReTainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_ReTainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_MrBrighamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 12, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area for lease (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_TermOfExtensionOfLease', window );">Term of extension of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,560,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,571,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,561,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area for lease (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,560,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,571,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,561,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,721,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems', window );"><strong>Operating Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Additional rent payment</a></td>
<td class="nump">$ 248,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_TermOfExtensionOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of extension of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_TermOfExtensionOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansAndLeasesReceivableDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansAndLeasesReceivableDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Schedule of Lease Costs and Other Lease Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 427,519<span></span>
</td>
<td class="nump">$ 348,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">66,523<span></span>
</td>
<td class="nump">36,774<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">494,042<span></span>
</td>
<td class="nump">385,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Lease</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">$ 577,260<span></span>
</td>
<td class="nump">$ 248,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">18 years 1 month 6 days<span></span>
</td>
<td class="text">19 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">7.11%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 711,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">349,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">356,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">363,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">371,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">5,578,344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments (undiscounted cash flows)</a></td>
<td class="nump">7,731,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest (discount effect of cash flows)</a></td>
<td class="num">(3,170,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating liabilities</a></td>
<td class="nump">$ 4,561,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">63 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,648,022<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation related to non-vested stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iccc_CommonStockRightsPlanMember', window );">Common Stock Rights Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Dividend shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Common stock purchase price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,500<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life of the options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember', window );">2010 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,500<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining life of the options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember', window );">2017 Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_StockOptionPlansMember', window );">Stock Option Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Stock options granted (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iccc_CommonStockIssuancesMember', window );">Common Stock Issuances [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,356,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,714,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_FeesInitiallyCapitalizedAndLaterOffset', window );">Legal, accounting and other fees amount (in Dollars)</a></td>
<td class="nump">$ 152,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold under at-the-market offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commissions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iccc_CommonStockIssuancesMember', window );">Common Stock Issuances [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Issuance and sale (in Dollars)</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_FeesInitiallyCapitalizedAndLaterOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_FeesInitiallyCapitalizedAndLaterOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iccc_CommonStockRightsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iccc_CommonStockRightsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_StockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_StockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iccc_CommonStockIssuancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iccc_CommonStockIssuancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Activity Under the Stock Option Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (1,071,121)<span></span>
</td>
<td class="num">$ (661,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested', window );">Weighted Average Exercise Price, Vested (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (582,340)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Weighted Average Exercise Price, Vested and expected to vest (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (870,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Grants (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.91<span></span>
</td>
<td class="nump">5.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="nump">7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercises (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (870,558)<span></span>
</td>
<td class="num">$ (1,071,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.46<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember', window );">2010 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,500<span></span>
</td>
<td class="nump">202,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">183,500<span></span>
</td>
<td class="nump">188,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Activity Under the Stock Option Plans [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">430,000<span></span>
</td>
<td class="nump">402,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested', window );">Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">136,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">480,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved for future grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Terminations/forfeitures</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(35,500)<span></span>
</td>
<td class="num">(94,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">480,500<span></span>
</td>
<td class="nump">430,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Terminations and forfeitures are recognized when they occur.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options exercisable weighted average vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandTenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iccc_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Additional Information About the Stock Option Plans (Details) - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Additional Information About the Stock Option Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Non-vested stock options as of beginning balance (in Shares) | shares</a></td>
<td class="nump">337,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of beginning balance</a></td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Non-vested stock options as of ending balance (in Shares) | shares</a></td>
<td class="nump">344,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 3.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Non-vested stock options as of ending balance</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Stock options granted (in Shares) | shares</a></td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options granted</a></td>
<td class="nump">$ 1.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options granted</a></td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Stock options that vested (in Shares) | shares</a></td>
<td class="nump">54,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options that vested</a></td>
<td class="nump">$ 4.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options that vested</a></td>
<td class="nump">$ 9.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Stock options that were terminated or forfeited (in Shares) | shares</a></td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value at Grant Date, Stock options hat were terminated or forfeited</a></td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Stock options hat were terminated or forfeited</a></td>
<td class="nump">$ 6.55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.77%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The dividend yield and expected volatility are derived from
averages of our historical data.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 26,493,169<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 22,893,721<span></span>
</td>
<td class="nump">$ 15,949,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product Sales</a></td>
<td class="nump">$ 3,599,448<span></span>
</td>
<td class="nump">$ 1,522,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=iccc_OtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=iccc_OtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 26,493,169<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember', window );">First Defense&#174; product line [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 26,314,250<span></span>
</td>
<td class="nump">$ 17,293,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember', window );">Other animal health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Schedule of Product Sales Disaggregated by Major Product Category [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total product sales</a></td>
<td class="nump">$ 178,919<span></span>
</td>
<td class="nump">$ 177,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of product sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_FirstDefenseProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_OtherAnimalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Other Expenses, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 42,666<span></span>
</td>
<td class="nump">$ 22,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Income from insurance recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 365,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_BusinessInterruptionPolicyMember', window );">Business Interruption Policy [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Other Expenses, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Income from insurance recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=iccc_VendorsPolicyMember', window );">Vendor&#8217;s Policy [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Other Expenses, Net [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Income from insurance recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 115,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#8217;s policy related to an equipment malfunction (in the amount of $115,127).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_BusinessInterruptionPolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_BusinessInterruptionPolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=iccc_VendorsPolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=iccc_VendorsPolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net - Schedule of Other Expenses Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Schedule of Other Expenses Net [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 568,725<span></span>
</td>
<td class="nump">$ 475,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,391<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(77,702)<span></span>
</td>
<td class="num">(96,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recoveries</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(365,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Income - other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 506,414<span></span>
</td>
<td class="nump">$ 21,893<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#8217;s policy related to an equipment malfunction (in the amount of $115,127).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating and nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 10,056<span></span>
</td>
<td class="nump">$ 4,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Loss income before income taxes, rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">3,705,923<span></span>
</td>
<td class="nump">$ 3,729,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeTaxExpense', window );">Non-cash income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 563,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Value of our deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">U.S. federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 17,647,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards not expire</a></td>
<td class="nump">15,935,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 1,711,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire
in 2034 through 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,194,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2037 through
2038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember', window );">Federal General Business [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 842,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in
2027 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember', window );">State Tax Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards expire</a></td>
<td class="nump">$ 777,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Expiration term</a></td>
<td class="text">expire in 2025 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_FederalGeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=iccc_StateTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Provision (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">10,056<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current subtotal</a></td>
<td class="nump">10,056<span></span>
</td>
<td class="nump">4,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(500,927)<span></span>
</td>
<td class="num">(1,179,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(59,032)<span></span>
</td>
<td class="num">(145,802)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred subtotal, gross</a></td>
<td class="num">(559,959)<span></span>
</td>
<td class="num">(1,325,276)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Valuation allowance</a></td>
<td class="nump">559,959<span></span>
</td>
<td class="nump">1,325,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred subtotal, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 10,056<span></span>
</td>
<td class="nump">$ 4,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Computed expected income tax expense rate</a></td>
<td class="num">$ (450,780)<span></span>
</td>
<td class="num">$ (1,211,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Computed expected income tax expense rate, percentage</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal expense</a></td>
<td class="num">$ (36,681)<span></span>
</td>
<td class="num">$ (117,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal expense, percentage</a></td>
<td class="num">(1.71%)<span></span>
</td>
<td class="num">(2.03%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Share-based compensation</a></td>
<td class="nump">$ 49,030<span></span>
</td>
<td class="nump">$ 56,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Share-based compensation, percentage</a></td>
<td class="nump">2.28%<span></span>
</td>
<td class="nump">0.97%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">$ (116,091)<span></span>
</td>
<td class="num">$ (53,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits, percentage</a></td>
<td class="num">(5.41%)<span></span>
</td>
<td class="num">(0.92%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 559,959<span></span>
</td>
<td class="nump">$ 1,325,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance, percentage</a></td>
<td class="nump">26.09%<span></span>
</td>
<td class="nump">0.09%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 4,619<span></span>
</td>
<td class="nump">$ 5,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other, percentage</a></td>
<td class="nump">0.22%<span></span>
</td>
<td class="nump">22.97%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 10,056<span></span>
</td>
<td class="nump">$ 4,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense/rate, percentage</a></td>
<td class="nump">0.47%<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">$ (1,833,727)<span></span>
</td>
<td class="num">$ (2,121,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Federal general business tax credits</a></td>
<td class="nump">842,565<span></span>
</td>
<td class="nump">726,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">3,705,923<span></span>
</td>
<td class="nump">3,729,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State tax credits and net operating loss carryforwards</a></td>
<td class="nump">900,569<span></span>
</td>
<td class="nump">886,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">&#167;174 R &amp; D expenditures</a></td>
<td class="nump">727,410<span></span>
</td>
<td class="nump">592,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Deferred compensation</a></td>
<td class="nump">82,370<span></span>
</td>
<td class="nump">50,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Prepaid expenses and other</a></td>
<td class="nump">24,718<span></span>
</td>
<td class="nump">37,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">UNICAP</a></td>
<td class="nump">22,443<span></span>
</td>
<td class="nump">32,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Incentive compensation</a></td>
<td class="nump">121,718<span></span>
</td>
<td class="nump">100,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(4,593,989)<span></span>
</td>
<td class="num">(4,034,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Reportable business segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="nump">$ 26,493,169<span></span>
</td>
<td class="nump">$ 17,471,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">18,552,125<span></span>
</td>
<td class="nump">13,602,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">7,941,044<span></span>
</td>
<td class="nump">3,869,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">3,898,582<span></span>
</td>
<td class="nump">4,394,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">3,466,072<span></span>
</td>
<td class="nump">3,088,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,216,549<span></span>
</td>
<td class="nump">2,134,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">9,581,203<span></span>
</td>
<td class="nump">9,617,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(1,640,159)<span></span>
</td>
<td class="num">(5,748,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">45,100,477<span></span>
</td>
<td class="nump">43,808,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,729,847<span></span>
</td>
<td class="nump">2,739,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">465,725<span></span>
</td>
<td class="nump">1,892,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember', window );">Scours [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="nump">26,314,251<span></span>
</td>
<td class="nump">17,293,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">18,382,949<span></span>
</td>
<td class="nump">13,453,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">7,931,302<span></span>
</td>
<td class="nump">3,840,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">243,578<span></span>
</td>
<td class="nump">11,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">2,909,799<span></span>
</td>
<td class="nump">2,447,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">3,153,377<span></span>
</td>
<td class="nump">2,458,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="nump">4,777,925<span></span>
</td>
<td class="nump">1,382,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">24,644,294<span></span>
</td>
<td class="nump">24,735,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,373,815<span></span>
</td>
<td class="nump">1,365,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">409,696<span></span>
</td>
<td class="nump">1,096,819<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember', window );">Mastitis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="nump">178,918<span></span>
</td>
<td class="nump">177,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="nump">169,176<span></span>
</td>
<td class="nump">148,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">9,742<span></span>
</td>
<td class="nump">28,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">3,493,298<span></span>
</td>
<td class="nump">4,242,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">556,273<span></span>
</td>
<td class="nump">641,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">4,049,571<span></span>
</td>
<td class="nump">4,883,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(4,039,829)<span></span>
</td>
<td class="num">(4,854,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">16,523,048<span></span>
</td>
<td class="nump">17,827,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,277,218<span></span>
</td>
<td class="nump">1,287,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">53,721<span></span>
</td>
<td class="nump">795,694<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Schedule of Segment Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Costs of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">161,706<span></span>
</td>
<td class="nump">141,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">2,216,549<span></span>
</td>
<td class="nump">2,134,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">2,378,255<span></span>
</td>
<td class="nump">2,275,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="num">(2,378,255)<span></span>
</td>
<td class="num">(2,275,715)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">3,933,135<span></span>
</td>
<td class="nump">1,244,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDepreciationAmortizationAndDepletion', window );">Depreciation and amortization expense</a></td>
<td class="nump">78,814<span></span>
</td>
<td class="nump">86,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital Expenditures</a></td>
<td class="nump">$ 2,308<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDepreciationAmortizationAndDepletion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDepreciationAmortizationAndDepletion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_ScoursMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_MastitisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party products purchased</a></td>
<td class="nump">$ 567,114<span></span>
</td>
<td class="nump">$ 231,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 52,097<span></span>
</td>
<td class="nump">$ 42,507<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Employee benefits paid (in Dollars)</a></td>
<td class="nump">$ 203,756<span></span>
</td>
<td class="nump">$ 178,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember', window );">Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryPercentage', window );">Employee&#8217;s salary percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember', window );">Employee One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Employee Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iccc_EmployeesSalaryContributionPercentage', window );">Employee&#8217;s salary contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary contribution percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeesSalaryPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee&#8217;s salary percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeesSalaryPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iccc_EmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Previously received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivable', window );">Settlement received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Sold amount</a></td>
<td class="nump">$ 18,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=iccc_ATMAgreementMember', window );">ATM Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold shares (in Shares)</a></td>
<td class="nump">3,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commissions</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iccc_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iccc_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>98
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *J ?%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *J ?%H=P6]"\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( *J ?%H9*0;B0 @  *$U   8
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M;L'O=+-AL07KCF[P2[GH)O9/(%9O.5A5F]E2:S*M385O-@/Y4#?E!+=W/;/
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M78<876*9>[2?))L<Z71=&] NR9&P-.TZEK%'RHU*8.$P3PL73](R=2T\$<Z
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MW8F2Z^QC ,P?)</L<"4XO(D4 /<74JK]2?I]X? ]:? O4$L#!!0    ( *J
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MI3YM09@"?7_-N7KLF V]/[^SOU!+ P04    " "J@'Q:T4SV(X0$  #]#P
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M^ :(Z9)L4OZ#;7^C=4*.Q(M86E9_P;:VM0P0;4K.LMI9K"!+\MU_\EH3<>
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M@?A]R1A_OY'?-)K/:M/_ %!+ P04    " "J@'Q:+9A(0D\"  #F!   &
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MTQ6D6.G:PO;P0-BH;]DGO664:0Z9[L$F(SW;9TS3CV&E4"52T7RIK:/BV.&
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M#4W5*Y)<UVK!>6I6.>QV\/OU];WG?MU0UO!'ST!F;<$2%H-Z2ENQ>%I^T[*
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MG:Y'"&\2$?"0Y*8Z5'5)+WUS:C)8#%FO)R?B%IGT)QF"78H*&2X/1@9SJMY
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M&_9]4&T#;2=&;ES3HCM+.7##DKXY4%D#VE]):?83&^#P%3/]&U!+ P04
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M<TWC'Z4)H/U<"+U?F 3]#V7R"U!+ P04    " "J@'Q: 6N 9(P'  #G$
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M8"M<%F@!?B\M;A/I@0[H7]R?_P=02P,$%     @ JH!\6N_2FC5/!   %PD
M !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&ULC5;;;N,V$'W/5PS4M'
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MP_GIH.NYPX?3F_ 7D&F'\@]+^%FP\0(X7VM,YO[#&SC^%J[^!5!+ P04
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M&DW__O1/9-IT7$E<7?J=#](BL;=[-+A,NG !@^$X'*4#6F6C03B8C#N_*&.
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M1>T,Z+Y4RNXW+L#A$9__"U!+ P04    " "J@'Q:=\>GQ:8)  !%%P  &0
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M'J86QI,PB^=L"B[S)/CZX?KJ\A/H$28)C./A+'(T@</IW'"P!3F;1&-8P.&
M8]P\3<)T,0T7<Y<F";(@<9DPJ,H/\Y=/OB-]@QW[CC89?-K<2IS'Z .N8>[D
MY+]R]D_[;\27_M/HPW+_@?D]CG,T,55R!=%HG*4CIOU'6W]CU<Y]*%TJ:]76
M76XDCA":%N#]2BG;W= &_9?SB_\#4$L#!!0    ( *J ?%J;(N/KB@4  /D,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*U76V_;-A1^]Z\@W*%(
M 2X6+Q*E-C&0:Q=@B8,XVS ,>Y MVA8J2QY))\U^_3Y2MI)T;M)B>TC,RSG?
MN7WGF#ZX;\PGN]#:D<_+JK:'_85SJ_>#@9TN]#*W^\U*U[B9-6:9.VS-?&!7
M1N=%4%I6 QY%R6"9EW5_>!#.KLWPH%F[JJSUM2%VO5SFYN%85\W]89_UMP<W
MY7SA_,%@>+#*YWJLW2^K:X/=H$,IRJ6N;=G4Q.C98?^(O3^67CX(_%KJ>_MD
M37PDDZ;YY#<7Q6$_\@[I2D^=1\CQ<:=/=%5Y(+CQUP:SWYGTBD_76_3S$#MB
MF>16GS35;V7A%H?]M$\*/<O7E;MI[G_2FWABCS=M*AO^D_M65L#B=&U=L]PH
M8[\LZ_8S_[S)PQ.%-/J* M\H\.!W:RAX>9J[?'A@FGMBO#30_"*$&K3A7%G[
MHHR=P6T)/3<<ZSE2[,A%W188F3H8. #[Z\%T W+<@O"O@#!.+IO:+2PYJPM=
M/ <8P*/.+;YUZYB_B'BJI_M$,$IXQ.4+>*(+4P0\\>UADC^.)M89T.+/71&W
M>'(WGF^5]W:53_5A'[U@M;G3_>';-RR)/KS@K>R\E2^A#\=G'R_/KF[)Q=7Y
MZ.;RZ/9B=+7+Q1=!=KO(DGVR YV,UB#WV@+"6H*.-R%%ENQ-=%G/B5MH4/T.
M+;SR::2]95ZO9TC=VFB2UP6Q>:5),R,KTQ3KJ;/0R!TIE]C?Z:"^T'GE%D%X
M(U3>E>[!*Q5Y:1["S43K&9GFSE7Z'<F--VJGIISH@I0UN6J<)FR?7*^-7>>U
MZ[F&G#1%.2NG;45OFU4Y)3R-*-D6_$:O&N-\#.>EL8Z<ZADFBB:HE9(?R,GE
M+41^O,7TVAX]W_9VJGTA<[HVVRS]KG/3=@%TIGHYT:;C<6\\;> ZN<RM*UUI
MR0@:!EZ[O.I=MTD)F;3D!\(3*IBD/&;8,)72C*58O7V3<L8_M (R$Y0E6>^D
ML4@Y,CEOFL(2VU0%82D5*:>9S A$*%-)IXNK..:4\;CWT30H.,;Q'-$HFL%5
M$7&2425Y)X]SR6@D9>?D$RX0_7GE4V,)EX+&*B4B^,6S%(8955&"DS2#S93W
MQB$Z7VK8_*1#81X!:!;!<I:1.$XH5Z+S )!)0B/%>T<%AF#I^]9/\T?=K>3V
MDU/.$AHC^F[5&[6\?FH2^8L%%4H1B0 S^,^@()!N'L=(0YPRRB/1NSJ[):/K
MLQMTR]5'=,[)Z/*,[/T\&H_?H122*H4D\1CK/0")C*8\(_YJ[Q$M;!E-9 2C
MN-W0IO<*;<1WT88I9%Z@D")L%%4B>48;"$@%+[Y&&Z0:&8F9)$RF-$4^.MH(
MFD0()_V"-J@N0I(,J89"$C^I6@KF\?05WC!&62201"Z!CKPQL$WR""<BDS2-
M7Z6-E(HRH4CB:0H&/CH0I<@]B[^#-DS D2Q^7.VB#4S& );>QS1%RB+E>:9B
MJIBG38(LBX2_0AL6.I2IK*5-&DO0E&]ILT4+6RQ1#1_;NQ?I$/Z3(VLU*IN'
MXOYK#/G9(4%#'YW?^.[@2)7T\R50!Z%[*LL8A4%EE?H67-'B*A&#"RW[T 7X
M$UF(E4L?8N1Q08PH!3;OG6I\-TW+=GS[^N9+/Z[_;@\V^2;%XWQ]\(VB=\_7
M-J4*Z"QN38+_/(Q-M&#*0N14<72G5/^K:=&:3F*:I6EK.E7H%A]MBL$E>&L:
M@R'A4>\D7Y4^GV?>2%'Z;U'['4%*3,DD\VV-3E6<!6P1><,2+BC,]?]@H8TE
MRA)DS%=.93&LR>=#! .=8T@(LNNU,WCR'%UJ,P^/;DM V]JU+]/NM'O7'[7/
MV4?Q]D?!91@QEE1Z!M5H7\5]8MJ'=KMQS2H\;B>-PU,Y+/'2*+3Q KB?-7@T
M;#;>0/=K9_@/4$L#!!0    ( *J ?%K[NS:2BP(  'D%   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;)64;6O;,!#'W_=3'"Z4#DKL..D#;6+(0\L"
M;1>2;&.,O5"L2RQJ2YXD-^VWWTE.O S2P-[8.NGNI__)_JNW4?K%9(@6WHI<
MFGZ065O>AJ%),RR8::D2):VLE"Z8I5"O0U-J9-P7%7D81]%56# A@Z3GYZ8Z
MZ:G*YD+B5(.IBH+I]R'F:M,/VL%N8B;6F7438=(KV1KG:+^64TU1V%"X*% :
MH21H7/6#0?MVV'7Y/N&;P(W9&X/K9*G4BPLFO!]$3A#FF%I'8/1ZQ1'FN0.1
MC-];9M!LZ0KWQSOZ@^^=>EDR@R.5?Q?<9OW@)@".*U;E=J8VGW';SZ7CI2HW
M_@F;.K=#R6EEK"JVQ:2@$+)^L[?M.>P5W$0?%,3;@MCKKC?R*L?,LJ2GU0:T
MRR::&_A6?36)$])]E+G5M"JHSB8SS)E%#E.F[3LL-).&^?,RO= 2WV6%Z98U
MK%GQ!ZQV#$]*VLS O>3(_P6$)*Q1%^_4#>.CQ#&F+>BT+R".XNX17J?IMN-Y
MG?_N%GX.EL9JBGX=:KS&=@]CG7%N3<E2[ ?D#(/Z%8/D[+1]%=T=$=UM1'>/
MT9/9_>-@<3^&Z6"V^ &+V>!Y/A@M)E^>YX>4'F>UKUOP,0_&[%7PDWD+%JIP
M_H?S4<:$!K4"56D8*J:Y"\9"DZN4-I] &&"0TF?7*J?=UJ V$GW%(R*G_U<B
M3&3:NJ TK@HT5J3 !9VU6%:$V+%+K7B56@/GEO9]$-K8DS&NR/X(9Z=Q.[K;
MI9RXIH!)#J.GQ:'S#??L4*!>>],;$EE)6SNCF6WNE4%MI[_I]:7TQ/1:T-^1
MXXI*H];U90"Z-GH=6%5Z<RV5):OZ849W(VJ70.LKI>PN<!LTMVWR!U!+ P04
M    " "J@'Q:<3$V^# #  #2!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6R=E6UOVS80Q]_G4QS4KF@!PWJPG7BI;2!.72S TAG)NF(8]H*6SA81
MBE3)DQ5_^QXIV_6PU!CV1N*1=S_][TB>)JVQ3ZY$)'BNE';3J"2JK^/8Y256
MPO5-C9I7UL96@MBTF]C5%D41@BH59TER&5="ZF@V"7-+.YN8AI34N+3@FJH2
M=C='9=IIE$:'B0>Y*<E/Q+-)+3;XB/2Y7EJVXB.ED!5J)XT&B^MI=)->SX?>
M/SC\(;%U)V/PF:R,>?+&73&-$B\(%>;D"8)?6[Q%I3R(97S=,Z/C)WW@Z?A
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M<%V@]K>,R4.@#^BG<?(;4$L#!!0    ( *J ?%HL=6B^0P(  (H&   9
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M6.J?!0@3H)_GG*OCQ&PP_'Z2-U!+ P04    " "J@'Q:N 'S9I,&   E%P
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MH,=&*LE47AJ5;Y(,O(U4IB-M+1TB?6-B;521*T0-K MX&7%;,:8:C-&V65[
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M*?RX9 OR$M6"C*2ZR OLYA6(S8(]%7,IV0Z&DC8[2$J&$JY&?#BH7?#3.JP
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M>].&'L#W]"<._"^T0?4G<U[]#U!+ P04    " "J@'Q:RAW!Q+ $  "/"P
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M7BZX;A/MW? G+B&"YAMOOUUX4)9)KXEYY%TQ4P"K<BA5Q9^Q6O0C=C?6Y-+
M+] -TOX@B+LQKM^_&\11?/%BU=Y[>^"-O!FK'K'B%_;%XV'02_I!/PP/G[X2
M2_?_BF68#H*T%[T2R?;V+7%$8=!#YP91^MKQ$8KV6XKVWTS1*U5EO,)2<NT9
M#^Z%>3S$N:,J#W-NSI!&8!68O6INVBG7QK,%%@ K"4-D(3Z+PA.JE5)IYYJE
M',!:J[S.+!BG#)F+H%DFY*O$'7G7M2L?NON3,[UM>!Z1M\GZE2K7K'J&*?32
M$_JU)S/HHA/=^,2!WQU>>(X)D.*[='BRY9'[W]/2)RW=?2UQA%J2DYWTP$D?
MRUW2YBYY<^X^(PD_51FB":<WRI@SN$-NHQ-(4Y@7B-6A1![7_WMMC46J(X >
M)BI[!+4F:F >*5T;C@FHE$7L,UGGNR0( QF362T;&BUXQFIL-Y0!OEQBF\&Q
MH)8Y7F 96?$A%[*F0>!%^I.D%X18P51H231PU9R[5'JDZ-FEDE,J?VY*3HAR
M&^"08M;<C1GR^?PG+NRQ@."3"!OV8:O%HG;L<72EN LE<V0I%M]I'$3])$CB
M(9S1MA^D:2_H#P=PYGUU P?U\B>N<7Z"K$'?$/K(DA]HP@?7SS,8!%&2!G&O
M!REVA31(!HEWO<-#(($0+4RNT_"!9IV<E.+\9QIPV8;IW+3-8?O]=YXX>_CV
MD"\M+&O$UTE3LR+/,?;P/$X:%,+SM(\ [#0=N#O$]L[>D(1-8.5&020/L:"9
ME]K3=MJ<-D/6C^?-J'K+]$H@+R5?HBB9]$$WXU^SL6KM1JZ%LMAQW++ B9EK
M>H#W2Z7L;D,&VAE\\@]02P,$%     @ JH!\6D=**15_ @  5@4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&ULA511;YLP$'[/K[#8-&T2+>! 2K($
M*6U7K0^5JK9;'Z8].' )5HW-;*=I__W.)J&9E&8O<'>^^_Q]X,_3C=)/I@:P
MY*41TLR"VMIV$D6FK*%AYE2U('%EJ73#+*9Z%9E6 ZO\4",B&L>CJ&%<!L74
MUVYU,55K*[B$6TW,NFF8?CT'H3:S( EVA3N^JJTK1,6T92NX!_NCO=6813U*
MQ1N0ABM)-"QGP3R9G*>NWS?\Y+ Q>S%Q2A9*/;GDNIH%L2,$ DKK$!B^GN$"
MA'! 2.//%C/HMW2#^_$._<IK1RT+9N!"B4=>V7H6Y &I8,G6PMZIS7?8ZLD<
M7JF$\4^RZ7HI#4BY-E8UVV%DT'#9O=G+]COL#>3Q.P-T.T ][VXCS_*2659,
MM=H0[;H1S05>JI]&<ERZGW)O-:YRG+/%M7P&:95^)9\?V$* ^3*-+.*ZU:C<
M8IQW&/0=C(22&R5M;<@W64'U+T"$A'I6=,?JG!Y%O(3RE R3D-"8ID?PAKW*
MH<<;_E?EK_G"6(UGX?<AG1U*>AC%^6-B6E;"+$ #&-#/$!2?/B2C^.L1CFG/
M,3V&7MRCWZJU **6I.=[B.11F,,DW_27"OUD+%1N&UL#62J!QN1R-1G,C2OZ
MY^".;?"86="<"4,^DB0<9J.0TMS'V3@-8YH/'M%Q)UR>M%J58 S)PK-T%.:C
M#*,\R<)DG ZNN.1X/BNR4JHR9!QFPYBD,0U'R7CPH"P3"'D6)@E6Z-#'>9*$
M>9J00U\UVCOK#>B5=[1!76MINV/?5_M+8]YYY:V]NW%NF%YQ:8B )8[&IV=9
M0'3GXBZQJO7.62B+/O1AC1<?:-> ZTNE["YQ&_17:?$74$L#!!0    ( *J
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M NT<<+]1RAXG+L#IK[;X&U!+ P04    " "J@'Q:)7J!9.D"  #9!@  &0
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M,BIE!K(<S5'/,TW35)$3_-$C?_1_YL_!!>_O#)K#D$_0$([$88#5>/+K+O@
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MN?XQVR^"W<8'Y,H&>(Y&<0/O?^/0 /;7UH9A@0G&_U$L_P%02P,$%     @
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MPB:UC1?Z?N*UK.;.:F''[N1J(3K=U!SO)*BN;9E\NL9&')9.X!P'[NNRTF;
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M6/,2#G.$#"XND8!L^LMFH$5E6[29T-CPV=<E]N0@S0+\/A="/P^,@K;+3[\
M4$L#!!0    ( *J ?%KN"30XI ,  #X4   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;*U876_;.!#\*X2N.+1 &XF2_)&<+2!Q4-P!31'$2/MPN =:
M6MM$*-%'4G;[[TM*CF0VBF#'?+%):6>\PZ568TYV7#S)-8!"/W)6R*FW5FIS
MY?LR74-.Y 7?0*'O++G(B=)3L?+E1@#)*E#._# (AGY.:.$ED^K:O4@FO%2,
M%G OD"SSG(B?-\#X;NIA[_G" UVME;G@)Y,-6<$<U./F7NB9W[!D-(="4EX@
M <NI=XVO9F%@ %7$-PH[>3!&1LJ"\R<S^2>;>H')"!BDRE 0_;6%&3!FF'0>
M_^])O>8W#?!P_,S^N1*OQ2R(A!EGWVFFUE-O[*$,EJ1DZH'O_H:]H('A2SF3
MU2?:[6,##Z6E5#S?@W4&.2WJ;_)COQ ' !R_ @CW@/!80+0'1)70.K-*UBU1
M))D(OD/"1&LV,ZC6ID)K-;0P99PKH>]2C5/)O"X?XDLTIZN"+FE*"H6NTY27
MA:+%"MUS1E,*$GU"<[V)LI*!B;Z6$I1$7* OE"PHH\K$W &1I8 ,$84^$RK0
M-\)*':_KA;[R0D!:"F%8;XBD$KV_!44HDQ\T>1O^T0[]]P[R!8C_=,SC_!:]
M?_=AXBLMW0CPT[W,FUIF^(K,6T@O4(0_HC (XP[X['AX9,-]O>#-JH?-JH<5
M7_0*7[UX5UTZ:F#<#30/]97<D!2FGGYJ)8@M>,F??^!A\%>7*D=DEL:HT1CU
ML2<S(M>(%!G*>0$_]9X53[HKD7ICR2[I-=^@XC/M9YM$H\$XC,*)OSU4]3+N
M<C0>Q;@)L_*-FWSCWIH<;./.PL0N"^.(S!(Z:(0.>@MS0XHGW>D6JDME#1T>
MKFT\' R"X+<:O(S#01SA,1YU5V'8)#?L3>X+;($AW#ST73GV,IQ:"4=DEMA1
M(W;TUC8P<JG1$9FE<=QH'#MN ^,76ZN[#;R,ZVL#ETV^EV>U@4N7A7%$9@G%
M0?OJ#][>"/JQW;FASC?K^42VO@-K@X_H)6%O+^FG.+6>KMALP:VKP&^V%=BI
MKW#%9NMLG05V;2WZ"4_9S><3V:);>X+/\R?8J4%QQ6:+;2T*/L.CX&--2D=@
MOTO!K4W!Q_B4J+^W.#4JKMALP:U5P6_V*MBI67'%9NML[0IV[5?Z"4_I+><3
MV:);SX//,SW8J>MQQ6;_]6YM3WB&[>G'GE!,!T2U/O_@<,><K-T1L:*%1 R6
MFCFX&.DF)^K#JGJB^*8Z[UEPI7A>#== ,A F0-]?<JZ>)^8(J3DR3'X!4$L#
M!!0    ( *J ?%IQ\TW9R0,   T5   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;+58;8_B-A#^*U8J5:UTMXD3EK<"TL*VNI-NI=6BMA]._6#" -8F
M-K4-W$G]\;6=D) HA .9+Q [,X]GGGFPAAD=N'B7&P"%OJ4)DV-OH]1VZ/LR
MWD!*Y /? M-O5ERD1.FE6/MR*X LK5.:^&$0=/V44.9-1G;O54Q&?*<2RN!5
M(+E+4R*^3R'AA[&'O>/&&UUOE-GP)Z,M6<,<U)_;5Z%7?H&RI"DP23E# E9C
M[PD/9V%@'*S%7Q0.\N09F506G+^;Q>?EV M,1)! K P$T5][F$&2&"0=Q[\Y
MJ%><:1Q/GX_H?]CD=3(+(F'&D[_I4FW&7M]#2UB17:+>^.$3Y D]&KR8)])^
MHD-N&W@HWDG%T]Q91Y!2EGV3;SD1)PZX>\8AS!W"ND/GC$.4.T0VT2PRF]8S
M460R$OR A+'6:.;!<F.]=3:4F3+.E=!OJ?93DWE6/L17:$[7C*YH3)A"3W',
M=TQ1MD:O/*$Q!8D^HKD6T7*7@+&><18#4X+8:NB--RK?T2_/H A-Y*_:>F:C
M!U$SM79?7R!=@/AGY"N=A G%C_. IUG X9F <8A>.%,;B7YG2UA6 7R=?4%!
M>*1@&K8B/D/\@"+\ 85!V&D(:/;C[E%+.%%1D<CB=<[@S7BZ)>P[>BI(0O^A
M-]@#VP&: HLWNF#M#+8>8"Z&H=R2&,:>_N5+$'OP)C__A+O!;TW9.P*K<-$I
MN.A8].B<.B\*[NL7[8(^*TAE(Q4=EU0X JM0\5A0\7A!%J?I"YW[![0%8?;T
M==N4>H8WL'CF-M]/@H=.;^3O3U.Z8%0)M5N$VKU>P?F-(K648Z![LM!5;=-P
MZQ'7%LX16(6-7L%&[\X:[KFDPA%8A8I^047?L8;[#?)\K&NXR:@3-6MX4(0Z
M^"$-3V^_A5L/N+9LCL J7."@;!*".VLX/\ 1&Z[0JG2<]$S8L8YSP*I&HYJ.
MFXW"9B'CL(PVO%[*UU['[6=<73]':%5&R@X+1_>6L],6RQ5:E8ZRR<*MC<LM
M<NXT*#7$=3TW647=,WHN&R%\H1,Z_J^X^69N/^#JZCE"J])1-ENX>V\Q.^VU
M7*%5Z2B[+=S:P=PBYEZ#3'OU)J/9:G!&S&5'A"^T1 UBOOIN;CWBZOHY0JL2
M4O9=>'!O.3MMO%RA54<39><5MK8R-\@Y!ZP)M5^3<[-57<[^R6!)BW1MYVT2
M67EF Y9B-YOI3?%P9D=?M?TG/'RR$RZ_A,D&A2]$K"F3*(&5AM0QZ-M49+.W
M;*'XUHZO%ESI7XI]W !9@C &^OV*<W5<F .*">CD?U!+ P04    " "J@'Q:
M*2?FH74#  #\"@  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RM5FV/
MVC@0_BNCW.FTE<KF!0CL'D1:X$Y7J3VAHEX_5/?!) .QUHDYVT#[[SMVLEE@
ML^F>NE\@=F:>>9X9>S*3HU3W.D<T\+40I9YZN3&[6]_7:8X%T]=RAR6]V4A5
M,$-+M?7U3B'+G%,A_"@(8K]@O/22B=M;JF0B]T;P$I<*]+XHF/HV0R&/4R_T
M'C8^\FUN[(:?3'9LBRLTGW9+12N_0<EX@:7FL@2%FZEW%][.P\ Z.(M_.![U
MR3-8*6LI[^WB73;U LL(!:;&0C#Z.^ <A;!(Q.._&M1K8EK'T^<']#^=>!*S
M9AKG4GSFF<FGWMB###=L+\Q'>?P+:T%#BY=*H=TO'&O;P(-TKXTL:F=B4/"R
M^F=?ZT2<.(3Q,PY1[1!=.@R><>C7#GTGM&+F9"V88<E$R2,H:TUH]L'EQGF3
M&E[:,JZ,HK><_$RRJLH'<@,KOBWYAJ>L-'"7IG)?&EYN82D%3SEJZ,&*#E&V
M%VBM_Z8C]JY,98%P]5YJ_0:6J& NBX**L\J9HOT%&L8%O>K!I]4"KGY],_$-
MD;:A_;0F.*L(1L\0#"/X($N3:_BCS# [!_!);2,Y>I \BSH1%YA>0S]\"U$0
M#5H(S5_NWN^@TV\JT'=X_><J\/^2^N5NK8VBT_]O6RZK4(/V4+8EW.H=2W'J
MT9W7J [H);_]$L;![VUY>"6PLZP,FJP,NM 3FPE!&0!FC.+KO6%K2I&10#<B
MO<^ER%!IN.(E+*003.G6HU7%&+H8MJ$=DEX4#N,XNIGXAU.I+8;#T6@PO!DW
MAF<RAHV,8:>,SZZ-8 ;L@(K:(J15+;6MI0;JJ]JP,K/WK <SIGG:)J.*$9^P
M&X?Q*!H,+E0\M2,-HW@<MXN(&Q%QIX@%%WO;;($75&]C#ZKCW[/],[.2Z*.B
M6=66CTQENDU$9XSVTP1MI_+G<<Z2,&J2,'J]2KJ,73:K*@VC%];RJ5UG+<>-
MC'%GMVGNU8X:B^-^V\9R_)I]Y)7 SO3>-'IO.LOF[M1IGW@4WMHQ*K3Q:2,(
MKJ/XHCBM5J-A>VG"X/%;'/SXHM$1>SG=&O!'?-O-GA#V3^:( M76C5<:W"A0
M?5^;W6J$F]D1SLXA%_LTVMVY@<9_A*GFP@],;7FI0>"&("T'#U0U:E4+(W=N
M6EE+0[./>\QI/$5E#>C]1DKSL+ !FH$W^0Y02P,$%     @ JH!\6@>QY;MG
M @  L0<  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULM95=;]HP%(;_
MBI5-4RMUY#NP+D1J05,KK1*"=;NH=F&2 UAUXLPVI/WWLYV004E1*[&;Q!_G
M?7+>8\>.*\8?Q0I HJ><%F)HK:0L+VU;I"O(L>BQ$@HULV \QU)U^=(6)0><
M&5%.;<]Q(CO'I+"2V(Q->!*SM:2D@ E'8IWGF#]? V75T'*M[<"4+%=2#]A)
M7.(ES$#>EQ.N>G9+R4@.A2"L0!P60^O*O1Q%.MX$_"10B9TVTD[FC#WJSFTV
MM!R=$%!(I29@]=K ""C5()7&GX9IM9_4PMWVEO[->%=>YEC B-%?)).KH36P
M4 8+O*9RRJH;:/R$FI<R*LP3575L$%DH70O)\D:L,LA)4;_Q4U.''8$;O"+P
M&H'W5H'?"'QCM,[,V!ICB9.8LPIQ':UHNF%J8]3*#2GT*LXD5[-$Z63R@^,,
MT%6:LG4A!9I""F2#YQ30V1@D)E2<H\_H?C9&9Q_/8UNJ3VJAG3;XZQKOO8(?
M0]I#OGN!/,<+.N2CM\O]?;FMC+9NO=:M9WC^N]T^?%>AZ%9"+GYWV:RY03=7
M_VJ7HL0I#"WU+PG@&["23Q_<R/G:9?I$L+T2^&T)_&/TI@1X6P+>EN "%2"[
MK->\T/#TH;!)_'[?=7VU()M=5X=QGCL(_<&_N+V$@S;AX&C"4Z!80H8FF,MG
M]' '^1QXYQH=Y;QWC4X$V[,<MI;#_[1-PU.6X$2PO1)$;0FB$V_3Z&#[A9[S
MI?]BDQY&!5[H]%]L47OG0-67V1WF2U((1&&A=$ZOKP"\OB#JCF2E.6/G3*H3
MVS17ZDX%K@/4_((QN>WH8[N]I9._4$L#!!0    ( *J ?%JL'TWB00(  (0%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*U4RV[;,!#\%4(MB@1H
M0[WL%*XLP(\6R2& $2/MH>B!EE86$8E42=I*_KY\R*J2VFX/O5C<Y<YPAN9N
MTG+Q*$L A9[JBLFI5RK53#"660DUD5>\ :9W"BYJHG0HME@V DAN076%0]\?
MXYI0YJ6)S:U$FO"=JBB#E4!R5]=$/,^AXNW4"[Q#XIYN2V42.$T:LH4UJ(=F
M)72$>Y:<UL DY0P)**;>+)@L8E-O"[Y2:.5@C8R3#>>/)KC-IYYO!$$%F3(,
M1'_VL("J,D1:QL^.T^N/-,#A^L#^Q7K77C9$PH)7WVBNRJGWT4,Y%&17J7O>
MWD#G9V3X,EY)^XM:5QOY'LIV4O&Z VL%-67N2YZZ>Q@ @O$)0-@!PM> ^ 0@
MZ@"1->J465M+HDB:"-XB8:HUFUG8N[%H[88R\R^NE="[5.-4>LOVP!07S^AB
M"8K02EZB#^AAO407;R\3K/01IA!G'=W<T84GZ((0W7&F2HD^LQSREP18:^L%
MA@>!\_ LXQ*R*Q0%[U'HA_$108M_AT=GY$3]?466+_KK?7V?;:02^AG^.'9-
MCB4^SF):<R(;DL'4T[TG0>S!2]^]"<;^IV,6_Q/9"\-Q;S@^QSXPW JJ /&B
M..;7D8PLB9D<^S3VQZ/Q*,'[H9,_RT;A=1!%?9G3B </N@:QM7TN4<9W3+FG
MTV?=*)GK46);[E5>CYB9[2S\F\;-ISLBMI1)5$&A*?VK:RU*N)YW@>*-;9L-
M5[H)[;+48Q*$*=#[!>?J$)@#^L&;_@)02P,$%     @ JH!\6HAW,-J$ @
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MSP*=;Q*^$ZC$P1CI2E:,O>C@<S*Q'"T(*,12,V#UVL(,*-5$2L;OAM-JM]3
MP_&>_:.I7=6RP@)FC/X@B4PGULA"":QQ2>43JSY!4X\1&#,JS!-53:YCH;@4
MDF4-6"G(2%Z_\:[QX0#0]R\ W ;@W@KP&H!G"JV5F;+F6.(HY*Q"7&<K-CTP
MWABTJH;D^BLN)5>K1.%DM.!08)*@#SMU+@0(A/,$?94I<#0K.8=<HJD0( 5Z
MAY;J""4E!<36Z';<W1PD)E3<*X;GY1S=O;X/;:FD:P%VW,A\K&6Z%V3.(>XA
MK_\6N8[K=\!GM\.]8[BM#&M=<UO77,/G7>#[-R=^3E="<G5P?W494._H=^^H
M+_-8%#B&B:5NJP"^!2MZ\ZH_<-YWV?&?R([,\5ISO&OL[9&"QI"N8FN&P##H
M1K.-O('C.L/0WAZ6<9[F!WX_<-NT(X%^*]"_*K#^.!QB(%N\HMT*:XK!X=9.
M$ 0G L^SO(>AYW7K"UI]P55]WYC$M$M3<&Z'XPP'[HFHCK0';S0*3E39!UU#
M=^POF&](+A"%M0(ZO:%BX'47K /)"M-(5DRJMF2&J?IQ -<):GW-F-P'NC>U
MOZ+H+U!+ P04    " "J@'Q:.C25HX4"  !Q!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6RM55UOTS 4_2M60&A(8_EJVFVDD=9V"!Z&JDV#!\2#
MF]PVUAP[L]UV^_=<.VGH2E8AQ$OBCWO./??&/DFW4CWH$L"0IXH+/?9*8^I+
MW]=Y"1759[(&@3M+J2IJ<*I6OJX5T,*!*NY'03#T*\J$EZ5N;:ZR5*X-9P+F
MBNAU55'U/ $NMV,O]'8+MVQ5&KO@9VE-5W 'YKZ>*YSY'4O!*A":24$4+,?>
M57@Y36R\"_C&8*OWQL16LI#RP4Z^%&,OL(* 0VXL \77!J; N25"&8\MI]>E
MM,#]\8[]DZL=:UE0#5/)O[/"E&/OW",%+.F:FUNY_0QM/4Y@+KEV3[)M8I/$
M(_E:&UFU8%10,=&\Z5/;ASU .'P%$+6 Z! P> 40MX#8%=HH<V7-J*%9JN26
M*!N-;';@>N/06 T3]BO>&86[#'$FFRL\$,H\GY(YI\(0*@IR_;AF-7XI<TJ^
MXCDZF8&AC.OWY .YOYN1D[?O4]]@;LO@YVV>29,G>B5/&)$;*4RIR;4HH'A)
MX*/H3GFT4SZ)CC+.(#\C<7A*HB :] B:_CT\/B(G[AH9.[[XWQOYXVJAC<*#
M^[.O?PW]H)_>7N9+7=,<QA[>5@UJ U[V[DTX##[VU?Z?R%YT8M!U8G",?:\3
M==<)V'6"%$S74E.N^WK0$">.V/K/)@OC(!XFJ;_9KZXG+ C"0=2%O="==+J3
MH[IG@,W(&77V D_HDQKZ1"9_9(^&P_-@-#I0V1=W,3J_&!W(]/=N;P5JY4Q-
MDURNA6FN0[?:^.8$?=/YR\$Z^NF5LQ'_-TUCQC=4K9C0A,,2*8.S$:I2C<$U
M$R-KYQ$+:=!QW+#$?P(H&X#[2RG-;F(3='^9[!=02P,$%     @ JH!\6D\=
M31V0!0  F"H  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&ULO9I=;^(X
M%(;_BL6N5AVIT\1V$D(7D*;MC':D=K>:JKL7H[UPP4 T^6!L!UII?_PZ@<:$
M!M,$)S<M 9_7QR_GF >3X3IA/_B"4@&>HS#FH]Y"B.6E9?')@D:$7R1+&LM7
M9@F+B)"7;&[Q):-DF@=%H85LV[,B$L2]\3!_[IZ-ATDJPB"F]PSP-(H(>[FB
M8;(>]6#O]8EOP7PALB>L\7!)YO2!BL?E/9-75J$R#2(:\R") :.S4>\3O+QV
M["P@'_%W0-=\YS'(EO*4)#^RBZ_34<_.,J(AG8A,@LA_*WI-PS!3DGG\W(KV
MBCFSP-W'K^I?\L7+Q3P13J^3\)]@*A:CGM\#4SHC:2B^)>L_Z'9!;J8W24*>
M_P7K[5B[!R8I%TFT#9891$&\^4^>MT;L!$#G0 #:!J#W!N!M ,X7NLDL7]8-
M$60\9,D:L&RT5,L>Y-[DT7(U09R]C0^"R5<#&2?&]TQ6!!,OY^ ^)+$ ))Z"
MSS_38"G?*G$._I2%]!$\R.*9IB$%R0QH \#9#14D"/D'&?7X< /.?OTPM(3,
M,YO-FFQSNMKDA [D=$,G%P##<X!LY%2$7[\_')?#+>E.81$J+$*Y'CZ@]_[5
M?[^5H>"KH!'_MVK9FWF<ZGFRAKWD2S*AHY[L2$[9BO;&O_T"/?OW*A,,B94L
MP84E6*>^4S7+P@:JJF;.$LZK#-BHNKEJML&LQHZ'![;;MX?6:G=Q50-M=^!A
M6 PL)>X4B3O:Q#]-)FF4AD30J6QVZ<PD(-EV4I7L1LG;R>$C@K8#71?N95LQ
M$OJ.CP>.7YVN6Z3KGN)S3$55XNZ;=)"+G8$-!WMY5PSLNWW7\W%UVEZ1MJ=-
M^Y8\)8R(A+WD&4<D3F=ROTY9$,]5_N#['8V>**ML%>T$=5O%D%C)BW[A1;^C
MW:-OTA)#8B5+_,(2OY7=PW];KA!A![G[=5TQT!ZXV+,/[!Z#(O&!-O&K- BG
MLH9YGG(0+5FRHEG27%O+6M&Z;YPAL=+ZH:UHP>ZHFK<3&7+%E%K9EAV(@JU4
M]%:V7*F^/\ #=Z^D*T?V?<?UW.J:A@IOH!85QG_-9L&$@EG*XD#NT;2<O;:R
M]<JUW\0VD 8JIH&XJ]K6TE-M6PRIE6U1Q 3UR-2XMITW# =MUX/.F])^BT_0
MQA[N.P<J6]$3U./3=1)SP=+-%\8@!G*_GDN+]+NU7K/VFV=(K>R  C'H=573
M1HG,E%K9%L5D4,LWQVKZ,Q=!E']'>.1TEH;@-EA1#LYD";U0PGCU=]H&2 4J
MO6F#S:"",]@.G6UE=_L=>?*3S';V^[T"S_J>C]"A?E=X!O5\=IOEJNUMHRAF
M2JU\*J%8#'7%8L@HBYE2*]NB6 R=Q&*->EL_98W>;B)TW)N=DRP]ZC7M[:WL
M;F^[T/.]_EYK'Q]73ERQ&=(?.-T%<1"E4='<X#]@X)!!/VGMNF^#TY#B-.1T
MM1UH@;"V+8;4RK8H!D0G':$UVP[T4^)-:*49;> @4CB(] =S%6W4\$Q#/U'M
M&FD#!Y'"0=35&1TR>DAG2JULBR)!=!()-FL=_930UO2.-K2I&PHND1XN*WKG
MA),3_62U"Z4-$L6*1'%7)(J-DJ@IM;(MBD1Q]R1Z9$K-1X\^LJD9"CVQ'CWO
MR',+!*>?M':]M/*;ZLZ/JET=0&*C8&M*K6R+ EM\T@%DLS;23ZG[&-*'-G5#
M\2S6PV5%'S5$./U$M8ND#;+%BFQQ5P>=V"C9FE(KVZ+(%G=_T'ED2CS0]$X;
M0(L5T&(]75;TS@D(IY^L=J&T0;=8T2T>=-4_1LG6E%KY;B%%MHX6$5OIGR-3
MZCY[]*%UW;!V;AO,[MF\(VP>Q!R$=";E[8N^W-+9YC;(S85(EOF=A$^)$$F4
M/UQ0,J4L&R!?GR6)>+W(;DXL;D8=_P]02P,$%     @ JH!\6M"T%"T2 P
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M_4$P>3>5>2*\R07.Y^F4 +KF' 1'9Q$(G!)^CCZCQX<(G7T\']I"+J42[+C
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MA*;W&)070W8O-E*W=K01NG4 I#-69@Q9/<PXW?98F@>&T@,G>\(US0NBR>3
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M#]G,E=&28B2@F9\8/I^9"D=H2&ZNM1($RP206YP83I^9"B6L",'.C3;4I$\
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M6"0TZ0$$>H!M:0"FG%D[/?MM>G-;2_QUFUTB!_^,;,L>H2^/ ;KXL7=F>DQ
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M9'1!N&C;2OG:=U:KJ><.UAR2%H#20E!:!$J+H6A=]^R7(+$'VW)BT.5'4%H
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M;OSZ&.V=>F)J\Q<JEZQ4>%(Y6CKG,;J0;;EK.UI438E9"(T%JVFN\!<!I%F
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ME8!YV<J5 \G6IGU:,*F:,?.8J/87N5Z@WB\9DW<#O4'=4$_^ 5!+ P04
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M=FM('4B7XU^YL"KW ]&SLC1>^<>$)F;4SH'>+Y2RNX7;H)K!I_\ 4$L#!!0
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M8 V-QI5&XSX*;'Q<8,;8,4?&8=X>&^I#1Y3BV&A/7Z?BZ?198,Y1^6B#L7W
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MT:.3Z O-->P'MSTC_\61: "84AI&Z8$?0[$DB0*6V-V(>S?BDVZ8&Q-?>7%
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M^V5C?QR@G(,]/TIISH9+,/V*\C]02P,$%     @ JH!\6J/"X/B0!P  12H
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M[;PA66:*U0F3JO0UMW/U=0)<#U#/IXS)=4-/4'[OA/\!4$L#!!0    ( *J
M?%J=5B;'60,  #P0   9    >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;*V8
M76_:,!2&_XJ535,G;4W(!] .(K5-IW5:)536[:+:A2$'B!K'U#;02OOQLYV0
M$IIZ13(7P4[\OO9YL(]R&&PHN^<+ ($>25[PH;,08GGJNGRZ (+Y,5U"(9_,
M*"-8R"Z;NWS) *=:1'+7][RN2W!6./% WQNQ>$!7(L\*&#'$5X1@]G0..=T,
MG8ZSO7&3S1="W7#CP1+/80SB=CEBLN?6+FE&H. 9+1"#V= YZYPF'5\)](A?
M&6SX3ANI4":4WJO.53IT/+4BR&$JE 667VNX@#Q73G(=#Y6I4\^IA+OMK?M7
M';P,9H(Y7-#\=Y:*Q=#I.RB%&5[EXH9NOD$54*3\IC3G^HHVY=A(SCA=<4%)
M)99]DA7E-WZL0.P(I$^[P*\$_KX@?$405(+@K8*P$H2:3!F*YI!@@>,!HQO$
MU&CIIAH:IE;+\+-"_>YCP>333.I$/%Y-.#RLH!#H<BVO'!TE('"6\X_H,[H=
M)^CH_<>!*^142N!.*]OSTM9_Q39 U[00"XXNBQ32IMZ52ZS7Z6_7>>X;#:\Q
M.T9^YQ/R/3]J6<^%6?X=%\<H>%V>F.5C6$JYI^6!(9J@IAYHO^#-U.]^R"'H
M2@#A?]IPEWYANY]*#J=\B:<P=.3IY\#6X,0?WG6ZWI<V5C;-$DMF#8YAS3$T
MN<<C!NN,KGC^)'/0%&0&2=O@&4T.A6?3+"G-(FVF4O0Z]B-/?@;NN@5+5&.)
MC%CVMQ>ZNP8R =:ZLXQ6A\*Q:998,FL@[-8(NY9/:-<F1YMFB26S!L=>S;%G
MWHH@1 Y$<32=4*/)H?!Z+PY5Z'>C?J\^5"462W,VL/1K+'TS%IJG"!.Z*D0;
MCOZ+"#K]?GC2#.#".,6AF\2268/&24WCQ$CC[.<U.ILS*/?)-EFAO^B@1&:<
MX] ]9-,LL6368-OQGM_P/,NIK#*TA-*J6V++K0ESYW6Y\_^#RQ=8>J.CK$!C
MW6Q_0RZ=NCNG.(@"?^\0F^<[F(XEMR8=_YF.;Z:#<\EE2@G)N*H,>2L7_T5V
MB_KA/A;C1 =CL>168G%WRBT";*[+5A6VS.9EY57?K4OC,UT0NL_#R[I:EC7S
MK. HAYF4>L<]2865I6K9$72IB[<)%;(4U,V%+.^!J0'R^8Q2L>VH">H_#.)_
M4$L#!!0    ( *J ?%H52%>5+0,  .H2   -    >&PO<W1Y;&5S+GAM;-U8
M74_;,!3]*Y$9$T@3:9L1FM%6VBHA3=HF)'C8&W(;I[7DV)GCLI9?CZ^=IA_X
M(L;#5M8*8M_C<^ZQ?8,M!K59"78S9\Q$RU+(>DCFQE2?XKB>SEE)ZS-5,6F1
M0NF2&MO5L[BN-*-Y#:12Q+U.)XU+RB49#>2BO"I-'4W50IHA.6]#D7]\S8>D
MFWXDD9<;JYP-R=W)^U\+92[?1?YY].'HJ'-W>KD?/W' *8F#HN<O$#W#9<]0
MX?1%PL\IH](7N])N^+$5\L1CC-8/T&R6#1,ZCAPW&S(:%$IN]B4A/F#5:<FB
M>RJ&9$P%GV@.K(*67*Q\N >!J1)*1\86A$W7A4C]X.&N[T&M-#HEETJ[W#Z#
M_SUIAN\!ZQX8Y$*T!GO$!T:#BAK#M+RR'3?8!9] 4=.^7576X4S35;=W3C8$
M][!))DKG3+=INF0=&@T$*\".YK,Y/(VJ8@"-4:5MY)S.E*3.PYK1-*SLE EQ
M R_2SV)'>UEL[5L'=DVV36NH:7H9WP'];36OO2W;>Y5N5/%[9;XL['2DZT.!
MLFO-"KYT_671&L#4N[@ZK2JQ^BSX3);,3_[%"4<#NN9%<Z7Y@\T&I3*U :9)
M=,^TX=/MR&]-JUNV-.MR6A:XY]X;]/QWUWG&)--4;)NVM7_(J_QJQ\W)\R\\
MNS\K^XZ#)I.+P_?8G+:';C)]"R;?Q';W#]]DDAVDQ[@YO[<N"3M7A#8:P55L
M2'[ Q4YLDD:3!1>&RZ8WYWG.Y).;@I4W=&(O\COZ=GS."KH0YK8%AV33_LYR
MOBBS=M0U+$0S:M/^!M/KINT]T.;B,F=+EH^;KIY-7#.R#9NU^0!A'[ERGS""
M<3P61@##\F .,(YG87G^I_GTT?EX#//6#R)]E--'.9X50L;NB^4)<S+["<\T
MRY(D3;$5'8^##L;8NJ4I_(35,&_ P/) IC];:WRW\0IYO@ZP/7VN0K"9XI6(
MS11?:T#"ZP:,+ OO-I8'&-@N8+4#^<-YH*;"G"2!7<6\86\PCF09AD MAFLT
M39'52>$;WA_L+4F2+ LC@(4=) F&P-N((Y@#\( A2>+.P;WS*%Z?4_'FOUNC
M1U!+ P04    " "J@'Q:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y
M;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI
M0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:W
MO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:
M>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%B
MM/XU@LD/['X 4$L#!!0    ( *J ?%HBI#V(VP4  ,DT   /    >&PO=V]R
M:V)O;VLN>&ULQ9M;3^,X%(#_BM6G68G=MKDRB")!878KL4-%T;R.W,1M+1*[
M8SM Y]>OG5!P:'JT+R<\M7$N_>+;YV.[Y\]2/2ZE?"0O92'T9+ Q9GLV'.IL
MPTJJ_Y);)NR9E50E-?90K8=ZJQC-]88Q4Q;#8#1*AB7E8G!QOG_67 W] VE8
M9K@4-M$E_.#L6;^?=X?DB6N^Y 4WN\F@_EZP 2FYX"7_S?+)8#0@>B.?_Y&*
M_Y;"T&*1*5D4D\&X.?&#*<.S@^2%@WR@2UVG&+J\IQ9D,DA&]H$KKK2IKZB?
M3RWC$[,7-T>5D=]X89BZIH;]K62UY6+M'F/?8NB]1IT/^\\F$\_4_\E&N5KQ
MC%W+K"J9,$T^*E8X0*$W?*L'1-"23093^<24>Q_[ [.\>3=CH;R<4F?<GE"S
MO,;#0[FL<F[(3#0WV[,>5@!@!;A85[2@(F.D+DSM,84 4]@G$_DRI\K>L&%U
M-=5_>) 1 !GA0B[<[[IK-)$K<K=EJKG&HXL!NKA/NH61V>-&%CE3^B>Y^55Y
MD D F7PBY,_ @TP!R+1/R"G5&_*MD,]^.9\"=*?(3:727#"MNRO@5P#L*W*V
M565)U:XN6+X6W-Y&A2&7628K8;C?)X^@3GF$B_F@:,[V5)K<LXSQ)UHSO ."
MUD#6QDP\V0NDVOE D"_&R,*8*[:E/"<W+_8AFFE"14[N;.^LR+12+=E""ADC
M.\0.G6R+,+L3,B]<Q7.4MN/C6W??"?$Q(8F,D2TRLP,RL78_2BZU;AMX#/EC
MC"R0MR8QISO7'NH,M(FJ8J[L?4S((&-DA5Q1\4BNV=+X0) MQLBZF-HAMAWM
MVHO(+:?UN)R_-I*I+$L?$]+&&-D;K[H0:W++J&W%/A=DC3&V-CZ.5&Q8XP^4
M(5<$R*ZX9[8KKGPS!) 9 F0S-'WNOAL^(=^9WP@",*9 =L1,9+)DY(&^M&I6
M  DA0!;"@JW=%<<B,$@" ;($[EVB[59MG&-VQ Y)A*;9Q[%< -D@0+;!3;DM
MY(XQ<L4$6_&6I@*H_P^P0XAJJ=FORA7LC1LHM< @#P3('K#:)$_6GDS5M[MP
M]IKKK)"Z4JTN!+) @&R!F=#<]K2NRN7.!9?*UKUU$^WXC) 1 F0C3'=+ZP*6
M5<JJ@-QS_4C^I8(VE(3Z,Q:0'$)D.>P#&YN+<UGPC+LN>;EK#G;^>#.$I!$B
M2P,,RUHA=P@))$07R&O40[X\N-%G:](G!*>FT.,*(/QI9R"DE!!9*6#XT\:$
MO!(B>^4@_.DL;T@P(;)@P#BHG9&0;D)DW;S%09T9"#DF[#G2Z 2$!!-^0LC1
M!1E!>HGZB3TZN2"?1/T'(9V,D$RB'J.13CC()U'_84DG([C2@;W4 0X:0A\3
MDDF$O>8!8D8^)F24"#UD@3!C'Q,R2H2][@%B)CXFI)<(62]')_#)EVMF_/ @
M@B03(4O&&] Z+-Y>QHPAM<3(:GE'^Y,L[//RRF:>+?77=!\3,DV,;!IXX.UW
M0C$DFQA]>00:>+<P(>W$G[D\TNHK8\@\<=_+(]W-!UQH[SV$:34C'Q.R3ORI
M<4RK7D+6B?N+8[H*&C)-C+W4_H;6[B?KI+F_\!E#IHF137,,<ZZXR/C6W_D!
M62=!M@ZX3M:*JQ/(.@EV?',0O794RP023H(LG /"=K'[F)!P$F3A@)CM\H:$
MDZ#OZNJ:#.@J<\@Y"?KNK@[*]PSU,<'M7>C[NP#,=IE#SDG0=WA!F+X:$\@_
M";)_]E- '[MUF5>9(0L?$_)/@NP?$+.]J0_R3XKLG\Z)JXYVGD+V23]A=LW+
M5Q\34E#:ZP1;5R9"YDF1S=.B^QCB9GY\FT+F2=%#'0"SW6X@]:3HX<Y13#=-
MY&-"ZDFQU=,UK=I5,\&=Q=CBZ8 \TKPA\:3HXCFV/:7.4A\3$D^*+)Z#/2J=
M!7X*2><463H'NU6Z$2'EG#;_HJDOUA?GN7U3P?+O]O':IF>TR.:*N(]Z*U\0
MQ6X[WZHJBJE-NQ.WDN;[?^+L_T5T\1]02P,$%     @ JH!\6JN<,4MN @
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M+GAM;%!+ 0(4 Q0    ( *J ?%H=P6]"\@   "L"   1              "
M <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *J ?%J97)PC$ 8
M )PG   3              "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ JH!\6ADI!N) "   H34  !@              ("!)0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *J ?%K)[&GZG0,
M #\)   8              " @9L0  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "J@'Q:B!"LI+P&  !;&@  &               @(%N
M%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ JH!\6ET7
M"B6Y @  RP<  !@              ("!8!L  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( *J ?%K13/8CA 0  /T/   8
M  " @4\>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "J
M@'Q:?+MI2Q(%  !B&P  &               @($)(P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ JH!\6BV82$)/ @  Y@0  !@
M         ("!42@  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( *J ?%I(-<5M%P@  ($D   8              " @=8J  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "J@'Q:'W"M900$  !S"
M&               @($C,P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ JH!\6F'U73?.%@  &#X  !D              ("!73<  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "J@'Q:2\L/3M,#
M  !A"   &0              @(%B3@  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( *J ?%KFU(1%!@,  #X&   9              "
M@6Q2  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ JH!\
M6HY[85"5 @  R 4  !D              ("!J54  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "J@'Q:L.%2PWX#  !M!P  &0
M        @(%U6   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( *J ?%K2HR"UO@,  -$(   9              " @2I<  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ JH!\6K=9:G+A @  7 8
M !D              ("!'V   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "J@'Q: 6N 9(P'  #G$   &0              @($W8P
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( *J ?%I.KJ+F
M]0D  ,07   9              " @?IJ  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ JH!\6N_2FC5/!   %PD  !D
M ("!)G4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "J
M@'Q:'SE/9[,+  #V'P  &0              @(&L>0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *J ?%H( Y,<KP0  "(*   9
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M970R-2YX;6Q02P$"% ,4    " "J@'Q:<3$V^# #  #2!@  &0
M    @('2H   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M *J ?%JDL!B$I0,  ,4'   9              " @3FD  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ JH!\6EG06*I% @  F04  !D
M             ("!%:@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "J@'Q:+'5HOD,"  "*!@  &0              @(&1J@  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( *J ?%JX ?-FDP8
M "47   9              " @0NM  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ JH!\6H&."S?O%P  /D<  !D              ("!
MU;,  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "J@'Q:
MRAW!Q+ $  "/"P  &0              @('[RP  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( *J ?%I'2BD5?P(  %8%   9
M      " @>+0  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ JH!\6@ ?T6E\ @  L 4  !D              ("!F-,  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "J@'Q:KI/C3"P#  #A!@
M&0              @(%+U@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( *J ?%HE>H%DZ0(  -D&   9              " @:[9  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ JH!\6DU_,*C)
M @  2 8  !D              ("!SMP  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "J@'Q:@,'8@BD%  !=#   &0
M@('.WP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( *J
M?%I,NL(!V0,  ,4(   9              " @2[E  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ JH!\6B'5^6XX!@  P0\  !D
M         ("!/ND  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    " "J@'Q:(MFL-RH#  #'!P  &0              @(&M[P  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *J ?%H SLQ"N@,  ,P'
M   9              " @0[S  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ JH!\6C5N FIG!0  X P  !D              ("!__8
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " "J@'Q:W!O^
M]0D%  #U"P  &0              @(&=_   >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    ( *J ?%HJ_2F5U@,  /$/   9
M  " @=T! 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
MJH!\6NX)-#BD P  /A0  !D              ("!Z@4! 'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    " "J@'Q:<?--V<D#   -%0  &0
M            @('%"0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    ( *J ?%HI)^:A=0,  /P*   9              " @<4- 0!X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ JH!\6@>QY;MG @
ML0<  !D              ("!<1$! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    " "J@'Q:K!]-XD$"  "$!0  &0              @($/
M% $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( *J ?%J(
M=S#:A (  -8&   9              " @8<6 0!X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ JH!\6G?2-!AN @  E@8  !D
M     ("!0AD! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J ?%J^Z>E.\@(  "\)   9              "
M@:8K 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ JH!\
M6CZV_29$$   \QD! !D              ("!SRX! 'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    " "J@'Q:XCXTP\T$  "-(   &0
M        @(%*/P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   ( *J ?%KBX1M%$P@  )4^   9              " @4Y$ 0!X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ JH!\6H.R(?^O!0  7S0
M !D              ("!F$P! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    " "J@'Q:Z^CKKM<$  #])   &0              @(%^4@$
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( *J ?%H'LP?8
M0@,  %L*   9              " @8Q7 0!X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ JH!\6@W<2+_Y @  @ @  !D
M ("!!5L! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "J
M@'Q:AV-YEL(+   JB@  &0              @($U7@$ >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( *J ?%H8N?P >P8  ,@C   9
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M970W,"YX;6Q02P$"% ,4    " "J@'Q:0$]R4-D#  ! #@  &0
M    @(%7@ $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    (
M *J ?%I=B]-%2 0  $D,   9              " @6>$ 0!X;"]W;W)K<VAE
M971S+W-H965T-S(N>&UL4$L! A0#%     @ JH!\6CT+'>E'!0  0"(  !D
M             ("!YH@! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"
M% ,4    " "J@'Q:5:@\&3P#   &#   &0              @(%DC@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( *J ?%I8=9H6#00
M ((/   9              " @=>1 0!X;"]W;W)K<VAE971S+W-H965T-S4N
M>&UL4$L! A0#%     @ JH!\6KSD>RC9 P  @0P  !D              ("!
M&Y8! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "J@'Q:
M_/-:BQ0"  "6!   &0              @($KF@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<W+GAM;%!+ 0(4 Q0    ( *J ?%JCPN#XD <  $4J   9
M      " @7:< 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%
M  @ JH!\6B*?E8RJ @  3@@  !D              ("!/:0! 'AL+W=O<FMS
M:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " "J@'Q:7;0U5Q$#  #[#
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M+G)E;'-02P$"% ,4    " "J@'Q:(J0]B-L%  #)-   #P
M@ $WL@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ JH!\6JN<,4MN @
MVB\  !H              ( !/[@! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ JH!\6D3DWU@> @  ERX  !,              ( !
MY;H! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %D 60!F&   -+T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>219</ContextCount>
  <ElementCount>400</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Statements of Stockholders??? Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Statements of Stockholders??? Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BusinessOperations</Role>
      <ShortName>Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Trade Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivable</Role>
      <ShortName>Trade Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Bank Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebt</Role>
      <ShortName>Bank Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Other Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNet</Role>
      <ShortName>Other Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995325 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Bank Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtTables</Role>
      <ShortName>Bank Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeases</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/Revenue</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Other Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetTables</Role>
      <ShortName>Other Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofConcentrationofRiskTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Trade Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/TradeAccountsReceivableDetails</Role>
      <ShortName>Trade Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/TradeAccountsReceivable</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/InventoryTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable</Role>
      <ShortName>Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IntangibleAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIntangibleAssetsTable</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Bank Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/BankDebtDetails</Role>
      <ShortName>Bank Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/BankDebtTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable</Role>
      <ShortName>Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable</Role>
      <ShortName>Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OperatingLeasesDetails</Role>
      <ShortName>Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OperatingLeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Operating Leases - Schedule of Lease Costs and Other Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable</Role>
      <ShortName>Operating Leases - Schedule of Lease Costs and Other Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable</Role>
      <ShortName>Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/StockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Stockholders??? Equity - Schedule of Activity Under the Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Activity Under the Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Stockholders??? Equity - Schedule of Additional Information About the Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Additional Information About the Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Stockholders??? Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable</Role>
      <ShortName>Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable</Role>
      <ShortName>Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Other Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/OtherExpensesNetDetails</Role>
      <ShortName>Other Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Other Expenses, Net - Schedule of Other Expenses Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofOtherExpensesNetTable</Role>
      <ShortName>Other Expenses, Net - Schedule of Other Expenses Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIncomeTaxProvisionTable</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable</Role>
      <ShortName>Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SegmentInformationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Segment Information - Schedule of Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/ScheduleofSegmentInformationTable</Role>
      <ShortName>Segment Information - Schedule of Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/RelatedPartyTransactions</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/EmployeeBenefits</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea0235481-10k_immucell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://immucell.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://immucell.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ea0235481-10k_immucell.htm">ea0235481-10k_immucell.htm</File>
    <File>iccc-20241231.xsd</File>
    <File>iccc-20241231_cal.xml</File>
    <File>iccc-20241231_def.xml</File>
    <File>iccc-20241231_lab.xml</File>
    <File>iccc-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="903">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>105
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0235481-10k_immucell.htm": {
   "nsprefix": "iccc",
   "nsuri": "http://immucell.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0235481-10k_immucell.htm"
     ]
    },
    "schema": {
     "local": [
      "iccc-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iccc-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iccc-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iccc-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iccc-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 361,
   "keyCustom": 39,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 38,
   "memberCustom": 31,
   "hidden": {
    "total": 112,
    "http://fasb.org/us-gaap/2024": 100,
    "http://immucell.com/20241231": 6,
    "http://xbrl.sec.gov/dei/2024": 6
   },
   "contextCount": 219,
   "entityCount": 1,
   "segmentCount": 70,
   "elementCount": 843,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 903,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/cyd/2024": 8,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Balance Sheets (Parentheticals)",
     "shortName": "Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://immucell.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://immucell.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Statements of Stockholders\u2019 Equity",
     "shortName": "Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "995305 - Statement - Statements of Stockholders\u2019 Equity (Parentheticals)",
     "shortName": "Statements of Stockholders\u2019 Equity (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iccc:OfferingCostsAtthemarketOfferingOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:OfferingCostsAtthemarketOfferingOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://immucell.com/role/ConsolidatedCashFlow",
     "longName": "995306 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://immucell.com/role/BusinessOperations",
     "longName": "995307 - Disclosure - Business Operations",
     "shortName": "Business Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "995308 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://immucell.com/role/TradeAccountsReceivable",
     "longName": "995309 - Disclosure - Trade Accounts Receivable",
     "shortName": "Trade Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://immucell.com/role/Inventory",
     "longName": "995310 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets",
     "longName": "995311 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNet",
     "longName": "995312 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://immucell.com/role/IntangibleAssets",
     "longName": "995313 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpenses",
     "longName": "995314 - Disclosure - Accounts Payable and Accrued Expenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://immucell.com/role/BankDebt",
     "longName": "995315 - Disclosure - Bank Debt",
     "shortName": "Bank Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitments",
     "longName": "995316 - Disclosure - Contingent Liabilities and Commitments",
     "shortName": "Contingent Liabilities and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://immucell.com/role/OperatingLeases",
     "longName": "995317 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://immucell.com/role/StockholdersEquity",
     "longName": "995318 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://immucell.com/role/Revenue",
     "longName": "995319 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://immucell.com/role/OtherExpensesNet",
     "longName": "995320 - Disclosure - Other Expenses, Net",
     "shortName": "Other Expenses, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://immucell.com/role/IncomeTaxes",
     "longName": "995321 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://immucell.com/role/SegmentInformation",
     "longName": "995322 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://immucell.com/role/RelatedPartyTransactions",
     "longName": "995323 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://immucell.com/role/EmployeeBenefits",
     "longName": "995324 - Disclosure - Employee Benefits",
     "shortName": "Employee Benefits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://immucell.com/role/SubsequentEvents",
     "longName": "995325 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c27",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c27",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://immucell.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://immucell.com/role/InventoryTables",
     "longName": "996002 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables",
     "longName": "996003 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "996004 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://immucell.com/role/IntangibleAssetsTables",
     "longName": "996005 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://immucell.com/role/AccountsPayableandAccruedExpensesTables",
     "longName": "996006 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://immucell.com/role/BankDebtTables",
     "longName": "996007 - Disclosure - Bank Debt (Tables)",
     "shortName": "Bank Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://immucell.com/role/OperatingLeasesTables",
     "longName": "996008 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://immucell.com/role/StockholdersEquityTables",
     "longName": "996009 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://immucell.com/role/RevenueTables",
     "longName": "996010 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://immucell.com/role/OtherExpensesNetTables",
     "longName": "996011 - Disclosure - Other Expenses, Net (Tables)",
     "shortName": "Other Expenses, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://immucell.com/role/IncomeTaxesTables",
     "longName": "996012 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://immucell.com/role/SegmentInformationTables",
     "longName": "996013 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable",
     "longName": "996015 - Disclosure - Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c33",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c33",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://immucell.com/role/ScheduleofConcentrationofRiskTable",
     "longName": "996016 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Concentration of Risk (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c38",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Net Income (Loss) Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://immucell.com/role/TradeAccountsReceivableDetails",
     "longName": "996018 - Disclosure - Trade Accounts Receivable (Details)",
     "shortName": "Trade Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c50",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://immucell.com/role/InventoryDetails",
     "longName": "996019 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://immucell.com/role/ScheduleofInventoryTable",
     "longName": "996020 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable",
     "longName": "996021 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://immucell.com/role/PropertyPlantandEquipmentNetDetails",
     "longName": "996022 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisposals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
     "longName": "996023 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://immucell.com/role/IntangibleAssetsDetails",
     "longName": "996024 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://immucell.com/role/ScheduleofIntangibleAssetsTable",
     "longName": "996025 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable",
     "longName": "996026 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccountsPayableTradeCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://immucell.com/role/BankDebtDetails",
     "longName": "996027 - Disclosure - Bank Debt (Details)",
     "shortName": "Bank Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LongTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
     "longName": "996028 - Disclosure - Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details)",
     "shortName": "Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ProceedsFromIssuanceOfDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RepaymentsOfBankDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable",
     "longName": "996029 - Disclosure - Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)",
     "shortName": "Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "iccc:DebtIssuanceCosts2025",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "iccc:DebtIssuanceCosts2025",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "longName": "996030 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c124",
      "name": "us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c124",
      "name": "us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://immucell.com/role/OperatingLeasesDetails",
     "longName": "996031 - Disclosure - Operating Leases (Details)",
     "shortName": "Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable",
     "longName": "996032 - Disclosure - Operating Leases - Schedule of Lease Costs and Other Lease Information (Details)",
     "shortName": "Operating Leases - Schedule of Lease Costs and Other Lease Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable",
     "longName": "996033 - Disclosure - Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)",
     "shortName": "Operating Leases - Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://immucell.com/role/StockholdersEquityDetails",
     "longName": "996034 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
     "longName": "996035 - Disclosure - Stockholders\u2019 Equity - Schedule of Activity Under the Stock Option Plans (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Activity Under the Stock Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c10",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable",
     "longName": "996036 - Disclosure - Stockholders\u2019 Equity - Schedule of Additional Information About the Stock Option Plans (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Additional Information About the Stock Option Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c171",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c171",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable",
     "longName": "996037 - Disclosure - Stockholders\u2019 Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
     "longName": "996038 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details)",
     "shortName": "Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c174",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable",
     "longName": "996039 - Disclosure - Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details)",
     "shortName": "Revenue - Schedule of Product Sales Disaggregated by Major Product Category (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c182",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://immucell.com/role/OtherExpensesNetDetails",
     "longName": "996040 - Disclosure - Other Expenses, Net (Details)",
     "shortName": "Other Expenses, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://immucell.com/role/ScheduleofOtherExpensesNetTable",
     "longName": "996041 - Disclosure - Other Expenses, Net - Schedule of Other Expenses Net (Details)",
     "shortName": "Other Expenses, Net - Schedule of Other Expenses Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestRevenueExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InterestRevenueExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://immucell.com/role/IncomeTaxesDetails",
     "longName": "996042 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable",
     "longName": "996043 - Disclosure - Income Taxes - Schedule of Income Tax Provision (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable",
     "longName": "996044 - Disclosure - Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Expense Differs from the Expected Tax Computed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable",
     "longName": "996045 - Disclosure - Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details)",
     "shortName": "Income Taxes - Schedule of Significant Components of Our Deferred Tax Assets Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://immucell.com/role/SegmentInformationDetails",
     "longName": "996046 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://immucell.com/role/ScheduleofSegmentInformationTable",
     "longName": "996047 - Disclosure - Segment Information - Schedule of Segment Information (Details)",
     "shortName": "Segment Information - Schedule of Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://immucell.com/role/RelatedPartyTransactionsDetails",
     "longName": "996048 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://immucell.com/role/EmployeeBenefitsDetails",
     "longName": "996049 - Disclosure - Employee Benefits (Details)",
     "shortName": "Employee Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iccc:EmployeesSalaryPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://immucell.com/role/SubsequentEventsDetails",
     "longName": "996050 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c216",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c216",
      "name": "us-gaap:OtherReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235481-10k_immucell.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "iccc_ATMAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ATMAgreementMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement [Member]",
        "label": "ATMAgreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r1001"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r61",
      "r1061"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 capital",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable \u2013 trade",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r55"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r731",
      "r820",
      "r1108",
      "r1109"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts receivable",
        "verboseLabel": "Trade accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r119"
     ]
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r155",
      "r585"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r984",
      "r985",
      "r986",
      "r988",
      "r1075",
      "r1140"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used for) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r881",
      "r916"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r868",
      "r884",
      "r919"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r945"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r911",
      "r920",
      "r924",
      "r932"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "label": "Other Operating Segment [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r251",
      "r763",
      "r764"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r432"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs and debt discounts",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r348",
      "r977",
      "r1091"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r774",
      "r775",
      "r977",
      "r1091"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Intangible amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r288",
      "r294",
      "r770"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive amounted (in Shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfLand",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area for lease (in Square Feet)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "terseLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r130",
      "r159",
      "r186",
      "r220",
      "r228",
      "r246",
      "r250",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r473",
      "r475",
      "r495",
      "r576",
      "r671",
      "r763",
      "r764",
      "r799",
      "r827",
      "r1026",
      "r1027",
      "r1097"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r167",
      "r186",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r473",
      "r475",
      "r495",
      "r799",
      "r1026",
      "r1027",
      "r1097"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT ASSETS:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "iccc_BankDebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "BankDebtDetailsTable",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "BankDebtScheduleofDebtProceedsReceivedandPrincipalRepaymentsDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt - Schedule of Debt Proceeds Received and Principal Repayments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "BankDebtScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt - Schedule of Principal Payments Due Under Bank Loans Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_BankLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "BankLoansMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Loans [Member]",
        "label": "Bank Loans Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingImprovementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and improvements [Member]",
        "label": "Building Improvements [Member]",
        "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building [Member]",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r843",
      "r861"
     ]
    },
    "iccc_BusinessInterruptionPolicyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "BusinessInterruptionPolicyMember",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Interruption Policy [Member]",
        "label": "Business Interruption Policy Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CapitalExpendituresCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CapitalExpendituresCommitted",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures committed",
        "documentation": "Capital expenditures committed.",
        "label": "Capital Expenditures Committed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and money market accounts",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r153",
      "r751"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "BEGINNING CASH AND CASH EQUIVALENTS",
        "periodEndLabel": "ENDING CASH AND CASH EQUIVALENTS",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r87",
      "r183"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r87"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation limits",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in capital expenditures included in accounts payable and accrued expenses",
        "documentation": "Change in capital expenditures included in accounts payable and accrued expenses.",
        "label": "Change In Capital Expenditures Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in payments of debt discounts included in accounts payable and accrued expenses",
        "documentation": "Amount of change in payments of debt discounts included in accounts payable and accrued expenses.",
        "label": "Change In Payments Of Debt Discounts Included In Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r160",
      "r161",
      "r162",
      "r186",
      "r208",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r264",
      "r317",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r355",
      "r356",
      "r358",
      "r359",
      "r361",
      "r495",
      "r622",
      "r623",
      "r624",
      "r625",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r657",
      "r680",
      "r703",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r961",
      "r979",
      "r989"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162",
      "r222",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r622",
      "r623",
      "r624",
      "r625",
      "r776",
      "r961",
      "r979"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r122",
      "r579",
      "r656"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r309",
      "r310",
      "r733",
      "r1018",
      "r1023"
     ]
    },
    "iccc_CommitmentsRelatedToCommercialManufacture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CommitmentsRelatedToCommercialManufacture",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments related to commercial manufacture",
        "documentation": "Commitments related to commercial manufacture.",
        "label": "Commitments Related To Commercial Manufacture"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved for future grants",
        "verboseLabel": "Common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockDividendsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsShares",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend shares",
        "label": "Common Stock Dividends, Shares",
        "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "iccc_CommonStockIssuancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CommonStockIssuancesMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Issuances [Member]",
        "label": "Common Stock Issuances Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r819",
      "r821",
      "r822",
      "r823",
      "r824",
      "r984",
      "r985",
      "r988",
      "r1075",
      "r1139",
      "r1140"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "iccc_CommonStockRightsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CommonStockRightsPlanMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Rights Plan [Member]",
        "label": "Common Stock Rights Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r657"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r65",
      "r657",
      "r677",
      "r1140",
      "r1141"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.10 par value per share, with 15,000,000 shares authorized and 9,042,392 and 7,814,165 shares issued and 8,979,091 and 7,750,864 shares outstanding as of December 31, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r580",
      "r799"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "iccc_CompanyAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CompanyAMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company A [Member]",
        "label": "Company AMember"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_CompanyBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CompanyBMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company B [Member]",
        "label": "Company BMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFITS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Provision [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r257",
      "r619",
      "r732"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r257",
      "r732",
      "r967"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r136"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Concentration of Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r52",
      "r53",
      "r257"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r52",
      "r115",
      "r732"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress [Member]",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostDepreciationAmortizationAndDepletion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostDepreciationAmortizationAndDepletion",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Cost, Depreciation, Amortization and Depletion",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives, and reduction in quantity of natural resource due to consumption directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs of goods sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r539"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r982",
      "r1074"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current subtotal",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r458",
      "r982"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r968",
      "r982",
      "r1074"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r257"
     ]
    },
    "iccc_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "CustomerMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Member]",
        "label": "Customer Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships [Member]",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r941"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850",
      "r942"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846",
      "r938"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r845",
      "r937"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Third Party Engaged [Flag]",
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847",
      "r939"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r940"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848",
      "r940"
     ]
    },
    "us-gaap_DebtConversionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionLineItems",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Debt [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BANK DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r185",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r316",
      "r326",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r342",
      "r349",
      "r350",
      "r352",
      "r503"
     ]
    },
    "iccc_DebtDiscountCost2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCost2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost, 2025",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCost2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost, 2026",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCost2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost, 2027",
        "documentation": "Amount of debt discount cost.",
        "label": "Debt Discount Cost2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCost2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost, 2028",
        "documentation": "Represent the amount of debt discount cost 2028.",
        "label": "Debt Discount Cost2028"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCost2029": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCost2029",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost, 2029",
        "documentation": "Represent the amount of debt discount cost.",
        "label": "Debt Discount Cost2029"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCostThereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount cost, Thereafter",
        "documentation": "Amount of debt discount cost thereafter.",
        "label": "Debt Discount Cost Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtDiscountCostTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtDiscountCostTotal",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt discount cost, Total",
        "documentation": "Amount of total debt discount cost.",
        "label": "Debt Discount Cost Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r56",
      "r57",
      "r118",
      "r121",
      "r190",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r797",
      "r980",
      "r1019",
      "r1020",
      "r1021",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r121",
      "r353"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal payment",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r503",
      "r504",
      "r772",
      "r773",
      "r797"
     ]
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance and sale (in Dollars)",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt Proceeds Received and Principal Repayments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r351",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r797",
      "r980",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r190",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r797",
      "r980",
      "r1019",
      "r1020",
      "r1021",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon principal payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodFiveMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #5 [Member]",
        "label": "Debt Instrument, Redemption, Period Five [Member]",
        "documentation": "Period five representing fifth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #4 [Member]",
        "verboseLabel": "Loans #4 [Member]",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #1 [Member]",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "iccc_DebtInstrumentRedemptionPeriodSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtInstrumentRedemptionPeriodSevenMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #7 [Member]",
        "label": "Debt Instrument Redemption Period Seven Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtInstrumentRedemptionPeriodSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtInstrumentRedemptionPeriodSixMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #6 [Member]",
        "label": "Debt Instrument Redemption Period Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #3 [Member]",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable",
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan #2 [Member]",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan amortization, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCosts2025",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, 2025",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCosts2026",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, 2026",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCosts2027",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, 2027",
        "documentation": "Amount of debt issuance costs.",
        "label": "Debt Issuance Costs2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCosts2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, 2028",
        "documentation": "Represent the amount of debt issuance costs 2028.",
        "label": "Debt Issuance Costs2028"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCosts2029": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCosts2029",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, 2029",
        "documentation": "Represent the amount of debt issuance costs.",
        "label": "Debt Issuance Costs2029"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtIssuanceCostshereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtIssuanceCostshereafter",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, Thereafter",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costshereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DebtServiceCoverageRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DebtServiceCoverageRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DSC ratio",
        "documentation": "Ratio applied to the debt service coverage ratio.",
        "label": "Debt Service Coverage Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset and operating lease liability",
        "documentation": "Represent the amount of (Decrease) increase in operating lease right-of-use asset and operating lease liability.",
        "label": "Decrease Increase In Operating Lease Rightofuse Asset And Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation agreement annual base salary percentage",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred subtotal, gross",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsCurrentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross, Current",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt financing",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt issuance costs, Total",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1029",
      "r1089",
      "r1090",
      "r1092"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred subtotal, net",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r142",
      "r982"
     ]
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOtherTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Other Tax Expense (Benefit)",
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1072"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of our deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Components of Our Deferred Tax Assets Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails",
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards not expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax credits and net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards expire",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNICAP",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, plant and equipment",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal general business tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\u00a7174 R &amp; D expenditures",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from compensation and benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofSignificantComponentsofOurDeferredTaxAssetsNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits paid (in Dollars)",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r1033"
     ]
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r888"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest fixed rate",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r114",
      "r646",
      "r648",
      "r662",
      "r663",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r691",
      "r692",
      "r693",
      "r694",
      "r697",
      "r698",
      "r699",
      "r700",
      "r716",
      "r717",
      "r718",
      "r719",
      "r754",
      "r817",
      "r819",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed technology [Member]",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Sales Disaggregated by Major Product Category [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Major Product Category",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r873",
      "r874",
      "r888"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861",
      "r912"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861",
      "r912"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net loss per share (in Dollars per share)",
        "verboseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r208",
      "r214",
      "r215",
      "r216",
      "r219",
      "r469",
      "r472",
      "r484",
      "r485",
      "r573",
      "r590",
      "r756"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Net Income (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net loss per share (in Dollars per share)",
        "verboseLabel": "Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r208",
      "r214",
      "r215",
      "r216",
      "r219",
      "r469",
      "r472",
      "r484",
      "r485",
      "r573",
      "r590",
      "r756"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r218"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense/rate, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r789"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r789",
      "r983",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal expense, percentage",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r789",
      "r983",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits, percentage",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r446",
      "r983",
      "r1064"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss income before income taxes, rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r983",
      "r1064",
      "r1066"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails",
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Computed expected income tax expense rate, percentage",
        "terseLabel": "U.S. federal corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446",
      "r983",
      "r1064"
     ]
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r957"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r956"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r958"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r960"
     ]
    },
    "iccc_EmployeeBenefitsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "EmployeeBenefitsDetailsTable",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefits (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "EmployeeMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee [Member]",
        "label": "Employee Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "EmployeeOneMember",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee One [Member]",
        "label": "Employee One Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation related to non-vested stock options (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1060"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Payment Arrangement, Option [Member]",
        "netLabel": "Employee Stock Option [Member]",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock purchase price (in Dollars per share)",
        "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased",
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryContributionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "EmployeesSalaryContributionPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary contribution percentage",
        "documentation": "Employee\u2019s salary contribution percentage.",
        "label": "Employees Salary Contribution Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_EmployeesSalaryPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "EmployeesSalaryPercentage",
     "presentation": [
      "http://immucell.com/role/EmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s salary percentage",
        "documentation": "Employee\u2019s salary percentage.",
        "label": "Employees Salary Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r959"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r147",
      "r171",
      "r172",
      "r173",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r221",
      "r265",
      "r266",
      "r300",
      "r362",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r505",
      "r507",
      "r520",
      "r589",
      "r613",
      "r614",
      "r615",
      "r631",
      "r703"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r865",
      "r881",
      "r916"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow account",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r734"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "iccc_ExpenseRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ExpenseRecognitionPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense Recognition",
        "documentation": "Entire disclosure of accounting policy for expense recognition.",
        "label": "Expense Recognition Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r493",
      "r790"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnNonrecurringBasisTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis",
        "label": "Fair Value Measurements, Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities by class, including financial instruments measured at fair value that are classified in shareholders' equity, if any, that are measured at fair value on a nonrecurring basis in periods after initial recognition (for example, impaired assets). Disclosures may include, but are not limited to: (a) the fair value measurements recorded and the reasons for the measurements and (b) the level within the fair value hierarchy in which the fair value measurements are categorized in their entirety (levels 1, 2, 3)."
       }
      }
     },
     "auth_ref": [
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r532",
      "r533",
      "r534",
      "r772",
      "r773",
      "r784",
      "r785",
      "r786",
      "r790",
      "r793"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r491",
      "r790",
      "r1078",
      "r1087"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r384",
      "r389",
      "r488",
      "r493",
      "r532",
      "r784",
      "r785",
      "r786",
      "r790"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r384",
      "r389",
      "r488",
      "r489",
      "r493",
      "r533",
      "r772",
      "r773",
      "r784",
      "r785",
      "r786",
      "r790"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r534",
      "r772",
      "r773",
      "r784",
      "r785",
      "r786",
      "r790",
      "r793"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r486",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r532",
      "r533",
      "r534",
      "r772",
      "r773",
      "r784",
      "r785",
      "r786",
      "r790",
      "r793"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Nonrecurring [Member]",
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r491",
      "r790",
      "r1078"
     ]
    },
    "iccc_FederalGeneralBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "FederalGeneralBusinessMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal General Business [Member]",
        "label": "Federal General Business Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_FeesInitiallyCapitalizedAndLaterOffset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "FeesInitiallyCapitalizedAndLaterOffset",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal, accounting and other fees amount (in Dollars)",
        "documentation": "Fees initially capitalized and later offset. Fees include legal, accounting and fees categorized as other.",
        "label": "Fees Initially Capitalized And Later Offset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableLoanInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancingReceivableLoanInProcess",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance loan provided",
        "label": "Financing Receivable, Loan in Process",
        "documentation": "Amount of undisbursed portion of financing receivable balance. Excludes financing receivable covered under loss sharing agreement."
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset amortized, useful lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r273",
      "r293",
      "r770"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r540",
      "r541",
      "r747"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Value",
        "verboseLabel": "Intangible assets gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r293",
      "r541",
      "r770"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Line Items]",
        "terseLabel": "Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r293",
      "r295",
      "r296",
      "r298",
      "r540",
      "r747",
      "r770"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r747"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Net Book Value",
        "netLabel": "Intangible assets net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r540",
      "r1013"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_FirstDefenseProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "FirstDefenseProductLineMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Defense\u00ae product line [Member]",
        "label": "First Defense Product Line Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r920"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r920"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r920"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r920"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r920"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r842",
      "r872"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r683"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r274",
      "r572",
      "r764",
      "r769",
      "r792",
      "r799",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1006"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairments",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r275",
      "r281",
      "r285",
      "r769",
      "r792"
     ]
    },
    "iccc_GorhamSavingsBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "GorhamSavingsBankMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gorham Savings Bank [Member]",
        "label": "Gorham Savings Bank Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross margin",
        "terseLabel": "Gross margin",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r78",
      "r129",
      "r186",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r495",
      "r758",
      "r763",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996",
      "r1026"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r840",
      "r843",
      "r861"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of recognized",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37",
      "r97",
      "r791"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r98"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r124",
      "r129",
      "r574",
      "r587",
      "r758",
      "r763",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsAndDisposalOfDiscontinuedOperationsNetOfTaxPerBasicShareAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share:",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r439",
      "r440",
      "r450",
      "r456",
      "r789",
      "r1070"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r439",
      "r440",
      "r450",
      "r456",
      "r789",
      "r1070"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r435",
      "r439",
      "r447",
      "r448",
      "r449",
      "r451",
      "r455",
      "r461",
      "r463",
      "r464",
      "r465",
      "r627",
      "r789"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/IncomeTaxesDetails",
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable",
      "http://immucell.com/role/ScheduleofIncomeTaxProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r143",
      "r203",
      "r204",
      "r220",
      "r236",
      "r250",
      "r438",
      "r439",
      "r462",
      "r592",
      "r789"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income Tax Expense Differs from the Expected Tax Computed [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r436",
      "r437",
      "r451",
      "r452",
      "r454",
      "r457",
      "r621"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r789",
      "r1064"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computed expected income tax expense rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r789"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal expense",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r789",
      "r1064"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofIncomeTaxExpenseDiffersfromtheExpectedTaxComputedTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r446",
      "r1064"
     ]
    },
    "iccc_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r89",
      "r978",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued expenses",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Trade accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total accrued amount",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive impact of share-based compensation awards",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r216",
      "r396"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r911",
      "r920",
      "r924",
      "r932"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r936"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r936"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r844",
      "r936"
     ]
    },
    "us-gaap_InsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceRecoveries",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails",
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Insurance recoveries",
        "terseLabel": "Income from insurance recoveries",
        "label": "Insurance Recoveries",
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_InsuranceSettlementsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InsuranceSettlementsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement received",
        "label": "Insurance Settlements Receivable",
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_IntangibleAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "IntangibleAssetsDetailsTable",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r297",
      "r299",
      "r746",
      "r747"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ]
    },
    "iccc_InterestPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "InterestPaymentsTerm",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments, term",
        "documentation": "Amount of interest payments term.",
        "label": "Interest Payments Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestRevenueExpenseNet",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Income (Expense), Operating and Nonoperating",
        "documentation": "Amount of interest income (expense) classified as operating and nonoperating."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r228",
      "r250"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r752",
      "r799"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r152",
      "r164",
      "r267",
      "r268",
      "r270",
      "r538",
      "r755"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory write off",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r269"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land [Member]",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r798"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Costs and Other Lease Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r519"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease",
        "label": "Leases, Operating [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs and Other Lease Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments (undiscounted cash flows)",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest (discount effect of cash flows)",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1093"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://immucell.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATING LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r56",
      "r57",
      "r58",
      "r60",
      "r61",
      "r62",
      "r63",
      "r186",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r474",
      "r475",
      "r476",
      "r495",
      "r655",
      "r757",
      "r827",
      "r1026",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r123",
      "r582",
      "r799",
      "r981",
      "r1002",
      "r1088"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r151",
      "r186",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r474",
      "r475",
      "r476",
      "r495",
      "r799",
      "r1026",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CURRENT LIABILITIES:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r60",
      "r61",
      "r62",
      "r63",
      "r186",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r474",
      "r475",
      "r476",
      "r495",
      "r1026",
      "r1097",
      "r1098"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LONG-TERM LIABILITIES:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Long-Term Line of Credit",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r121",
      "r1107"
     ]
    },
    "iccc_LoanToValueRatio": {
     "xbrltype": "percentItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LoanToValueRatio",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan to value ratio",
        "documentation": "The ratio of loan to value.",
        "label": "Loan To Value Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansAndLeasesReceivableDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansAndLeasesReceivableDisclosureLineItems",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRADE ACCOUNTS RECEIVABLE",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r997"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r121",
      "r339",
      "r354",
      "r772",
      "r773",
      "r797",
      "r1107"
     ]
    },
    "iccc_LongTermDebt2025": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebt2025",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total 2025",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2025"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2026": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebt2026",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total 2026",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2026"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2027": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebt2027",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total 2027",
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt2027"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebt2029": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebt2029",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total 2029",
        "documentation": "Represent the amount of long term debt total.",
        "label": "Long Term Debt2029"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt obligations, net of current portion",
        "label": "Long-Term Debt and Lease Obligation",
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r577"
     ]
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of debt obligations",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "documentation": "Amount of long-term debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r1030"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, 2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, 2029",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, 2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, 2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "During the Years Ending December 31, 2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r190",
      "r344"
     ]
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bearing interest percentage",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "iccc_LongTermDebtThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebtThereafter",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Thereafter",
        "documentation": "Long term debt thereafter",
        "label": "Long Term Debt Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_LongTermDebtTotal2028": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "LongTermDebtTotal2028",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total 2028",
        "documentation": "Represent the amount of long term debt total.",
        "label": "Long Term Debt Total2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Principal Payments Due Under Bank Loans Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_MaineTechnologyInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "MaineTechnologyInstituteMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maine Technology Institute [Member]",
        "label": "Maine Technology Institute Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r257",
      "r779",
      "r809",
      "r814",
      "r1031",
      "r1110",
      "r1111",
      "r1112",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and manufacturing equipment [Member]",
        "label": "Manufacturing Facility [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "iccc_MastitisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "MastitisMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mastitis [Member]",
        "label": "Mastitis Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r391",
      "r433",
      "r491",
      "r537",
      "r611",
      "r612",
      "r618",
      "r647",
      "r648",
      "r709",
      "r711",
      "r713",
      "r714",
      "r720",
      "r744",
      "r745",
      "r768",
      "r776",
      "r787",
      "r793",
      "r794",
      "r795",
      "r796",
      "r810",
      "r1028",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r391",
      "r433",
      "r491",
      "r537",
      "r611",
      "r612",
      "r618",
      "r647",
      "r648",
      "r709",
      "r711",
      "r713",
      "r714",
      "r720",
      "r744",
      "r745",
      "r768",
      "r776",
      "r787",
      "r793",
      "r794",
      "r795",
      "r810",
      "r1028",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_MortgageBankingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MortgageBankingMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage Note [Member]",
        "label": "Mortgage Banking [Member]",
        "documentation": "Origination or servicing of loan secured by real property."
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "iccc_MrBrighamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "MrBrighamMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Brigham [Member]",
        "label": "Mr Brigham Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://immucell.com/role/BusinessOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used for investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used for) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r90"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable",
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss",
        "netLabel": "Net loss attributable to stockholders (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r90",
      "r125",
      "r149",
      "r168",
      "r169",
      "r173",
      "r186",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r213",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r469",
      "r472",
      "r485",
      "r495",
      "r588",
      "r679",
      "r701",
      "r702",
      "r825",
      "r1026"
     ]
    },
    "iccc_NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Include, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Not Yet Adopted Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "iccc_NisinDrugSubstanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "NisinDrugSubstanceMember",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nisin Drug Substance [Member]",
        "label": "Nisin Drug Substance Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r869",
      "r885",
      "r911",
      "r920"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NON-CASH ACTIVITIES:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncompeteAgreementsMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-compete agreements [Member]",
        "label": "Noncompete Agreements [Member]",
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1013",
      "r1014",
      "r1015"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses, net",
        "negatedTerseLabel": "Other expenses (income), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://immucell.com/role/SegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable business segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r767",
      "r992"
     ]
    },
    "iccc_OfferingCostsAtthemarketOfferingOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "OfferingCostsAtthemarketOfferingOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs at-the-market offering of common stock",
        "documentation": "Offering costs at-the-market offering of common stock.",
        "label": "Offering Costs Atthemarket Offering Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office furniture and equipment [Member]",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating expenses",
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET OPERATING LOSS",
        "terseLabel": "NET OPERATING INCOME (LOSS)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r758",
      "r991",
      "r993",
      "r994",
      "r995",
      "r996"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r798"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Lease Payments Required Under Non-Cancelable Operating Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails",
      "http://immucell.com/role/ScheduleofFutureLeasePaymentsRequiredUnderNonCancelableOperatingLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total operating liabilities",
        "verboseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r515"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r798"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r798"
     ]
    },
    "iccc_OperatingLeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "OperatingLeasesDetailsTable",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofAccountsPayableandAccruedExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherAnimalHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "OtherAnimalHealthMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other animal health [Member]",
        "label": "Other Animal Health Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://immucell.com/role/PrepaidExpensesandOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDeferredCompensationArrangementsLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherDeferredCompensationArrangementsLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation",
        "label": "Other Deferred Compensation Arrangements, Liability, Current",
        "documentation": "Amount of the liabilities, classified as other, for deferred compensation arrangements payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r104"
     ]
    },
    "us-gaap_OtherExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_OtherExpensesNetDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "OtherExpensesNetDetailsTable",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses, Net (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofOtherExpensesNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income - other",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r681",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash rent (benefit) expense",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_OtherNoncashIncomeTaxExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeTaxExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash income tax expense",
        "label": "Other Noncash Income Tax Expense",
        "documentation": "The portion of the noncash component of income tax expense for the period other than the portion from the net change in the entity's deferred tax assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER EXPENSES, NET",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Expenses Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously received",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r665",
      "r764",
      "r1108"
     ]
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development expenses",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1062"
     ]
    },
    "iccc_OtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "OtherStatesMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other [Member]",
        "documentation": "Continent of Other States.",
        "label": "Other States Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r867",
      "r883",
      "r918"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r886",
      "r921"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r870",
      "r886",
      "r921"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParticipatingMortgageLoansUnamortizedDebtDiscountAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ParticipatingMortgageLoansUnamortizedDebtDiscountAmount",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage debt",
        "label": "Participating Mortgage Loans, Unamortized Debt Discount, Amount",
        "documentation": "The amount of the related debt discount at the end of the accounting period."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional rent payment",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "iccc_PaymentsOfDebtDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "PaymentsOfDebtDiscounts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt discounts",
        "documentation": "Payments of debt discounts.",
        "label": "Payments Of Debt Discounts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of equity issuance fees",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPrepaidExpensesandOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r271",
      "r272",
      "r753"
     ]
    },
    "us-gaap_PrincipalAmountOutstandingOnLoansManagedAndSecuritized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalAmountOutstandingOnLoansManagedAndSecuritized",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal balance",
        "label": "Loan, Managed and Securitized or Asset-Backed Financing Arrangement, Principal Outstanding",
        "documentation": "This is the sum of principal amount outstanding for both securitized and unsecuritized loans of all types."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sold amount",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from At-The-Market Offering",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow",
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt issuance",
        "verboseLabel": "Proceeds from Debt Issuance",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of loan",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r622"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from line of credit",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r980"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property, plant and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/OtherExpensesNetDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r539",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r749",
      "r777",
      "r808",
      "r810",
      "r811",
      "r815",
      "r816",
      "r1024",
      "r1025",
      "r1031",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/OtherExpensesNetDetails",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r253",
      "r539",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r749",
      "r777",
      "r808",
      "r810",
      "r811",
      "r815",
      "r816",
      "r1024",
      "r1025",
      "r1031",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r519"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r137",
      "r140",
      "r141"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisposals",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment disposals",
        "label": "Property, Plant and Equipment, Disposals",
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r154",
      "r586"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r519",
      "r575",
      "r586",
      "r799"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, net",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r137",
      "r140",
      "r584"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentSalvageValuePercentage",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset depreciated percentage",
        "label": "Property, Plant and Equipment, Salvage Value, Percentage",
        "documentation": "Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://immucell.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r519"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, Estimated Useful Lives (in years)",
        "verboseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_PurchaseofInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "PurchaseofInventory",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of inventory",
        "documentation": "Represent the amount of purchase of inventory.",
        "label": "Purchaseof Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r383",
      "r391",
      "r422",
      "r423",
      "r424",
      "r433",
      "r491",
      "r535",
      "r536",
      "r537",
      "r611",
      "r612",
      "r618",
      "r647",
      "r648",
      "r709",
      "r711",
      "r713",
      "r714",
      "r720",
      "r744",
      "r745",
      "r768",
      "r776",
      "r787",
      "r793",
      "r794",
      "r795",
      "r796",
      "r810",
      "r819",
      "r1022",
      "r1028",
      "r1078",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r383",
      "r391",
      "r422",
      "r423",
      "r424",
      "r433",
      "r491",
      "r535",
      "r536",
      "r537",
      "r611",
      "r612",
      "r618",
      "r647",
      "r648",
      "r709",
      "r711",
      "r713",
      "r714",
      "r720",
      "r744",
      "r745",
      "r768",
      "r776",
      "r787",
      "r793",
      "r794",
      "r795",
      "r796",
      "r810",
      "r819",
      "r1022",
      "r1028",
      "r1078",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104"
     ]
    },
    "iccc_ReTainMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ReTainMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Re-Tain [Member]",
        "documentation": "Re-Tain [Member]",
        "label": "Re Tain Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesNetCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesNetCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r999"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r862",
      "r878",
      "r913"
     ]
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r390",
      "r524",
      "r525",
      "r578",
      "r583",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r676",
      "r678",
      "r708"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r524",
      "r525",
      "r526",
      "r527",
      "r578",
      "r583",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r676",
      "r678",
      "r708"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r684",
      "r685",
      "r688"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party products purchased",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/EmployeeBenefitsDetails",
      "http://immucell.com/role/RelatedPartyTransactionsDetails",
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r390",
      "r524",
      "r525",
      "r578",
      "r583",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r676",
      "r678",
      "r708",
      "r1096"
     ]
    },
    "iccc_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r525",
      "r528",
      "r628",
      "r629",
      "r630",
      "r686",
      "r687",
      "r688",
      "r706",
      "r707"
     ]
    },
    "us-gaap_RepaymentsOfBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfBankDebt",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofDebtProceedsReceivedandPrincipalRepaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Principal Repayments",
        "label": "Repayments of Bank Debt",
        "documentation": "The cash outflow to settle a bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Debt principal repayments",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Line of credit repayments",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r980"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r747",
      "r763",
      "r1105"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r863",
      "r879",
      "r914"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r880",
      "r915"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r871",
      "r887",
      "r922"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r102",
      "r581",
      "r616",
      "r617",
      "r626",
      "r658",
      "r799"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r265",
      "r266",
      "r300",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r477",
      "r479",
      "r480",
      "r482",
      "r483",
      "r505",
      "r507",
      "r613",
      "r615",
      "r631",
      "r1140"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total product Sales",
        "verboseLabel": "Total product sales",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r220",
      "r229",
      "r230",
      "r244",
      "r250",
      "r253",
      "r255",
      "r257",
      "r379",
      "r380",
      "r539"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r748"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://immucell.com/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r381"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://immucell.com/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Sales Disaggregated by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable",
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyMajorProductCategoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of product sales",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "iccc_RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "RevenueScheduleofProductSalesDisaggregatedbyGeographicAreaDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue - Schedule of Product Sales Disaggregated by Geographic Area (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product sales",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r174",
      "r186",
      "r220",
      "r229",
      "r230",
      "r244",
      "r250",
      "r253",
      "r255",
      "r257",
      "r264",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r495",
      "r574",
      "r763",
      "r1026"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Sales Disaggregated by Geographic Area [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares sold",
        "verboseLabel": "Sold shares (in Shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesCommissionsAndFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesCommissionsAndFees",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales commissions (in Dollars)",
        "verboseLabel": "Sales commissions",
        "label": "Sales Commissions and Fees",
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofConcentrationofRiskTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r966"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r392",
      "r987"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r392",
      "r962",
      "r987"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://immucell.com/role/AccountsPayableandAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfActivityUnderTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfActivityUnderTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Activity Under The Stock Option Plans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfAdditionalInformationAboutTheStockOptionPlansAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Additional Information About The Stock Option Plans Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfAssetsOrLiabilitiesMeasuredAtFairValueOnANonrecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Assets Or Liabilities Measured At Fair Value On ANonrecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Provision",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "iccc_ScheduleOfConcentrationOfRiskAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfConcentrationOfRiskAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Concentration Of Risk Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfDebtProceedsReceivedAndPrincipalRepaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Debt Proceeds Received And Principal Repayments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt Proceeds Received and Principal Repayments",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Components of Our Deferred Tax Assets Net",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Income (Loss) Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Expense Differs from the Expected Tax Computed",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r789",
      "r1064"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofIntangibleAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r293",
      "r295",
      "r296",
      "r298",
      "r540",
      "r747",
      "r770"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r1012"
     ]
    },
    "iccc_ScheduleOfIntangibleAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfIntangibleAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://immucell.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://immucell.com/role/BankDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Principal Payments Due Under Bank Loans Outstanding",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Expenses Net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfPrincipalPaymentsDueUnderBankLoansOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Principal Payments Due Under Bank Loans Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfProductSalesDisaggregatedByGeographicAreaAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Geographic Area Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfProductSalesDisaggregatedByMajorProductCategoryAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Product Sales Disaggregated By Major Product Category Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property Plant And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofPropertyPlantandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r519"
     ]
    },
    "iccc_ScheduleOfSegmentInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScheduleOfSegmentInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Segment Information Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Additional Information About the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity Under the Stock Option Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Concentration of Risk",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r52",
      "r115"
     ]
    },
    "iccc_ScoursMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ScoursMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scours [Member]",
        "label": "Scours Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r220",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r257",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r298",
      "r307",
      "r308",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r760",
      "r763",
      "r764",
      "r769",
      "r813",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r643",
      "r644",
      "r645",
      "r710",
      "r712",
      "r715",
      "r724",
      "r730",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r750",
      "r778",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r812",
      "r819",
      "r1031",
      "r1110",
      "r1111",
      "r1112",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://immucell.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r220",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r240",
      "r242",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r759",
      "r761",
      "r762",
      "r763",
      "r765",
      "r766",
      "r767"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that were terminated or forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options hat were terminated or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Non-vested stock options as of beginning balance (in Shares)",
        "periodEndLabel": "Number of Shares, Non-vested stock options as of ending balance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Fair Value at Grant Date, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r410"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, Stock options that vested (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value at Grant Date, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Stock Option Grant Using Black-Scholes Option Pricing Model with Weighted-Average Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r424"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity Under the Stock Option Plans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested (in Dollars per share)",
        "documentation": "Share based compensation arrangement by share based payment award options exercisable weighted average vested.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Terminations/forfeitures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options granted (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning balance (in Dollars)",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding, Ending balance (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning balance",
        "periodEndLabel": "Outstanding, Ending balance",
        "terseLabel": "Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance (in Dollars per share)",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance (in Dollars per share)",
        "terseLabel": "Exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "iccc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested (in Dollars)",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercises (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Terminations/forfeitures (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Grants (in Dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r400",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r428",
      "r429",
      "r430",
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Additional Information About the Stock Option Plans [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://immucell.com/role/ScheduleofFairValueStockOptionGrantUsingBlackScholesOptionPricingModelwithWeightedAverageAssumptionsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of the options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options hat were terminated or forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Non-vested stock options as of beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, Non-vested stock options as of ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life of options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "iccc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Stock options that vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average price (in Dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://immucell.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank debt",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r118",
      "r799",
      "r1106"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r184"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State [Member]",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "iccc_StateTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "StateTaxCreditMember",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Tax Credit [Member]",
        "label": "State Tax Credit Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofSegmentInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r148",
      "r220",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r257",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r298",
      "r301",
      "r307",
      "r308",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r760",
      "r763",
      "r764",
      "r769",
      "r813",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r160",
      "r161",
      "r162",
      "r186",
      "r208",
      "r212",
      "r214",
      "r216",
      "r222",
      "r223",
      "r264",
      "r317",
      "r319",
      "r320",
      "r321",
      "r324",
      "r325",
      "r355",
      "r356",
      "r358",
      "r359",
      "r361",
      "r495",
      "r622",
      "r623",
      "r624",
      "r625",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r657",
      "r680",
      "r703",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r961",
      "r979",
      "r989"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r65",
      "r68",
      "r69",
      "r147",
      "r171",
      "r172",
      "r173",
      "r191",
      "r192",
      "r193",
      "r195",
      "r200",
      "r202",
      "r204",
      "r221",
      "r265",
      "r266",
      "r300",
      "r362",
      "r459",
      "r460",
      "r466",
      "r467",
      "r468",
      "r470",
      "r471",
      "r472",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r505",
      "r507",
      "r520",
      "r589",
      "r613",
      "r614",
      "r615",
      "r631",
      "r703"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r643",
      "r644",
      "r645",
      "r710",
      "r712",
      "r715",
      "r724",
      "r730",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r750",
      "r778",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r812",
      "r819",
      "r1031",
      "r1110",
      "r1111",
      "r1112",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r221",
      "r507",
      "r539",
      "r620",
      "r642",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r682",
      "r683",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r820"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://immucell.com/role/BankDebtDetails",
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/IntangibleAssetsDetails",
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r392",
      "r962",
      "r963",
      "r987"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r221",
      "r258",
      "r507",
      "r539",
      "r620",
      "r642",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r657",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r667",
      "r668",
      "r669",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r682",
      "r683",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r703",
      "r820"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r866",
      "r882",
      "r917"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Offering of common stock, net of $291,834 of offering costs (in Shares)",
        "verboseLabel": "Shares sold under at-the-market offering",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r102",
      "r622",
      "r703",
      "r726"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable",
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in Shares)",
        "negatedLabel": "Exercises",
        "verboseLabel": "Stock options exercised during period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r102",
      "r406"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Offering of common stock, net of $291,834 of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r102",
      "r631",
      "r703",
      "r726",
      "r826"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3",
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "verboseLabel": "Exercise of stock options (in Dollars)",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r65",
      "r68",
      "r69",
      "r102"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "iccc_StockOptionPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "StockOptionPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Plans [Member]",
        "label": "Stock Option Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of common stock",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r64",
      "r65",
      "r102",
      "r625",
      "r703",
      "r728"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet",
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r94",
      "r659",
      "r677",
      "r704",
      "r705",
      "r799",
      "r827",
      "r981",
      "r1002",
      "r1088",
      "r1140"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "StockholdersEquityScheduleofActivityUndertheStockOptionPlansDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity - Schedule of Activity Under the Stock Option Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "StockholdersEquityScheduleofAdditionalInformationAbouttheStockOptionPlansDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAdditionalInformationAbouttheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity - Schedule of Additional Information About the Stock Option Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r530"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r530"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r530"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://immucell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r530"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://immucell.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://immucell.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r531"
     ]
    },
    "iccc_SubtotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "SubtotalMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofPrincipalPaymentsDueUnderBankLoansOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subtotal [Member]",
        "label": "Subtotal Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://immucell.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisDetailsTable",
     "presentation": [
      "http://immucell.com/role/ScheduleofAssetsorLiabilitiesMeasuredatFairValueonaNonrecurringBasisTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://immucell.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH PAID FOR:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://immucell.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration term",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "iccc_TermOfExtensionOfLease": {
     "xbrltype": "durationItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TermOfExtensionOfLease",
     "presentation": [
      "http://immucell.com/role/OperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of extension of lease",
        "documentation": "Term of extension of lease.",
        "label": "Term Of Extension Of Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "iccc_TradeAccountsReceivableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TradeAccountsReceivableDetailsTable",
     "presentation": [
      "http://immucell.com/role/TradeAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r933"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://immucell.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 63,301 shares as of both December 31, 2024 and 2023",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r68"
     ]
    },
    "iccc_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "documentation": "Two thousand seventeen plan.",
        "label": "Two Thousand Seventeen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandSeventeenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TwoThousandSeventeenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Plan [Member]",
        "label": "Two Thousand Seventeen Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TwoThousandTenPlanMember",
     "presentation": [
      "http://immucell.com/role/ScheduleofActivityUndertheStockOptionPlansTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "documentation": "Two thousand ten plan.",
        "label": "Two Thousand Ten Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iccc_TwoThousandTenPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "TwoThousandTenPlansMember",
     "presentation": [
      "http://immucell.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Plan [Member]",
        "label": "Two Thousand Ten Plans Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://immucell.com/role/ScheduleofProductSalesDisaggregatedbyGeographicAreaTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://immucell.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r134",
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ScheduleofLeaseCostsandOtherLeaseInformationTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r798"
     ]
    },
    "iccc_VendorsPolicyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://immucell.com/20241231",
     "localname": "VendorsPolicyMember",
     "presentation": [
      "http://immucell.com/role/OtherExpensesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor\u2019s Policy [Member]",
        "label": "Vendors Policy Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted average common shares outstanding - Diluted",
        "terseLabel": "Diluted weighted average common shares outstanding (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r216"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://immucell.com/role/ConsolidatedIncomeStatement",
      "http://immucell.com/role/ScheduleofNetIncomeLossPerCommonShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic weighted average common shares outstanding (in Shares)",
        "verboseLabel": "Weighted average common shares outstanding - Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r216"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481212/470-30-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-4"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>106
<FILENAME>0001013762-25-004072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-25-004072-xbrl.zip
M4$L#!!0    ( *J ?%I@5/=7#7," +3L%  :    96$P,C,U-#@Q+3$P:U]I
M;6UU8V5L;"YH=&WLO7MSVTB2+_H_/@6.MV=7BD/*(B6_/3XARW*W9OQ:2SV]
M<V[<N $211)M$.#@(9KSZ6_^,K,*!9)ZV);5DIL;L=,6"1;JD97O_.7S__-Y
MFH9GIBB3//OK?_5V=O\K--DPCY-L_-?_.C@Y/#[^K__S(GC^O[K=\&>3F2*J
M3!P.%N%A/IV=#)/PM(BR<I07TW"KFFZ'W7!25;.G]^_/Y_.=(3U3#I/"E'E=
M#$V)#\)N5X<[+ P&>QK^1B.^C8JP_S#L[S[=??AT;S?\]?20_N@_D,<G%4V2
M)IJ53W7,O][3]ZQ[QSWW;)U5Q<(]^WE0I#NE&>Z,\[/[^N5]>LN^^\$B/N?A
M1=QZ,#;)^@?IB_:#5>$>Q);PPWDQOD]?W*\6,X.G^]W=O>Y>S_[&#,^9!7W1
M&CP9#H?NR60ZK8<F3;$!_%2OWPR9E/E^O_=H_53ZN[M[]_4)]X//YSW;HV>S
M-,G,_[S\^*9YO%K_?//H_<I22E01K6&*N]W=?K?7]P;ITE); ]FE7S1.[T%W
M][&W?_3DIPM6BJ\'46GLXV71S'T4E0-^DCYL;75==L=1-%M]4+]8?AA'6ZY]
MFK]I/WX>C=!TG]RG;^V#^")>(CQ][N%]^=)_-+GHN+.RBK*AVX3/Z04/_\\;
MVK+FR>7MG>_QH[TG3Y[<YV_=H^6ZYVC(WOW_>?OF9#@QTZB[,I,R^?)?G3\?
ML(Y[8"$FBE\$(?[O>954J7D1/K\O_PB"YU-31>$PSRJ3$3%4YG-UGW_(W*QK
M_E4G9W^]=RC?=T_I!._=IS'ORZ#/!WF\>/$\3L["LEJDYJ_W1O3DT["W.ZO"
MTV1JRO"=F8<?\VF4=>2#3GABBF1TCW]%$Z IW,>_GL_:0PSR-+[".,_":52,
MD^QIB$=WGX5803=*DS%]-*0YFX)>=7]F7[?^9=_M/>#VKQ.3$J__6*>F^R$:
M&S#VY2WKCJ)IDBZ>7C:)>1)7$\QW]R_W6H,,\B(V1;?*9T_#EVDT_!3V:9YE
MGB;QLU 7>?D:=91!7E7YU [4LP/1&\M9E'WYO.^]^,__Z#W<??;\/G[_0O=F
M98?NKVS1=S^PKUW/\X%;TN"%6]8-4=DW3/K7=\>G1Z^"D].#TZ.3YX."[O+)
MT>&O'X]/CX].PH-WK\*C_SG\Y>#=ST?AX?NW;X]/3H[?OY/G?HO*":E&54[C
MOMHYW"$EY<'^D_7K_YX;H)\E66PPYFZ2??=SO.Y;+&OLIF9$"XCJ*G<?%<EX
MXC[3R]Y_<.E=[^T\^.+;_J/=YC^ +OY0D?7XCV0F0F7=,OFWD>/C+7O]_N/;
MX'GR^6F69^_J*3TX%-7B<_71C/YZ;[A[+\RB*;V)C(6GK_(A/9-5K%2$"6G^
MR>>S;F_O\>[^O1>]W>[?G]]O#?7B[O!:W9ZYD>N<065/5^[-32QA[:W8,+@?
MAL'=*$_ZLVE+!^_>_7KP)OAX].']Q]/PPZ\?3WX]>'<:GKX/26DZ)<TH[.V%
M[S^&O0=;\7;X_G5X^LM1Z.E33I<Z.#S%U[TG>_MW; ONY+F]SHN@FIAPE)3#
M* T7)BI"0]<F#B\13N);@2"JGL919;I3>F "D=6-HT47 W5-MDZ(?:#Q\O@H
MBU_1S]K2[ '-Z9M>VW[C85T4],+7O+9_THS6OO3AO1>OS-!,!Z8(]WK+DK1S
MV4:L+K!YWVOZI&R_[=&]%W#KK KLNRK _V#:O^KA'&554BU>)ZFA9^FHFU-Y
M]/ ;E!>>4VR&><&.QJ=A39>G@!O2.0(&+W9W>]U>?YFC+1_X[3_EK<-\.DU*
M1 &"$>UDF/%6;O]AFO_-4NP?;$9<B=1:H\-1WDT^=R=)3(K0TU#^2^\;5MW=
M>R^.I]/ZT*1I<)@7,QW5;<:=8C];1Y]I30%N>YB/PL*,DQ(1@"J,RK"<F6$R
M2DBD)5F85&4XG$1%]85D>U?M[BH:T#U%R&<6Q1RONT=L\8N7YCE3G>MSF*=I
M-"O)JK7_<E_19(;T+FS%YV?W7H3/J^)KEDB_BY<,G25_Z[*M<]6[=&:**B$A
M;<]'AG7KW'\",^L/D5B>@H/K^[2L2&&9%?D9B+NMWHA(.\Z&S?4]P=.'$K0\
MS&-?TV'EZAN([95)HWE4F,MDV/TJ;AW<%[+]Y9,AR[:Q?O]R(W)@:0%_%LI;
M)JS3Z/,Q&!7QSB$3U[+BU.OM?=O>DUJTN_>X_^3Q[E6(BOZGN!96<O5-74N,
MURZ\^-)";B7^5=Z^B"9OTQ*6/$#7-E-[,ZY]OX]W/NZ<[(1'TUF:+\CHXZ!-
MV*;U\%V^LW("2H'W6:BJH+TF=>'Z]G^C =QZ/OP-Q/N%//P@C@M3EOJ?-V0K
M]-KNB,?W7CQX&![1;HP+4B_"5T5R9K[!!])Z[2']\WUQFL^S]DN?W'OQ(2^J
M-,KB+W[5%^M'.A=FLN^+#_1DPBDAWH1Z=/W>1K0YEWEAOE&WT0OH2)B)=Z/R
MW!Z51VGE0TY4E?[?9+:D0N_WOE'?V>_M[MT15>>[25_=8^@[LX*N8C*+TM!\
M-L.Z(M9#'Y,(-N5&^_E>^T]D'8*NOT&[N<,^O#]^TJW?+OOTG$OO"U@7I.Q!
M8:(E9D5BC=C55G_WT?8RG[EZXL&;G$CRPR3/5KSF&+]_[\7C1X^[_4>/=E=9
MV9WT(WYTGL/__(_'_=ZC9V50F=3,L -_,F_W#5HP)\3\BZ1*3!F(Z]84)@YG
M=5'6\.%6.3TX9*NLU]\:;$-T(&9Y,*R>WL;E_+@&V7JG]GK1]3V--UW[7O]V
M&FFGR!@/B$I--)R$PS0JRZM8$E==_3EFA+,8OILV<[5#_"+RW;MF V=]MMUI
M$6''PG(Q)8Z\=;EVN3F*[W44[S1&QU?#?!Y.HFQ,'V3A?)+0)PW_/T<]_3JV
MM=8.&-">C8N<="XPSKQX&A;C 2E,^YW^WN-._\&#[:\UIK[)%%5IN.CU!\Q(
M/)WKR=?'<-:<!J+YM/$G53[\U E_VMWI[1)!%^%9E-8FG!G:Z0D'?,XQ5K_Z
MWMP"<^N;3DC9R0ESD^9X^KM?KS6L.9[CP\/#/\_>7]NVG9)F^(4^1+"A5?>A
MO8='RJ3 N=KVS]X]8F=E'/UK^7S"PVB65%&*BM5/IKJA&,*UIA?<3 +V]<SU
MB^R'<<M^"-_!LKL;RY0C^:,GV]RU+]'9B9UE,6)K)A@LPN'$D+I"+_\4)G(6
M7LI.4H91."?SJ/LIR^?T<A.5=$@Q?5'6IN@@IR<VHR23C!ZDEH?[NP_LJ3;$
M@ />"?])__C/_WCR:'__V9>&,7ZC2?P=<SC1*1SS#-I,8)^80+[" /B-#^_(
M_;E+=_U+R"C+*_KD7W4"=D!<@',6"S/+BZI<SQ[VPKS0'/6&27P3#?TC3^NL
MB@I./2W:R<"]!^MH)]C0SLW2SGQBZ*2+90+:ZFV'$^(UH)HXC-+4D8Y/4P.C
M#]"8%Y"1QY6L/A$0:>%KE#J$,7U+!BH>G15F:-A<[?5#3F\OPRT:C[26L*S)
M1BHG.?(7H:$G.4UB$E7+<Y]'Y2KE\X]U#=O$1K,XW.IO!UCC +'?LA[\3BO
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M>I)&CYC^?$UH**#?H;Z@?<PX@H%'4X$[B03GZ)U;>P$T&"9F!!9\#+NJLI\
MEL/:3H.<. )&,9_)+FGTO[:R9N6$L$ZB4%_7% J*#6G&0WM-]1 P5@+-6"4H
MFS10+$'U ]* Y9I$G^E<:1%9.*N+&7$NWJ&8]>6<K[FG);.-I=IUX!E3;$'M
MA*=\E[SG(Y9A%9MV*N?/2*!AGY?:CSF&+](GLEJBW> S&:^TZDL,TXZ44MK(
M,C11 0.4*10<O\,O)KY(;\VS=6]S=[#CJ^Y$,+!_1D*5$=W7J6I#2R^F;3'Y
M2#>J, '8X+B.T$37&-\"\!3]=3;+69Z2&/B40:2(;BC_)NWF4ZF?#*6<C8F0
M]Y^L3"+-FG8:\P'" 9V5:^/FQ EK.)TKV2!L'PPGL/STG',8VMB@@GY)C"1.
MB,+%6"[RJ8HX-<BPR07(+&U,\M($YQM;G4:G%7MMV5:3X<_;A):IAHDE0UJJ
M"M^8OER42ZI!)Z@,7[#..K[7\=BNY5F?Y/(N*7&AI^YC[[_<Y&"%^1++9[OC
MF 5FI,SB$K;0:83\JFD$Y4TL:.$S@5V06[I/#=#<DW'&"NG 5'-CUC%'.GGZ
MT'+P1IEE ;BT3RV&[^DFVYV@.=H%+EP.+F9B49:6#&.Z++78Q6ZI'-OCVSEG
M80 +@HV%"#-*28L'1<K;:%DQ!$-+2Q+S)SC7_'$71JT7M\=P"(A=LZ15=3Q;
M0/BY=^>$I)?EJ+(^IHT5;<>3[/BK40MX;&;0YUV4V- _4QI,[JQJ5OQ?6NV(
M)!MXYAP7_9-Q6QXT?CL>\^BS"$GN"IY(<\BMDZ/#;>\:\S+^FQ@@,0SB%N)5
M+'V7XW]W^)F6V[%L^R2M\#O4[5A^Z''W[^?ST//V0#ET(PR\#?=E3:F>HQ;W
M!*L-A/6UF&'-&WD6%4E>ERS\ +85MHD>,[+?$:T@4Y1,(\P/< L:!@J/CY^&
M[T]_.?H8'K][_?[CVX/3X_?O.J&$+PZZ'X]/_AZ^/C@\??_Q) !S6%TAT\ \
M <,D+D0+B\7X"5DTMC9\AQN;Q-*]$VS60(<2KVJ6L\ KF&^PG+':(':VTWYI
MP)S6\5?:9E& :.EU*=; P"@;Y['FOLJ_$_YF9!LJ$%X&UT)J_<,T]WK&0O9"
MCUW'6B'!G&@5#EN(MP+<W E)%F&D;:R0O_LQ>Y[UM*V5FS0@X)U&K_?6BA?9
M/=^Y,Q&!\P(85TC4V+NEB1I_6(;&04%VP7 U.Z-W;G;&#Y.7\4/$0[^>**XY
M'^,'6MX-1*Z76>(W\4.:\OM?3]\<OSL*3M^KO V7TP6^;X2:_W>_M_/H 0ZD
MM;;N=^/W.G?.*B3J2-,9%()L_-=[N_>^?#WS)*XF>'3W+U>B,<?F2ZBQV1@?
M?GY&R_RZ#-NU&;#!5V9ZZEITY^^_N)9AOOX NZUTT*^9R[?=#E?<Y-T FYAZ
M25;JYCYL[L,/=Q\^-+[Y\ O^[U -=C*]-!RE#=387W+H1T@V5VUSU397C:[:
M099,%:[HJO_WBXG2:F+O5;FY2INKM+E*T.*B5'L:7_7_!"^6@PJ;6[2Y19M;
MU.A^7W2/7C4^X\T]VMRCS3U"]4@3U][<B<V=V-P)Q 6RBJC#<.#YBP0,":49
MG<O&0[>Y29N;A)LD?<R@<'W1/?HH*6$;F;2Y29N;)#?I:#I+\X4Q&P_ YD9L
M;@1[ .I!F@R_2*X<-XED7W^--B $5PQ-W]7\NULZW7792N$\0KUQS=4<21;V
MGCSNNZ).%&NA:H2^(/L>]05\8\(<V;.:2X_,Z!S3R8>?=(!'.^'!J#*V_H!S
MO34OWY8:F/"0DYA041#^PR -%_@3X<LD3_-Q,J1)_[ISLA.^,BBUX[1U>M?!
MN."Z *1O;OUZ\NI@&]F?)2UI-6T?=+2<B2_S>]+K('=UE ]KY ]/\[*RE9U:
M#A?&D@^/>=+SNZ[$!,4$565002*IWII$&DYJVF^7,=\JYM8:$\Z-31?X'1W6
M)SQ;F80K=)*1/AQP81EV8+$3OC1$"9D4Q&(63WC6A>G:B?O54[:2?6'KC:^V
M'WX9 V?P(O^==B"0JIA6&36180W<!>.*4;6XR"_VS>H*:>9Y+64(6&&7SFQ"
MNYW'KNH-96SS24+BF::FE7[X_E]D+B.LSIGXT<A4BYW@O5^K,3'I#,G.*%&1
MBN<BG^/GLO\3"1@.<^0U9WBBR.OQ1,M"X[ NM4"U2@9)3G*5BTKPZJZ\0LH2
M$*@L>3NXHK.I@8R#DH0P'Q<1I!2N8X02 9ES:]8OW?F.E#;PWYSHK"55=*K>
MZR3=D"LW38"K3'<2)4+[C_O,UW$,F9F3]I$M'UV:H.R.+NC=3VV^I=/]S00*
MLR$GR!5&?+.)[-ZAKEVJM)F3@>>M+?FFI]*(BQ>(#N4,A_F\#+>\ZJ)UU 2L
MESKEJNL\92R?Y-^&[_ \6FCB?U1,45;#LW!O[$C)*;V.[B(888OBI""-R%I@
M"XCQIWG)A60->U"N0/SJ=4ULV*N3X4L12,ETZ>B;!D9EF$WC1X$*RGMF18)Z
M-2LE]"IANR5O('Q5U./PH.&KX=:[ _!_18L1:1(N29.W=%N&N& !"Y/7X#'<
M%8X'BZ>T_\PW>;S7-%QSZ;5T+@[I8T]ZY7@':HBD)&D$< 1E\/[.G;H"X1-;
MU:E5MS%+/$]0\,#\7JG!G(?1/$J8 OC54B*D12YX-[$<(AY;M:,O'R4C^MP"
M(J2K$^A(F3I$"/^Z0I4VT=O?HJS&5M$X_=W^ Y+<E98A3XVMJS!:\PD=@"=V
MS&6\6MU![["93[6KD7<'SD! <5*2R"I%PYCF7'R!,J80Y=1%L+ZNY<[<_;O'
MJB)&;>#B&PN*834?%+^C("C2@F>O$MN56/V,>_2V53GX 9 'P"W9&O[\]L.V
M+<EDR@>V2)JNK;H/FEH\2Z!Z3U##4Q)G <1*[-6-<T77"+> KKO))A'7'X)B
MK?(  =^\KH4UL80CXFKP=X+?!-@@R:0,3-Z'F=/399YE)NV$F-C,]=M5:((%
MT7/L%+BRA5'AH!B:0G]ODNU2Q VY?Z?IOC\C#L.X.B3SP@R(/0L3H;0/-H#8
M/>VCZ'!M:U740[5^B ]WE:"-"H^3>E!*.>[6JY/M]:@57.D6GBNZ Y'=7-+/
MY ;H@FB65,0"?2KRJ-@O%K5 %Q<5+(=- 7);TW]MK; 1?AG\2ZH\10CT'CJ]
MF04!A#\3;O-(7RPH!K_@'8K&8]H@*=\/]SL/'NQU=GN/!!*F7+82.V$1"=(/
M:=!E*<@;)F9=@07B9R[C)QOAI_[#G4<PE]*$H0Y(QGZF"9%)B%=57K=7LA1E
M[VER^Q=-KM?I]Q_3_Y\[N6#]Y,+5R>WO/+1SZ[@MXX+8JGLZ,5U)N JW#D[?
M;H?OU63F<DUV$#*K):$Z!;@.*U0)=+<SBSRANA/0%_R56E7 X4N43<-O(>HA
MEVA"RP(981MLV>545INQ4Q'>459%;(5IV:X1E@T,9 9VBV3/K-:&8>=1 8@$
M.H%WAG4BAN; C_EZ8"3^!#H FE0*. ]/=!+%RWO:V]UYX!\XO07WC!'3>!@!
M;7AEAF8ZH#W<(TK$D;.LBK1.=FG,O9V^&W+MSWL/ '/!^K?>.7HSN+V:H@(V
M(E<SF- 09%1E'=TD^H-!"-@D7^;^7WEOS\,V8W"/!D='K'0/:JJ-P+;6[K1'
M5QCQ1=#,P 29;8$I1(QME D2$"G;F)G1LF+2M3\9,V,8%: <Y21EP5TA;NT\
MBV0\46GKD&<8"JJYHJSKB6H)0JYR<+R(U$,8^-"][1;R8G_:?[#3N_C\Z/@Q
M]^"GGG<ESSOJCM,$_(MC71IZZCCD]BSZCSS"O&06NY?/0@FN ,A+*=76]/F3
MOS#:S4][WBWHM*BRM5E<!Q_V'MB?]1[N/'$_"_R?7;!4G* <"61C%[(12D^2
MQW=?);E"'?3^IN1YI>2YOREYOA/1EUM3\OQ#+.S61\B\8K6O+4"[JXS\EDY7
M%)J !+H$9P9D9@#$L42\H!2 4P=X=UU&W7DH5-!2]G:=XD$#L:<-N)<0ZHSD
MUIBF'O(B2">C)3;^#4"X+FFSZR8[-^P6!+[1T*@G-C#0KMA([.^0A$%D41PA
M\CGC/S&&9MNB[+.CL/*U\'C]2^DQ4H!%=Y7HR9S]B8)OZB(IP1J@2G&%6T\L
M8&T0/AP6T:SEO77(BNR6K0"KE]C("Y&)$2Q//PS5>E?'1\_";27[R.G=8H]Y
M\<5!E%I8+S;(Q<.[M#E\>)G_,S;<EQ[;6]X*M=U;LPMX)R38E^9S>BX&.MT2
M02JF*ES]@//!&S,#?$SXBILM %YFJ="8=H,8LY1A,16NFD'(:#8QV0YA&<&-
MW,;374+Y5"3.AAYM.+FDJ1>(E]!Z)A9O%X]B4^P&6]_@TI',6W$\ *TR$:[9
M&G^7UU'JWDYX I*9>8!M;#JM0T;U$+V\W;4K1#C%E(I5)-[Q*! 5?S@!"+M8
M>ZM@MFN<$;N/.KN[N_R^GQ[TY8^X\8GP%T(C]+J9(%NFBR;@,6!(..L<#7P3
M'\QA[>)HXXER#V9%DNKF[-]]H^&63O>X"L#Z!&<.1P<T_5G*)%+4R$L(<9W7
MB14+;P^*)@G![D^' HA\B' +7^5DNW/P")D5K5C<E4+:VX&26(^)JA4.7>&1
MEH(X',4PE+&;$1B>)==],!OP7KEB=>E?>99OG$RQA5Y\<-E.MP-^D+]"S)/Q
M-?EU12@6";N5K -NG7SS\*09!UB?8;>'Q0H43,35A<XEA(<;Y><*T&G18=%^
M&L?>C,5.9T=*V<A1QNFLF-]),D:8@A5TRV&4MN;)"P7_+**Y@[(+!<'1K9V]
MDD&:$"^-O;W;"9%7P1%?FAB]A..]NKHFPV3PNS"*,I0HD4*W<3R0YCFJTQ%P
MX42.,2(C1S84P5$D?\;\;8H .:=7@(03SLUT8(L,[D@GM&A =YN$"#_:[#(:
M:"]&%B:3UL*>1HW8BE<)/1[@G6,&V@1V6.V)N>W!S&3&!G]5^/+0"F>.5Z6&
M/<"(:Y5$]PE/##-QV-]T,TZ+I'LR@?&Y5DGK:*8+W59B\E%F\KHD<DBC.J,)
M$Z>-Y-YVAQQ^GQ71HAL7B2=<+"OF:SE,T6*D$TJ/#G<+EB?))".[!/2_B5*;
MSIUVC"5IVNQ5L+I7R&_1U!;^K86+92G/R4<T=,R4RZC';@?MFQ;NA#;MF;X=
M.>$B-(3;+KSNF*PE93NX1.9I:*WEGD]*OX6*BJS) EHGIVL!*13Y/-8#ZX26
MR%].2\OC1<@)<RS7(%.(0="/;(9=V9@BQ$4BUHO'">=8#A+2?+?#NB)E^M\6
MP)5^1KS!5-#;SZ+AT(81SLU!#%T.(C.*4\\8#:Z<T=9DL WHOYE;F\.[MHEJ
MQ*$@7;AGB.WR4V<L'?P6(IS3F$B;!F_]@:R?%RY3%;:(8)-@AC,'1.")Y-&6
MSH4=2LA^ B@S4IR0H!(5Q<1$&NZ9+&(5#+0Y2U-EA9Z[2:4FBL$T YC[ (TM
MD^&GS!I$4'!HJ,C.[,O3 EE\02_+Z*3!_+L:CX&( _=>!+%!:A\'[V2-,XZV
MM 2H)H2J6(,>J"N1G Z6)P[1GA0&8WAE I;/NY/;+21#S":+Q=H/@SZVR-/-
MH4=H'U;R'>"&)6JJ5<:9/]@<**[2KV,*!<1E?M)?@R2FOT1)F7'*:S'E8*[>
M$)?58<'G+TJ.#+'5*Z;S"$8-R !)4G-TJL(LTV1D "3;IDR;T&07 +V)K,"J
M9H)F\ZF<@#:9MN67;$'98^&$&\CILBX!Y)TH@8MEJ-1:2CH49P%B&@(+C&""
MM:%U3OP6;8CFFC?9$SKE2')AD'I5S?,NPGG!-(]--Q]U;3;9Z"MSA$,E.*)U
M,B'!,T)F;3DZ#]4IFLVIMC^FRRQG#RW;N[*ZC8[BW%45-2E*2]M2@+5%!39F
MW.TV"\&>1H.2B(4M9]43!RFL9&0Y3FWO@F%2#&M%YVX&"4:D@/%NI,DG&BG,
MT&<:N1<D"N*N=AT@0@92=E).U3]E%OQBHLG2D%E0^>_F-?,1>FT12#!)JX2&
M?J[$5<\1,!R]SQ)V9N4(.N-.,I?+.$V!+]70<%XB^$:>-7?U2N<=>$T Y::0
M508T[HE0LL]Q<3W)QBQKZ;LRC:K5]+^EK*X,20^?.6*>(&L]!Y. 4RY'1HJ9
ML@.".$<G$'K@?045U0/[CG+Y)79T@&63#6L:WDT"CXR1)H/-[69$5AMR5VW>
MEDO ]%@EN* IT Z,)@9K"BCW4'3!7"QR/0N,/$57.U:5MY5[>.D(<LEQ1EVY
M$6U>'8F!A8&8DXR1H<O@Y#R+&5$-=.XT$$1\7)MVRR574A%'4WW#%I@FN 4G
MB.!U5OB7VW[7$A6::[Q<^_(.\=WN[3&9%+&22)1ES 4T<?1BYT'KI+0 P\L%
M.,?EN=]15/=I+0Z/)LE^Y>*L37@2WQ3^1[K3S2).0-UK0O.X%IN\N^^I0[>8
M%S/"DIVQ+:LYO#S0H8ON6(U(^%)SHSI\NB"290TA1%%-<Z69"; J)10*[[?(
M'ZL(-:+'5RG"=?465H*9B!B<"VVLUY\PU\#JH<^3%T<[T/Z3Y_>3%T@W+$C"
MG25%K;[TO)*_MC5-Q*6+VZ3T]B6++[Y+O4?2!Y7X1YH@S3!PG3C>%V,2;L/P
MK7J/RO C2<RHH 4=9R@1J&GM6^_??CS>OB3XP!$P9O7H'$M62F6;$-2V28.^
MBSU3.\N>DV4J0\LYH>)[JS+*78+!BX"XV0!\332:ULZJ@\W?7*=":'-<<;JS
M,R.AK?2ZTPFMN*/P?\O-$D4/[K)L)0$5L(!2]6BADDJ/CRCG7S6I)L38XXI)
M18G-QBI:KI72C\5H9*&1':Z+3*/AEVT5/Q E5-;7* 'P_\[ST.44B@B4B8@8
MT&GR<KNL%'&;NR%)X:U_O/FPW5B&6E."I97-#JX&.%P.4NEM)$T>"B3GEUO[
M%[$D51>G: 9B92#[;DF_=4J@-6&]J1"9H5A.BE42GM4L)V[ *C;LYY(;9+$_
M%!TDH#6SH$5K.M6B2>L0G0G]A.F[;;@IW8QI-338U%5"J)-,2P"Y_)!53TM!
M+35EC:)W:8(N9XW-FEZPUC$+:77;^?XE8NJ"5*P'FU2LE52LO4TJUG5Z4[^S
M#G6OE7QXUQ*@-IE=MX>+KO5 7YX@;L,WVNTO,Z-$58@Y?!%>%[D+VF1S Z6L
M"<4%59ZGXM*0! G58U=\HU8#5"V]I05+94 D]=(TT)RT1"YXP0_%DT#K?6D6
M2%CY!TMY(<"5@AFLNNGF-XS(T"9RTG)^UH4\]U&CM-DHVEDS-EPGP'5Q6H7G
MXN,*$V3W*R !W*T<*A7-8B=8Z].]_(0*,\W/5%M%LS';ZW6Y3U[4-MLY:2-W
M+4!)-Z?-=0[78+W#==EOFAA;E2]MO=AP8=^1O)*+'DC)<D,X1T7+<U7PQD2
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M*=REN?Y0%-._JZ=PE^;Z0U',WET]A;LTUQ^*8O;OZBG0_Q37;M8\8X3K,0=
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M1Q<1B%-&Q>.67MK_XFT2QZD)CR)D&6:>0."-HY62.)$NGL&KHAX+QSDMT"B
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MUG=,MSBN HW)N1R^"$X'2;3TU [C52&5B.581\+ZE!E6":SFRD8.4XR$$=6
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M)$ZE)YM5*XU(;HQJN-HYSI.G*LGK;#@1]8Z#:^A"8"WD>D8:F9\4UX'-R0
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M4",IK.^0I&BI[)R/(#D1QM%(VUX&KI<D\659GC"CR'=FJA+KZ/%A<]:BSGE
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M63.V_EBA4<KA,HEGK&[1XE<<U!@9AJ3!?&8L(_$"%S:O6#/0)=4_F5"@A!#
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MI158'^Z[9!_OK;./V]G'.^OLXP?U#'S)%21(G$-,*%S---S%R<4KZ)AYJAK
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M.*9T'VUT9>)*.U\:3ZW%E5;777J70O/]=:%YN]!\=UUHOMKN_"_?#FO6JO;
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MXL&&=*N+,S$:L=-D:,9L^M5_6>.'?\)>^IMB^@?KF'X[IK^WCNG_F 'F=2[
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MA%+FN,AGU2B?B'!))E)!PZ=4=YDX[SVDUB8BIROLP ]:#%2IS0.[!,\<>BE
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M+93L0\$'D+EP6T1%?4\0A8';-ZA8\H%G[Z4B]\PR7EX3MU]?O 6[ 7?(@6[
M[6^L8!:/N /TMH\-$46 5%-]N!2H8(F!VK-6FW"K4J9D+,$>XH@,JOJ6\\,S
M]='1:@J\=HA"S1<@*-V$"*(&?'*1$YS/Z5BM^\+(MM9:=F68D%)7'^<W4(^
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MT!-EU"LE;\&S-1'HQ!U[+Z[89QA:ER5_A^,:(!/'E,U3+!;VH>8-H+@GYU/
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M611&6]'X\=E;MG2PM&%TJ:"/CAT3WL8'#9;0!2?Y%2.0C&D1+">?-TIN@]8
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M-_RDU4WOB\$-7]P6J*+GNT[2L)6EH(W9G0<\--4U>A9TD#0%<&2*"Q1F\8R
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MO%IK0QQSUM-'C_TI$EF2I)XGZ?1$I5,^238GRE+(G,3E@UQ<P4!R8AEI9_J
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MK_31[5]K$+/^^=G(8H_A=\_[?1?4S"W.:'#7X:=?,S17_ZYB^I97+C/2 8N
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M4/D'YX,!8^R7LSRKIC-G#,<L2"8RH@##/@H_P"2 *BG-=!#<6R39],Q_O3[
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M25.':O&E"],AYUV>$M7B\+V"@['YW1'Z5(1U)?:=2'4BU8G4H?&GZ]KX<C,
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M4!!5KNB4WP_62JMIU0\/TC#+&:!$$>6ETT0U%N?)XJ"T$W+Z@#R->@0F7:4
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M>#>-P'PW9(.(XKYZ#&#[.JW?D#&^UT$#MY50)Z31OKES.U&7N%0)ZBCU.3&
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MG&0A#%BQY<HS?>1K#P.$A7,?".PQ+C'3I8;96KVA+$9G87-=IV[KVT*VPO1
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M $H!*AU(6B#XD*E+2QU)8TM&(@DOS%YL_PCZ/&=LP@3&TJ&!K$@@081C,=$
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M&XT>29M,%*J8 (48DSE.#"$2-QA$VB$Q]3]Z&9TJ?C0/?TGT/F*7Y@ E)"\
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MZ%>'CXQ&]FR39)X<F5F+^F[ER)[G0>GEN/.4)89"P@#K3T"2]%+BX>ZV!::
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M"O1%K;)P/",=.E/?LV$!')1\$PJA"9LU=1!AI_+3\3<.G,86AJ()]_J@'XL
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M$PLB9,<NJP%U!)+(IA 'V-WM4Z06!PUO30'N]CWSV0G&#,; 'XF_#4T@UT<
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M1NZK=,PH;JO\)<A%S.!A@B%"C5J DW,H2+9$I?A>PJ4_57_!94YYIFJ7<>9
M[@_7C\ZN?6!R^/R9^$],A3'Y+"JJ7E2$GVFCUI<W43-^4LBZP]T/ELQ5YUTY
MU'EGU'DW#W7>:T%]\[PP/1L^WT$.M=Z'6N_-U'J75ZOU-I:M]8XT;#>X$#6I
MW8<KL+.N,(:^5D!CE6<G0AL5?>=U<V 7_$[1-5&XB6<]H<.*.,<;#FVLB>D"
M!#DXZLLS6=-A4/(+7,*3R \HZ0!V-(@ D#JW]DZ;VMHQ8[F'B+AD.T<:YSWD
M+$ EMF.Q?H!<@, B(YO"".061*YT,I_Q.':LJ/V2$CO1W$N:%3=Y;711L)D1
M$#+M/2HR&3#Y-1IU2#?#'2I#]MX<&F3)A1%8-JPE!DU.>S_)AEL!&8[[9\2E
MT867<^.H:G%UQSV<Z;E_C:(B= L\!B$0Z]S,_I.6B&I/WIX:ET=VE'U,'#]\
M$M$ &:V7/0FA"&[0%S@ID?*?XU$^%,BAT9DT%T/.[)1K%9*?1'R1)T\'2Z2_
M.)L;)["6\<X:RWAGS0SO+(E-,TQF9Y;HS57(*7O[:8!+  5Y-%] 6(PY5;36
M1+C<#TQJ2F/GFM(Y5O&D[,VIB;.^416Y+E9E:]XJ]+!OU0H:*241:!DG_?F3
MZ'F:V&;./SPZ2P0=A7!0$K'-08(HM.3L-.Z/>79"BF&!4$L.'5/O_"%P7<,H
M:3B]; :1D0"\B*,U.,/L-/4<)7J.B-*'B;BKENC]H8*? '@0F])XX 2]B,)S
M\6TXRDYSU\A@\)Y87:6FH=W3G-1L$/ $NA&=2HQ>Y@(?LE-X) B%V(7MF7@,
MZQ.>/1Z*Z+G]W1EQ>YJL>!*SK+EEC>LY2%G=VU%)C$I)%YP Z F5AV:*3.5C
M%QJ.<#?C3664_Q%#_4!=T4=$3?B]/7K!0;$B*HDSI1VTL@@[K!@3UZ=$$-?Z
M$ @4*O*!L_HX"NH_-"U%#J)*?S$%"E;;8C8WO_F$\_#))#R5TJ#R_?_LO6UW
MHTB2*/R=7\%ZMI]3/@=[! (D5?7Z')?+U>N]U;9OV3U]Y],<)"&;*01J0'9I
M?_T3$9G)BP0"";T@6_=N3]DR2C(C(N/])9J=L2 _P#P3I4<,)A0@6:S]U1D3
MX<\.*!'!X)E54!6@,YL,Q9HDLBC*9)HJM!+>]=BD2$,^ 3-%/Z1\F)7W[L@H
M22)<ATENHD';?-<L):\-AI*4T"D2Y5DYR;#&5#<8D4@K5$[VJ?BMTNA'IH:Q
M<H,T@$6G%-%_3 J33!@&8D9"O!%/NE,,NY_4 =OR?K#AE#REG4HD0P%9RG*;
M4REY15S&-9^IBX3;>U>T-.ISM,R0IR5^(RK2."EPHL^E+X=:MS"^&'[<MS8T
M)QZT[KE:FEE:5VZVUY:;Z.G@!;; T?B81FJJMC*P7IUA](R/MGZ)/<K8G,::
MA" "Q4_QGS#3'MZ%,/OYZ:1D0B5@8''T)'_AO&:2,Z4P?I(>9)2E+G]2K,GG
MFJ8>O;@'V<#L-V)22+E_3?V(VIUC9_=4^A)-<:78&&.S+$F.V3382"JQ'#/Y
MI'&8>X&/51WIF0%8'FC6^6PC[^7W>OXEZ\"96CDY8X!UD ])JEOG7X][Z?M]
MS)A@O-IVB.VRO%9WQAX7ORF\5Q35PZ$'PIWQ6![(?N*FHD$[YA?[?=$9D;P1
MR5N$; ?\66\&?^WU\#?U4G 1WI@"U''_B9)!(._!/)<6P;04VD3G$ZST2NH!
MSYH4&B5_5?QIGLK%=+UIR,8T\_TG"0YI;>,\?W;G.Y,\^MJ2I]T$BTTD;@]8
M<CAKMIRHGEBMP,Y#^I7$%5@+=%K,5*;BW63"#^DE>1E*L:I"?DM*54F]D*DS
MA4IM2J%/EI0RVD]&B<[XT80J'3LCTWD;/&4A7S5G6?.I3!Q^K&2! ;E"+7Z!
MILB$^;N6K8L7"QO&XI4-[&@FTBE"6619\!ILUMPB%-T2Y=@$X<LG37EI=A19
M0E1;-_8]>R9N=ZQ(<^64=$_^H3#YJ(@-<^/9)!"0O@O]<:D%2$KS3<XFJJ]C
MZHBK_9(-AO-(@B^CN4MN]2EOGI$DL/&%&YTZ47"E]AT=+6VCUXA=-7\_R[)/
MC&/V24[VB=HZII^\R<O[GE-#&DX(&TT5T==+%6F?E.UC==786%NIUO>N5&=S
MX[,J<5HCLECC-&G>PZ$DO=Q&J/X)!SE?:;%TCV4#1Y@$+\J2J?:!37 3N>V+
MJ>TLX=IB>OZS+<6.>V<QM4"X-;/UD8']9 5#82'.3: K/,%2\X UOI#*8[\9
MMW7 .SQ[?N%KJSC \93<-R8J*?)U7JQXR7IB%OU<(B(SS+C0<W5S4J%39\CU
M!Q1MA8HW/=]+1BVQ4HB%2HCY3.;'A9R(4-1Y+M^N5+2T@&3:+S_DZC[MF"_$
M7H;(YJ4-?")F/"B72'9A-";0PHL3^!Y+L$&2+=C^R/EI#T5UI7"UEVZ:V['#
MN.JH8-?K!?998A3G8\,[[S:%,9HCMGZ(O_K2V18WP+E9C2R''K 6B;N7DJ@3
MBRJP2B(<QS ?CV]:N*%Z)EL]U&Q>Z)EK"SUC<S&,)6&+O/#&2C$,AK1\[VHJ
M I')$>C[[O"3S(^4J/UH&^4'/&"_F$+P7R>J'A^_S+Z:RTM@[\S3* M$R/P)
M<K>;\Y*3%7W3NP6@MGGXI0-/M>%U. ?6WMN!V^_GP(_8J65O#(")KH_B_66G
MGX/NDE\/Z=M5X?:)>C%C$JPW1 GG!Q_EX*G_06OIBM;N*IIAG"X&V04NL7X'
MU0L5]8M8&AK:+WEE/O,$H"-I7BW5JN=I2(C;7PI66Q+MSR5N^)(\I/E.B2C/
MV?O)Q7_.[Z3J<KVYY4AKBPM)"KJ MNJ-Q5N<L7@977&K@)2H2F/RVOK)15OI
M&$ #;6VA ^AJF,D#:3Y3>SL83GEQE^6!:V8JH80<6$?(;@BRG2-D-\F5:@[K
MW!!7,G;'E:K+T$+S8QGNJY)7#J+*'\Q;\+B9 ]C,=A2WBV^)TW2Y9GQ$P7$S
M&^6()39#13OAL_!9EYF5M27N)L1L':VE6Z*UU%)5#@9:2S41=7U-A/I_/MK!
M^+/H.!E6TSM 3>\INFDH1L[8\/>)HZH4W3M2]!9UZ[4INK-EBEXI"3H3Y5H,
M::T4NUHANO268D1;#PCEYA/M.YMIKFO,OK>3'PUK)Y7;J^+L& )[@P&28PCL
MK1_X& +;^[>W&P);.=:5?)BQ@(\AL%R%6&^$LQEL\5ZGJW1T]1@ VU:8IMTZ
MAFFV!%GU"-E-\J1.(WA2;U<\Z1C^.FZFP1&&8_CKN)G&$N>BO5#/1G@WX:^V
M=@P6E.DAQNZ#!7H+1S\K>EM5NFKG&/]:B:3;1Y+>HFJ]-DFKVR;IT@#8 92(
M52[JN_)I3"PK?/_NA#^N GL(H(>?JA;O+5DBU9&W@QFSN^W(^^]3.;,W#/'@
MKMY"/]XJ>!,=>*OA>-_%Y@NH&M N@1&%/UCE-HY]9AW5I9QFG=B7)]W7WG7&
MCIAS)SI#\7EWU$;A]=D?LYFY/^QT8S@Y!!Z$=<P^+#Z<XMPMV 'K(^]/ 078
MI9R5Q5-M=WI@56![3UABSDN/X]=9WE!ADVZQE)JW$U'BT5E4OIZJ2\\<*PT&
M^^>$&NOB6?GY<"*;1"-D+=:9UL(BU[A#?MQQ7ZSC^C0WF(;5#7&R'S8KPFE\
M5C"#'4TC$(*P[8 /%7CE P6QH3SV*@T<W/HPTWLJL[*4FB](TV)!=#I#K.B/
MIPWZZ?;M"9!H^[-L"ZID!MF3[3\%UN09.)H5V-:*M<L/@V? )>#U;I2AL[L1
MWH+/,_Q?-KUM,=V@A/VML716H('J_( DAQ#+@%5 ALV38QU>&6#5UB\T_LQG
M'7;9B.U)X .Y1HQ^J;G"T :B< L+H#_.,\!#K'_>')X%NZQ'*V7%U%68<7L%
MQKW!IJ^[3(;)LZ]%$':)&KQ.F-BLFRO3O_B2C''X)[7RN,96'K_V@[]?9))&
MF&:QUK[7B!>O"</F1M_C O1*X"N+P!_4N=N;._=N(N@=,S>T<\7:A<N7N>>)
M(QM+$;4T=E3^O?D@47R/EYJRW;0IJZT6)9IGT_=V@!]83[8:V[1G6LJHG8 .
MEU4"VB<7^J(U^\LVX--$Z/?V"WU]"]#?LMN9LRIQWS[7%9=KB<A2HEA3XBZC
M%;VU7UK!2L;%Q.M\6BG@WRN!\$WB4-TO#DW X6(9:FT<=K5V;R<RN$(,2FVQ
MCN%)1F.%13;M@M[4:M6(2MLO475.+CI5A<CJ;NDWC[WV?K'7!>SUMH:]]8(*
M!^1XJ>*JT%=P:^Q_HL!C8 WM7(_L<&JSQHHI;YV4\BV7>.O0T<L\=E'A*ZIY
M[P[/6U?;P:;E.-@J$Y5^F+ZR33O$5O%@+*N7(O^7E'6 D4N,^7'6=H4=RAG;
MNW#W;=Y),W=OS]16GO8X.6!GCJ[O5Y?HG5P8[]>9HQM[A;[1.KG0VP?HS%G]
M7KXCIX^Y7YI23RZTQ<3]H]-G)1QV]HM#4!W;YA9QN ^?SSS'0)_//,_00#-_
M9YZ@_09S##!>.]VC)VA=[.TW&&3HC?,$%<Z)V_%(G[1QOY?A2*N.-S./X\WR
MQINIQ_%F!WL%CI/,]L#V%AL6;6]VF;'>[#(]EJK5,F*_XU"MJ?TU\,<@-",4
M<W\ZT?,5=V,7]=XJ289=;=54>4#7Z.RZ/.#'J<RW"__&\[X.LSB *&9ME.X[
MU/)G:@X<_,1PDC.Z[<H?THW (TN/_@2(W&R9BORK<R$P27$9<?J0?RT.S7RX
M?+C"KP!'<2[.9?X;9M-;,D[PQ<B /YX$]K/MA30!S1_:+B72#\CGXC#&Q8>*
M)V/D)'Q$[-P*'!H'3'L99/<2AXGXT#*,"?&J!5;"0-&CUS1 :"@>A9,P>B1>
M0A4,./$8GL7$?%87T;?9_'0,&XF1[/$P//CV!+;DX)2\)]\?TE@VG.!.8]^P
M3B(&%)4'6*F4_3Z6%X3L-+Z[?"F)%R*P/:='O;-!@F(>-"/=]/YY"(R :__D
MT_[8.7P ^<*;: 8WJN"X$IO C64<0RL8QK.HI:$3XH#F:1#/$_2L"'Y3^ [A
M>\X8\87-?*8>+Q:)9FEHTQAK;/@S<OW7L"J&_Z2S4E*^/PVD_A2^A-,4L\_!
ME@)_^O2,L\N<H0P&"1P<3DNJ)CLN9?3SWU-SKCD<[6%J#[A3*V %&S1R;FA/
M;+IO.%[/]VS)@C\]VP&0OSRQ S*N\(;Y?1#4G)O@?>#X)3J/UZ>!W8*>+!E
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M@2MS]X3,W#TO)*$&[G1H<W* W<90S5!&"!MUPHA9&7.#1"3,AD<FAAGC:+3
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M?UU?&F3MJ97(J(L7OZ5TS'+9<'3*;DQ\UT 8AE5Z;:7;79U5U_?4OG5GTGV
M[4FBV;V+@]^\X?5?4V>"2;(E/@I-S6DTM-7SF^A=NKN__O[X3T6^_W:)KJ3;
M+_+U__WCYO[WZ]M'!;W%;\VM5(B> J3L,)>WT''$=JS($]PS:Z,F=GW,+CU$
M9]&F_2&B/^*0^43^".W1U)6_.2^VF"/XP?%88.'TC7EYCEZOP_5Z&>U<'\$W
MJX\5,1B&9#T1O"D.%V$1LICSU?/3:+_DPWB99#&R_7MQ#LK'X33 :U59RK"K
M^<T9V1F5K(?UUO.:T=G2S;2WMQGUY$)M+>IMS?:+&;4TZP((_1;X%;,1>]K)
MA:8"S0/=&^7I2F_ $6G4"*%O N!MG&FJ](RV8K;*4T[VXI4\N?@\=5QDORS<
MYZ0:Z:R:L%N)0YG;8PIZ'E-8SJ(ZV]N-@:ZK(A:UCQQHH[O?VV#2;>AV>TJ[
M=YA9Y$9OOQ#L$ 0[73TWI:C)^>0G%W>CD8/=2:8!' _[:&2,Q&VP&K.UO<O=
M7549,M7M;::W3!G:QSTQM7W>$["LL7:H99B*JA\FHS%K.<WK U E +9-I=W9
M7=U*%2YRY7MA%/ \0(=2 9^"-6JR8OY1<6JD#B3E_=U*38S<%V7LU8906VA#
M*&:OK?1:=2EC3P#<JTV@MM F4#HF"$ZMV25A!2ZE;R"WZX>[%^]BH0^K\A55
M<Z[HVPS(F^9^:1@,+4/%8M#R=*9C(D4:;YW]XLW8,MZVDRXUERFQ--BDR$\(
MCF4"I@$R:,_:':9!@6K7:RE&I[S*M(E"?,]*4(< V#)ZBMDN]^LUR0XOE+*7
M@\%T/&4] (?V) #@\8Y?=1ER^3<.F=\OGZU8KT&N0,B7%#[@9]?&'X!T+\<X
MI8<U'2\DZVH4W:700$M7%<-8O3BR4#@LA'+?&'[K]1#>(7[11=15]"[8;7IY
M.Y55\;O=-.EE:9,ER@!E!]5+T2M[_JUE_VU#-ZE8HJVJ+6!#AM+6>TIKC88*
MQU3-G2(+>YAW0(4T%#.GB?GVTS1W.+6W^17UEZ4MXP<IUZF4<IVF\O/2-=FP
MVL2:B8$JKS@I"'/W?NU??'6",)*Q^-4+[5_#Z03AT-$!#O@S9F.FB[4'%N:V
M13.L$,-!'*Q^F\:;PMZD)$W0LVT^1J\?%YHC/:.,%%-5K-">@%R11X[KXC/8
MZQYV]-T^>[0<+W\O +YG?QKRAN1L**D5ACX*7#Z##W?$Q(B4E\ X=,*)'\(=
MDU_MP-Y>FX%E>;EL ]4NI@;"OMU2VCMO.["I [0QH-525'TQ7;]N&X)S.:UM
MQ0/ <!["UO":?F,U .CD93>[2JNS7L?Y76[68"&!CM+-:X]?%U\'T-VA2@/Y
MWK&!?%X#>?W80/[80'[O.STVD(_[!D66]^2 MEVI:4G;W'5!4 ?[R#]>WOYV
M\_G;=:/;RNR[M[M I&C94MH?JX;ACWT3(QN+.8;S%%3=JZZ:H/7UT FY&)-@
MBC<.#(3+.0UQ]A J%('MXK!M:A\5^#/+!3.#S_@C:P&^T[=IX"'SI#'S@ID
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MG@UT9&>$_C5R&#M#F2G:Y$\[<MH23JLO1NCS;@_CM.D0?0E;K!5=JAT_[^+
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MTM@:VO('^R=>2B%OM\;45LW$ S:_U*1Q>0XBX^NG7"*2[L#5'%0^4GJD$-S
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ME7:%\I%CZ[V]X'45'0(;A7=4[,VW>J^Q-X_.BJ*G4Q;0/0*N '!EP8PCX H
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M3UNO['X\/2*I*I(JJF68\P0ZK+[!Z//A(ZER^*,L%_;=A3^J JXL"?<(N +
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M!9$$MC/N3X.0CB]P) @&)$\R*'5L(4WYB@P? LSZ]K/ECN"U2A$136#9J87
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M+R.NF-K)N?3'!+8<)C 0_N:,7S+Q;BGI;W/W9U@*-+"(0.7,@  P J;AQ'+
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M $W4_SHQ8WBLUDT]%<M*^9MP:F((RESP]POIFBR\="(!"X&LO&'J=+@J%%<
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MY?2T+&;% 2_9^;Z+X\59:VH6M^K)A=H]5Q?C%DW@J,L 5#W?M1Z , &V5Q=
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M,>^/Q:>/C+L6Q_@JH+@J[^ZU<#+;'IKC-H ?;!,3F&^Q87;10V_4>;LNNSA
M1&W"QS%_43:-'&TC3;SFD@3G$V[H=P2NXTTMMCPF#DL23R!N2D9A=E?_<78F
M?W5L=_A1O@=0?X)7_S7%1+>/LFE^8F%XV*Q\=L:_2#3)OIO*I4[O5-5R$L!,
M_*PL0+[>'//%"'JE?+23BZ]GZ>.+@W^2'V<3./-E8/6=P2?Y%FB> >?61S!H
M:OI;?Q=?(PA1B%O I@A6_<"V?ISU;;AIL/"$H)[>KYFS7X1I00)3!K?Y+T_O
M%P^28+/9Q+G;7<TG8?0O;L;CZ97MNO*5'TS\@&XU:RO:M)W>^A&\*_+ER^F0
M%+:OH,5Y \=RY8<(.">)0_D#9T_V\'3N&,VF@SG&2KS]7R1:GGT7.$K()/^E
M-UQ0#,(X'?!LT/H7KO(O;3TVL\%S9KKA+BU#,3#(R+O8SL4825\7*;\+&KI4
MH*&?RU\JJ?)M15ZN.!@KE7#M:N90KUTT<V@Y]/HSV??@@_'$]6>V+;\ZT;/\
MGSN' (G;Z@# (K/,Z74L-%8Z9L[Q'=B^%3Z?2YBW:L6SX)VYA'=_%(.HD+:*
M2$9^M<(2H!DU0+:9KA-)6]A'/[+<XIJ^8B@;-#8@IQG!N8S ?15IC1;/B0OL
ML>5X $')=49SB?VA[*=Z!%+= /U5:ZDM^=X%-H&)XOR3#O\D/[N P&]-)H'_
M$^ 7V>Y,7I:,K>IF!O[(ASX"IA'#F];TB^MJOPO87,'>$(Y3R\4\>2T+<A.N
M];S"3;3($NF7GM-0<\\YAH>>&W=0[$+46C@I[35D=[>8O.0\\K*39BL)>84V
MSSD_/%(J;AY3!&$U"^'NR8563$I+ZQ=V2DJU#]H[N>@641(Q*L'@9:H7JL27
MR@A'D>EX0WD4^.-2 ?K&9OGHK19E(>9(7]#,RX"QS?%V>P$&=CUIG;<6H\KR
M!"B&OL$X6O7>\KO5&-9*?=!;6F'JPYP.NF)ZBOQL8:%@S/<7KV\9B9EOC<3:
M!5'R%(7)I12V1YUT30I#-5_3<DE,JD-B[?HDUGEK) ;*OG&N+B:6SY.84,O.
M!.P(]!*5\E*=,-E78=K *D!.6,@ 4-5EAA9:KV6HZ#8E-R;VWU<SM@H081;D
M*!%4RF#1>UNP "M!.^_F")B8*$$1LT-L:..\@/9^+E^&4KZ^%J$5#.],U1X3
M"SDCO13+U^,SPY*NQ1O3>86I[\*U4(:4&MZ3:^ZF>;"#%[C1^1B*HTN$C)"L
M_?3?K_PPNO6C?]JP'W'TM.NEBB] ;V%1D6DHJI9#F*Q8_]5Q7;EO2RD ^\ B
M9&N9)3<A8D%FL1TK;&L09%3^U0_X1_B<F@49V"5JK@&V65-^CT=4T0XH-+U*
M*N1C'_UEA%[NG)KX-)-)4RQR$L:<PG Z9I]E2^)C'[BZ>B7^^F_-PD;EI?.Q
M3$0JMRVX*6E&PAM>/%NAU,=V&X DN@-P)[Q,CPSVW#04$I2"BF=P -]%:<L+
M[ '0^,#8']JN0CVM\-G)-)CX(97M#Z8ALCO'DS&4(FL?O%.%>8&C=)V_M"#F
MK>34'Q=#PA.*K30EJL*Z,^2$4K9%9!?-Z"-0I8M 4:*%"+*E,@%*!^$L/AU7
MBYLK5(L7Q/I2 9Q_HKK(JN:O%W1&%N);>;^4Y[!%B*U5=K_UDOLX>ZW"E*/E
MY>D'<=;V9LY:D5:J93?F5--VS-PZS\U-$_WNA#_.1H%-@3 PJL)(#K#5Q%RK
MJ62*:&[);R'^JU:KYGQGG=+@C*],KSB'<<,SN>,<K91\0"A_!2#?<!A_MZ+$
MXCG34OHU2&0;?3J=@G;NE8'[2_.Q9:R#K0W/8-D,MHS>1K!5F9LP7K%!-O#%
M>7% :1K*,\R2FN\%EKW]1910F61JW>JJTU7;VZ<3T3!7 *^,3@JRF)?#\)?]
MP7VE@(R ^X:;%.\9[AN7[QN\LP(,\HOO CA=)YJ]A8MK[(Z _A$#KHR$C(+B
M_;=U=\U&@KZ@*G>CUW=[EQ-34MBU;._R6F[L("7.ND)WJZ"I3C%-K9,;LHRF
M6 K(A7YNYJ>W%)DQI8 ^7 P9%3#4W3F&S/."!*2U,,0O>=S2=X<=0^EBBZVP
MNWWL6+WYCM7:TJ;"SS;<J5PO!O:)9E$\$(]_G#^<RX^!;85P 9B=$TKH"+<
MK-$T %&4BC4)!V,\BXH[TK$^]-A7>O=]I=ME)##,6+#9.6*)@DQ=I@$\S@M/
MT9-X&(/E)4P#^=D)(S] ^&"$Q3KB>F5<M^OB6B_#M9U6KO"2PPD'4Q::GR*B
M_U=<W] 93^ AQQY*8SMZ]H<*#TI/0YMUMA\[P[.)#VPCT]@>8Z*I,+1(01\D
M^:;$"3 +-)K?4,56Y9E*R;VUN=[96]FD$YG5W7_'1T-*YM_M/JI$"/>[E1N
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M7*?P]5A9#BN&%J8C1K8U%M:4AUD[^%/@3Y^>,0<Q"IS^%/GNN7Q'FT!<S/B
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M2?AW_A58U>8KNQ:2"1"\G+>JHBY'B:Z5Y.0Y6ULIB!B1B$& QB&)^>N_[@%
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MFG\F)]!]?O[:AS?4FP[=#8_J1\-;B,7?XJ-#*E!:.A2](W7B@XK0^U]$B4L
M^$@X12XV77!L:W.O678\>A(_O)P[*26BY@4<BU\F8=XC2<KAX^FGIBRHP6?]
MC6B'_Q#;6NM3+30#+-5\'0BO\8$QM5?Y'0N@W*Q1PF*H;T4_"X$VB1H*U75M
M_<E#KD4+[/@^K<\W+SI 3E47/$^G>IDR(C7W3Q/*4O3:&S59T.Z!9WO1D84?
MB,] C8X<]H3&/GQJ::1&[\'  ,T<)\>7QS[51V-#I=?D)L@FN!4C4&HN_8SE
M"W @:;Y_.KUD7QO-4Z?$QTF@"FJ^*D _1N@/57- /63K%0))9ZB/PT.<6J.Q
M:D+$J:(S]XR>7,6."Z" PG[6C6@^-;!<(:Z%KT</1U.OX&_P]1Q-I_Q"W04'
M2(&_\%V%Z*\=:@WZH7H$\PW6W+2"JX+I=2I]#_#3 )2Y_Q5065;X:=>_P(W8
M8>HEB_[-+19Q6'8-'"C5\/U7^">X#Z9,L/@J$XR!9ODNR NRZ@14&KJ6 Y,:
MW(@5],T\?B+@IL! A&A!QX>R%W*MZ@\OJ#U/AQ<XT^$%1_[\#'9O"2-3/GRH
MTHQPZ50C7))&N#2J$2[;%\?%&)&1&27O9YH*HPII5J\00.X[#^A_IBU,R#*:
M938+!#T*RT0DWCXON<U=/A"$;DYD(.L5,?6S!%@U%:38J2#%+HC99!#(ECNC
MHH-!?%BJ]5'5^JC2=BIMP1I!9B9\?]K#)_1,S*-]Q5_S>VZ9,Z3]'M<+/\1;
M>:REK8ZQ0;)9^O0Z27UZJ3OE=PIZ-Q/H67K39K-KEDC_[,<!U0.=0!W#13@C
M$SN*:&;<8CU,ZH<6/M1FWCD,M S%8L_4KBR@UG8E?AUI:5WBIN398IW/^R!T
MANK-' DM+ZOES)O.9;>>S[GNAU(]0>M06Q/@$I/8+BXDV$YS)_-/^;*?I:ZW
MTT@M]/F:O7R0EUV>,B%/22M(!8^=2L'RX=5:P=1:_\$266<;8$I061%J'4EQ
M>M6/&IAQR.0/IT918?..0GX+CI%)S)K84E\7NUL)VL>=8C"#@LH3@]AR(DKM
MKJBTEXPE*&H*4IHY&>D$(C%0X&=355D"-^<@9F*:-HA=5ZPWEDP>RS $96_I
MEX.XYT<_[&92FF)GV>BX4J;8%./8)ZD)_Z<S3V?JW8L" . X>V))\P@ L4X4
M1+N;4%?^?@QJ#HCL8E>7V)";HMS>)H J92;4YI;V]WCI(/=ZNVCII,7;6W*1
ME%X<W\UBSX*C_SS()F\B_%SDSU*JCG4YAHCE#4?.<<V#*6]?T!JLO'UY=\*;
M%G%2$8@K?-+B9F[I96Q2Q;I3<KEP<T=#-;KI\]BL+]1D>BEJ)AJE3I=GGZJX
M6/!<*W',8EF;P=(-0EE6#MC$050,E /ZO51)@WS\MBIGVE=5PU_TW:!.'LO?
M/?S+$^V -29AN=A<PT _*)D-6@OP#];SZM:E>N&C:<[?R&CL+DPD7CV:IMO<
M1*:9@1I7CB=M\HB-V GZ?)>-V%DW8:<6F[ S-V"'MN#X%:5.54^:2SWIPFRW
M5)YJ_#OQ@C5)R;I4;M=%\$%U*F58>KZT_YO6NBY=?Q>?<YD:T]M4,*ZD<?JJ
MSS1D+Z""&%[K5[NFY,_$&M!]0$$C=Q3DS4L9L+9)U? 2%/UG)I"8.<9/^W&,
MBAK%9_X"=Z I)]1%;E!%%WK@4[\\P8FW5U7W9MUK&/_TDJ+, M=ZA2[SG+N\
M)$SNN9&[)\^U[,F<R[W9JH(NCN1LUL5V9\EVJ[2XC%W*YT"?E=6^V8FDL!+@
M=## .4J8;KT9!7YB743R2!GM0$1POJ@H2Y+8ZJZO>]H#(6DR*"3->CU7(<DW
MKY_6V-%J@;F<A.B/#GF>YIH6TOJ\U9DLD=/D>J3Y8?=K);&)(]4;+;'56;+7
ME>&*DX(-SUK\HG#%$1R7,KR./FKSA]_\34M.+(M72E);E!3.JZ08YED%+,-1
M?<FNK7Q+I\KM,'H8JC8Y]"<6XDT%&(9@;D>A7%&4;4C%%'CD$SSQ:>3 YV]]
MXCCPA="_H\L"TMP7-NM-"'"P 'F]X\!B;U+1=B,5NN^(C4F)M)X:WM<<R1TN
M\9W!CNR&O;&^O@71R38=&8RAFQ/VAFB]?M3=>;O>5A;E<3KFG-M*]B7NVFQ9
M2SJYP:!>:HGU+G^^;O%)K$5,KI8("4+SYI'"'R+S#QHVY$()B[8;HLP[[EA@
M0IFJY?5=2MQ% 2L:*7;ND>8B-*=T^NVE&1O</#UY+SQX.JEJ9.E,VKU35+!^
MWP;=:V0/(_#649U/=.=O!7)GZ&:V#C'&<,P%2[?0G&3FZ!*:W9>9#=J4E+)V
M@.'NCW)-$45:;SIV/J47YZ^U3-CEG;)>:G][=W9HYB@IIS\R!Y<N&3F;A?H2
M#?7E'#O?WP-=\[>GVTDE]J>+<F+E>$6]75GJ'*12QDH .4T&CLMVV<2>P&5&
M/MX/^"FI5FXO&LYVTQ38E--/M&2]*7 #'9(;H?)0(:?^P'S 3K >TS+3IH5D
MFA92-M<5\C)=$:NRVPOAVDTW9U-N%-C-N8^RE;MYSB);"HV1UU_T;BI;:]MP
M6>J[RZ,)-Y:WP+*8V4K3Y?VW;:7#1/\MENGHS^ DF2ZM5/'WBR3M_@L6+]*Z
M1[':V+&;C1U%K^>(2C9C+94]IX:]VW012(;>R&TBAFKC!S^G+7GC1Z8.++HN
M8?O[Q3L;-U>Z$Q%W7YK^7G#RP]/'H\CB$59;2E:MB$TYO6MJ=$-$W"$:P *?
MATA(Y\K22YI.HR&V-QN*7TZ;2*Y85]C!.A8;BI(LB5TEGPZVW11F!?U*P@""
M)_SOD^?H)MTX75K%5FER-JWM.(VNR$U'[O;!<4>1Q6:KR>4]:)Z"DP6-$#6T
MY=:6@[QWF2W=5)[6+6;>%YFZ#<]X!4?<@B&Z!\=@N.I-L2MOTTBQ7Y*5$9F-
M.D6FW!6;*=H562P3]OL4(Z:'.H65+,VU+*7C!>G@N%NO@\'BLSBJ'+': J\R
M. (=L&"9^TQ8M6 (8_MGJ:T(]\+_4T?CGX4S_XX/Y-&SR=Y(&VX]#GX67"!$
M>S6 *8+[!(=>':=CC@:Z-VU1D?AL^LK92\P=O0KN])#%KI35"=^-=9M.F&:E
MIW(GXI2.U$U0L[+8:%>"E#-B6[B."IS$;1H6>#!?=S89J[H6EJ7X'J05K4G=
M/TF[)PZQ7PC>WO7Z?=N#M]#_DNAE7CKV:!\<RXK8EOCLHBU6[G)$<P<BM;8H
MR>6E0;9?OOCUYO*T=[<OTK.!N]'%>C]14:K$1'JD*9B#D,56O;P^Y7+MRZ6)
MMW7Z"WDG7ER"TMN &["&498J>U( :G%B4KTNRHRE^C)V#^WC]J[R;I*W[/-3
M:#5DL]L0NYT<FXGV?5]FGMIA6\HI2+EZ0TDU:(CU19F96A+.(L5^0J38C]NR
MZ;3[I^0-]T^Q5L%<+K8:^6-K3=DP_7O?+W=6?;G$%]=J 0 EU2?&)G6/=P9'
M[-7_<7@H7.C$T#X+=^H */Q ?G@$E.!GH=7]64#E"'^4A,/#X(N4Z_SO1@@?
M!4>2(_"$KV_AS]99@NU*1N/U?,O1,X>-B\/H\<.#_RP\3L9PYIZM/NG]GX4;
M,!\^<FXL1(.L1+_U*?P:Q1"M)@UQLPQ73S91OQ_ZVVH^@T)%K$?A;27 BSB-
M8L?_=7".6<GRDI='X<6#S*CYOB5AU_7)EZ.1=TH,0S@-UDW1>':'>%D*Z8WE
MPKM<2^AYFH[%^Q>Z":Z2KAH"O<FE3;K"AT#7$NWCKLF[FLTR='"0 9[UG@"]
M\&+[3'?ZAN5X=G*W1A>G]95Z;*EU)#R<?[D^OWD4+F\N;N^O>X^7MS<A'MCJ
MK]@M*+>>/:NZM*:]4,*')Q(N#=/("S$L6IPJU@ :#UT9(#:]VW @2, NEK%M
M:5X?^-\=JJZ@C^#O+X1^?4A4PQW2#P<?TE]T=X)?TE3=GM#?/!'R+/15US7(
M1T&U\:5.W]:?Z&(, 24/;*1PY]F.IYIN#83PU-)HZPT-C!ZM,?"PW*F+PK_T
MXX _A2F#@@]T+ JO)#@@SB*?;[O98*O=?*2%SAY&6Z]@U1UB+DH*2-<3L6^?
M?4C0/PM@2T[4QWK-E.;!L?MJQ4(KP9X^<$8])WCT9T'_*#ST+4 6Q:T.?[U6
M'5=W=>>HAGU+P2^#+X3M2$[8C002=*';CBM@4(-3V1UOC#S;5H!G\<\H2"$Q
M!0/>?B3@8_NX>LXE_:$)0=A@ N<"3V>V7'#^K34=U\KU/9SR"P@?6\8$E(@)
MRA0(K#\!=8GC/S:$?0JO;O8-#QB$=EF%C"<BV*?7CP("A\>&O]Z3PT=5-Q/A
M/TK^0&WV"7@C//SO8&VB!3SJBX.M0QSJXRH"U.N0F+A,$?E>0Q:AHI$*,?$#
M.K4(:E2,;\$(Z58?^!:XQH"?W^A ]>#IP-$#"P3I%<7F&<B!*_LPS)#K/].4
M'OVS]/,,<9Z)^2W\HB:HVD@W@?PH^2^^4,,1;!!;K1:_QISBVW]WM -.[?=Q
M@"N>"JBI]W42<I1#ILRY1+AE$.Z GQ!M_L<0-V,;Y,Z>U%#G $[AB( 6_)I&
M "4(.;P.^2 B$>&[?! '>!KZ,9L,/$/%O1B"ZKE#RT8U].&46GA*L=_QF6#4
MX0,G.I)*[P-?T:689V2LVG0.!S92]09@,SV#:D'\8CJ)@0\FO^R::( NDP3O
MNK LC6+\S/8&0B]"'^"&X'6K6/LCRA8H*PM8)\!;6H1=JR;XQI0)1Q:H)2O0
M(>2%9HC(C$=!DU(]B&X_W3+JTPWD9*Y@LA:L??B A9,?!?03B#$Y$OX@E,2F
M!9^U!ZJI_^.O(QT0:V"KXR&H<R 7'/@(&&3&/4,56!2,!4C%8  ?0 [VR6R#
ME0*O*P!WRK<AFZ/)(&I_.(5?I6LR(>8:H03A9S7=!EGW5:89<+O_&]U\L8P7
M?(?J@(I"E.&GPC9.>!H!"1X%IA-.,9JB\4@XQ[?.\#&3\4!8-916=TAF':1A
M ^E4LR/-7P$E0^%YZG+JIF^&D">0W"^J;DPA"\FE!3P/R@;!PH?VASIYKLT*
M6M&R.?"0PY'ZG02,TM<Q"2$,K5>D9XA#7 L*3^@'.(9/8I[+<:C S[CA2%CC
M6DX=Y![8T+]F[<"+;N7E[(0GD^"74P?SL%__"Q_TEY2VVWBCQ\];X9;O)U'4
M"<M11PU2[0[0I&LD:"D[/;\]BJ=D&'#\%KNYHRDB>O@<*'.\1\W#.?5M;K2C
M-67CYMELP2_N0$U8@2KDU\GZ#MI^?4?U_33^AO[G^SEQ^BF1>W'<1\M5C7+%
M?Y?+-><BB=TW%:_,+<AU:?M[W/O YTUW68O%E2VQ(0$!FNO' VZ_?8\=U,IE
MH;9S<"RU.V(W1:$1'WA->Y^IK+G/Y..T!<W?VXR'NE0\E6Y#E%)TS:5&+%/U
M5:=6D&8<6);FH!73N*_2*4Z]([9NG[\@JGJF!J'0BP[!]P/:Y#0<U:R#5NJ(
MC8XL=E/LX:OFP>9E.[+2#<M66UU12C'U_MT1+:UA:FY8:+/WB"O(QF7E=9GJ
M*/BO*,GK^RJY&&V\: R/I+@YE.M'M)KEBXWS!/RDW2Y+S3/9*7H("+K2CC]M
M8J.RV&U(8J.>M1%P5^C*8!XV1A<XV5VQK;"+JK1*N;5&*;-(Z@RZ<6-"-ZE<
M*))85UAJS5NEP$HAT/H/EL@M%3!Y L.B<?9_.LLC1@J@IC?+W!KK8!6%0U2[
M/P27[6QVN* Q+)VNP@F$2D-LMOGLK<MDP?/"81LG9F'&1^[RBL4,_6-Y81&3
MKRU);-?Y7!*7P<'("X-T#%ZG"W%8I[S!''EKZP>_;LS4,)SZ3FB%!O?:^H$8
MN"\(:'L='FH3RK9P:9#8K4/XT.5S$ELF/9T5>[BG&-?,M]F=P9 V]&J_K] K
M*^5E:IE;+;'>YFU44<HKFE6JM#=?$KRH1?E-@J:5EDZ5/=X.<=T*<25YSU_\
MD>DXO6-.6C=2<PUT#V2I)3:K"\+RTH)Y4$XIG'*E% XDVY_IR-P],CW%)71"
M9 7\DZ[<I-5$#T=J-L1&NZ"5HOM+K2RIH^VHU:*#5I2NV&Q7FWU+3%%M1RVL
MM 2YHCY[1:VRDF';T:J#EZO-CB0"H^S:D&X= %:7=14P3%W6Q?ET3:O"!B.X
M5F4N;LX?A=N[\_O>X^7-%^'RYO3V^ESX<'7[\+!V'!RSLZ6*]QS]U;BXGR*=
MSNRB-])NM\7N%C5;>SD ;/6HOGP\QF0J80?^?Q\<KB!7N^Y/Z>N*'7GS6''I
MUF)N!6H=K?+P%[>FE93%=7QOM,K#6]R:4EBY*K:4.@31^4O5PE"_\KK%$\9&
MO?L=T!OU;$=)RM@2:+]/O+:F3[Q1[82NFL.KYO!W<]RJ.3SV"E9Z3P$?)76?
MMAO8P2S*.(2]L3X/QG];KUQOEH5:!5';%MN-]?6)?. U93$ ^')[WQU>&A,U
MJ7PJ;0@YJN[P?;GMR*3?,W9>MEO 40U1:3;$IK2^VZBZI<K+>&2E6QOHIG3$
M3G41G,$R256=6BE&+BNS=ZB2:M5EL=&IVL-W6(6?P5!MV@;;]MM1E+JH2+PV
M+600F4W1U<$>#[ 'K:QKJ8O#56JUO&Z9$(O$+I/4$I6,5E>4.U6#^#Y55E3
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MJ53VU;_J&,C_ZY-ZS +$(%4/\ .55B"Q<$>_W(EG":J[B$E%'6V#[.AV4"X
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MHH".%WAD#L3:MFH8]/(99W[BY3,= C >6SHX>PDBA1D;O!*@GS/4UV?/$%0
MVC;)!("EK1/^,P;3LB/XC"&,K5=BH]>)L3Y]5SARP":'T9^)]/[%\P\3)'4=
MEZ@:S2S3BW5\/#RRKZ(GA+ZKB+XG8F/N]Q!@FIKO!%/'>.JIUL)/:%;?\S]
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M*YDE\7^DT;<L6F!KI(B*V1S4P(R,:9E-Z_VK[^AK; 8B8GUGXYJM')+S54:
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ML:B#$CY:FBG 2B54&%JHM@(B?LM>L"(HAZB88^[P,0Q:!1A"L6NJY'R-=_Q
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M?'78._Z*9^35Q\'9Z<'_ U!+ P04    " "J@'Q:M,S7^$PH  "!]0  '
M &5A,#(S-30X,3 Q97@Q.5]I;6UU8V5L;"YH=&WM7>MOVT:V_RY _\/< +=(
M %EY-.WN)MX 3NQN#:2);^QLT8\C<61-0Y$JA[2C_>OO><V#%.4XW=A)915H
M$DGD/,^<YV_.V?_Y[)?7+X:#_9^/#@[A;X7_[9\=G[T^>K'_D/^&7Q_*S_LO
MWQ[^ID[/?GM]],][L[*HGZG'CY:U.K,+X]0;<ZG>E0M=C/B+D3HUE9W=@Q?A
MU9/V>Y,RSZ[Q\G.UT-6Y+9XI?/31<U6;C_6>SNTY?%79\WE][\71Q[F=V%H]
M_L?^PY,OT=E>72ZIP_#%I*SK<B'?I4.8FJ(VU;T7WQ43MWR^_Q)6#?_O'\9_
M.5W?%_1RO%@TKTR>JU=EM2PK7=NRN)V>9:*W,\LWI\>'1^_4V;N#P^,W_U(G
M;U\?O_KMB_9]4W.B=O??OSAI8'^<4?L/W]\D:?S>N-K.5H$.;Z:7W,P\^=LB
M,]CBH_$/MKCWXFQNG3HNG,U,I<XJG=GB7)V4N9VNAH/[]=RH[_+LCZ9\SM]]
M5]&'!VI9E1?PCE/G#?R5VP+^>6GKN:J,6YIIK>I2U94NG)XBB3ME"X6M3<O%
MHBR4J\OI!U7.5-]Y4&F_K\K%4A>AX^% %QFU-(=_Y#A::&5:%C.+\[(ZAYYF
M9;7@EO2D;&IZ7-I1_O4I?;9^V)=S.YVW'LQ*^&W2.)R:&ZNS^--WE<.QN.'@
M9:FK# =P:"N8=%DY&)93.BN7M<%^8'%YX7 ]8,T69<U=YU874\-]SPPL/@P<
MA^9J#4\X,VTJ6^/H<GWIH"%=X^O,+J>FJC6LY])4#I9V.+B<ETI71NE+_!.&
M [,'FH FB[)8-A,80&M5[LO:_O+FY#CL*"^5EH59J5F%?/.^?8#[2&0!728#
M@VYH6/+\\^&@K.!QZVD#W\ .<.8E+&SEQZMPN N]HG9-MU4FDXEV-G:1C!TW
M(BZJ:[!-@W2(BU>99:ZG!E9$ T69CQ;.%HQBB0];>08&-S594_D9Q WWZ\M3
MY1/AI\ZMYQIW-;8POFFF<!ML.^T,^9YLTFDS^=V?8U@D7O"[P R%M/02SBCT
M /,'8@+BGLTL'#SH(0MG':G"P%DN5V:-G%H<@\A=YZY4F8&3N0">PI3=/AAN
M7C:@[TR  :2K'P8U&@Y< VP*6 QP/*!-'@:<._CHFKS61<W':ZXO@!U,X2S0
M#/ <MD\.#2:9XTPO; [C-(L)39(')A]Q:EI&&9D?#-:9.2IHM [ ?.D$T\C*
M/(>3,EF%U^#K"U/Q=^F,<"YP?*>5G>"/)B\OM_%4G:6B<'>T MFE*L)P(#I"
M1\RV= :@S"6O(@K4IIJ"O#6?? N/"!Y#INIZM20IF8@=.HQ)*\,!GECK7&.(
M1"]118&_NRI-T@0]3/3-O80#<0F?>(AR%$QQKL]%H.+72:,*CI1+Y1TPG@D*
M>V@95)0<-(:R^H#OPA,M=K.%A^:XR"PH$@WH,>] JX0E!_&<VWK;SXH7P?U"
M !@O,G<#7TU%:<S-.?RK!#WO7(?#L0"J(361M=VH(,,"(O5?0TTN07^LF5Q)
M3UL[K?YI/F1,H*B8E@[(V&'+T!$I@6L]C-75TU0+V(5._S;GF29:&1Q4?([%
MV45I6;D'#F-T11HVSG0!*MLR:G-C=:1!BMI(7M!KY2D,IH!G:Z'IF+FF,H$[
MK%AU7[':WA;,;%? <Z0[I])TI**DY&^0'1%[6*&P=J;-5E"'WR#_25I:-VU@
M?45:CGCN/# P!3HCNW&^\)7.R'&!:IF: O>'EG#/JQ:+& YP$[VVA3L);)CX
MLBXZ.]]/L-!<[?Q&DPWBWQG1X:!#PCQ;;):EKNJ.$@ATX3^)P?>6U4AUG_2>
M&3%VVL<';1GEU4K\UBN<*.]< SI>]ZC<A]_HM4OKS .V7/'DP,RPQ4L-RX$:
M(E!< ]8E'R*=7=@IM6]1=T2SL[TT:  J&#8OJ&H*-(A(=D\UGI*.D3I6OY4-
MT.&Z!NL,JG[<[7"P-(7.:V^.(35;:++055A/4A$C*YK)PL ,LF8:[> U99)6
M<./XVJKF<$"KCDNT*&%P0"G:YC))<B\8YC'!#5$X\T=C8 ])'?ZW+7/FM6)
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MGJY!8#V@@^ 6Z%-*+::1S+26Z4"K%-1J.;/0F=;%6[)6,1S <2S/"^"4=,I
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M)TKW%S.BMU-@BDK63I.N"U*D, <?/QL4MQIQ$*S&)]ETE%?TDUYOYQ[EIOL
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M%*>'2]2;44JW7N9+6A?:U>&@E?=C,P=BM6-MJ)(/,<-D4J8]2O+ ,XD:3HF
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M;75C96QL+FAT;<U66V_:,!1^K]3_<!2ITR9QR8465C(D(+"B41I!JJJ/3F+
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M9^_"F_[HGI:COI;HZTAY/]'7F!]02P,$%     @ JH!\6CX$[QDO!P  (BD
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MO%V[*'Q?4?AABWR\,0@%BV4&2!*Z%Q ,$($0QV.]]%QF,1*VS\LR"Y,BPIR
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M"BO;#OH_\0N\Z@.XU8AT^K3I&T?_T2-]&_D_4$L#!!0    ( *J ?%K@JQS
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MF*8^5H0; S*#G5NI)3Z6(OPDH'(*2= ,],Q@,.]41H-5-,;O'N.BW4H![]H
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M=4^%PT0ZEN^.%#QD2:_[89V24@>ZA;TGC"9&4739]?Q"TKR+_D<#TES1';^
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MNO8J@-Q?$K:6)K].,LX-[ELIESQX2-Z>+"/@TLA[5A 9XYAZI'61MU:)@-9
MQIXZ!_;NP.9%DXV0MI>GQ*^BC.HS_.:+*6_51(6%@5:F 2O[X+( +:O<3S 6
M:ROCK-=1EEC>RG ##/[BZ2 UEF++8KS43+T>0CIGW2_SY51$*=^0>#F@X!3)
MCT^8JK@J>..QR_U*-J_'6_"7#L/<%*BJSJ-B5Z-5:OQRT$%[*NRJ*KQI;%TN
MIS6RK/0YL'=-,JO3+$74QH:T6V@7QZ!Z)$6<-X=,=TAH3KB("TTF;NK?8:\;
M (;L+2.#(L\ ^"M6QP77C2M"Y^6[*?%R+C]2J)/)O1-[>Z$HNMQ9]._"JXVV
M:.0[-90&E77+<V[JVLWBC(KR5DF2+8N?#:Y /9@;77EY8-E(XT$0JEOF^5S2
MX[U'_MV(:M ?TRG'H1-4Z6S)P?H#B>:QLUKX[B2F]AKJ:NK#B<6M5[-.O3[(
M2$Z7(S]QYO.8S*L8O=I:0(M$4*)I,ZM719J*R*G4:L+M-X#Q*CJZM@/;4XI3
M-[\JFC^,I:#%A,5M3;D;@2F^=L(&-KT),-;&R%L4;"7)+@)1R+)=6.QB2:J4
M8UDP=J#EHL^)Q36CV=V@%][X5_;CV8RPNQ[9<'3EI'F>?>CZ@9\??D/%SNNS
M8CE0V% 13# ?((.B"J.D_!11*Y/00DR"'A?C5 !-I%5+3F(W04%RD(^U%\K6
M,=(:N@;9P;K\QP&\4UI<C*=GBBG,-CJ"EKQ&LV)91W%M55=9D4ZZ29>,0F<W
M0Y(M,F O52L_L[G;;+,UKRI&BN"I)E\4!7*:DB5T-0=8WLRRZ=62JB&D>T12
MQP^:0A:FX5MB#=%+[00!)P870TLWR?ZV9+R[#45A2E?T<9!7&OCE>5+L7+ O
M*AL&#]:U^H$G<=XWP5U/'GRT=2R@B'?H+.B7L9O=DA?TI_1"Y6];MA5*M@?K
MO#-C7B0?>6$Y4YNKJ[CDAOA1?H!CJ8> (J)-4BG%"Z\Q.<X&)%\TLDJ=.V"J
MM.C$$..?K^P($EF*9.9D03JT&!F8*A?QGCOVYH^_^B2FDU^LS\@="7 W;1%1
M1&M@Q!NW4$PJU2BAEGRRR\E@>SB?]A[MY@H+2K83"##&<M)JL3'(/B\4]G[L
M^)BB5MO^>XGZ-%QE:9*S_/J\X4&!%FL')9M/\D;[6J<DNR!$"R#OHOIF,,&]
M>:R">],2'/RS1Q?5[P83W'>/57#?M00'WR:KD^VZ&8<K1 E5B^_2&G=ZZ0G8
MA>>0;04GZ:$3QVM*/6<-6)AJ-/=B;4*[0C5AQY'Y]2**4Y:<>!#%<73/BLE!
MOXIU4-B'I8DESDY$%3T56$]@C>J045X=4O:V9;:#M)NN8+U4"0@9^N]V1NQX
M%X)GN_;",^C[CEQ0PEXZ8.\I,*(Z6-_0SQ!\<B)*:$*3NN'45%8HP#IB2D\;
M,$N*?H3B#1-1PK,=E%Q?"LHJ7FHUS-"NS@*JX,XLJ:S0I25R7\&)2_&!0D=<
M29S^>>[\%<6;7!;5/8]^69,-_=M6+IQ!+;X/J^]O/$#D'G]=V"^<95[5HT9+
M?2>3H,\?V]+>)=:S"G@!)* OK$)::MM3/P%8V9!ZR@#S>;1CCSP@H;M8.O&7
M88RP)KF16V(M[-#:L^V2K@@/8Y.UR>V?8=:IQ6+IM2$<SD1KD<:WTSKEMV_&
M6F\1(IAM>=@$RSARPO6DRR7.B3=M?6+!::9D^6S".MM3!%\+=2H'^D >C S(
M [27MX)*R80.D,U/]A_(UA317L*NG8 D95KZ!4E1WKVZ:=BKG*1J3S2<X]TX
MH41D5C5DKXA+_#MFD*&(A4O&XB.'B6CX<*'=(\K5N<,MBIQDU/9H(>WZ21L6
MC PVE-6T0^V27HWH#YPY>8UM>=9)V:W9U//=I(&9U:0XNOD6*;-G4<+:AU&3
M8QF%>5DIR<N@B?)T]RG#22X5TS)])V_@!<QQ<VR["JXDJ683W@8P:/??3\2?
M+U+B3>Y(3-?/1<;F4!9"2Z99FK"N/>4#O0LL(#W:5M-YM>6GB2M.S"W5H"+:
MR0EJ&U$R2=/8O\W2/ <_VJUY%\=.."^BI( E#L"0/7M"6P<@X%>X6@$N^[+!
MY8Z6#K/PN=1MQJE!K7P^M*6(OX.^!W1R/H15,*8UR@&IE,GWP,NN3:U4"F2A
M5%1&9@)QP2J%\X/,&,(R\INM=_DFO>FA78Z.UYRMDX3Y1K,9[LJY/W=2$OM.
M &\Y=-&PM]&(I-2T 3JQP4JHVY#[%,5?3L/+.'()^,6*0\3F*:TMCA8^:$DX
M&X*L=5Y"=Y /4>2A":1)9%0":>&#]J109PQQ6QT7^#D6*G8HYK&JW,:;>^*:
MZ(.H,;.%[MW]^P77QRZQ0^6_HF'O+-818;,I<"=6:+ZVG*WM.Q"K;(TC( &A
M\4E)A!K:L:W0KGW 3:$F/'N'"LPJXT"I<MRC'CV<-O72&YZA=G&ZD>\\>V$W
M=3]KE!7L5R.4WV,=(>5+F2S>FN%F@:F+M[L*J Q(@/PP[4CQ*^:3!DJ+V(Z%
M=!HI!QCK*F\5'UY# [Z"W8: >KR&"N#U>@RVLA]VM*@!J$: 8P\\05(;VHA:
MRF10P5,I\A;T%$/+&U6AN <)5B:[BA:H*I77@"T3M!Q3%8JVZZQI:+J2++62
M3Y'$")[8H"A(BWD->&+$3 L[=\)L1N]6&:N3<>*X19MAC%!.$26;[DR-3:DN
M-R%P:$Z>@\P/V+O^Z7(51W=%& >*M 2$;#IYC$0E @UK74UG,]\E&P919-1-
M8W3BX4"EZ+0QB8E.Z! N R9_HYO'),%91$)2=N,E#&4E!D_ZQF,BKS,G]%"D
M4QO8LNO32!1U7( #BO(T=@K",EN">0F:XUD!G./ZV-2D:,X8.HBBJ WP  MJ
M8[R]!+4Y8ZSCEKN&/B9DE@5G_@S:1:Q"<3^W%:&?6 E(G*J&7-(?8OCT#0FQ
MQR2Y$CZ<)(")ZV;++'!2XAV154S<HOLB_7- <LA";[)D[<:^YC_G,@DL7C"V
M]O)F*M0#.(E@6>!<DO!!4T)2>VJ!FZWRO0BR.F7OVW/_-B!8 54LD"\E9_X=
M\=K$=G"#*EVM0M+P<K-UY@NHX+YP2PD/7^A41\C=C]QR-"V5014P=K NJF,$
M3J)<(A!&C7<HV^Q79+XT&E79=7!&[!/'9V/+!"N-@M-O2).ZY>)>!FM#4>3=
M6..TE-/C K[MD(G,K18$&U;LF(]I1ZR#![7/O!OB+L(HB.;K*Y:NB>-=EE&S
M]Q!@N.O5I2J%$J=>2EFEY8H$^>4H6?@KI*<! 26KC3/ZBTX((HX7XB)BU2Q6
M)"63>4P0GT4%A$:]W$0 2MT P,<DAKM/2FY/UYSPNB/'<&@+I^9[JON8AA,F
MCP&K_EP$^7*!1NNNR^<%WFLG(?;8A%EWW=G*4:D*"5XZ:W:E=D*/_H12WB1,
MRG)5^A1[+(E.-D1KW9VJ!$V<9$D3#GI6MBQ)W<2.AY1!*:)D\YSK(>ZNFI>=
M0*(6)2TIUA.'<477H/3X1-<$$B6-H&23$J13#6Z<!X*482D@9.]F "<V+HAH
MI10JHG$T(PGS(CG!"<&6'H>858L#6(@\/+$*A14)N3R.@>4H(?88Y"C#4R$6
ML,]Z+.J&XF^D'70>@_0$**H4'D.VLNU9UY:#,7#L&S'4I;S?"EVA6/>](W*;
MYO6IB%<6CR<>O?1=QG[H^BLGN"*KHF"H[.)G]DYRFY[F@>2890EX5$Q;;QPX
MX1<VI@F(1R1U_* KDH/3M .,V/#1&Q+I;OI\P.'9/Y:COQ9?$8\L5WE$'8G]
MR$.(X% @B)4M+HW:0%DAS0=!.=HJ<1SPDD8)W5 BB9_P*HC64%=_=3&B1F:H
MD 8/QU"5H]4(##Q1XD9;B.A/0YS.0:I4+382TMFNU 5: Q2XA(H:_9O[R()
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M9RU^/ :+[KR>K):!]6@O,Z]&NAK,=?Y)XZ$U JWZ*][:+1[F1V?)M-A^LF1
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MCQ](R.K;L!<";TEQ8DY.%@6+(R\9M?$)38J?RINYV399A?-4;9N@=\6=\??
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MDXS>*[#:,?,I]>C;4P[ZB5Z>R%%T#WU<=Q"P7<!>*K!F1?I=@-02]6&5N.'
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M("2MYH9&J,IHXQQ6@P,B5 )2YY*#=?U?$.(G- A;CJG04>CZ5J8#K4+0!8"
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MP'>GLQEAW3B 9:5.=QR;HP:."CG5?'_WSR\9:=;YE&T^_Q]02P,$%     @
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M+5?)\S)N#D;N;?*V8I,>,T S.,MOGM54JIM\=S'<.KZ7ISH:A=XL?8!QK=)
M3QI7AK+A.TL)UABK,>\!%"FDR*4EZ07D'>0Y]0=D+RI H8I)V4E3OM7D$;*
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M@1MDIV_@I(#T W!'\CODE[\K"B\BPTI(# R]1,S8WTJ%!B]T(:*\%.K;[W_
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MV7"RG+!$4D46=6QJ!:APC28"QO<P6L?.]@%7:])4D(K=MY$;>"X+##A4/QM
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MDI4+R*V>J[QMR)V"! /LLKQSXG2_C)TP0<CL\9JKE9S1&]4V;IAAA:09(.U
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M(&$VW"BSHGX[1[T>U'W%02=BX?Z-RHCJ;;,--S977#6W-7NHBK=CZ'"!4[_
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M'2XF&+K!SL..8>9%<YY0_BB4@?$@3Q,IT\]"];#-#;,!ARJ!6=!"WC_Z?48
M?^!(A3H8?TBH%TCE\T.-LZ_R\K0@CWHF#ULR_^E5$:[9UQ+10,[8H4$SXZT+
M99N3*(-JR^#9Y[A<] &KL60TR4)Q8SF$*34B[V[PSW-<"R!:[9(L.AT1K_^]
MB&':"RT<?=1,NGOTLLY*25 ^20SPYR#&_9U&JU/48_8&A2R-Z.BSH.C6DA^Y
M'Q"5BT3OK*N> "A5*TG>(,T&/Y.,A2R5+%Z$*I*> "<E;R=.P.M7)Z_.SLOJ
M[V0[N(_2!X D"W%A$?#J_ 3@J2#P1O]X9=6OT";JEF*FASGJ$LP9A>4RSYP8
M_90#8]/1:+R+0X[)#DMCI@\(/H6-0')!63Y$\J5V=&CDC+6G];X4.->SN:+=
MFM5%@&_-<*-OOB!9='B)]][Q0_R:?A92H@_[BF,5)*K3?!)?X6+,,98[;@BB
M$)\CME&"CN #CUZ5$W^M+J#X-"F#DZS<TG75WQ[#IF-ECV&RP_)41N$I2202
MXSJX7]_#$*[\]!O*TV,+"&N58154_)&KWXNP7KO,D7WG/^(#J_Z[LG:2NCSB
MXL@288MI/#L>/'A"XO)[V]<LXK(5>P%U-!/JX2=-$MC]'J(&)A[L56E9.)IQ
M&6)>W&5?[&VG01&2'!]-QZ/M=JM_U/E=#+>.[UW!%8SCTL6&_0I8?_:20D61
MB4$@3X139A 4:7HX/1#W%CE0N+N8[+?'J5<&@5<9A/"!+#QY6A%..K_,9M@0
MGBDDA[!!-]GB>AH:B8 & DBV0%N>V-.'WR$H-+_)6$8C%YU28FCL\:8X87U!
MR>+($V>/I2H14P].(O=@TTK0J#0":M&C<O.DF 5B#K>U&S?-6&QT;U[3';/
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M]P(2#B'32&&SPLVG=<AS:3GC3+O,&MLN>[2=:JK2LQWUO\E*D3:^H<IPQ[0
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M'@[MQT-1U?>W3I+ZJ2\CPJ,F9C5ZG3@S_CG[: A+DS[!I2 IX^GP2CP(,FL
MKOL+)V00,7_:HC,B9]#9>!'.%5+M/3A[@(J'<!+"BHLNQNE^&3MAXI!74\G%
MOOJ7T9.O.T>V!&'M0 HX&!+GBYFHB'Q&WF22)(/9C[B9CX]_N*GM=^+R4J^B
M4'**))&)7X&0PPM&^,*%H1/[D2@ 6][IT/OMP<*D(8S) -/RR#YI0,;P>QVN
M,(IW.^R!*>>@KEXT]:" * 0, 8'- :\>_.%+B@ZQ']C 4A:,0:K7Q][=)_"W
M'>IKC+W12]2D!W"PJ!A&"(,-]A5C_C4@GP/\_3%8;'B2^2*K^9,Y U:'3*&;
M+@,G268KXK3N S1,.OKOJ;BH8?'!>IJ%/P/1"F2W$ , 3)O ZE<0O-&JYJ7/
M._O%P47*TUE,W@SV@!DV';.88?+1AIF\!8AB0-K8M%:$A5=[S,<=N7JE\+Q\
MS&B7/D2QW\L9BD'$Z'F)S@._,"VN'/377>PGGI\E'!D 9O@"HU:N:HY8]N)S
M[_W[<G^/W1KN#G=$<G8ZH;,F"NTNCER8)#"YCF)<?"-)<(HE#_W%7^W1/T>A
M1SY&_\1/%YPT6<*G] +1^B1RD;KW\DO4O5>Y0.V/)8/!&OV-@J4.J\2R9+('
M<J"D!U9(39843T"%Y@EQ&!1D04X7_!-3!H2T)9]E_R E%]#]2DSOPEP^^''F
MY!B':_0[[SIPUGTM.3HQ<\Y5%?:45@GIB?C)]B#O"_P3]V;MI-L%!@*@9D^=
MPMT-@Q82J^\$P7Y$ZMI!#]DWT$FBT+D/]C?^)QCLE]'Q5W.X]M&!'5E#O>TG
MNM@R%^33ZSADUDO1&2AH$M.[I HRLB"-FM^" VG6QC*$]:49LYR5J%-\\I=T
MO3#5QU:D@:/GO5!E]S1=:[2Q^SWWQ2FX0VJ2EJ8E>1$YL3=;7?DQ(A/%R>P1
M_1U["7K:'@7HV3Y+M;,HOEQ(7]B55/8&RNX8VY3M92"."";(!6=0LT<A2GQR
M53N++Z/-QD]3B(O2)%OT*_\^@'V>8X1H#^98(\*MFB^@Z!AO"8>N0:7O8[UO
M&^UJ^!$YU8M.LK[SD"CI_CUIP@P\FS71T4DFLC &N1MT0)6&14([A>A<*>,G
M7&#<3^!L=?BER94BSL!@5HHPRTHKI>P=&TV5WS^GE2*-*H&5(C?K'5*,73K)
MP_75Y'(2XG+"WFB#7T_IOABFTC!>8X_&!>N9#/1@[ 3 @UNLLH"/V^ "\<"-
MXFV4%]H+?*3"$MNQ2UP)UFZ'F1.@'I1]%T<8J'O\C#8=A5Y9^&+A!(\(MJ0^
M[!V,<2T_]*-F8,E2-Q_&+<DAJP!8DL 4@Q$=L'P2@KLMF]B&GR("JL!4F23%
M4,SW4>1]]H-@LMDZ?HQIW$2)[E@&!A'SZ*,SP@!9\3$NX)1_G5@-8^#+J@H@
MSC@5<7+H:;:ZB<+UC?^(-"9>ALF/,/"NH_A#HEN;B=$TCR(AOEA1,F5;;. A
M]16M0_]WZ-D,R9.2;2U:1G@B%%$W"LC?H;=X<&)XX230PR5389@0@P,;A:%V
MV D2M5'\28PU7AZ*TWO<"+B55G8K9DI)^.B]E.A<*$<7C\+4]_Q@ER)@+[)S
MB0^3\9,;[#SH7:.18)*[E%"<K<9.'.*R?VAK)DSU<GC0PY/Y$J\ZV&:9@ZCO
MTZ)SX)!/$<B_]D- &B??V$VWHA5&M36@;5([G)@G(0[GC^+]+X@\O(H^A]I#
M81L$;"C?)AO,2-C\0_ 9?XDV^I7E\%>6@.JAK]3A*>M.YB'FRD^V4>($ND\9
M @2-:[UVGA@8*AJ>@"UN>E0%U"M:V]5KXB(6.MW6YZ2#1KKV<58F8HU.T DY
M7&,/(;%+D3VZV@4W_DJWT2A$TK2'3X0II@XKO@<.<;:@735.\4GE!.Q(8Q"@
M?A.;YQ89,5<!*#PM78H$K& <HRW8#[&7]#)*TN1RAWX3IE.HVR)L(68EQ3>/
M(]Y+V!5I@8P4RZ_HQ018?PS;.F;5!T?C!/']^2KSO6L&3[UO&W95C0,&-K)O
M@..29'96K2FJ,*I :(Y'O21Q%*Z7,-[@I7'P]UY )T8KY-I_(@H,(JFD<W02
MUHP,2>*F-S<Y]ABXRC\'?OXI_1[! LK4)%^KEBP_/XJ9X8I^[IP]<9)CJG4L
M,G)+41N:SOM+8X)M%.4HR;\] >@7&ZLI?WF37^:=8HY12P*/IKPU)_"HX,)F
MJ1(.,D@!@-Q$)LZ6(V183^%Q#(N6$6JJ=Y-5#O#=''>X^^3""8(H"HM?11?P
MSO&]7O$CP8;=^FWBC++VL^QCL$5*WO6W3E"HJN$@41X3;+Q*SE>'L Z<X0M/
M:(HVSUNTS/&;/E(/ZT-8GHPQ;U=^0DS47ES_JEQ8. $JLLI*\9AW #S4PK+/
MJQL2:HZP#G.D>I2\*Q1#UM=LER:I$WJ(@5E(2&?1==X(EP3(+A00$]H]M4I,
M6/#>JO#)RDEY:%U1S_=.@+T%MOVX74!1]^TJSU@'?^^-'\+9ZC*&GG;W2*UK
M\Z$F5?(LTQ-G*8]6P"4?V=SG:6*HG4B/!Z/E]''MN/U<M#/)6"XS?>"$>7<T
M6..O*2RV<7<TSDYEHV/_T<&7Y'W[S'B4S&L/#C=M'HX5;@!B]*5=\+0*KHX?
M_G@5]0U)4 .]!,=33))DAS?L+."M\*_IO\EN(VCC)KN%)_9--FD(L&B!GS?%
M.U: # ++USSBHCVZP1:9"]4L_=A06D8DR'N.G4E"OM1&(Z,%-(^I\]QD:00>
M\8> O!JQ5U>%-<VEUY0Z*&7/V'5QLSF'+D1JZCX@9[U)F.>_TA^0P"=G?CMJ
M8XE9HH=<J!)U@6OS//I>)5[:BMH0E>51U$'[Z%6*<V%]LX#QHX\OG1]AC,Y7
MXFJ#V=A\(6<:&ZQ0@<7EL?:P</72-O&UPKK,T?429/(^UO^*IY6<#0.7SQ(O
MTJ2T1%S<RJZ5*R9'P6B3P\A5W_J$;@R=!%[![+^3<.2Z\:YB4)<:3'\PDR1Q
MT_<U<NPQ\+<DQ:*=K&$>KV[U 9"2P(_RYLI.2X?"1UD44'+G['&'H]#+B=WX
MSKT?D!CX?"V@OTW1^+,?-"-5F0W3F%5EE/7:(N\.>Y<<$B :>B688?;LQG)@
M<E>$U-Y8=)D]=9"36E"%EJ\^;!KA7.99_H.D8&%_V0O"U7BP$:BAQ"G3.LBZ
M83R2LP+H3FBHHEE]HCJ$A'"I_>*G#Y/0\]&Q;N<$."?#Z+,3>\E[G.X/>KWE
M2M#&ECVSMROK,@L ..L89KEHG##<D:O+!(+$"9QX/YBP2=U8HYG<6F9=Y:!_
MZ6Q]9#B2EZV>G^X0MHJL44<W](S#/K<#X[5X>=RP<B=E33(K(V^#49HULNH,
M$!%.Z1!H';I2>=X[))\'M"BC5?F63P@6M'9FW3\4#EBW"?F7^/[ +[ZUYT/F
M3'DI;-;@%*.M,Z"0?3HOR;B,\.^0?O&=X-8)=RO'Q9 24PG"O1F]3Q!FBZ4H
M#NU!4:4SC8BJR+H FT,?%NL%2POSH$*D9D@] P(ZSL]6-^B(I_OT?.C80GCB
M@3KKD(L^(!5= NS.R%()_+9S8@BN(4R_L>FM:8JD=ERMCTPU3O &5V2!,V37
MD>C$&SP+^')SMKJ,PC1&T-(=:-5.T/B==SM/K'M. IKCMR$V0K*$Q5@+U!(;
M=Y>(/0J%.0SA9R?HX35)&S7C3]?X_#"+3Y,OCF$U$%11I-<&J>,A*QI$&3+'
M3RDZE)$T)Z1S(>N'T=3<B9[#!>ON 'V,C5]8?$XB:7 #J\<?OA!*JX4SU [:
MI'C6=AW%<_U>T./>K;RFJ+' LED\CV231CH">^T:T9^6WDM095-_!]$<G:K=
MLG "F->)G>XV]S!&/Y 44#A."U]'58K::\:)%&GCMHP,=YQ#%=(W":DDG)#&
M((D"R[$X*A*OU1B6G9@>'&6/,+Z/],KOC"+ !1)6(3AZ<K3_" F>J09&D%[O
MCS,-9K3R@K&_0^]#Z,&8<#/;XK_C/$?)^ D?S!-X%_LNG&.?<?5M#/DN^07B
M&C'0&V4A0K4F%W#MASAYVT7V8.A<M_(:TM L[+!#&C]#_19] "?K!+\B<S/7
MQ%44!$Z<X&N8;'W;7],#FD^JSA@0?YT,GOJ;F4SCE0^ M%^9\FA9?A9UQ [K
M@4L1]8>#5A*T<537SS?6DTX)R)+]8(HV ZIO$*XAVCY#=)S 1?CRZRJ\(D:A
M=X.+\\U6J^0X]H]QR!;LROC]HQA?3 _?V@E.BH14^$TO!E2$HRO "I<VRJ+Z
M&.@R?3J7DV9Y6I>8H2[GM>SN,\$.@01UC:GV<#2C4;$1JL3@A96T&W^=77%G
MG[/TE26[G2.[8Q.=-6CMWC;!TQ2#'^K!Z5@*7\+$GW6(3J2;3Y5HF(O]X9/<
MOT/"8<9/6S^K%I3E;C%RC%'ARXIJT,4]KP( B(B)BF-H\C;XV( :6<:T;D2U
M6_NJ$ZM\F4ZO5-!DX^*8C?Q441PCT*:<L4,>$DS"%)E\B>^2EXI]+*B^6;9U
MWN]Y7.PW]ME'^3/8:)4OR02MR:Q7;TBG$I.H;2Q:$R)2MEU5M4K.8,5M<.0O
MF,.-XV,707'?OLNN25\.9;OL,(+!./=Z'::H#R\N.@"!OZKI@NA = @*P [.
MM6SB':5H2SWD^@L_.A+DU\RE0+\C>(;J06&8ZNHA?8#'Y@(F_$R-]^Y0UZDA
M5 7924-TL'#(TY+2O!F8Y7_$G+7SM+8A"!RJ$[#.7OL,8<?6#BR=QCEE:JT=
MJ^N\D)^NG!0.^EPMQK/IP%8CHY)9AT.^'3>%V/Z6+4] ZK[E\68;1'L(\XPY
M=):G4?@($[Q!DT>6Y&A?_3M.B#*-TH\09Y[(:^Q6+O)U7S"9X=GT<C8R*LEJ
MM=7G7&$4GF:T\Z#$8O4/R'MF%,VU,D3&A#? I9[I)Q)03'Z%O]-].C;,O(6#
ML=D1MIR)3\NPMP'<5MD!KI'ES9:-ZC$WBQLG:N,*IT> H9=DD7::5R2'D.FM
MD\T**^E&_E4>GVWS@6F[O*I ;!EIAQ@#W.4<;O/G\][5#E<NR^#9"WP$")I_
MMM'*$\M^PG\D=0$JKS:LGWN$15H[M(C-08<'9*4R):;-YQ!)Y<'?XFC?\6)V
M=^0++/(YD&#>XJE!\4O=7CB=G-FT(+JS+_(HJ8"(1&C\G_^_TU/PSU]N?W[]
MKW_^W=WNGCZ&W[_S?G_SN/ZX#S]<[3Z_?Q._>_/3RU\_+/=)\.;1_?TL^&OZ
M(EW O_[^YM6GIW/W)CW[Q_7UR\5/+QZ?+BX_GCUZB_C^X\O]C[/?//@_]^G;
MZ4.8_/KI]O,D_.7W3[[S\:^;^/W%W]^-IC_>_S9]_9/K[:=O7J1!]#]O?_=3
M]^(?L^T_O.^O?_ET]?#Q]6)R-W\W<7[\M'7?WUU%-ZN_O7ORIK??+=)/+]/O
MIC]]_.7%[&7XZ1_QFYO;'S\\_3K^\,9#9!_25\GHU[N/RS=G'Z?O_O%Z.IMN
M+RXOWF\_?+<.QI]^_=&[O;]WMC].%Q?KUU?O/[Q^/?KNP\VOP9N__<_M[=E?
M_W'YXOJGA^1LG_[C<KY*%_[-[S?+R^V;]?(?/[V.+ZYO7M_^/5A__/T?[Q]?
M/-V-WOSCY4^+_WGW_E_@<C$_/;6R:?6PA*GFEB8@J]I2HTJ-P=FJS"E-\K^.
M0J^H%*5[:Q0F:R.7AR!OK%>SE>9XO_0XR8$M;9NR0J_E Y&9'>4"U:L5=''=
MC4F(S VX=)YPS0U\@$#$ I\01[_,2O\D) >A[GU2@0/C[C1Y'IEU%)($^*07
M< ]7$;+T\I]2YPDF)_7"+79.R.J0J.E=Q3GKGE4=]3I*$H@Z+9-6H%F_=.)X
MCR:<G*?1T7FQN_\5,;B,#I&BFI'=G1\+.KDSTPS@3V$*HJ(K$.!EX%8[ V&4
M9I'- TE$V1E%M R4W695_:6A,/5!K0KFDACJBM"X'(Z6PK 7@OY5P%D"*BN@
MW&BJ1*Y@XL;^M@>,MY(SC^(VEA@X/4S_4?8J"X 4%6(5<D+#5@05L5EPVG@G
M>2B-G'&61E\SH+BDK*5M9S#$4GE1>(H_KQB\1=$!V\<T$4DV<K'S1M\YY7JI
M(O77::&2&(*ER2Z[\G/YW&87HV-^GN0< \@A+:VJ)9[(N+O?M.,+[")ESAQN
MHSC%L:\+N";YN#0CAD/(]$F<S0HS]V+Q(;C?)7X(D:65Y$TL!YBTRZ\*GY:1
MJQ^;\R3$N*;]OI)OJ?!ZDEJ9U6\T@TN:O(WM3I9))ABS"*@M_@971/1V+B['
M4SB8;>^#JE"HXE1IJM2S7.<U?OHL;$:G8:L6E$B9LK+04UQ^;!M:7$'1JC;I
MJ#M&<J$4%T#)@E0\896E8>3 8;<V:#+Q.6$=W?+O__B'MR_/W_PIX51\,9W5
MIE4D92(;_J!5:K$<]4B>!?GWNSQ30 =H,'HRG))8B"E)Q+B53@8('[X(65#B
MS$R'>!1DY",;T[N (?I'BF^9\?\R>S__97+G^+J#383)VCGG"?'6 DIPGW^+
MK">?G6;!T@E02NA'IT+QV5$]*4["9!?C6_$%3-, YK5'BOU5,Q9;B%E ()\C
M5AA>^6UN15E_&R@FQ7IQU]:!JT**N, .?>EV.32Z-VUN'S/ JFH5PT<_VB7!
MGHH2:\Y,BF0:#LSCT:F[$.[BR(70(V>[(D]GGG[P;G<?^.YLM8(X]%,S2L3I
MFH:/,&<L[8,3?A_5E[92!$!6LK7R %*3H Z_"R?QD]EJ5*;TO(M0Y_OL_Y?P
M*;U [3]IQIX@41O>*C'6&,@CC;&O':FV!!O%V$"VO//)";@*08FI4/9!D8JA
MH8?_,_YMAS1J@/?9?M$G1M/\-;,07\P:H<D#2<9+_E%I;E4#2DFW]KQ&>"H4
M[Y\K^W>_8.,0,KVOLEEA55V*'0^"TB$Z;SI$K?C9VR17]ZASQZR^;Y953?N%
M#Y.,\3=9+$Z8^1X;96KMG/OX8JJ?^#@C[%*H*\;1:ND>.R=2I-6P1MOB\V2_
MT!$F:Z.TER!OS)-CUOP$D [(QE=V<0)"F%HVNF1%?F3YB\]-MTJGI Y=SQL@
MCY)Y&XO##0-K99PER%H-H0@E5V[- I3LX2I:3^^CR/OL!P%"YP2=<L*UCS;8
MS._:+Y@D")O'ECAS[!S)>2N0-2.*K>C6JB4O+_$J#"5G1A&5D\W6\6.L*6?Q
ME9]LH\0)9JN;*%S?8-^B"7PJL6 >J2IL<L(+RU>$N(=3TD4.8*N8[8*'FEVH
M.EN*.+Y&U$C4YBW2V[L8'O;^?L$K3M?TR568,P9(<7N0!<)6>K =PR@MYRHH
MY:9$_9Q[B<>!L[_B-3[WDT_9DP#\+]UN.0XE"\XX-C?,G R5%E@;XF_M6HL"
MPJLGM>&/6=G7AL[5.XAO,HI$PK_XZ</E+DFC#8S[]K])$3?ODY-ACQD:2SH!
ME=Q5MB]2U61>]]Q)SXQJD&/V^*0R>UQ(LB+:6GLQ7NNOE27VPS7<CH4GXR%K
MHO(YA*L)#5P](BA_M=2WZY=!QH+KE\X)\QA+WJ@M<5(&FS<%;7*J^WXY0^S@
M^Z5G*,SRB)+3,-YPT2F"U-C-:&N&D0H'P\B@S>61FT"7= 6J?=G>#SO@H#V3
M=?M$=4A6Z\2X D1R!V-"O%^=UT;->/(:/C^<! 4D60UJ!O)4;:2Y36TH*,A:
M&AJ!T:LCZT,"9ZMQDOH;)]4> WG4N?$MLTZ?@1/T$3XGEI_95E)TB50101E6
MA\UQ"C]7@HOB*$3_=#/7C E_ES1Y&_%HLDPR5=)G<.@'U#L"TR@%'Y'2&GG1
MME['Q<;37D54U![\JLR:=! ;.6MP2&5)IO-)%4 TXV39C8*I+;,[J\\7NOJ
M4!YAN\^D(IS]Q ^OXMUZL;O'A0-=> OQXWDQI+(:&]M_N6RP (8_!_A[4#8
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M<@"&'7O.2UDSQJ;DSEE^CI8/T2YQ0F\)28H^F47/;FW:AF=RPA#[R[/S,_)
M?1@[?*L82N'S!ZIR9*OTN,!Q_2GL! 1J'T:W@!9FV(AXPT"$133P)$+#!'/
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M5B<A7J':S4W#2OKH-L=OO<3#65L.:]7>#/DSC\AR[B1]'![L!-5BC;:!P9!
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MJME;1#"N(O(]BQDX@(XM,9?^?9S5"!G>.=EE6_!ZN+4_]12BA$=8R?:<L?7
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M8H#UL/#A"DGP/']BU]$%X %_'$@ZUD"+"R)&+0@?1S[.I9N=@RML00:%$#9
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M[0,U*I5X?EPW!?.AI!M!Y,/'/WS\KY\^_O&GW_VHTO^82C9@ </XV8&,L:"
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M$77V[,P7_>IH*A(]'Y]V-5_SU>9S4N907<N.$VXXN35BDSAIJ!-%7J7,ZA?
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M6]B] [B^>T#-AF8EL.9/=A/+ U5WB%XL!-V!>7FAY0H:'"-=-+_19!!8W+C
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MJ\[SQZ>2+3J?BMN)H(<0<\Q<^GXX&,)/^0'^YY8UR'XI<DZ.D"<(?Q#$L*S
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MHAXD[,D9N$)[\^Y]3A;. M[9!AR56[8F(-=<8LZ]R6.[V\)A"/59')F[NQH
M) 8K!/A3O6T;_%YH3;=_ 2#<!#H+!K)HKHHJ$][?$I8\JVM*JVM:/;%?93[P
MYLXL):+)DZ(DS0N(\0:\H\R<,I:\930B>VFDW .>;=?T2?J$5YL+'\249@ $
M.R_FA9ABY0:_TIVLA].BP1F2Y/N3P<L%GB(GL4^_]G1[IQ_&36!%U\3"49%X
MV<3F:G?'-+75AIF#S/CS@P72P7Q)@P@B1%&)Z]/S9A;[!D9**O@ZRFIJX:XV
M0I:K_*)(\DJ<L%!J<"/.7:@_L*?R)_E"7E<I3\DP!L&-Q3T#'TZ2]7< ]F_
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M-.5+&RA7;04,]9A^6#:"B]?"">;N=3(=&%]5S8.FISOP6XIL0)Y56)GMH!6
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M>N1?=S,K^A20NTMOR_3;#W8R_!S^&,H>W@9D8U'G_'E#O)"$EN?,V6(+3N.
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M%3EC^@YU/O,VY&R%$+HU\.)3BB1R30/%-=*.?)-$-8Z3X+6I*FQ>>ELF&#^
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M0@,CIGWK?[]BZ^>$Z;1SZJ\WQ NSE1E8WI+PE7&R._Q)MEAF3U;@7!EJDP;
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M/N?75V* A^%ZG:0"NF5L;LFA(=(=#;\8>.??2@HK+&_4))5[3K4)&J8L@';
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M*"$9])X)S8HJ!@PJ%#1[N)XM Y+$H10<R8;/L.\JVJ78-$_40'H6_?_9XG'
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M]6?RO;8 #'Z>"I,.KE(,@:3[P'<EKXLK@B8M[!'QW-X1KB'!"Z+(:B:::(N
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MRS#H&!PQUCCG<PPUF?]I[ P[4$[&_8[N@.H$KC1%V0W0;RY1V4NNXI3+L8;
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M*)5F<)8;R<4A-'G\G<&;DTQ,3#WGI70B20_ AW2"7C(6)HIL &YS2OND#B:
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M-N6JPBPBJC#9AY D%29"1RZ:/RK1*I\^P#6C2>F2/Z)Q*VAC,G:@"O.X7^9
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MN0H[ILPVJ,?+)1#J3>&L1[X<[278E(WV'>1R.L"]\;)><3Q+/[)N9V/GU'S
MX>==)VN[3C14)XWT(0W3_6JZ2LX@:D 15U'S1Y&S)4\J%>9[R.;@JBZJ$R*9
MCN?,WR-H8*\2HB@5X,X.SA;07ESC8SX4X)AWYW.:PJ5]AT=UQGXX-%^6H68-
M;8<[T?45HR:WKB86'Y]OS7K83G@NE(M6!+EOR!R.H<3*CEY?'';+T"M!EE^>
MDZ6Y+.)%WF%-T?K5>>B%7N):0*&P2IM;#]HB^D2K$1(V7K) V<E9 SO1E=N5
M/1(]%>:T"I-:G_,2TA1REB%1)DGL\+E#2E&A.=(!8_G.]*OQV!5 Z>XP&=GH
M>#]Z\-F;"G: 7))6N$Y<[8*P3TP4;D=:">%S6&5[Z$:U,F!P5B(!"D8&+5Q$
M#UW;PY37-E:BNZ&$J\3UR$P+U1C>TPQ_\J+XP?O**F*"0#$0X(VT<*P9@MER
M(+U7,$M*M9\P"1VN3WZJ.10PK5NNPKBQTKB003,7?>4[G_18A7DS*J>@BR"*
M"K/='U%A?IS)P55?IPJ-N:NH.]^#BWM(D8D&/ET.4=Q(?*87[.+6+1HKE[,R
M=H#+:^:+/H,4?.N#I]T$WR(@3+ZMPU:Y@2=_6SV_9X*W=80$78_V0R[?1WQL
M>P62S*?*WPH=D'ZX=4[:R[M$BQEW:U*[.#&N!5^021CL!">>&E=T"*M*AD.M
M$9&4:0I0Y!'\%]2E@4A#JX7!3R,<A^X?NLIN"OV0+&PJZG9_N*\:@WLJ>>O,
MFM?E6*DP33Y+5)@OENY_<C/@4PSJ#S]IG-.@MO?E5,+6 C\G 3.-MI"X JE3
M[+OUY#W@U.I<Q\.N!"/$H);3S4I"3+$Y<8)W>8;/7"PL"Q(J"A:.[NV2<^&?
M>E'<HZ'9#WWFXW4__=[XD3Z^AOE,P&HEWW0B+XAG].&^%T_I!%'ZM!4&H/>;
MJ0MSFY%R^6\2#5M:9 /3K U^M,7!QU"M])#,.$]:VE:DUI9TJ 'ZS9F!KLG[
MN]+B'O8M=LP\0$DG&]"DUDFTK[>+YS35$N5^+U^":$DERE/E\*",4$<VH6[G
MS6T'>A44H=E$$EGGXSRK!KL *.9QJZT%(CJ5"/\NT>'8HO;0Z=P2@*D@70>C
M9-PTIKX,61LAGU@)>(<]1GK]DPX7NIC[R.W5&DZ77A;]AIJB%"CQL":#%"Y*
M(FZ&G=(F")3'T42C2#^A:>;YTON*K/4'NFML<;Q"!\[ME;+KG[\(..9/.]&]
M\8^"]QJ5EA,?S-ZIB*+$ZU_%7E(V=].&XF$GY4) #?%W-Y.>QI-GS4$O%>9J
MH8X*\^G /T[X_^KU5Z__J5Y_:Q0_B>MW:73W1:X]>1LU;2P>D)!#RZ[;GAFK
M&#]YZ?.3SY_+H(ISP<'!N\W:"5^<]R[?_\?^D?3]$$Y3*297,1A*,Z!.@5/3
MXAC6@AB:%EOSR4BH&<SB/R1<@'*P&H#?L<Z:E=5M&;$T@4F>)2>KQ.W"^?/A
MCK=HERX9,UG#>:6,BJ& H)N,BN& WL);<WN!*RU*.T0+SFWA.$$366"P5**'
M[H!+Z7*N#NKTE.F/7*L $HY \_,Y51'2RLV]3GFL=)Q/GJS:=7NK3<.\NV_P
M%1<SG3V?@3-G28YLH\=N\* T8=P@"M;DTW!H,*2_B[C4!VJ;+H5ZQS+DDH74
M;LF*LP17>0V<7,N\ *7T2[WO/P0#,V01J6N@VT/?;B[;S&T=(NO6^&"1)+*8
M)#-M9$.,++;?N06S'E"OD(I!1#*>.@:2ZB49,+G%YN'[*!TY,X6S40TY+%V[
MRI-_\[Q2:GZA9=:JO%1GWVN7\BB[BJS>OMC.3YHY&P*+;:]))9F2)<3U0%(K
M41^Y,G<8,!-2-R,7*>Y\['+$2:[9S#) DIK*O!N9![LT,^-B#0YRNL"M9QS,
M@@N(DS$7>TCAC76%G30[X%06E8+8P@'R"Z #K$R&K5LEA@Z[.!O0 )C4PGW[
M18YM%=U@0$D*=SYP5JFK5L[!YD(&T10)D]%YEPBZ ZOA,CIQ2_"04@W%+93D
MP4,0/JE:I$^.[#7.[2.GJ<?IDNB>X>Q"UR)&4.B,S&=< TH%E\YG*>W #6K8
M4P32(BAILPZ2I(@>H@GBUFQ"7810RKRD:?:2OM,^*Y )GI?\ETG\=1I43<#)
M*YV:G[83BW< ^3RMRJO42D1#/M.L5M5*HUXT'JJ;+H3(?-8BX&CP+P1?!1X#
M?)%.9((VLI>3X\ZVY$-T,HREQS6Z[^_X^+3S-/T(F^'+KKL2XGR,%:$5N^Y
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M+T!,/+T":X8SO_2BMJW !EGXZA68%[TE0OJ -DI10W\9O8*3WHLD31[T)UT
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M6^(8!G!&N2TT3<D?$%,S6V"1S-@%T)*> 3%-U"04W!5<S3H&'GSS?)*(A"@
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MH L:IS2NXZL1%,+ R+. =0J4.)H6.8-B^?9%KQHE(: ?40@WX N/GR0WQ%O
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M%\6Z.M [C>;+4PEB6R.4IWR\L_Z,R(1\6G5DCT*>^QXL7-S#P2>(2P$C1@I
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MQ?./7<QVPEYZE9P](OMWRIAX_@0.A]B%4/>L@)3Q)<T'6.C[\.C),#[3E9[
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M.S$$^\Q&:X*S'A&QZ;E'GI][@3OR[!N/,YM8[9[E8WO>J??>RJPI?E/^,$=
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MPPKL@5TB>OKO=M)"(!F=AB^1G2$:RL'JFQR/2_LH@Q;_@[8W#VLBZ_9&T^V
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MN]OP#$5!=)QK:S71/3IV%7]XB%G7L! 9K'5"YL<U^M4)T# +DVB*WWOU9>U
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MN+9[%JDE)9";2)<KAEL!B]L)#*&1&X$ +,QI D-<1&IP%RN)NY B\A0:B"Z
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MA_BQ#SUX,ZLP13RI.71S'MZLXX2 FLH*1BAC?+&QB%\)'GQR GT3=(_S"]J
MX)P*C^&H$_<09 =1+GRW=6T4.9JN[S+[D+1ER>NA=H<^@CR7H^BGD9RC$=?B
MSZVM W5R*G@1JA>RS@.S@IV(Z^+_1EI!7L!R6^9".SF&I$*P!2\)DJ$.;A)Y
MA",P!Y!DH@KA..#51M8F[(EST4A>A6EY)0D206J<",Z#RT*AO%$HL8_+B-S[
MB+A[RMT("L2;=-H9F#/3.WB4[<>+0B[A)]MRI$P5I JR0%PK.0F]"9H!HOBX
M1NPZO%YC':*5%,]6@P*OUU%B5F%>V>>&&BV69\$"* T+W>=OIA^>X6Q'70H(
M">13-^+);8Z'H#?-<#D_%D%[!U#4"\-X_\.W?!+EP;/I@N%=6K3-P(P4D2IW
M0<H.SC8,F8H#+@+T(OGTK/PIP+)UX&.7M$R>\:V43:EJC\_.ZUR/9!_P>GQD
MM-</<!$\ 1>22./YN"H"IH+<)'][P4[\G*XR+6!QYM1!S)E'J12>[-@^T8'N
MQ9F_R'ZO7*:6!;U3=.4J$KK+%;P>2M1]/#AS'$C)*7*_Z?-G*3W:,AM3ZAEX
M107Q2[1=;\NUFPW]*\TQ.F'#F>4]^5;;_8O.;187K@.2WU8:EU?\6?T$8-O$
MI >T.HG/!-E_..R*ZBW9KSL_]+%BZ>A=$66=ZL&WG]L5K;85'KP<N)W\A3S7
M(SPN<A"7HVYPNU*(NKT+P:2''!;[*(!I]%,OP]F]::@&DND:6:TK0X+@VMKO
MI%O3O3,YFF_!#2S7,58KZEZ.>@VC05O]&1_*9(0QQJNUUP$9S5*%7B(53G#"
MYA?.^-!F;85>M/&WL(TIUTMWOGG]ACS^?:>/5HY?5A$GHG-IJ3_-W5>UTA7G
MWF4YUM*'&2\C^>'7,=^B,IB?52P.Q;A.8M9R/PL/5T_S*X(#AY^K:&^Y2"L:
M!XXX'V+^?J<B,-^*4OTJ=Z["M& 5EHY^]#PT@8]4./C[H:K"]#NAF\8/W5==
M?^>+5]A1L_/ HE%(B<-77[7G,Q9MEXLRO=X]Z9_A&U7GG1W WU)1R5R1$9Q7
M-)^[)#0NJWIT^@ZG"M[T:'UE\[)"NQ&4PJU02CN^0]"%.B-T/G-Q8NS+;_9>
M\:\?D=[^0W SXA@CJA([AL!C;;D?DJK^);K,*^(!QT;Q+L:7$"9"L.\C9LG_
M_#3@*#GMM"Q..81;*7OVK\LU_YAM??:X+NLYW>]#TM:E#A%NR,RICN.V^+KO
MKZOKOHW>B ^XDG:\S^5*+^VHSM=VLD2'91..CD+7%H]T%75LI?C(K23HZ0_6
MI)M]?'@KSQ,"N=GA[H #U9,'E_%C+40OC1U>D;]D.X@R+YT.T\XOG'9X/3;J
M/&UF7G=CH*PU?ZFZ0;RHLGSGK%;+-G<W:Z7X#$49<<0J+%)*+M\/B=!KL2D!
MBJ24DF0*C>)&77]I_FST[ Y6QC-HJR97=,\LW>GD-JQZ\OO#R7:&1^*O!6UU
MYCB5I7=M.UCQ-:70H2%TOM7I5:OUS[1$B)-RE[B']['P '^K7L?A4G?C;=$M
M7^^3MD\.GZ^AJY0C-A5[3&9T=_(?"JXH311NP9^W_#FY4'CTG:1R%=9DOK:V
MP5K+(%\3UT3=C,_C+[<RE+XYUXKTL;7>:',H@=^EAG<7SB*V$(**1DD^4) ]
M>-XAC#P2H%^VH$^;4IW-3&G(7[R?/J"T"KO\CX -I)T8X!SI)X;\@+-\F;1T
MGG"*.ON8H0!R9&.: ^^Y83?',#T.=,2]KGR*,M2$QQ0>H#$/)STOXKZ&?&_?
M-DIV_;R#E7PIS3X1EP>=C&^YA@_01-GMIN_SLV@YCMWF3M_MJ[?A@>_!D!G'
MS$3_:F53I5'? S6<_S;T '$_\15) P=<KJ)A1QG\%].J*K6.GA)E<K9E]LL:
MLRY*% 5^GNA6NER77.$?_P(]\[[V[[+=/WUY>T4B:G?7OS&"YKHJK\+VAFXA
MC1Q]O J;KM]*4@&QHB>BTZLPSX_2 7BI!/&: ISZMG04XTM!E#\-];QQ!^.U
MH*R:<:&OW/2(,P*ZRMERTNJUBV^FS<O\C[<J-3-.GPH^9/3H.GDE]E]#_L3]
M5Q%."U-QW^\8803[UA8.-=5()R$;::W\X4*-FYP5DMS_*.""XQ>9*2\P7SIG
M;&Q:Q/42"\/<0+^0>QCNU9]](RP;SUL_H:/ 8OM75E?XJPZ5X<0]\[0L0F(O
M,KU\-[;K@UCNWUO95Y2;<-^M[Q2*TYXA)26O)\& _QP-5ORK=#!N>3&XYL:>
M+_F;T:=_3RH>'@FM!:EI(<7WWTDUA/JO]S$W!ZM(>V[J_# 7YW6RLP@4 QKG
MF^J_.KPV<J"=7:(QG+B;(YXU%<LY?H<G8[X'XN,D4Z25PD9$+UN=]%Y1VDUC
M)Z5D'<_\;_V5I)P$D"AA_(P.2P8P5<V?WRO5R@I_$]U4[%B/#)!+@\>S]VY_
M+[<=>Q<XM? N+V;^MK;)+HW[YYYI3DZO: KJUF+<B@L9LURZE)=-OP<-"#]P
MW^;/KL)VNV9(6D8PDN*[>5#X6G[[<I^U#0%2K'1P>OC_:XN H?^I1?KI_QLM
M\G^GG.E;!Z$DN8SQA&Z_[\0/;(R_WJ6>V;+VN76\OT!?#:WY0F-;*2N<Y)[U
M40D/4)C:_TC)J+C9/WN@Y_.GYM.IF&'L/]!@[RKLGXOBQ/>.@'4"Y?N=([62
M=E/&DJ8!YC4$EYQA:Z["*MPP8DRJ'LN Y=)2VS?ZV>T!8:K,X,:;VD>U1I>4
M2X<ROI_XU?\B-=1(7SUJ_^])4?_?AE"<D!$IY[6Y'X+"A:9X3!O+H#W5@(Z
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MGI]L1Y<F/J^ESCQ.M,?'I_BS,\LGU!&]=X#J;^)M4*U7/Z/GLOEKPQFJ(=+
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MK9'3,-Z7XU:K"-F%/]O=PZN(:OG.>E-U]XWXX?_95X @L4-*C!>QOXJL(!+
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M&T](Q(7>N3SGBM>QZJ?6MIPQ"XBL^@@]*A--K2?5<6RD#-E-IB'D*=;EQ2R
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MO:Q*5K<#HIAAF&L$;VR9* F_Z5F($()1=IF;[Y_I4,N'UQF9OY7:13^8TMA
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MNF)JV7 K2N>=JZ@+^KFY"8.%%XJW@@U5'MK$1<@BR&^X//M#SUE6N4"AOY0
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M(P9B]M1:*!JIOLE!TIS(1[C_HB[Y]#MQ'#;MY@M.^]^;=H/-& HECP8!DU;
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M7T%9"HU:UY.\I>OAG= GT,(9HG:151FKFBQUH):7'BNA0 E_%Q6R92[M0U1
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M!5 NM48)\($TOE0EE+ ]@E%L$*SW2$LT=<3%&2NQ.Z#<<,,*:H_JW_WZKW:
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M'U#_?,,O)H=1OPD%_HOA*O_W];3_>4S*/^II4]UU.U21&\2R[G^1B";V<#6
M[[E_>_YGAO\,;B4-3=HN+=RQIF!WTZ_O0."$6^:15+$_0NF%RSM@K,D7^Z.O
M[T X/W_-_2\O\@8@8%A5P /QY:4+H4*0+'8>&)5N($>0"%T&Y"Z QX]@:H'4
MB,Q2,CVXRRC<$"8^A'U ?K3E<H:]A%_.G4,_=R!/8GXY#\58BWP[Y27=4;2A
MH'ZB,C1XJF2UK<KH4UDJ<Q6S+EE!,CQ0(^:$DQ=;+J5(NITAMM0<\A<GQAXC
MD;4*Q:QH&]!"S.6Q9U-\A0&&1YL8BX6<'^@L7N>*EF+K<V*; ,_*Y!6>)^[W
M(&J;34Y0Q+=8OT B$=!VRQ5DAAV64,5&O$%Y44M,W@NN H0(JMD*BZL3@86>
M!>^*/1F,<R*]=GPT>\%0OJUU1>&DEH;D=K)ZRRF:1J\30=D%^GVK/S9N_FCN
M9\LMLE@&[83$6TA]B0^E+B7I""D11+GCR$)_]6-<%:9ROT"-Y,WQY\K!5-'P
M4FB/>-)#,ED%7%(WB$U(I]+]7@LJBG:DA2T;,N@N9OW<2#)7R W_0PY%KM[B
M,0&:;[WY5]C+!O/Z0SRDHD(>?S&=L[<^J^U(;F-0@+%MDNW*U^.#E^_H#P49
M^RJU;ZO[HV!X[>Y??]S%56!0(1"LF5B;O[F[@AR]F3.HG 9Q)KPA'JC2UEYE
MN0@*$ND!"^ C$#D5<G/);RA&\]I\;EFG$I>%2B4 =@^9TQG?M0SV%FNJDHQ3
M3+3,%GOXR>^?CJ^D*I0:P)Z-Q<&2FBY"Y*D:U@4M7=GMAY"7N(:F  7OE+1!
MDV)63-;XTN+]7=QYK7WJU2R2NW"+4;F6QL46N[HQRB(HM\*I+3Q=K'#TJD:3
MY*-K5FZ5C50#BA9[9:70I/M@USK$\!I$Z"*?]R DOJ0N&"I5+H@7\2.=VDS3
M*HA+_7T?P]90AA877$R-X&FIN[D[E3&,13%+#U)#XLO>!IF9O=32!(&NZFJC
M]ZF-_>Q%B'X?-V\G6\QM97?A*VS\:4LA*U'+I4S8&(P7(K=$ 4=;["0<&,V]
M\G0SA!SA85H(!HT1SE*N>(/LRZ<.2-Y>>T=_;WOFD:;UAV*%3,8QR ;L1_DJ
M)9*MGL^/W4RHIH1Y6#0?SX)MA,/AS"7Q9<3%I<N \A6/.ZN%ER":4"!_R.A"
ML<M]>J'+_@=0)U6COXC42:B[XK'AJEO'#E.3Q ESD%!1X[Y','$/RG\ NZ^5
M&%4!N&(CH_.ERSH8V@&Z/+9*9IX_Y;+E^N8&1X@%.FT!Q*NY^'"224%1YD7(
MFZ>^_FFI5#?T=M^Q@-N"68AESWH!PQXTKQ L9!R'.B0"X9<C7KC0<D!IL'1A
M[]G3)5WS3!PRZ-557,EUV :ZE]+?J=N<3YY/M[2U<2B@XB'_W75CM7Y;C%^>
MC6G.T$2=OYJI#3T'0R>BH#L2"U%:%4N9,;\>4835);I7AH.X\G0;45J4*9=
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ML^6+78NYG9G&,B8#!\NZG-UF^^ZB>-U2F9_G;./=B]*"9PG#4C)VMLAW[^/
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MWH;W?$/QNZ?\V1(>LLU[CNW\#\O]?^.SJW<M]YG8IJKX?4C=?QZ\>"<%PCK
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M\,"?%--NNXF&;P@Y>:])X#M^IO89U</M9OZ>%.J)T48WL!8)5$$RZ3SE3V4
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M^Y&&IH]S<BA*4/IF2!J1]/"47Z=OIU^U07E^OG!_!>TKRO+]]T(>V,[.O:T
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M1^.*=MGC8D$NN0*Z3=SL.:$'#@79SHO49!9M$V2B4C!GS"R^J*9;%<LACZ'
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M^=]'.Q@73J9B&6;M$$5Q:!&6PE'KX:H8+VRFJSO=8G3$/!G?:_-C?TQG4&!
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MY^3^&]9+R\=M4S[I7V=:_30 ?WEB:>%LS'^S=S['37HNG'T?+3_&O+Z IIX
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MB6%/4A1F"^>>CEQ&B+#K0KN0;EPG%TG4N567VNG (ZHE-*>RWQV#LHNZ\8&
MV96D"0RK@*^Y_8\/U C0I(-]OTC]I>VM[9R_OII^.0QG1<&J'2>8:EQZ</YV
MP*8#=W<N]/<LS,Y^PQJ*H"<*O9&:6#!62MI D0;V<O^>8=N./M(Y0TVE9UMR
M?";+ON+O"J^PDCSP5KC)[254KS[T+M"WW8-QOK_*-?;ME:%C+T'7Y@))\9C!
MH0^]K(R2NJ :YHA?S^PO!:1I:$+):+WMI/ZWG,>/Q@=D]7./(F[Y3[0O?/=>
MYT)> G5*(IQDM!WCWTJ\O_52*VO=ITM4LI=_I;E *!7<W&5X.BVFRC<8$#<^
M 9'BO'B?(SYV:IO[0EX&E![S+QWS[,=F&<^,/)4#VUF8,_6@*,#A^ZU.WDTO
M3A\^?N[)D[0USY<XBV_#MOV^!A9[RZ:#E2YG&X7(=+0^WQ8(+@"1$HPSZ/I$
MR891$*+C+%\F'CQ60:8_^T[&#[H>^2R4<DKDY9%>3(QP #W3IIS=;7IC?&S_
MY@X[ALE^[HT)]_V#)+Q*OY/O\0)Z< $PE8PLUQ<8'*E>W>ZD4-Q=O!GF.\JA
M\0[,UNRC?H0)[I9;S_TN43+W;F=KBRUQQ>UT9X^]$=L_=+<I=HT)N>Y_1#A!
M"6"]"GL/;51GI<GD9<TJ@2EE2'F.?1S/1"X7.!)HJP;*9+%2ANWVOKKY@90R
MH"-9V4P0N.FV\HD^OG[]SCM Z=W.L3AYYOW*)1_Q*P48"C-,7XX^ 3;A@.PT
MJJ]ZF'BD!V.INPY97E*'L=)M&<G4]4:*M<=30@[H"^F7C++\MB3JN.Z</K]:
M=VE=T060+!)L[JF,1<*A''M_\>[W>8=><]_>F%TFPM=B6U@FU%#048(SU;D!
MAG3P5/M+176S.A=57]#XJK_]]H![(,F*$R9J#!:JM_=P^XR#.).W51(!;KMI
M_6"\\7[!YO7/_QZ8&%]PH"0HT?(K%964@7"H5<U9#5F*D*L,FZ&*#H,]X/KD
M.74_Y*M\Q=N(WJ^DK^4DZ]R?'EQ;Z_?\&#5<33@Q*]S422JN?KF[MCNFP@E;
M'04KS"@I'XN_QBS#C]MV%%PJ'O4ZD_>NZ'ET3MX':]N;N66#A^8\LP?F!D[Z
MD2(C">3-CSX,GP_<;.YKU^E4Z/0#K"EB"=BI^5VX&I?*QZK82Z.-WF\[I4?:
M[B5,I9H9,7(SD/<"D-YQB>F4VD&=8L,/($G+-HZC*04G\CT/:/-NE0^_CD7+
MI]-U^TM"W[^)W73MJNXS=NB&4G(?[:[I% Y*Q5[P222XK"7>AYU>"@4HL1:$
M>7*F+DAUY]G9'9P*:,\ _GX/RE)"+)(F)!0%E3R9H9N/>]31-C'.U0C[M^2@
MF(*=4.&0YMO+6ED9B.U0/8#2+L+PEE1/&747.8Z@AJ<C:[,S2;H]#/&(-V!(
MUM@?>3.F4$7<=POW/JQ_BEE!>4ARHQ"/YVQR6S5I=[Z/ZAVSA <@U>%",2I]
M7C+I!VSM%2OL:.:TGCW0,E7(Y!;@1ON<MK&^G3[($7M1<S[F6\MB2-@S_=-N
MDZ>4S6KJH7X>W@KZ\8UA$190UT7UA8LYJ8WW:Y6OIV.(9(%@%>T/I DV,H%M
M>9[JU#6;9XNU*$GY9^\L;B.E5BSW3]%YET1$SV=E*Z5+" @'66R0=TO^FMY8
MO#E17L).X;N02D;-1Z('G%W^.''.EW!*B9TPL->@=#<TTHWC<D<Q+G,1MF%Z
M)I>3)MP0(UTZ.@(+"@D"WJ644B+;$)9=NOV$YY341),VQ,9N[K^.Y15]@%AA
MCV>9^ANAKP0/QX,?7YKW,*I&)7(#5"&*, &F>$:<V42<QZ;PG51O,5^"!_A^
M:K,CO0'=,:0]W6NS/>59)8G.UEDW7SS=_CG_],&6=T>7+XL7A!GW4=0D3MD4
M^G7$#+IF_$KH"\;(QLB@;1^7V8SL [X8ES;%4\6ZH\ QQ0(4&">&6Q7/8UB-
MFE.\EX V2U8;6#GL7WX^_/S7^1V9E40/#/'9(JSUR"+LRO:>:^B#*KKE.,:S
MF^]>\?4U>/BKP%8VPS:G[@1VU&5WB<#D=LPJ,(65RB<]TSGUSD9QA\QNM(]8
M&ID][6H,,_R,>],C_>/(N%_R-U6&?6MG;M@V(+R(M-$%@)%B\@K=/X"I7%"C
MI>C+^*C"T9'],K19,25,$DH6V\/;Z)L+4]OP)L21C2PQPJ[V)4"^AVH7,C".
ME&.1P$H!B3=>X=T<M50RH:@(@Y@2Q"ZH"D@X"MIT( ?_TG) ="-Y<AG0J0[J
MSE4K)H3@-9]U1!]R !A\1],<4,:'PI^=_:/1/]VP.3SP1JQRKKF'QV&\H#!4
M4\W63R[,>;8B!YN4BHG12]6CQO&D[L*F5O']W).CM_XE%GP/'GXY.O^#  ^'
MX@)>@5?JJZ1/(7_1[NCX>Q&VP/WT'6Q5\PIWT[]*"3=[\!$!WIB5.M,>P;IS
ME++@YO[O0$X[+CVT"_1LYV340F0_0,;33/Z*Y/H65[UC%QYVF=$O:Y.?7X2]
MC[#H,O0FZEG%'8<'Y*DE<>71(2.3W[JOV&NFTS FT#F5#UZ"7\\_4P"AVFPW
M[/*H4,/-Q\P)C:1G6:?KZQCO\GZ3WDJ(=?:(3TRI>9OX3(%;\3BSN?T#T*:T
MSZ1>7SA*D]7H5@EE,]_R3G<-T'8%*%'+"=@-&*?ALU"1"+.VEV^E]*&'R73[
M5?_BCD]OD*Y%_ !E:H(B1;0M-0!.U+RK:HK7P"6FN<YF(L9/ )\$34^J:</X
M-==T\ KJ$0AK/R"!KZ-Z@\>R+X"*(\#M?C=ING 5VNS96?R'8>KA9NB,VFQ-
M9T>.@5W4:9;R:8IE-""-*=.IVV1\OZ<8[OSRQJ!IB76C9P8U$?06T6OG6H7W
MO;+%T\GQ[=(4(1&9C-S,U>-$>!L>?7#A1#??MVHLQU\TS0P>V0%NB&-;&<PI
M%2>"KN!2O#*'%R!%JV!K:N<Q?LX\?!U!\%U/BT^8E@1D)3\_J/YV0'=D8*Z1
M?3*P1!^<!/%#KIBV6Y@;#DK:X/;GO];-QV4:S'7D7CZ!O@A;[<%3-3!2!WP!
M05'<6@,:@&?$S &>F95ER/>&'8PI:9)P*<V.)A58-0-TD;U3<"\W#Q?&%GN5
M2-+09]1L.Z*\NLHUKS3JQ8<QV@XP_V4UE*2/T2\[W(W&EAR\\>SURMS"*/FU
MW,C-P=IG7$42=H7.'?!M\XQ?F?'Z^;AA!XAHUDC3$9ZO>KAY3N'0 ]"AO?[/
M:($S*$PK[*YRGC#J>]CHO>";+]JU)#L_7L^,G5GCS>PHYH0;[(3?K3GQ-!.Y
MUF *'?M+0K?FQZG(C CXBRS3!/9Z2E-H3;=;:UQ,.^GJA7SM64'_L_":&OG9
MT'3.M2?G2,H'O]U>\M4=P$^&+^"@(E4E9K?1>V/64QY)YDT87.PZPK<R1_^G
MU,/TU'SWFE=0U?5;*NDJHYBNX-.0,G=L.GXSZM?8<$N1_,QTZDFYEK[N[#E*
M)D]_Q92$+8#N+$3HUC< V4GN363K\^/(VB\=Q2!<M""5QZGH]]Q>4^T 3OL\
M-SC>/W7".(R9\)->4M'"VU^G3PAZN5*[3JLZME)J,Q@U3T]SY2:\#7U#$<0!
M]0P#BHH'@WD+/U#&U7&9DYCMM'\C]@,<,3N%SE,D\[U5X0D_@9>SZI7AN$.]
MU/T@N6W$L8>'-])"VS /2@3W:%VBWW*E+Z"4;ZTQTPQVV3_R><)>!UC]PCKZ
M16A!65>[X$$1M=4A[821>MP!\%B3$G_O3TIT/W47&-B&V %FZJ49U&]IE1:M
MUT:6Z@O15NJ\*U.='32[IMX)85T)-[O=]G#HM:*R<:^;3^9-@5SEG(A\)W]=
M'6#3)C0=HN#:9 /9\>DU&7.G^SFH6"?-QL8^7N*-"$&_^R3Y9,X^TF3N<9F[
M]WAK)"'RY]JJO+Q*\W8@0663+%A%L0D$D$F3FT@DDZ'8YIM:.SAT5$=2,__E
MHI'IKFN\]5Z=.$8H2$]WK ]\2P[V^.?JSX,KN-9UUK*;-PT%WX+-;[KST">
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M0M%6-[+O42OIV1 G;1&F,F_JOS:SCQJ ^.V=:UD/EC=1UEO:G+I_"Z_) _C
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MD_Z^W :0K=N2C8=3'=0^6W3A9,V_EL_O>%(TB,K@Y<*[V'>$:V(4J8@-3\H
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M:)**#M@[%N_QI-3.[/"R3UCY*6TV8#.YY#G5 _B<7025281+=-CG$;H?H2^
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M;2\IJ4KA6@=[R+0W;[[<9EV7]4\)F41:_J/%OG\D61TMR'!;<G)?]XD-*\[
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M?]H[U[@DT^WOT]%*#=/4PI3.5J;4I%F&4)F9.49E14K*E%.*C#%-'NX4H?*
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MY5,]:LRXG/+JBXHHT:-F4K<!/\TO'_DF"%O4BFPC6B3&F#_MIR?)490-_%E
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MS%R*1.9JD\HIQ5L[M$MFJ!MLP+/[]-:-X]I0/6KV;! -,UKUJ'I"J]2<ZOD
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MD2=M_)F(- OG@D0JV>*)0C:F'!S&%O2/=[U4L-#4,%![EYNE74O=&@]-DP_
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MG[D6]\3D+!W\]!KA7JG7UI^\<*N9ZQWCP&S:MBG.\MG-7X9"^1 ^XP/^%'Y
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MU->XG8P;G_V4*TT3([FT=1YZ_JJ'A@-71_2F94QDN\0!%9,&H:GK+-><+*Z
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M5P#?QB2H*>3?37O2/M4B.7 [K!'_"^&_/<TH83K3<$Z_E"AX"HR5J0"6BNM
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M$'H^(:6(>\6M%7O:]7_6)!YL[YN6BL6:<=E2WUT(T;7:#[_3E<#W45XK[N?
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M+8>VGKYHX06&)WI;G+BKO2GUC[-?+*P<.NZK>]Y-N&&#YQIT2E CK$8D50[
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MX][#>&6XIBE["?@KVIAX!5.N60,=_]5,^<V\ &+%Y,%&N60#.OPJ?VQ(-O$
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MJ-5F>S(%?GXF=>>K5,M]J?O\$HQN#*S8>^:VUOH#"E>%BVO.W-9&_[K*WW%
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M"=4X:JTUTKL%]$T=K>U:D*;II4I9#I\+#JPY#W[^\6F +OE ^>,SB?N.S&)
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M15Q@6>S5CP;<SIK6J1NP60:,%]QC,_1H'G>.PLSJJB7Q3PG;JMII,N"X!0Q
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MU):Q:]@*EN_7/5G$J\0M!,[RF<N\//)C(**@)XXUK9M/7TM-<6@5-AS3N/7
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M6+2$2:?[3H4R;^<D'VH<%<P7NVX0\H"Y;.--UN[+CUB=^UB^]')[IS7P9@^
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MW<8BSI-KH]NO=6X)^WACM<5/OP1PGA:7.B_3^O8-[E%LZ^$WP$'?>%2#]A(
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MR?9?$D&FR*BV/(>ZE"&V.DU=!/IP)1:9J^&L[UG@T5&I4Q+>21IN\#S;MC1
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MO;XEP1)Q;#K$7K0+3A1O?BHM-/!L1&QT$UDNIW(Z>^T7L\8XZ,R*\2UPE$B
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MPXK#.E5O I.NB.B5BGO[-)9S.P%5.)^_YFP.KR"_R%RNN,]\"6X\9P+3R\
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MR9XR->$,6#GI>R^TH$ED?5);<);Y2RL^//(^XMLXS)A$*=@*.7&?VSP%?$O
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MLU<X>_@#S@\RSKK#5SQX<-]H^S6Z-&@9?O:D477MH?)J(9WM *7RZ;J(+EP
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M_8"7T>VG7 WMA'*D^;,)3.P,&%)\N4$6H@5V?T21]9[Y(U@FL/G/XL$*X*]
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MM.N?8$3'3#.FH%WAHJUIJRD1LA!Y&4UU%]KD4Y:12UU9W(SWSO&A3&!VG_Y
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M^>W?9ET7OPF]!+ LRM0R@-FP)+::",=;V8!5UPB8T[TJO9$%#<ZJRZVQ)(\
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M#JHW+<Q[  >KF/)S^S2;2.73]=/JA..EP,KK.3QEX#VIGRDOD('"K8&J"$2
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MS&+XP2T/X[[>&OZ;#^.1%L@1893UA01;1O\L&M%[%XK%]&N+:"./D+XBR?_
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M_!K"_ZD5"ED@!##FMD-./E!>E&=LZTX)Q;S*U]N/W"][G6 \?3)94Y)<U[E
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M1*/LW*H@-U8QL@XI4X-FR\)\U%4!2GTZK,'.M\K4W034O4Y4]E-IK:)BATU
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MTJQ^0G],JTARQ;;HM?B>>5I1795\V'!3TI[,FYP@S\O7GOS=CV_WX\:VWZH
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M736F+(RDK]+B0DP0W_V#@=$;3:O.J>SG]&[XA;.;-:HJJ^*LU9Z=4?+3V^.
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MB=@L-4Z@!EZ@E@B:B;K\V!K%$=-JP.HZSY9E<[C"W\JZTX@<AI&F&?,0';H
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MVL7W^V[9J"6G5OD&/T+A_*A;1@2&A)\Z:,K]XZGNY&QW@@64I4YAV3!E>;K
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M?LYID!Y+W$+8TXZP9+TPM0*]Z#R- 5CB+%*&9]V',Y<CG( H0)/_ME8\@13
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M:M=AC-'X1QKG$%3?1DW\<3 (F1T.37<^V#MRMGN>;PFXGX&]Q.3CBO5?#BJ
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M;</+.MIW7XP.C0($\]%[I/ ]:SY@5JMUK8UAWK2=E5KA6 ,ECLS4/$9^08Q
MF<\E:1.U&L%K-O/O&BIO])C;09_2]]5B-M+WAF3O7U6M1%IO.#".+3;+7P*A
MXARO.+6K:G8#PAD*.KRF56&=J>HTZ 475U!^^7+OGGT.<YTN0PS"N8;F?JSN
MM\\%"7N=!/8#C4OU_B^:&EZ\N.]#_2'EW]P7B0;'[[C1I+>.-S7N&E>)LZ$@
M//&SM-".NN=4),@+FJ^:7<AJQ%64#E "M>NA*!:D %>Y4UF\\T_KY';]M8TT
MITCDFYC+6U;][52(U)-@9;M5L/]GKEJGME@N]X@(\;!9\M-TB*SF!D/;\HWA
M2YJU4']=;BAL?Z(!XC\H\Z+15+Z>WE*U.XSW-D(LM>BB=7!;98RYV<UC"Q!-
M&<SI%#W_D( /]<5XD^U)??-4HQ54*Q_2$3--*5YI>'&TFFLPX^$5H9HF=8GO
MXPI<[KG<HX.Y6FL]UI/V'5RI-BE!0L79QI0VU30.Q(=V:[8"EN)\%Y@GB;4[
MDN)DQ?Y/ZC$!') \,\MR\#LKE+(/A2XXH#UK<L\U-Y/1XISPYL[W]0FU6Z3.
M)C*L%97,."2H"CTG:IH9^V_^Q^J\A;S2B1]WU94&AY8-'+M1&O[5@#+H2-3:
MZ(1[94'A"M^_CGU__WAV#J7B<FCYN/R+PAB'KWL5?[T%M;!K/%)EOT"2.7,5
MF'9K%^A3RD +ID8K9J89:N((^K;UMN:@6;3:'VDL#T3BCL&N*6KRH_#\;61\
MJYMI0<&$/Q[*!+BMT<V#_#:\X?EQG"W,)L7*XCRL=R\=3T%]8.]0^>J\XAA!
MHEM-]I<6F0D>6U6#QJWYVZ3%PC[LH7W.&(/Q+ 4NX_+NX@HR-;PA3C&^<!TZ
MO% :<Z.,7!L"+DR HSZ[.2G_373Y$1^.?NN+IUGYM3#L[OJU1J^E6,-R,3%%
MP:9L>RH38*S95DC\M>'E* G%L)<_OY4D%T?_KK%!;JC\+H(WG ?]E\2+L;+F
M&-5[J<?1Q>L5C/GE+:N&_TDW3*"NGV/&+U(3OY6Q"+-Q0B,XZJ:'+A@;<X:*
M>%=ZZ(XXQ)R0"S ;)C+#3!O6/P0==LMBUXB_//\:U+<_TV^.,$]H]\?K%.S1
M4-)<'K/\/P5O3UT@*08W9$TH].ZMA0:_=MR1?E&_OS%Y^\LD[TJ;?)U5JH=?
MV9Y<8[-WM+3P)BZVFZ,_8;UMN4"X1WU6RI\K@9S:G1(YNKU-3)7]S[;Y"[,@
M_N8,EF'F"U]PG\Z13KG5BP=/OFY=?-\D=PRU-H7@E'X3Q_>Y,C9ZF+])[0I%
M);!7#7<>JN5N0%R/2M6'5'G;E!.D^S0+@WL,J_P'Q4'DB4_9BW&!M+K3GI<O
M;OKT0U7Q3YM)1]X/'-GDT]?SKPRZX=4^QG$DL['R?9IUU#$+8IO>T@IJ(TVQ
MOAY,W2 @ZXD7W!+O.ELZF2 I*RB?K)D65H1J5J>+/^F_^#4EJ.O)X!]'2@>\
M'1V_T^D?>X3^38]IB61T4,V=8T-;\VVAC*D/2[%A"E9]:U<*;U53+.,)DJG*
MZ."O'S?-MX%+4D%]MY'CIISM?6SCX-!2I%Y"U=,<&$MAH?5\8JK4SG#)P]VE
M3PB/^/W<FJZIJD*V.>\XG%Y4%C3(_D;3CA0_GEQ!0<E'KCUBNZ6>0*K@$.K=
M'Q"BF+.EZ65?]3ZV S0B"<BI?@"-'L*:9!-[FXZ #V<<[@QMI\>Z*_=Q+!%[
M(G*K6NU7W]VCV0ZDBA<#[LRCC8>&)D@/YJS->JKMFI]#,\G613&L4%6>D>_Q
M47* 7Z_:E?'X+3VZ([N2?DHY\?V1*$S$_RK*+?-6[L3^N:5I._]G-?W.56?>
M3)[LF^L\KM ;Q)^6SGX;0W]M.>G^4Y9BYLV,(M!AIJK:YK[N\#WP@;7K9;R-
M=C(UQX5:GGKS (Y3R=.<.$:('5EZ18!/7S2+$QS.YFU37U0QF,>:H6W1H[=B
M5&]KN0;'2OZ@95LP4]E1A?144&D%G(2%5A,*-LGYNJ*3_\=/IW1LAHFK$(**
M%S_E83;,L-:"^B+YS3-6R5CW!269-#Y=32=E)&$W[$LON!:%K;K9-T^0/Y7N
M>. \O;/S46]M;I#5%V_>_*:L+OP7UO\[5M[^?U!+ P04    " "J@'Q:GVTH
MD8I;  !L?0  #0   &EM86=E7S P,RYJ<&?LO 54G,N6-OSB3H([! L$#>X>
M+!T@N$,(#L$= DT@D. ."1#<-;A+\. .P=TA0'#I_IHS]]Q[3\Z9>V;FG_NM
MF>^_S=IK]6KJW56[:LNS:U>]T&GH$G#_J8R\#  '!P>\@/T!T%E "D!%1D9!
M1D)%04%!0T-%Q\3'PL3 P"3!Q;N'3T%*14E!2D[^@(Z-X0$-"RTY.2/?(Y;'
M'-S<W%0, B+\G,)L7-R<=TS@4-'0,#$PB;&PB#FIR:DY_],?:"N @PKL(N(A
MP-$ \#AP"#APT Z "@#@D.!^^0!_^<#!(R B(:.@HJ%CP!I4W0?@X1 0X!$1
MD) 0$6'_]8;]'T#$0<*EYI! QE,V0J%QP.=\$Y6.2BM9]H5 9>20CNNEHQ\:
M.B$1,0DI_4,&QD=,W#R\?/P"@E)/I&5DY>2?JJJI:VAJ:>L8FYB:F5M86CDY
MN[BZN7MX^K\-"'SW/B@X.B8V+C[AP\?$C,RL[)S<O/R"\HK*JNJ:VKKZMO:.
MSJ[NGJ^]HV/C$Y-3T]]FEE=6U]8W-K>V=XZ.?YR<GIU?7%[=R04'(,#]^OE#
MN7!@<L$C(B(@HMS)!0?O=M< !Q&)F@,95T(9Q<@!CX;S#2J^9%1ZV1<T6BZ5
M0X*7CB/HA'3<R_1'=Z+](ME_3#"__Y)D?Q7L;W+- )@(<+#%0\ !Q(#S*\8,
M7W3&HA;<'56+!8*)4Y!+6&YY>>(*3R1N=A0&8"_1)9N7AO64.?6:*E1L2R@=
M"BPEVD&>9N[Y/(8":0?OH("?9<LEDZ\@^O^#32*F;(6-,MR]5"=:JDX$FMLM
M68?B;J,XOT\'5&_N,Y!T<?GK!P#XRM)_)=.=Y@=C)]8A7EXM597GJ-_Q7:M5
M]<K4F(BC<#D (HF8\(Q\*-!FF@T%ADKJ8!TQ+T*XI#=O8D7((%\TH< 5[V@]
M.K )!98Y1Z' YI0>%/A"\!T*D&1"\%C9(=XN0S<X!E#@*'&+,0T;_--O8C\_
M5.(7_+^)5W$(QJZWDF)U2T5,?U5]T,. LZ@Z8OA<E*A(69TR6*LW8FLI[M:0
M+QHM5X\L$-(R@C?7CX079]S.- PH)NP@[4SMW,,BY3D_2.7?;#PK\M$FJ@*<
M\37%H  :-FS2)<U@\PTN:KFDB;B0<U&ZPN,9NKXUA0)?\>&&E6'<;^@$<V_1
M$C=O(>508"U8;)EZ0FSKV938]],$*$#W'$5"V@D*'$;NI)X\M$X]O^J# M&,
M4.#M.S4HD,X%>[YETO F2IP"B6 (ML!2!>#ACR7@Q5UVB%PF!)="%?)VP D"
M!;3!Q]+_Y$$Q";S6=+)Z8;V(L<L;"7+ :DFEBP_-&^TIRZ=F,.O:I(!+PXX.
M9DR#_PTQ)TRQ(N>NLE*V>25M[>LJ-7V,'CVSMADLUT6BZ^A51*@Q5!6GD/Y%
M-+([W9V$#=M_=A$B(GM#76]X<VN=>B'2! 56Q_\R[-_^"/[IH5]GZ7\#*_43
M(8D<]SZMSWX;5R#UL;T<M8:FQ$WKR@3J]YP5.)$A8\//492E\9_#_4-R\,3V
MMRGZ-K^PL+#+*F3EMGW=]/* 'CU!)<,W_\%S^#QBP+E8Z4+*N>7R:DKLT,L+
M"G3GP30<-HB??H1I'!\("J06P]8=I:;EQO,71_:[7R/^Q>M_-J]#(_"%[((
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M:R1]\%8.S$$$/R*)PZ^X7X LSP"@ VG."@)%;"P*GWG/<2M''YZM?ZLA1!%
M<:,E_K(=K, N]7GD9LR</,6D@\0LQ2U1LUMAB);K/J<]VDK66%48EV:X//>
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MU0=[?J-.9VYE*3>3[!<9P8\P_PW\_PD O+/XOT., K_UT3! L@#^*C72LD<
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M)D+VCQVB:@X.-L7<-6S>^5=9>ULM'"B_B.EV'1LH['2@KF\(C;G.E?1%^H)
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M.5]??V4K$<ZH&.S7JN %O:A61+;GFD;/2$$?554=J;JW6'FE\+G:GXVW_DT
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MRW]&Q?]KE'']C.K'C-CUUG/$2C5#2W^(ERP4\$87'4.Y.8N 7.'#L1(0S;R
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MER7U,A\H/->HTU@IYXB+(2EE.\ZETNI5:O$*J^J(2^"*0\X XN%N:^FBFUJ
MH.//[H,^W\9)U!V&[']]LP>]PK.5OP(('\]@G8+44W84JS[:$PYG:M-=D]]#
MED8IUC6SCH/L0O*R]=L%O?CK0[48)5Z%682-4-&+U87(HB %;!9,<P6W+AX_
MDP+'O[Q5YI<E=P70GQ!&S(UF[ELL>S0F/.VR&>6%M$BM)/B,X:**_,N*332#
M9LMLW1HAIR4F*;)G2'%M^H\EW8&SB29F_;Y_%L6Z\K"*WG.C\CLW,XXDQ]=9
ME^[FFP_EPXOX#F[,7D3(/]RP7-88A$WT!3HS300%P4N(*H(<XXZ&#<)\'B1-
MJ(PNIGY4AHF"&X.$4\.DLUX5FRX XSS@1/[]Q5HEP,*M>C--9^$<5RY$F#=]
MM,ZC2:^(QQ.LQ[^9J[(@E/TQDG^6>-??+2[INHWDU8AHK!_M#11'WM7>?U*W
MHE)]VR:(6"2A^<*UL@EU=-X2^!/G!BF.5&ZF32CG/UFAB="-UT0_1"2AA.0F
MA0IE XV)2/L7O:(>H_<O\'9^7W+K)4G_1ENFB5&H"JW:R'F0S;."2*M@>4@$
MLBY<U=6#EH8JL2?"\#5^<4%15&4?4-#SR>'0=F*NX$@_ &]A]IZ/AU<%=N<E
M&XSG R<Z>Z:7M%O.&YB(]=I45&J8'R5\(=(JWI/4LTH!RTM]FT=2:=0PZ5O.
MV+JC*S:T9&X;(L(OI91KX')ZWU^V[ %3RKX-1JQVJ8[W.4KR7<R%'%FCLP=E
M8X_\NY48F>1S4;VY*=[!E+45XV-DNK6C1++9'%95,"?T>ZQ1QK;*1IXNB09L
MQ9P[V:H^9HD3;$?!-"LSYE)=^3?L#J3HJS(!>W"@T"7;UM)3T?ZVL6_+-A'-
M[X6U^Y];*#HJ111H>[JS:M<X#WN(,=D)@JM\XGXL(9R%*I0:R3H.A+#C[AB6
MA%^/]@KL^IUL%20^;"HJZGI,,WV]I].>,=:*%L1Q]4F/XK?8HCD-7%;U^NBB
M$6:6'QXBA-ZM3J)X&<_?A&4<;+K*83",;0^V3ZDIW%NJ[9'^(/\RH<@29&AY
M]4<M- \2BH'(H8"![=,]^WR&9_@B?+-R+W.":;TLYK#ZS&%>7-$FCR9H>J4_
MA\V"8YUFCU%](4&%]_6CW=RY*=:P/8D]48\$4AF,6 9+ EV!&;HUZ;@:X3WA
M!]M^SQ/BEKN4PO&,]:(*,JS=?#/NXB,/[LVCG=S3^T1S@K+']>K0B4E#8TOS
M)NMO:/CQ0_?Y&OV7O;CL$AT*FIJ@,TO:/Q)MKSLRW#7=2X6E.*&5EHB5YAC9
M/*\8F#I%Y3%Q,F./"WVC65KB=\J0KH/0SSV=KN34.8/F22/R](,RN_Q_A[O]
M*G[K[\95X \^&@I27[=5?IH@$(360.URB<UO(?T/Z3 O&>AN/4@G*-)V+38Q
M:8UWMH>XHT)/8K@>+YM3.6'/CJ\ (I?MCPY%$"V!D!"_S^H>%)X]2) U!R@W
M9'S.R.,.D.\+JOKE-F9/7_>QLO 2$69]?(CJ[PB3,^<*454D"XD&,LLQ2KL&
M:B]K>F>>+N*8D&(J<4O.[47,H:+2I' \MWVT6LYO>O''6VO4U>G>-_.% 3WH
MA@O=;SL/VW 'H@)^)NP*XHVS"20^(!--^IQ5X !+9/Y6C2#7F-(30::<8<D&
MOWQGZ?ITW%&+0.P[P*#0%WG6'F@(1B/=BQ T7F(&I.6@X>BH*%6>)_3Z#6JO
M'GA0<@>9*-U57K86*64/_;;B#](ID.4@06HHZRQ.?_O:@D#]M*W)WN[X/.C[
M,+!;!$16S/(Q\I52-\N.RQX0O3<CV5K3T&QRN0*G\VQ_"I,C2YL9F^G#(RI"
M2!T0Y C3DC:?D2FOO,:[N5-01(%<8/!; Z4'IZIC!M'0MWJ.!R+Z>IFK6 [X
MEHN,50SF(2V-)JU5$KTDF9B>/L$R/"G\8<N7R+X9<'FZ,:^-P=AN('X3Q'AH
M>Z=[B6W6(?I;\)PM#;;F3Q(A1QI++*/,3XOIT<JO:Y1$4S3ZY*&;ZRI#KW,/
MC'Y*A IWSN\>8>4#_#"C%&1OXM4B4!$+O2U.N!#+;VB7H>VT7P-8?:VA4I)-
MW?L6K?1M<M/LC3$R-F!>D<12(U;Q$[H6Y^*Y.8]SEM0&Y*7E8.SS@%D">,Q_
MXG+R9IG<&#!Z7\3AE03K;A]:4K,%V=I*\]Z4T*VBJJ>>@S^J3WLMT<+/,$H'
M75D%WU[JFA%X.[9E&VTT%K06 6_45#TFV[C0^?&"\EN+,MPUFGA;%;4D>*A_
MKLE <%"55(_S%6(_],_>T:G-=CA' =WC^K>U1@&V)@QN%Q95A;NE^:C% F&O
M\R)CDGV22NM1A_?[T5S9A.)%[;C%%'=#9SS @UP:*,X1Y8M-C7:7.-<VIGGW
M)J&<M/]<EODU;2/<.*O4[1P273F>)I+MRW^NB=2D#>NXP)%K_O6O'=\IXVSC
MVS\C+VG0@'G6?2Y[>%(%6" =9-P-GGD;4XVKMFH#IK=-"%4MD>*DHG\9VB:'
M$ZMR>O73A6S==ZZCU]1#2(6OJ5A;"CYHQL89O;."8FAC2)-X$ZR?T?*7'@%\
M<XTY/Y_.(L_\,AL##$B_Q7J/A"4<*TW;Y'U!(-O".P,\Z'HX(VU3"<HN*"D<
MR3_/F>=0[9A-+PC1PM_4:)W\J/#DX,7[>I 4*N"^5C0..^J^]<*P)KT(XRTE
M"FH^X9&L=2W82E-RG)?8 8:)^K>GXA=_V_24I3W7E>KKD@;*"[CZOK:PC@5)
M7W.K7-W5V7Z\D;-I[>2I!ED5>LW KI6O5?FXT(5.!;,(*,.[G#W(VW,MU(RW
ME8__FQIVQ(_^/^Z0__^Y0P))=R8GH9$8!MNX@?4;E8\W\)HZG\0.L!K<N%#9
M')HK0,^9Y6]-H3HL5#N8=XO".H+@[T8_ 1H>@]*"-"S3O2\V_,.>+.SUZ8W)
M.)IM9NV,ZH.?_+A7X9RN>"8B"<PASNJM*2EX9ISE.RG9&UTQ2MJCH64$I3[Q
MEKG@ P.#8&>9ZNOP_OTO7=HK^@V<QMLL*1Y&8GQ]0; %X[ZVY,7 G*=(=#$]
M'*HJ&+FAVJS0AJ?;WJ/=N2T:-W.\D5R\354=7((QKZ/@@]-YD^0.%"9KH-81
ML!E=J=&?!;(P^@@=G@E;_+*6]IPM&X/&!8= R4F$5"PH]F%3FFQFVX%@!.P'
M"0%;<G;V],3SAS$"@<8,MEKYJM%/0+G45GQ'HJE[U9"C'5EW7"%-]YWU3U>
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MU=+YS#KUROWW4.'5_'\!4$L! A0#%     @ JH!\6F!4]U<-<P( M.P4 !H
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M &5A,#(S-30X,3 Q97@R,RTQ7VEM;75C96QL+FAT;5!+ 0(4 Q0    ( *J
M?%H^!.\9+P<  "(I   <              "  ?C- @!E83 R,S4T.#$P,65X
M,S%?:6UM=6-E;&PN:'1M4$L! A0#%     @ JH!\6N"K',!J!0  01(  !P
M             ( !8=4" &5A,#(S-30X,3 Q97@S,E]I;6UU8V5L;"YH=&U0
M2P$"% ,4    " "J@'Q:<=68.E<5  !C\P  $0              @ $%VP(
M:6-C8RTR,#(T,3(S,2YX<V102P$"% ,4    " "J@'Q:Q2,NK@ 1  #LW
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M,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ JH!\6MQ=ALR#IP$ O@ "  T
M             ( !QF0$ &EM86=E7S P,2YJ<&=02P$"% ,4    " "J@'Q:
MZN'-)SUW 0#E\P$ #0              @ %T# 8 :6UA9V5?,# R+FIP9U!+
M 0(4 Q0    ( *J ?%J?;2B1BEL  &Q]   -              "  =R#!P!I
B;6%G95\P,#,N:G!G4$L%!@     /  \ " 0  )'?!P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>ea0235481-10k_immucell_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iccc="http://immucell.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iccc-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2025-03-21</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:NisinDrugSubstanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CompanyBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">iccc:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2027-09-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2027-09-30</startDate>
            <endDate>2027-09-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:MaineTechnologyInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:GorhamSavingsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:MortgageBankingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:BankLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:DebtInstrumentRedemptionPeriodSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">iccc:SubtotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:MrBrighamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:ReTainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-09</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-09</startDate>
            <endDate>2024-04-09</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iccc:CommonStockIssuancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:StockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iccc:CommonStockRightsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandTenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iccc:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">iccc:OtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:FirstDefenseProductLineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:OtherAnimalHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:BusinessInterruptionPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">iccc:VendorsPolicyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:FederalGeneralBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">iccc:StateTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:ScoursMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MastitisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iccc:EmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000811641</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-13804">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-13805">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-13806">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-13807">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityFileNumber contextRef="c0" id="ixv-76">001-12934</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-105">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="ixv-113">01-0382980</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-13808">56 Evergreen Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-13809">Portland</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0" id="ixv-13810">ME</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-141">04103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0" id="ixv-13811">(207)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0" id="ixv-13812">878-2770</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0" id="ixv-195">Common Stock, $0.10 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0" id="ixv-200">ICCC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0" id="ixv-13813">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-13814">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-13815">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-13816">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-13817">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-13818">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-13819">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-13820">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-13821">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-13822">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-13823">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c1" decimals="0" id="ixv-13824" unitRef="usd">30634000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-13825"
      unitRef="shares">8982623</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c0" id="ixv-13826">Portions of the registrant&#x2019;s definitive Proxy Statement to be filed in connection with the 2025 Annual
Meeting of Stockholders are incorporated by reference into Part III hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-3054">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Risk
Management and Strategy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
regularly assess risks from cybersecurity threats, monitor our information systems for potential vulnerabilities and test those systems
pursuant to our process. Our cybersecurity risk assessment is part of our overall risk management program. We also regularly engage outside
consultants to assess, identify and manage material risks from cybersecurity threats, including those threats associated with our use
of third-party service providers. These consultants recommend, implement and monitor systems to protect against cybersecurity threats.
Based on the information available to us through the time of this filing on March 28, 2025, we are not aware of any risks from cybersecurity
threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial
condition. However, despite our cybersecurity risk management processes, there can be no assurance that we, or the third parties with
which we interact, will not experience a cybersecurity incident in the future that may materially affect us. Refer to the risk factor
captioned &lt;i&gt;&#x201c;Increasing dependence on the continuous and reliable operation of our information technology systems&#x201d;&lt;/i&gt; under
&lt;b&gt;PART I, ITEM 1A &#x2013; RISK FACTORS&lt;/b&gt; above for additional description of cybersecurity risks and potential related impacts on
the Company.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c0" id="ixv-13827">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-13828">Based on the information available to us through the time of this filing on March 28, 2025, we are not aware of any risks from cybersecurity
threats that have materially affected or are reasonably likely to materially affect our business strategy, results of operations or financial
condition.</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-13829">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-3079">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Our
Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to
cybersecurity. Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our
President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity
risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents. While our management
team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks. Our Board of Directors
reviews cybersecurity threats and risk controls at quarterly meetings based on information provided by management and outside consultants.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c0" id="ixv-13830">Our
Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to
cybersecurity. Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our
President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity
risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-13831">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-13832">While our management
team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks. Our Board of Directors
reviews cybersecurity threats and risk controls at quarterly meetings based on information provided by management and outside consultants.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorFirmId contextRef="c0" id="ixv-13833">344</dei:AuditorFirmId>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c27" id="ixv-13834">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c27" id="ixv-13835">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c27" id="ixv-13836">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c27" id="ixv-13837">false</ecd:Rule10b51ArrAdoptedFlag>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-7375">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;Opinion on the Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.5in"&gt;We have audited the accompanying balance
sheets of ImmuCell Corporation (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, and the related statements of operations,
stockholders&#x2019; equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively
referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each
of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States
of America.&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="c0" id="ixv-13838">WIPFLI LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0" id="ixv-7483">Radnor, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-13839" unitRef="usd">3758232</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-13840" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-13841" unitRef="usd">3771133</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-13842" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-13843" unitRef="usd">7112623</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-13844" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-13845" unitRef="usd">400762</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-13846" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" id="ixv-13847" unitRef="usd">15042750</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="0" id="ixv-13848" unitRef="usd">11469850</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-13849" unitRef="usd">25349019</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-13850" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" id="ixv-13851" unitRef="usd">4560679</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="0" id="ixv-13852" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c3" decimals="0" id="ixv-13853" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c4" decimals="0" id="ixv-13854" unitRef="usd">95557</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-13855" unitRef="usd">19104</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-13856" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="0" id="ixv-13857" unitRef="usd">33368</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c4" decimals="0" id="ixv-13858" unitRef="usd">57655</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-13859" unitRef="usd">45100477</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-13860" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c3" decimals="0" id="ixv-13861" unitRef="usd">1497619</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c4" decimals="0" id="ixv-13862" unitRef="usd">1428807</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" id="ixv-13863" unitRef="usd">432072</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="0" id="ixv-13864" unitRef="usd">644276</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-13865" unitRef="usd">2482522</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-13866" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-13867" unitRef="usd">4412213</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-13868" unitRef="usd">4197420</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c3" decimals="0" id="ixv-13869" unitRef="usd">9040975</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c4" decimals="0" id="ixv-13870" unitRef="usd">10540496</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" id="ixv-13871" unitRef="usd">4129102</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="0" id="ixv-13872" unitRef="usd">4077109</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="0" id="ixv-13873" unitRef="usd">13170077</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="0" id="ixv-13874" unitRef="usd">14617605</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="0" id="ixv-13875" unitRef="usd">17582290</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c4" decimals="0" id="ixv-13876" unitRef="usd">18815025</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="2"
      id="ixv-13877"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="2"
      id="ixv-13878"
      unitRef="usdPershares">0.1</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="0"
      id="ixv-13879"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="0"
      id="ixv-13880"
      unitRef="shares">15000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="0"
      id="ixv-13881"
      unitRef="shares">9042392</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="0"
      id="ixv-13882"
      unitRef="shares">7814165</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="0"
      id="ixv-13883"
      unitRef="shares">8979091</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="0"
      id="ixv-13884"
      unitRef="shares">7750864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" id="ixv-13885" unitRef="usd">904240</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c4" decimals="0" id="ixv-13886" unitRef="usd">781417</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="0" id="ixv-13887" unitRef="usd">40916155</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="0" id="ixv-13888" unitRef="usd">36357239</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" id="ixv-13889" unitRef="usd">-14163726</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c4" decimals="0" id="ixv-13890" unitRef="usd">-12007097</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c3"
      decimals="0"
      id="ixv-13891"
      unitRef="shares">63301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c4"
      decimals="0"
      id="ixv-13892"
      unitRef="shares">63301</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c3" decimals="0" id="ixv-13893" unitRef="usd">138482</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c4" decimals="0" id="ixv-13894" unitRef="usd">138482</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-13895" unitRef="usd">27518187</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-13896" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" id="ixv-13897" unitRef="usd">45100477</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="0" id="ixv-13898" unitRef="usd">43808102</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-13899" unitRef="usd">26493169</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" id="ixv-13900" unitRef="usd">17471669</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-13901" unitRef="usd">18552125</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-13902" unitRef="usd">13602385</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-13903" unitRef="usd">7941044</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-13904" unitRef="usd">3869284</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-13905" unitRef="usd">3898582</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-13906" unitRef="usd">4394852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-13907" unitRef="usd">3466072</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-13908" unitRef="usd">3088215</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-13909" unitRef="usd">2216549</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-13910" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-13911" unitRef="usd">9581203</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-13912" unitRef="usd">9617362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-13913" unitRef="usd">-1640159</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-13914" unitRef="usd">-5748078</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-13915" unitRef="usd">-506414</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-13916" unitRef="usd">-21893</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" id="ixv-13917" unitRef="usd">-2146573</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" id="ixv-13918" unitRef="usd">-5769971</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-13919" unitRef="usd">10056</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-13920" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-13921" unitRef="usd">-2156629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-13922" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-13923"
      unitRef="shares">8167244</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-13924"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-13925"
      unitRef="usdPershares">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-13926"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-13927"
      unitRef="shares">8167244</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-13928"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-13929"
      unitRef="usdPershares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-13930"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-13931"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="0" id="ixv-13932" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="0" id="ixv-13933" unitRef="usd">35978364</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="0" id="ixv-13934" unitRef="usd">-6232499</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-13935"
      unitRef="shares">67301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="0" id="ixv-13936" unitRef="usd">-147233</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="0" id="ixv-13937" unitRef="usd">30380049</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="0" id="ixv-13938" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-13939" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="0" id="ixv-13940" unitRef="usd">10009</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c14"
      decimals="INF"
      id="ixv-13941"
      unitRef="shares">-4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c14" decimals="0" id="ixv-13942" unitRef="usd">8751</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c5" decimals="0" id="ixv-13943" unitRef="usd">18760</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c12" decimals="0" id="ixv-13944" unitRef="usd">368866</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" id="ixv-13945" unitRef="usd">368866</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="ixv-13946"
      unitRef="shares">7814165</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="0" id="ixv-13947" unitRef="usd">781417</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="0" id="ixv-13948" unitRef="usd">36357239</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="0" id="ixv-13949" unitRef="usd">-12007097</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ixv-13950"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="0" id="ixv-13951" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="0" id="ixv-13952" unitRef="usd">24993077</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c21" decimals="0" id="ixv-13953" unitRef="usd">-2156629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-13954" unitRef="usd">-2156629</us-gaap:NetIncomeLoss>
    <iccc:OfferingCostsAtthemarketOfferingOfCommonStock contextRef="c0" decimals="0" id="ixv-13955" unitRef="usd">291834</iccc:OfferingCostsAtthemarketOfferingOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c19"
      decimals="INF"
      id="ixv-13956"
      unitRef="shares">1228227</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c19" decimals="0" id="ixv-13957" unitRef="usd">122823</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20" decimals="0" id="ixv-13958" unitRef="usd">4233365</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="0" id="ixv-13959" unitRef="usd">4356188</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c20" decimals="0" id="ixv-13960" unitRef="usd">325551</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c0" decimals="0" id="ixv-13961" unitRef="usd">325551</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c23"
      decimals="INF"
      id="ixv-13962"
      unitRef="shares">9042392</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="0" id="ixv-13963" unitRef="usd">904240</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="0" id="ixv-13964" unitRef="usd">40916155</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="0" id="ixv-13965" unitRef="usd">-14163726</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="INF"
      id="ixv-13966"
      unitRef="shares">63301</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="0" id="ixv-13967" unitRef="usd">-138482</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" id="ixv-13968" unitRef="usd">27518187</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-13969" unitRef="usd">-2156629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-13970" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-13971" unitRef="usd">2668077</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" id="ixv-13972" unitRef="usd">2697897</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-13973" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" id="ixv-13974" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="0" id="ixv-13975" unitRef="usd">42666</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c5" decimals="0" id="ixv-13976" unitRef="usd">22619</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" id="ixv-13977" unitRef="usd">325551</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" id="ixv-13978" unitRef="usd">368866</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="0" id="ixv-13979" unitRef="usd">-15391</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c5" decimals="0" id="ixv-13980" unitRef="usd">-8099</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="0" id="ixv-13981" unitRef="usd">149741</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="0" id="ixv-13982" unitRef="usd">-95724</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" id="ixv-13983" unitRef="usd">1585750</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" id="ixv-13984" unitRef="usd">426783</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" id="ixv-13985" unitRef="usd">-699218</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" id="ixv-13986" unitRef="usd">1773302</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="0" id="ixv-13987" unitRef="usd">-93123</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="0" id="ixv-13988" unitRef="usd">87830</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="0" id="ixv-13989" unitRef="usd">-24287</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c5" decimals="0" id="ixv-13990" unitRef="usd">-18973</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="0" id="ixv-13991" unitRef="usd">362606</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c5" decimals="0" id="ixv-13992" unitRef="usd">156995</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" id="ixv-13993" unitRef="usd">357903</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" id="ixv-13994" unitRef="usd">-4674236</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-13995" unitRef="usd">465725</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-13996" unitRef="usd">1892513</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="0" id="ixv-13997" unitRef="usd">4500</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c5" decimals="0" id="ixv-13998" unitRef="usd">2474</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" id="ixv-13999" unitRef="usd">-461225</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" id="ixv-14000" unitRef="usd">-1890039</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c5" decimals="0" id="ixv-14001" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c5" decimals="0" id="ixv-14002" unitRef="usd">2000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="0" id="ixv-14003" unitRef="usd">4648022</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfDebt contextRef="c0" decimals="0" id="ixv-14004" unitRef="usd">1468338</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c5" decimals="0" id="ixv-14005" unitRef="usd">1185774</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c5" decimals="0" id="ixv-14006" unitRef="usd">2000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c0" decimals="0" id="ixv-14007" unitRef="usd">5037</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c5" decimals="0" id="ixv-14008" unitRef="usd">35425</us-gaap:PaymentsOfDebtIssuanceCosts>
    <iccc:PaymentsOfDebtDiscounts contextRef="c5" decimals="0" id="ixv-14009" unitRef="usd">46107</iccc:PaymentsOfDebtDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c0" decimals="0" id="ixv-14010" unitRef="usd">291834</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c5" decimals="0" id="ixv-14011" unitRef="usd">18760</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="0" id="ixv-14012" unitRef="usd">2882813</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" id="ixv-14013" unitRef="usd">1751454</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="0" id="ixv-14014" unitRef="usd">2779491</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c5" decimals="0" id="ixv-14015" unitRef="usd">-4812821</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-14016" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c10" decimals="0" id="ixv-14017" unitRef="usd">5791562</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" id="ixv-14018" unitRef="usd">3758232</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" id="ixv-14019" unitRef="usd">978741</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid contextRef="c0" decimals="0" id="ixv-14020" unitRef="usd">7293</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c5" decimals="0" id="ixv-14021" unitRef="usd">6466</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" id="ixv-14022" unitRef="usd">528907</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" id="ixv-14023" unitRef="usd">444954</us-gaap:InterestPaidNet>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c0" decimals="0" id="ixv-14024" unitRef="usd">4421</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses contextRef="c5" decimals="0" id="ixv-14025" unitRef="usd">50086</iccc:ChangeInCapitalExpendituresIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses contextRef="c5" decimals="0" id="ixv-14026" unitRef="usd">16566</iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses>
    <iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability contextRef="c0" decimals="0" id="ixv-14027" unitRef="usd">103115</iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability>
    <iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-14028" unitRef="usd">2472203</iccc:DecreaseIncreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c0" id="ixv-9281">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;1. BUSINESS OPERATIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;ImmuCell Corporation (the &#x201c;Company&#x201d;,
&#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d;) was originally incorporated in Maine in 1982 and reincorporated in Delaware in
1987, in conjunction with an initial public offering of common stock. We are an animal health company whose purpose is to create scientifically
proven and practical products that improve the health and productivity of dairy and beef cattle. We focus on the two most critical stages
of dairy productivity, those being the first 30 days of life and the first 30 days of lactation. Our concentrated colostrum and purified
Nisin technologies offer unique animal health solutions during these periods when immunity is at its most vulnerable. As disclosed in
Note 16, &#x201c;Segment Information&#x201d;, one of our business segments is dedicated to Scours and the other is focused on Mastitis.
We manufacture and market the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line, providing &lt;b&gt;Immediate Immunity&#x2122;&lt;/b&gt; to prevent
scours in newborn dairy and beef calves. We have expanded this line into four different products with formulations targeting &lt;i&gt;E. coli&lt;/i&gt;,
coronavirus and rotavirus pathogens. We are also developing &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;, a treatment for lactating dairy cows with
subclinical mastitis. Mastitis is the most significant cause of economic loss to the dairy industry. These products help reduce the need
to use traditional antibiotics in food producing animals. We are subject to certain risks including dependence on key individuals and
third-party providers of critical goods and services, competition from other larger companies, the successful sale of existing products
and the development of new viable products with appropriate regulatory approvals, where applicable. A combination of the conditions, trends
and concerns related to or arising from inflation, rising interest rates and potential recessionary conditions in the United States and/or
internationally, could have a corresponding negative effect on our business and operations. We are experiencing price increases in key
components, supportive services, transportation and other supplies that are causing our costs of goods sold to increase. We have experienced
contamination events from time to time in our production process, beginning in the third quarter of 2022, as disclosed previously. We
implemented a production slowdown during 2023 to remediate this problem, which led to the recognition of lower sales and gross margin.
The last identified contamination event occurred during the first half of April of 2024, and we have been operating without further contamination
events since then and through the time of this filing on March 28, 2025.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-9296">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(a) Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We have prepared the accompanying audited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(b) Cash and Cash Equivalents &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(c) Trade Accounts Receivable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Accounts receivable are carried at the original
invoice amount less an estimate made for credit losses, when applicable. Management determines the allowance for credit losses on a monthly
basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors.
Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due
accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the years ended
December 31, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of December
31, 2024 or 2023. As of December 31, 2024 and 2023, we determined that no allowance for credit losses was necessary. Accounts receivable
are written off when deemed uncollectible. No accounts receivable were written off during the years ended December 31, 2024 or 2023. Recoveries
of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the years
ended December 31, 2024 or 2023. See Note 3.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 4.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(e) Property, Plant and Equipment, net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; (&lt;b&gt;Building 33&lt;/b&gt;) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production facility at 175
Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 6 for additional disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(f) Operating Leases&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We account for our real estate leases using a
right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the
lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related
to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received
and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs
are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease.
When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of
determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets
or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined
lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent
payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes.
These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use
an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease
payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset
may not be recoverable. See Notes 2(h) and 11 for additional disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(g) Intangible Assets and Goodwill&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-36"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill impairments were recorded during the years ended
December 31, 2024 or 2023. See Notes 2(h) and 7 for additional disclosures.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(h) Valuation of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recognized during the years ended December 31, 2024 or
2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(i) Fair Value Measurements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In &lt;span style="font-style: normal; font-weight: normal"&gt;determining&lt;/span&gt;
fair value measurements, we follow the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. Codification
Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements.
The topic provides a consistent definition of fair value which focuses on an exit price, which is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The topic
also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes
a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of
the measurement date. As of December 31, 2024 and 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory,
prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their
short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.
Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;Level 1&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Level 2&lt;/td&gt;
    &lt;td&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Level 3&lt;/td&gt;
    &lt;td&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 28.1pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the years ended December 31, 2024 and 2023, there were no transfers between levels. As of December 31, 2024 and 2023, our Level 1 assets
measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities
measured at fair value on a nonrecurring basis as of December 31, 2024 or 2023. The carrying values of our cash and money market accounts
as of December 31, 2024 and 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the
carrying values of our fixed rate bank debt as of December 31, 2024 and 2023 differed from their fair market values. These values are
reflected in the following tables:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-26"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-27"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(j) Concentration of Risk&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years Ended&lt;br/&gt; December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;30%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;32%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#x202f;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 10.1pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;77%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;57%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;43%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;21%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;36%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;78%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(k) Revenue Recognition&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We recognize revenue in accordance with Codification
Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 13 for additional disclosures.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(l) Expense Recognition &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(m) Income Taxes&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We account
for income taxes in accordance with Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax liability
or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary
differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning strategies
in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine that it is
more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over a reasonably
short period of time, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise,
if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in the future, an
increase to the valuation allowance would be charged to income in the period such determination was made.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2024 or 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 15.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(n) Stock-Based Compensation &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We account for stock-based compensation in accordance
with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $325,551 and $368,866 during the years ended December 31, 2024 and 2023, respectively. See Note 12.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(o) Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Net loss per common share has been computed in
accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years &lt;br/&gt; Ended December 31, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(2,156,629&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(5,774,598&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(p) Use of Estimates&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in
the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation
of inventory, deferred tax assets and costs of goods sold.&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(q) New Accounting
Pronouncement Adopted&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In November of 2023, the FASB issued ASU 2023-07,
&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments require disclosure of significant
segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and loss. The adoption
of ASU 2023-07 did not have a material impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(r) New Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In November
of 2024, the FASB issued ASU 2024-03, &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, to provide disaggregated disclosures of specific
expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements
will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal
years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is
permitted. We are evaluating ASU 2024-03 to determine its impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In December
of 2023, the FASB issued ASU 2023-09&lt;i&gt;, Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments
that enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to assess the
impact on our financial statement disclosures and to determine the transition method in which the new guidance will be adopted.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-9301">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(a) Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We have prepared the accompanying audited financial
statements reflecting all adjustments (which are of a normal recurring nature) that are, in our opinion, necessary in order to ensure
that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB).
The FASB sets Generally Accepted Accounting Principles (GAAP) that we follow to ensure we accurately report our financial condition, results
of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB &lt;i&gt;Accounting Standards Codification&lt;/i&gt;&#x2122;
(Codification). We believe that the disclosures are adequate to ensure that the information presented is not misleading.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-9310">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(b) Cash and Cash Equivalents &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We consider all highly liquid investment instruments
that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities
backed by the U.S. government. We hold no cash or cash equivalents in excess of Federal Deposit Insurance Corporation (FDIC) limits of
$250,000 per financial institution per depositor.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c3" decimals="0" id="ixv-14029" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c0" id="ixv-9318">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(c) Trade Accounts Receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Accounts receivable are carried at the original
invoice amount less an estimate made for credit losses, when applicable. Management determines the allowance for credit losses on a monthly
basis by identifying troubled accounts and by using historical experience applied to an aging of accounts and other relevant factors.
Accounts receivable are considered to be past due if a portion of the receivable balance is outstanding for more than 30 days. Past due
accounts receivable are subject to an interest charge. It was not necessary to charge interest on past due accounts during the years ended
December 31, 2024 or 2023 because the time past due was not significant, and there was no accrual for such interest charges as of December
31, 2024 or 2023. As of December 31, 2024 and 2023, we determined that no allowance for credit losses was necessary. Accounts receivable
are written off when deemed uncollectible. No accounts receivable were written off during the years ended December 31, 2024 or 2023. Recoveries
of accounts receivable previously written off are recorded as income when received. No such recoveries were recorded during the years
ended December 31, 2024 or 2023. See Note 3.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-9349">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(d) Inventory&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Inventory includes raw materials, work-in-process
and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or net realizable value (determined as the
estimated selling price in the normal course of business, less reasonably predictable costs of completion, disposal and transportation).
Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. At each balance sheet date, we evaluate
our ending inventories for excess quantities and obsolescence. Inventories that we consider excess or obsolete are written down to estimated
net realizable value. Once inventory is written down and a new cost basis is established, it is not written back up. We believe that supplies
and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than
one source of supply for the components used in our products when feasible. See Note 4.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-9357">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(e) Property, Plant and Equipment, net&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We depreciate property, plant and equipment on the
straight-line method by charges to operations and costs of goods sold in amounts estimated to expense the cost of the assets from the
date they are first put into service to the end of the estimated useful lives of the assets. The facility we have constructed at 33 Caddie
Lane to produce the Nisin Drug Substance (DS) for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; (&lt;b&gt;Building 33&lt;/b&gt;) is being depreciated over 39 years
from when a Certificate of Occupancy was issued during the fourth quarter of 2017. We began depreciating the equipment for our Nisin DS
facility when it was placed in service during the third quarter of 2018. Approximately 86% of these assets are being depreciated over
10 years. We began depreciating the leasehold improvements to our new &lt;b&gt;First Defense&lt;sup&gt;&#xae; &lt;/sup&gt;&lt;/b&gt;production facility at 175
Industrial Way (&lt;b&gt;Building 175A&lt;/b&gt;) over the remainder of the 10-year lease term beginning when a Certificate of Occupancy was issued
during the second quarter of 2020. During August of 2022, this lease term was extended to January of 2043 in connection with a new lease
covering additional space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;). As a result, the net book value of these leasehold improvements
as of August 31, 2022 is now being depreciated over the remainder of the extended lease term. Significant repairs to property, plant and
equipment that benefit more than a current period are capitalized and depreciated over their useful lives. Insignificant repairs are expensed
when incurred. See Notes 2(h) and 6 for additional disclosures.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="c3" decimals="2" id="ixv-14030" unitRef="pure">0.86</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c28" id="ixv-14031">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c29" id="ixv-14032">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-9372">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(f) Operating Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We account for our real estate leases using a
right-of-use model, which recognizes that at the date of commencement, a lessee has a financial obligation to make lease payments to the
lessor for the right to use the underlying asset during the lease term and recognizes a corresponding right-of-use (ROU) asset related
to this right. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future
lease payments over the expected lease term. The ROU asset is also adjusted for any lease prepayments made, lease incentives received
and initial direct costs incurred. For operating leases with lease payments that fluctuate over the lease term, the total lease costs
are recognized on a straight-line basis over the lease term. Our leases, at times, may include options to extend the term of the lease.
When it is reasonably certain that we will exercise the option, we include the impact of the option in the lease term for purposes of
determining future lease payments. For all underlying classes of assets, we made an accounting policy election to not recognize assets
or liabilities for leases with a term of twelve months or less and to account for all components in a lease arrangement as a single combined
lease component. Short-term lease payments are recognized on a straight-line basis. Certain of our lease agreements include variable rent
payments, consisting primarily of amounts paid to the lessor based on cost or consumption, such as maintenance and real estate taxes.
These costs are recognized in the period in which the obligation is incurred. Because our leases do not specify an implicit rate, we use
an incremental borrowing rate based on information available at the lease commencement date to determine the present value of the lease
payments. We evaluate our ROU asset for impairment when events or changes in circumstances indicate that the carrying value of the asset
may not be recoverable. See Notes 2(h) and 11 for additional disclosures.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0" id="ixv-9380">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(g) Intangible Assets and Goodwill&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We amortize intangible assets on the straight-line
method by charges to costs of goods sold in amounts estimated to expense the cost of the assets from the date they are first put into
service to the end of the estimated useful lives of the assets. We have recorded intangible assets related to customer relationships,
non-compete agreements and developed technology, each with defined useful lives. Amounts paid in excess of the fair value of the net assets
(including tax attributes) are recorded as goodwill under the acquisition method of accounting. We assess the impairment of intangible
assets that have indefinite lives (when applicable) and goodwill (at the reporting unit level) on an annual basis (as of December 31&lt;sup&gt;st&lt;/sup&gt;)
and whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. We would record
an impairment charge if such an assessment were to indicate that the fair value of such assets was less than the carrying value. Judgment
is required in determining whether an event has occurred that may impair the value of goodwill or identifiable intangible assets. Factors
that could indicate that an impairment may exist include significant under-performance relative to plan or long-term projections, significant
changes in business strategy and significant negative industry or economic trends. Although we believe intangible assets and goodwill
are properly stated in the accompanying financial statements, changes in strategy or market conditions could significantly impact these
judgments and require an adjustment to the recorded balance in the future. &lt;span style="-sec-ix-hidden: hidden-fact-36"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-37"&gt;No&lt;/span&gt;&lt;/span&gt; goodwill impairments were recorded during the years ended
December 31, 2024 or 2023. See Notes 2(h) and 7 for additional disclosures.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0" id="ixv-9417">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(h) Valuation of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We periodically evaluate our long-lived assets,
consisting principally of property, plant and equipment, operating lease right-of-use asset and amortizable intangible assets, for potential
impairment. In accordance with the applicable accounting guidance for the treatment of long-lived assets, we review the carrying value
of our long-lived assets or asset group that is held and used, including intangible assets subject to amortization, for impairment whenever
events and circumstances indicate that the carrying value of the assets may not be recoverable. Under the held for use approach, the asset
or asset group to be tested for impairment should represent the lowest level for which identifiable cash flows are largely independent
of the cash flows of other groups of assets and liabilities. &lt;span style="-sec-ix-hidden: hidden-fact-38"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-39"&gt;No&lt;/span&gt;&lt;/span&gt; impairment was recognized during the years ended December 31, 2024 or
2023.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-9427">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(i) Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In &lt;span style="font-style: normal; font-weight: normal"&gt;determining&lt;/span&gt;
fair value measurements, we follow the provisions of Codification Topic 820, &lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. Codification
Topic 820 defines fair value, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements.
The topic provides a consistent definition of fair value which focuses on an exit price, which is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The topic
also prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information and establishes
a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of
the measurement date. As of December 31, 2024 and 2023, the carrying amounts of cash and cash equivalents, accounts receivable, inventory,
prepaid expenses and other current assets, other assets, accounts payable and accrued expenses approximate fair value because of their
short-term nature. The amount outstanding under our bank debt facilities is measured at carrying value in our accompanying balance sheets.
Our bank debt facilities are valued using Level 2 inputs. The three-level hierarchy is as follows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.5in"&gt;Level 1&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are quoted prices available in active markets for identical assets or liabilities as of the measurement date.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Level 2&lt;/td&gt;
    &lt;td&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are quoted prices for similar assets or liabilities, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;Level 3&lt;/td&gt;
    &lt;td&gt;&#x2014;&lt;/td&gt;
    &lt;td&gt;Pricing inputs are unobservable for the assets or liabilities, that is, inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability.&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In certain cases, the inputs used to measure fair
value may fall into different levels of the fair value hierarchy. In such cases, the level of an asset or liability within the fair value
hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance
of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.
We also hold money market accounts in our bank account, which are classified as cash equivalents and measured at fair value. The fair
value of these investments is based on their closing published net asset value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We assess the levels of the investments at each
measurement date, and transfers between levels are recognized on the actual date of the event or change in circumstances that caused the
transfer in accordance with our accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. During
the years ended December 31, 2024 and 2023, there were no transfers between levels. As of December 31, 2024 and 2023, our Level 1 assets
measured at fair value by quoted prices in active markets consisted of cash and money market accounts. There were no assets or liabilities
measured at fair value on a nonrecurring basis as of December 31, 2024 or 2023. The carrying values of our cash and money market accounts
as of December 31, 2024 and 2023 approximated their fair market values. Due to inflation and the changing interest rate environment, the
carrying values of our fixed rate bank debt as of December 31, 2024 and 2023 differed from their fair market values. These values are
reflected in the following tables:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-26"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-27"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="c0" id="ixv-14033">These values are
reflected in the following tables&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 4pt"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-26"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-27"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;3,758,232&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-28"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-29"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;9,465,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;As of December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Cash and money market accounts&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-30"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-31"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;978,741&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Bank debt&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-32"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-33"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,431,817&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c30" decimals="0" id="ixv-14034" unitRef="usd">3758232</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c33" decimals="0" id="ixv-14035" unitRef="usd">3758232</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c31" decimals="0" id="ixv-14036" unitRef="usd">9465500</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c33" decimals="0" id="ixv-14037" unitRef="usd">9465500</us-gaap:ShortTermBorrowings>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c34" decimals="0" id="ixv-14038" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c37" decimals="0" id="ixv-14039" unitRef="usd">978741</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermBorrowings contextRef="c35" decimals="0" id="ixv-14040" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c37" decimals="0" id="ixv-14041" unitRef="usd">10431817</us-gaap:ShortTermBorrowings>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-9726">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(j) Concentration of Risk&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Concentration of credit risk with respect to
accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess
the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We
maintain an allowance for potential credit losses when deemed necessary, but historically we have not experienced significant credit losses
related to an individual customer or groups of customers in any particular industry or geographic area. Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years Ended&lt;br/&gt; December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;30%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;32%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#x202f;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 10.1pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;77%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;57%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;43%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;21%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;36%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;78%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c0" id="ixv-14042">Sales to significant customers
that amounted to 10% or more of total product sales are detailed in the following table:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years Ended&lt;br/&gt; December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;47%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;30%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;32%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#x202f;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 10.1pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;77%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;As of&lt;br/&gt;
 December 31,&lt;br/&gt; 2023&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Company A&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;57%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;43%&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Company B&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;21%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;36%&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;78%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;79%&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c38" decimals="2" id="ixv-14043" unitRef="pure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c39" decimals="2" id="ixv-14044" unitRef="pure">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c40" decimals="2" id="ixv-14045" unitRef="pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c41" decimals="2" id="ixv-14046" unitRef="pure">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c42" decimals="2" id="ixv-14047" unitRef="pure">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c43" decimals="2" id="ixv-14048" unitRef="pure">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c44" decimals="2" id="ixv-14049" unitRef="pure">0.57</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c45" decimals="2" id="ixv-14050" unitRef="pure">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c46" decimals="2" id="ixv-14051" unitRef="pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c47" decimals="2" id="ixv-14052" unitRef="pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c48" decimals="2" id="ixv-14053" unitRef="pure">0.78</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c49" decimals="2" id="ixv-14054" unitRef="pure">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c0" id="ixv-9857">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(k) Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We recognize revenue in accordance with Codification
Topic 606, &lt;i&gt;Revenue from Contracts with Customers (ASC 606)&lt;/i&gt;. ASC 606 is a single comprehensive model for companies to use in accounting
for revenue arising from contracts with customers. The core principle is that we recognize the amount of revenue to which we expect to
be entitled for the transfer of promised goods or services to customers when a customer obtains control of promised goods or services
in an amount that reflects the consideration we expect to receive in exchange for those goods or services. In addition, the standard requires
disclosure of the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. We conduct our
business with customers through valid purchase orders or sales orders which are considered contracts and are not interdependent on one
another. A performance obligation is a promise in a contract to transfer a distinct product to the customer. The transaction price is
the amount of consideration we expect to receive under the arrangement. Revenue is measured based on consideration specified in a contract
with a customer. The transaction price of a contract is allocated to each distinct performance obligation and recognized when or as the
customer receives the benefit of the performance obligation. Product transaction prices on a purchase or sales order are discrete and
stand-alone. We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer
when product ships to a customer. Amounts due are typically paid approximately 30 days from the time control is transferred. Shipping
and handling costs associated with outbound freight are accounted for as a fulfillment cost in costs of goods sold. We do not bill for
or collect sales tax because our sales are generally made to distributors and thus our sales to them are not subject to sales tax. We
generally have experienced an immaterial amount of product returns. See Note 13 for additional disclosures.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <iccc:ExpenseRecognitionPolicyTextBlock contextRef="c0" id="ixv-9865">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(l) Expense Recognition &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We do not incur costs in connection with product
sales to customers that are eligible for capitalization. Advertising costs are expensed when incurred, which is generally during the month
in which the advertisement is published. All product development expenses are expensed as incurred, as are all related patent costs. We
capitalize costs to produce inventory during the production cycle, and these costs are charged to costs of goods sold when the inventory
is sold to a customer or is deemed to be in excess or obsolete.&lt;/p&gt;</iccc:ExpenseRecognitionPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-9873">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(m) Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We account
for income taxes in accordance with Codification Topic 740, &lt;i&gt;Income Taxes&lt;/i&gt;, which requires that we recognize a current tax liability
or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary
differences and carryforwards to the extent they are realizable. We consider future taxable income and feasible tax planning strategies
in assessing the need for a valuation allowance against our deferred tax assets at the end of each quarter. If we determine that it is
more likely than not that we will realize our deferred tax assets in the future in excess of the net recorded amount over a reasonably
short period of time, a reduction of the valuation allowance would increase income in the period such determination was made. Likewise,
if we determine that it is more likely than not that we will not realize all or part of our net deferred tax asset in the future, an
increase to the valuation allowance would be charged to income in the period such determination was made.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Codification
Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before
being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate
tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing
authorities. With few exceptions, we are no longer subject to income tax examinations by tax authorities for years before 2021. We have
evaluated the positions taken on our filed tax returns and have concluded that no uncertain tax positions existed as of December 31,
2024 or 2023. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 15.&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-9886">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(n) Stock-Based Compensation &lt;/b&gt;&lt;/p&gt;We account for stock-based compensation in accordance
with Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense
for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of
grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation
of $325,551 and $368,866 during the years ended December 31, 2024 and 2023, respectively.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="0" id="ixv-14055" unitRef="usd">325551</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c5" decimals="0" id="ixv-14056" unitRef="usd">368866</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-9895">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(o) Net Loss Per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Net loss per common share has been computed in
accordance with Codification Topic 260-10, &lt;i&gt;Earnings Per Share&lt;/i&gt;. The net loss per share has been computed by dividing the net loss
by the weighted average number of common shares outstanding during the period. All stock options have been excluded from the denominator
in the calculation of dilutive earnings per share when we are in a loss position because their inclusion would be anti-dilutive. Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years &lt;br/&gt; Ended December 31, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(2,156,629&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(5,774,598&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-14057">Outstanding
stock options that were not included in this calculation because the effect would be anti-dilutive amounted to 664,000 and 618,500 during
the years ended December 31, 2024 and 2023, respectively.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years &lt;br/&gt; Ended December 31, &lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 4pt"&gt;Net loss attributable to stockholders&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(2,156,629&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; width: 9%; text-align: right"&gt;(5,774,598&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average common shares outstanding - Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Dilutive impact of share-based compensation awards&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-34"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-35"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Weighted average common shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;8,167,244&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,747,686&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net loss per share:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in"&gt;Basic&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in"&gt;Diluted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.26&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(0.75&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-14058"
      unitRef="shares">664000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c5"
      decimals="0"
      id="ixv-14059"
      unitRef="shares">618500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" id="ixv-14060" unitRef="usd">-2156629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" id="ixv-14061" unitRef="usd">-5774598</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-14062"
      unitRef="shares">8167244</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c5"
      decimals="0"
      id="ixv-14063"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-14064"
      unitRef="shares">8167244</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c5"
      decimals="0"
      id="ixv-14065"
      unitRef="shares">7747686</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-14066"
      unitRef="usdPershares">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c5"
      decimals="2"
      id="ixv-14067"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-14068"
      unitRef="usdPershares">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c5"
      decimals="2"
      id="ixv-14069"
      unitRef="usdPershares">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-10036">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(p) Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during
the period. Although we regularly assess these estimates, actual amounts could differ from those estimates and are subject to change in
the near term. Changes in estimates are recorded during the period in which they become known. Significant estimates include our valuation
of inventory, deferred tax assets and costs of goods sold.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-10043">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(q) New Accounting
Pronouncement Adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In November of 2023, the FASB issued ASU 2023-07,
&lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,&lt;/i&gt; which is intended to improve reportable segment
disclosure requirements, primarily through enhanced disclosures about significant expenses. The amendments require disclosure of significant
segment expenses that are regularly provided to our chief operating decision-maker and included within segment profit and loss. The adoption
of ASU 2023-07 did not have a material impact on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock contextRef="c0" id="ixv-10054">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;(r) New Accounting Pronouncements Not Yet Adopted&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In November
of 2024, the FASB issued ASU 2024-03, &lt;i&gt;Disaggregation of Income Statement Expenses&lt;/i&gt;, to provide disaggregated disclosures of specific
expense categories underlying all relevant income statement expense line items on an annual and interim basis. The disclosure requirements
will be applied on a prospective basis, with the option to apply it retrospectively. The effective date for the standard is for fiscal
years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is
permitted. We are evaluating ASU 2024-03 to determine its impact on our financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In December
of 2023, the FASB issued ASU 2023-09&lt;i&gt;, Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which includes amendments
that enhance income tax disclosures, primarily through standardization and disaggregation of income tax rate reconciliation categories
and income taxes paid by jurisdiction. The amendments are effective for annual periods beginning after December 15, 2024, with early
adoption permitted, and may be applied either prospectively or retrospectively. We are currently evaluating ASU 2023-09 to assess the
impact on our financial statement disclosures and to determine the transition method in which the new guidance will be adopted.&lt;/p&gt;</iccc:NewAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="c0" id="ixv-10069">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;3. TRADE ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Trade accounts receivable amounted to $3,771,133
and $2,185,383 as of December 31, 2024 and 2023, respectively. No allowance for credit losses or product returns was recorded as of December
31, 2024 or 2023. We consider a broad range of information to estimate credit losses. Historically, we have experienced a very low level
of credit loss expense, and most of our trade receivables are collected by the due date or within a few days of the due date. We anticipate
no future events or conditions that would impact our ability to collect our accounts receivable. Because of the generally short duration
from the balance sheet date to the date of collection, our collection rate is not expected to be significantly impacted by events occurring
after the balance sheet date. The trade accounts receivable balances included $52,097 and $42,507 due from a related party as of December
31, 2024 and 2023, respectively. See Note 17.&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" id="ixv-14070" unitRef="usd">3771133</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c4" decimals="0" id="ixv-14071" unitRef="usd">2185383</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c50" decimals="0" id="ixv-14072" unitRef="usd">52097</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c51" decimals="0" id="ixv-14073" unitRef="usd">42507</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-10097">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;4. INVENTORY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Inventory consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,356,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,594,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,746,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,815,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,112,623&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,811,841&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;These inventory figures are net of write-offs of
scrapped inventory in the amounts of $406,565 and $527,133 during the years ended December 31, 2024 and 2023, respectively, that resulted
principally from contamination events and other production process losses.&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-10101">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Inventory consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,356,228&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,594,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Work-in-process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,746,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,815,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;402,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,112,623&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,811,841&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" id="ixv-14074" unitRef="usd">1356228</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="0" id="ixv-14075" unitRef="usd">1594028</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" id="ixv-14076" unitRef="usd">5746865</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="0" id="ixv-14077" unitRef="usd">5815194</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" id="ixv-14078" unitRef="usd">9530</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="0" id="ixv-14079" unitRef="usd">402619</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c3" decimals="0" id="ixv-14080" unitRef="usd">7112623</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c4" decimals="0" id="ixv-14081" unitRef="usd">7811841</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown contextRef="c0" decimals="0" id="ixv-14082" unitRef="usd">406565</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c5" decimals="0" id="ixv-14083" unitRef="usd">527133</us-gaap:InventoryWriteDown>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-10161">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;5. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Prepaid expenses and other current assets consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;360,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;454,152&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;400,762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;493,885&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0" id="ixv-10165">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Prepaid expenses and other current assets consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of &lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;360,207&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;454,152&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other receivables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,555&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,733&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;400,762&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;493,885&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c3" decimals="0" id="ixv-14084" unitRef="usd">360207</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="0" id="ixv-14085" unitRef="usd">454152</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="0" id="ixv-14086" unitRef="usd">40555</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c4" decimals="0" id="ixv-14087" unitRef="usd">39733</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" id="ixv-14088" unitRef="usd">400762</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c4" decimals="0" id="ixv-14089" unitRef="usd">493885</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-10213">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;6. PROPERTY, PLANT AND EQUIPMENT, net&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Property, plant and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Useful Lives &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%; text-align: left"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;3-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21,234,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;20,953,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Buildings and improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;10-39&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,889,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,784,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,768,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Land&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,390,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,059,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,041,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,483,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,349,019&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,575,683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;As of December 31, 2024 and 2023, construction
in progress consisted principally of payments toward the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; production capacity expansion project and
equipment needed to bring the formulation and aseptic filling for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; in-house. The costs associated with property,
plant and equipment disposals were $130,365 and $100,142 during the years ended December 31, 2024 and 2023, respectively. Depreciation
expense was $2,668,077 and $2,697,897 during the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-10217">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Property, plant and equipment consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&lt;br/&gt; Useful Lives &lt;br/&gt; (in years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 53%; text-align: left"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;3-10&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21,234,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;20,953,601&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Buildings and improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;10-39&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,889,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,784,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3-10&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,056,145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,036,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Construction in progress&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-40"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,768,224&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Land&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-41"&gt;n/a&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;516,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in"&gt;Property, plant and equipment, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,390,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;46,059,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(21,041,551&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,483,948&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in"&gt;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,349,019&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,575,683&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c52" id="ixv-14090">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c53" id="ixv-14091">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c54" decimals="0" id="ixv-14092" unitRef="usd">21234259</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c55" decimals="0" id="ixv-14093" unitRef="usd">20953601</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c56" id="ixv-14094">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c57" id="ixv-14095">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c58" decimals="0" id="ixv-14096" unitRef="usd">20889395</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c59" decimals="0" id="ixv-14097" unitRef="usd">20784565</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c60" id="ixv-14098">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c61" id="ixv-14099">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="0" id="ixv-14100" unitRef="usd">1056145</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="0" id="ixv-14101" unitRef="usd">1036374</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c64" decimals="0" id="ixv-14102" unitRef="usd">2693904</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c65" decimals="0" id="ixv-14103" unitRef="usd">2768224</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c66" decimals="0" id="ixv-14104" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c67" decimals="0" id="ixv-14105" unitRef="usd">516867</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" id="ixv-14106" unitRef="usd">46390570</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="0" id="ixv-14107" unitRef="usd">46059631</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-14108" unitRef="usd">21041551</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-14109" unitRef="usd">18483948</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" id="ixv-14110" unitRef="usd">25349019</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="0" id="ixv-14111" unitRef="usd">27575683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c0" decimals="0" id="ixv-14112" unitRef="usd">130365</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:PropertyPlantAndEquipmentDisposals contextRef="c5" decimals="0" id="ixv-14113" unitRef="usd">100142</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:Depreciation contextRef="c0" decimals="0" id="ixv-14114" unitRef="usd">2668077</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c5" decimals="0" id="ixv-14115" unitRef="usd">2697897</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c0" id="ixv-10363">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;7. INTANGIBLE ASSETS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Intangible assets of $191,040 were valued using
the relief from royalty method and are being amortized to costs of goods sold over their useful lives, which are estimated to be 10 years.
Intangible amortization expense was $19,104 during both of the years ended December 31, 2024 and 2023. The net value of these intangibles
was $19,104 and $38,208 as of December 31, 2024 and 2023, respectively. Intangible asset amortization expense is estimated to be $19,104
during the year ending December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Intangible assets as of December 31, 2024 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Carrying &lt;br/&gt;
Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(165,690&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,076&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;564&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(171,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,104&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Intangible assets as of December 31, 2023 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Carrying &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated &lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(147,280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(152,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,208&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-14116" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c3" id="ixv-14117">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c0" decimals="0" id="ixv-14118" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c5" decimals="0" id="ixv-14119" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-14120" unitRef="usd">19104</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-14121" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c68" decimals="0" id="ixv-14122" unitRef="usd">19104</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c0" id="ixv-10369">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Intangible assets as of December 31, 2024 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Carrying &lt;br/&gt;
Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated&lt;br/&gt;
 Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(165,690&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,410&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,170&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,076&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;564&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(171,936&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,104&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Intangible assets as of December 31, 2023 consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Gross&lt;br/&gt;
 Carrying &lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accumulated &lt;br/&gt; Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Net Book&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Developed technology&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;184,100&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(147,280&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,820&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Customer relationships&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,040&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Non-compete agreements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,640&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,512&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,128&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;191,040&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(152,832&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;38,208&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c69" decimals="0" id="ixv-14123" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c69" decimals="0" id="ixv-14124" unitRef="usd">165690</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c69" decimals="0" id="ixv-14125" unitRef="usd">18410</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c70" decimals="0" id="ixv-14126" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c70" decimals="0" id="ixv-14127" unitRef="usd">1170</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c70" decimals="0" id="ixv-14128" unitRef="usd">130</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c71" decimals="0" id="ixv-14129" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c71" decimals="0" id="ixv-14130" unitRef="usd">5076</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c71" decimals="0" id="ixv-14131" unitRef="usd">564</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c3" decimals="0" id="ixv-14132" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c3" decimals="0" id="ixv-14133" unitRef="usd">171936</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c3" decimals="0" id="ixv-14134" unitRef="usd">19104</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c72" decimals="0" id="ixv-14135" unitRef="usd">184100</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c72" decimals="0" id="ixv-14136" unitRef="usd">147280</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c72" decimals="0" id="ixv-14137" unitRef="usd">36820</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c73" decimals="0" id="ixv-14138" unitRef="usd">1300</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c73" decimals="0" id="ixv-14139" unitRef="usd">1040</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c73" decimals="0" id="ixv-14140" unitRef="usd">260</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c74" decimals="0" id="ixv-14141" unitRef="usd">5640</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c74" decimals="0" id="ixv-14142" unitRef="usd">4512</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c74" decimals="0" id="ixv-14143" unitRef="usd">1128</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c4" decimals="0" id="ixv-14144" unitRef="usd">191040</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c4" decimals="0" id="ixv-14145" unitRef="usd">152832</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c4" decimals="0" id="ixv-14146" unitRef="usd">38208</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-10523">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;8. ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Accounts payable and accrued expenses consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts payable &#x2013; trade&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;934,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable &#x2013; capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,195,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;942,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,552&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,482,522&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,124,337&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-10527">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Accounts payable and accrued expenses consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As of&lt;br/&gt; December&#160;31,&#160;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accounts payable &#x2013; trade&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;934,883&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;874,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts payable &#x2013; capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,175&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,195,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;942,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234,552&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;192,754&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income tax payable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,815&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.125in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,482,522&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,124,337&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="0" id="ixv-14147" unitRef="usd">934883</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="0" id="ixv-14148" unitRef="usd">874558</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c3" decimals="0" id="ixv-14149" unitRef="usd">8754</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="0" id="ixv-14150" unitRef="usd">13175</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c3" decimals="0" id="ixv-14151" unitRef="usd">1195703</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c4" decimals="0" id="ixv-14152" unitRef="usd">942999</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="0" id="ixv-14153" unitRef="usd">102815</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c4" decimals="0" id="ixv-14154" unitRef="usd">97800</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14155" unitRef="usd">234552</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14156" unitRef="usd">192754</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c3" decimals="0" id="ixv-14157" unitRef="usd">5815</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c4" decimals="0" id="ixv-14158" unitRef="usd">3051</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c3" decimals="0" id="ixv-14159" unitRef="usd">2482522</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c4" decimals="0" id="ixv-14160" unitRef="usd">2124337</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-10615">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;9. BANK DEBT&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loans #1 and #2&lt;/b&gt;: During the first quarter
of 2020, we closed on a debt financing with Maine Community Bank (formerly known as Gorham Savings Bank) (MCB) aggregating $8,600,000,
which was comprised of a $5,100,000 mortgage note (Loan #1) that bears interest at a fixed rate of 3.50% per annum (with a 10-year term
and 25-year amortization schedule and a balloon principal payment of $3,145,888 due during the first quarter of 2030) and a $3,500,000
note (Loan #2) that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule). The proceeds from
the 2020 debt refinancing were used to repay all bank debt outstanding at the time of closing and to provide some additional working capital.
During the first quarter of 2022, we closed on an additional $2,000,000 in mortgage debt, which bears interest at the fixed rate of 3.58%
per annum. This was accomplished through an amendment of the original mortgage note (Loan #1) that increased the then outstanding principal
balance from $4,233,957 to $6,233,957 bearing interest at the blended fixed rate of 3.53% per annum. This increased the balloon payment
from $3,145,888 to $3,687,608 and extended the due date of the balloon payment from the first quarter of 2030 to the first quarter of
2032.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Line of Credit (LOC)&lt;/b&gt;: Also during the first
quarter of 2020, MCB extended a $1,000,000 LOC to us that is available, as needed, through September 11, 2025. Interest on borrowings
against the LOC is variable at the National Prime Rate per annum. There was no outstanding balance under this LOC as of December 31, 2024
or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loan #3&lt;/b&gt;: During the second quarter of 2020,
we received a loan from the Maine Technology Institute (MTI) in the aggregate principal amount of $500,000. The first 2.25 years of this
loan were interest-free with no interest accrual or required principal payments. Beginning during the fourth quarter of 2022, Loan #3
became subject to quarterly principal and interest payments at a fixed rate of 5% per annum over the final five years of the loan, through
the third quarter of 2027 if not repaid before then.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loan #4&lt;/b&gt;: During the fourth quarter of 2020,
we closed on a $1,500,000 note with MCB that bears interest at a fixed rate of 3.50% per annum (with a 7-year term and amortization schedule).
Proceeds of $624,167 were used to prepay a portion of the outstanding principal on our mortgage note (Loan #1), which reduced the outstanding
balance to 80% of the most recent appraised value of the property securing the debt, which allowed MCB to release the $1,400,000 that
had been held in escrow. The remaining proceeds were available for general working capital purposes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loan #5&lt;/b&gt;: On June 30, 2021, we executed definitive
agreements covering a second loan from the MTI in the aggregate principal amount of $400,000, proceeds from which were received in July
of 2021. The first two years of this loan were interest-free with no interest accrual or required principal payments. Principal and interest
payments at a fixed rate of 5% per annum are due quarterly over the final 5.5 years of the loan, beginning during the third quarter of
2023 and continuing through the fourth quarter of 2028 if not repaid before then.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loan #6: &lt;/b&gt;During the third quarter of 2023,
we closed on a $2,000,000 term loan bearing interest at a fixed rate of 7% per annum from MCB. The Finance Authority of Maine (FAME) provided
$1,000,000 of loan insurance to MCB. This loan is repayable under a 7-year amortization schedule with a balloon payment of $1,285,047
due during the third quarter of 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;b&gt;Loan #7:&lt;/b&gt; Also during the third quarter of
2023, we closed on a $1,000,000 term loan bearing interest at a fixed rate of 8% per annum from FAME. The loan is repayable under a 7-year
amortization schedule with a balloon payment of $649,259 due during the third quarter of 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Loans #1, #2, #4, #6 and #7 are secured by liens
on substantially all of our assets and are subject to certain restrictions and financial covenants. Loan #7 is subordinated to Loans #1,
#2, #4 and #6. Reflecting our poor financial performance during 2023 and into the first nine months of 2024, the debt service covenant
(DSC) requirements for the twelve-month periods ended December 31, 2023, June 30, 2024, September 30, 2024 and December 31, 2024 were
waived pre-emptively by our lenders. We are required to meet a minimum DSC ratio of 1.35 for the year ending December 31, 2025 and annually
thereafter. In connection with these credit facilities, we incurred aggregate debt issuance and debt discount costs of $173,305. The amortization
of these debt issuance and debt discount costs is being recorded as a component of interest expense, included in other expenses, net,
and is being amortized on a straight-line basis over the underlying terms of the notes. Loans #3 and #5 are unsecured and subordinated
to our indebtedness to MCB and FAME. Failure to make timely payments of principal and interest, or otherwise to comply with the terms
of the agreements of Loans #3 and #5, would entitle the MTI to accelerate the maturity of such debt and demand repayment in full. These
loans may be prepaid without penalty at any time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;During
the Year Ended &lt;br/&gt;
December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;During
the Year Ended &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Proceeds
from&lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Debt&#160;Principal&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Repayments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;230,763&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;213,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,468,338&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,185,774&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Principal payments (net of debt issuance and debt
discount costs) due under bank loans outstanding as of December 31, 2024 (excluding our $1,000,000 line of credit) are reflected in the
following table by the year that payments are due:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 16%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,604&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;257,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;276,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,321,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,611,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;690,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,671,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;715,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;840,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,539,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,341,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;798,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,321,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,626,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,174&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt discount cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(32,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,497,619&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,316,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;793,389&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;344,110&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;273,207&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,313,934&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,538,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c75" decimals="0" id="ixv-14161" unitRef="usd">8600000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:EscrowDeposit contextRef="c76" decimals="0" id="ixv-14162" unitRef="usd">5100000</us-gaap:EscrowDeposit>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c76" decimals="4" id="ixv-14163" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <iccc:InterestPaymentsTerm contextRef="c77" id="ixv-14164">P10Y</iccc:InterestPaymentsTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c77" id="ixv-14165">P25Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c78" decimals="0" id="ixv-14166" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c79" decimals="0" id="ixv-14167" unitRef="usd">3500000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c79" decimals="4" id="ixv-14168" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <iccc:InterestPaymentsTerm contextRef="c80" id="ixv-14169">P7Y</iccc:InterestPaymentsTerm>
    <us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount contextRef="c81" decimals="0" id="ixv-14170" unitRef="usd">2000000</us-gaap:ParticipatingMortgageLoansUnamortizedDebtDiscountAmount>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c81" decimals="4" id="ixv-14171" unitRef="pure">0.0358</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c82" decimals="0" id="ixv-14172" unitRef="usd">4233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized contextRef="c83" decimals="0" id="ixv-14173" unitRef="usd">6233957</us-gaap:PrincipalAmountOutstandingOnLoansManagedAndSecuritized>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c3" decimals="4" id="ixv-14174" unitRef="pure">0.0353</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c82" decimals="0" id="ixv-14175" unitRef="usd">3145888</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c83" decimals="0" id="ixv-14176" unitRef="usd">3687608</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:LineOfCredit contextRef="c84" decimals="0" id="ixv-14177" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c85" decimals="0" id="ixv-14178" unitRef="usd">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c86" id="ixv-14179">P2Y3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DerivativeFixedInterestRate contextRef="c87" decimals="2" id="ixv-14180" unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c88" id="ixv-14181">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c89" decimals="0" id="ixv-14182" unitRef="usd">1500000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c89" decimals="4" id="ixv-14183" unitRef="pure">0.035</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c90" id="ixv-14184">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c91" decimals="0" id="ixv-14185" unitRef="usd">624167</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <iccc:LoanToValueRatio contextRef="c91" decimals="2" id="ixv-14186" unitRef="pure">0.80</iccc:LoanToValueRatio>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c92" decimals="0" id="ixv-14187" unitRef="usd">1400000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c93" decimals="0" id="ixv-14188" unitRef="usd">400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DerivativeFixedInterestRate contextRef="c93" decimals="2" id="ixv-14189" unitRef="pure">0.05</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c94" id="ixv-14190">P5Y6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c95" decimals="0" id="ixv-14191" unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c95" decimals="2" id="ixv-14192" unitRef="pure">0.07</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:FinancingReceivableLoanInProcess contextRef="c95" decimals="0" id="ixv-14193" unitRef="usd">1000000</us-gaap:FinancingReceivableLoanInProcess>
    <us-gaap:DebtInstrumentTerm contextRef="c96" id="ixv-14194">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c97" decimals="0" id="ixv-14195" unitRef="usd">1285047</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c98" decimals="0" id="ixv-14196" unitRef="usd">1000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="c98" decimals="2" id="ixv-14197" unitRef="pure">0.08</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:DebtInstrumentTerm contextRef="c99" id="ixv-14198">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid contextRef="c100" decimals="0" id="ixv-14199" unitRef="usd">649259</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <iccc:DebtServiceCoverageRatio contextRef="c68" decimals="2" id="ixv-14200" unitRef="pure">1.35</iccc:DebtServiceCoverageRatio>
    <us-gaap:DeferredFinanceCostsCurrentGross contextRef="c3" decimals="0" id="ixv-14201" unitRef="usd">173305</us-gaap:DeferredFinanceCostsCurrentGross>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c0" id="ixv-10674">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Debt proceeds received and principal repayments
made (excluding our $1,000,000 line of credit) are reflected by loan during the periods as described in the tables below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;During
the Year Ended &lt;br/&gt;
December 31, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;During
the Year Ended &lt;br/&gt;
December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Proceeds
from&lt;br/&gt;
Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Debt&#160;Principal&lt;br/&gt;
 Repayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Proceeds&#160;from&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Debt Issuance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Debt&#160;Principal&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;Repayments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-42"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;230,763&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-43"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;223,222&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-44"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;512,139&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-45"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;494,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-46"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,104&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-47"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;91,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-48"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;213,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-49"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;205,884&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-50"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;235,393&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;114,242&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;45,696&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,468,338&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,000,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,185,774&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LineOfCredit contextRef="c3" decimals="0" id="ixv-14202" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:RepaymentsOfBankDebt contextRef="c102" decimals="0" id="ixv-14203" unitRef="usd">230763</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c103" decimals="0" id="ixv-14204" unitRef="usd">223222</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c104" decimals="0" id="ixv-14205" unitRef="usd">512139</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c105" decimals="0" id="ixv-14206" unitRef="usd">494455</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c106" decimals="0" id="ixv-14207" unitRef="usd">96104</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c107" decimals="0" id="ixv-14208" unitRef="usd">91446</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c108" decimals="0" id="ixv-14209" unitRef="usd">213227</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c109" decimals="0" id="ixv-14210" unitRef="usd">205884</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c110" decimals="0" id="ixv-14211" unitRef="usd">66470</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c111" decimals="0" id="ixv-14212" unitRef="usd">32017</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c112" decimals="0" id="ixv-14213" unitRef="usd">235393</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c113" decimals="0" id="ixv-14214" unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c113" decimals="0" id="ixv-14215" unitRef="usd">93054</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c114" decimals="0" id="ixv-14216" unitRef="usd">114242</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c115" decimals="0" id="ixv-14217" unitRef="usd">1000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c115" decimals="0" id="ixv-14218" unitRef="usd">45696</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c0" decimals="0" id="ixv-14219" unitRef="usd">1468338</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c5" decimals="0" id="ixv-14220" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:RepaymentsOfBankDebt contextRef="c5" decimals="0" id="ixv-14221" unitRef="usd">1185774</us-gaap:RepaymentsOfBankDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c0" id="ixv-10898">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Principal payments (net of debt issuance and debt
discount costs) due under bank loans outstanding as of December 31, 2024 (excluding our $1,000,000 line of credit) are reflected in the
following table by the year that payments are due:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2027&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 16%"&gt;Loan #1&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;239,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;248,604&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;257,649&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,537&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;276,720&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,321,768&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,611,142&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #2&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;530,738&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;549,881&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;140,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,221,042&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #3&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;101,001&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;106,146&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;83,143&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #4&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220,998&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,965&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240,438&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;690,401&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loan #5&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73,415&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,156&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81,086&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-64"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-65"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;301,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Loan #6&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;253,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,418,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-66"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-67"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-68"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,671,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Loan #7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;124,364&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;715,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-70"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-71"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-72"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-73"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;840,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,539,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,341,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;798,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;276,720&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,321,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,626,003&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Debt issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(21,314&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(13,580&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,420&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,513&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7,834&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,174&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Debt discount cost&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(20,891&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(11,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-74"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-75"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-76"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-77"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(32,235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,497,619&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;3,316,335&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;793,389&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;344,110&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;273,207&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,313,934&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,538,594&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LineOfCredit contextRef="c101" decimals="0" id="ixv-14222" unitRef="usd">1000000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c116" decimals="0" id="ixv-14223" unitRef="usd">239864</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c116" decimals="0" id="ixv-14224" unitRef="usd">248604</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c116" decimals="0" id="ixv-14225" unitRef="usd">257649</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c116" decimals="0" id="ixv-14226" unitRef="usd">266537</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c116" decimals="0" id="ixv-14227" unitRef="usd">276720</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c116" decimals="0" id="ixv-14228" unitRef="usd">4321768</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c116" decimals="0" id="ixv-14229" unitRef="usd">5611142</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c117" decimals="0" id="ixv-14230" unitRef="usd">530738</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c117" decimals="0" id="ixv-14231" unitRef="usd">549881</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c117" decimals="0" id="ixv-14232" unitRef="usd">140423</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c117" decimals="0" id="ixv-14233" unitRef="usd">1221042</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c118" decimals="0" id="ixv-14234" unitRef="usd">101001</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c118" decimals="0" id="ixv-14235" unitRef="usd">106146</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c118" decimals="0" id="ixv-14236" unitRef="usd">83143</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c118" decimals="0" id="ixv-14237" unitRef="usd">290290</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c119" decimals="0" id="ixv-14238" unitRef="usd">220998</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c119" decimals="0" id="ixv-14239" unitRef="usd">228965</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c119" decimals="0" id="ixv-14240" unitRef="usd">240438</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c119" decimals="0" id="ixv-14241" unitRef="usd">690401</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c120" decimals="0" id="ixv-14242" unitRef="usd">69856</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c120" decimals="0" id="ixv-14243" unitRef="usd">73415</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c120" decimals="0" id="ixv-14244" unitRef="usd">77156</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c120" decimals="0" id="ixv-14245" unitRef="usd">81086</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c120" decimals="0" id="ixv-14246" unitRef="usd">301513</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c121" decimals="0" id="ixv-14247" unitRef="usd">253003</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c121" decimals="0" id="ixv-14248" unitRef="usd">1418550</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt contextRef="c121" decimals="0" id="ixv-14249" unitRef="usd">1671553</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c122" decimals="0" id="ixv-14250" unitRef="usd">124364</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c122" decimals="0" id="ixv-14251" unitRef="usd">715698</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt contextRef="c122" decimals="0" id="ixv-14252" unitRef="usd">840062</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c123" decimals="0" id="ixv-14253" unitRef="usd">1539824</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c123" decimals="0" id="ixv-14254" unitRef="usd">3341259</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c123" decimals="0" id="ixv-14255" unitRef="usd">798809</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c123" decimals="0" id="ixv-14256" unitRef="usd">347623</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c123" decimals="0" id="ixv-14257" unitRef="usd">276720</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c123" decimals="0" id="ixv-14258" unitRef="usd">4321768</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c123" decimals="0" id="ixv-14259" unitRef="usd">10626003</us-gaap:LongTermDebt>
    <iccc:DebtIssuanceCosts2025 contextRef="c3" decimals="0" id="ixv-14260" unitRef="usd">21314</iccc:DebtIssuanceCosts2025>
    <iccc:DebtIssuanceCosts2026 contextRef="c3" decimals="0" id="ixv-14261" unitRef="usd">13580</iccc:DebtIssuanceCosts2026>
    <iccc:DebtIssuanceCosts2027 contextRef="c3" decimals="0" id="ixv-14262" unitRef="usd">5420</iccc:DebtIssuanceCosts2027>
    <iccc:DebtIssuanceCosts2028 contextRef="c3" decimals="0" id="ixv-14263" unitRef="usd">3513</iccc:DebtIssuanceCosts2028>
    <iccc:DebtIssuanceCosts2029 contextRef="c3" decimals="0" id="ixv-14264" unitRef="usd">3513</iccc:DebtIssuanceCosts2029>
    <iccc:DebtIssuanceCostshereafter contextRef="c3" decimals="0" id="ixv-14265" unitRef="usd">7834</iccc:DebtIssuanceCostshereafter>
    <us-gaap:DeferredFinanceCostsNet contextRef="c3" decimals="0" id="ixv-14266" unitRef="usd">55174</us-gaap:DeferredFinanceCostsNet>
    <iccc:DebtDiscountCost2025 contextRef="c3" decimals="0" id="ixv-14267" unitRef="usd">20891</iccc:DebtDiscountCost2025>
    <iccc:DebtDiscountCost2026 contextRef="c3" decimals="0" id="ixv-14268" unitRef="usd">11344</iccc:DebtDiscountCost2026>
    <iccc:DebtDiscountCostTotal contextRef="c3" decimals="0" id="ixv-14269" unitRef="usd">32235</iccc:DebtDiscountCostTotal>
    <iccc:LongTermDebt2025 contextRef="c3" decimals="0" id="ixv-14270" unitRef="usd">1497619</iccc:LongTermDebt2025>
    <iccc:LongTermDebt2026 contextRef="c3" decimals="0" id="ixv-14271" unitRef="usd">3316335</iccc:LongTermDebt2026>
    <iccc:LongTermDebt2027 contextRef="c3" decimals="0" id="ixv-14272" unitRef="usd">793389</iccc:LongTermDebt2027>
    <iccc:LongTermDebtTotal2028 contextRef="c3" decimals="0" id="ixv-14273" unitRef="usd">344110</iccc:LongTermDebtTotal2028>
    <iccc:LongTermDebt2029 contextRef="c3" decimals="0" id="ixv-14274" unitRef="usd">273207</iccc:LongTermDebt2029>
    <iccc:LongTermDebtThereafter contextRef="c3" decimals="0" id="ixv-14275" unitRef="usd">4313934</iccc:LongTermDebtThereafter>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c3" decimals="0" id="ixv-14276" unitRef="usd">10538594</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-11293">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;10. CONTINGENT LIABILITIES AND COMMITMENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Our bylaws, as amended, in effect provide that the
Company will indemnify its officers and directors against any liability arising from their responsibilities as officers and directors
to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings with each director through a separate
indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically
unlimited and is impossible to determine. We maintain directors&#x2019; and officers&#x2019; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460&lt;i&gt;, Guarantees&lt;/i&gt;. Accordingly, we have recorded no liability
for such obligations as of December 31, 2024 or 2023. Since our incorporation, we have had no occasion to make any indemnification payment
to any of our officers or directors for any reason.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The development, manufacturing and marketing of
animal health care products entails an inherent risk that liability claims will be asserted against us during the normal course of business.
We are aware of no such claims against us as of the time of this filing on March 28, 2025. We believe that we have reasonable levels of
liability insurance to support our operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We enter into agreements with third parties in the
ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The
precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification
obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging
any of these indemnification obligations and based on our analysis of the nature of the risks involved, we believe that the fair value
of the liabilities potentially arising under these agreements is minimal. Accordingly, we recorded no liabilities for such obligations
as of December 31, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We plan to purchase certain key parts (syringes)
and services (formulation, aseptic filling and final packaging) pertaining to &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; Drug Product (DP), our Nisin-based
intramammary treatment of subclinical mastitis in lactating dairy cows, exclusively from contractors. The contract for formulation, aseptic
filling and final packaging of DP terminated on November 30, 2024. This contract was extended through March of 2026 for the purpose of
final packaging of existing DP inventory, but this contract extension does not anticipate the production of new DP inventory. During 2019,
we initiated an investment in the necessary equipment to perform the DP formulation and aseptic filling services in-house, but this investment
has been paused at the present time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Effective March 28, 2022, we entered into an Amended
and Restated Separation and Deferred Compensation Agreement (the &#x201c;Deferred Compensation Agreement&#x201d;) with Mr. Brigham (our
President and CEO) that superseded and replaced in its entirety a March 2020 severance agreement between the Company and Mr. Brigham.
Upon separation from the Company for any reason, Mr. Brigham&#x2019;s Deferred Compensation Agreement allows Mr. Brigham to be paid, among
other amounts, all earned and unused paid time off. Accordingly, an expense of $222,379 for earned and unpaid sick time was accrued during
the first quarter of 2022 and a related accrual of $230,162 was included in accounts payable and accrued expenses as of December 31, 2024
and 2023. Additionally, Mr. Brigham was paid $300,000 in deferred compensation during the first quarter of 2025 (which was accrued over
the three-year period ending in December 2024). This deferred compensation payment vested as to $300,000, $200,000 and $100,000 on January
1, 2025, 2024 and 2023, respectively. Deferred compensation of $300,000 and $200,000 was included in accounts payable and accrued expenses
on the accompanying balance sheets as of December 31, 2024 and 2023, respectively. In addition, upon termination of Mr. Brigham&#x2019;s
employment (a) by the Company other than for cause, (b) due to death or disability or (c) by Mr. Brigham for good reason, in each case
as described and defined in the Deferred Compensation Agreement, the Company agrees to pay Mr. Brigham 100% of his then current annual
base salary and a lump sum payment equal to the employer portion of the costs of continued health benefits for Mr. Brigham and his covered
dependents for a twelve-month period following termination, and certain equity incentive awards granted to Mr. Brigham would continue
to vest following such termination in accordance with the terms of the Deferred Compensation Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Incentive
compensation agreements may be entered into with Mr. Brigham, Ms. Brockmann (our Vice President of Sales and Marketing) and Ms. Williams
(formerly our Vice President of Manufacturing Operations), which, at times, allow these executives to earn incentive compensation if certain
regulatory and financial objectives are met during the year to which the agreement relates, as specified in their agreements. Amounts
related to these incentive compensation agreements are accrued over the period they are earned (when it is probable that the amounts will
be earned) based on our best estimate of the amounts expected to be &lt;/span&gt;earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In addition to the commitments discussed above,
we had committed $67,000 to increase our production capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line, $1,629,000 to
the purchase of inventory and $686,000 to information technology services and other obligations as of December 31, 2024.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c124" decimals="0" id="ixv-14277" unitRef="usd">222379</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c125" decimals="0" id="ixv-14278" unitRef="usd">230162</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c126" decimals="0" id="ixv-14279" unitRef="usd">230162</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c127" decimals="0" id="ixv-14280" unitRef="usd">300000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c128" decimals="0" id="ixv-14281" unitRef="usd">300000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c129" decimals="0" id="ixv-14282" unitRef="usd">200000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent contextRef="c130" decimals="0" id="ixv-14283" unitRef="usd">100000</us-gaap:OtherDeferredCompensationArrangementsLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" id="ixv-14284" unitRef="usd">300000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="0" id="ixv-14285" unitRef="usd">200000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="c131"
      decimals="2"
      id="ixv-14286"
      unitRef="pure">1</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <iccc:CapitalExpendituresCommitted contextRef="c3" decimals="0" id="ixv-14287" unitRef="usd">67000</iccc:CapitalExpendituresCommitted>
    <iccc:PurchaseofInventory contextRef="c0" decimals="0" id="ixv-14288" unitRef="usd">1629000</iccc:PurchaseofInventory>
    <iccc:CommitmentsRelatedToCommercialManufacture contextRef="c132" decimals="0" id="ixv-14289" unitRef="usd">686000</iccc:CommitmentsRelatedToCommercialManufacture>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-11366">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;11. OPERATING LEASES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;On September
12, 2019, we entered into a lease covering approximately 14,300 square feet of office and warehouse space with a possession date of November
15, 2019 and a commencement date of February 13, 2020. The property is located at 175 Industrial Way in Portland (&lt;b&gt;Building 175A&lt;/b&gt;),
which is a short distance from our headquarters and manufacturing facility at 56 Evergreen Drive. We renovated this space to meet our
needs in expanding our production capacity for the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line. The original lease term was ten
years with a right to renew for a second 10-year term and a right of first offer to purchase. At the time we entered into this lease,
we were not reasonably assured that we would exercise this renewal option in place of other real estate options. For that reason, a 10-year
period was reflected in the right-of-use (ROU) asset and lease liability on our balance sheet. During the third quarter of 2022, we committed
to lease an additional 15,400 square feet of space at 175 Industrial Way (&lt;b&gt;Building 175B&lt;/b&gt;), which is connected to the original space,
over a 20-year term. The ROU asset and lease liability for the committed space at &lt;b&gt;Building 175B&lt;/b&gt; was recorded as of April 1, 2023
after construction of the building shell was completed in accordance with the lease agreement. Monthly lease payments commenced as of
August 1, 2023. In connection with the lease commitment for space at &lt;b&gt;Building 175B&lt;/b&gt;&lt;span style="font-style: normal; font-weight: normal"&gt;,&lt;/span&gt;
the term of the original lease for &lt;b&gt;Building 175A&lt;/b&gt; was extended by approximately 13 years. On November 14, 2023, June 11,
2024 and September 20, 2024, we amended this lease further to provide for certain tenant improvements on the leased premises to be paid
for by our landlord. These improvements will provide heat to an unfinished space, provide additional warehouse space, and create a new
primary shipping and receiving facility. As a result of these three amendments and in consideration for the landlord agreeing to pay
for the cost of those certain tenant improvements, we agreed to make additional rent payments of $20,000 per month from November of 2023
through June of 2025 and a one-time additional rent payment of $248,743 in July of 2025. Because of these modifications to the lease
payments, the ROU asset and lease liability associated with the space at &lt;b&gt;Building 175B&lt;/b&gt; were remeasured as of the modification
dates. Our leases include variable non-lease components. Such payments primarily include common area maintenance charges. As of December
31, 2024, the balance of the operating lease ROU asset was $4,560,679 and the operating lease liability was $4,561,174. As of December
31, 2023, the balance of the operating lease ROU asset was $4,571,149 and the operating lease liability was $4,721,385. The calculated
amount of the ROU asset and lease liability is impacted by the length of the lease term and the discount rate used for the present value
of the minimum lease payments. We elected not to separate lease and non-lease components for all classes of underlying assets, and instead
to account for them as a single lease component. Variable lease cost primarily represents variable payments such as real estate taxes
and common area maintenance. The following tables describe our lease costs and other lease information:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years &lt;br/&gt;
Ended December 31,&lt;/b&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;Lease Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;427,519&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;348,929&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36,774&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;494,042&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;385,703&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Operating Lease&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cash paid for operating lease liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;577,260&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;248,595&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;18.1&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;19.1&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in"&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.6&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;7.11&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Future lease payments required under non-cancelable
operating leases in effect as of December 31, 2024 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;During the years ending December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;711,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,578,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments (undiscounted cash flows)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,731,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest (discount effect of cash flows)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,170,283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,561,174&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="c133"
      decimals="0"
      id="ixv-14290"
      unitRef="sqft">14300</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c134" id="ixv-14291">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c134" id="ixv-14292">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:AreaOfLand
      contextRef="c135"
      decimals="0"
      id="ixv-14293"
      unitRef="sqft">15400</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c135" id="ixv-14294">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <iccc:TermOfExtensionOfLease contextRef="c0" id="ixv-14295">P13Y</iccc:TermOfExtensionOfLease>
    <us-gaap:PaymentsForRent contextRef="c136" decimals="0" id="ixv-14296" unitRef="usd">20000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c137" decimals="0" id="ixv-14297" unitRef="usd">248743</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c134" decimals="0" id="ixv-14298" unitRef="usd">4560679</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c134" decimals="0" id="ixv-14299" unitRef="usd">4561174</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c138" decimals="0" id="ixv-14300" unitRef="usd">4571149</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c138" decimals="0" id="ixv-14301" unitRef="usd">4721385</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0" id="ixv-14302">The following tables describe our lease costs and other lease information:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years &lt;br/&gt;
Ended December 31,&lt;/b&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;Lease Cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; width: 76%; text-align: left"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;427,519&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;348,929&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;66,523&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36,774&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;494,042&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;385,703&lt;/td&gt; &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Operating Lease&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Cash paid for operating lease liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;577,260&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;248,595&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;Weighted average remaining lease term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;18.1&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;19.1&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in"&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;6.6&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;7.11&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" id="ixv-14303" unitRef="usd">427519</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="0" id="ixv-14304" unitRef="usd">348929</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c0" decimals="0" id="ixv-14305" unitRef="usd">66523</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c5" decimals="0" id="ixv-14306" unitRef="usd">36774</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="0" id="ixv-14307" unitRef="usd">494042</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c5" decimals="0" id="ixv-14308" unitRef="usd">385703</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-14309" unitRef="usd">577260</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c5" decimals="0" id="ixv-14310" unitRef="usd">248595</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-14311">P18Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-14312">P19Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="3" id="ixv-14313" unitRef="pure">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="4" id="ixv-14314" unitRef="pure">0.0711</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-11508">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Future lease payments required under non-cancelable
operating leases in effect as of December 31, 2024 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;During the years ending December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;711,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,744&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;356,732&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;363,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2029&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;371,144&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,578,344&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments (undiscounted cash flows)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,731,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest (discount effect of cash flows)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,170,283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total operating liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,561,174&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="0" id="ixv-14315" unitRef="usd">711623</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="0" id="ixv-14316" unitRef="usd">349744</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="0" id="ixv-14317" unitRef="usd">356732</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c3" decimals="0" id="ixv-14318" unitRef="usd">363870</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c3" decimals="0" id="ixv-14319" unitRef="usd">371144</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c3" decimals="0" id="ixv-14320" unitRef="usd">5578344</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="0" id="ixv-14321" unitRef="usd">7731457</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="0" id="ixv-14322" unitRef="usd">3170283</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" id="ixv-14323" unitRef="usd">4561174</us-gaap:OperatingLeaseLiability>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-11576">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;12. STOCKHOLDERS&#x2019; EQUITY&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Common Stock Issuances&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;From February of 2016 to April of 2021, we sold
the aggregate of 4,553,017 shares of common stock in six different transactions raising gross proceeds of $26,714,403 at the weighted
average price of $5.87 per share. These funds have been essential to funding our business growth plans.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;On April 9, 2024, our shelf registration on Form
S-3 relating to the offer, issuance and sale by the Company of up to $20,000,000 of securities was declared effective by the Securities
and Exchange Commission. Also on April 9, 2024, we entered into an At-The-Market (ATM) Agreement with Craig-Hallum Capital Group LLC,
pursuant to which we may offer and sell up to $11,000,000 of shares of our common stock. Legal, accounting and other fees in the amount
of $152,272 associated with the completion of the shelf registration and the ATM Agreement were initially capitalized and then were offset
against the initial proceeds received during the second quarter of 2024. As of December 31, 2024, we have sold 1,228,227 shares under
the ATM Offering conducted pursuant to the ATM Agreement. Net proceeds through December 31, 2024 from shares sold pursuant to the ATM
Agreement (net of the upfront legal, accounting and other fees), less sales commissions of $139,562, were $4,356,188.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Stock Option Plans&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In June of 2010, our stockholders approved the 2010
Stock Option and Incentive Plan (the &#x201c;2010 Plan&#x201d;) pursuant to the provisions of the Internal Revenue Code of 1986, under which
employees and certain service providers may be granted options to purchase shares of the Company&#x2019;s common stock at no less than
fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2010 Plan and
subsequently no additional shares have been reserved for the 2010 Plan. Vesting requirements are determined by the Compensation and Stock
Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2010 Plan expire no later than 10 years
from the date of grant. The 2010 Plan expired in June of 2020, after which date no further options can be granted under the 2010 Plan.
However, options outstanding under the 2010 Plan at that time can be exercised in accordance with their terms. There were 183,500 and
188,500 options outstanding under the 2010 Plan as of December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In June of 2017, our stockholders approved the
2017 Stock Option and Incentive Plan (the &#x201c;2017 Plan&#x201d;) pursuant to the provisions of the Internal Revenue Code of 1986, under
which employees and certain service providers may be granted options to purchase shares of the Company&#x2019;s common stock at no less
than fair market value on the date of grant. At that time, 300,000 shares of common stock were reserved for issuance under the 2017 Plan.
An amendment to the 2017 Plan increasing the number of shares reserved for issuance under the 2017 Plan from 300,000 shares to 650,000
shares was approved by a vote of stockholders at the Annual Meeting of Stockholders in June of 2022. Vesting requirements are determined
by the Compensation and Stock Option Committee of the Board of Directors on a case-by-case basis. All options granted under the 2017 Plan
expire no later than 10 years from the date of grant. The 2017 Plan expires in March of 2027, after which date no further options can
be granted under the 2017 Plan. However, options outstanding under the 2017 Plan at that time can be exercised in accordance with their
terms. As of December 31, 2024 and 2023, there were 480,500 and 430,000 options outstanding under the 2017 Plan, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Activity under the stock option plans described
above was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2010 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2017 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate &lt;br/&gt;
Intrinsic &lt;br/&gt;
Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;402,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(661,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;480,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(870,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(582,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;480,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(870,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Reserved for future grants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;151,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Terminations and forfeitures are recognized when they occur.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;The following table displays additional information about the stock
option plans described above:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average &lt;br/&gt; Fair Value at Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options granted during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that vested during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that were terminated or forfeited during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85"&gt;No&lt;/span&gt; stock options were exercised during the year
ended December 31, 2024. During the year ended December 31, 2023, 4,000 stock options were exercised by one employee with $18,760 in cash.
The aggregate intrinsic value of options exercised during the year ended December 31, 2023 was $1,040. The weighted average remaining
life of the options outstanding under the 2010 Plan and the 2017 Plan as of December 31, 2024 was approximately 4 years and 10 months.
The weighted average remaining life of the options exercisable under these plans as of December 31, 2024 was approximately 2 years and
8 months. The exercise price of the options outstanding under these plans as of December 31, 2024, ranged from $3.60 to $10.04 per share.
The 86,000 stock options granted during the year ended December 31, 2024 had an average exercise price of $3.91 per share. The 122,000
stock options granted during the year ended December 31, 2023 had an average exercise price of $5.16 per share. The weighted-average grant
date fair values of options granted during the years ended December 31, 2024 and 2023 were $1.84 and $2.80 per share, respectively. As
of December 31, 2024, total unrecognized stock-based compensation related to non-vested stock options aggregated $365,124 which will be
recognized over a weighted average remaining period of approximately 1 year and 3 months. The fair value of each stock option grant has
been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following
weighted-average assumptions:&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years&lt;br/&gt; Ended December 31,&lt;/b&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.77&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.59&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;52&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;54&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.6 years&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.2 years&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The dividend yield and expected volatility are derived from
averages of our historical data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;Common Stock Rights Plan&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;In September of 1995, our Board of Directors
adopted a Common Stock Rights Plan (the &#x201c;Rights Plan&#x201d;) and declared a dividend of one common share purchase right (a &#x201c;Right&#x201d;)
for each of the then outstanding shares of the common stock of the Company. Each Right entitled the registered holder to purchase from
the Company one share of common stock at an initial purchase price of $70.00 per share, subject to adjustment. The description and terms
of the Rights were set forth in a Rights Agreement between the Company and Equiniti Trust Company, LLC, as Rights Agent. At various times
over the years, our Board of Directors, which has the authority to amend the Rights Plan, voted to authorize amendments to the Rights
Plan to extend the expiration date of the Rights Plan. During 2024, our Board of Directors determined not to further extend the Rights
Plan because these plans are generally considered not to be stockholder friendly. With no further extension, the Rights Plan expired as
of September 19, 2024. No shares were issued under Rights Plan while it was in effect.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c139"
      decimals="0"
      id="ixv-14324"
      unitRef="shares">4553017</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c139" decimals="0" id="ixv-14325" unitRef="usd">26714403</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c140"
      decimals="2"
      id="ixv-14326"
      unitRef="usdPershares">5.87</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:DebtInstrumentIssuedPrincipal contextRef="c141" decimals="0" id="ixv-14327" unitRef="usd">20000000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c142"
      decimals="0"
      id="ixv-14328"
      unitRef="shares">11000000</us-gaap:CommonStockSharesAuthorized>
    <iccc:FeesInitiallyCapitalizedAndLaterOffset contextRef="c143" decimals="0" id="ixv-14329" unitRef="usd">152272</iccc:FeesInitiallyCapitalizedAndLaterOffset>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c144"
      decimals="0"
      id="ixv-14330"
      unitRef="shares">1228227</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SalesCommissionsAndFees contextRef="c144" decimals="0" id="ixv-14331" unitRef="usd">139562</us-gaap:SalesCommissionsAndFees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c144" decimals="0" id="ixv-14332" unitRef="usd">4356188</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c145"
      decimals="0"
      id="ixv-14333"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c146" id="ixv-14334">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c145"
      decimals="0"
      id="ixv-14335"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c147"
      decimals="0"
      id="ixv-14336"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c148"
      decimals="0"
      id="ixv-14337"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c149"
      decimals="0"
      id="ixv-14338"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c150"
      decimals="0"
      id="ixv-14339"
      unitRef="shares">650000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c151" id="ixv-14340">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c148"
      decimals="0"
      id="ixv-14341"
      unitRef="shares">480500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c152"
      decimals="0"
      id="ixv-14342"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-11616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Activity under the stock option plans described
above was as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2010 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2017 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate &lt;br/&gt;
Intrinsic &lt;br/&gt;
Value&lt;sup&gt;(1)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;202,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;402,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(661,310&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-78"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;5.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(94,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-79"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;430,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.82&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,071,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 10.1pt"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-80"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Terminations/forfeitures&lt;b&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(35,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Exercises&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-81"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-82"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-83"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;480,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(870,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Vested as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;136,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.97&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(582,340&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Vested and expected to vest as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;183,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;480,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;6.46&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;(870,558&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Reserved for future grants&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-84"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;151,500&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Terminations and forfeitures are recognized when they occur.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c161"
      decimals="INF"
      id="ixv-14343"
      unitRef="shares">202500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c162"
      decimals="INF"
      id="ixv-14344"
      unitRef="shares">402500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c10"
      decimals="2"
      id="ixv-14345"
      unitRef="usdPershares">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c10" decimals="0" id="ix_0_fact" unitRef="usd">-661310</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c164"
      decimals="INF"
      id="ixv-14347"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-14348"
      unitRef="usdPershares">5.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c163"
      decimals="INF"
      id="ix_5_fact"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c164"
      decimals="INF"
      id="ix_6_fact"
      unitRef="shares">94500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ix_7_fact"
      unitRef="usdPershares">7.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c163"
      decimals="INF"
      id="ixv-14352"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-14353"
      unitRef="usdPershares">4.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c165"
      decimals="INF"
      id="ixv-14354"
      unitRef="shares">188500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c166"
      decimals="INF"
      id="ixv-14355"
      unitRef="shares">430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c4"
      decimals="2"
      id="ixv-14356"
      unitRef="usdPershares">6.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c4" decimals="0" id="ix_1_fact" unitRef="usd">-1071121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c168"
      decimals="INF"
      id="ixv-14358"
      unitRef="shares">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-14359"
      unitRef="usdPershares">3.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c167"
      decimals="INF"
      id="ix_8_fact"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c168"
      decimals="INF"
      id="ix_9_fact"
      unitRef="shares">35500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ix_10_fact"
      unitRef="usdPershares">6.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c169"
      decimals="INF"
      id="ixv-14363"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c170"
      decimals="INF"
      id="ixv-14364"
      unitRef="shares">480500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-14365"
      unitRef="usdPershares">6.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="0" id="ix_2_fact" unitRef="usd">-870558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c169"
      decimals="INF"
      id="ixv-14367"
      unitRef="shares">183500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested
      contextRef="c170"
      decimals="INF"
      id="ixv-14368"
      unitRef="shares">136500</iccc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested
      contextRef="c3"
      decimals="2"
      id="ixv-14369"
      unitRef="usdPershares">6.97</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageVested>
    <iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" id="ix_3_fact" unitRef="usd">-582340</iccc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c169"
      decimals="INF"
      id="ixv-14371"
      unitRef="shares">183500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c170"
      decimals="INF"
      id="ixv-14372"
      unitRef="shares">480500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-14373"
      unitRef="usdPershares">6.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c3" decimals="0" id="ix_4_fact" unitRef="usd">-870558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c170"
      decimals="INF"
      id="ixv-14375"
      unitRef="shares">151500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-11885">&lt;p style="margin: 0pt 0 0pt 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;The following table displays additional information about the stock
option plans described above:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt;
Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average &lt;br/&gt; Fair Value at Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Average &lt;br/&gt;
Exercise &lt;br/&gt;
Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3.66&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7.14&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Non-vested stock options as of December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;344,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options granted during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1.84&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that vested during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;9.73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Stock options that were terminated or forfeited during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;3.33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.55&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c171"
      decimals="INF"
      id="ixv-14378"
      unitRef="shares">337500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c171"
      decimals="2"
      id="ixv-14379"
      unitRef="usdPershares">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c171"
      decimals="2"
      id="ixv-14380"
      unitRef="usdPershares">7.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c172"
      decimals="INF"
      id="ixv-14381"
      unitRef="shares">344000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c172"
      decimals="2"
      id="ixv-14382"
      unitRef="usdPershares">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c172"
      decimals="2"
      id="ixv-14383"
      unitRef="usdPershares">6.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c173"
      decimals="INF"
      id="ixv-14384"
      unitRef="shares">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14385"
      unitRef="usdPershares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14386"
      unitRef="usdPershares">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c173"
      decimals="INF"
      id="ixv-14387"
      unitRef="shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14388"
      unitRef="usdPershares">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14389"
      unitRef="usdPershares">9.73</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c173"
      decimals="INF"
      id="ixv-14390"
      unitRef="shares">40500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14391"
      unitRef="usdPershares">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="c173"
      decimals="2"
      id="ixv-14392"
      unitRef="usdPershares">6.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c153"
      decimals="0"
      id="ixv-14393"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c153" decimals="0" id="ixv-14394" unitRef="usd">18760</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c5" decimals="0" id="ixv-14395" unitRef="usd">1040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c146" id="ixv-14396">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c151" id="ixv-14397">P10M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c146" id="ixv-14398">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c151" id="ixv-14399">P8M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c154"
      decimals="2"
      id="ixv-14400"
      unitRef="usdPershares">3.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c155"
      decimals="2"
      id="ixv-14401"
      unitRef="usdPershares">10.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c0"
      decimals="0"
      id="ixv-14402"
      unitRef="shares">86000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c156"
      decimals="2"
      id="ixv-14403"
      unitRef="usdPershares">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="c5"
      decimals="0"
      id="ixv-14404"
      unitRef="shares">122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c157"
      decimals="2"
      id="ixv-14405"
      unitRef="usdPershares">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c158"
      decimals="2"
      id="ixv-14406"
      unitRef="usdPershares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c159"
      decimals="2"
      id="ixv-14407"
      unitRef="usdPershares">2.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c3" decimals="0" id="ixv-14408" unitRef="usd">365124</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c146" id="ixv-14409">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c151" id="ixv-14410">P3M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-14411">The fair value of each stock option grant has
been estimated on the date of grant using the Black-Scholes option pricing model, for the purpose discussed in Note 2(n), with the following
weighted-average assumptions:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years&lt;br/&gt; Ended December 31,&lt;/b&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.77&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;3.59&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend yield&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;0&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;52&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;54&lt;/td&gt; &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected life&lt;sup&gt;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.6 years&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.2 years&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The dividend yield and expected volatility are derived from
averages of our historical data.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(3)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ix_11_fact" unitRef="pure">0.0377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" id="ix_12_fact" unitRef="pure">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ix_13_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" id="ix_14_fact" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" id="ix_15_fact" unitRef="pure">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="2" id="ix_16_fact" unitRef="pure">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ix_17_fact">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5" id="ix_18_fact">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommonStockDividendsShares
      contextRef="c160"
      decimals="0"
      id="ixv-14423"
      unitRef="shares">1</us-gaap:CommonStockDividendsShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c160"
      decimals="0"
      id="ixv-14424"
      unitRef="shares">1</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c160"
      decimals="2"
      id="ixv-14425"
      unitRef="usdPershares">70</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c0" id="ixv-12096">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;13. REVENUE&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
primarily offer the &lt;b&gt;First Defense&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Symbol"&gt;&lt;sup&gt;&#xd2;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;product
line to dairy and beef producers to prevent scours in newborn calves. Generally, our products are promoted to veterinarians as well as
dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select
international regions and may expand this international reach in the future. There were no material changes between the allocation and
timing of revenue recognition during the years ended December 31, 2024 or 2023. We do not have any contract assets for which we have satisfied
the performance obligations, but do not yet have the right to bill for, or contract liabilities such as customer advances. All trade receivables
on our balance sheets are from contracts with customers. We incur no material costs to obtain contracts.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The following table presents our product sales
disaggregated by geographic area:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22,893,721&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;86%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,949,382&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;91%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,599,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;14%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,522,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;9%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The following table presents our product sales disaggregated
by major product category:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; &lt;span style="font-style: normal; font-weight: normal"&gt;product line&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,314,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;99%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;99%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other animal health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c0" id="ixv-12108">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The following table presents our product sales
disaggregated by geographic area:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;22,893,721&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;86%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;15,949,382&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;91%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,599,448&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;14%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,522,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;9%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c174" decimals="0" id="ixv-14426" unitRef="usd">22893721</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c175"
      decimals="2"
      id="ixv-14427"
      unitRef="pure">0.86</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c176" decimals="0" id="ixv-14428" unitRef="usd">15949382</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c177"
      decimals="2"
      id="ixv-14429"
      unitRef="pure">0.91</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c178" decimals="0" id="ixv-14430" unitRef="usd">3599448</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c179"
      decimals="2"
      id="ixv-14431"
      unitRef="pure">0.14</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c180" decimals="0" id="ixv-14432" unitRef="usd">1522287</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c181"
      decimals="2"
      id="ixv-14433"
      unitRef="pure">0.09</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-14434" unitRef="usd">26493169</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c3" decimals="2" id="ixv-14435" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-14436" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c4" decimals="2" id="ixv-14437" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c0" id="ixv-12186">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The following table presents our product sales disaggregated
by major product category:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;First
    Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; &lt;span style="font-style: normal; font-weight: normal"&gt;product line&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,314,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;99%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;99%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other animal health&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,919&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;1%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total Product Sales&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: center"&gt;100%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c182" decimals="0" id="ixv-14438" unitRef="usd">26314250</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c183"
      decimals="2"
      id="ixv-14439"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c184" decimals="0" id="ixv-14440" unitRef="usd">17293933</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c185"
      decimals="2"
      id="ixv-14441"
      unitRef="pure">0.99</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c186" decimals="0" id="ixv-14442" unitRef="usd">178919</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c187"
      decimals="2"
      id="ixv-14443"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c188" decimals="0" id="ixv-14444" unitRef="usd">177736</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="c189"
      decimals="2"
      id="ixv-14445"
      unitRef="pure">0.01</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c0" decimals="0" id="ixv-14446" unitRef="usd">26493169</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c3" decimals="2" id="ixv-14447" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c5" decimals="0" id="ixv-14448" unitRef="usd">17471669</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage contextRef="c4" decimals="2" id="ixv-14449" unitRef="pure">1</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-12294">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;14. OTHER EXPENSES, NET&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Other expenses net, consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years&lt;br/&gt;
 Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;568,725&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;475,598&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on disposal of property, plant and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,391&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(77,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(96,570&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance recoveries&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income - other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Other expenses (income), net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506,414&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,893&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#x2019;s policy related to an equipment malfunction (in the amount of $115,127).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-12298">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Other expenses net, consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;During the Years&lt;br/&gt;
 Ended December 31,&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expense&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;568,725&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;475,598&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Loss on disposal of property, plant and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;15,391&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest income&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(77,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(96,570&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance recoveries&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-86"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(365,127&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Income - other&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-87"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(107&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Other expenses (income), net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506,414&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;21,893&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0%"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#x2019;s policy related to an equipment malfunction (in the amount of $115,127).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestRevenueExpenseNet contextRef="c0" decimals="0" id="ix_19_fact" unitRef="usd">-568725</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet contextRef="c5" decimals="0" id="ix_20_fact" unitRef="usd">-475598</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c0" decimals="0" id="ixv-14452" unitRef="usd">15391</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets contextRef="c5" decimals="0" id="ixv-14453" unitRef="usd">8099</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:InterestIncomeOther contextRef="c0" decimals="0" id="ixv-14454" unitRef="usd">77702</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="c5" decimals="0" id="ixv-14455" unitRef="usd">96570</us-gaap:InterestIncomeOther>
    <us-gaap:InsuranceRecoveries contextRef="c5" decimals="0" id="ix_21_fact" unitRef="usd">365127</us-gaap:InsuranceRecoveries>
    <us-gaap:OtherIncome contextRef="c5" decimals="0" id="ixv-14457" unitRef="usd">107</us-gaap:OtherIncome>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" id="ixv-14458" unitRef="usd">-506414</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" id="ixv-14459" unitRef="usd">-21893</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="0" id="ixv-14461" unitRef="usd">42666</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c5" decimals="0" id="ixv-14462" unitRef="usd">22619</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InsuranceRecoveries contextRef="c190" decimals="0" id="ixv-14464" unitRef="usd">250000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries contextRef="c191" decimals="0" id="ixv-14465" unitRef="usd">115127</us-gaap:InsuranceRecoveries>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-12401">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;15. INCOME TAXES&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Our income tax expense aggregated $10,056 and $4,627
(amounting to less than 1% of our loss before income taxes) during the years ended December 31, 2024 and 2023, respectively. As of December
31, 2024, we had federal net operating loss carryforwards of $17,647,250 of which $15,935,343 do not expire and of which $1,711,907 expire
in 2034 through 2037 (if not utilized before then) and state net operating loss carryforwards of $5,194,515 that expire in 2037 through
2038 (if not utilized before then). Additionally, we had federal general business tax credit carryforwards of $842,565 that expire in
2027 through 2042 (if not utilized before then) and state tax credit carryforwards of $777,459 that expire in 2025 through 2042 (if not
utilized before then).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The provision for income taxes is determined using
the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the estimated future tax
effects of temporary differences between book and tax treatment of assets and liabilities and carryforwards to the extent they are realizable.
During the second quarter of 2018, we assessed our historical and near-term future profitability and recorded $563,252 in non-cash income
tax expense to create a full valuation allowance against our net deferred tax assets (which consist largely of net operating loss carryforwards
and federal and state credits) based on applicable accounting standards and practices. At that time, we had incurred a net loss for six
consecutive quarters, had not been profitable on a year-to-date basis since the nine-month period ended September 30, 2017 and projected
additional net losses for some period going forward before returning to profitability. Should future profitability be realized at an adequate
level, we would be able to release this valuation allowance (resulting in a non-cash income tax benefit) and realize these deferred tax
assets before they expire. We will continue to assess the need for the valuation allowance at each quarter and, in the event that actual
results differ from these estimates, or we adjust these estimates in future periods, we may need to adjust our valuation allowance. Currently,
we adjust the valuation allowance at the end of each quarter to reduce the value of our deferred tax assets to zero.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Net operating loss carryforwards, credits, and other
tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code
contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the
event of a change in ownership of the Company, as defined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We file income tax returns in the U.S. federal jurisdiction
and several state jurisdictions. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or
penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying audited
financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The income tax provision consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years&lt;br/&gt;
 Ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 0.3in"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(500,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,179,474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59,032&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(145,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Deferred subtotal, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(559,959&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,325,276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;559,959&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,325,276&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred subtotal, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The actual income tax expense differs from the
expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before income taxes during the years ended December
31, 2024 and 2023 respectively, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;During
                                            the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Computed expected income tax expense rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(450,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,211,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State income taxes, net of federal expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,681&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.71&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117,149&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.03&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(116,091&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(53,241&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;559,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,325,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Income tax expense/rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The significant components of our deferred tax
assets, net, consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;As
of &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Property, plant and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,833,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,121,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal general business tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;842,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;726,474&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,729,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State tax credits and net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900,569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;886,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&#xa7;174 R &amp;amp; D expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;727,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,915&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Deferred compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;UNICAP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Incentive compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,593,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,034,030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14466" unitRef="usd">10056</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14467" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="c5" decimals="2" id="ixv-14468" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c192" decimals="0" id="ixv-14469" unitRef="usd">17647250</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c192" decimals="0" id="ixv-14470" unitRef="usd">15935343</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c192" decimals="0" id="ixv-14471" unitRef="usd">1711907</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c193" id="ixv-14472">expire
in 2034 through 2037</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c194" decimals="0" id="ixv-14473" unitRef="usd">5194515</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c195" id="ixv-14474">expire in 2037 through
2038</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c196" decimals="0" id="ixv-14475" unitRef="usd">842565</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c197" id="ixv-14476">expire in
2027 through 2042</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c198" decimals="0" id="ixv-14477" unitRef="usd">777459</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c199" id="ixv-14478">expire in 2025 through 2042</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:OtherNoncashIncomeTaxExpense contextRef="c200" decimals="0" id="ixv-14479" unitRef="usd">563252</us-gaap:OtherNoncashIncomeTaxExpense>
    <us-gaap:DeferredTaxAssetsNet contextRef="c3" decimals="0" id="ixv-14480" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0" id="ixv-12434">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The income tax provision consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Years&lt;br/&gt;
 Ended&#160;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 76%; padding-bottom: 1.5pt; padding-left: 11.5pt"&gt;State&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Current subtotal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Deferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 0.3in"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(500,927&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,179,474&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;State&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(59,032&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(145,802&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Deferred subtotal, gross&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(559,959&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,325,276&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 0.3in"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;559,959&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,325,276&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred subtotal, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14481" unitRef="usd">10056</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14482" unitRef="usd">4627</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14483" unitRef="usd">10056</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14484" unitRef="usd">4627</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14485" unitRef="usd">500927</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14486" unitRef="usd">1179474</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14487" unitRef="usd">59032</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14488" unitRef="usd">145802</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14489" unitRef="usd">559959</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14490" unitRef="usd">1325276</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14491" unitRef="usd">559959</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14492" unitRef="usd">1325276</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14493" unitRef="usd">10056</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14494" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0" id="ixv-12565">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The actual income tax expense differs from the
expected tax computed by applying the U.S. federal corporate tax rate of 21% to the loss before income taxes during the years ended December
31, 2024 and 2023 respectively, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;During
                                            the Years Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;%&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Computed expected income tax expense rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(450,780&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,211,694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State income taxes, net of federal expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(36,681&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.71&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117,149&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.03&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Share-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,214&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(116,091&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.41&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(53,241&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.92&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;559,959&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,325,276&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.09&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,619&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;0.22&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;5,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22.97&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Income tax expense/rate&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;10,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.47&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,627&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c0" decimals="2" id="ixv-14495" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c5" decimals="2" id="ixv-14496" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="0" id="ixv-14497" unitRef="usd">-450780</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c0" decimals="4" id="ixv-14498" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c5" decimals="0" id="ixv-14499" unitRef="usd">-1211694</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome contextRef="c5" decimals="4" id="ixv-14500" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="0" id="ixv-14501" unitRef="usd">-36681</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c0" decimals="4" id="ixv-14502" unitRef="pure">-0.0171</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="0" id="ixv-14503" unitRef="usd">-117149</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c5" decimals="4" id="ixv-14504" unitRef="pure">-0.0203</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c0" decimals="0" id="ixv-14505" unitRef="usd">49030</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c0" decimals="4" id="ixv-14506" unitRef="pure">0.0228</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c5" decimals="0" id="ixv-14507" unitRef="usd">56214</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c5" decimals="4" id="ixv-14508" unitRef="pure">0.0097</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c0" decimals="0" id="ixv-14509" unitRef="usd">116091</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c0" decimals="4" id="ixv-14510" unitRef="pure">0.0541</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c5" decimals="0" id="ixv-14511" unitRef="usd">53241</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c5" decimals="4" id="ixv-14512" unitRef="pure">0.0092</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="0" id="ixv-14513" unitRef="usd">559959</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c0" decimals="4" id="ixv-14514" unitRef="pure">0.2609</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="0" id="ixv-14515" unitRef="usd">1325276</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c5" decimals="4" id="ixv-14516" unitRef="pure">0.0009</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c0" decimals="0" id="ixv-14517" unitRef="usd">4619</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c0" decimals="4" id="ixv-14518" unitRef="pure">0.0022</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c5" decimals="0" id="ixv-14519" unitRef="usd">5221</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c5" decimals="4" id="ixv-14520" unitRef="pure">0.2297</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" id="ixv-14521" unitRef="usd">10056</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="4" id="ixv-14522" unitRef="pure">0.0047</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" id="ixv-14523" unitRef="usd">4627</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c5" decimals="4" id="ixv-14524" unitRef="pure">0.0008</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-12748">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;The significant components of our deferred tax
assets, net, consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;As
of &lt;br/&gt;
December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Property, plant and equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,833,727&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(2,121,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal general business tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;842,565&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;726,474&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Federal net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,705,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,729,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;State tax credits and net operating loss carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;900,569&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;886,428&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&#xa7;174 R &amp;amp; D expenditures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;727,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,915&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Deferred compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,722&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Prepaid expenses and other&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;37,124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;UNICAP&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,607&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Incentive compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;100,200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,593,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,034,030&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"&gt;Deferred tax assets, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c3" decimals="0" id="ixv-14525" unitRef="usd">1833727</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c4" decimals="0" id="ixv-14526" unitRef="usd">2121940</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c3" decimals="0" id="ixv-14527" unitRef="usd">842565</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c4" decimals="0" id="ixv-14528" unitRef="usd">726474</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="0" id="ixv-14529" unitRef="usd">3705923</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="0" id="ixv-14530" unitRef="usd">3729500</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c3" decimals="0" id="ixv-14531" unitRef="usd">900569</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="c4" decimals="0" id="ixv-14532" unitRef="usd">886428</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="c3" decimals="0" id="ixv-14533" unitRef="usd">727410</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="c4" decimals="0" id="ixv-14534" unitRef="usd">592915</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c3" decimals="0" id="ixv-14535" unitRef="usd">82370</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c4" decimals="0" id="ixv-14536" unitRef="usd">50722</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c3" decimals="0" id="ixv-14537" unitRef="usd">24718</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c4" decimals="0" id="ixv-14538" unitRef="usd">37124</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c3" decimals="0" id="ixv-14539" unitRef="usd">22443</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c4" decimals="0" id="ixv-14540" unitRef="usd">32607</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c3" decimals="0" id="ixv-14541" unitRef="usd">121718</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther contextRef="c4" decimals="0" id="ixv-14542" unitRef="usd">100200</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="0" id="ixv-14543" unitRef="usd">4593989</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="0" id="ixv-14544" unitRef="usd">4034030</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0" id="ixv-12907">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;16. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;Our business operations (being the development,
manufacture and sale of products that improve the health and productivity of dairy and beef cattle) are described in Note 1. Pursuant
to Codification Topic 280, &lt;i&gt;Segment Reporting&lt;/i&gt;, we operate in the following two reportable business segments: i) Scours and ii) Mastitis.
The Scours segment consists of the &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; product line. The core technology underlying the Scours segment
is focused on polyclonal antibodies. The Mastitis segment includes our products, &lt;b&gt;CMT &lt;/b&gt;and &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;. &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;
&lt;/sup&gt;&lt;/b&gt;is projected to be the driver of this segment when approved for sale. The core technology underlying the Mastitis segment is
focused on a bacteriocin called Nisin. The category we define as &#x201c;Other&#x201d; includes unallocated administrative and overhead
expenses and other products. The significant accounting policies of these segments are described in Note 2. Product sales are the primary
factor we use in determining our reportable segments. The governing regulatory authority (Center for Veterinary Biologics, U.S. Department
of Agriculture for &lt;b&gt;First Defense&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt; or Center for Veterinary Medicine, U.S. Food and Drug Administration for &lt;b&gt;Re-Tain&lt;sup&gt;&#xae;&lt;/sup&gt;&lt;/b&gt;)
is also a factor in determining our reportable segments. Management monitors and evaluates segment performance from sales to net operating
income (loss) closely. We are not organized by geographic region. No segments have been aggregated. The revenues and expenses allocated
to each segment are in some cases direct and in other cases involve reasonable and consistent estimations by management. Each operating
segment is defined as the component of our business for which financial information is available and evaluated regularly by our chief
operating decision-maker in deciding how to allocate resources and in assessing performance. Our chief operating decision-maker is our
President and CEO.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,314,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;178,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,382,949&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,552,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,931,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,941,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,578&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,493,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,898,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,909,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;556,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,466,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,216,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,216,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,153,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,049,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,378,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,581,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,777,925&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,039,829&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,378,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,640,159&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;During
the Year Ended December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,453,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,602,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,869,284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,242,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,394,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,447,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,088,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,458,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,883,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,617,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,179&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,854,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,748,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,644,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,523,048&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,933,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45,100,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,735,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,827,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,244,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,808,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,373,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,277,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,729,847&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,287,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,739,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;409,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;53,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;465,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,096,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;795,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,892,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments contextRef="c0" decimals="0" id="ixv-14545" unitRef="pure">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0" id="ixv-14546">Our chief operating decision-maker is our
President and CEO.&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;During the Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,314,251&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;178,918&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;26,493,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,382,949&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;169,176&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,552,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,931,302&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,941,044&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243,578&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,493,298&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;161,706&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,898,582&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,909,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;556,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,466,072&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-99"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,216,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,216,549&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10.1pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,153,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,049,571&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,378,255&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,581,203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;4,777,925&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,039,829&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,378,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(1,640,159&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"&gt;&lt;b&gt;&#160;During
the Year Ended December 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;Product sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,293,933&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;177,736&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;17,471,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"&gt;Costs of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,453,514&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148,871&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13,602,385&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Gross margin&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,419&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,869,284&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Product development expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,242,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;141,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,394,852&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Sales and marketing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,447,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;641,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,088,215&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,134,295&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10.1pt; padding-left: 20.2pt"&gt;Operating expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,458,240&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,883,407&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9,617,362&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -10.1pt; padding-left: 20.2pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -10.1pt; padding-left: 10.1pt"&gt;NET OPERATING INCOME (LOSS)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,179&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(4,854,542&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(2,275,715&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(5,748,078&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Scours&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Mastitis&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2024&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;24,644,294&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;16,523,048&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,933,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;45,100,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -10pt; padding-left: 10pt"&gt;Total Assets as of December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;24,735,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;17,827,839&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,244,850&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;43,808,102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,373,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,277,218&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;78,814&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,729,847&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Depreciation and amortization expense during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,365,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,287,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;86,032&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,739,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;409,696&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;53,721&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,308&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;465,725&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -10.1pt; padding-left: 10.1pt"&gt;Capital Expenditures during the year ended December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,096,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;795,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,892,513&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c201" decimals="0" id="ixv-14547" unitRef="usd">26314251</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c202" decimals="0" id="ixv-14548" unitRef="usd">178918</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c0" decimals="0" id="ixv-14549" unitRef="usd">26493169</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c201" decimals="0" id="ixv-14550" unitRef="usd">18382949</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c202" decimals="0" id="ixv-14551" unitRef="usd">169176</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c0" decimals="0" id="ixv-14552" unitRef="usd">18552125</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c201" decimals="0" id="ixv-14553" unitRef="usd">7931302</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c202" decimals="0" id="ixv-14554" unitRef="usd">9742</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" id="ixv-14555" unitRef="usd">7941044</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c201" decimals="0" id="ixv-14556" unitRef="usd">243578</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c202" decimals="0" id="ixv-14557" unitRef="usd">3493298</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c203" decimals="0" id="ixv-14558" unitRef="usd">161706</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="0" id="ixv-14559" unitRef="usd">3898582</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c201" decimals="0" id="ixv-14560" unitRef="usd">2909799</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c202" decimals="0" id="ixv-14561" unitRef="usd">556273</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="0" id="ixv-14562" unitRef="usd">3466072</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c203" decimals="0" id="ixv-14563" unitRef="usd">2216549</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" id="ixv-14564" unitRef="usd">2216549</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c201" decimals="0" id="ixv-14565" unitRef="usd">3153377</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c202" decimals="0" id="ixv-14566" unitRef="usd">4049571</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c203" decimals="0" id="ixv-14567" unitRef="usd">2378255</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" id="ixv-14568" unitRef="usd">9581203</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c201" decimals="0" id="ixv-14569" unitRef="usd">4777925</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c202" decimals="0" id="ixv-14570" unitRef="usd">-4039829</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c203" decimals="0" id="ixv-14571" unitRef="usd">-2378255</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" id="ixv-14572" unitRef="usd">-1640159</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues contextRef="c204" decimals="0" id="ixv-14573" unitRef="usd">17293933</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c205" decimals="0" id="ixv-14574" unitRef="usd">177736</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="0" id="ixv-14575" unitRef="usd">17471669</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c204" decimals="0" id="ixv-14576" unitRef="usd">13453514</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c205" decimals="0" id="ixv-14577" unitRef="usd">148871</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c5" decimals="0" id="ixv-14578" unitRef="usd">13602385</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c204" decimals="0" id="ixv-14579" unitRef="usd">3840419</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c205" decimals="0" id="ixv-14580" unitRef="usd">28865</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" id="ixv-14581" unitRef="usd">3869284</us-gaap:GrossProfit>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c204" decimals="0" id="ixv-14582" unitRef="usd">11103</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c205" decimals="0" id="ixv-14583" unitRef="usd">4242329</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c206" decimals="0" id="ixv-14584" unitRef="usd">141420</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c5" decimals="0" id="ixv-14585" unitRef="usd">4394852</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c204" decimals="0" id="ixv-14586" unitRef="usd">2447137</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c205" decimals="0" id="ixv-14587" unitRef="usd">641078</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c5" decimals="0" id="ixv-14588" unitRef="usd">3088215</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c206" decimals="0" id="ixv-14589" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="0" id="ixv-14590" unitRef="usd">2134295</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c204" decimals="0" id="ixv-14591" unitRef="usd">2458240</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c205" decimals="0" id="ixv-14592" unitRef="usd">4883407</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c206" decimals="0" id="ixv-14593" unitRef="usd">2275715</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" id="ixv-14594" unitRef="usd">9617362</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c204" decimals="0" id="ixv-14595" unitRef="usd">1382179</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c205" decimals="0" id="ixv-14596" unitRef="usd">-4854542</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c206" decimals="0" id="ixv-14597" unitRef="usd">-2275715</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" id="ixv-14598" unitRef="usd">-5748078</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets contextRef="c207" decimals="0" id="ixv-14599" unitRef="usd">24644294</us-gaap:Assets>
    <us-gaap:Assets contextRef="c208" decimals="0" id="ixv-14600" unitRef="usd">16523048</us-gaap:Assets>
    <us-gaap:Assets contextRef="c209" decimals="0" id="ixv-14601" unitRef="usd">3933135</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" id="ixv-14602" unitRef="usd">45100477</us-gaap:Assets>
    <us-gaap:Assets contextRef="c210" decimals="0" id="ixv-14603" unitRef="usd">24735413</us-gaap:Assets>
    <us-gaap:Assets contextRef="c211" decimals="0" id="ixv-14604" unitRef="usd">17827839</us-gaap:Assets>
    <us-gaap:Assets contextRef="c212" decimals="0" id="ixv-14605" unitRef="usd">1244850</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="0" id="ixv-14606" unitRef="usd">43808102</us-gaap:Assets>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c201" decimals="0" id="ixv-14607" unitRef="usd">1373815</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c202" decimals="0" id="ixv-14608" unitRef="usd">1277218</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c203" decimals="0" id="ixv-14609" unitRef="usd">78814</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c0" decimals="0" id="ixv-14610" unitRef="usd">2729847</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c204" decimals="0" id="ixv-14611" unitRef="usd">1365988</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c205" decimals="0" id="ixv-14612" unitRef="usd">1287600</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c206" decimals="0" id="ixv-14613" unitRef="usd">86032</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CostDepreciationAmortizationAndDepletion contextRef="c5" decimals="0" id="ixv-14614" unitRef="usd">2739620</us-gaap:CostDepreciationAmortizationAndDepletion>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c201" decimals="0" id="ixv-14615" unitRef="usd">409696</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c202" decimals="0" id="ixv-14616" unitRef="usd">53721</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c203" decimals="0" id="ixv-14617" unitRef="usd">2308</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c0" decimals="0" id="ixv-14618" unitRef="usd">465725</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c204" decimals="0" id="ixv-14619" unitRef="usd">1096819</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c205" decimals="0" id="ixv-14620" unitRef="usd">795694</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c5" decimals="0" id="ixv-14621" unitRef="usd">1892513</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-13493">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;17. RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;David
S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the &lt;b&gt;First
Defense&lt;/b&gt;&lt;/span&gt;&lt;b&gt;&lt;span style="font-family: Symbol"&gt;&lt;sup&gt;&#xd2;&lt;/sup&gt;&lt;/span&gt;&lt;/b&gt; &lt;span style="font-family: Times New Roman, Times, Serif"&gt;product
line and &lt;b&gt;CMT&lt;/b&gt;). His affiliated company purchased $567,114 and $231,405 of products from us during the years ended December 31, 2024
and 2023, respectively, all on terms consistent with those offered to other distributors of similar status. Our accounts receivable (subject
to standard and customary payment terms) due from this affiliated company aggregated $52,097 and $42,507 as of December 31, 2024 and 2023,
respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c0" decimals="0" id="ixv-14622" unitRef="usd">567114</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c5" decimals="0" id="ixv-14623" unitRef="usd">231405</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsReceivableNet contextRef="c50" decimals="0" id="ixv-14624" unitRef="usd">52097</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c51" decimals="0" id="ixv-14625" unitRef="usd">42507</us-gaap:AccountsReceivableNet>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-13509">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;18. EMPLOYEE BENEFITS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We have a 401(k) savings plan (the Plan) in which
all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum
amount allowed by the Internal Revenue Service. We currently match 100% of the first 3% of each employee&#x2019;s salary that is contributed
to the Plan and 50% of the next 2% of each employee&#x2019;s salary that is contributed to the Plan. Under this matching plan, we paid
$203,756 and $178,150 into the Plan for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <iccc:EmployeesSalaryPercentage contextRef="c0" decimals="2" id="ixv-14626" unitRef="pure">1</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryPercentage
      contextRef="c213"
      decimals="2"
      id="ixv-14627"
      unitRef="pure">0.03</iccc:EmployeesSalaryPercentage>
    <iccc:EmployeesSalaryContributionPercentage contextRef="c0" decimals="2" id="ixv-14628" unitRef="pure">0.50</iccc:EmployeesSalaryContributionPercentage>
    <iccc:EmployeesSalaryContributionPercentage
      contextRef="c214"
      decimals="2"
      id="ixv-14629"
      unitRef="pure">0.02</iccc:EmployeesSalaryContributionPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c0" decimals="0" id="ixv-14630" unitRef="usd">203756</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid contextRef="c5" decimals="0" id="ixv-14631" unitRef="usd">178150</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-13518">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&lt;b&gt;19. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 0.25in"&gt;We have evaluated subsequent events through the
time of this filing on March 28, 2025. First, in January of 2025, we settled a long outstanding insurance claim related to previously
disclosed contamination events in our production process incurred from late 2022 through April of 2024. As a result of the settlement,
we received $426,587 during January of 2025, which is in addition to the $250,000 that was previously received on this claim and recognized
for financial statement purposes during the third quarter of 2023. Second, net proceeds from January 1, 2025 through March 21, 2025 from
3,532 shares sold pursuant to our ATM Agreement (less sales commissions of $584) were $18,849. As of the time of this filing on March
28, 2025, there were no additional material, reportable subsequent events.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:InsuranceSettlementsReceivable contextRef="c215" decimals="0" id="ixv-14632" unitRef="usd">426587</us-gaap:InsuranceSettlementsReceivable>
    <us-gaap:OtherReceivables contextRef="c216" decimals="0" id="ixv-14633" unitRef="usd">250000</us-gaap:OtherReceivables>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c217"
      decimals="0"
      id="ixv-14634"
      unitRef="shares">3532</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SalesCommissionsAndFees contextRef="c217" decimals="0" id="ixv-14635" unitRef="usd">584</us-gaap:SalesCommissionsAndFees>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c218" decimals="0" id="ixv-14636" unitRef="usd">18849</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <dei:EntityRegistrantName contextRef="c0" id="hidden-fact-0">IMMUCELL CORP /DE/</dei:EntityRegistrantName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c14"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c11"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c11"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c14"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c19"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c19"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c21"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c22"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c0"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="c0"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c5"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="c0"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:PaymentsOfDebtDiscounts
      contextRef="c0"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c5"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:ChangeInPaymentsOfDebtDiscountsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="c0"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c31"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c32"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c30"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c32"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c35"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c36"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c34"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermBorrowings
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c0"
      id="hidden-fact-34"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c5"
      id="hidden-fact-35"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c0"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c64" id="hidden-fact-40" xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c66" id="hidden-fact-41" xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c102"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c103"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c104"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c105"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c106"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c107"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c108"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c109"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c110"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c111"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c112"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c114"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c0"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c117"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c117"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c117"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c118"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c118"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c118"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c119"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c119"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c119"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c120"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c120"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="c121"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c121"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c121"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c121"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="c122"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="c122"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="c122"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="c122"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2027
      contextRef="c3"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2028
      contextRef="c3"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCost2029
      contextRef="c3"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <iccc:DebtDiscountCostThereafter
      contextRef="c3"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c163"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c164"
      id="hidden-fact-79"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c167"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c167"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c168"
      id="hidden-fact-82"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-83"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c169"
      id="hidden-fact-84"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:InsuranceRecoveries
      contextRef="c0"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c0"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c5"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c3"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c203"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c203"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c203"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c203"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c201"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c202"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c206"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c206"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c206"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c206"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c204"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c205"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c206"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-14746">0000811641</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-14747">false</dei:AmendmentFlag>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-14748">true</dei:DocumentAnnualReport>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-14749">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-14750">false</dei:DocumentTransitionReport>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Intrinsic value is the difference between the fair market
value of the underlying common stock as of the date indicated and as of the date of the option grant (which is equal to the option exercise
price).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Terminations and forfeitures are recognized when they occur.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The risk-free interest rate is based on U.S. Treasury yields
for a maturity approximating the expected option term.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_16_fact"
          xlink:label="ix_16_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_15_fact"
          xlink:label="ix_15_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_14_fact"
          xlink:label="ix_14_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_3_footnote" xlink:label="ix_3_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The dividend yield and expected volatility are derived from
averages of our historical data.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_16_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_15_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_14_fact"
          xlink:to="ix_3_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_18_fact"
          xlink:label="ix_18_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_17_fact"
          xlink:label="ix_17_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_4_footnote" xlink:label="ix_4_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The expected life is calculated utilizing the simplified
method, which uses the mid-point between the vesting period and the contractual term as the expected life.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_18_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_17_fact"
          xlink:to="ix_4_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_19_fact"
          xlink:label="ix_19_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_20_fact"
          xlink:label="ix_20_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_5_footnote" xlink:label="ix_5_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Interest expense includes amortization of debt issuance and
debt discount costs of $42,666 and $22,619 during the years ended December 31, 2024 and 2023, respectively.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_19_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_20_fact"
          xlink:to="ix_5_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_21_fact"
          xlink:label="ix_21_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-86"
          xlink:label="hidden-fact-86"
          xlink:type="locator"/>
        <link:footnote id="ix_6_footnote" xlink:label="ix_6_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The income from insurance recoveries resulted from claim
benefits paid to us under our business interruption policy related to product contamination losses (in the amount of $250,000) and a
recovery from a vendor&#x2019;s policy related to an equipment malfunction (in the amount of $115,127).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_21_fact"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-86"
          xlink:to="ix_6_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
